Proteomics by unknown
Proteomics 
Human Diseases and Protein Functions
Edited by Tsz-Kwong Man and Ricardo J. Flores
Edited by Tsz-Kwong Man and Ricardo J. Flores
Photo by Ugreen / iStock
Biomedical research has entered a new era of characterizing a disease or a protein on a 
global scale. In the post-genomic era, Proteomics now plays an increasingly important 
role in dissecting molecular functions of proteins and discovering biomarkers in 
human diseases. Mass spectrometry, two-dimensional gel electrophoresis, and high-
density antibody and protein arrays are some of the most commonly used methods 
in the Proteomics field. This book covers four important and diverse areas of current 
proteomic research: Proteomic Discovery of Disease Biomarkers, Proteomic Analysis 
of Protein Functions, Proteomic Approaches to Dissecting Disease Processes, and 
Organelles and Secretome Proteomics. We believe that clinicians, students and 
laboratory researchers who are interested in Proteomics and its applications in the 
biomedical field will find this book useful and enlightening. The use of proteomic 
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Preface 
Advances in the biological and computational fields during the past two decades have 
unsealed new realms of possibilities embodied in the Omics fields. Genomics, the
study of the genome, has made great strides toward unraveling and characterizing 
important gene functions and regulations of numerous organisms. However, because
of the lack of correlation between mRNA and proteins, and the importance of post-
transcriptional regulations and protein modifications in protein functions and human 
diseases, proteomics has become increasingly important in the research field.
Proteomics is the study of the proteome in the cell, which represents the complete set
of proteins encoded by the genome. Since the introduction of gel electrophoresis for 
protein separation in the 1960’s, the methods for protein collection, identification, and 
quantification have continued to rapidly evolve and be refined. Protein research has 
expanded from the biochemical characterization of individual proteins to the high-
throughput proteomics analysis of a cell, complex cell populations, and even an entire 
organism. This remarkable development highlights the potential of using proteomics
methods to study protein functions and human diseases. New generations of mass 
spectrometry with higher resolutions and better quantification capabilities have also
fueled the use of proteomics in biomarker and functional research. Proteomics 
approaches have been commonly used in the recent literature to identify biomarkers
for disease screening, diagnosis, classification and monitoring. A potential application
of proteomics in the field of oncology is in the discovery and validation of prognostic 
and predictive biomarkers, which play a fundamental role in personalized therapy for 
cancer patients.   
The goal of this book is to provide a succinct overview of proteomics advances,
including descriptions of the challenges that have been conquered and those yet to be
resolved. The intended readers of this book include scientists and students involved in 
protein research from a basic, translational, or clinical perspective. The book consists
of 19 chapters written by leaders in their fields and is organized into four major 
sections. The first section is comprised of five chapters on proteomics research for 
disease biomarkers, which include discovery of atherosclerosis biomarkers,
proteomics analysis of bronchial fluids after lung injury, proteomics approaches for 
urinary exosome characterization, traumatic brain injury diagnosis and management,
and circadian proteomics. The second section focuses on the use of proteomics to
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disease biomarkers, which include discovery of atherosclerosis biomarkers, 
proteomics analysis of bronchial fluids after lung injury, proteomics approaches for 
urinary exosome characterization, traumatic brain injury diagnosis and management, 
and circadian proteomics. The second section focuses on the use of proteomics to 
unravel and characterize important human protein functions. The section consists of 
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six chapters, which include elucidation of the function of a novel gene (BRE), 
characterization of the RB/E2F transcriptional regulatory pathway, analyses of 
essential proteins such as ATP synthetase and Wnt-dependent Disheveled-based 
supermolecular complexes, identification of a novel plasminogen receptor (Plg-RKT), 
and the study of posttranslational modifications of myosin light chains. The third 
section contains four chapters that recapitulate proteomics efforts in dissecting human 
disease processes.  The first two chapters describe proteomics studies on esophageal 
squamous cell carcinoma and identification of endothelial signals for vascular 
remodeling. The last two chapters in this section focus on the role of microtubule-
dissociating Tau in neurological disorders, and identification of factors involved in 
neurogenesis recovery following adult mouse brain irradiation. The final section 
reports recent proteomics research on specific subproteomes and cellular organelles. 
The section consists of four chapters, which detail the analyses on organelle dynamics, 
mitochondrial proteome, plasma membrane of the blood brain barrier, and muscle 
secretome. 
Finally, we would like to thank everyone who has made this book a reality and helped 
us to serve as subject editors of the InTech Proteomics Book series, and as editors of 
this volume. The whole experience has been very rewarding and exciting for us. This 
book would not have been created without the constant assistance and support of 
InTech staff members, especially our Publishing Process Manager, Ms. Martina 
Durovic. We truly appreciate the kind assistance from all of you!  
Tsz-Kwong Man, PhD and Ricardo J. Flores, MD 
Baylor College of Medicine, 
Texas Children’s Hospital, 
USA 
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Overview of Current Proteomic  
Approaches for Discovery of Vascular 
Biomarkers of Atherosclerosis 
Lepedda Antonio Junior, Zinellu Elisabetta and Formato Marilena 
University of Sassari/Dipartimento di Scienze Fisiologiche, Biochimiche e Cellulari 
Italy 
1. Introduction 
Cardiovascular diseases are the leading cause of mortality and morbidity in developed 
countries being atherosclerosis the major contributor. Atherosclerosis is a form of chronic 
inflammation characterized by the accumulation of lipids and fibrous elements in medium 
and large arteries (Libby, 2002). The retention of apoB-100 containing lipoproteins (mainly 
LDL and Lp(a)) in the subendothelial space and their subsequent oxidation is thought to be 
the leading event in the development of atherosclerotic lesions (Williams & Tabas, 1995). 
The degree of inflammation, proteolysis, calcification and neovascularization affects the 
stability of advanced lesions. Plaque rupture and thrombosis are the most important clinical 
complications in the pathogenesis of stroke, coronary arteries and peripheral vascular 
diseases (Lutgens et al., 2003). So, the identification of early biomarkers of plaque presence 
and susceptibility to ulceration could be of primary importance in preventing such a life-
threatening event. Disease aetiology is very complex and includes several important 
environmental and genetic risk factors such as hyperlipidemia, diabetes, and hypertension. 
In this regard elevated plasma levels of LDL cholesterol and low levels of HDL cholesterol 
have been long associated with the onset and development of atherosclerotic lesions. 
Although enormous efforts have been done to elucidate the molecular mechanisms 
underlying plaque formation and progression, they are not yet completely understood. In 
the last years, proteomic studies have been undertaken to both elucidate pathways of 
atherosclerotic degeneration and individuate new circulating markers to be utilized either as 
early diagnostic traits or as targets for new drug therapies. 
This chapter will provide an overview of latest advances in proteomic studies on 
atherosclerosis and some related diseases, with particular emphasis on vascular tissue 
proteomics and lipoproteomics.  
2. Application of proteomic technologies to the study of atherosclerosis 
Atherosclerosis is a very complex pathology in terms of cell types involved, inflammatory 
mechanisms and multifactorial aetiology. Many efforts have been done to shed light on the 
mechanisms underlying atherogenesis and to identify new circulating biomarkers which, 
along with traditional risk factors, will help in early diagnosis and prevention as well as in 
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monitoring the effects of pharmacological agents. To address these issues, proteomic studies 
have been focused on different matrices such as vascular cell/tissues, looking at both 
proteomes and secretomes, plasma/serum, urine, and purified plasma lipoprotein fractions 
(fig. 1).  
 
 
Fig. 1. Overview of the main targets of proteomic studies searching for both mechanisms of 
atherogenesis and biomarkers of atherosclerotic lesion presence and progression. Dotted 
lines represent almost unexplored paths. LCMs, laser-captured microdissections 
To date, several proteomic approaches, such as 1D-2D electrophoresis (1DE-2DE) followed 
by mass spectrometry (MS) analyses, western arrays, protein arrays, and gel-free MS based 
proteomics, have been applied in the search of vascular biomarkers of atherosclerosis. Often, 
classical biochemical methods, mainly western blotting (WB), ELISA, and 
immunohistochemistry (IH) have been used to validate the proteomic results. 
2.1 Vascular tissue proteomics 
Even though tissue analyses frequently provide useful data, there are major drawbacks in 
analysing human atherosclerotic specimens. Atherosclerotic plaques are quite complex in 
terms of vascular cells and extracellular components. In this respect, besides vascular 
smooth muscle cells (VSMCs) and endothelial cells (ECs), they are composed of 
inflammatory cells, filtered plasma proteins, new-formed extracellular matrix, cellular 
debris and end-products of lipid and protein oxidation. Another critical point in the in situ 
analysis of protein expression within atherosclerotic plaques is the choice of the appropriate 
control. It would be desirable to utilize control specimens from the same vascular district of 
the same patient, in order to minimize intrinsic tissue differences, and from surgical 
endarterectomy rather than from post-mortem material, to avoid the occurrence of 
proteolytic modifications prior to analysis. Also the availability of a significant number of 
human specimens could be limiting. Because of the complexity of advanced lesions (Stary, 
2000; Virmani et al., 2000) in terms of necrotic core dimension, fibrous cap thickness, 
inflammatory and proteolytic components, careful histochemical classification is needed. 
Moreover, results from different advanced lesion typologies are difficult to interpret because 
they could be either associated to the lesion development or merely a consequence of the 
advanced condition. In the latest years proteomic technologies have been applied to human 
diseased tissues to both characterize mechanisms of advanced atherosclerotic plaque 
development, mainly those responsible for its instability, and to identify markers useful in 
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diagnosis and patients treatment. Compared to tissue specimens of human origin, animal 
models, mainly rodents, have been utilized to study the mechanisms underlying the early 
stages of lesion formation. 
2.1.1 Studies on animal models 
Apolipoprotein E-deficient mouse is the most popular murine model in cardiovascular 
research and has revealed important insights into mechanisms affecting atherogenesis. Mayr 
et al. analysed aortic lesions from apolipoprotein E-/- and wild type mice classified as light, 
medium, and severe according to lesion-covered areas on the aortic surface (Mayr et al., 
2005). As expected, authors found an increase of inflammatory cells, a decrease of VSMCs, 
and an accumulation of serum proteins associated to an impaired endothelial barrier 
function with lesion progression. Interestingly, immunoglobulins, that were barely 
detectable in apolipoprotein E+/+ mice, accumulated even in aortas of young apolipoprotein 
E-/- mice. The authors identified 79 differentially expressed spots. Moreover, they suggested 
an increase in oxidative stress with lesion progression evaluating the ratio between the 
oxidized and the reduced forms of peroxiredoxin, the former resulting in a charge shift 
toward a more acidic isoelectric point. Overall, they found a linear relationship between the 
degree of peroxiredoxin-Cys oxidation and the extent of lesion formation in aortas of 
apolipoprotein E-deficient mice. Almofti et al. applied 2DE coupled to matrix-assisted laser 
desorption/ionization time of flight (MALDI TOF) MS analysis to a rat model of 
atherosclerosis. They induced atherosclerosis by a single dose of vitamin D3 associated with 
a high fat diet and identified 46 proteins differently expressed in diseased tissues. Among 
them, 18 proteins, including a group of oxidization-related enzymes, were found to be up-
regulated, while 28 proteins were found down-regulated (Almofti et al., 2006). Vascular 
endothelium plays important physiological roles in vascular homeostasis, coagulation, 
inflammation, as well as tissue growth and repair. Impairment of the endothelial function is 
an early event in atherosclerotic lesion formation leading to overexpression of adhesion 
molecules as well as secretion of pro-inflammatory and chemotactic cytokines. An affinity-
based proteomic approach was used by Wu et al. (Wu et al., 2007) to identify vascular 
endothelial surface proteins differentially expressed in aortic tissues of apolipoprotein E 
deficient mice. After in situ perfusion of vascular bed with a solution containing a biotin-
derivative, biotinylated endothelial proteins were extracted, purified by affinity enrichment 
with streptavidin-agarose beads, and resolved by SDS-PAGE. The whole gel lanes were cut 
into slices that were subjected to tryptic digestion for nano liquid chromatography (LC) 
MS/MS analysis. In this way, 454 proteins, mainly extracellular or associated to cell 
membrane, were identified. Among them, there were cell adhesion molecules, accounting 
for the largest category, followed by proteins involved in signal transduction and transport. 
Interestingly, proteins associated with immune and inflammatory responses were more than 
doubled in atherosclerotic aorta (13%) in comparison to normal aorta (6%). On the other 
hand, proteins involved in lipid metabolism were decreased by 34% in atherosclerotic aorta. 
A rat model has been recently used for a proteomic study on the effects of blood shear stress 
on atherogenesis (Qi et al., 2008). It is well known that blood shear stress affects endothelial 
cell shape and orientation, as well as vascular wall permeability. Indeed, regions of arterial 
branching or curvature, where blood flow is not uniform, are preferential sites for lesion 
formation. By comparing homogenates of aortas kept under two levels of shear stress in a 
perfusion culture system for 24 hours, Qi et al. detected a reduced expression of protein 
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diagnosis and patients treatment. Compared to tissue specimens of human origin, animal 
models, mainly rodents, have been utilized to study the mechanisms underlying the early 
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membrane, were identified. Among them, there were cell adhesion molecules, accounting 
for the largest category, followed by proteins involved in signal transduction and transport. 
Interestingly, proteins associated with immune and inflammatory responses were more than 
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perfusion culture system for 24 hours, Qi et al. detected a reduced expression of protein 
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demonstrated, by siRNA technology, that this reduction enhances VSMC migration and 
apoptosis. 
2.1.2 Studies on human tissues 
As from 2003, 14 researches on human atherosclerotic plaque proteomics have been 
published; the diseased tissues used as matrices were coronary arteries (2/14), carotid 
arteries (11/14), and aortas (1/14).  
Most of them were conducted by using two-dimensional electrophoresis coupled to mass 
spectrometry as analytical method (10/14). The sample source, the methodology applied, 
and the most relevant findings of these studies are summarized in table 1. 
In 2003, You et al., by analysing 10 diseased (coronary artery disease, CAD) and 7 normal 
autoptic coronary arteries, reported about 2 fold increase of the ferritin light chain in the 
pathological specimens (You et al., 2003). Quantitative analysis by real-time PCR showed a 
decrease in ferritin light chain mRNA expression in diseased tissues suggesting that the 
increased expression of ferritin light chain in CAD coronary arteries may be related to 
increased protein stability. This result highlights the importance of protein expression 
analysis in studying disease-associated gene expression. Donners et al. analysed 5 stable 
plaques and 6 lesions with a thrombus from patients undergoing carotid endarterectomy, 
classified according to Virmani et al. (Donners et al., 2005). By 2DE analysis, they identified 
vinexin-β and α1-antitrypsin as differentially expressed. However, neither 
immunohistochemistry nor western blotting confirmed vinexin-β differential expression 
underlining the importance of validating proteomic results by other biochemical methods. 
Conversely, western blotting of 2D gels revealed, in lesions with a thrombus, the expression 
of six isoforms of the acute phase protein α1-antitrypsin, one of which was uniquely 
expressed in thrombus-containing plaques. Sung et al. analysed non-diseased and 
atherosclerotic specimens from 7 patients undergoing aorta bypass surgery. They identified 
a panel of 27 proteins differentially expressed in the atherosclerotic aorta involved in a 
number of biological processes, including calcium-mediated processes, migration of VSMCs, 
matrix metalloproteinase activation and regulation of pro-inflammatory cytokines (Sung et 
al., 2006). A different approach was adopted by Martin-Ventura et al. who analysed the 
protein secretion profiles obtained from 35 cultured atherosclerotic plaques (10 femoral, 25 
carotids) and 36 control arteries (24 mammary, 12 radial) in the search of new biological 
markers potentially released by the arterial wall into the plasma (Duran et al., 2003; Martin-
Ventura et al., 2004). In particular, they isolated and analysed the secretomes from non-
complicated and ruptured/thrombosed areas of the same cultured carotid plaque so 
avoiding the variability of the control specimens. They showed that, compared to control 
arteries, heat shock protein 27 (HSP27) secretion into the culture medium was significantly 
lower in atherosclerotic plaques and barely detectable in complicated plaque supernatants, 
as confirmed by WB analysis. They also evidenced a 20-fold reduction in HSP27 levels in the 
plasma of patients with carotid stenosis respect to healthy controls so identifying HSP27 as a 
possible marker of atherosclerosis. The same research group evaluated the effects of 
incubation with atorvastatin, a 3-hydroxy-3-methylglutaryl CoenzymeA reductase inhibitor, 
on the secretomes of cultured atherosclerotic plaques (Durán et al., 2007). They identified 24 
proteins that were increased and 20 proteins that were decreased in atherosclerotic plaque 
supernatants compared to controls. Interestingly, the presence of atorvastatin in culture 
medium reverted secretion of 66% proteins to control values. In this report, authors 
identified cathepsin D as a potential target for therapeutical treatment of atherosclerosis.  
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Human tissues (Methods) Results Known functions Ref. 
10 coronary arteries from CAD 
patients vs 7 normal autoptic coronary 
arteries 
 
(2DE of homogenates, LC-MS/MS, 
WB, rt-PCR) 
↑ ferritin light chain 




You et al., 2003 
6 carotid plaques containing a 
thrombus vs 5 advanced stable lesions
 
(2DE of homogenates, MALDI-
TOF/TOF MS, LC-MS/MS, WB, IH) 
↑ α1-antitrypsin acute-phase protein Donners et al., 
2005 
7 atherosclerotic aortic specimens vs 
biopsies of the normal tissue from the 
same patients 
 
(2DE of homogenates, MALDI-TOF 
MS, WB) 








Sung et al., 
2006 
35 atherosclerotic endarterectomies (10 
femoral, 25 carotids) vs 36 control 
endarteries (24 mammary, 12 radial) 
 
(2DE of secretomes, MALDI-TOF MS, 
LC-MS/MS and IMAC combined with 
MALDI Q-TOF MS/MS, WB, ELISA, 
IH) 
↓↓ HSP27 secretion 
↓↓ HSP27 plasma levels
anti-inflammatory 
down-regulation of the 
apoptotic signaling 
pathway 
Duran et al., 
2003; Martin-
Ventura et al., 
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regions with/without atorvastatin 
treatement vs fibrous regions (ex vivo)
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2007 
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↓ Rho GDP-dissociation 
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↓ HSP 20 
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demonstrated, by siRNA technology, that this reduction enhances VSMC migration and 
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Human tissues (Methods) Results Known functions Ref. 
10 carotid plaques vs reference 
synthetic gel 
 
(2DE of homogenates,  LC-MS/MS) 
Identification of proteins 
exclusive to plaque 
Terzuoli et al., 
2007; Porcelli 
et al., 2010) 
IMAC, immobilized metal affinity chromatography. ↑, increase. ↓, decrease. 
Table 1. 2DE coupled to MS studies on the human atherosclerotic plaque.  
Since carotid plaque rupture and thrombosis are the most important clinical complications 
in the pathogenesis of cerebro-vascular diseases, many efforts have been done to elucidate 
mechanisms underlying plaque vulnerability and to identify reliable specific markers of 
plaques prone to rupture. In a previous study we provided evidence for a wide 
fragmentation of some apolipoproteins and arterial proteoglycans and for a pro-
inflammatory microenvironment in unstable and much less in stable endarterectomy carotid 
plaques (Formato et al., 2004). Recently, we evaluated differential protein expression in a 
considerable number (n=48) of plaques obtained from carotid endarterectomy classified by 
immunohistochemistry in stable and unstable (Lepedda et al., 2009). Our study was carried 
out on the premise that plaque stability/instability is associated with distinct patterns of 
protein expression. We analysed extracts from finely minced tissues in order to allow 
enrichment in both topically expressed and filtered/retained proteins. A total of 57 distinct 
spots corresponding to 33 different proteins were identified in both stable and unstable 
plaques by peptide mass fingerprinting (PMF) analysis, most of which were of plasma 
origin (about 70%). This suggested the existence of an impaired endothelial barrier function 
independent from plaque typology. Compared to stable plaques, unstable ones showed 
reduced abundance of protective enzymes superoxide dismutase 3 and glutathione S-
transferase, small HSP 27 and 20, annexin A10, and Rho GDP-dissociation inhibitor and a 
higher abundance of ferritin light subunit, superoxide dismutase 2 and fibrinogen fragment 
D. These proteins are described to play a role in either oxidative or inflammatory processes 
and in the formation and progression of the atherosclerotic plaque. Our proteomic 
approach, trying to differentiate unstable from stable human carotid plaques, identified, in 
the former, a panel of proteins with pro-oxidant and pro-inflammatory potentials according 
to our current understanding of the molecular basis of the atherosclerotic process. 
To overcome inter-individual variations in protein expression, Olson et al. applied 2-D 
differential in gel electrophoresis (2D DIGE) in combination with MS/MS to compare 
protein distribution in 10 complicated segments located in the internal carotid artery (ICA) 
with that in 10 more stable segments in the common carotid artery (CCA) from the same 
patient (Olson et al., 2010). In this way, they identified 19 proteins with differential 
distribution between ICA and CCA segments. To overcome the problem of plaque 
heterogeneity, Terzuoli et al. proposed a method for selecting proteins exclusive to plaque 
by constructing a reference synthetic gel (Terzuoli et al., 2007; Porcelli et al., 2010). This gel, 
obtained by averaging the positions, shapes and optical densities of spots in 2DE maps from 
10 carotid plaque samples was compared with an equivalent synthetic gel constructed using 
10 plasma samples from the same carotid surgery patients. The comparison allowed 
discriminating between plasma and plaque proteins, the latter being potential markers of 
plaque vulnerability. 
Some alternative proteomic approaches have been applied to date in the search of new 
biomarkers of the atherosclerotic process (table 2). 
Overview of Current Proteomic Approaches  








12 carotid endarterectomy 
specimens vs 7 non-
atherosclerotic mammary arteries
 



















4 pooled unstable carotid plaques
vs 4 pooled stable carotid plaques
 
(protein microarray analysis of 
the expression of 512 proteins) 
↑ 21 proteins







Slevin et al., 
2006 
Histological sections from 35
coronary vessels in paraffin or 
frozen blocks 
 








Carotid plaques from 80 patients 
that had a secondary 
cardiovascular event vs 80 sex 
and age matched event-free 






osteopontin and the 
occurrence of new 
vascular complications
de Kleijn et 
al., 2010 
↑, increase. ↓, decrease. 
Table 2. Alternative approaches in proteomics of the atherosclerotic plaque.  
High-throughput western blot analysis, also called western array, was used to screen cell 
lysates from 12 carotid endarterectomy specimens and 7 non-atherosclerotic mammary 
arteries, obtained during bypass surgery, with 823 monoclonal antibodies mainly directed 
against signal-transducing proteins (Martinet et al., 2003). Western arrays showed a highly 
reproducible pattern of protein expression but also a high rate of false-positive signals 
(differential protein expression of only 7 of the 15 proteins detected by using this method 
was confirmed by standard immunoblot assay). A strong down regulation of apoptosis-
linked gene 2 (ALG-2) was found, suggesting a novel mechanism inhibiting cell death in 
human advanced atherosclerotic plaques.  
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By using microarray technology, Slevin et al. compared the expression of 512 proteins 
associated with inflammatory, pro/anti-apoptotic, and angiogenesis pathways between 4 
pooled fibrous stable carotid plaques and 4 pooled ulcerated, hemorrhagic unstable plaques 
(Slevin et al., 2006). In spite of the high sensitivity of protein microarrays, allowing detecting 
nanogram quantities, errors can occur because of weakly reacting or nonspecific antibodies, 
degraded proteins, and/or the efficiency of sample fluorescent labelling. However, western 
blotting analyses confirmed differential expression between stable and unstable plaque 
pools for all 11 proteins selected suggesting a high level of specificity of the array antibodies 
and the usefulness of this proteomic approach in the study of plaque pathogenesis. 
Atherosclerotic tissue could also be laser-microdissected, which would allow one to 
compare different areas of the plaque such as necrotic core and shoulders/fibrous cap, 
providing valuable spatial information. Bagnato et al. applied the direct tissue proteomic 
(DTP) approach to paraffin or frozen blocks from 35 coronary atherosclerotic lesions 
classified by histopathological examination in early, intermediate, and advanced (Bagnato et 
al., 2007). In particular, different plaque regions were laser-microdissected (LCMs) from 
both paraffin and frozen sections and subjected to tryptic digestion followed by LC MS/MS 
to obtain area-specific proteomic information. Frozen sections were also homogenized and 
proteins resolved by SDS PAGE and analysed by LC MS/MS. Moreover, they used AQUA 
(absolute quantitation) methodology to quantify Stromal Cell-derived Factor 1 α (SDF1-α) 
and growth factors not detected by the above mentioned methods. These multiple 
approaches allowed them to identify 806 unique proteins with high confidence so obtaining 
a large scale protein profile of human atherosclerotic coronary arteries.  
Recently, de Kleijn et al. analysed carotid endarterectomy specimens from 80 patients that had 
a secondary cardiovascular event in the 3-year follow-up and 80 sex and age matched event-
free patients, by two HPLC fractionations coupled to MS (de Kleijn et al., 2010). They identified 
osteopontin as potential biomarker and validated data by assaying its level in a group of 574 
patients that underwent carotid endarterectomy and a group of 151 patients that underwent 
femoral endarterectomy included in the follow-up. Osteopontin resulted highly predictive for 
secondary manifestations of cardiovascular events in other vascular territories.  
Atherosclerosis is characterized by high oxidative and proteolytic activities. This process 
may lead to a pathological remodelling of aorta characterized by dilatation that can evolve 
toward vessel wall rupture (aortic aneurysm). Recently, Dejouvencel et al. focused their 
attention on intraluminal mural thrombus that develops in human abdominal aortic 
aneurysm (Dejouvencel et al., 2010). In particular, they analysed the protein released from 
three different aortic layers of the intramural thrombus (luminal, intermediate and 
abluminal), after 24 hours incubation on RPMI medium, by surface-enhanced laser 
desorption/ionization (SELDI) TOF MS profiling. They identified a peptide that was largely 
abundant in newly formed luminal layer respect to the other areas as hemorphin 7, a 
proteolytic fragment of the hemoglobin. The levels of this peptide were confirmed (by 
ELISA) to be higher in sera of abdominal aortic aneurysm patients respect to controls, and 
positively correlated with the volume of the thrombus. This peptide has been suggested as a 
potential marker of pathological vascular remodelling. 
2.2 Vascular cell proteomics 
As mentioned above, the study of atherosclerotic specimens are complicated by both the 
heterogeneous cellular composition and the inflammatory/proteolytic environment. In this 
respect, cell culture systems could represent a useful tool to partially overcome drawbacks 
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of tissue analyses, allowing researchers to study single aspects of the atherosclerotic process 
in very controlled conditions. In the last years, studies on proteome (the intracellular 
proteins) and secretome (the proteins released into the cell culture medium) by 2DE and MS 
of ECs (Bruneel et al., 2003; Chen et al., 2007; Tunica et al., 2009), VSMCs (McGregor et al., 
2001; Dupont et al., 2005; Lee et al., 2006), and monocytes/macrophages (Dupont et al., 2004; 
Fach et al., 2004; Slomianny et al., 2006; Zhang et al., 2007; Zhao et al., 2009) have been 
performed. Moreover, in the attempt to help in elucidating the mechanisms of 
atherogenesis, several proteomic studies have been carried out on vascular cells cultured in 
different experimental conditions (table 3). The most applied proteomic methodologies were 
1DE-2DE coupled to MS analyses. Very few studies applied gel free proteomic approaches 
such as LC MS/MS (Fach et al., 2004; X.L. Wang et al., 2007; Zhao et al., 2009; Tunica et al., 
2009; Zimman et al., 2010) and microarrays (Sukhanov et al., 2005). 
2.3 Plasma/serum proteomics 
Plasma is one of the most useful matrices to investigate for identifying new biomarkers. It 
carries resident proteins that represent the majority of plasma proteins, together with 
proteins released from vascular cells and other tissues. In this respect, variations in plasma 
proteome could reflect directly or indirectly a cardiovascular disease or other pathological 
conditions. Moreover, monitoring plasma proteome could be successful in patients follow 
up and in relation to drug therapies. Besides plasma, also serum is widely investigated, 
although its proteome is known to be drastically affected by blood coagulation. Plasma 
proteomic studies are challenging due to both the high dynamic range of protein 
concentrations and the number of low expressed proteins. Plasma is composed for up to 
99% by 21 most abundant proteins and for the remaining 1% by about 50,000 low expressed 
protein variants, representing the so called “deep proteome” (Righetti et al., 2005). Plasma 
protein levels range from 40-50 mg/ml for albumin to less than 10 ng/ml for interleukins, 
chatepsins and peptide hormones. Therefore, differential proteomics of unfractionated 
plasma provides only limited information. In this regard, several pre-analytical depletion 
systems that imply affinity/immunoaffinity steps for simultaneous removal of the most 
represented plasma proteins have been set up. However, due to non-specific binding, many 
other proteins could be depleted. Besides depletion systems, also protein enrichment 
technology has been developed. This relies on solid-phase combinatorial ligand libraries, 
made of hexapeptides, to reduce the high dynamic range of protein concentration 
preventing the co-depletion of low-abundance proteins (Boschetti et al., 2007). Since 
variations in plasma protein expression can provide useful information on both 
physiological and pathological conditions of the different tissues in the body, many efforts 
have been made in characterizing the entire human plasma proteome. In this regard, during 
2003-2005, 55 laboratories worldwide participating to the Human Plasma Proteome Project 
(HPPP) analysed reference specimens by using emerging technologies in the field of 
proteomics, and generated integrated databases for proteins detectable and identifiable in 
human serum and plasma (http://www.hupo.org/research/hppp/). They confidently 
identified 3020 proteins with a minimum of two high-scoring MS/MS spectra that have 
been searched for relevance to cardiovascular function and disease using PubMed search 
engine and specific keywords. On the basis of the current knowledge, the study 
individuated a subset of 345 proteins showing cardiovascular-related functions (markers of 
inflammation and/or cardiovascular disease, proteins implicated in coagulation, signalling, 
growth, differentiation, and vascular remodelling) (Berhane et al., 2005).  
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positively correlated with the volume of the thrombus. This peptide has been suggested as a 
potential marker of pathological vascular remodelling. 
2.2 Vascular cell proteomics 
As mentioned above, the study of atherosclerotic specimens are complicated by both the 
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Table 3. Literature overview of experimental conditions adopted in proteomic studies on 
ECs, VSMCs and monocytes/macrophages. 
In the latest years, proteomics has been applied to plasma/serum to identify early 
diagnostic markers in relation to several cerebro-cardiovascular pathologies such as stroke 
(Allard et al., 2004; Kiga et al., 2008; Brea et al., 2009; Prentice et al., 2010), acute coronary 
syndrome (Mateos-Cáceres et al., 2004; Dardé et al., 2010), angiographic coronary disease 
(Donahue et al., 2006), acute myocardial infarction (AMI) (Distelmaier et al., 2009), coronary 
heart disease (CHD) (Prentice et al., 2010), coronary artery bypass grafting (CABG) (Banfi et 
al., 2010), aortic atherosclerotic plaque (Tabibiazar et al., 2006), and peripheral arterial 
disease (Wilson et al., 2007). Moreover, differential proteomic analysis has been addressed to 
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elucidate effects on plasma proteome of different pharmacological treatments (Alonso-
Orgaz et al., 2006; López-Farré et al., 2007). In this regard, the most applied proteomic 
methodologies were gel electrophoresis coupled to mass spectrometry analyses followed by 
gel free proteomic approaches such as LC MS/MS (Donahue et al., 2006; Wilson et al., 2007; 
Prentice et al., 2010) and microarrays (Tabibiazar et al., 2006). Almost all of these analytical 
approaches were preceded by one or more fractionation steps, mainly immunoaffinity 
depletion of the most abundant plasma protein species and ion exchange chromatography, 
to reduce the high complexity of plasma samples in terms of both number and dynamic 
range of protein species. Since many genetic and environmental factors affect atherosclerosis 
aetiology, one of the main drawbacks in differential analysis is the choice of a proper control 
group. In particular, results could be affected by coexisting pathological conditions such as 
dyslipidemia, hypertension and diabetes. 
2.4 Urine proteomics 
Urine is an easily accessible body fluid, stable against proteolytic degradation even after 
long storage times, and it represents a rich source of information. Urine protein and peptide 
composition results from glomerular filtration and proximal tubular absorption of 
circulating proteins (30%) and from the kidney and the urinary tract (70%) (Decramer et al., 
2008). Urine proteomics is emerging as a powerful tool for identifying new biomarkers 
useful in diagnosis and monitoring of several human diseases. However, the urinary 
proteome analysis is not a simple task because the urine shows low protein concentration 
and high levels of salts or other interfering compounds. Moreover, urinary proteome is 
highly influenced by both inter-individual and intra-individual variability, the latter due to 
physical training, diet, drugs, caffeine consumption, etc. One of the priorities in this field 
during the coming years is to optimize sample preparation methods for urine proteomics 
(Thongboonkerd V., 2007). 2DE coupled with MS has represented for years the technique of 
choice for the analysis of urine proteins. Recently, Candiano et al. resolved 1118 spots in 
normal urine samples, 275 of which were characterized as isoforms of 82 proteins, 30 (108 
spots) corresponding to typical plasma components (Candiano et al., 2010). However, the 
identity of most of the proteins found in normal urine by 2DE remains to be determined, the 
majority being low-molecular weight proteins (<30 kDa). By means of 1DE and HPLC as 
fractionation methods, and nano LC MS/MS and MS3 as analytical methods, Adachi et al. 
identified 8041 peptides corresponding to 1543 proteins, probably representing the most 
advanced proteomic approach to urine characterization (Adachi et al., 2006). 
The study of urinary proteome in relation to atherosclerosis is in its infancy but, in the last 
years, many efforts have been done. In particular, multiple urinary biomarkers of CAD have 
been described (Zimmerli et al., 2008; von Zur Muhlen et al., 2009; Delles et al., 2010) by 
means of capillary electrophoresis coupled online to micro time-of-flight mass spectrometry. 
A pattern of 238 CAD-specific polypeptides (49 of which have been sequenced) that 
identifies patients with high sensitivity and specificity has been defined. 
2.5 Lipoproteomics 
In 1995 Williams and Tabas published the “response-to-retention” hypothesis. According to 
this theory, early events in atherogenesis are related to a selective retention of LDL in the 
sub-endothelial space by means of specific interactions with some extracellular matrix 
components (Williams & Tabas, 1995). The molecular mechanisms underlying these 
processes are not completely understood, but knowledge of lipoprotein structure, 
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apolipoprotein composition and their post-translational modifications could help in this 
respect. There are several types of lipoproteins differing for chemical compositions, physical 
properties and metabolic functions. They may be classified according to their densities in 
chylomicrons (d< 0.95 g/ml), very low density lipoproteins (VLDL, d< 1.006 g/ml), low 
density lipoproteins (LDL, 1.019<d<1.063 g/ml), high density lipoproteins (HDL, 
1.063<d<1.21 g/ml) (Vance & Vance, 2008). A further class of lipoprotein particles is known 
as lipoprotein(a) (Lp(a)). Lp(a) is a LDL-like particle that carries, linked to apoB100 by a 
single disulfide bond, an heavily glycosylated multi-kringle protein named 
apolipoprotein(a). The physiological role of Lp(a) is unknown, although it is considered a 
risk factor for cardiovascular disease. Lipoproteins have attracted a great deal of interest 
because of their implication in the development of cardiovascular diseases, such as 
atherosclerosis. Although it is well known that high LDL-cholesterol and low HDL-
cholesterol are positively correlated with the risk for the development of cardiovascular 
disease, clinical studies suggest that levels of apo B-100 and apo A-I may be better predictors 
(Walldius et al., 2001). Since the protein component of these particles is largely responsible 
for carrying out their various functions, detailed information about the apolipoprotein 
composition and structure may contribute to reveal their role in atherogenesis and to 
develop new therapeutic strategies for the treatment of lipoprotein-associated disorders. 
Applying proteomics to the study of lipoproteins seems to contribute significantly to the 
achievement of this goal. Indeed, recent proteomic studies have revealed that lipoproteins 
carry an array of proteins previously unsuspected. Among proteomic approaches, 2DE was 
applied to the study of lipoprotein particles for the first time in the 1970s (Emes et al., 1976) 
and allowed to reveal several protein isoforms (Zannis, 1986). With the improvement of 2DE 
technologies, due to the advent of immobilized pH gradient strips, in the last ten years 
several studies have been done in the attempt to elucidate the apolipoprotein cargo of the 
different lipoprotein species. In this respect, besides 2DE, several gel-free mass spectrometry 
based proteomics have been applied. So far, 31 proteomic studies on VLDL, LDL and HDL 
have been published, while no proteomic studies on chylomicrons or Lp(a) are present in 
literature. Among them, only 9 focused on lipoproteomics in relation to atherosclerosis in 
humans (table 4). 
Before overviewing lipoproteomic studies, it is worth mentioning that the method used to 
isolate lipoproteins significantly affects the protein content of the resulting particles. 
Traditional methods, established in the 1950s (Havel et al., 1955), imply ultracentrifugation in 
high-salt media containing KBr or NaBr. Several lipoproteomic studies have been published 
using these procedures of lipoprotein isolation (Banfi et al., 2009; Davidson et al., 2009; Green 
et al., 2008; Heller et al., 2005, 2007; Hortin et al., 2006; Karlsson et al., 2005a, 2005b; 
Khovidhunkit et al., 2004; Mancone et al., 2007; Mazur et al., 2010; Rezaee et al., 2006; Vaisar et 
al., 2007, 2010; Alwaili et al, 2011). However, the high ionic strength and the high centrifugal 
field forces might cause either the dissociation of proteins or their exchange between different 
lipoprotein classes, altering the pattern of associated exchangeable apolipoproteins. Indeed, 
some of these studies reported a loss of proteins after a second step of ultracentrifugation 
(Banfi et al., 2009; Davidson et al., 2009; Mancone et al., 2007). Some others employed two 
ultracentrifuge procedures, using both salts and other compounds, such as sucrose and 
iodixanol (Bondarenko et al., 1999; Sun et al., 2010), reporting comparable results. By the way, 
Stahlman et al. reported that deuterium oxide (D2O) is to be preferred over salts at least for 
LDL and HDL, since for VLDL isolation, the ionic strength of the solution is not so  
relevant (Ståhlman et al., 2008). Alternatively, lipoprotein can be isolated by means of  
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apolipoprotein composition and their post-translational modifications could help in this 
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Khovidhunkit et al., 2004; Mancone et al., 2007; Mazur et al., 2010; Rezaee et al., 2006; Vaisar et 
al., 2007, 2010; Alwaili et al, 2011). However, the high ionic strength and the high centrifugal 
field forces might cause either the dissociation of proteins or their exchange between different 
lipoprotein classes, altering the pattern of associated exchangeable apolipoproteins. Indeed, 
some of these studies reported a loss of proteins after a second step of ultracentrifugation 
(Banfi et al., 2009; Davidson et al., 2009; Mancone et al., 2007). Some others employed two 
ultracentrifuge procedures, using both salts and other compounds, such as sucrose and 
iodixanol (Bondarenko et al., 1999; Sun et al., 2010), reporting comparable results. By the way, 
Stahlman et al. reported that deuterium oxide (D2O) is to be preferred over salts at least for 
LDL and HDL, since for VLDL isolation, the ionic strength of the solution is not so  
relevant (Ståhlman et al., 2008). Alternatively, lipoprotein can be isolated by means of  
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Subjects analysed Purification methods 
Proteomic methods 
Results Ref. 
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↑ apo C-III Bondarenko et al., 
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in 21 markers in 
both groups 
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↓ apo A-IV 
↑SAA 
↑complement C3 
Alwaili et al., 2011 
↑, increase. ↓, decrease. 
Table 4. Overview of the lipoproteomic studies related to atherosclerosis in humans 
reviewed in the chapter. 
immunopurification methods that rely on antibodies specific for the dominant protein of 
each class (Levels et al., 2007, 2011; Ogorzalek Loo et al., 2004; Rashid et al., 2002; Rezaee et 
al., 2006). Although this procedure does not lead to loss of weakly associated protein, it 
tends to nonspecifically co-purify associated proteins as serum contaminants and other 
lipoprotein fractions having the same antibody target (e.g. apolipoprotein A-I is the main 
HDL apolipoprotein but it is also present in both VLDL and LDL fractions). Other 
lipoprotein isolation methods that have been applied in lipoproteomic studies, involve 
electrophoretic techniques, specifically free solution isotachophoresis (Böttcher et al., 2000), 
and chromatographic techniques, such as fast protein liquid chromatography (Collins & 
Olivier, 2010; Richardson et al., 2009) and size exclusion/affinity chromatographies (Gordon 
et al., 2010). 
2.5.1 VLDL 
Both 2DE coupled to MS and gel-free MS approaches have been applied to the study of 
VLDL protein composition. Mancone et al., by using 2DE coupled to MALDI TOF/TOF MS 
analysis, provided a detailed map of VLDL, isolated by the classical ultracentrifugation 
method, from a plasma pool of 3 healthy volunteers. They identified two newly VLDL-
associated proteins, namely apo L-I and prenylcysteine lyase that were known to be 
associated with HDL, and some post-translational modifications of Apo E 
(Thr212glycosylations) and apo L-I (Ser296phosphorylation) (Mancone et al., 2007). Sun et al. 
used two different analytical approaches to compare the protein content of VLDL and LDL 
isolated from pooled samples of healthy subjects by either NaBr or iodixanol gradient 
ultracentrifugation. By using a gel-free approach based on LC coupled to MS/MS analysis 
of tryptic digests labeled with iTRAQ (isobaric tag for relative and absolute quantitation) 
tags, they revealed 15 proteins differentially expressed in the two classes of lipoproteins. By 
using 2DE coupled with LC MS/MS, they further revealed 6 proteins differentially 
expressed as well. Moreover, the 5 apo A-I isoforms were found to be phosphorylated. This 
study, besides describing the VLDL and LDL lipoproteomes, provided insights into the 
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metabolic changes, in terms of protein composition, during physiological VLDL to LDL 
transition (Sun et al., 2010). While the studies described above focused on the human 
lipoproteome of mature VLDL particles, other researches tried to shed light on VLDL 
assembly and maturation in animal models. For example, Rashid et al. immunopurified apo 
B from rat liver microsomes treated with chemical crosslinkers. Then, using LC MS/MS 
technology, they identified 99 unique proteins that co-immunoprecipitated with apo B, 
many of which were ribosomal proteins (Rashid et al., 2002). 
Bondarenko et al. applied MALDI TOF and ESI TOF MS techniques to identify low 
molecular weight proteins constituting VLDL from 3 healthy subjects and 1 hyperlipidemic 
subject without previous tryptic digestion. By this approach they identified 15 apo C 
isoforms and 1 apo E isoform and observed higher level of apo C-III in the hyperlipidemic 
subject (Bondarenko et al., 1999).  
2.5.2 LDL 
LDL particles have been studied using different proteomic approaches. Karlsson et al. 
provided a 2DE map of LDL-associated proteins from a pooled plasma of 4 healthy subjects 
purified by KBr density gradient ultracentrifugation. Their results confirmed the presence of 
proteins known to be associated with LDL particles, showing that many of these were 
present in different isoforms. In particular, they detected three proteins not previously 
identified in LDL: serum amyloid A-IV, calgranulin A, and lysozyme C. To confirm that the 
proteins identified were truly associated with LDL rather than adsorbed during the isolation 
procedure, LDL was also purified by size-exclusion chromatography (Karlsson et al., 2005a). 
Moreover, they described three isoforms of apo M that were characterized for PTMs in a 
following work (Karlsson et al., 2006). Stahlman et al. applied 2DE coupled to MALDI 
TOF/TOF and SELDI TOF MS as well, to compare VLDL, LDL and HDL isolated from 
pooled plasma of 5 healthy donors by ultracentrifugation using either KBr or D2O/sucrose 
to generate the gradient. VLDL profiles obtained with the two procedure of isolation were 
almost identical. Conversely, 2DE maps and SELDI TOF profiles of LDL and HDL were 
qualitatively similar, but differed in relative abundance of some protein species. Moreover, a 
reduced protein-lipids ratio was detected in LDL and HDL fractions purified by using KBr 
indicating that in the D2O buffer the lipoproteins retained a higher content of exchangeable 
apoproteins (Ståhlman et al., 2008). LDL-associated proteins have also been studied using 
other proteomic approaches. Banfi et al. applied liquid-phase IEF and 1DE coupled with LC 
MS/MS to characterize the proteome of LDL isolated by density gradient 
ultracentrifugation from healthy subjects. They identified LDL-associated proteins not 
previously described, including prenylcysteine lyase (PCL1), orosomucoid, retinol-binding 
protein, and paraoxonase-1. The authors analysed PCL1 distribution in all the lipoprotein 
classes isolated by ultracentrifugation from 6 healthy subjects showing a decline from VLDL 
to LDL to HDL and its absence in lipoprotein-depleted plasma. Due to the oxidizing role of 
PCL1, they hypothesized that lipoproteins can themselves generate pro-oxidant species, 
thus suggesting a new role for lipoprotein in the development of atherosclerosis (Banfi et al., 
2009). Bancells et al. analysed the proteome of LDL subfractions isolated by anion exchange 
chromatography after sequential ultracentrifugation of pooled healthy subjects plasma. 
Proteomic analysis, performed by LC MS/MS method, revealed the presence of 28 proteins 
most of which were involved in inflammation, coagulation and innate immunity, besides 
apolipoproteins involved in lipid metabolism. They observed that electronegative LDL, a 
minor subfraction of LDL fraction, has a higher content of minor proteins, especially apo F 
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each class (Levels et al., 2007, 2011; Ogorzalek Loo et al., 2004; Rashid et al., 2002; Rezaee et 
al., 2006). Although this procedure does not lead to loss of weakly associated protein, it 
tends to nonspecifically co-purify associated proteins as serum contaminants and other 
lipoprotein fractions having the same antibody target (e.g. apolipoprotein A-I is the main 
HDL apolipoprotein but it is also present in both VLDL and LDL fractions). Other 
lipoprotein isolation methods that have been applied in lipoproteomic studies, involve 
electrophoretic techniques, specifically free solution isotachophoresis (Böttcher et al., 2000), 
and chromatographic techniques, such as fast protein liquid chromatography (Collins & 
Olivier, 2010; Richardson et al., 2009) and size exclusion/affinity chromatographies (Gordon 
et al., 2010). 
2.5.1 VLDL 
Both 2DE coupled to MS and gel-free MS approaches have been applied to the study of 
VLDL protein composition. Mancone et al., by using 2DE coupled to MALDI TOF/TOF MS 
analysis, provided a detailed map of VLDL, isolated by the classical ultracentrifugation 
method, from a plasma pool of 3 healthy volunteers. They identified two newly VLDL-
associated proteins, namely apo L-I and prenylcysteine lyase that were known to be 
associated with HDL, and some post-translational modifications of Apo E 
(Thr212glycosylations) and apo L-I (Ser296phosphorylation) (Mancone et al., 2007). Sun et al. 
used two different analytical approaches to compare the protein content of VLDL and LDL 
isolated from pooled samples of healthy subjects by either NaBr or iodixanol gradient 
ultracentrifugation. By using a gel-free approach based on LC coupled to MS/MS analysis 
of tryptic digests labeled with iTRAQ (isobaric tag for relative and absolute quantitation) 
tags, they revealed 15 proteins differentially expressed in the two classes of lipoproteins. By 
using 2DE coupled with LC MS/MS, they further revealed 6 proteins differentially 
expressed as well. Moreover, the 5 apo A-I isoforms were found to be phosphorylated. This 
study, besides describing the VLDL and LDL lipoproteomes, provided insights into the 
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metabolic changes, in terms of protein composition, during physiological VLDL to LDL 
transition (Sun et al., 2010). While the studies described above focused on the human 
lipoproteome of mature VLDL particles, other researches tried to shed light on VLDL 
assembly and maturation in animal models. For example, Rashid et al. immunopurified apo 
B from rat liver microsomes treated with chemical crosslinkers. Then, using LC MS/MS 
technology, they identified 99 unique proteins that co-immunoprecipitated with apo B, 
many of which were ribosomal proteins (Rashid et al., 2002). 
Bondarenko et al. applied MALDI TOF and ESI TOF MS techniques to identify low 
molecular weight proteins constituting VLDL from 3 healthy subjects and 1 hyperlipidemic 
subject without previous tryptic digestion. By this approach they identified 15 apo C 
isoforms and 1 apo E isoform and observed higher level of apo C-III in the hyperlipidemic 
subject (Bondarenko et al., 1999).  
2.5.2 LDL 
LDL particles have been studied using different proteomic approaches. Karlsson et al. 
provided a 2DE map of LDL-associated proteins from a pooled plasma of 4 healthy subjects 
purified by KBr density gradient ultracentrifugation. Their results confirmed the presence of 
proteins known to be associated with LDL particles, showing that many of these were 
present in different isoforms. In particular, they detected three proteins not previously 
identified in LDL: serum amyloid A-IV, calgranulin A, and lysozyme C. To confirm that the 
proteins identified were truly associated with LDL rather than adsorbed during the isolation 
procedure, LDL was also purified by size-exclusion chromatography (Karlsson et al., 2005a). 
Moreover, they described three isoforms of apo M that were characterized for PTMs in a 
following work (Karlsson et al., 2006). Stahlman et al. applied 2DE coupled to MALDI 
TOF/TOF and SELDI TOF MS as well, to compare VLDL, LDL and HDL isolated from 
pooled plasma of 5 healthy donors by ultracentrifugation using either KBr or D2O/sucrose 
to generate the gradient. VLDL profiles obtained with the two procedure of isolation were 
almost identical. Conversely, 2DE maps and SELDI TOF profiles of LDL and HDL were 
qualitatively similar, but differed in relative abundance of some protein species. Moreover, a 
reduced protein-lipids ratio was detected in LDL and HDL fractions purified by using KBr 
indicating that in the D2O buffer the lipoproteins retained a higher content of exchangeable 
apoproteins (Ståhlman et al., 2008). LDL-associated proteins have also been studied using 
other proteomic approaches. Banfi et al. applied liquid-phase IEF and 1DE coupled with LC 
MS/MS to characterize the proteome of LDL isolated by density gradient 
ultracentrifugation from healthy subjects. They identified LDL-associated proteins not 
previously described, including prenylcysteine lyase (PCL1), orosomucoid, retinol-binding 
protein, and paraoxonase-1. The authors analysed PCL1 distribution in all the lipoprotein 
classes isolated by ultracentrifugation from 6 healthy subjects showing a decline from VLDL 
to LDL to HDL and its absence in lipoprotein-depleted plasma. Due to the oxidizing role of 
PCL1, they hypothesized that lipoproteins can themselves generate pro-oxidant species, 
thus suggesting a new role for lipoprotein in the development of atherosclerosis (Banfi et al., 
2009). Bancells et al. analysed the proteome of LDL subfractions isolated by anion exchange 
chromatography after sequential ultracentrifugation of pooled healthy subjects plasma. 
Proteomic analysis, performed by LC MS/MS method, revealed the presence of 28 proteins 
most of which were involved in inflammation, coagulation and innate immunity, besides 
apolipoproteins involved in lipid metabolism. They observed that electronegative LDL, a 
minor subfraction of LDL fraction, has a higher content of minor proteins, especially apo F 
 
Proteomics – Human Diseases and Protein Functions 
 
18
and apo J, compared to electropositive LDL (Bancells et al, 2010). Collins et al. performed a 
proteomic analysis, applying LC MS/MS, to compare the lipoprotein-associated proteins 
derived from plasma and serum samples. They isolated both HDL and LDL from healthy 
subjects by means of fast protein liquid chromatography-size exclusion chromatography 
(FPLC-SEC). 16 proteins, several of which were complement subcomponents, were found 
only in the LDL fraction. 65 proteins were identified to be unique to HDL, while another list 
of proteins was found to overlap between the two lipoprotein fractions. Regarding the 
differences between plasma- and serum-derived LDL and HDL particles, the authors 
reported that the most relevant differences regarded fibrinogen proteins which were 
depleted in serum. Therefore, they stated that, apart from significantly higher levels of apo 
B-100 in LDL purified from serum samples, comparative proteomic analysis of plasma and 
serum gives similar results (Collins & Olivier, 2010).  
Up to date, only few studies on LDL proteomics and atherosclerosis have been reported. 
2DE coupled with LC MS/MS and label-free quantitative MS (LFQMS) was applied by 
Richardson et al. to the analysis of LDL in the early stages of atherosclerosis in an animal 
model. LDL was isolated by fast protein LC (FPLC) from non-diabetic hyperlipidemic, 
diabetic dyslipidemic, diabetic dyslipidemic under exercise training, and healthy Yucatan 
pigs (Richardson et al., 2009). They identified 28 unique proteins and detected several 
differential expression patterns for apo E, A-I, C-III, fibrinogen, apo B, adiponectin, alpha-2-
macroblobulin, complement C1q, ficolin, and apo J. Since LDL was isolated from pigs in the 
early stages of atherosclerosis, the alterations observed might be involved in the initiating 
stages of the disease. LDL-associated proteins have also been studied using other proteomic 
approaches. For example Davidsson et al. applied SELDI TOF technologies to compare LDL 
associated proteins from atherosclerotic patients (having either metabolic syndrome or 
diabetes) to that from healthy subjects. They focused on small dense LDL isolated by means 
of gradient ultracentrifugation using D2O. The results showed that LDL from patients had 
lower content of apo A-I, apo C-I and apo E and higher content of apo C-III, the latter 
responsible for higher affinity for arterial proteoglycans that could facilitate LDL in situ 
oxidative modifications (Davidsson et al., 2005). 
2.5.3 HDL 
HDL is the most studied among lipoprotein particles, probably because of its anti-
atherogenic functions. Proteomic studies in humans succeeded in identifying, besides the 
known apolipoproteins involved in the lipoprotein metabolism, other associated proteins 
such as acute-phase response proteins, proteinase inhibitors, and members of the 
complement activation. Therefore, characterizing the HDL proteome should help in the 
identification of novel anti-inflammatory and cardioprotective actions of HDL and could 
provide insights into lipid therapy. The most used among the several proteomic approaches 
that have been applied to characterize the HDL-associated proteins is 2DE coupled with MS. 
Böttcher et al. applied two-dimensional non-denaturing gradient gel electrophoresis (2D-
GGE) and immunoblotting to analyse HDL subfractions isolated from healthy subjects. By 
means of free solution isotachophoresis (FS-ITP), they separated 3 HDL subfractions, 
namely fast (fHDL), intermediate (iHDL) and slow-migrating (sHDL). Proteomic analysis 
showed compositional differences in HDL subfractions. In particular, they observed that 
fHDL and iHDL contained the bulk of HDL and of apo A-I. Apolipoproteins other than apo 
A-I and apo A-II were not detectable in fHDL, while sHDL contained several minor 
apolipoproteins such as apo A-IV, apo D, apo E, apo J, and factor H. Apo C-III was found 
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mainly in iHDL and sHDL with only little apo C-III in fHDL (Böttcher et al., 2000). A study 
performed by Ogorzalek Loo et al. suggests that a synergy between classical 2D gels and 
virtual 2D gels can be useful for studying HDL protein composition. Virtual 2DE is based on 
combining a first-dimensional isoelectric focusing (IEF) separation on polyacrylamide gels 
with MALDI MS surface scanning of the dried gel. In such a way, a virtual 2D gel can be 
created, generating an image in which mass spectrometry substitutes the second-dimension 
SDS-PAGE separation. By this approach the authors examined HDL isolated from human 
sera by selected-affinity immunosorption of apo A-I and revealed 42 unique masses for 
protein species with isoelectric points between pH 5.47–5.04 (Ogorzalek Loo et al., 2004). 
Heller et al. by using multiple proteomic approaches such as native or denaturing PAGE 
coupled with LC MS/MS, shotgun LC MS/MS and MALDI TOF MS profiling, analysed the 
protein complement of HDL3, HDL2, HDL2/LDL and LDL/VLDL enriched fractions, 
isolated from a plasma pool of 10,000 healthy donors by density gradient 
ultracentrifugation. Therefore, they were able to characterize comprehensively the protein 
composition of the purified lipoprotein fractions (Heller et al., 2005). Karlsson et al. 
provided a detailed 2DE map of HDL2 and HDL3 isolated by salt gradient 
ultracentrifugation from pooled plasma of 4 healthy volunteers. Besides several isoforms of 
apolipoproteins already described to associate with HDL, they identified new proteins such 
as α-1-antitrypsin, two isoforms of salivary-α-amylase in HDL2 and a glycosylated apoAII in 
HDL3 (Karlsson et al., 2005b). By using 1DE and 2DE MALDI TOF MS and isotope-coded 
affinity tag (ICAT), Rezaee et al. detected many more proteins than Karlsson et al. in 
ultracentrifugally isolated HDL. This was the first study employing an ICAT method to 
identify lower abundance proteins. The overall identified proteins are known to be involved 
in different functions, such as lipid transport and metabolism, inflammation, immune 
system, hemostasis and thrombosis (Rezaee et al., 2006). The higher number of identified 
proteins could be ascribed to the use of ICAT method, that improve the sensitivity of the 
detection, as well as to the use of a single step of ultracentrifugation to isolate HDL. 
Khovidhunkit et al. investigated changes in proteins associated to HDL during 
inflammation by means of 2DE and LC MS/MS in an animal model. For this purpose, they 
analysed HDL isolated by salt gradient ultracentrifugation from sera of mice injected with 
normal saline or with endotoxin so detecting increased levels of SAA, apo E, apo A-IV and 
apo A-V and decreased levels of apo A-I and apo A-II in acute-phase HDL (Khovidhunkit et 
al., 2004).  
Besides 2DE analyses, several groups have applied different gel-free proteomic approaches 
to characterize HDL proteome in healthy subjects. One of the first attempts was performed 
by Bondarenko et al. that used MALDI TOF MS and ESI TOF MS techniques to the analysis 
of intact protein of HDL isolated by density gradient ultracentrifugation in sucrose solution. 
They observed forty-nine peaks in the MALDI spectrum and 11 species in the ESI MS 
spectrum corresponding to the most abundant apolipoproteins, such as apo A-I, apo A-II, 
apo C-I, apo C-II, and apo C-III showing different isoforms due to post-translational 
modifications (Bondarenko et al., 2002). Applying immobilized pH gradient isoelectric 
focusing coupled with MALDI TOF MS, Farwig et al. were able to detect also SAA-IV in 
HDL isolated by ultracentrifugation in CsBiEDTA. They developed a successful method for 
recovering the apolipoproteins from immobilized pH gradient gels prior to MALDI 
analysis, demonstrating the analytical power of linking the IPG pI profile with MALDI TOF 
MS analysis (Farwig et al., 2003). Hortin et al. focused on HDL-associated low molecular 
weight peptides. By using HPLC and MALDI TOF MS or HPLC-ion trap mass spectrometry, 
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B-100 in LDL purified from serum samples, comparative proteomic analysis of plasma and 
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Richardson et al. to the analysis of LDL in the early stages of atherosclerosis in an animal 
model. LDL was isolated by fast protein LC (FPLC) from non-diabetic hyperlipidemic, 
diabetic dyslipidemic, diabetic dyslipidemic under exercise training, and healthy Yucatan 
pigs (Richardson et al., 2009). They identified 28 unique proteins and detected several 
differential expression patterns for apo E, A-I, C-III, fibrinogen, apo B, adiponectin, alpha-2-
macroblobulin, complement C1q, ficolin, and apo J. Since LDL was isolated from pigs in the 
early stages of atherosclerosis, the alterations observed might be involved in the initiating 
stages of the disease. LDL-associated proteins have also been studied using other proteomic 
approaches. For example Davidsson et al. applied SELDI TOF technologies to compare LDL 
associated proteins from atherosclerotic patients (having either metabolic syndrome or 
diabetes) to that from healthy subjects. They focused on small dense LDL isolated by means 
of gradient ultracentrifugation using D2O. The results showed that LDL from patients had 
lower content of apo A-I, apo C-I and apo E and higher content of apo C-III, the latter 
responsible for higher affinity for arterial proteoglycans that could facilitate LDL in situ 
oxidative modifications (Davidsson et al., 2005). 
2.5.3 HDL 
HDL is the most studied among lipoprotein particles, probably because of its anti-
atherogenic functions. Proteomic studies in humans succeeded in identifying, besides the 
known apolipoproteins involved in the lipoprotein metabolism, other associated proteins 
such as acute-phase response proteins, proteinase inhibitors, and members of the 
complement activation. Therefore, characterizing the HDL proteome should help in the 
identification of novel anti-inflammatory and cardioprotective actions of HDL and could 
provide insights into lipid therapy. The most used among the several proteomic approaches 
that have been applied to characterize the HDL-associated proteins is 2DE coupled with MS. 
Böttcher et al. applied two-dimensional non-denaturing gradient gel electrophoresis (2D-
GGE) and immunoblotting to analyse HDL subfractions isolated from healthy subjects. By 
means of free solution isotachophoresis (FS-ITP), they separated 3 HDL subfractions, 
namely fast (fHDL), intermediate (iHDL) and slow-migrating (sHDL). Proteomic analysis 
showed compositional differences in HDL subfractions. In particular, they observed that 
fHDL and iHDL contained the bulk of HDL and of apo A-I. Apolipoproteins other than apo 
A-I and apo A-II were not detectable in fHDL, while sHDL contained several minor 
apolipoproteins such as apo A-IV, apo D, apo E, apo J, and factor H. Apo C-III was found 
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proteins could be ascribed to the use of ICAT method, that improve the sensitivity of the 
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inflammation by means of 2DE and LC MS/MS in an animal model. For this purpose, they 
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focusing coupled with MALDI TOF MS, Farwig et al. were able to detect also SAA-IV in 
HDL isolated by ultracentrifugation in CsBiEDTA. They developed a successful method for 
recovering the apolipoproteins from immobilized pH gradient gels prior to MALDI 
analysis, demonstrating the analytical power of linking the IPG pI profile with MALDI TOF 
MS analysis (Farwig et al., 2003). Hortin et al. focused on HDL-associated low molecular 
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68 peptides in the 1-5 kDa size range were identified in ultracentrifugally isolated HDL. 
Among these, 19 were fragments derived from well-known HDL-associated protein while 
others were derived from non-lipoprotein plasma proteins as fibrinogen, α1-proteinase 
inhibitor, and transthyretin, suggesting that HDL particles may represent significant 
reservoirs of small peptides in the circulation (Hortin et al., 2006). Levels et al. applied 
SELDI TOF MS technologies to HDL isolated from normolipidemic individuals by means of 
immunocapturing directly on a SELDI protein chip covalently bound with anti-apo AI or 
anti apo-AII antibodies. In this way, 95 peaks in the 3–50 kDa molecular mass range and 27 
more peaks between 50 and 160 kDa were detected (Levels et al., 2007). Gordon et al. 
applied MS-based proteomic approaches to the analysis of HDL purified from healthy 
subjects by means of gel filtration chromatography. To overcome problems related to 
nonspecific co-purification, they isolated only phospholipid-containing particles using 
calcium silicate hydrate (CSH), that were subjected to trypsin digestion while still bound to 
the CSH for identification by means of LC MS/MS. By this approach 47 proteins were 
identified. Among these, 14 were described as newly discovered HDL-associated proteins 
that support roles for HDL in complement regulation and protease inhibition (Gordon et al., 
2010). To investigate the role of specific subspecies in the anti-atherogenic effects of HDL, 
Davidson et al. applied LC MS/MS to investigate the distribution of associated proteins 
across 5 subpopulations of HDL from healthy human volunteers. Subjecting one set of 
samples to sequential ultracentrifugation followed by salt gradient ultracentrifugation, and 
the other one to a single step of salt gradient ultracentrifugation they identified 22 and 28 
proteins, respectively. Among them, the majority were apolipoproteins already known to be 
associated with ultracentrifugally-isolated HDL, while several complement factors and 
protease inhibitors already documented in other proteomic studies were not detected. By 
using peptide counts determined by MS, they monitored the relative abundance of a given 
protein across the HDL subfractions. Some proteins were found to associate preferentially to 
a specific subclass, while others were uniformly distributed across the subpopulations. This 
finding supports the proposal that HDL is composed of distinct subpopulations of particles 
that have discreet biological properties (Davidson et al., 2009).  
A limited number of studies have focused on HDL proteomes in relation to atherosclerosis. 
Vaisar et al. used a shotgun LC MS/MS approach to identify proteins associated to total 
plasma HDL isolated from 20 healthy individuals. In this way, they described 48 proteins, 
13 of which not yet known to associate to HDL. Moreover, they compared plasma HDL3 
fraction isolated from 6 healthy donors and 7 CAD patients. By means of Gene Ontology 
(GO) Consortium analysis, they were able to associate the array of HDL proteins to 
biological processes. Members of the complement pathway and endopeptidase inhibitors 
were found, suggesting that HDL plays also roles in regulating the complement system and 
protecting tissue from proteolysis. Thereafter, they found that some proteins associated to 
HDL3 were upregulated in CAD patients, in particular apo C-IV, PON1, complement C3, 
apo A-IV, and apo E. Interestingly, they found three of these proteins also in HDL isolated 
from human carotid atherosclerotic tissues, being apo E the most abundant (Vaisar et al., 
2007). In another study, they investigated whether combined statin and niacin therapy, 
which increase HDL cholesterol levels and reduce CAD risk, could reverse the changes in 
the protein composition observed in HDL3. For this purpose HDL3, isolated from 6 CAD 
patients before and 1 year after combined therapy, were subjected to LC–Fourier Transform 
Ion Cyclotron Resonance MS. By means of spectral counting and extracted ion 
chromatograms they found that treatment decreased apo E levels and increased apo J, apo F, 
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and phospholipid transfer protein levels (Green et al., 2008). In a successive study, they 
investigated if protein composition was altered in HDL2 isolated from CAD patients. 
Ultracentrifugally isolated HDL2 was digested with trypsin and analysed by MALDI TOF 
MS and pattern recognition analysis. The most significant informative features were then 
subjected to LC MALDI MS/MS for identification. This analysis revealed that HDL2 of CAD 
subjects carried a distinct protein cargo with increased levels of apo C-III and decreased 
levels of apo C-I, two apolipoproteins involved in the metabolism of HDL particles. 
Moreover, they found increased levels of apo A-I peptides containing oxidized methionine 
indicating the occurence of oxidative processes in CAD patients (Vaisar et al., 2010). Heller 
et al. used a shotgun LC MS/MS approach to characterize HDL protein composition of 7 
hypercholesterolemic subjects and 9 normolipidemic ones. They used the peptide match 
score summation index, based on probabilistic peptide scores for absolute protein 
quantitation. By this approach, they found that in hypercholesterolemic subjects apo A-I 
levels were reduced while apo C-I, apo C-III, and apo E levels were increased, suggesting 
that HDL protein composition could be altered in lipemic disease (Heller et al., 2007). Mazur 
et al. applied differential top-down mass spectrometry to compare HDL3 protein profiles 
between 3 subjects having low HDL cholesterol and 3 subjects having high HDL cholesterol. 
Differently from the so called “bottom up” proteomic methods that are based on the 
digestion of proteins into short peptides, “top-down” proteomic techniques characterize 
intact proteins. In this study HDL3 samples were analysed by a reverse-phase nano-HPLC 
coupled to a linear trap quadrupole Fourier transform (LTQ-FT) hybrid mass spectrometer. 
The authors found 380 peaks that changed significantly in protein abundance between high 
HDL-c and low HDL-c subject groups demonstrating that this approach is suitable for the 
detection of quantitative differences in proteins and protein isoforms in human HDL 
samples (Mazur et al., 2010). 
Very recently, Levels et al., applied SELDI TOF MS to HDL isolated, by apo A-I 
immunocapturing, from healthy subjects having low HDL-c and high HDL-c challenged 
with an endotoxin for 24 hours. Overall they observed profound changes in 21 markers in 
both study groups proteome irrespective of HDL cholesterol levels (Levels et al., 2011). 
Alwaili et al. applied 1D followed by LC-MS/MS to HDL isolated by sequential 
ultracentrifugation from male control, stable CAD, and ACS subjects (n=10/group). They 
identified 67 HDL-associated proteins involved in lipid binding, acute-phase response, 
immune response, and endopeptidase/protease inhibition. By means of spectral counting 
they found that nine proteins were differently abundant. Among them, apo A-IV was 
significantly reduced, whereas serum amyloid A and complement C3 were significantly 
increased in ACS patients compared to either controls or CAD subjects, as confirmed by 
western blotting and ELISA (Alwaili et al, 2011). 
Recently, our research group started to study lipoproteomic profiles in relation to 
atherosclerosis (Formato et al., 2011). For this purpose we purified plasma VLDL, LDL, and 
HDL from patients undergoing carotid endarterectomy and from healthy normolipidemic 
donors by single isopycnic salt density gradient ultracentrifugation, followed by a second 
step of ultracentrifugation. Samples were subjected to 2DE followed by PMF analysis as 
reported in figure 2. In this way, we identified 21 spots corresponding to about 96% of 52 
protein spots detected in VLDL, 22 spots corresponding to about 92% of 43 spots in LDL, 
and 20 spots corresponding to about 96% of 60 spots in HDL. The relative abundance of 
several identified lipoprotein-associated proteins differed between patients and healthy 
subjects (paper in preparation).  
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Fig. 2. Schematic workflow of the proteomic analysis of plasma lipoproteins adopted in our 
laboratory. Representative 2D maps of isolated VLDL and whole plasma are reported. 
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Plaque rupture and thrombosis are the most important clinical complications in the 
pathogenesis of vascular diseases. To date, many efforts have been done to elucidate 
mechanisms underlying plaque vulnerability and to identify reliable specific markers of 
plaques prone to rupture. In the last years, with the improvement of proteomic tools, large-
scale technologies have been proved valuable in attempting to unravel pathways of complex 
diseases and biomarkers for early diagnosis and patients follow up. Collecting multiple 
biomarkers would be preferable over single markers in terms of higher sensitivity and 
specificity for the diagnosis of cardiovascular diseases. In this chapter, we have reviewed a 
great deal of information obtained by applying proteomics to the study of 
proteome/secretome from atherosclerotic tissues and plasma lipoproteins. In tissue 
proteomics, major drawbacks such as the plaque complexity, tissue sampling and 
availability, and the choice of the proper controls could affect the analysis. Even though 
results reported above seem to be quite promising, large-scale clinical studies are required 
to validate the usefulness of newly identified biomarkers. Moreover, there are several 
aspects of the atherosclerotic process that deserve further investigation. The analysis of laser 
captured microdissections by proteomics is still in its infancy but it could reveal valuable 
topological differences between specific areas of such a heterogeneous environment. 
Atherosclerotic plaques are characterized by the presence of an imbalance between oxidant 
and antioxidant species toward the former, leading to deep protein modifications. In this 
respect, recent advances in protein post-translational modifications analysis by mass 
spectrometry could be helpful. To date, many studies have been performed on proteome of 
purified plasma lipoproteins focusing mainly on HDL and LDL due to their association with 
atherosclerosis. As far as we know, no proteomic analyses have been performed on Lp(a). 
Since it is well known that elevated Lp(a) plasma levels are an important risk factor in 
atherogenesis, it would be of great interest to elucidate its apolipoprotein composition in 
relation to cardiovascular diseases. Another promising topic for future investigations is the 
characterization of proteomes of lipoproteins retained in atherosclerotic plaque. Finally, 
besides the great deal of work to be done in the future in both improving proteomic 
technologies and providing clues for the many aspects not yet investigated, it will also be 
necessary to put efforts on a comprehensive analysis of the huge quantity of data provided 
by the several proteomic studies. 
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1. Introduction 
Lung cancer is one of the most common cancers in the world (Chiang et al., 2010; Landis et 
al., 1998). Surgical removal of the tumor mass offers the best chance for a cure in patients 
with non-small-cell lung cancer. A tumor in stages I (confined to the lung without nodal or 
distant metastasis), II (involvement of only lymph nodes within the lung), and IIIA 
(involvement of nodes on the same side as the tumor) is considered potentially resectable 
for cure (Martini et al., 1995). 
Based on tumor size and location, lung surgery is mainly divided into three types: wedge 
resection (removal of a small area in one lobe of either right or left lung), lobectomy 
(removal of one lobe from a right or left lung), and pneumonectomy (removal of an entire 
right or left lung). The mortality rate is much higher after pneumonectomy (61%) than 
lobectomy (35%) (Gunluoglu et al., 2011). Among the post-surgical factors, aberrant local 
inflammation and abnormal fluid drainage are the most common for inducing pulmonary 
edema. Excessive accumulation of fluid in the alveoli causes lung injury and hinders 
functional recovery. A severe form of acute lung injury results in acute respiratory distress 
syndrome. Sudden and life-threatening lung failure is the most detrimental factor in post-
surgical mortality (Jordan et al., 2000).  
With the progression from lung injury to acute respiratory distress syndrome, 
proinflammatory cytokines are increased, such as interleukin-1β (Donnelly et al., 1996; 
Geiser et al., 2001) and tumor necrosis factor-α (Tremblay et al., 2002). However, the 
production of vascular endothelial growth factor is reduced in the early stage but not 
altered in the late stage (Medfor & Millar, 2006). Interleukin-1β and tumor necrosis factor-
α are further elevated in the sustained phase (Bhatia & Moochhala, 2004). The increases in 
proinflammatory cytokines are not correlated with injury-induced mortality (Donnelly et 
al., 1996). Corticosteroid which alters host inflammatory responses do not show beneficial 
effects in the early stage of acute respiratory distress syndrome (Kollef et al., 1995). 
Current reviews suggest that activation of inflammation-independent pathways in the 
early stage and inflammation-dependent pathways in the late stage contribute to the 
development of acute respiratory distress syndrome (Spragg et al., 2010; Bhatia & 
Moochhala, 2004).  
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To effectively reduce post-surgical mortality, early detection of acute respiratory distress 
syndrome may provide in-depth information for the design of management plans, including 
non-pharmacological therapies (Villar et al., 2011).  
2. Proteomic analysis of bronchoalveolar lavage fluid in biomarker studies 
To effectively identify the biomarkers of various lung diseases, bronchoalveolar lavage fluid 
from the lower airways and alveoli is collected for genomic or cytological analysis of cellular 
components (Meyer, 2007). This lung-specific fluid can be used for protein analysis. 
Identification of the non-cellular components in bronchoalveolar lavage fluid may provide 
valuable data for the early detection of acute lung injury.  
2.1 Current advances in proteomic analysis of bronchoalveolar lavage fluid 
In the past decades, over 100 human proteins or protein isoforms have been identified in 
bronchoalveolar lavage fluid from patients with various lung diseases (Wattiez et al., 
1999; Lenz et al., 1993; Sadaghdar et al., 1992; Sabounchi-Schütt et al., 2001; Vesterberg et 
al., 2001). The major challenge today is to identify the lead proteins and validate the 
potential biomarkers (Turtoi et al., 2011a). To overcome this difficulty, integration of 
clinical studies with proteomic analysis of bronchoalveolar fluid is a potential solution 
(Turtoi et al., 2011b).   
2.2 Sampling concern in proteomic analysis of bronchoalveolar lavage fluid 
In clinical proteomics, the most difficult challenge before sample analysis is patient selection 
and sample collection (Apweiler et al., 2009). In the case of lung cancer patients, the major 
concern is to collect bronchoalveolar lavage fluid from those who may develop post-surgical 
lung edema. Although both bronchoalveolar lavage fluid and bronchial washings are 
collected using similar procedures, the former is collected from terminal alveoli after 
instilling more than 140 ml of sterile saline and the latter is collected from major airways 
after instilling less than 140 ml of saline. Because of the concern that excessive fluid 
accumulation may cause the complication of lung edema, bronchial washing is a better 
choice for conducting clinical proteomics. 
2.3 Technical limitations in proteomic analysis of bronchoalveolar lavage fluid  
In conventional proteomic analysis, two-dimensional gel electrophoresis provides good 
protein separation. However, it restricts the discovery of proteins with extreme 
biochemical properties such as size, isoelectric point, and solubility (Rabilloud, 2002). In 
comparison, one-dimensional gel electrophoresis provides easy comparison of banding 
patterns in protein profiling but is less efficient in protein separation. Moreover, the high 
salt concentration in the bronchoalveolar lavage fluid interferes with the resolution of 
protein separation to a lesser extent in one-dimensional gel electrophoresis (Plymoth, 
2003).  
2.4 Application of 1D gel with liquid chromatography and MS/MS in biomarker 
discovery 
The rapid development of LC/MS/MS offers a better solution to one-dimensional gel 
electrophoresis (Schirle et al., 2003). A similar approach has been used to discover proteins 
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with molecular weight greater than 100 kDa (such as α2-macroglobulin). The discovery of 
hundreds of proteins in bronchoalveolar lavage fluid demonstrates its feasibility in 
biomarker identification (Wu et al., 2005; Chang et al., 2007).  
2.5 Sensitivity and specificity of the lead proteins after proteomic analysis 
To accelerate the translation of biomarker discovery from bench to bedside, the 
development of techniques has been divided into 5 stages (Pepe et al., 2001). In Phase 1, 
potential biomarkers are discovered by various approaches, such as proteomic analysis. 
After the leads are identified by biochemical studies, measurable classifiers or outcomes are 
developed in Phase 2. Based on the analysis of their specificity and sensitivity, the cutoff 
point of the measurable outcome is determined and used in Phase 3. Based on patient 
history and clinical data, the number and nature of clinical cases is well defined in Phase 3. 
Suitable criteria for a clinical trial are determined in Phase 4. Phase 5 is a randomized trial to 
compare the specificity and sensitivity of the leads with those of current biomarkers in the 
market. 
Today, the importance of sensitivity and specificity in biomarker selection has shifted 
proteomic studies from large-scale analysis to clinically-relevant validation. In addition to 
large-scale analysis in protein or metabolite identification (Mou et al., 2011; Huang et al., 
2011), the leads are selected based on their sensitivity and specificity.  
3. Translational study from protein identification to clinical application 
The purpose of this study was to discover potential biomarkers for the early detection of 
acute respiratory distress syndrome. To avoid sampling-induced complications, bronchial 
washings from lung cancer patients before and after surgical therapy (lobectomy) were 
collected. To reduce population heterogeneity, cancer stage, hormonal variation, and tumor 
location were well-defined. Only patients older than 60 years, had right lung cancer at 
stages IA and IB, and agreed to receive right lung lobectomy were recruited.  
Those patients who met the inclusion and exclusion criteria were selected as controls. The 
inclusion criteria were: defined cancer in any lobe of the right lung, non-smoker, age ≥60 
years, elective operation, operation period <210 min, forced expiratory volume in 1 s (FEV1) 
>80%, and no prior major lung resection or thoracic irradiation. Exclusion criteria were: age 
<60 years, operation period >210 min, FEV1 <60%, emergency or urgent operation, and 
prior major lung resection or distant thoracic irradiation. Based on our criteria, 7 patients (5 
females and 2 males with ages ranging between 61 and 77 years) were included as controls. 
A review was conducted from the medical records and prospective database. The study 
protocol was approved by the Human Medical Studies Committee at National Cheng Kung 
University Medical College Hospital. Informed consent was given by all participants or their 
legal guardians .  
Prior to a large-scale analysis of proteins in bronchial washings, the protein profiles of 
washings from different compartments of the lungs before and after lobectomy were 
compared. In the right lung where tumor tissues were identified, no clear bands at 
molecular weights >75 kDa were found in washings collected before or after lobectomy. In 
the left lung, no clear bands at molecular weights >75 kDa were found in the washings 
collected before lobectomy. After lobectomy, more bands at molecular weights >75 kDa 
were found. The intensity of each band was much greater (Fig. 1). Similar patterns were 
found in all samples studied.  
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To effectively reduce post-surgical mortality, early detection of acute respiratory distress 
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Fig. 1. Protein profiling of bronchial washes from right (RL) and left lungs (LL) from 
patients before (Pre-Op) and after (Post-Op) right lung lobectomy. Bovine serum albumin 
(BSA) was used a positive control because albumin was identified in various bands. 
The banding pattern allowed us to hypothesize that the proteins at molecular weights >75 
kDa are exuded into alveoli after surgery. One-dimensional gel electrophoresis coupled with 
LC/MS/MS allowed us to identify the proteins in 13 major bands. As listed in Table 1, 8 
proteins had molecular weights >100 kDa, including α2-macroglobulin.  
To test our hypothesis that protein exudation is surgery-dependent, the relative abundance 
of α1-antitrypsin (47 kDa) and α2-macroglobulin (162 kDa) in bronchial washings was 
measured by Western blot analysis. α1-antitrypsin was found in washings collected before 
and after lobectomy (data not shown) but α2-macroglobulin was only found after lobectomy 
(Fig. 2).  
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1 28780 apo-B100 precursor  516.384 6 2% 285 
2 1174412 spectrin α chain, erythrocyte  280.904 5 3% 257 
3 134798 spectrin β chain, erythrocyte  247.040 7 4% 291 
4 179674 complement component C4A 194.365 5 4% 216 
5 4557385 complement component 3 precursor 188.612 8 7% 451 
6 224053 α2-macroglobulin  162.096 2 1% 86 
7 4557485 ceruloplasmin (ferroxidase) 122.998 2 2% 91 
8 1483187 inter-α-trypsin inhibitor family 
heavy chain-related protein (IHRP) 
103.553 2 2% 82 
9 4507021 solute carrier family 4, anion 
exchanger, member 1 
102.017 3 4% 213 
10 6005942 valosin-containing protein  89.962 4 9% 130 
11 28592 serum albumin  71.351 12 19% 615 
12 3287489 hsp89-α-δ-N 63.850 2 5% 85 
13 4504489 histidine-rich glycoprotein 
precursor 
60.527 2 4% 69 
14 553788 transferrin 55.233 4 10% 177 
15 69990 α1-glycoprotein 52.488 2 6% 84 
16 386789 hemopexin precursor 52.266 2 2% 81 
17 38408 immunoglobulin M heavy chain 50.135 3 9% 112 
18 229601 Ig G1 H Nie 49.812 3 12% 127 
19 177827 α1-antitrypsin 46.790 2 7% 67 
20 10334547 immunoglobulin heavy chain 42.319 2 8% 57 
21 123510 haptoglobin-related protein 
precursor 
39.505 2 6% 114 
22 121039 Ig gamma-1 chain C region 36.605 3 14% 118 
23 121043 Ig gamma-2 chain C region 36.500 2 11% 55 
24 183817 β-globin 19.209 4 33% 221 
25 442753 Chain D, Hemoglobin Ypsilanti 16.021 5 50% 206 
Table 1. Proteins identified in bronchial washings from the left lung of a patient receiving 
right lung lobectomy. 
3.1 Vascular endothelial growth factor and lobectomy-induced inflammation 
Since vascular endothelial growth factor is a potent inducer of vascular permeability (Lee, 
2005) and its expression is positively correlated with inflammation-induced protein 
exudation and leukocyte infiltration (Chang et al., 2005), it is plausible to suggest that an 
increase in vascular endothelial growth factor is associated with surgery-induced protein 
exudation and leukocyte infiltration.  
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3.1 Vascular endothelial growth factor and lobectomy-induced inflammation 
Since vascular endothelial growth factor is a potent inducer of vascular permeability (Lee, 
2005) and its expression is positively correlated with inflammation-induced protein 
exudation and leukocyte infiltration (Chang et al., 2005), it is plausible to suggest that an 
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As shown in Table 2, the vascular endothelial growth factor level was positively correlated 
with total protein concentration (y = 0.0025x + 1.0755, R2 = 0.7359, P <0.05) and cell count  
(y = 0.0696x - 0.6441, R2 = 0.8463, P <0.05) but not with operation duration or PaO2/FiO2. The 
correlation analysis supported the hypothesis that the induction of vascular endothelial 














1 152 270.167 2.5 0.641 162.80 
2 191 202.500 67.0 3.412 613.68 
3 234 435.000 100.0 4.826 1517.40 
4 160 220.800 22.5 1.737 89.95 
5 196 336.000 3.5 2.462 99.79 
6 140 338.333 0.5 0.660 109.64 
7 221 505.600 5.0 1.302 359.69 
PaO2: arterial partial pressure of oxygen; FiO2: inspired oxygen fraction; PaO2/FiO2: oxygenation index 
Table 2. Clinical data of 7 patients who received right lung lobectomy without complications  
3.2 α2-macroglobulin and α1- antitrypsin in lobectomy-induced inflammation 
The relative expression of α2-macroglobulin at bands 2, 4, and 5 from bronchial washings 
was correlated with protein concentration, leukocyte number, and the level of vascular 




Fig. 3. Correlation analysis of α2-macroglobulin and VEGF/total cells in bronchial washings. 
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Likewise, the relative expression of α1-antitrypsin at bands 5, 7, and 8 from bronchial 
washing was positively correlated with protein concentration, leukocyte number, and the 
level of vascular endothelial growth factor (data not shown). These data supported our 
hypothesis that the increase of vascular endothelial growth factor after surgery facilitates 
leukocyte infiltration and the exudation of acute-phase proteins (such as α1-antitrypsin and 
α2-macroglobulin) into alveoli.  
3.3 Characterization of α2-macroglobulin and α1-antitrypsin in lobectomized patients 
with acute respiratory distress syndrome  
Based on the report of the joint American–European Consensus Conference, the acute 
respiratory distress syndrome is well defined as follows: bilateral infiltrates on frontal chest 
radiography, the absence of left atrial hypertension (pulmonary capillary wedge pressure 
<18 mmHg or no clinical signs of left ventricular failure), and severe hypoxemia with a 
PaO2/FiO2 ratio <200 mmHg (Bernard et al., 1994). Five patients who received lung surgery 
and met these criteria were studied.  
3.3.1 Characterization of patients with acute respiratory distress syndrome 
The group with lobectomy free of complications had levels of total protein and total 
leukocyte numbers in their bronchial washings similar to those who developed acute 
respiratory distress syndrome (P >0.05, Fig. 4). These data indicate that lung surgery induces 
inflammation (leukocyte infiltration and protein exudation) in the groups with and without 
the complication of acute respiratory distress syndrome. So, factors other than inflammation 







































*Significant difference from pre-op. 
Fig. 4. Total leukocyte number and protein concentration in patients before (pre-op) and 
after lobectomy (post-op) with no complication and those with acute respiratory distress 
syndrome (ARDS).  
In lung cancer patients, an increase of vascular endothelial growth factor is positively 
associated with poor prognosis (P = 0.018; Han et al., 2001) but not with a worse 
postoperative year-survival rate (P = 0.0643; Liao et al., 2001). These reports are also 
consistent with our finding that the increase of vascular endothelial growth factor after lung 
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3.3.2 Protein profiling of bronchial washings from lobectomized patients with acute 
respiratory distress syndrome 
Unlike patients with no complications, those with acute respiratory distress syndrome 
showed white or gray patches on the chest X-ray. In one-dimensional gel electrophoresis, 
the protein profiling of bronchial washings from patients without complications showed a 
much clearer banding pattern than those from patients with acute respiratory distress 
syndrome (Fig. 5). Eight bands from each gel were cut and subjected to LC/MS/MS for 
protein identification. No protein was identified in Lane 1. The most significant difference 
was that albumin appeared in almost every band of the samples from patients without 
complications but not in those with acute respiratory distress syndrome. In contrast, α1-
antitrypsin was identified only in bands 6 and 7 from the group without complications but 




Fig. 5. Comparison of chest X-rays and protein profiling of bronchial washings in 
lobectomized patients with no complications (lobectomy, Lob) and those with acute 
respiratory distress syndrome (ARDS).  
3.3.3 α2-macroglobulin and α1-antitrypsin in bronchial washings from lobectomized 
patients with acute respiratory distress syndrome 
As shown in Fig. 6, both α2-macroglobulin and α1-antitrypsin were detected in bronchial 
washings after surgery.  
After quantification, the total amounts of α2-macroglobulin at bands 2, 4, and 5 and α1-
antitrypsin at bands 5, 7, and 8 did not show any statistical difference between the groups 
with and without complications. The most important finding was lower levels of α1-
antytrypsin at bands 7 and 8 in the group without complications than the acute respiratory 
distress syndrome group (Fig. 6). It is likely that α1-antitrypsin variants at bands 5, 7, and 8 
can be used as biomarkers for the early detection of acute respiratory distress syndrome. 
In bronchial washings collected from the patients with acute respiratory distress syndrome, 
leukocyte number was not correlated with the total amounts of α2-macroglobulin or α1-
antitrypsin. Our analyses again supported the notion that surgery-induced inflammation is 
not an important indicator in the early phase of acute respiratory distress syndrome. 
It has been reported that α1-antitrypsin can be produced by lung epithelial cells (Venember 
et al., 1994) but α2-macroglobulin cannot. Our preliminary data confirmed the expression of  
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Fig. 6. Relative expression of α1-antitrypsin and α2-macroglobulin (macroglobulin) in the 
lobectomized group without complications (lobectomy) and in the group with acute 
respiratory distress syndrome (ARDS). 
α1-antitrypsin in A549, a lung epithelial cell line. The changes in α1-antitrypsin variants 
could be due to functional changes in lung epithelial cells. 
3.4 Specificity and sensitivity of α1-antitrypsin variants as potential biomarkers for 
acute respiratory distress syndrome 
It is of importance to turn the relative expression of α1-antitrypsin in bronchial washings 
into a measurable outcome because only the measurable outcome is used to determine the 
cutoff value. Based on the cutoff value, sensitivity (the proportion of subjects who test 
positive among those with the condition) and specificity (the proportion of subjects who test 
negative among those without the condition) can be calculated.  
As shown in Fig. 6, α1-antitrypsin variants at bands 7 (47 kDa) and 8 (40 kDa) had a lower 
abundance in the group without complications than the group with acute respiratory 
syndrome. To avoid variations in sample loading and the intensity in each calculation, the 
ratio of the expression of α1-antitrypsin at band 5 (70 kDa) to that at bands 7 and 8 was used 
as the measurable outcome. Based on this calculation, the cutoff value was 0.5. A ratio <0.5 
was considered an indication of acute respiratory distress syndrome.  
Table 3 shows the ratio for each patient from the complication-free group. Four out of 7 
patients had a ratio <0.5. The specificity of α1-antitrypsin for true negative patients was 0.43 
(3/7).  
Table 4 shows the ratio for each patient from the complication group. Three out of 5 patients 
had a ratio <0.5. The sensitivity of α1-antitrypsin for true positive patients was 0.6 (3/5). 
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Ratio of expression of α1-antitrypsin at band  
5 to that at bands 7 and 8 
Cutoff value = 0.5 
1 0.000: 0.027 <0.5 
2 0.043: 0.099 <0.5 
3 0.019: 0.024 >0.5 
4 0.017: 0.023 >0.5 
5 0.018: 0.087 <0.5 
6 0.000: 0.006 <0.5 
7 0.042: 0.053 >0.5 
 
Table 3. Ratio of the expression of α1-antitrypsin at band 5 to that at bands 7 and 8 in the 
lobectomized patients without acute respiratory distress syndrome.  
 
Patient No Ratio of expression of α1-antitrypsin at band  
5 to that at bands 7 and 8 
Cutoff value = 0.5 
A 0.081: 0.177 <0.5 
B 0.043: 0.199 <0.5 
C 0.081: 0.086 >0.5 
D 0.015: 0.040 <0.5 
E 0.025: 0.048 >0.5 
 
Table 4. Ratio of the expression of α1-antitrypsin at band 5 to that at bands 7 and 8 in 
lobectomized patients with acute respiratory distress syndrome.  
3.5 Further improvement of specificity and sensitivity for detecting acute respiratory 
distress syndrome using dual biomarkers 
As shown in Tables 3 and 4, the sensitivity of α1-antitrypsin variants for detecting acute 
respiratory distress syndrome (0.6) was better than the specificity (0.43). The major concern 
is how to optimize the cutoff value and improve the specificity. In table 3, patients 1 and 6 
with ratios <0.5 showed the lowest values in cell counts and protein concentration. 
Meanwhile, the expression of α2-macroglobulin was almost undetectable, which indicates 
minor inflammation in the patients. The lower ratio of relative expression of α1-antitrypsin 
at band 5 to that at bands 7 and 8 was false-positive. 
α1-antitrypsin was found in the lungs before and after surgery; α2-macroglobulin only 
occurred in the lungs after surgery. To avoid the lower levels of α1-antitrypsin variants 
which may create a false-positive result, α2-macroglobulin can be recruited as a second 
biomarker. The ratio of α1-antitrypsin variants was considered as a true result only when 
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the sample expressed detectable α2-macroglobulin in bronchial washings. Accordingly, the 
specificity for true negative patients changed to 0.71 (5/7). The prediction for true negatives 
was improved.  
4. From identification of leads to further validation using α2-macroglobulin 
and α1-antitrypsin variants as an example 
After the discovery of potential biomarkers by proteomic analysis in this study, the first 
challenge was to identify the leads from the proteins discovered after developing a quick 
screening test. After Phase 1, the second challenge was to provide clear justification to 
optimize the cutoff values.  
4.1 Contribution of this study to the discovery of biomarkers for detecting acute 
respiratory distress syndrome 
Ideally, quantitative proteomic analysis should be used to reveal lobectomy-induced 
changes of all proteins in bronchial washings. However, the unique compartment of the 
lung allowed us to analyze exudate components which may not exist before surgery, such as 
α2-macroglobulin. Based on the important mechanism of surgery-induced inflammation in 
the early phase of lung injury, one-dimensional gel electrophoresis in this study was an easy 
and suitable tool to identify α2-macroglobulin as an indicator of vascular endothelial growth 
factor-mediated permeability.  
The second contribution of this study was to take advantage of one-dimensional gel 
electrophoresis with pattern analysis to reveal the pattern changes of α1-antitrypsin between 
the groups with and without post-surgical complications. The difference found allowed us 
to identify α1-antytripsin variants as biomarkers for the early detection of acute respiratory 
distress syndrome.  
4.2 Limitations of this study 
In this study, α1-antitrypsin variants were considered as biomarkers for acute respiratory 
distress. No mechanistic data are provided to explain why and how the formation of α1- 
antitrypsin variants are related to the progression from surgery-induced inflammation to 
acute respiratory distress syndrome.  
The association between α1-antitrypsin variants and infection was first reported in 2010 
(Zhang et al., 2010). The decrease of the α1-antitrypsin variant at 130 kDa and the increase of 
the variant at 40 kDa is associated with human immunodeficiency virus-induced infection. 
Glycoproteomic analysis shows that changes in α1-antitrypsin variants may be due to a shift 
of glycosylation. In future, glycoproteomic analysis of α1-antitrypsin variants should be 
further explored.  
Although the analysis of their specificity and sensitivity, the cutoff point of the measurable 
outcome, and criteria for patient selection are clearly and easily determined, the small 
number of clinical cases in this study limits the generalization of α2-macroglobulin and α1-
antitrypsin as markers for acute respiratory distress syndrome. To use them as measurable 
biomarkers in Phase 3, it is necessary to increase the number and the complexity of clinical 
cases for further validation on whether the cutoff points determined are suitable for early 
diagnosis of acute respiratory distress syndrome.  
One-dimensional gel electrophoresis does not offer a good way for protein separation. 
Comparative proteomic analysis only compares the intensity of each spot. These two 
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approaches may our discovery of new proteins. The technology of stable isotope dimethyl 
labeling coupled with LC/MS/MS permits further quantification of specific peptides of each 
protein and provides a better quantification tool after one-dimensional electrophoresis (Huang 
et al., 2006). This approach then compensates for the limitation of one-dimensional gel 
electrophoresis. 
5. Conclusion 
Both inflammation -dependent and -independent mechanisms contribute to the progression 
from lung injury to acute respiratory distress syndrome. Stage-dependent changes in 
biomarkers allow us to monitor the progression of the diseases and develop new treatments 
in a stage-dependent manner.  
In this study, α2-macroglobulin and α1-antitrypsin were positively correlated with vascular 
endothelial growth factor, clearly showing lobectomy-induced inflammation. The total 
amount of α1-macroglobulin can be used as a biomarker of increased vascular permeability 
in the lung. The severity of lobectomy-induced inflammation is similar to that of 
inflammation in acute respiratory distress syndrome but respiratory function becomes much 
worse in patients with the syndrome. Concomitantly, the patients with acute respiratory 
distress syndrome had lower levels of α1-antitrypsin at higher molecular weights and 
higher levels of α1-antitrypsin at lower molecular weights. Similarly, human 
immunodeficiency virus-induced infection is associated with the decreased abundance of 
α1-antitrypsin at higher molecular weights and the increased abundance of α1-antitrypsin at 
lower molecular weights (Zhang et al., 2010). Because α1-antitrypsin exists in lung epithelial 
cells (Venember et al., 1994), the changes of α1-antitrypsin variants in the patients with acute 
respiratory distress may reflect lung epithelial damage.  
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1. Introduction 
Exosomes represent a distinct class of membrane nanovesicles of endocytic origin that are 
released to the extracellular microenvironment from diverse cell types under both 
physiological and pathological conditions. Remarkable roles of exosomes have been 
revealed in intercellular communication, immune regulation, infection, aging and cancer. 
Exosomes carry and transfer proteins, nucleic acids and lipids, and are ubiquitous in most 
biofluids, such as urine, plasma, cerebrospinal fluid, etc. Membrane vesicles secreted by the 
epithelial cells of the urinary tract hold the promise to be an excellent source of disease 
relevant cargo proteins. In clinical proteomics urine is one of the most attractive biofluids as 
it can be obtained non-invasively, in large quantities and is relatively stable. Current 
isolation methods however are not sufficiently proficient to produce urinary exosomes 
(UEs) at a purity grade and with reproducibility suitable for downstream LC-MS based 
quantitative proteomics applications. Consequently urinary exosome based protein 
biomarker research today exclusively relies on targeted protein studies (Table 1). 
This chapter describes the current state-of-the-art in exosome research in general and 
urinary exosomes in particular with a special focus on the potential of UEs in protein 
biomarker discovery. Recently we have developed an improved isolation/purification 
method based on double-cushion sucrose/D2O ultracentrifugation (Raj et al., 2011b). The 
method relies on the solubilization of the major impurities associated with UEs in a carefully 
selected buffer solution. The new method separates exosomes from the heavier membrane 
fragments and/or vesicles more efficiently than current protocols and is compatible with 
LC-MS-based quantitative proteomics workflow. 
2. Cell-derived exosomes: Biogenesis, composition and biological role 
Cells rely on two basic mechanisms for active, vesicle-mediated macromolecular transport 
through the cellular plasma membrane: exocytosis and endocytosis (Figure 1). Both make 
use of membrane vesicles for the packaging and trafficking of molecules. While endocytosis 
is the process in which the extracellular substances enter into a cell without directly passing 
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through the cell membrane, exocytosis is the primary means of cellular secretion. During 
both constitutive and regulated exocytosis the secretory-vesicles dock and/or fuse with the 
plasma membrane. Endocytic pathway (EP), which is primarily responsible for the uptake, 
trafficking and sorting of internalized proteins has a role in vesicle secretion too (Thery et 
al., 2002). In the EP, transmembrane proteins are sorted into lumenal vesicles of 
multivesicular bodies (MVBs). MVBs can have different destinies: they can fuse or mature 
with lysosomes where the degradation of their protein cargo takes place, or can fuse with 
the cell membrane to secrete the intraluminal vesicles (ILVs) into the extracellular space. 
These extracellularly released ILVs are called exosomes (Gruenberg et al., 2004, Keller et al., 
2006). During this process, the second inward budding of the endosome membrane results 
in a positive orientation of the ILVs lipid membrane. Thus when the ILVs are released to the 
extracellular environment, they have the same orientation as the cell membrane and have 
been shown to display many of the surface markers from their cell of origin (Thery et al., 
2002). The sorting process of membrane proteins during ILV formation is considered to be 
an active process and thus, exosomal surface proteins seem not to be a plain one-to-one 
representation of the surface markers for the cell of origin. 
While the regulation of endocytic cargo sorting and its delivery to lysosomes have been 
extensively studied (Williams et al., 2007) relatively less is known about the factors which 
regulate the formation, the release and the cargo sorting into vesicles destined to be 
exosomes. The involvement of ubiquitinization and ESCRT (endosomal sorting complex 
required for transport) protein complexes have been shown by different groups (Gan et al., 
2011, Shen et al., 2011). Though, ESCRT-independent mechanisms by means of ceramide-
mediated budding of exosomes into ILVs within the MVBs have also been identified (Marsh 
et al., 2008, Trajkovic et al., 2008). Further evidence of ESCRT-independent pathway of ILV 
formation has come from studying the protein Pmel17, a main component of the c fibrils of 
pre-melanosomes, which is targeted to intraluminal vesicles of MVBs independently of 
ubiquitination, ESCRT0 and ESCRTI (Raposo et al., 2001). The most recent model on the 
formation of ILVs combines the lipid-driven membrane deformation theory with the 
ESCRT-regulated sorting mechanism (Babst, 2011). 
Microvesicles (MVs) are generated by the outward budding and fission of membrane 
vesicles from the cell surface (Fig. 1) (Lee et al., 2011). MVs (100–1000 nm) are generally 
bigger in size than exosomes (30-100 nm). Yet due to the analytical difficulties in 
distinguishing between exosomes and MVs, which are also shed by normal and diseased 
cells, they are often grouped together. 
Many mammalian cells like dendritic, mast, epithelial, neural, stem and hematopoietic cells, 
reticulocytes, astrocytes, adipocytes, and tumor cells have been reported to release exosomes 
(Denzer et al., 2000, van Niel et al., 2006). Exosomes purified from the cell culture 
supernatants are usually heterogeneous in size and contain functional mRNA translatable to 
proteins, mature microRNAs, lipids and proteins. Proteins of exosomes have been analyzed 
both by proteomics and targeted immunochemical methods, like Western-blot, FACS with 
immunolabeling, and immunoelectron microscopy. Protein composition analysis of exosomes 
shows a rather limited sub-cellular localization for the exosomal proteins. In fact, usually the 
preparations of exosomes are mostly enriched in cytosolic and membrane proteins and 
contain less proteins of nuclear, mitochondrial, endoplasmic-reticulum or Golgi-apparatus 
origin. Secondly, exosomes express a common set of proteins. These are structural 
components and proteins with a role in exosome biogenesis and trafficking. Cell type  
specific components which presumably reflect the biological function of the parent cell on  
 




Fig. 1. Schematic representation of extracellular vesicles biogenesis. The formation, release 
and cargo sorting into vesicles destined to be exosomes may involve: i) ESCRT dependent 
pathway – involving the ubiquitination and ESCRT protein complexes and ii) ESCRT –
independent pathway – like ceramide mediated budding. Microvesicles, membrane 
particles and exosome like vesicles are secreted by outward budding or fission from the cell 
surface. 
the other hand could also be identified in exosome preparations (van Niel et al., 2006). 
Protein contents of exosomes from different cells have been mapped by proteomics and the 
most of the data obtained has been catalogued in Exocarta database (Mathivanan et al., 
2009). 
Despite their role in immune system modulation (Li et al., 2006), the biological role of 
exosome secretion remained largely elusive until recent years when Lötvall’s group 
demonstrated that exosomes can transfer genetic information from one cell to another 
(Valadi et al., 2007, Taylor, 2010). Since then several mechanisms have been proposed to 
describe exosome-cell interactions: (i) cellular binding via conventional receptor–ligand 
interactions, similar to cell–cell communication. (ii) attaching/fusing with target cell 
membrane and (iii) internalization by recipient cells by endocytosis in a transcytotic manner. 
Besides the physiological roles of exosomes to remove the unwanted cellular debris, recent 
findings uncover an entirely new and exciting modes of cell–cell communication and 
paracrine signalling mediated by exosomes (Thery et al., 2002, Camussi et al., 2011). 
Emerging data shows their involvement in different diseases including inflammation, renal 
diseases, Alzheimer diseases, aging, bacterial and viral infections, allergies and cancer. 
Using different sources of tumor-derived exosomes, several groups claim that exosomes can 
prevent tumor development, induce tumor specific immunity, and provide a possible 
strategy for therapeutic tumor vaccination reviewed by van Niel et al. (van Niel et al., 2006). 
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3. Urinary exosomes 
3.1 mRNA, miRNA and protein biomarkers in urinary exosomes 
Urinary exosomes originate from those ILVs that are shed into the urinary space by the 
fusion of the outer membrane of MVBs with the apical plasma membrane of cells lining 
the urinary tract, including glomerular podocytes, renal tubule cells, and bladder. The 
number, and the physical, chemical and biological properties of UEs may change over 
time in association with disorders that affect the urinary system. Respect to the total urine 
sample, UEs result in a remarkable enrichment of low-abundance biomolecules with 
potentially high diagnostic value regarding the physiological and pathological state of the 
renal system. Therefore, it is not surprising that there is a great interest in the use of UEs 
as a novel biomarker source for early disease detection, classification, prediction severity, 
outcome and response to treatment. Since the first publication on proteomic profiling of 
UEs by the group of Knepper (Pisitkun et al., 2004), an increasing number of articles with 
keywords “exosome and urine” are to be found in the PubMed database. The principal 




AKI - acute kidney injury 
FSGS - focal segmental glomerulosclerosis 
BC - bladder cancer 
PC - prostate cancer 
I/R - renal ischemia/reperfusion 
GKD - glomural kidney disease 
NSCL – non-small cell lung cancer 
Table 1. Different isolation/purification, protein separation, identification and quantitation 
methods used in urinary exosome related targeted protein biomarker studies. 
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mRNA transcripts encoding specific genes from various regions of the nephron, the 
collecting duct, the prostate and the bladder have been isolated from urinary exosome 
preparations (Miranda et al., 2010, Keller et al., 2011). Interestingly, RNA of UEs was found 
to be protected from RNase degradation which may suggest a functional role for the nucleic 
acids present in exosome (Keller et al., 2011). In the mRNA sample isolated from the urinary 
exosomes of prostate cancer patients PCA-3 and TMPRSS2:ERG, two known prostate cancer 
related biomarkers were detected (Nilsson et al., 2009). Urinary exosomes seem to be 
particularly rich in miRNAs too. The use of miRNA as diagnostic biomarkers in exosome 
research is an emerging field due to important potential advantages over standard mRNA 
(Li et al., 2010). 
There are over a thousand proteins identified from UE preparations published in the 
Exocarta (Mathivanan et al., 2009) and the Urinary Exosome Protein Database (Pisitkun et 
al., 2004) including the six exosome markers commonly used in exosome research (Alix, 
Tsg101, CD63, CD9, CD81, HSP70). Proteins of UEs show a different profile from that of 
total urinary proteins but with a high degree of overlap. UEs are enriched in membrane and 
cytosolic cargo proteins from the different epithelial cells lining the urinary tract (Pisitkun et 
al., 2004, Gonzales et al., 2009). For clinical biomarker discovery, LC-MS based large-scale 
quantitative proteomic analysis would be the method of choice. However, at the urinary 
exosome level it is still a daunting task (Gonzales et al., 2008, Mitchell et al., 2009, Keller et 
al., 2011). Therefore, protein quantitation and expression analysis has mainly been 
performed by targeted studies like antibody-based Western blot analysis (Table 1). For this 
reason only a few protein biomarker candidates have so far been identified in UEs. 
3.2 Isolation and purification 
Protocols for collection, storage and processing of human urine for exosome isolation and 
protein characterization have recently been published (Zhou et al., 2006b). Concerning the 
isolation of UEs, current methods rely on ultracentrifugation or filtration, or the 
combination of these two. The majority of the studies use a two-step differential 
centrifugation protocol developed by Pisitkun et al (Pisitkun et al., 2004). The initial step is a 
low velocity sequential centrifugation which serves to remove cells and cellular debris 
(urinary sediment) from urine, leaving the exosomes in the supernatant. The second step is 
the ultracentrifugation for 1h to overnight of the supernatant at 100,000-200,000g velocity to 
sediment exosomes. The major short comings of this process are the high level of 
contamination from uromodulin (see later) and the lack of separation of exosomes from the 
other MVs and membrane particles. 
To obtain higher purity grade UEs, the crude preparation obtained by the two-step 
differential centrifugation method can be further processed using the sucrose gradient or 
the sucrose cushion centrifugation. Sucrose gradient centrifugation can be performed on 
linear or step gradients typically using sucrose concentrations between 2.0 M – 0.25 M 
(Keller et al., 2007, Hogan et al., 2009, Simpson et al., 2009, Mathivanan et al., 2010). 
Instead of gradient, a small density cushion typically composed of 30% sucrose in 
deuterium oxide (D2O), can also be employed for the purification of UEs (Mitchell et al., 
2009, Simpson et al., 2009, Welton et al., 2010). In the sucrose cushion, formation of a mini 
density gradient takes place in the range of 1.10-1.18 g/cm3. This range was shown to be 
suitable to enrich and purify exosomes preventing vesicle aggregation that pelleting could 
cause. Sucrose gradient and cushion centrifugations thus allow a better separation of 
exosomes from the vesicles of different densities respect to the differential centrifugation 
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3. Urinary exosomes 
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keywords “exosome and urine” are to be found in the PubMed database. The principal 




AKI - acute kidney injury 
FSGS - focal segmental glomerulosclerosis 
BC - bladder cancer 
PC - prostate cancer 
I/R - renal ischemia/reperfusion 
GKD - glomural kidney disease 
NSCL – non-small cell lung cancer 
Table 1. Different isolation/purification, protein separation, identification and quantitation 
methods used in urinary exosome related targeted protein biomarker studies. 
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mRNA transcripts encoding specific genes from various regions of the nephron, the 
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method, however it does not seem to eliminate the problem of the co-purifying 
uromodulin (Hogan et al., 2009). 
Filtration-based protocols generally use polyether sulfone nano-membranes in a spin 
concentrator to isolate urinary exosomes (Cheruvanky et al., 2007). The method is simple, 
fast and is capable to isolate UEs from small volumes of urine (0.5–10 mL). Therefore it is 
very promising, especially for mRNA and miRNA based exosome biomarker research. 
Drawbacks of this method for protein biomarker research are the low yield and the high 
level of contamination caused by urinary proteins binding to the filter. To overcome this, 
recently a low protein binding membrane (hydrophilized polyvinylidene difluoride) has 
been used to isolate urinary exosomes (Merchant et al., 2010). 
3.3 The uromodulin problem 
Current methods are characterized by a high and variable level of uromodulin contamination 
(Hogan et al., 2009, Fernandez-Llama et al., 2010, Rood et al., 2010). Uromodulin, also referred 
to as Tamm–Horsfall glycoprotein, is a major glycoprotein produced by kidney cells. 
Uromodulin assembles into intracellular filaments in urine (Porter et al., 1955, Schaeffer et al., 
2009). The filaments have an average width and length of 100 Ǻ and 2.5 µm, respectively and 
tend to form a three-dimensional matrix with pores as shown by electron microscopy (Porter 
et al., 1955). This filament network traps exosomes and prevents their efficient isolation and 
purification by traditional methods. The uromodulin problem is one of the bottle neck of UE 
protein research because it considerably reduces sample yield and reproducibility (Fernandez-
Llama et al., 2010). In order to facilitate the removal of high molecular weight aggregates 
recently, dithiothreitol (DTT) was applied to reduce the intermolecular disulfide bonds of 
uromodulin (Pisitkun et al., 2004, Fernandez-Llama et al., 2010). Treatment with DTT result in 
a higher yield of urinary exosomes. Notwithstanding it does not solve the problem efficiently. 
For this reason, urinary exosome samples prepared by the current methods are far from being 
ideal for quantitative proteomic analysis. 
4. Interfacing urinary exosome isolation/purification and lysis with 
quantitative proteomics for protein biomarker research 
Biomarkers support the diagnosis and medical management of various disorders. The 
remarkable progress made in proteomic technologies in the past decade have enabled 
researchers to consider designing studies to identify diagnostic and therapeutic biomarkers 
by analyzing complex proteome samples using unbiased mass spectrometry based methods. 
In urinary exosome research this has been hampered by the high and variable concentration 
of uromodulin causing low sample quantity, quality and low reproducibility. To meet the 
need of a global protein biomarker discovery platform we have set-up new protocols for the 
isolation/purification and also for the lysis and subsequent solubilization of membrane 
proteins. Paragraph 4.1 describes a novel urinary exosome preparation called double-
cushion ultracentrifugation method and paragraph 4.2 shows its compatibility with 
downstream analysis. 
We have employed a multiplex quantitative proteomics method, iTRAQ (isobaric Tagging 
for Relative and Absolute protein Quantification), in conjunction with multidimensional 
chromatography, followed by tandem mass spectrometry (MS/MS), to measure relative 
differences in the protein composition of urinary exosome samples (Figure 2). The aim of 
this work was to compare the protein content of UEs obtained by single- and double- 
 




Data normalisation and statistical analysis








































































































Fig. 2. Scheme of the MudPIT based 4-plex iTRAQ quantitative analysis comparing the 
double-cushion ultracentrifugation method with that of single-cushion. 
cushion ultracentrifugation methods. Simultaneously, we compared samples obtained from 
a single person with a pool of healthy volunteers divided into two age groups (25-50 years 
and 50-70 years) in order to study feasibility of analysis of single patient versus pooled 
samples in the discovery phase of protein biomarker research. 
4.1 A novel isolation/purification method based on uromodulin solubilization and 
double-cushion ultracentrifugation 
The urinary exosome isolation/purification method which we have recently developed (Raj 
et al., 2011b) employs a double-cushion ultracentrifugation step performed in a carefully 
chosen buffer solution. Respect to other ultracentrifugation based methods which generally 
use a PBS buffer (150 mM NaCl at pH 7.2) the novel method employs a solubilising buffer 
composed of 20 mM Tris at pH 8.6. We have found that Tris buffer efficiently solubilizes 
uromodulin aggregates, keeps uromodulin in solution and does not lyses exosomes. This is 
in accordance with a previous in vitro study on uromodulin solubility which underlines the 
importance of alkaline pH, low sodium and calcium concentrations and sample dilution to 
prevent the formation of uromodulin aggregates (Kobayashi et al., 2001). After solubilizing 
the pellet obtained in the differential ultracentrifugation step, double-cushion 
ultracentrifugation is performed. The double-cushion is made of sucrose 1 M and sucrose 2 
M prepared in 20 mM Tris pH 8.6 in D2O and subsequently under layered below the sample 
in the centrifuge tube. This step was found to considerably improve the separation of 
exosomes from the heavier vesicles and/or membrane fragments. 
4.2 Analysis of urinary vesicles at the various steps of isolation/purification 
Exosomes were purified from pooled urine samples of ten healthy donors and separated on 
4-12% gradient polyacrylamide gel then stained with colloidal Coomassie blue. SDS-PAGE 
analysis at the various phases of the isolation/purification process is shown in Figure 3. 
Total urinary protein profiles before (Figure 3.A, Lane 1) and after exosome depletion 
(Figure 3.A, Lane 2) do not markedly differ from each other and show the typical pattern of  
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a higher yield of urinary exosomes. Notwithstanding it does not solve the problem efficiently. 
For this reason, urinary exosome samples prepared by the current methods are far from being 
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quantitative proteomics for protein biomarker research 
Biomarkers support the diagnosis and medical management of various disorders. The 
remarkable progress made in proteomic technologies in the past decade have enabled 
researchers to consider designing studies to identify diagnostic and therapeutic biomarkers 
by analyzing complex proteome samples using unbiased mass spectrometry based methods. 
In urinary exosome research this has been hampered by the high and variable concentration 
of uromodulin causing low sample quantity, quality and low reproducibility. To meet the 
need of a global protein biomarker discovery platform we have set-up new protocols for the 
isolation/purification and also for the lysis and subsequent solubilization of membrane 
proteins. Paragraph 4.1 describes a novel urinary exosome preparation called double-
cushion ultracentrifugation method and paragraph 4.2 shows its compatibility with 
downstream analysis. 
We have employed a multiplex quantitative proteomics method, iTRAQ (isobaric Tagging 
for Relative and Absolute protein Quantification), in conjunction with multidimensional 
chromatography, followed by tandem mass spectrometry (MS/MS), to measure relative 
differences in the protein composition of urinary exosome samples (Figure 2). The aim of 
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cushion ultracentrifugation methods. Simultaneously, we compared samples obtained from 
a single person with a pool of healthy volunteers divided into two age groups (25-50 years 
and 50-70 years) in order to study feasibility of analysis of single patient versus pooled 
samples in the discovery phase of protein biomarker research. 
4.1 A novel isolation/purification method based on uromodulin solubilization and 
double-cushion ultracentrifugation 
The urinary exosome isolation/purification method which we have recently developed (Raj 
et al., 2011b) employs a double-cushion ultracentrifugation step performed in a carefully 
chosen buffer solution. Respect to other ultracentrifugation based methods which generally 
use a PBS buffer (150 mM NaCl at pH 7.2) the novel method employs a solubilising buffer 
composed of 20 mM Tris at pH 8.6. We have found that Tris buffer efficiently solubilizes 
uromodulin aggregates, keeps uromodulin in solution and does not lyses exosomes. This is 
in accordance with a previous in vitro study on uromodulin solubility which underlines the 
importance of alkaline pH, low sodium and calcium concentrations and sample dilution to 
prevent the formation of uromodulin aggregates (Kobayashi et al., 2001). After solubilizing 
the pellet obtained in the differential ultracentrifugation step, double-cushion 
ultracentrifugation is performed. The double-cushion is made of sucrose 1 M and sucrose 2 
M prepared in 20 mM Tris pH 8.6 in D2O and subsequently under layered below the sample 
in the centrifuge tube. This step was found to considerably improve the separation of 
exosomes from the heavier vesicles and/or membrane fragments. 
4.2 Analysis of urinary vesicles at the various steps of isolation/purification 
Exosomes were purified from pooled urine samples of ten healthy donors and separated on 
4-12% gradient polyacrylamide gel then stained with colloidal Coomassie blue. SDS-PAGE 
analysis at the various phases of the isolation/purification process is shown in Figure 3. 
Total urinary protein profiles before (Figure 3.A, Lane 1) and after exosome depletion 
(Figure 3.A, Lane 2) do not markedly differ from each other and show the typical pattern of  
 




Fig. 3. SDS PAGE analyses A) at the different stages of urinary exosome 
isolation/purification through the double-cushion (lanes 1-7) and the single-cushion (lane 9) 
methods and, B) of the 1 M and 2 M sucrose fractions obtained after the double-cushion 
ultracentrifugation method (major proteins identified by in-gel digestion proteomics are 
indicated next to the band). Lanes in Figure A as follow: 1- Total urine; 2- Exosome depleted 
urine; 3- Crude exosome fraction after differential centrifugation; 4- 15,000g pellet;  
5- 15,000g supernatant; 6- Purified exosomes (1 M sucrose fraction); 7- 2 M sucrose fraction; 
M- Protein molecular weight markers (kDa); 9- Urinary exosomes prepared by the single 
sucrose/D2O cushion method. Lanes in Figure B are as follow: 1- 1 M sucrose fraction and  
2- 2 M sucrose fraction and M- Protein molecular weight markers (kDa). 
the major urinary proteins, like albumin, various IgG chains, uromodulin etc. After the two-
step differential centrifugation the crude exosome pellet (Figure 3.A, lane 3) still contains a 
considerable amount of contaminating urinary proteins and in particular uromodulin at 85 
kDa. These are in part removed after the solubilization step by low-speed centrifugation 
(Figure 3.A, lane 4-5) and, in part by the double-cushion ultracentrifugation. The later yields 
two fractions: the 1 M sucrose fraction which contains the exosome vesicles (Figure 3.A, lane 
6) and the 2 M fraction which contains vesicles heavier than exosomes (Figure 3.A, lane 7). 
The efficiency of the uromodulin removal by the double-cushion sucrose ultracentrifugation 
methods can be appreciated by comparing the 1 M fraction (Figure 3.A, lane 6) with the 
crude exosome fraction (Figure 3.A, lane 3) and with the exosomes purified by the single-
cushion method (Figure 3.A, lane 9). In Figure 3.B SDS-PAGE image of the two vesicle 
containing fractions, 1 M (lane 1) and 2 M (lane 2) are shown together with the major 
proteins identified in the gel bands. It is of note that not only the protein pattern but also the 
proteins identified in the major SDS-PAGE bands were found to be different, indicating the 
presence of two different types of vesicles in the two fractions. Semenogelin 1 and 
semenogelin 2 and olfactomedin for example have previously been identified in 
prostasomes, i.e. the secretory particles in human seminal fluid (Utleg et al., 2003). Therefore 
it is plausible to presume that the 2 M sucrose fraction contains heavier vesicles, like urinary 
secreted prostasomes. 
 
Urinary Exosomes for Protein Biomarker Research 
 
57 
Western blot analysis was performed to monitor the enrichment in exosomes and the 
reproducibility of sample preparation by the double-cushion ultracentrifugation. Exosomal 
proteins were separated on 4-12% gradient SDS-PAGE and electro blotted to PVDF membrane. 
Blots were probed with antibodies against two known exosome markers Alix and TSG101, 
together with NKCC2 a renal sodium transporter known to be present in urinary exosomes 
(Figure 4.). The enrichment of exosomes is excellent in the samples prepared by the double-
cushion (Figure 4., lane 4-6) respect to the starting and exosome depleted urine samples 
(Figure 4., lane 2-3) and also to the sample prepared by the differential centrifugation method 
(Figure 4., lane 1). Importantly a very high degree of reproducibility was achieved in three 
independent urinary exosome preparations (Figure 4., lanes 4-6). 
 
 
Fig. 4. Western blot analysis of urinary exosomes prepared by two different methods. Lane 
1- Exosome purified by differential centrifugation; Lane 2- Total urine; Lane 3- Exosome 
depleted urine; Lane 4-6 – Exosomes purified in three independent experiments from 
pooled urine samples of ten healthy volunteers by the double-cushion method. 
Exosome-like vesicles isolated from culture supernatant are limited by a lipid bilayer and in 
literature often described as saucer- or cup-shaped particles. Urinary exosomes isolated by 
the double-cushion ultracentrifugation method have a similar morphology as single cell line 
derived exosomes. The transmission electron microscopy (TEM) image shows (Figure 5) that 
diameters of the vesicles purified in the 1 M fraction are between 30 and 80 nm. 
Interestingly, the shape of the exosomes appeared to be nearly spherical with only a few 
elongated or cup-shaped specimens. After the double-cushion ultracentrifugation the 
sample is basically free from the long uromodulin filaments known to contaminate UEs 
prepared by traditional methods. 
 
 
Fig. 5. Transmission electron microscopy image of urinary exosomes isolated and purified 
by the double-cushion ultracentrifugation method (1 M fraction). The image shows the 
typical morphology and size distribution of the vesicles. Frame shows the enlarged image 
(central) and the arrow shows a single vesicle enlarged on the right image. 
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5. Quantitative proteomics of urinary exosomes for protein biomarker 
discovery 
Recently, we have developed protocols for lysis, protein extraction and in-solution digestion 
of UEs for MudPIT application to quantitative proteomics (Raj et al., 2011a). For the 
solubilization of exosomal membrane proteins the use of an acid cleavable detergent was 
found to be particularly useful. In a preliminary study four exosomal protein samples were 
prepared in parallel (Table 2) according to single- (sample 4) and double-cushion protocols 
(sample 1) from a pooled urine sample of 20 healthy donors (male, age group 25-45 years). 
Effects of age (sample 2) and sample pooling (sample 3) on the protein expression were also 
monitored in the same experiment.  
 
Sample Age (years) Number of samples Exosome preparation method Label 
1 25-45 20 Double-cushion iTRAQ-114 
2 50-70 20 Double-cushion iTRAQ-115 
3 43 1 Double-cushion iTRAQ-116 
4 25-45 20 Single-cushion iTRAQ-117 
Table 2. Samples analysed by in-solution digestion based MudPIT proteomics and iTRAQ 
labeling. 
The 4-plex iTRAQ method (Ross et al., 2004) based on covalent labeling of the N-terminus 
and side-chain amines of peptides with four tags of varying mass was used for the protein 
quantitation (Figure 2.). 
Protein samples were denatured, reduced, alkylated, enzymatically digested by trypsin and 
then labeled according to the manufacturer’s protocol (iTRAQ reagent kit, Applied 
Biosystems). After iTRAQ labeling equal amounts of each sample (100 µg) were mixed, 
vacuum dried, detergent was acid cleaved and the resulting sample was desalted. The 
purified sample was then separated by two-dimensional HPLC. For strong cation-exchange 
(SCX) chromatography, in the first dimension, the following conditions were used: 95% 
solvent A (20% acetonitrile, 0.05% formic acid) and 5% solvent B (20% acetonitrile, 0.05% 
formic acid, 500mM KCl) for 3 min, solvent B ramped up to 90% in 40 min and maintained 
at 100% for 7 min. 47 fractions were collected between 0-55 min. Fractions were further 
separated in the second dimension on a reversed phase monolithic nano column using the 
following conditions: 95% solvent C (2% acetonitrile, 0.1% formic acid) and 5% solvent D 
(98% acetonitrile, 0.1% formic acid) for 5 min, ramp to 50% solvent D in 90 min and in 6 sec 
to 98% solvent D for 10 min. Eluting peptides were analyzed online by a QTOF type of 
tandem mass spectrometer (Qstar Elite) in an information dependent acquisition mode 
which facilitates both the protein identification and the multiplex quantitative analysis of 
the four samples. Tandem mass spectra were extracted and peak lists were generated by 
Analyst QS 2.0 software using the default parameters. Peak lists containing all acquired 
MS/MS spectra were searched against SwissProt 2010_09 (519348 sequences) database using 
Mascot Server (version 2.2) with trypsin specificity and allowing for up to one missed 
cleavage. iTRAQ at lysine residue and the N termini of the peptides and 
carbamidomethylation of cysteines were considered as fixed modifications whereas 
oxidations of methionine and iTRAQ at tyrosine residues were set as possible variable 
modifications. Mass tolerance was set to 50 ppm for precursor and to 0.1 Da for fragment 
ions, respectively. Low molecular mass reporter ions were used to relatively quantify the 
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peptides and the proteins from which they originate by Mascot iTRAQ 4-plex quantification 
method. Proteins which were quantified with a minimum of two unique peptides and 
p<0.05 significance threshold using MudPIT scoring have been considered. 
More than hundred proteins were quantified in the iTRAQ analysis. Table 3. shows the 
weighted median ratios of the first 25 proteins ranked by Mascot protein score. Expression 
level of the major proteins isolated and purified by the double-cushion method are different 
from those purified with the single-cushion protocol (Table 3., ratio 117/114). In particular, 
cytoskeletal proteins (cubulin, megalin, actin, cofillin, moesin, tubulin, etc.) seem to be less 
abundant in the sample. They may be due to heterogeneous constituents of the cytoskeleton 
filaments present in urine which co-purify with the UEs in traditional methods. On the other 
hand a marked enrichment was observed in proteins which are related to the VPS4 complex 
of ESCRT machinery (IST1, VPS4A, and VPS4B), its associated proteins (CHM2A, CHMP5,  
 
UniProt ID Protein Name Mascot 
score 
115/114 116/114 117/114 
AMPN_HUMAN Aminopeptidase 1315 0.845 1.306 0.237 
IST1_HUMAN IST1 homolog 656 1.037 0.706 0.406 
ACTB_HUMAN Actin, cytoplasmic 430 1.408 1.631 0.733 
DPEP1_HUMAN Dipeptidase 1 370 0.857 0.700 0.430 
VPS4A_HUMAN Vacuolar protein sorting-associated protein 4A 
350 1.150 0.742 0.473 
CHM2A_HUMAN Charged multivesicular body protein 2a 341 1.242 1.493 0.595 
UROM_HUMAN Uromodulin 282 0.958 0.578 22.450 
CHMP5_HUMAN Charged multivesicular body protein 5 279 1.082 0.569 0.161 
RS27A_HUMAN Ubiquitin-40S ribosomal protein S27a 275 1.051 0.764 0.445 
GGT1_HUMAN Gamma-glutamyltranspeptidase 267 0.840 1.045 0.342 
NEP_HUMAN Neprilysin 258 0.897 0.995 0.381 
EZRI_HUMAN Ezrin 254 1.245 1.093 0.776 
ANX11_HUMAN Annexin A11 252 1.393 0.435 0.601 
PSCA_HUMAN Prostate stem cell antigen 231 1.415 5.214 0.345 
HSP7C_HUMAN Heat shock cognate 71 kDa protein 208 1.186 0.990 0.428 
PDC6I_HUMAN Programmed cell death 6-interacting protein 
231 1.093 0.684 0.500 
CDC42_HUMAN Cell division control protein 42 homolog 208 1.044 1.773 0.190 
VPS4B_HUMAN Vacuolar protein sorting-associated protein 4B 
195 1.063 0.601 0.500 
CHM4B_HUMAN Charged multivesicular body protein 4b 181 1.308 0.923 0.559 
POTEF_HUMAN POTE ankyrin domain family member F 176 1.394 1.404 0.510 
DPP4_HUMAN Dipeptidyl peptidase 4 175 0.931 0.837 0.320 
AQP1_HUMAN Aquaporin-1 167 0.898 0.679 0.573 
THY1_HUMAN Thy-1 membrane glycoprotein 151 1.316 2.332 0.354 
MUC1_HUMAN Mucin-1 145 0.945 0.523 0.743 
PROM1_HUMAN Prominin-1 140 1.014 0.655 0.500 
Table 3. The weighted median ratios of the 25 top-ranking proteins in the MudPIT based 4-
plex iTRAQ experiment. 114, 115, 116 and 117 indicate sample-labeling by iTRAQ according 
to Table 2. 
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5. Quantitative proteomics of urinary exosomes for protein biomarker 
discovery 
Recently, we have developed protocols for lysis, protein extraction and in-solution digestion 
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(sample 1) from a pooled urine sample of 20 healthy donors (male, age group 25-45 years). 
Effects of age (sample 2) and sample pooling (sample 3) on the protein expression were also 
monitored in the same experiment.  
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to 98% solvent D for 10 min. Eluting peptides were analyzed online by a QTOF type of 
tandem mass spectrometer (Qstar Elite) in an information dependent acquisition mode 
which facilitates both the protein identification and the multiplex quantitative analysis of 
the four samples. Tandem mass spectra were extracted and peak lists were generated by 
Analyst QS 2.0 software using the default parameters. Peak lists containing all acquired 
MS/MS spectra were searched against SwissProt 2010_09 (519348 sequences) database using 
Mascot Server (version 2.2) with trypsin specificity and allowing for up to one missed 
cleavage. iTRAQ at lysine residue and the N termini of the peptides and 
carbamidomethylation of cysteines were considered as fixed modifications whereas 
oxidations of methionine and iTRAQ at tyrosine residues were set as possible variable 
modifications. Mass tolerance was set to 50 ppm for precursor and to 0.1 Da for fragment 
ions, respectively. Low molecular mass reporter ions were used to relatively quantify the 
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CHM4B) and proteins involved in the ubiquitination process (RS27A). The most abundant 
protein according to SDS-PAGE and MudPIT analyses is aminopeptidase (AMPN) known 
to reflect a periodicity in renal tubular function. Other proteins like AQP1, NEP, DPEP1 
and DPP4 also related to renal function were identified among the most abundant 
proteins. Based on statistical analysis of the data, more than a 2-fold change was 
considered to be significant. Data obtained confirms that the double-cushion method 
efficiently removes the major urinary protein contamination characteristic of the current 
purification methods (more than a 20-fold change). In different single-cushion 
preparations (data not shown) the relative protein quantities vary considerably respect to 
that of uromodulin (i.e. mean of the fold changes of all quantified proteins unless 
uromodulin/uromodulin fold change). This can be explained by the poor reproducibility 
and it causes considerable complications in protein quantification and normalization. 
Comparing the two different age-groups we analysed, no significant difference in the 
expression was found in the 25 top-ranking exosomal proteins (Table 3., ratio 115/114). 
The individual sample, on the other hand shows few characteristic differences when 
compared with the pooled samples (116/114). In our study, the expression levels of PSCA 
and THY1 and ANX11 were found to be significantly altered respect to the age-matched 
control group. For a protein biomarker discovery platform which employs urinary 
exosomes as biomarker source, it is highly advisable to use a pooled control sample with a 
high number and clinically well defined individual samples. 
6. Conclusions 
Given the non-invasive nature of urine sample collection and the evolving biological 
significance of secreted membrane vesicles, unbiased quantitative analysis of 
biomolecules isolated from urinary exosomes is a step forward in clinical biomarker 
research. Recently we have set-up a multiplex quantitative approach for the analysis of 
protein contents of purified urinary exosomes (Figure 2.). This includes protocols for i.) 
the removal of major urinary exosome contaminations, ii.) the separation of urinary 
membrane vesicles of different sizes iii.) vesicle lysis and protein solubilization and, iv) 
the quantitative proteomics based urinary exosomal biomarker research. The novel 
isolation/purification procedure efficiently removes the major urinary exosomal 
contaminations and separates exosomes from other membrane vesicles. Thus it provides a 
good basis for the development of optimized methods for protein biomarker research. 
Quantitative MudPIT analysis performed on biological, analytical and technical replicates 
shows excellent reproducibility. No significant expression difference was found among 
normal healthy subjects grouped by age. Preliminary data suggests a superior 
performance in single sample biomarker analysis design over a pooling design. All 
together, these results suggest a prolific future of urinary exosomes in clinical proteomics 
of different diseases involving the renal and urinary tract. 
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Circadian Proteomics and Its Unique Advantage 
for Discovery of Biomarkers of Heart Disease 
Peter S. Podobed, Gordon M. Kirby and Tami A. Martino 
Cardiovascular Research Group, Biomedical Sciences,  
University of Guelph, Ontario 
Canada 
1. Introduction 
Current statistics from the World Health Organization, Heart and Stroke Foundation of 
Canada, and the American Heart Association show that cardiovascular disease remains a 
leading cause of death (Heart and Stroke Foundation of Canada [HSFO], 2011; Roger et al., 
2011; World Health Organization [WHO], 2011). Innovative and integrative approaches 
aimed at understanding and treating heart disease are needed. In this chapter we introduce 
a novel field of investigation called cardiovascular circadian proteomics. This approach is 
based on the application of high throughput proteomic technologies for discovery of 
molecular processes in cardiovascular tissues over the 24-hour day/night cycles. Time is a 
crucial but frequently overlooked factor affecting our physiology in health and disease. 
Circadian cardiovascular proteomics offers considerable promise to advance our 
understanding of heart disease (indeed disease in general), and opens new avenues for 
treatment of patients clinically.  
2. The circadian system and its importance to cardiovascular physiology 
Life on earth is subject to a 24-hour day/night (circadian or diurnal) cycle. Circadian 
systems have evolved to allow physiological and behavioural processes to be synchronous 
with this cycle – mammals are adapted to sleep either during the day or at night.  Circadian 
clocks allow us to entrain to environmental cues and hence anticipate the differing 
physiologic and behavioural demands of daily events.  In mammals, the system is organized 
as a hierarchy with multiple oscillators, as has been well reviewed (Hastings et al., 2003; 
Rajaratnam & Arendt, 2001; Reppert & Weaver, 2001, 2002). At the top is the hypothalamic 
suprachiasmatic nucleus (SCN), a brain region functioning as a master rhythmic regulator 
(Figure 1A).  The SCN integrates light information received from the eyes to coordinate 
clocks throughout the body. There are additional circadian regulatory systems such as the 
food entrainable clock (Storch & Weitz, 2009) which we are just now beginning to 
understand, but are beyond the scope of this review. We observe the output of the entrained 
clocks as daily physiologic rhythms, many of which are crucial to the cardiovascular system, 
such as the cyclic variation in heart rate (HR) and blood pressure (BP). Daily HR and BP 
follow the diurnal variation of our autonomic nervous system and increase around wake-
time to help sustain cardiac output, then decrease during the period of vagal dominance at 
night and in the early morning (Guo & Stein, 2003; Imai et al., 1990).  
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Circadian rhythms also underlie the timing of onset of adverse cardiovascular events. The 
incidence of myocardial infarction in humans peaks in the morning (~6:00A.M.-12:00 noon) 
(Cohen et al., 1997; Goldberg et al., 1990; Muller et al., 1985). A similar pattern is observed in 
the incidences of sudden cardiac death (Muller et al., 1989; Willich et al., 1987), ventricular 
tachyarrhythmia (Eksik et al., 2007; Tofler et al., 1995), and rupture of aortic aneurysms 
(Manfredini et al., 2004; Mehta et al., 2002; Sumiyoshi et al., 2002). Precursor risk factors 
such as vasomotor tone, platelet aggregability, and other factors involved in thrombosis or 
thrombolysis also exhibit daily rhythms (Andrews et al., 1996; Angleton et al., 1989; 
Decousus et al., 1985; Maemura et al., 2000; Otto et al., 2004). Recent studies link timing of 
onset of adverse cardiac events  with a circadian clock mechanism, reviewed in (Durgan & 
Young, 2010; Martino & Sole, 2009; Sole & Martino, 2009).  
Proteins involved in the molecular clock mechanism have been identified in the last 10+ 
years, and daily oscillations of this mechanism in peripheral tissues, including the 
myocardium, are believed to be primarily combination of self-sustaining cycling along with 
neural/hormonal cues from the SCN. It is illustrated in Figure 1B and described in many 
excellent reviews (Hastings et al., 2003; Reddy et al., 2005; Roenneberg & Merrow, 2005). 
Though we focus here on protein cycling, it is important to note that there are post-
translational rhythms as well, such as phosphorylation. Though beyond the scope of this 
review the reader is directed to several examples (Akashi et al., 2002; Lowrey et al., 2000; 
Iitaka et al., 2005; Yin et al., 2006). 
In the following sections, we describe how application of the circadian concepts, in 
combination with state-of-the-art proteomics, provides significant new opportunities for 
understanding disease physiology, for biomarker discovery, and helping patients 
clinically. 
3. Discovery of the circadian heart proteome 
Our laboratory is focussed on discovering the circadian heart proteome both in normal 
tissue and in disease. Initial studies are done using murine models of cardiovascular 
disease, and later are translated clinically. Here we describe the circadian proteome in 
normal C57Bl/6 mouse heart, and in our well-established murine model of heart disease 
termed pressure-overload induced cardiac hypertrophy by Transverse Aortic Constriction 
(TAC). To induce heart disease, eight week old male mice were entrained to a 12:12 light 
(L): dark (D) cycle and administered TAC surgery where a ligature was placed distal to 
the third bifurcation of aorta (Figure 2A). In sham operated animals the surgical 
procedure was identical, but the ligature was not tightened. (Figure 2A). For proteomic 
studies, heart tissues were collected one week later (as the heart remodels), at six time-
points 4 hours apart over the 24-hour L:D cycle (Figure 2B). The proteome was analyzed 
by two-dimensional difference in gel electrophoresis (2D-DIGE) and mass spectrometry 
(MS). Figure 2B illustrates the experimental workflow design. The technical details are 
described below. 
3.1 Protein purification and labelling 
The cytoplasmic soluble proteome was purified from either TAC or sham left ventricular 
heart tissue. Cardiac tissue was immersed in 600 l ice-cold cell lysis buffer (10 mM Tris pH 
8, 8 M Urea, 4% w/v 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate 
(CHAPS), and protease inhibitors). The lysis buffer helps to solubilize, denature, and  
 






A) Light activates dedicated retinal receptors and signals the hypothalamic suprachiasmatic nucleus 
(SCN). The SCN is a master body clock, and orchestrates physiologic and molecular rhythms in 
peripheral organs including the heart. Rhythms relevant to the heart include the daily cycling of heart 
rate and blood pressure, also timing of onset of acute cardiac events such as myocardial infarction.  
B) The molecular clock mechanism is dependent upon oscillating levels of proteins that interact via a  
24-hour autoregulatory feedback. On the positive arm BMAL1 and CLOCK combine as heterodimers 
and bind to E-box elements upstream in the coding regions of other core clock elements, PERIOD and 
CRYPTOCHROME. These are phosphorylated by CASEIN KINASE 1 EPSILON (or DELTA), form 
heterodimers, then translocate to the nucleus.  There, they bind to the same E-box elements thus 
negatively regulating their own expression. The positive loop also initiates production of RETINOIC 
ACID-RELATED ORPHAN NUCLEAR RECEPTOR ALPHA resulting in its inhibition, and completion 
of the 24-hour cycle. CAPITAL=Proteins; italic=mRNA. 
Fig. 1. The Circadian System. 
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disaggregate proteins. Cell disruption was carried out using a Potter-Elvehjem tissue 
grinder. Following centrifugation the supernatant was collected and proteins were 
quantified by Bradford assay.  
Prior to protein separation, 50 g of each sample was labelled with CyDyes (Cy3/Cy5), and 
an internal control was pooled from both lysates and labelled with Cy2 (Figure 2B). To 
account for any bias due to preferential binding of CyDyes, a dye swap approach was also 
done in a separate experiment, so that the samples were alternatively labelled with the 
reciprocal dye. CyDyes form a covalent bond between their NHS ester reactive group and 
epsilon amino group of protein’s lysine residues. The labelling reaction does not cause a 
significant change in isolectric point because lysine carries an intrinsic +1 charge at neutral 
or acidic pH, which is replaced by CyDye’s +1 charge. CyDyes were added so that there was 
a stoichiometric excess of proteins and thus only 1-5% of lysines were labelled. The reaction 
was carried out for 30 minutes in the dark, and then quenched with 10 mM lysine.  
3.2 First dimension isoelectric focussing 
Proteins were separated in the first dimension by isoelectric focusing (IEF) based on our 
standard operating protocol (Hobson et al., 2007). In the experiment shown here (Figure 3) 
we used nonlinear 13 cm immobilized pH gradient (IPG) strips pH 3 – 10 (GE Healthcare). 
The CyDye labelled samples were combined and mixed with rehydration buffer (8 M urea, 
2% w/v CHAPS, Dithiothreitol (DTT), 0.5% v/v carrier pharmalytes). Then, samples in 
rehydration buffer were applied at the bottom of the IPG strip holder. The strip was put on 
top of the sample solution and covered with paraffin oil to prevent crystallization of urea, 
water loss and carbon dioxide dissolving at the alkaline end of the strip. IEF was done using 
an Ettan IPGphore unit. The initial step was active rehydration, allowing proteins to slowly 
enter the strip along its whole length under the influence of a small current (30 V for 10 h). 
The next series of steps were 500 V step and hold for 2 h, 1000 V gradient for 1 h, 8000 V 
gradient for 2.5 h, 8000 V step and hold for 16000 V h, 500 V step and hold for 2 h. The result 
was that proteins migrated to a position in accordance with their isoelectric point.  
3.3 Second dimension electrophoresis 
For the second dimension, the sample containing IPG strips were equilibrated with sodium 
dodecyl sulfate (SDS) running buffer (75 mM Tris (pH 8.8), 6 M Urea, 30% v/v Glycerol and 
2% w/v SDS). DTT was added to reduce disulfide bonds, and iodoacetamide (IAA) to 
alkylate thiol groups what prevented disulfide bonds from reforming. After equilibration 
the IPG strip was applied directly on top of a large format 16 X 14 cm 12% acrylamide gel. 
Agarose was poured on top of the strip to prevent air from getting underneath and to hold 
strip in place. Molecular markers were applied 4 cm from the positive end of the strip. The 
proteins were then separated vertically according to their molecular weight by SDS-
polyacrylamide gel electrophoresis (PAGE) on a DALT 6 electrophoresis unit at 20 0C,  
6 W/ gel for 18 h.  
3.4 Protein detection and bioinformatics analysis  
After 2D-DIGE, the relative abundance of proteins from the TAC heart disease versus sham 
protein lysates was detected using a high resolution fluorescent scanner Typhoon 9410 (GE 
Healthcare). The excitation/emission wavelengths for the CyDyes were as follows: Cy2,  
480 nm/530 nm (blue), Cy3, 540 nm/590 nm (green) and Cy5, 620 nm/680 nm (red). Images  
 




A) Heart disease model. Pressure overload cardiac hypertrophy is induced by transverse aortic 
constriction (TAC). A ligature is placed distal to the third bifurcation of aorta. Sham animals undergo the 
same procedure except the ligature is not tightened. B) Two-dimensional difference in gel electrophoresis 
(2D-DIGE) and mass spectrometry (MS) approach to characterize the circadian cardiovascular proteome in 
health and disease. Heart tissue is collected from TAC disease and sham control animals at 6 timepoints 
over the 24-hour light/dark cycle. The cytoplasmic proteome from TAC vs. sham hearts is labelled with 
Cy3 and Cy5 dye, respectively. An internal control consists of pooled samples labelled with Cy2. After 2D-
DIGE protein expression is analyzed with DeCyder. SYPRO Ruby gel for picking spots of interest is 
created. Proteins are excised and identified by MS. Results are validated by Western blot. 
Fig. 2. Experimental design. 
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were visualized with Image Quant TL software. An overlay image of Cy3 and Cy5 scans is 
illustrated in Figure 3A. Proteins that had higher abundance in TAC heart disease vs. sham 
appeared as a red spot. Lower levels in TAC heart disease vs. sham appeared green. Equal 
amounts of protein in TAC heart disease vs. sham were yellow.  
Statistical analysis and quantification of protein expression was achieved by DeCyder 
software (GE Healthcare). In the first step of DeCyder workflow, difference in gel analysis 
(DIA) used a codetection algorithm to detect and match differently labelled samples (Cy2, 
Cy3 and Cy5) within the same gel. It was necessary to define a specific area of interest 
within a gel and then manually confirm that the program detected all the spots within that 
area. Spot intensity corresponding to protein abundance was quantified after background 
subtraction and normalization. The second step termed biological variance analysis (BVA) 
simultaneously analyzed multiple DIGE gels by matching all the spots to a master gel, 
defined by user. Protein expression was compared between gels and statistically verified. 
Based on spot intensity, DeCyder constructed 3D views of relative protein abundance. The 
standardized volume of the peaks was used to calculate fold change.  
In this study, and as shown in Figure 3B, we found three spots (# 596, 615, and 1012) that 
were upregulated in TAC heart disease compared to sham at our sleep-wake transition 
timepoint (ZT23). Spot # 596 had a 1.18 fold change, spot # 615 had a 1.48 fold change, and 
spot # 1012 had 1.77 fold change. To identify the proteins of interest, a pick gel was created 
containing 300 g of unlabelled protein. Glass plates were treated with Bind-Silane  
(-methacryloxypropyltrimethoxysilane) so that the gel was covalently attached to the 
surface. After electrophoresis, proteins were fixed in 10% methanol and 7% acetic acid 
solution for 2 hours, then stained with SYPRO Ruby for 18 hours and destained in 40% 
methanol/10% acetic acid solution for 2 hours. The gel was scanned with a Typhoon 9410 
scanner at 532 nm (670 BP 30 emission filter). Images were uploaded to DeCyder and 
matched to the previous DIGE gel. Unique coordinates for each spot were created using 
position markers. After manual confirmation, an Ettan Spot picker (GE Healthcare) was 
used to excise proteins from the gel.  
3.5 Trypsin digestion and mass spectrometry 
To determine the identification of the proteins in gel spots # 596, 615 and 1012, we used an 
In-Gel Tryptic Digestion Kit (Thermo Scientific) followed by mass spectrometry (MS). 
Trypsin is a serine protease that cleaves the peptide bonds at the carboxyl side of lysine and 
arginine amino acids. Following digestion, tryptic peptide fragments were separated by 
nano-LC which consisted of a trap column (300μm ID) and an analytical column (75 μm ID) 
packed with 5μm, 300Å Zorbax SB C18 beads. A linear binary gradient was used where 
solvent A was 98% H2O:2% CH3CN and 0.1% (v/v) formic acid and solvent B was 2% H2O : 
98% CH3CN and 0.1% (v/v) formic acid. Peptides were eluted over a 2 - 95% solvent B 
gradient for 100 min at a rate of 300 nL/min. The eluant from the nano-LC was coupled to a 
hybrid triple/quadrupole linear ion trap mass spectrometer (QTRAP 4000, ABSciex) 
through a nano-spray ionization source equipped with a 15 μm ID emittor tip. Our 
preferred database for searching was Mascot (http://www.matrixscience.com). This 
database contains information on more than 10 million proteins, with inherent redundancies 
built in since peptides can correspond to more than one protein. Each of the spots generated 
a list of possible protein candidates, and Mascot score and E value helped identify the 
correct match. The molecular weight and pI of the identified protein was comparable to the 
expected molecular weight and pI of the corresponding spot from the 2-DE gel. 
 




A) 2D-DIGE image. The gel on the left had proteins purified from TAC (heart disease) labelled with Cy3 
and those from sham heart labelled with Cy5. Gel on the right shows alternatively labelled samples, 
where TAC proteins are labelled with Cy5 and sham with Cy3. Location of the proteins of interest is 
shown with arrows. B) DeCyder computer analysis of three identified protein spots # 596, 615 and 1012. 
Based on standardized abundance these protein spots increased in TAC vs. sham. Expression changes 
are shown by 3D and Graph views. 
Fig. 3. Circadian Cardiovascular Proteomics. 
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3.6 Role of proteins identified in TAC heart disease 
Our laboratory is interested in circadian cardiovascular proteomics to better understand 
molecular processes underlying heart disease and clinical treatments. The TAC upregulated 
spots 519, 615 and 1012 were identified by MS as Succinyl-CoA:3-ketoacid-coenzyme A 
transferase 1, mitochondrial (SCOT), Desmin (DESM), and PDZ and LIM domain protein 1 
(PDLIM1) respectively. Three examples from ZT23 (one hour before lights on, murine sleep-
time) were shown here; other proteins were identified from different times of day or night. 
Figure 4 shows a representative mass spectrum for one of the identified proteins, SCOT 
(spot #519), as well as the number and list of tryptic hits, Mascot score, E-value, and protein 
sequence. Functionally, SCOT is a mitochondrial matrix protein and is the key rate limiting 
enzyme for ketone body metabolism (Fukao et al., 2004; Orii et al., 2008). That it exhibits 
increased expression around sleep time suggests that it plays a role in changing cardiac 
energy sources. The second identified protein, DESMIN (spot # 615) is crucial for muscle 
structure and function, as reviewed in (Paulin & Li, 2004). The third protein, PDLIM1 (spot 
#1012) is a cytoskeletal protein involved in cardiac contractility and cardioprotection, as 
reviewed in (Arias-Loza et al., 2008; Johnsen et al., 2009).  
3.7 Validation: Western blotting 
Candidate circadian biomarkers identified by 2D-DIGE and MS are validated by Western 
blot protein expression analyses using an independent set of cytoplasmic soluble proteins 
from TAC and sham hearts. Proteins (20 g) are separated according to their mass by 12% 
SDS-PAGE and transferred to polyvinylidene fluoride membrane (Bio-Rad) using a semi-
dry transfer apparatus (Bio-Rad). Membranes are blocked for 2 hours at room temperature 
with 5% non-fat dry milk in TBS-T 0.05 % (20 mM Tris Base, 137mM NaCl, 0.05 % Tween 20, 
pH 7.6) and incubated overnight at 4 0C with primary antibodies against SCOT, DESM or 
PDLIM1. The antibodies are diluted according to the manufacturer’s instructions. Anti-actin 
antibody (1:40000, Milipore) is used as a loading control. Immunoreactive protein bands are 
visualized with horseradish peroxidise-conjugated secondary antibodies (1:5000, Sigma) and 
ECLplus reagent (GE Healthcare). Blots are scanned using Storm 860 molecular imager (GE 
Healthcare) and protein expression is quantified by Image J software (NIH). Expression 
levels of SCOT, DESM and PDLIM1 in TAC samples at ZT23 are compared to sham, thus 
independently validating 2D-DIGE approach. Validating the candidate proteins/biomarkers 
in human samples will increase their significance and is key to translational applications.  
4. Circadian proteomes in other body organs 
Our time-of-day circadian approach led to discovery of SCOT, DESMIN, and PDLIM which 
were upregulated in TAC cardiac hypertrophy at sleep time. Other groups have also met with 
success investigating circadian proteomics in different tissues and clinical paradigms. A 
summary of identified circadian proteomes is shown in Table 1. The first identification of a 
circadian proteome was reported by Reddy and colleagues (Reddy et al., 2006), using a 2D-
DIGE/MS approach to study murine liver. Mice were entrained to 12:12 L:D cycles, then placed 
in constant darkness (12:12 D:D) and sacrificed at 6 consecutive time-points 4 hours apart. It was 
observed that 135 (21%) out of 642 detected protein spots rhythmically cycled over the 24-hour 
period. Many of the newly identified circadian proteins were key rate limiting enzymes 
including ketohexokinase, succinate dehydrogenase 1, aldolase 2, enolase 1/aconitase 2, 
carbamoyl phosphate synthetase 1, CPS1, arginosuccinate synthetase 1, and arginase 1. 
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The circadian proteome of the mouse retina was characterized by 2D-PAGE and Coomassie 
Brilliant stain (Tsuji et al., 2007). C57Bl/6 mice were entrained at 12:12 L:D cycle, then placed 
in constant darkness (12:12 D:D) and sacrificed on the fourth day at 4 timepoints: CT2, CT8, 
CT14, and CT20. CT2 corresponded to subjective dawn and CT12 to subjective dusk. A total 
of 415 protein spots were detected and 11 exhibited circadian rhythms. The cycling proteins 
were important in vesicular transport (N-ethylmaleimide-sensitive fusion protein, charged 
multivesicular body protein 4b), calcium-binding (calbindin D28, reticulocalbin-2 
precursor), RNA-binding (heterogeneous ribonucleoprotein A/B), protein folding  
(T-complex 1 delta), metabolism (leukotriene A4 hydrolase), and protein degradation 
(proteasome subunit alpha1). 
The circadian peptidome released from rat hypothalamic SCN was characterized using a 
gel-free approach (Hatcher et al., 2008). Long-Evans/BluGill rats were entrained to 12:12 
L:D and then transferred to constant darkness. Animals were sacrificed during subjective 
day-time (CT 0-12) and brain slices containing SCN and optic nerve were prepared. SCN 
releasates were obtained from extracellular fluid with pipettes containing solid-phase 
extraction material or from the SCN itself with micrometer-sized beads with solid-phase 
extraction material. Samples of releasate were collected at the beginning and end of CT 0–4, 
4–8, 8–12, 12–16, 16–20, and 20–24 intervals and analyzed with MALDI TOF MS. Identified 
peptides were independently verified with LC-MS/MS. Arginine vasopressin showed a 
robust circadian rhythm with a peak during sleep time. Other identified peptides were 
angiotensin I, arginine vasopressinb, proenkephalin, galanin, neurokinin-B, neurotensin, 
melanotropin , PEN, big LEN, little SAAS, somatostatin-14b, proSomatostatin, substance  
P and thymosin -4. Interestingly, this study also detected previously unknown peptides, 
which prompted further investigation of their biological role. 
5. The circadian proteome helps to understand disease and identify new 
biomarkers 
Disturbances of the circadian rhythm, such as might occur in humans in shift work or sleep 
disorders, can affect many physiologic processes (e.g. circadian rhythms of heart rate, body 
temperature, sympathetic nervous activity, chemical, inflammatory, and metabolic 
processes). The proteome should characteristically change as well, revealing de novo 
biomarkers. We investigated this using a +/tau hamster model bearing a mutation in the 
core circadian clockwork protein casein kinase 1 epsilon (Martino et al., 2008). The circadian 
rhythm disruption in these animals etiologically caused heart and kidney disease. The 
animals exhibited profound proteinuria. To detect proteomic changes, urine samples 
collected from +/tau vs. controls were analyzed on 10-20% tricine gels stained with 
Coomassie dye. Bands were excised from the gel, trypsin digested, subjected to MS/MS on a 
LCQ DECA XP ion trap, and analyzed using Sequest. Protein identification was validated 
by Western blot. As shown in Table 1, a ~15 kDa protein band, appearing only in the urine 
of the +/tau animals, was identified by MS as cytochrome c, a biomarker of cellular 
apoptosis. Apoptosis was confirmed in the renal tissues of +/tau mutants by terminal 
uridine deoxynucleotidyl transferase dUTP nick end labelling (TUNEL) staining. Thus by 
using circadian approaches, a novel biomarker of renal disease was discovered. This was a 
particularly exciting discovery as there are notably very few biomarkers of developing renal 
disease. For example, a usual biomarker for kidney disease is creatinine, however, this 
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represents just chemical waste generated from muscle metabolism and is only an indirect 
marker of renal function. Here we identified a direct indicator of early and ongoing tissue 
damage, by investigating circadian proteome expression. This marker is easily obtained by 
collecting urine samples, thus making it potentially ideal for point-of-care or routine 
diagnostics. Additional examples of circadian-based biomarkers, including many 
fundamental to human health and disease, are described below. 
6. Circadian biomarkers in blood 
Circadian proteomics can be used for discovery of de-novo blood biomarkers of  
heart disease. Established cardiovascular factors (e.g. hypertension, smoking, diabetes) do 
not fully explain the risk for heart disease, and there is substantial interest in the 
development of new biomarkers to identify persons at risk and who may be targeted for 
preventative measures. In those with heart disease, biomarkers are in demand to  
help track disease progression and aid physicians in better treating their patients. 
Although a number of strategies are currently used to identify biomarkers, there have 
been very few clinical advances, and thus new approaches such as circadian proteomics 
are warranted.  
As an example, we recently investigated diurnal proteome cycling in murine blood 
(Martino et al., 2007). Blood was the preferred tissue for biomedical investigation because 
of its ease of accessibility and minimal invasiveness for sampling. As shown in Table 1, 
the first approach was proof of concept and used surface-enhanced laser desorption 
ionization (SELDI) MS. Only proteins retained on ion exchange solid phase 
chromatographic surfaces (or chips) were examined; substances with other biochemical 
properties remain open to future investigation. Expression profiles were collected over a 
wide mass range; those of lower molecular weight (1-10 kDa range) classically contained 
bioactive peptides, while those in the midrange (10-50 kDa) and larger (>50 kDa) reflected 
peptides/proteins involved in cell structural and functional processes. With SELDI MS we 
essentially created a fingerprint of blood protein expression over the 24-hour time, from 
which one could then quantify, statistically analyze and graph data to visualize daily 
protein rhythms.  
Since one of the drawbacks of SELDI MS was a relative inability to further identify the 
fingerprint proteins, the diurnal blood proteome was also characterized following 
prefractionation on column chromatography with an ion exchange resin (Martino et al., 
2007). As shown in Table 1, proteins comprising effluent, salt elution, and bead retentive 
fractions were visualized by SDS-PAGE and silver stain. Protein bands that exhibited cyclic 
variation over 24 hours were excised, trypsin digested, and then injected by electro spray 
ionization (ESI) into a LCQ DECA XP ion trap. Proteins were identified by comparison 
searching molecular mass against murine databases. Many of the identified blood proteins 
with diurnal expression linked to cycles in physiology were those released from liver, such 
as transthyretin, apolipoprotein A1 precursor, apolipoprotein E precursor, apolipoprotein J, 
plasminogen and complement C3 precursor. Ultimately, comparing daily rhythms in sera 
from healthy individuals vs. heart disease patients would allow for the creation of new 
biomarker profiles and discovery platforms. 
Another study examining diurnal biomarkers in blood measured 24-hour profiles of small 
chemical substances (peptides, amino acids, hormones) (Minami et al., 2009). As shown in 
Table 1, blood was drawn every 4 hours over the 24-hour period from CBA mice maintained  
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A) Representative mass spectrum of the SCOT peptide: RGGHVNLTMLGAMQVSKY. B) A total of  
24 peptides were identified, corresponding to 13 unique sequences. The Mascot score is 150, E-value is 
4.0 ×10-21. C) Identified peptides and their corresponding match to the SCOT protein sequence. 
Fig. 4. MS based identification of Succinyl-CoA:3-ketoacid-coenzyme A transferase 1, 
mitochondrial (SCOT). 
 
Circadian Proteomics and Its Unique Advantage for Discovery of Biomarkers of Heart Disease 
 
79 
under L:D or D:D conditions and LC-MS analysis was performed that led to the detection 
of 176 negative and 142 positive ion peaks. Importantly, in transgenic murine model of 
clock disruption (Cry1-/- and Cry2-/-), expression of these metabolites was altered, 
suggesting that they were controlled by the clock mechanism. The authors demonstrated 
that their metabolite timetable could be used to accurately determine body time in mice 
with different genetic background, age, sex and feeding regime. The overall purpose of 
doing this was to create maps of body time, which could be applied clinically to optimize 
understanding of disease or determine the best times for administering drugs and 
therapies. 
7. Circadian rhythms in neuro/hormone biomarkers 
Long before protein cycling was even discovered, it was already known that some key 
neuroendocrine hormones important to the heart had daily rhythmic patterns of expression. 
Cycling of many of these hormones drives the protein rhythms we observe in normal heart 
and other tissues, and the changes that occur in disease.  Further details are described below 
and in Figure 5 and Table 2.  
7.1 Sleep-time hormones 
The first example is melatonin, and its expression in humans is elevated in the dark  
but suppressed by light (thus it is sometimes called the “hormone of darkness”) 
(Brzezinski, 1997). It has a cardioprotective effect through antioxidant and anti-
inflammatory activity, reviewed by (Tengattini et al., 2008). It is a useful circadian 
biomarker of heart disease. Nocturnal melatonin levels were low in patients with acute 
myocardial infarction (MI) vs. healthy controls within the first 24 hours after hospital 
admission (Dominguez-Rodriguez et al., 2002). Also, patients with ST-segment MI who 
developed adverse events during follow-up had significantly lower nocturnal melatonin 
levels than patients without the events (Dominguez-Rodriguez et al., 2006). In another 
study it was revealed that nocturnal melatonin levels were reduced in patients with 
cardiac syndrome X vs. controls (Altun et al., 2002). Second, the renin-angiotensin-
aldosterone system (RAAS) also exhibits circadian rhythm. Aldosterone produced by the 
adrenal cortex regulates Na+ and K+ homeostasis. Aldosterone plasma levels peak during 
sleep time (11:00 P.M. – 7:00 A.M.) (Charloux et al., 1999). As a biomarker of heart disease, 
it has been reported that while normal subjects showed an 81% decrease during the wake 
period, there was only a 40% decrease in low renin hypertensive patients (Grim et al., 
1974). Similarly, plasma renin activity (PRA) cycles in healthy subjects with peak activity 
during sleep (Charloux et al., 1999). Patients with hypertensive heart disease exhibited a 
greater increase in PRA during sleep-time as compared to normotensive patients (Tuck et 
al., 1985).  
Finally, growth hormone secretion by the anterior pituitary gland is pulsatile and has a 
circadian rhythm with the highest peak occurring at midnight (Surya et al., 2006). Growth 
hormone is involved in regulation of cardiac metabolism and contractility, reviewed by 
(Volterrani et al., 2000). In some heart failure patients (New York Heart Association classes 
I-III) there is a loss of circadian rhythm and overall reduction of growth hormone secretion 
(Duncan et al., 2003).  
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Left; Melatonin, aldosterone, plasma renin activity, growth hormone peak during sleep time. Right; 
cortisol, epinephrine, vasoactive intestinal peptide peak during wake time. X-axis: white bar = light 
period, black bar = dark. Rhythms illustrated here are based on the references listed in Table 2. 
Fig. 5. Dirunal cycling of hormones in blood. 
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Table 2. Circadian rhythms in neuro/hormones in humans 
7.2 Wake time hormones 
Cortisol exhibits diurnal variation with serum levels peaking early in the morning around 
wake time and troughing late in the evening (Charloux et al., 1999; Lightman et al., 1981). It 
may also be a useful biomarker or mediator of disease as plasma cortisol peaks earlier at 
4:00 A.M. in some low renin hypertensive patients, as compared to 8:00 A.M. in normal 
controls (Grim et al., 1974). Epinephrine stimulates sympathetic activity including in the 
cardiovascular system. It exhibits a robust endogenous circadian rhythm that peaks during 
wake time (Linsell et al., 1985), and this expression changes in obstructive sleep apnea heart 
failure patients, in which there is increased nocturnal sympathetic tone (Alonso-Fernandez 
et al., 2005; Bradley & Floras, 2009). Lastly, vasoactive intestinal peptide affects vasodilation, 
heart rate and force of contraction, reviewed by (Henning & Sawmiller, 2001). It has a 
circadian rhythm with a peak before sleep time (20:00) and a trough later at night (0:00) 
(Cugini et al., 1991). The rhythm of this peptide is lost in patients with orthotopic heart 
transplant (Cugini et al., 1993). 
 
Circadian Proteomics and Its Unique Advantage for Discovery of Biomarkers of Heart Disease 
 
83 
8. Clinical translation 
Discovery of the circadian cardiovascular proteome and it’s endogenous drivers provides a 
new understanding of cardiovascular health and disease, where time is a new paradigm of 
functional significance. Proteomic biomarkers can be easily implemented with ELISA-type 
point-of-care diagnostic platforms that could be routinely applied in physician offices, or 
even potentially in the consumer’s home. One of the practical applications of cardiovascular 
circadian proteomics is chronotherapy, which requires easily accessible markers of body 
time for optimizing the timing of drug treatments. For example, we recently demonstrated 
that the efficacy of treatment with the angiotensin converting enzyme inhibitor (ACEi) 
captopril exhibits a diurnal pattern, consistent with the diurnal variation in ACE expression 
(Martino et al., 2011). ACEi are common medications given to cardiovascular patients with 
hypertension, after a myocardial infarction or with heart failure. We found that drug 
administration at sleep-time improved heart function, but wake-time did not differ from 
placebo. This approach can be used in other diseases such as cancer (Hrushesky & 
Bjarnason, 1993; Innominato et al., 2010) and neuroendocrine disorders (Chung et al., 2011) 
as well. 
9. Conclusion 
Circadian cardiovascular proteomics is an important new area of research that provides an 
excellent opportunity to elucidate molecular processes that underlie our health and disease 
across the 24-hour light/dark period. At this early stage, temporal analysis of the proteome 
in cardiovascular tissues (i.e. heart or blood) of experimental animal models reveals 
remarkable 24-hour variations in protein abundances. Diurnal protein profiles differ 
remarkably between health and disease. Characterization of these proteins is the key to 
understanding normal body physiology as well as providing new diagnostic capabilities, 
and new approaches to treatment by aiding in the design of personalized therapeutics. 
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1. Introduction 
There are an estimated 10 million people affected annually by traumatic brain injury (TBI) 
across the globe.1 In the United States, TBI is a major cause of death and disability2 with 
about 52,000 annual deaths and 5.3 million Americans impaired by its effects. TBI is a 
contributing factor to over 30% of all injury-related deaths in the United States and it has 
been referred to as the silent epidemic of our time. 3, 4 European TBI prevalence data is not 
consistently reported by each country but it has been estimated that 1.6 million head-injured 
patients are hospitalized annually in Europe with an incidence rate of about 235 per 100,000. 
There is an average mortality rate of about 15 per 100,000 and a case fatality rate of about 11 
per 100. The TBI severity ratio of hospitalized patients is about 22:1.5:1 for mild vs. moderate 
vs. severe cases, respectively.5 According to the World Health Organization, TBI will 
surpass many diseases as the major cause of death and disability by the year 2020.1 
Brain injuries can be focal, diffuse or a combination of focal and diffuse. The degree of brain 
injury depends on the primary mechanism/magnitude of injury, secondary insults and the 
patient’s genetic and molecular response. Following the initial injury, cellular responses and 
neurochemical and metabolic cascades contribute to secondary injury.6, 7 Focal brain injuries 
include contusions, brain lacerations, and hemorrhage leading to the formation of 
hematoma in the extradural, subarachnoid, subdural, or intracerebral compartments within 
the head. Traumatic brain injury represents a spectrum of injury severity. The number, 
types, and location of lesions as well as the magnitude of overlapping injuries across this 
spectrum of injury severity are still not clearly described and are challenging to classify.  
There are two aspects to injury caused by TBI - the damage caused by the initial impact or 
insult, and that which may subsequently evolve over the ensuing hours and days referred to 
as secondary insults. Secondary insults can be mediated through physiologic events which 
decrease supply of oxygen and energy to the brain tissue or through a cascade of cytotoxic 
events. These events are mediated by many molecular and cellular processes.  
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1. Introduction 
There are an estimated 10 million people affected annually by traumatic brain injury (TBI) 
across the globe.1 In the United States, TBI is a major cause of death and disability2 with 
about 52,000 annual deaths and 5.3 million Americans impaired by its effects. TBI is a 
contributing factor to over 30% of all injury-related deaths in the United States and it has 
been referred to as the silent epidemic of our time. 3, 4 European TBI prevalence data is not 
consistently reported by each country but it has been estimated that 1.6 million head-injured 
patients are hospitalized annually in Europe with an incidence rate of about 235 per 100,000. 
There is an average mortality rate of about 15 per 100,000 and a case fatality rate of about 11 
per 100. The TBI severity ratio of hospitalized patients is about 22:1.5:1 for mild vs. moderate 
vs. severe cases, respectively.5 According to the World Health Organization, TBI will 
surpass many diseases as the major cause of death and disability by the year 2020.1 
Brain injuries can be focal, diffuse or a combination of focal and diffuse. The degree of brain 
injury depends on the primary mechanism/magnitude of injury, secondary insults and the 
patient’s genetic and molecular response. Following the initial injury, cellular responses and 
neurochemical and metabolic cascades contribute to secondary injury.6, 7 Focal brain injuries 
include contusions, brain lacerations, and hemorrhage leading to the formation of 
hematoma in the extradural, subarachnoid, subdural, or intracerebral compartments within 
the head. Traumatic brain injury represents a spectrum of injury severity. The number, 
types, and location of lesions as well as the magnitude of overlapping injuries across this 
spectrum of injury severity are still not clearly described and are challenging to classify.  
There are two aspects to injury caused by TBI - the damage caused by the initial impact or 
insult, and that which may subsequently evolve over the ensuing hours and days referred to 
as secondary insults. Secondary insults can be mediated through physiologic events which 
decrease supply of oxygen and energy to the brain tissue or through a cascade of cytotoxic 
events. These events are mediated by many molecular and cellular processes.  
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2. The importance of mild and moderate TBI 
Research in the field of TBI has long been dominated by research on severe brain injury. 
However, of the estimated 1.8 million people in the United States who sustain a TBI each 
year, over 90% will have either a “moderate” (GCS 9-12) or “mild” (GCS 13-15) injury; far 
outnumbering severe injuries.2, 8, 9 Moderate TBI comprises over 10% of all TBI and mild 
TBI over 80%.8 The majority of these patients will present to emergency departments 
(ED’s) around the country for assessment and treatment.10 The direct medical costs for 
treatment of TBI in the United States have been estimated at more than $4 billion 
annually.11 If the costs of lost productivity that result from TBI are added to this then the 
overall estimated cost is closer to $56.3 billion. Moreover, mild TBI is significantly under-
diagnosed and the likely societal burden is therefore even greater.12 Mild and moderate 
TBI are often difficult to assess and distinguish clinically during the first hours after injury 
because neurological examinations are of restricted value. The distinction between mild, 
moderate and severe TBI is initially based on a GCS score and this may be influenced by 
factors such as perfusion and intoxication from drugs or alcohol, sedative medications, 
and other distracting injuries. 
The term “mild TBI” is actually a misnomer. Individuals who incur a TBI and have an initial 
GCS score of 13-15 are acutely at risk for intracranial bleeding and diffuse axonal injury.13 
Additionally, a significant proportion is at risk for impairment of physical, cognitive, and 
psychosocial functioning.14-18 Although some patients with mild TBI may be admitted to the 
hospital overnight, the vast majority are treated and released from emergency departments 
with basic discharge instructions. Most receive little guidance with respect to follow-up 
care. This group of TBI patients represents the greatest challenges to accurate diagnosis and 
outcome prediction. With perhaps no overt signs of acute head injury and a lack of clinical 
tools to detect the subtle cognitive deficits the patient is considered “unimpaired” and is 
discharged home and typically left to deal with persisting neurocognitive deficits on their 
own.19 Accordingly, a significant minority has incomplete recoveries and has outcomes 
disproportionately worse than would have been predicted by the objective facts of the 
injury.19, 20 The lack of clinical tools to detect the deficits that affect daily function leads to a 
state of frustration for patients and families that arises out of a failure to understand the 
nature of the difficulties encountered daily. Treatment protocols for mild TBI have only 
slowly begun to emerge and are still experimental. The injury is often seen as “not severe” 
and subsequently therapies have not been aggressively sought for these individuals. 
Unfortunately, despite the better understanding of the anatomical, cellular and molecular 
mechanisms of TBI, these advances have not yet yielded significant improvements in 
treatment. Among the potential barriers to treatment are the heterogeneity of traumatic 
brain injury, difficulty with stratification of patients by injury severity and lack of early 
markers of injury.21-24  
3. The problem with current assessment of TBI 
Prognostic tools for risk stratification of TBI patients are limited in the early stages of injury 
in the emergency setting for all severities of TBI. Unlike other organ-based diseases where 
rapid diagnosis employing biomarkers from blood tests are clinically essential to guide 
diagnosis and treatment, such as for myocardial ischemia or kidney and liver dysfunction, 
there are no rapid, definitive diagnostic tests for traumatic brain injury. Moreover, the 
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reference standard for TBI is also more difficult to define than say cardiac ischemia. There is 
no early gold standard for stratification of patients by severity. Currently, diagnosis of TBI 
depends on a variety of measures including neurological examination and neuroimaging. 
Neuroimaging techniques such as CT scanning and MRI are used to provide objective 
information. However, CT scanning has low sensitivity to diffuse brain damage and confers 
exposure to radiation. MRI can provide information on the extent of diffuse injuries but its 
widespread application is restricted by cost, the limited availability of MRI in many centers, 
and the difficulty of performing it in physiologically unstable patients. Additionally, its role 
in the clinical management of TBI patients acutely has not been established.25, 26 
While increasing CT use has reduced hospital admissions,27 it has also raised concern over 
unnecessary exposure to ionizing radiation.28-32 Although the calculation of projected cancer 
risk is still controversial, some studies suggest that CT scans of the head may be among the 
largest contributors to radiation exposure due to the frequency with which they are 
performed.33 There is significant consensus that efforts should be made to prevent 
unnecessary radiation exposure while maintaining quality of care.28, 29, 34, 35 
4. Challenges to the clinical application of biomarkers 
There have been a number of cerebrospinal fluid (CSF) and serum biomarkers evaluated in 
TBI animal models and in humans. However, many of these candidate biomarkers have 
failed to exhibit adequate sensitivity and specificity for brain injury, and they have added 
minimal diagnostic and prognostic information. As a result many are skeptical about the 
potential of neurotrauma biomarkers to influence future clinical management and clinical 
trials. This reservation is based on a handful of biomarkers studied using compromised 
research designs and without the advantage of advancements made in the field of 
proteomics. Even though the application of proteomics in brain injury is still in its infancy36, 37, 
neuroproteomics is penetrating the field of neurotrauma and brings great potential for 
improvements in research and patient care. As this technology advances and integrates 
other technologies such as bioinformatics and neuroimaging, characterization of CNS 
proteins will occur quickly and many more potential markers will be validated in a shorter 
timeframe.  
Another important challenge in validating biomarkers for TBI will be that traditional 
outcome measures used to measure injury severity are, in and of themselves, limited. This is 
true for all severities of injury, and is particularly germane to the less severe injuries where 
neuroimaging, such as computed tomography (CT), may not demonstrate any obvious 
pathology. Traditionally, TBI has been separated into three very broad categories: mild, 
moderate and severe. Unfortunately, this classification scheme fails to capture the spectrum 
of TBI and the different types of injuries associated with it. The difficulty in classifying 
injury severity is one which has made clinical trials in the field of TBI challenging. 
Therapeutic clinical trials for TBI have met with negative results at a cost of over $200 
million.38, 39 These failures have been attributed to a multitude of factors but particularly to 
the heterogeneity of TBI which makes classification of the different injury types problematic. 
This heterogeneity, together with the lack of early definitive measures of severity opens the 
door for using biomarkers as early prognostic indicators. Potentially, biomarkers could 
provide early outcome measure for clinical trial obtainable much more reliably and 
economically than conventional neurological assessments, thereby significantly reducing the 
risks and costs of human clinical trials. 
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The release of substances and potential biomarkers after an injury is not a static process. 
Understanding the biokinetic properties of a biomarker will be essential to understanding 
the release pattern and “optimum” time for measurement. Clinicians and researchers will 
have to keep in mind that different injury types (for instance, mass lesions versus diffuse 
injuries) may demonstrate different kinetic parameters and, thus, may produce different 
quantities of a marker with different peaks and rates of decay. Moreover, secondary insults 
may also contribute to secondary elevations in a marker, altering its sensitivity and 
specificity at different time-points.  
For markers measured in serum, the level of a biomarker may also reflect the extent of blood 
brain barrier disruption. Furthermore, extracranial sources of the biomarker may limit its 
specificity by creating false positives, thus compromising its clinical utility. For instance, the 
release of a potential CNS marker into the serum from other traumatized tissues or organs 
would hamper its clinical value in the setting of polytrauma. Another possible situation in 
which false positive marker values could occur is in the presence of a pre-existing disease 
state that may alter the metabolism or clearance of the marker, as with kidney or liver 
disease. Such factors need to be carefully assessed in rigorously designed clinical studies. 
Future studies should also ensure that adequate control groups are selected for comparison. 
Ongoing studies by our group are currently being conducted to more fully elucidate the 
relationships between novel biomarkers and severity of injury and clinical outcomes in all 
severities of TBI patients. Before clinical application neurochemical markers will have to be 
rigorously evaluated and the above mentioned challenges taken into consideration.  
5. Proteomic techniques in neurobiomarker discovery 
Two dimensional gel electrophoresis (2D GE) and mass spectrometry has classically been 
the gold standard for protein identification. It is an excellent technique for discovering a 
multitude of proteins and is widely used. However, it requires specialized training and 
technical expertise. Some of the disadvantages include sample to sample variation, the 
inability to detect certain classes or sizes of proteins, and the need for many samples and 
controls.40 
There are also non–gel-based mass spectrometry methods for identifying proteins that use 
high-resolution chromatography to separate complex mixtures of proteins prior to mass 
spectrometry. Typically the technique uses capillary chromatography for sensitivity and 
high-resolution mass spectrometry for identification of proteins. There is no need for two-
dimensional gel electrophoresis for initial separation and it can analyze a wider range of 
proteins. However, the technique requires significant expertise and the cost of the materials 
and equipment to run this technique is much higher.40 
Newer proteomic techniques are employing antibody-based methods such as high 
throughput immunoblotting and antibody panels and/or arrays (ELISA’s). Antibodies are 
significantly more specific and selective than traditional techniques and allow the detection 
of proteins amid complex high-protein content biofluids such as serum or plasma.41 
Methods of amplifying the signal are under development so that only very small samples 
will be required for analysis. The drawback of this technique is its reliance on the sensitivity 
and specificity of the antibodies, and the inability to identify a wide range of proteins 
because the protein of interest must be pre-selected. 
Examples of these techniques will be taken from studies conducted by our group. In two 
studies published in the Journal of Neurotrauma in 2007 by Pineda et al.42 and in 2009 by 
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Brophy et al.43 an immunoblotting technique employing sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) was used to measure alpha-spectrin. 
Quantitative evaluation of intact αII-spectrin and its breakdown products (SBDP150, 
SBDP145 and SBDP120) was performed via computer-assisted densitometric scanning. 
An example of the ELISA technique is taken from a study published in Critical Care 
Medicine in 2010 by Papa et al.44 that measured Ubiquitin C-terminal hydrolase. In this 
study samples were measured using a standard UCH-L1 sandwich ELISA where reaction 
wells were coated with capture antibody and detection antibody was added to wells. The 
wells were developed with substrate solution and read with a spectrophotometer. 
6. Status of biomarker research 
Although there are a number of biochemical markers that have been investigated in TBI, our 
discussion will include the most current and widely studied ones. The most extensively 
studied among these are glial protein S-100 beta(β) 45-55, neuron-specific enolase (NSE)56-63, 
and myelin basic protein (MBP)41, 59, 64-66 Although some of these published studies suggest 
that these biomarkers correlate with degree of injury; conflicting results exist.67-75  
S100β is the major low affinity calcium binding protein in astrocytes 76 and it is considered a 
marker of astrocyte injury or death. It can also be found in non-neural cells such as 
adipocytes, chondrocytes, and melanoma cells.77 Elevated serum levels have been associated 
with increased incidence of post concussive syndrome and impaired cognition.78, 79 Other 
studies have reported that serum levels of S-100β are associated with MRI abnormalities and 
with neuropsychological examination disturbances after mild TBI.80, 81 A number of studies 
have found significant correlations between elevated serum levels of S-100β and CT 
abnormalities.82-84 It has been suggested that adding the measurement of S-100B 
concentration to clinical decision tools for mild TBI patients could potentially reduce the 
number of CT scans by 30%.84 Other investigators have failed to detect associations between 
S-100β with CT abnormalities.67, 85, 86 87 The vast majority of these clinical studies have 
employed ELISA to measure levels of S100B. Although S-100β continues to be actively 
investigated and remains promising as an adjunctive marker, its utility as a biochemical 
diagnostic remains controversial. Some studies have observed high serum S-100β levels in 
trauma patients without head injuries suggesting that it lacks CNS specificity and is released 
from peripheral tissues.88-90 
Neuron specific enolase is one of the five isozymes of the gycolytic enzyme enolase found in 
central and peripheral neurons and it has been shown be elevated following cell injury.91 It 
has a molecular weight of 78 kDa and a biological half-life of 48 hours.92 This protein is 
passively released into the extracellular space only under pathological conditions during cell 
destruction. Several reports on serum NSE measurements of mild TBI have been 
published.59, 62, 91, 93 Most of these studies employed an enzyme immunoassay for NSE 
detection. Many of these studies either contained inadequate control groups or concluded 
that serum NSE had limited utility as a marker of neuronal damage. Early levels of NSE and 
MBP concentrations have been correlated with outcome in children, particularly those under 
4 years of age.64, 65, 94, 95 A limitation of NSE is the occurrence of false positive results in the 
setting of hemolysis.96 
A supposedly cleaved form of tau, c-tau, has also been investigated as a potential biomarker 
of CNS injury. Tau is preferentially localized in the axon and tau lesions are apparently 
related to axonal disruption.97, 98 CSF levels of c-tau were significantly elevated in TBI 
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patients compared to control patients and these levels correlated with clinical outcome.99, 100 
Though levels of c-tau were also elevated in plasma from patients with severe TBI, there 
was no correlation between plasma levels and clinical outcome.101 A major limitation of all 
of these biomarkers is the lack of specificity for defining neuropathological cascades.  
Alpha-II-spectrin (280 kDa) is the major structural component of the cortical membrane 
cytoskeleton and is particularly abundant in axons and presynaptic terminals.102, 103 It is also 
a major substrate for both calpain and caspase-3 cysteine proteases.104, 105 A hallmark feature 
of apoptosis and necrosis is an early cleavage of several cellular proteins by activated 
caspases and calpains. A signature of caspase-3 and calpain-2 activation is cleavage of 
several common proteins such as cytoskeletal αII-spectrin.106 In a rat model, mean levels of 
both ipsilateral cortex (IC) and cerebral spinal fluid (CSF) spectrin breakdown products 
(SBDP) at 2, 6, and 24 h after two levels of controlled cortical impact (1.0 mm and 1.6 mm of 
cortical deformation) were significantly elevated by injury using immunoblotting.107 Using 
the same proteomic Western blot technique, levels of spectrin breakdown products (SBDP’s) 
have been reported in CSF from adults with severe TBI and they have shown a significant 
relationship with severity of injury and clinical outcome.42, 108-113 Following a TBI the 
axonally enriched cytoskeletal protein α-II-spectrin is proteolyzed by calpain and caspase-3 
to signature breakdown products (SBDPs). Calpain and caspase-3 mediated SBDP levels in 
CSF have shown to be significantly increased in TBI patients at several time points after 
injury, compared to control subjects. The time course of calpain mediated SBDP150 and 
SBDP145 (markers of necrosis) differs from that of caspase-3 mediated SBDP120 (marker of 
apoptosis). Average SBDP values measured early after injury correlated with severity of 
injury, CT scan findings and outcome at 6 months post injury.43  
A promising candidate biomarker for TBI currently under investigation is Ubiquitin C-
terminal Hydrolase-L1 (UCH-L1). UCH-L1 was previously used as a histological marker for 
neurons due to its high abundance and specific expression in neurons.114 This protein is 
involved in the addition and removal of ubiquitin from proteins that are destined for 
metabolism.115 It has an important role in the removal of excessive, oxidized or misfolded 
proteins during both normal and pathological conditions in neurons.116 In initial studies, 
UCH-L1 was identified as a protein with a two-fold increase in abundance in the injured 
cortex 48 hours after controlled cortical impact in a rat model of TBI.117 Subsequently, a 
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neurodegenerative disorders124, 125 and stroke126 to severe traumatic brain injury.127-131 
Recently, Vos et al. described serum GFAP profile in severe and moderate TBI (GCS <12).54 
In a recent study by our group, GFAP was systematically assessed in human serum 
following mild and moderate TBI. We confirmed that the GFAP levels were significantly 
elevated in this population using ELISA analysis, including those with mild TBI. GFAP was 
able to discriminate TBI patients from uninjured controls. Additionally, serum levels were 
able to distinguish orthopedic and motor vehicle controls form TBI patients. GFAP was 
detectable in serum within a few hours of injury and was associated with measures of injury 
severity including the GCS score and CT lesions.132, 133 The present work extends findings 
from studies in severe TBI to mild and moderate TBI.  
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Clinical researchers have developed methodological standards for developing clinical 
decision tools in order to ensure the validity of study results.136, 137 As TBI biomarker 
research transitions from the bench to the bedside there are a number of important 
methodological issues that researchers will have to consider as they design their clinical 
protocols. Since TBI biomarkers are being designed for clinical management, the outcome or 
diagnosis being examined will need to be clearly defined and clinically important. In order 
to ensure external validity and the generalizability of the results, study patients will have to 
be selected without bias and represent a wide spectrum of clinical and demographic 
characteristics. When interpreting the data, clinical variables that potentially affect outcome 
will require careful consideration in the analysis. Multivariate statistical and bioinformatics 
models will also further improve classification of patients and help reduce systematic 
bias.138 Another essential consideration will be the examination of biokinetic properties and 
temporal profiles of the biomarkers as well as systematic comparisons to controls. 
8. The potential clinical role of biomarkers 
Biochemical markers could help with clinical decision making by elucidating injury severity, 
injury mechanism(s), and monitoring progression of injury. Temporal profiles of changes in 
biomarkers could guide timing of diagnosis and treatment. Biomarkers could have a role in 
management decisions regarding patients at high risk of repeated injury. Accurate 
identification of these patients could facilitate development of guidelines for return to duty, 
work or sports activities and also provide opportunities for counseling of patients suffering 
from these deficits. Repeated mild TBI occurring within a short period (i.e. hours, days, or 
weeks) can be catastrophic or fatal, a phenomenon termed "second impact syndrome."139, 140 
Acute CT or MRI abnormalities are not usually found after these injuries, but levels of some 
neurotransmitters remain elevated, and a hypermetabolic state may persist in the brain for 
several days after the initial injury.141 During this time the brain appears to be particularly 
vulnerable to additional TBI, which may result in severe sequelae, including greatly 
increased cerebral edema and even death.139, 140  
Biomarkers could serve as prognostic indicators by providing information for patients and 
their families about the expected course of recovery. It opens the door to the initiation of 
early therapies. Identifying at-risk patients with less apparent TBI or differentiating injury 
pathology in those with more severe intracranial processes would be tremendously valuable 
in the management of these patients. For example, in a patient with a normal CT scan or 
MRI, a biomarker that could predict worsening neurological status or long-term disability 
would have great clinical utility.  
There have been a large number of clinical trials studying potential therapies for traumatic 
brain injury (TBI) that have resulted in negative findings. Biomarkers measurable in blood 
would have important applications in clinical research of these injuries. Biomarkers could 
provide clinical trial outcome measures that are cost-effective and more readily available 
than conventional neurological assessments, thereby significantly reducing the risks and 
costs of human clinical trials. Biomarkers that represent highly sensitive and specific 
indicators of disease pathways have been used as substitutes for outcomes in clinical trials 
when evidence indicates that they predict clinical risk or benefit. 
Lack of quickly accessible pathophysiologic information during the post-injury course has 
made pharmacologic intervention problematic. Biomarkers could provide more timely 
information on disease progression and the effects of interventions such as drugs and 
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surgery. Biomarker measurements could potentially relate the effects of interventions on 
molecular and cellular pathways to clinical responses. In doing so, biomarkers would 
provide an avenue for researchers and clinicians to gain a mechanistic understanding of the 
differences in clinical response that may be influenced by uncontrolled variables. 
Intoxicated, unconscious, sedated, or polytraumatized patients suspected of having a TBI 
pose a particular challenge to emergency and trauma physicians. Biomarkers could expedite 
the evaluation of such patients by providing information on the degree of brain injury prior 
to neuroimaging. Biomarkers in this setting could also help determine the need for early 
neurosurgical consultation or transfer to facilities with neurosurgical capabilities. 
There are potential military applications as well. Serum biomarkers could help diagnose 
and/or triage brain injured military servicemen and women. TBI is a leading cause of 
combat casualty with an estimated 15-20% of all injuries sustained in 20th century conflicts 
being to the head.142-144 America's armed forces are sustaining attacks by rocket-propelled 
grenades, improvised explosive devices, and land mines almost daily in the recent conflicts 
in Iraq and Afghanistan.145 It has been suggested that over 50% of injuries sustained in 
combat are the result of such explosive munitions including bombs, grenades, land mines, 
missiles, and mortar/artillery shells. Neuroimaging techniques to diagnose brain injury 
acutely and other monitoring tools that assess secondary insults are not immediately 
available in combat zones and such casualties have to be evacuated. Triage and 
management of brain injured soldiers could be significantly improved if first responders 
had a quick and simple means of objectively assessing severity of brain injury and of 
monitoring secondary insults.  
There is a unique opportunity to use the insight offered by biochemical markers to shed 
light on the complexities of the injury process. Accordingly, certain markers could be used 
as indicators of damage to a particular cell type or cellular process or may be indicative of a 
particular type of injury. Neuroanatomically, that could include evidence of, say, primary 
axonal damage versus glial damage. With such heterogeneity the solution may not lie with a 
single biomarker but more with a complementary panel of markers that may prove useful in 
distinguishing different pathoanatomic processes of injury.  
9. Conclusion 
The exploration and validation of biomarkers for TBI using advances in proteomics, 
neuroimaging, genomics, and bioinformatics must continue. Biomarkers of TBI measured 
through a simple blood test have the potential to significantly improve the management of 
TBI patients by providing timely information on the pathophysiology of injury; improving 
stratification of patients by injury severity; monitoring of secondary insults and injury 
progression; monitoring response to treatment; and predicting functional outcome. 
Biomarkers could provide major opportunities for the conduct of clinical research including 
confirmation of injury mechanism(s) and drug target identification. Ultimately the goal is 
improve outcome in patients suffering from these injuries. 
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Proteomics was developed in the early 1990s to allow proteins expressed by cells and tissues 
to be systematically studied (Celis et al., 1999; Arrell et al., 2001). The word proteome was 
coined by Marc Wilkins et al (Wilkins et al, 1996) from the words “protein and genome”. It 
is therefore defined as protein equivalent of the genome. Generally, unique spectrum of 
proteins is only synthesized by specific cell types, for example amylase is secreted by the 
parotid gland, insulin by the pancreas and thyroxin by thyroid follicles. Protein synthesis is 
a complicated process formed by the different combination and length of the 20 unique 
amino acids found in our body (Arnstein, 1965). For example, following the transcription of 
genes encoded in the DNA, the mRNAs translocate into the cytoplasm where they are 
translated into a specific type of protein by the ribosomes (Lengyel, 1966). This is then 
followed by post-translational modification of the peptide chain to configure the protein so 
that it becomes biologically active. Post-translational modifications of proteins involve 
glycosylation, alkylation, methylation and sulfation (Blundell et al., 1993, Fleischer, 1983). 
The co- and post-translational modifications allow the protein to be transported and 
secreted during cellular homeostasis (Finnerty et al., 1979; Mao et al., 2011). In this chapter, 
we have described the comparative 2-dimensional electrophoresis (2-DE) proteomics 
workflow for protein identification by mass spectometry. Comparative proteomics was used 
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to identify proteins that were differentially expressed in the tissues after treatment with 
various small molecules and siRNAs. 
2. Proteomics research and applications 
Protein properties are diverse and complex. They are dynamically influenced by 
physiological change in their environment, such as hormones, factors present in 
inflammatory response and enzymes activated by the presence of drugs. Proteomics is 
founded on three basic procedures: (1) the isolation and separation of proteins from cells 
and tissues, (2) the identification of the proteins by mass spectrometry and (3) the resolution 
of analyzed protein peptides by bioinformatics. Advancement in proteomic technologies has 
allowed researchers to investigate the proteome of many diverse biological systems – 
allowing breakthroughs to be made in biomedical and biological sciences. Proteomics has 
also enabled the identification of important biomarkers of many human diseases and allows 
the discovery of novel targets for drugs. In this section, we will to discuss how proteomic 
technologies have been applied in biomedical sciences research and the limitations 
encountered. 
2.1 History of protein research 
Swedish biochemist Pehr Victor Edman first developed the technique called Edman 
Degradation which allowed the amino acid sequence in peptides to be elucidated (Edman, 
1950). Determination of the protein structure could be performed under micro scale. Pehr 
Victor Edman also developed an instrument, the protein sequenator, which allowed the 
amino acids sequence to be determined following Edman degradation reaction (Edman and 
Begg, 1967). This sequenator was commercialized by the company Beckman. The discovery 
popularized the studying of protein chemistry. However, there are several disadvantages 
associated with this method. Firstly, the technique can only accurately determine amino acid 
sequences up to 50-60 residuals after using Edman reagent, phenyl isothiocyanate for 
degradation. Secondly, the peptide N-terminal, with NH2-group, has to react with the 
Edman reagent. Thirdly, sequencing can only work on a single pure peptide and not a 
protein mixture. Finally, only the primary peptide structure can be determined but not 
information on the secondary structure, such as the position of disulfide bridge. 
Nevertheless, it has the advantage that only small quantity (10-100 pico-moles) of peptide is 
needed for the Edman reaction and can be performed directly from PVDF membranes. For 
its time, it was a pioneering and sophisticated method for studying protein chemistry, 
allowing the important amino acid sequence of hormones to be discovered (Niall et al., 1969 
and Birr and Frank, 1975). 
In the early 1970s, mass spectrometry was used to try and resolve all the peptide sequences 
derived from a protein mixture (Lucas et al., 1969; Morris et al, 1971). This early work has 
now developed leaps and bounds and protein mixtures can routinely be analyzed by 
computer aided high resolution mass spectrometry (MS). Consequently, John Fenn was 
awarded the 2002 Nobel Prize for his work in developing the electrospray ionization for 
mass spectrometry which provided a new platform for protein research (Fenn et al., 1989, 
2002). The electrospray ionization mass spectrometer can rapidly, accurately and sensitively 
analyze peptide sequences from recombinant proteins, large biomolecules, protein mixture 
and body fluids (Chowdhury et al., 1990; Andersen et al., 1996; Bergquist et al., 2002). The 
parallel development of protein databases, search engines and new softwares has made it 
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now even easier to conduct proteomic studies. Protein databases are essential tools that 
allow the matching and identification of peptides from peak spectrums obtained from MS 
studies. In particular, the Protein Prospector (Chalkley et al., 2005) and Mascot (Perkins et 
al., 1999) databases are user-friendly and contain many years of interpreted MS data for 
protein identification.  
2.2 New era in studying the protein profile 
Protein chemistry has now shifted to studying the proteome which permits a better 
understanding of interaction between cells, hormones with cells and bioactive molecules with 
cells. Profiling of protein mixtures is still difficult, despite recent development in using a 
partial enzyme digestion strategy and advancement in instrumentation - such as electrospray 
ionization tandem (triple quadrupole) and mass spectrometry (ESI-MS/MS) (Ceglarek et al. 
2009), quadrupole ion trap MS (Schwartz and Jardine, 1996) and Matrix-assisted laser 
desorption/ionization-time of flight mass spectrophotometer (Maldi-TOF MS) (Hillenkamp et 
al., 1991; Andersen et al., 1996). Studying the proteome also depends on the use of two 
dimensional electrophoresis (2-DE) (O’Farrell, 1975). This technique allows complex mixture of 
proteins found in cells to be separated into individual protein spots by isoelectrical focusing 
(IEF) and sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE). Proteinase 
inhibitors are always added to protein lysates freshly prepared from cells or tissues to prevent 
protein degradation. Contaminants such as phospholipids, nucleic acid and ionic molecules 
are also present and can be removed by gel filtration, dialysis and protein precipitation. 
Although O’Farell improved the IEF procedure, he used non-equilibrium pH gradient 
electrophoresis which cannot be reproducible from batch to batch - as the pH gradient is 
difficult to maintain during IEF. However, Bjellqvist et al. (1982) developed the immobilized 
pH gradients (IPG) method which replaced the use of the carrier-ampholyte. Development of 
the IPG strip was a milestone in proteomics and is now widely used in resolving individual 
proteins from complex protein mixtures (Weiss and Görg, 2009). In the IPG strip, proteins 
migrate under a high electrical field (up to 5000V) but always stop at same pI point. If several 
protein spots co- exist within the same pI, then a wider range of IPG strip could be flexibly 
used. SDS-PAGE is used to separate the protein spots according to their molecular weight. The 
limitation with this method is that it can only resolve proteins ranging from 120 kDa to 10 kDa. 
The protein spots resolved in the 2-DE gel need to be stained before it can be analyzed. Gels 
are most commonly stained with coomassie blue because it is inexpensive, and compatible for 
MS analysis. However, the sensitivity of this staining method is limited and cannot stain-up 
protein spots lower than 30 g. Silver staining is also another method widely used for 
revealing the resolved protein spots in the gel and only need 1 g of protein. Fluorescent dyes 
(CyDyes) have now been developed to label protein samples for Difference Gel 
Electrophoresis (DIGE). The DIGE technique is very sensitive, with protein detection range 
down to 125 pg per spot, giving it high precision in terms of protein quantification and use in 
comparative proteomics (Conrotto and Souchelnytskyi, 2008; Larbi and Jefferies, 2009). 2-
DE/MS is now a well-established technique for large-scale protein expression studies. 
However, there are drawbacks with the method which hold it back from being developed for 
clinical diagnosis. Drawbacks such as the high abundance of plasma and albumin present in 
biofluids which interfere with detection of lower abundant proteins. Resolving hydrophobic, 
very acidic and basic proteins is also a major deficiency with the 2-DE/MS technique (Altland 
et al., 1988;  Görg et al., 2009). 
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3. Breakthroughs in proteomics 
Proteins are separated according to their isoelectrical points and molecular weights by 2-DE. 
In addition, their m/s ratio and peptide sequences in MS can resolve up to 2,000-4,000 single 
protein spots at a time (Görg et al., 2004). Moreover, proteins that cause abbreviated changes 
in normal tissues may be identified and use as potential biomarkers in medical diagnosis. 
This is especially important in oncology where early detection of the cancer could be 
properly treated and not metastasize. In the last decade, advancement in 2-DE, mass 
spectrometry and bioinformatics has allowed potential cancer biomarkers to be identified in 
serum and biofluids in the blood (Voss, et al., 2001; Gioia et al., 2011), colon (McKerrow et 
al., 2000), breast (Sauter et al., 2002; Lau et al., 2007; Galvão et al., 2011), ovaries (Zhang et 
al., 2004; Tung et al., 2008) and prostate (Ornstein et al., 2004; Ornstein and Tyson, 2006). 
However, the 2-DE technique still has its limitation – where proteins with extreme 
isoelectric point and molecular mass are not resolvable and identified. Also, it is very 
difficult to resolve membrane proteins and non-water soluble proteins by 2-DE. Another 
approach is to use non-gel based proteomic techniques (for example, ionic exchange affinity, 
reverse-phase and liquid chromatography) followed by MS/MS provide a novel platform 
for identifying proteins and therefore it can resolve the disadvantage of 2-DE technique. 
Now, the development of laser capture micro-dissection and MALDI-MS has allowed 
proteomics to be performed on a specific cell population isolated from heterogeneous 
tissues (Marko-Varga, 2003). It is possible to surgically isolate cancer tissue from normal 
tissues in histological sections of biopsies for proteomic analysis. This will accelerate the 
discovery of cancer biomarkers as the laser capture micro-dissection will remove 
“background noise” generated by normal tissues. 
4. Comparative proteomics 
Comparative Proteomics is the identification of the differentially expressed proteins from 
comparison of two or more 2-DE protein profiles, for example, isolated from cells that were 
treated and untreated with a drug. This method allows proteins that are differentially 
expressed to be identified and quantified. It is a very powerful technique for identifying the 
molecular targets of drugs and understanding the function of novel genes. The comparative 
proteomic technique is schematically summarized in Figure 1. Basically, it involves image 
analysis of 2-DE by matching different sets of gels together; identifying and isolating of 
proteins which are differentially expressed; mass spectrometry and bioinformatics. The 
proteome of a wide variety of biological systems can be investigated that includes cells, 
tissues, organs, fractionated cell lysates, and immuno-precipitated cell lysates. Since the 
technique only requires micrograms of materials to create a complex protein profile, the 
proteomes of bacteria, yeast and insect have also been investigated (Chen and Snyder, 2010; 
Han et al., 2011; Novak et al., 2011; Sirot et al., 2011).  
5. As an example of the usefulness of comparative proteomics in identifying 
gene function, a gene called BRE which has anti-apoptotic properties, was 
analyzed 
We have been interested in genes that are responsive to DNA damage (Li et al., 1995; Dong 
et al., 2003), and identified a novel human gene which we named BRE in this context. The  
Comparative Proteomics:  




Fig. 1. The principle and workflow involved in comparative proteomics. 
gene is highly Expressed in Brain and Reproductive organs and that is why we named it, 
BRE. The gene is down-regulated after treatment of cells with DNA damaging agents such 
as ultraviolet light (UV), 4-nitroquinoline-1-oxide and all-trans retinoic acid (Li et al., 1995). 
The BRE gene encodes a 1.7-1.9 kb mRNA which give rise to a protein with 383 amino acid 
residues and a molecular weight of 44 kDa. Using the yeast two-hybrid assay, it was 
reported that BRE interacts with the juxtamembrane (JM) region of p55-TNFR, but has no 
affinity for the p75-TNFR, Fas or p75-NGFR of the TNFR family (Gu et al., 1998). 
Meanwhile, over-expression of BRE in the human 293 embryonic kidney cells that was 
treated with TNF-α could inhibit the activation of the transcriptional factor NF-B (Gu et al., 
1998). Since NF-B is known to induce the survival pathway associated with TNF receptor, 
it is likely that BRE can modulate the cell death process. The expression of the BRE gene has 
been investigated in various biological models including adrenal glands (Miao et al., 2001), 
testis (Miao et al., 2005) and hepatocellular carcinoma cells (Chan et al., 2008), but the 
function of BRE has still not been clarified - the protein structure of BRE do not have 
identifiable functional domain. It has been suggested the BRE contained 2 ubiquitin-
conjugating enzyme family-like regions (Hu et al., 2011). However, these regions lacked the 
critical Cys residues required for ubiquitination but retain the ability to bind ubiquitin. The 
multifunctional nature of BRE and the lack of positive identifiable functional domains on 
BRE, make it an ideal candidate for study using proteomics. We therefore used comparative 
proteomics to examine the function of this novel gene in different cell types and also in vivo.  
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5.1 Materials and methods 
5.1.1 Tissue cultures 
All of the cell cultures were maintained at 37oC and 5% CO2 in a humidified cultured 
chamber. C2C12 myoblasts (ATCC) and D122 Lewis lung carcinoma cells (gift from Lea 
Eisenbach) were cultured in DMEM medium supplemented with 10% FBS and 
penicillin/streptomycin. Two stably transfected cell lines were produced from D122 using a 
pcDNA3.1 expression vector. D122v3B harbor the empty vector, while D122a4 cells over-
express the full length BRE (Chan et al., 2005). D122v3B and D122a4 were maintained in 
DMEM plus 10% FBS and 400 mg/mL of G418 (Invitrogen), Immortalized human 
esophageal epithelial (SHEE) cell line and the malignantly transformed esophageal 
carcinoma cell line (SHEEC) were cultured in DMEM medium plus F-12 Nutrient Mixture 
(1:1) supplemented with 10% FBS (GibcoBRL) and penicillin/streptomycin (Shen et al., 
2000). Chang cells (ATCC, CCL-13) were cultured in Minimum Essential Medium Eagle plus 
10% FBS.  
5.1.2 Transgenic mice 
The transgenic mice were generated carrying the full-length BRE gene and the transthyretin 
(TTR) promoter. The TTR promoter is specifically expressed in hepatocytes in the liver 
(Ching et al, 2001). All mice were maintained in the Laboratory Animal Services Centre, 
Chinese University of Hong Kong. Ethical approval has been obtained from the animal 
ethics committee, Chinese University of Hong Kong before performing the animal 
experiments. 
5.1.3 Subcellular fractioning of soluble proteins 
SHEE and SHEEC cells were extracted in lysis buffer (8M Urea, 2M Thiourea, 2% CHAPS, 
0.01% TBP, 0.01% NP-40) containing protease inhibitors (GE Healthcare). After extraction, 
the lysates were incubated on ice for 30 min and then centrifuged at 8000 rpm for 15 min to 
remove all cell debris. The fractions (cytosol, membrane, and nucleoplasm) were obtained 
using a ProteoExtract Subcellular Proteome Extraction Kit (Calbiochem) following 
instructions provided by the manufacturer. The total protein concentration for each fraction 
was determined using a Bio-Rad Protein Assay kit (Bio-Rad, Richmond).  
5.1.4 BRE gene silencing analysis 
Two BRE-specific siRNAs were designed corresponding to 5’-
TCTGGCTGCACATCATTGA-3’ (nucleotides 124–142, nucleotide position number 1 being 
the start of the initiation codon), and 5’-CTGGACTGGTGAATTTTCA-3’ (nucleotides 491–
509). siRNA sequence 5’-AAGCCUCGAAAUAUCUCCU-dTT-3’ with no known mRNA 
targets was used as a control. 
5.1.5 Semi-quantitative RT-PCR analysis 
The total RNA was isolated and purified by using TRIzol solution (Invitrogen Corporation, 
United States). 1 µg of the total RNA was used for reverse-transcription to synthesize the 
complementary DNA (cDNA) according to the procedures of ImProm-II™ Reverse 
Transcription System. cDNA was used as the template for PCR amplification. 20 μl of PCR 
mixture containing 1 μl of cDNA, 2.5 μl of PCR 10X buffer (Bio-firm, Hong Kong), 0.75 μl of 
magnesium chloride solution (25 mM, Bio-firm, Hong Kong), 1 μl of dNTP mix (10 mM, 
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Promega Corporation, United States), 1 μl of forward primer, 1 μl of reverse primer, 0.25 μl of 
Taq polymerase (Bio-firm, Hong Kong) and DEPC-treated water in a PCR microcentrifuge 
tube was placed into the thermal cycler for PCR amplification. All of the primers used in this 
study were manufactured and desalted by Invitrogen Corporation. The primers’ sequences 
and the annealing temperature and duration shown in Table 1 were designed with Primer3  
 
Primers Sequences Annealing
 temp & 
duration 
mouse β-actin Forward: 5’-TGAGACCTTCAACACCCCAG-3’ and 
Reverse: 5’-TTCATGAGGTAGTCTGTCAGGTCC-3’  
or 
forward: 5’-TGAGACCTTCAACACCCCAG-3’  
reverse: 5’-TTCATGAGGTAGTCT GTCAGGTCC-3’ 
59 oC , 45s 
55 oC , 60s 
mouse BRE Forward: 5’-CTAGTCGCCGGTTACTGA-3’ 
Reverse: 5’-TTCATGAGGTAGTCTGTCA-3’ 
or 
Forward: 5’-CCACATTCCCACATACCTTCTC-3’  
Reverse: 5’—GCCATTTCATTTCCATCCCATC-3’ 
56 oC, 45s 
 
55 oC, 60s 
mouse Mdm4 Forward: 5’-CTCCAAGCAAGAGGTACTG-3’  
Reverse: 5’-AATGACCTGGTCCTCCTAG-3’ 
54 oC, 60s 
Mouse Akt-3 Forward: 5’- CTGGCACCAGAGGTATTAGA-3’ 
Reverse: 5’-AGGAGAACTGAGGGAAGTGT-3’ 
56 oC, 60s 
Mouse 26S Proteasome Forward: 5’-TGATCTGTAACCTGGCCTAC-3’ 
Reverse: 5’-GTTACCCTCAGTGTCTTGGA- 
57 oC, 60s 
mouse Prohibitin Forward: 5’-TGAGTGATGACCTCACAGA-3 
Reverse: 5’-CAGTCTGCATAGGCACTTG-3’ 
54 oC, 45s 
mouse p53 Forward:5’-ACTCTCCTCCCCTCAATAAG-3’  
Reverse: 5’-CTGGAGTCTTCCAGTGTGAT-3’ 
54 oC, 60s 
human β-actin Forward: 5’-ATGGATGATGATATCGCCGCG-3’  
Reverse:  5’-CTCCATGTCGTCCCAGTTG GT-3’ 
55 oC, 45s 
human BRE Forward: 5’-ATCTTGCCTCCTGGAATCCT-3’ 
Reverse: 5’-CACGTACTGCACCTTGTTGG-3’ 
57 oC, 60s 
human Prohibitin Forward: 5’- CGGAG AGGACTATGATGAGC-3’  
Reverse: 5’- GGTAGGTGATGTTCCGAGAG-3’ 
57 oC, 60s 
human cyclin A Forward: 5’-TCCTGTCTTCCATGTCAGTG-3’  
Reverse: 5’- TAGGTCTGGTGAAGGTCCAT-3’ 
57 oC,60s 
Human TNF-R1 Forward: 5’- ACCAAGTGCCACAAAGGAACC -3’ 
Reverse: 5’-TACACACGGTGTTCTGTTTCTCC -3’ 
56 oC, 60s 
human p53 Forward: 5’-GCCTGACTCAGACTGACATT-3’ 
Reverse 5’-GACAGCTTCCCTGGTTAGTA-3’ 
54 oC, 60s 
mouse TUSC4 Forward: 5’-CTGGTATCC ATCCTCCAGTA-3’ 
Reverse: 5’-GTCTTGCAGCAGATCTCATC-3’ 
53 oC, 60s 
mouse ENO1 Forward: 5’-CTACGAGGCCCTCTAAGAACTCC-3’ 
Reverse: 5’-TCCTTCCCGTACTTCTCCTT-3’ 
58 oC,  60s 
mouse DPF2 Forward: 5’-TCCTTGGCGAGC AATACTAC-3’  
Reverse: 5’-GCTGCCATCCTGAGAGATAA -3’ 
53 oC, 60s 
mouse HSPA7 Forward: 5’-GCAGTCGGATATGAAGCACT-3’ 
Reverse: 5’-CTCCTCCCAAGTGGGTATCT-3’ 
58 oC, 60s 
mouse HSPA2 Forward: 5’-GACGAATGTCAGGAGGTGAT-3’ 
Reverse: 5’-CTAAGTTGTTGCACCTCTCC-3’ 
58 oC, 60s 
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5.1 Materials and methods 
5.1.1 Tissue cultures 
All of the cell cultures were maintained at 37oC and 5% CO2 in a humidified cultured 
chamber. C2C12 myoblasts (ATCC) and D122 Lewis lung carcinoma cells (gift from Lea 
Eisenbach) were cultured in DMEM medium supplemented with 10% FBS and 
penicillin/streptomycin. Two stably transfected cell lines were produced from D122 using a 
pcDNA3.1 expression vector. D122v3B harbor the empty vector, while D122a4 cells over-
express the full length BRE (Chan et al., 2005). D122v3B and D122a4 were maintained in 
DMEM plus 10% FBS and 400 mg/mL of G418 (Invitrogen), Immortalized human 
esophageal epithelial (SHEE) cell line and the malignantly transformed esophageal 
carcinoma cell line (SHEEC) were cultured in DMEM medium plus F-12 Nutrient Mixture 
(1:1) supplemented with 10% FBS (GibcoBRL) and penicillin/streptomycin (Shen et al., 
2000). Chang cells (ATCC, CCL-13) were cultured in Minimum Essential Medium Eagle plus 
10% FBS.  
5.1.2 Transgenic mice 
The transgenic mice were generated carrying the full-length BRE gene and the transthyretin 
(TTR) promoter. The TTR promoter is specifically expressed in hepatocytes in the liver 
(Ching et al, 2001). All mice were maintained in the Laboratory Animal Services Centre, 
Chinese University of Hong Kong. Ethical approval has been obtained from the animal 
ethics committee, Chinese University of Hong Kong before performing the animal 
experiments. 
5.1.3 Subcellular fractioning of soluble proteins 
SHEE and SHEEC cells were extracted in lysis buffer (8M Urea, 2M Thiourea, 2% CHAPS, 
0.01% TBP, 0.01% NP-40) containing protease inhibitors (GE Healthcare). After extraction, 
the lysates were incubated on ice for 30 min and then centrifuged at 8000 rpm for 15 min to 
remove all cell debris. The fractions (cytosol, membrane, and nucleoplasm) were obtained 
using a ProteoExtract Subcellular Proteome Extraction Kit (Calbiochem) following 
instructions provided by the manufacturer. The total protein concentration for each fraction 
was determined using a Bio-Rad Protein Assay kit (Bio-Rad, Richmond).  
5.1.4 BRE gene silencing analysis 
Two BRE-specific siRNAs were designed corresponding to 5’-
TCTGGCTGCACATCATTGA-3’ (nucleotides 124–142, nucleotide position number 1 being 
the start of the initiation codon), and 5’-CTGGACTGGTGAATTTTCA-3’ (nucleotides 491–
509). siRNA sequence 5’-AAGCCUCGAAAUAUCUCCU-dTT-3’ with no known mRNA 
targets was used as a control. 
5.1.5 Semi-quantitative RT-PCR analysis 
The total RNA was isolated and purified by using TRIzol solution (Invitrogen Corporation, 
United States). 1 µg of the total RNA was used for reverse-transcription to synthesize the 
complementary DNA (cDNA) according to the procedures of ImProm-II™ Reverse 
Transcription System. cDNA was used as the template for PCR amplification. 20 μl of PCR 
mixture containing 1 μl of cDNA, 2.5 μl of PCR 10X buffer (Bio-firm, Hong Kong), 0.75 μl of 
magnesium chloride solution (25 mM, Bio-firm, Hong Kong), 1 μl of dNTP mix (10 mM, 
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Promega Corporation, United States), 1 μl of forward primer, 1 μl of reverse primer, 0.25 μl of 
Taq polymerase (Bio-firm, Hong Kong) and DEPC-treated water in a PCR microcentrifuge 
tube was placed into the thermal cycler for PCR amplification. All of the primers used in this 
study were manufactured and desalted by Invitrogen Corporation. The primers’ sequences 
and the annealing temperature and duration shown in Table 1 were designed with Primer3  
 
Primers Sequences Annealing
 temp & 
duration 
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Reverse: 5’-TTCATGAGGTAGTCTGTCAGGTCC-3’  
or 
forward: 5’-TGAGACCTTCAACACCCCAG-3’  
reverse: 5’-TTCATGAGGTAGTCT GTCAGGTCC-3’ 
59 oC , 45s 
55 oC , 60s 
mouse BRE Forward: 5’-CTAGTCGCCGGTTACTGA-3’ 
Reverse: 5’-TTCATGAGGTAGTCTGTCA-3’ 
or 
Forward: 5’-CCACATTCCCACATACCTTCTC-3’  
Reverse: 5’—GCCATTTCATTTCCATCCCATC-3’ 
56 oC, 45s 
 
55 oC, 60s 
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Reverse: 5’-CAGTCTGCATAGGCACTTG-3’ 
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Reverse: 5’-CTGGAGTCTTCCAGTGTGAT-3’ 
54 oC, 60s 
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human p53 Forward: 5’-GCCTGACTCAGACTGACATT-3’ 
Reverse 5’-GACAGCTTCCCTGGTTAGTA-3’ 
54 oC, 60s 
mouse TUSC4 Forward: 5’-CTGGTATCC ATCCTCCAGTA-3’ 
Reverse: 5’-GTCTTGCAGCAGATCTCATC-3’ 
53 oC, 60s 
mouse ENO1 Forward: 5’-CTACGAGGCCCTCTAAGAACTCC-3’ 
Reverse: 5’-TCCTTCCCGTACTTCTCCTT-3’ 
58 oC,  60s 
mouse DPF2 Forward: 5’-TCCTTGGCGAGC AATACTAC-3’  
Reverse: 5’-GCTGCCATCCTGAGAGATAA -3’ 
53 oC, 60s 
mouse HSPA7 Forward: 5’-GCAGTCGGATATGAAGCACT-3’ 
Reverse: 5’-CTCCTCCCAAGTGGGTATCT-3’ 
58 oC, 60s 
mouse HSPA2 Forward: 5’-GACGAATGTCAGGAGGTGAT-3’ 
Reverse: 5’-CTAAGTTGTTGCACCTCTCC-3’ 
58 oC, 60s 
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software (version 0.4.0, Rozen and Skaletsky; http://frodo.wi.mit.edu). The PCR mixtures 
were reacted in a PTC-100 thermal cycler (MJ Research, Watertown, MA, USA) set under the 
following amplification conditions: initial denaturation at 95°C for 2 min, followed by a total of 
35 cycles of denaturation at 95°C for 1 min, annealing at different temperature according to the 
primer’ conditions as shown in Table 1 and extension at 72°C for 1 min. An additional 7 min 
extension step at 72ºC was performed at the end of the last cycle. After the electrophoresis, the 
PCR products were analyzed on a 1.5% agarose gel with ethidium bromide staining, the 
intensities of the PCR products were visualized and determined using the GelDoc-It imaging 
system (UVP, BioImaging System, USA). β-actin was used as a house keeping gene for internal 
control and normalization. The experiments were  repeated three times. 
5.1.6 Western blot analysis 
Control and treated cells were lysed in 200 μl of lysis buffer (50 mM NaCl, 20 mM Tris, pH 
7.6, 1% NP-40, 1 X protease inhibitor mixture) for 60 min. The lysates were cleared by 
centrifugation at 16 000×g at 4 oC for 10 min. Crude protein concentration was measured by 
using a protein assay kit (Bio-Rad). 30 to 50 μg of total protein lysate were resolved on 10 to 
12% SDS-PAGE, with Rainbow molecular weight markers and electroblotted onto Hybond 
NC membranes (GE Healthcare). The blots were incubated with Akt-3 (1:100, sc-11521 Santa 
Cruz Biotechnology), Bre (1:500 to 1000, Chan et al,. 2008), mdmX (1:100, sc-14738, Santa 
Cruz Biotechnology), prohibitin (1:000, sc-18196, Santa Cruz Biotechnology),p53 (1:000, sc-
6243, Santa Cruz Biotechnology) or -tubulin (1:1000 to 1500, Zymed Laboratories), -
tubulin (1:1500, Zymed Laboratories), cyclin A (1:1000, sc-11521, Santa Cruz Biotechnology), 
prohibitin (1:600, sc-18196, Santa Cruz Biotechnology), TNF-R1 (1:800, sc-8436, Santa Cruz 
Biotechnology), CDK2 (M2) (1:800, sc-163 Santa Cruz Biotechnology). Bound antibodies 
were detected using the appropriate horseradish peroxidase-conjugated secondary 
antibodies (Southern biotechnology), followed by development with an ECL Western 
blotting Detection kit (GE Healthcare). The blots were analyzed using Quantity One 
software (Bio-Rad) and the intensity of the bands produced for each antibody was 
normalized against the tubulin band (internal control) produced from each sample. Three 
replicates of each sample were studied. 
5.1.7 In situ hybridization 
All of the procedures performed were according to Lee et al. (2001).  The liver samples were 
fixed in 4% paraformaldehyde (w/v, Sigma, United States) for 24 hrs.   The fixed samples 
were washed in Dulbecco’s Phosphate Buffered Saline (DPBS, Invitrogen Corporation, 
United States) for 15 min with three changes. The samples were then dehydrated, cleared 
and embedded in paraffin wax. Finally, the specimens were sectioned at 7 μm and mounted 
onto TESPA treated slides. The riboprobe was prepared from pGEM-T plasmid containing 
1,205 bp encoding BRE sequence. The plasmid cDNA was linearized by EcoRI and in-vitro 
transcribed to generate digoxigenin (DIG)-labeled sense and antisense BRE riboprobe using 
a DIG RNA labeling kit (Roche Applied Science, United States). After dewaxing the paraffin 
sections, the specimens were rehydrated and equilibrated in DPBS for 10 min. The sections 
were digested with 10 μg/ml of proteinase K (Fermentas Life Science, Canada) for 7 min 
and post-fixed in 2% paraformaldehyde for 5 min. After washing in DPBS for 10 minutes 
twice, the samples were incubated in pre-hybridization buffer (2X SSC, 1X Denhardt’s 
reagent, 5mM EDTA , 0.1% sodium dodecyl sulfate, 10X Dextran sulfate (Chemicon, United 
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States), 50 μg/ml salmon sperm DNA and 50% formamide) for 2 hrs.  The samples were 
then added and hybridized in 0.5 μg/ml of DIG-labeled antisense riboprobe. The sense 
probe was used as a negative control. The hybridization temperature was 55oC and the 
incubation time was 16 hrs. Following hybridization, the samples were washed in 2X SSC at 
42oC for 20 mins with two changes, 0.1% SDS (w/v) in 0.2X SSC buffer for 15 min and then 
0.2X SSC buffer for 10 mins.  The alkaline phosphatase-conjugated digoxigenin antibody 
(1:50, Roche Applied Science, United States) was added to the specimens for 2 hrs and then 
washed in DPBS for 10 min with four changes. Nitroblue tetrazolium salt and 5-bromo-4-
chloro-3-indolylphosphate (NBT/BCIP, Roche Applied Science, United States) were used as 
the color substrates. After color development, the sections were mounted in 50% glycerol 
(v/v, USB, United States).  The experiment was performed in triplicates.  
5.1.8 BrdU (Bromodeoxyuridine) labeling assay 
Chang liver cells were cultured in 8-well glass slide (Nalge Nunc international, Naperville) 
with Minimum Essential Medium Eagle plus 10% FBS.  After 80% confluent, the cultures 
were transfected with Ctl-siRNA or BRE-siRNA respectively according to maufacturers’ 
instructions.  Forty-eight hours after transfection, BrdU was added into the cultures to a 
final concentration of 20 M and incubated at 37oC for 4 hrs.  The treated cultures were then 
fixed with 2% paraformaldehyde for 24 hr. The fixed cultures were processed for 
immunohistochemistry by using mouse BrdU antibodies (1:1000, Sigma-Aldrich, United 
States).  The BrdU positive and negative cells were counted and analysed by Spot Digital 
Camera & Carl Zeiss Microscope Axiophot 2 Integrated Biological Imaging System.  
5.1.9 First dimensional separation of samples – Isoelectric focusing 
The cell lysate for the first DE was performed on an IPGphor IEF system using 11-cm long 
IPG electrode strip with 4-7 pH gradient (Amersham Biosciences, United Kingdom) and an 
Ettan IPGphor Strip Holder (Amersham Biosciences, United Kingdom). 150 μg of protein 
was applied for each IPG strip. The total volume of protein sample and rehydration buffer 
(8M Urea, 2% CHAPS (w/v), 1% IPG buffer (v/v, Amersham Biosciences, United 
Kingdom), 40 mM DTT loaded onto the strip holder was 210 μl. 1ml of IPG Cover Fluid 
(Amersham Biosciences, United Kingdom) was applied to each strip so as to minimize 
evaporation and urea crystallization. The rehydration step was done under voltage and 
followed by a separation process. The electrophoresis condition for step 1 was 30 V for 13 
hrs; step 2 was 500 V for 1 hr; step 3 was 2000 V for 1 hr and step 4 was 5000 V for 20 hrs. 
The program was stopped when the total volt-hours reached 40000.  
5.1.10 Second dimensional separation – Sodium dodecyl sulphate polyacrylamide-gel 
After first DE was completed, the IPG strips were removed from the strip holders. Each strip 
was then treated with 1% DTT in 6.5 ml of equilibration buffer (50 mM Tris, 6M of urea, 30% 
glycerol, 2% SDS, 0.1% bromophenol blue) for 30 min. The strips were further treated with 
1% iodoacetamide (IAA, w/v, Sigma-Aldrich, United States) dissolved in the 6.5 ml of the 
same equilibration buffer. The strips were treated in the solution for 30 min. The 
equilibrated strips were then loaded on the 12% SDS-acrylamide separating gels. The 2-DE 
was performed in an ISO-DALT apparatus (Hoefer Scientific Instruments). Prestained 
protein molecular weight marker (Fermentas Life Science, Canada) with the range of 20 to 
120 kDa was used to determine the sizes of the proteins on the gel.  
 
Proteomics – Human Diseases and Protein Functions 
 
116 
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5.1.11 Gel to gel matching 
The gels were stained and scanned by using a GS 800 Densitometer (Bio-Rad Laboratories, 
United States) and images were captured for further analysis. The protein spots on the gel 
were analyzed by the discovery series, PDQuest 2D Analysis Software (Bio-Rad 
Laboratories, United States) version 7.13 PC. The experiment was performed in triplicate. 
5.1.12 Protein identification by mass fingerprinting 
All protein spots of interest were isolated from the gel and processed for destaining. The gel 
pieces were first washed in MilliQ water, immersed in 200 μl of destaining solution (15 mM 
potassium ferricyanide and 50 mM sodium thiosulphate) and then incubated at room 
temperature until they turned into colorless. Each gel piece was then washed with 400 μl of 
MilliQ water for 15 min, three times. The destained gel pieces were equilibrated in 200 μl of 
10 mM ammonium bicarbonate/50% acetonitrile each for about 15 min. The solution was 
discarded and the equilibrated gel pieces were dehydrated by incubating in 200 l of 
acetonitrile for 15 min. The solution was then poured off and the spots were dried in an 
incubator at 30ºC for 5 min. Fifteen μg/ml trypsin working solution in 40 mM ammonium 
bicarbonate/50% acetonitrile (v/v) was used for in-gel digestion. Twelve μl of the working 
solution was added to each gel sample. The samples were then incubated at 35ºC for 16 hrs. 
After trypsinization, 3 μl of extraction solution (50% acetonitrile (v/v) and 5% trifluoroacetic 
acid (Fluka Chemika, Switzerland) were added to each gel piece to stop the reaction.  
They are then centrifuged at 3,000 rpm for 2 min at room temperature. Three μl of  
reaction mixture from each sample was mixed with α-cyano-4-hydroxycinnamic acid  
matrix and then spotted onto a sample plate (Applied Biosystems, United States) for  
the MALDI-TOF mass spectroscopy. The mass spectrums generated were analyzed using  
the software Data Explorer Version 4.0.0.0 (Applied Biosystems, United States) and by  
mass fingerprinting search using the search engine provided by Protein prospector 
(http://prospector.ucsf.edu/ucsfhtml4.0/msfit.htm). To determine the significance of 
variance in the experiments, data were analyzed using the two-tailed, paired student’s t-test. 
P<0.05 was considered to be statistically significant. All statistical analysis was performed 
using the SPSS software.  
5.2 Results and discussions of the comparative proteomic analysis of BRE 
5.2.1 Comparative proteomic analysis reveals BRE regulates prohibitin and p53 
expression 
BRE gene encodes a highly conserved stress-modulating protein. To gain further insight into 
the function of this gene, we used comparative proteomics to investigate the protein profiles 
of C2C12 and D122 cells resulting from small interfering RNA (siRNA)-mediated silencing 
as well as overexpression of BRE. It was found that silencing BRE expression in C2C12 cells 
would up-regulate Akt-3 and carbonic anhydrase III expression. In contrast, 26S proteasome 
regulatory subunit S14 and prohibitin expressions were down-regulated as shown in 
Figures 2 (2-DE gel) and 3 (semiquantitative RT-PCR and Western blot analyses). It has been 
reported that prohibitin is normally expressed in different cellular compartments involved 
in regulating cell proliferation, mitochondrial activities and protein processing (Mishra, 
2010). Prohibitin can apparently directly interact with p53 in response to stress (Fusaro et al., 
2003; Joshi et al., 2007). We established that cell proliferation was significantly increased 
after silencing BRE expression and this was accompanied by a reduction in p53 and  
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Fig. 2. Representative 2-DE gel of protein extracts from C2C12 cells that had been 
transfected with CTL- or BRE-siRNAs. Four differentially expressed proteins were identified 
(Swiss-Prot accession number provided). Silencing BRE expression up-regulated protein 
spots Q9WUA6 and P16015, but P6778 and Q9Z2X2 were down-regulated. pI 4–7 (x-axis) 
and MW in kDa (y-axis) (Tang et al., 2006). 
 
 
Fig. 3. Semiquantitative RT-PCR (A) and Western blots (B) analyses confirming the 
comparative proteomic results that silencing BRE, down-regulated prohibitin and 26S 
proteasome regulatory subunit S14 expression, while Akt-3 expression was up-regulated. β-
actin and α-tubulin serve as internal controls (Tang et al., 2006). 
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5.2 Results and discussions of the comparative proteomic analysis of BRE 
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Fig. 2. Representative 2-DE gel of protein extracts from C2C12 cells that had been 
transfected with CTL- or BRE-siRNAs. Four differentially expressed proteins were identified 
(Swiss-Prot accession number provided). Silencing BRE expression up-regulated protein 
spots Q9WUA6 and P16015, but P6778 and Q9Z2X2 were down-regulated. pI 4–7 (x-axis) 
and MW in kDa (y-axis) (Tang et al., 2006). 
 
 
Fig. 3. Semiquantitative RT-PCR (A) and Western blots (B) analyses confirming the 
comparative proteomic results that silencing BRE, down-regulated prohibitin and 26S 
proteasome regulatory subunit S14 expression, while Akt-3 expression was up-regulated. β-
actin and α-tubulin serve as internal controls (Tang et al., 2006). 
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prohibitin expression. We also identified Akt-3 that was affected by BRE silencing which 
suggests BRE might be involved in the P13/AKT signaling pathway (Madhunapantula et al., 
2009). We observed that cell proliferation was suppressed when BRE was overexpressed in 
the D122a4 cell line as shown in Figure 4. This was accompanied by an increase in p53 and 
prohibitin expression as shown in Figure 5. It has been reported that in the nucleus BRE is  
 
 
Fig. 4. MTT assay of D122, D122v3B and D122αa4 cell lines. The chart shows BRE 
overexpression in D122αa4 inhibited cell proliferation. Values = means +SEM, P, ≤0.01, * 
D122αa4 significantly different from D122 and D122v3B (Tang et al., 2006). 
 
 
Fig. 5. Semiquantitative RT-PCR (A) and Western blot (B) showing that D122a4 cells 
overexpressed prohibitin, p53 and mdm4. β-actin and α-tubulin serve as internal controls 
(Tang et al., 2006) . 
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one of the components of BRCA1 A complex that is essential for tumor suppression (Harris 
and Khanna, 2011). BRE peptide has an ubiquitin E2 variant domain which has been 
determined to bind ubiquitin in co-immunoprecipitation experiments (Hu et al., 2011; Li et 
al., 2004). Coincidently, a 26S proteasome regulatory subunit S14 was one of the proteins 
found to be down-regulated by BRE over-expression. It is now known that the ubiquitin-
proteasome pathway plays an important role in regulating the proteolytic processes that 
occur during signal transduction, transcriptional regulation and cell-cycle progression 
(Clague and Urbé, 2010). In this context, we speculate that BRE participates in the ubiquitin-
proteasome pathway to regulate protein turnover within cells. In the 2-DE profiling of 
D122α4 cells, where BRE was stably overexpressed, we identified five proteins that were up-
regulated. They were granulin precursor, TNF receptor associated factor 6 (TRAF6), mitogen 
protein kinase 8, Mdm4 and baculoviral IAP repeat-containing protein 4 as shown in 
Figures 6 (2 DE gel) and 7 (semiquantitative RT-PCR and Western blot analyses).  
 
 
Fig. 6. Representative 2-DE gel of protein extracts from D122v3B and D122αa4 cell lines. Five 
protein spots (O35618, P28798, Q07174, P70196 and Q60989) were up-regulated in D122αa4 
cells (Swiss-Prot accession number provided)  (Tang et al., 2006). 
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Fig. 7. Semiquantitative RT-PCR (A) and Western blot (B) showing that D122αa4 cells 
overexpressed prohibitin, p53 and mdm4. β-actin and α-tubulin serve as internal controls 
(Tang et al., 2006). 
Interestingly, TRAF6 is a unique member of the TRAF family of adaptor protein. It is 
associated with a diverse range of cellular responses to pathogens, growth factors or 
intracellular stress (Chung et al., 2007). Recent finding also showed that TRAF6 was 
involved in the RANK-TRAF6-NF-B pathways during osteoclastogenesis (Inoue et al., 
2007). Overexpression of BRE in human 293 embryonic kidney cells has been reported to 
inhibit NF-B activation in response to TNFα (Gu et al., 1998). This finding suggests that 
BRE indirectly cross-talk with TRAF6 and NF-β, where it may play a central role in 
regulating cell proliferation, differentiation and survival. BRE may also mediate in post-
translational sumoylation, similar to the action of PML and MO25α proteins (Kretz-Remy 
and Tanguay, 1999). Our results established a crucial function for BRE in regulating key 
proteins of cellular stress-response and provided an explanation for the multifunctional 
nature of BRE. 
5.2.2 Comparative proteomic analysis reveals differentially expressed proteins 
regulated by a potential tumor promoter, BRE, in human esophageal carcinoma cells 
Esophageal cancer is one of the most common malignancies that cause high mortality. 
Esophageal carcinogenesis is a complex and cascading process that involve the interaction 
of many genes and proteins (Kuwano et al., 2005). In this study, we have used 
comparative proteomic approaches to identify proteins that maybe involved in 
esophageal carcinogenesis. Two dimensional electrophoresis (2-DE) and MALDI-TOF-MS 
analyses of esophageal carcinoma, SHEEC and control cells SHEE revealed 10 proteins 
that were up-regulated as shown in Figure 8 of the 2-DE. Additional 10 proteins were 
down-regulated as shown in Figure 9. Interestingly, BRE, prohibitin, cyclin A and p53  
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Fig. 8. Representative 2-DE gel of nucleic proteins extracted from SHEE and SHEEC cells. Ten 
silver-stained protein spots were found to be up-regulated in SHEEC cells (Chen et al., 2008). 
 
 
Fig. 9. Representative 2-DE gel of nucleic proteins extracted from SHEE and SHEEC cells. Ten 
silver-stained protein spots were found to be down-regulated in SHEEC cells (Chen et al., 2008). 
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Fig. 10. Semiquantitative RT-PCR (A) and Western Blot (B) analyses of SHEE and SHEEC 
cells. The results confirmed the proteomic data that BRE, prohibitin and cyclin A were 
highly expressed in SHEEC cells. The SHEEC cells also expressed relatively higher levels of 
TNF-R1 but lower levels of p53, when compared with SHEE cells. β-actin and α-tubulin 
serve as internal controls (Chen et al., 2008). 
expression were up-regulated in the cancer cells and this was confirmed by both 
semiquantitative RT-PCR and western blot analyses (Figure 10). Among these 20 
differentially expressed proteins, BRE protein was identified as a potential tumor promoter. 
Furthermore, we have also determined p53 expression was down-regulated; whereas TNF-
R1 expression was up-regulated in SHEEC cells (Figure 10). It has been reported that BRE 
can interact with the intracellular juxtamembrane domain TNF-R1 and inhibit the TNF-α 
induced activation of NF-B (Gu et al., 1998). Therefore, we propose that BRE plays an anti-
apoptotic role in SHEEC cells. To gain more insight into BRE’s function, we silenced BRE 
expression in esophageal carcinoma cells using BRE-specific small interference RNA. It was 
found that silencing BRE expression corresponds to down-regulated prohibitin expression 
but up-regulated tumor-suppressor gene, p53 as shown in Figure 11. These findings 
contradicted  the results with previous data (Tang, et al., 2006) that may due to 
multifunctional nature of BRE. Besides BRE, cyclin A and CDK2 expressions were 
suppressed in the SHEEC cells. Cyclin A is an important regulator of the cell cycle that rises 
in early S phase and falls in mid M phase (Parwaresch and Rudolph, 1996). Recent finding 
showed the cyclin A might be a prognostic marker in early breast cancer (Ahlin, et al. 2007). 
In summary, these results imply that BRE may be a survival factor and plays a proliferative 
role in esophageal carcinoma.  
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Fig. 11. Semiquantitative RT-PCR analysis of SHEE and SHEEC cells transfected with CTL- 
and BRE-siRNAs. The results showed that our BRE construct can silence BRE expression, as 
well as suppressed prohibitin and cyclin A expressions. β-actin served as an internal control 
(Chen et al., 2008). 
5.2.3 Livers over-expressing BRE transgene are under heightened state of stress-
response, as revealed by comparative proteomics 
BRE is normally expressed at very low levels in the liver (Chan, et al., 2008). It binds to TNF-
R1 and Fas, and modulates the actions of these cytokines (Li, et al., 2004; Chan et al., 2010). 
In this study, we demonstrated that BRE expression was rapidly induced when the liver was 
insulted with carbon tetrachloride (CCl4) or in human hepatocellular carcinoma (HCC) as 
shown in Figure 12. We produced transgenic mice that specifically over-expressed BRE in 
the liver to determine the effect of high levels of BRE in the liver. The livers of these 
transgenic mice were determined to be histologically normal. Because of the lack of a 
phenotype, we conducted comparative proteomics to determine whether there were any 
differences at the protein level (Figure 13). The 2-DE revealed four up-regulated protein 
spots and nine down-regulated protein spots as summarized in Table 2. It was established 
that several stress responsive proteins were up-regulated in the BRE-transgenic liver 
including: Alpha enolase (ENO 1), Heat shock-related 70 kDa protein 2 (HSPA2), Putative 
heat shock 70 kDa protein 7 (HSPA7), Zinc-finger protein Ubid 4 (DPF2) and Tumor 
suppressor candidate 4 G21 protein (TUSC4) as shown in Figure 14. Recently, it has been 
reported that HSPA7 is a biomarker for early detection of HCC (Park, 2011). In addition, we 
have silenced BRE expression in Chang liver cells and inversely demonstrated that it did not 
affect cell proliferation rate as confirmed by BrdU Labelling assay (Table 3). We have 
previously reported that BRE is not only expressed in the cytoplasm but also in the nuclei of 
HCC cells. BRE also accumulates in the nuclei of esophagus cancer SHEEC cells (Chen, et 
al., 2008). Since BRE is one of the components of BRCA1 A complex, it could be involved in 
DNA repair, as well as responding to environmental stress. We propose that the livers in 
our BRE transgenic mice were under a heighten state of stress response and this may explain 
why the transgenic mice was more resistant to liver toxic drugs. 
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Fig. 12. In situ hybridization (A–D and G–I). BRE is normally expressed at very low levels in 
normal mouse liver (A). CCl4 insult induced increased BRE expression in the affected 
hepatocytes at 6 h (B) and 12h (C). Twenty-four hours after CCl4 insult, BRE expression 
declined. This was probably the result of the affected hepatocytes starting to die off (D). 
Immunohistological staining revealed that BRE expression was strongly induced in the 
affected hepatocytes by CCl4 (E, F). BRE expression remained low in the unaffected cells. 
We also examined BRE expression in HCC cells. BRE was expressed at low levels in non-
tumor human liver tissues (H). In HCC tissues, all the cells strongly expressed BRE (I). Sense 
control (G). Arrows, hepatocytes overexpressing BRE. C, liver central veins (Tang et al., 
2009). 
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Fig. 13. A representative 2-DE gel of BRE transgenic liver. Protein spots 1–15 were identified 
to be differentially expressed when compared with control gels. Protein spots 1–4 were 
downregulated in the transgenic (trans) liver, while protein spots 5–15 were upregulated in 
the wild type (wt) liver. These results were acquired from three independent liver samples 
and 2-DE was correspondingly performed three times (Tang et al., 2009). 
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Fig. 14. Semi-quantitative RT-PCR revealed that the proteins  identified were differentially 
expressed in BRE transgenic livers were also correspondingly affected at the transcriptional 
level. *p<0.05, **p<0.01, denote significant difference in the staining intensity of wt and BRE 
transgenic PCR bands (Tang et al., 2009).  
 
Table 2. Proteins that are differentially expressed in BRE transgenic liver (Tang et al., 2009). 
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Table 3. Effects of silencing BRE expression on Chang liver cell proliferation (Tang et al., 
2009). 
6. Future perspective of proteomics 
Conventional “gel-based” electrophoresis and improved mass spectrometry have 
provided useful tools for revealing molecular changes in cells and tissues that otherwise 
maybe missed by morphological observation alone (Vercauteren et al., 2007). 
Nevertheless, the 2-DE protocol is still to be refined and improved so that 2-DE is more 
reproducible and sensitive. Therefore, it has still some distance to go before it can be 
adopted as a standard “diagnostic tool” in the 21st century (Colucci-D'Amato et al., 2011). 
The “shotgun” methodology has been used as a high-throughput screen to identify 
proteins that are differentially expressed in cells or tissues, as a result of some 
experimental procedure or changes in environmental condition (Lill, 2003; Zhu et al., 
2010). Liu et al. (2011) recently described the SELDI-TOF-MS technology that could be 
used to screen and detect differentially expressed proteins in the serum of patients with 
cancer. Liquid chromatography interfaced plasma mass spectrometry has now been 
developed for absolute quantitation of proteins (Esteban-Fernández et al., 2011). 
Furthermore, latest development of computational tools for analyzing high-throughput 
‘shotgun’ proteomic data also play a vital role in moving proteomic research forward 
(Dowsey et al., 2010). All of these improvements will allow proteomics to be rapidly 
developed as a practical, robust, accurate and inexpensive analytical tool for routine use 
in the clinical setting. The proteomics will also allow many novel disease biomarkers to be 
discovered and also lead to the discovery of new drugs.  
7. References 
[1] Ahlin C, Aaltonen K, Amini RM, Nevanlinna H, Fjällskog ML, Blomqvist C. (2007) Ki67 
and cyclin A as prognostic factors in early breast cancer. What are the optimal cut-
off values? Histopathology. 51(4):491-8.  
[2] Altland K, Becher P, Rossmann U, Bjellqvist B. (1988) Isoelectric focusing of basic 
proteins: the problem of oxidation of cysteines. Electrophoresis. (9):474-85. 
[3] Andersen JS, Svensson B, Roepstorff P. (1996) Electrospray ionization and matrix 
assisted laser desorption/ionization mass spectrometry: powerful analytical tools 
in recombinant protein chemistry. Nat Biotechnol. 14(4):449-57. 
[4] Arnstein, HR (1965). Mechanism of protein biosynthesis. Br Med Bull. 21(3):217-22. 
[5] Arrell DK, Neverova I, Van Eyk JE. (2001) Cardiovascular proteomics: evolution and 
potential. Circ Res. 88(8):763-73. 
 




Fig. 14. Semi-quantitative RT-PCR revealed that the proteins  identified were differentially 
expressed in BRE transgenic livers were also correspondingly affected at the transcriptional 
level. *p<0.05, **p<0.01, denote significant difference in the staining intensity of wt and BRE 
transgenic PCR bands (Tang et al., 2009).  
 
Table 2. Proteins that are differentially expressed in BRE transgenic liver (Tang et al., 2009). 
Comparative Proteomics:  






Table 3. Effects of silencing BRE expression on Chang liver cell proliferation (Tang et al., 
2009). 
6. Future perspective of proteomics 
Conventional “gel-based” electrophoresis and improved mass spectrometry have 
provided useful tools for revealing molecular changes in cells and tissues that otherwise 
maybe missed by morphological observation alone (Vercauteren et al., 2007). 
Nevertheless, the 2-DE protocol is still to be refined and improved so that 2-DE is more 
reproducible and sensitive. Therefore, it has still some distance to go before it can be 
adopted as a standard “diagnostic tool” in the 21st century (Colucci-D'Amato et al., 2011). 
The “shotgun” methodology has been used as a high-throughput screen to identify 
proteins that are differentially expressed in cells or tissues, as a result of some 
experimental procedure or changes in environmental condition (Lill, 2003; Zhu et al., 
2010). Liu et al. (2011) recently described the SELDI-TOF-MS technology that could be 
used to screen and detect differentially expressed proteins in the serum of patients with 
cancer. Liquid chromatography interfaced plasma mass spectrometry has now been 
developed for absolute quantitation of proteins (Esteban-Fernández et al., 2011). 
Furthermore, latest development of computational tools for analyzing high-throughput 
‘shotgun’ proteomic data also play a vital role in moving proteomic research forward 
(Dowsey et al., 2010). All of these improvements will allow proteomics to be rapidly 
developed as a practical, robust, accurate and inexpensive analytical tool for routine use 
in the clinical setting. The proteomics will also allow many novel disease biomarkers to be 
discovered and also lead to the discovery of new drugs.  
7. References 
[1] Ahlin C, Aaltonen K, Amini RM, Nevanlinna H, Fjällskog ML, Blomqvist C. (2007) Ki67 
and cyclin A as prognostic factors in early breast cancer. What are the optimal cut-
off values? Histopathology. 51(4):491-8.  
[2] Altland K, Becher P, Rossmann U, Bjellqvist B. (1988) Isoelectric focusing of basic 
proteins: the problem of oxidation of cysteines. Electrophoresis. (9):474-85. 
[3] Andersen JS, Svensson B, Roepstorff P. (1996) Electrospray ionization and matrix 
assisted laser desorption/ionization mass spectrometry: powerful analytical tools 
in recombinant protein chemistry. Nat Biotechnol. 14(4):449-57. 
[4] Arnstein, HR (1965). Mechanism of protein biosynthesis. Br Med Bull. 21(3):217-22. 
[5] Arrell DK, Neverova I, Van Eyk JE. (2001) Cardiovascular proteomics: evolution and 
potential. Circ Res. 88(8):763-73. 
 
Proteomics – Human Diseases and Protein Functions 
 
130 
[6] Bergquist J, Palmblad M, Wetterhall M, Håkansson P, Markides KE. (2002) Peptide 
mapping of proteins in human body fluids using electrospray ionization Fourier 
transform ion cyclotron resonance mass spectrometry. Mass Spectrom Rev. 21(1):2-
15. 
[7] Birr C, Frank R. (1975) Control for uniformity of synthetic peptides: quantitative 
evaluation of the Edman degradation of support-bound human insulin B 22-30 
synthetized by the Merrifield method. FEBS Lett. 55(1):68-71. 
[8] Bjellqvist B, Ek K, Righetti PG, Gianazza E, Görg A, Westermeier R, Postel W. (1982) 
Isoelectric focusing in immobilized pH gradients: principle, methodology and 
some applications. J Biochem Biophys Methods. 6(4):317-39. 
[9] Blundell TL, Johnson MS. (1993) Catching a common fold. Protein Sci. 2(6):877-83.  
[10] Ceglarek U, Kortz L, Leichtle A, Fiedler GM, Kratzsch J, Thiery J. (2009) Rapid 
quantification of steroid patterns in human serum by on-line solid phase extraction 
combined with liquid chromatography-triple quadrupole linear ion trap mass 
spectrometry. Clin Chim Acta.401(1-2):114-8.  
[11] Celis JE, Celis P, Ostergaard M, Basse B, Lauridsen JB, Ratz G, Rasmussen HH, Orntoft 
TF, Hein B, Wolf H, Celis A.(1999) Proteomics and immunohistochemistry define 
some of the steps involved in the squamous differentiation of the bladder 
transitional epithelium: a novel strategy for identifying metaplastic lesions. Cancer 
Res. 59(12):3003-9. 
[12] Chalkley RJ, Baker PR, Huang L, Hansen KC, Allen NP, Rexach M, Burlingame 
AL.(2005) Comprehensive analysis of a multidimensional liquid chromatography 
mass spectrometry dataset acquired on a quadrupole selecting, quadrupole 
collision cell, time-of-flight mass spectrometer: II. New developments in Protein 
Prospector allow for reliable and comprehensive automatic analysis of large 
datasets. Mol Cell Proteomics 4(8):1194-204.  
[13] Chan BC, Ching AK, To KF, Leung JC, Chen S, Li Q, Lai PB, Tang NL, Shaw PC, Chan 
JY, James AE, Lai KN, Lim PL, Lee KK, Chui YL. (2008) BRE is an antiapoptotic 
protein in vivo and overexpressed in human hepatocellular carcinoma. Oncogene. 
27(9):1208-17.  
[14] Chan BC, Li Q, Chow SK, Ching AK, Liew CT, Lim PL, Lee KK, Chan JY, Chui 
YL.(2005). BRE enhances in vivo growth of tumor cells. Biochem Biophys Res 
Commun 326(2):268-73. 
[15] Chan JY, Li L, Miao J, Cai DQ, Lee KK, Chui YL.(2010) Differential expression of a novel 
gene BRE (TNFRSF1A modulator/BRCC45) in response to stress and biological 
signals. Mol Biol Rep. 37(1):363-8. 
[16] Chen HB, Pan K, Tang MK, Chui YL, Chen L, Su ZJ, Shen ZY, Li EM, Xie W, Lee KK. 
(2008) Comparative proteomic analysis reveals differentially expressed proteins 
regulated by a potential tumor promoter, BRE, in human esophageal carcinoma 
cells. Biochem Cell Biol. 86(4):302-11. 
[17] Chen R, Snyder M. (2010) Yeast proteomics and protein microarrays. J Proteomics. 
73(11):2147-57.  
[18] Ching, A.K., Li, P.S., Li, Q., Chan, B.S., Chan, J.Y., Lim, P.L., Pang, J.C., Chui, Y.L. 
(2001). Expression of human BRE in multiple isoforms. Biochem. Biophys. Res. 
Commun. 288, 535-545. 
Comparative Proteomics:  
An Approach to Elucidating the Function of a Novel Gene Called BRE 
 
131 
[19] Chowdhury SK, Katta V, Chait BT. (1990) An electrospray-ionization mass spectrometer 
with new features. Rapid Commun Mass Spectrom. 4(3):81-7. 
[20] Chung JY, Lu M, Yin Q, Lin SC, Wu H. (2007) Molecular basis for the unique specificity 
of TRAF6. Adv Exp Med Biol. 597:122-30. 
[21] Clague MJ, Urbé S. (2010) Ubiquitin: same molecule, different degradation pathways. 
Cell. 143(5):682-5. 
[22] Colucci-D'Amato L, Farina A, Vissers JP, Chambery A. (2011) Quantitative 
neuroproteomics: classical and novel tools for studying neural differentiation and 
function. Stem Cell Rev. 7(1):77-93. 
[23] Conrotto P, Souchelnytskyi S. (2008) Proteomic approaches in biological and medical 
sciences: principles and applications. Exp Oncol. 30(3):171-80. 
[24] Dong Y, Hakimi MA, Chen X, Kumaraswamy E, Cooch NS, Godwin AK, Shiekhattar R. 
(2003) Regulation of BRCC, a holoenzyme complex containing BRCA1 and BRCA2, 
by a signalosome-like subunit and its role in DNA repair. Mol Cell. 12(5):1087-99. 
[25] Dowsey AW, English JA, Lisacek F, Morris JS, Yang GZ, Dunn MJ. (2010) Image 
analysis tools and emerging algorithms for expression proteomics. Proteomics. 
10(23):4226-57. 
[26] Edman, P. (1950) Method for Determination of the Amino Acid Sequence in Peptides. 
Acta Chem Scand 10: 283-293. 
[27] Edman, P. and Begg, G. (1967) A protein Sequenator. European J. Biochem. 1: 80-91. 
[28] Esteban-Fernández D, Scheler C, Linscheid MW. (2011) Absolute protein quantification 
by LC-ICP-MS using MeCAT peptide labeling. Anal Bioanal Chem. 401(2):657-66. 
[29] Fenn JB, Mann M, Meng CK, Wong SF, Whitehouse CM. (1989) Electrospray ionization 
for mass spectrometry of large biomolecules. Science. 246(4926):64-71. 
[30] Fenn JB. (2002) Electrospray ionization mass spectrometry: How it all began. J Biomol 
Tech. 13(3):101-18. 
[31] Finnerty V, Johnson G. (1979) Post-Translational Modification as a Potential 
Explanation of High Levels of Enzyme Polymorphism: Xanthine Dehydrogenase 
and Aldehyde Oxidase in DROSOPHILA MELANOGASTER. Genetics. 91(4):695-
722. 
[32] Fleischer, B. (1983) Mechanism of glycosylation in the Golgi apparatus. J Histochem 
Cytochem. 31(8):1033-40. 
[33] Fusaro G, Dasgupta P, Rastogi S, Joshi B, Chellappan S. (2003) Prohibitin induces the 
transcriptional activity of p53 and is exported from the nucleus upon apoptotic 
signaling. J Biol Chem. 278(48):47853-61.  
[34] Galvão ER, Martins LM, Ibiapina JO, Andrade HM, Monte SJ. (2011) Breast cancer 
proteomics: a review for clinicians. J Cancer Res Clin Oncol. 137(6):915-25.  
[35] Gioia R, Leroy C, Drullion C, Lagarde V, Etienne G, Dulucq S, Lippert E, Roche S, 
Mahon FX, Pasquet JM. (2011) Quantitative phosphoproteomics revealed interplay 
between Syk and Lyn in the resistance to nilotinib in chronic myeloid leukemia 
cells. Blood. 118(8):2211-21. 
[36] Görg A, Drews O, Lück C, Weiland F, Weiss W.(2009) 2-DE with IPGs. Electrophoresis. 
30 Suppl 1:S122-32. 
[37] Görg A, Weiss W, Dunn MJ. (2004) Current two-dimensional electrophoresis 
technology for proteomics. Proteomics. 4(12):3665-85.  
 
Proteomics – Human Diseases and Protein Functions 
 
130 
[6] Bergquist J, Palmblad M, Wetterhall M, Håkansson P, Markides KE. (2002) Peptide 
mapping of proteins in human body fluids using electrospray ionization Fourier 
transform ion cyclotron resonance mass spectrometry. Mass Spectrom Rev. 21(1):2-
15. 
[7] Birr C, Frank R. (1975) Control for uniformity of synthetic peptides: quantitative 
evaluation of the Edman degradation of support-bound human insulin B 22-30 
synthetized by the Merrifield method. FEBS Lett. 55(1):68-71. 
[8] Bjellqvist B, Ek K, Righetti PG, Gianazza E, Görg A, Westermeier R, Postel W. (1982) 
Isoelectric focusing in immobilized pH gradients: principle, methodology and 
some applications. J Biochem Biophys Methods. 6(4):317-39. 
[9] Blundell TL, Johnson MS. (1993) Catching a common fold. Protein Sci. 2(6):877-83.  
[10] Ceglarek U, Kortz L, Leichtle A, Fiedler GM, Kratzsch J, Thiery J. (2009) Rapid 
quantification of steroid patterns in human serum by on-line solid phase extraction 
combined with liquid chromatography-triple quadrupole linear ion trap mass 
spectrometry. Clin Chim Acta.401(1-2):114-8.  
[11] Celis JE, Celis P, Ostergaard M, Basse B, Lauridsen JB, Ratz G, Rasmussen HH, Orntoft 
TF, Hein B, Wolf H, Celis A.(1999) Proteomics and immunohistochemistry define 
some of the steps involved in the squamous differentiation of the bladder 
transitional epithelium: a novel strategy for identifying metaplastic lesions. Cancer 
Res. 59(12):3003-9. 
[12] Chalkley RJ, Baker PR, Huang L, Hansen KC, Allen NP, Rexach M, Burlingame 
AL.(2005) Comprehensive analysis of a multidimensional liquid chromatography 
mass spectrometry dataset acquired on a quadrupole selecting, quadrupole 
collision cell, time-of-flight mass spectrometer: II. New developments in Protein 
Prospector allow for reliable and comprehensive automatic analysis of large 
datasets. Mol Cell Proteomics 4(8):1194-204.  
[13] Chan BC, Ching AK, To KF, Leung JC, Chen S, Li Q, Lai PB, Tang NL, Shaw PC, Chan 
JY, James AE, Lai KN, Lim PL, Lee KK, Chui YL. (2008) BRE is an antiapoptotic 
protein in vivo and overexpressed in human hepatocellular carcinoma. Oncogene. 
27(9):1208-17.  
[14] Chan BC, Li Q, Chow SK, Ching AK, Liew CT, Lim PL, Lee KK, Chan JY, Chui 
YL.(2005). BRE enhances in vivo growth of tumor cells. Biochem Biophys Res 
Commun 326(2):268-73. 
[15] Chan JY, Li L, Miao J, Cai DQ, Lee KK, Chui YL.(2010) Differential expression of a novel 
gene BRE (TNFRSF1A modulator/BRCC45) in response to stress and biological 
signals. Mol Biol Rep. 37(1):363-8. 
[16] Chen HB, Pan K, Tang MK, Chui YL, Chen L, Su ZJ, Shen ZY, Li EM, Xie W, Lee KK. 
(2008) Comparative proteomic analysis reveals differentially expressed proteins 
regulated by a potential tumor promoter, BRE, in human esophageal carcinoma 
cells. Biochem Cell Biol. 86(4):302-11. 
[17] Chen R, Snyder M. (2010) Yeast proteomics and protein microarrays. J Proteomics. 
73(11):2147-57.  
[18] Ching, A.K., Li, P.S., Li, Q., Chan, B.S., Chan, J.Y., Lim, P.L., Pang, J.C., Chui, Y.L. 
(2001). Expression of human BRE in multiple isoforms. Biochem. Biophys. Res. 
Commun. 288, 535-545. 
Comparative Proteomics:  
An Approach to Elucidating the Function of a Novel Gene Called BRE 
 
131 
[19] Chowdhury SK, Katta V, Chait BT. (1990) An electrospray-ionization mass spectrometer 
with new features. Rapid Commun Mass Spectrom. 4(3):81-7. 
[20] Chung JY, Lu M, Yin Q, Lin SC, Wu H. (2007) Molecular basis for the unique specificity 
of TRAF6. Adv Exp Med Biol. 597:122-30. 
[21] Clague MJ, Urbé S. (2010) Ubiquitin: same molecule, different degradation pathways. 
Cell. 143(5):682-5. 
[22] Colucci-D'Amato L, Farina A, Vissers JP, Chambery A. (2011) Quantitative 
neuroproteomics: classical and novel tools for studying neural differentiation and 
function. Stem Cell Rev. 7(1):77-93. 
[23] Conrotto P, Souchelnytskyi S. (2008) Proteomic approaches in biological and medical 
sciences: principles and applications. Exp Oncol. 30(3):171-80. 
[24] Dong Y, Hakimi MA, Chen X, Kumaraswamy E, Cooch NS, Godwin AK, Shiekhattar R. 
(2003) Regulation of BRCC, a holoenzyme complex containing BRCA1 and BRCA2, 
by a signalosome-like subunit and its role in DNA repair. Mol Cell. 12(5):1087-99. 
[25] Dowsey AW, English JA, Lisacek F, Morris JS, Yang GZ, Dunn MJ. (2010) Image 
analysis tools and emerging algorithms for expression proteomics. Proteomics. 
10(23):4226-57. 
[26] Edman, P. (1950) Method for Determination of the Amino Acid Sequence in Peptides. 
Acta Chem Scand 10: 283-293. 
[27] Edman, P. and Begg, G. (1967) A protein Sequenator. European J. Biochem. 1: 80-91. 
[28] Esteban-Fernández D, Scheler C, Linscheid MW. (2011) Absolute protein quantification 
by LC-ICP-MS using MeCAT peptide labeling. Anal Bioanal Chem. 401(2):657-66. 
[29] Fenn JB, Mann M, Meng CK, Wong SF, Whitehouse CM. (1989) Electrospray ionization 
for mass spectrometry of large biomolecules. Science. 246(4926):64-71. 
[30] Fenn JB. (2002) Electrospray ionization mass spectrometry: How it all began. J Biomol 
Tech. 13(3):101-18. 
[31] Finnerty V, Johnson G. (1979) Post-Translational Modification as a Potential 
Explanation of High Levels of Enzyme Polymorphism: Xanthine Dehydrogenase 
and Aldehyde Oxidase in DROSOPHILA MELANOGASTER. Genetics. 91(4):695-
722. 
[32] Fleischer, B. (1983) Mechanism of glycosylation in the Golgi apparatus. J Histochem 
Cytochem. 31(8):1033-40. 
[33] Fusaro G, Dasgupta P, Rastogi S, Joshi B, Chellappan S. (2003) Prohibitin induces the 
transcriptional activity of p53 and is exported from the nucleus upon apoptotic 
signaling. J Biol Chem. 278(48):47853-61.  
[34] Galvão ER, Martins LM, Ibiapina JO, Andrade HM, Monte SJ. (2011) Breast cancer 
proteomics: a review for clinicians. J Cancer Res Clin Oncol. 137(6):915-25.  
[35] Gioia R, Leroy C, Drullion C, Lagarde V, Etienne G, Dulucq S, Lippert E, Roche S, 
Mahon FX, Pasquet JM. (2011) Quantitative phosphoproteomics revealed interplay 
between Syk and Lyn in the resistance to nilotinib in chronic myeloid leukemia 
cells. Blood. 118(8):2211-21. 
[36] Görg A, Drews O, Lück C, Weiland F, Weiss W.(2009) 2-DE with IPGs. Electrophoresis. 
30 Suppl 1:S122-32. 
[37] Görg A, Weiss W, Dunn MJ. (2004) Current two-dimensional electrophoresis 
technology for proteomics. Proteomics. 4(12):3665-85.  
 
Proteomics – Human Diseases and Protein Functions 
 
132 
[38] Gu C, Castellino A, Chan JY, Chao MV. (1998) BRE: a modulator of TNF-alpha action. 
FASEB J. 12(12):1101-8. 
[39] Han MJ, Lee JW, Lee SY. (2011) Understanding and engineering of microbial cells based 
on proteomics and its conjunction with other omics studies. Proteomics. 11(4):721-
43.  
[40] Harris JL, Khanna KK. (2011) BRCA1 A‐complex fine tunes repair functions of BRCA1. 
Aging (Albany NY). 3(5):461-3. 
[41] Hillenkamp F, Karas M, Beavis RC, Chait BT. (1991) Matrix-assisted laser 
desorption/ionization mass spectrometry of biopolymers. Anal Chem. 
63(24):1193A-1203A. 
[42] Hu X, Kim JA, Castillo A, Huang M, Liu J, Wang B. (2011) NBA1/MERIT40 and BRE 
interaction is required for the integrity of two distinct deubiquitinating enzyme 
BRCC36-containing complexes. J Biol Chem. 286(13):11734-45.  
[43] Inoue J, Gohda J, Akiyama T, Semba K. (2007) NF-kappaB activation in development 
and progression of cancer. Cancer Sci. 98(3):268-74. 
[44] Joshi B, Rastogi S, Morris M, Carastro LM, DeCook C, Seto E, Chellappan SP. (2007) 
Differential regulation of human YY1 and caspase 7 promoters by prohibitin 
through E2F1 and p53 binding sites. Biochem J. 401(1):155-66. 
[45] Kretz-Remy C, Tanguay RM. (1999) SUMO/sentrin: protein modifiers regulating 
important cellular functions. Biochem Cell Biol. 77(4):299-309. 
[46] Kuwano H, Kato H, Miyazaki T, Fukuchi M, Masuda N, Nakajima M, Fukai Y, Sohda 
M, Kimura H, Faried A. (2005) Genetic alterations in esophageal cancer. Surg 
Today. 35(1):7-18. 
[47] Larbi, NB and Jefferies, C. (2009) 2D-DIGE: Comparative Proteomics of Cellular 
Signalling Pathways. Methods Mol Biol. 517:105-32. 
[48] Lau TY, O'Connor DP, Brennan DJ, Duffy MJ, Pennington SR, Gallagher WM.(2007) 
Breast cancer proteomics: clinical perspectives. Expert Opin Biol Ther. 7(2):209-19.  
[49] Lee KK, Leung AK, Tang MK, Cai DQ, Schneider C, Brancolini C, Chow PH (2001).  
Functions of the growth arrest specific 1 gene in the development of the mouse 
embryo. Dev Biol 234(1):188-203. 
[50] Lengyel P. (1966) Problems in protein biosynthesis. J Gen Physiol. 49(6):305-30. 
[51] Li Q, Ching AK, Chan BC, Chow SK, Lim PL, Ho TC, Ip WK, Wong CK, Lam CW, Lee 
KK, Chan JY, Chui YL. (2004) A death receptor-associated anti-apoptotic protein, 
BRE, inhibits mitochondrial apoptotic pathway. J Biol Chem. 279(50):52106-16.  
[52] Li, L., Yoo, H., Becker, F.F., Ali-Osman, F. and Chan, J.Y. (1995). Identification of a 
brain- and reproductive-organs-specific gene responsive to DNA damage and 
retinoic acid. Biochem. Biophys. Res. Commun. 206, 764-774. 
[53] Lill, J (2003) Proteomic Tools for Quantitation by Mass Spectrometry. Mass Spect Rev. 
22: 182-194. 
[54] Liu C, Pan C, Wang H, Yong L. (2011) Effect of surface-enhanced laser 
desorption/ionization time-of-flight mass spectrometry on identifying biomarkers 
of laryngeal carcinoma. Tumour Biol. 2011 Aug 9.  
[55] Lucas F, Barber M, Wolstenholme WA, Geddes AJ, Graham GN, Morris HR. (1969)  
Mass-spectrometric determination of the amino acid sequences in peptides isolated 
from the protein silk fibroin of Bombyx mori. Biochem J. 114(4):695-702. 
Comparative Proteomics:  
An Approach to Elucidating the Function of a Novel Gene Called BRE 
 
133 
[56] Madhunapantula SV, Robertson GP. (2009) The PTEN-AKT3 signaling cascade as a 
therapeutic target in melanoma. Pigment Cell Melanoma Res. 22(4):400-19.  
[57] Mao LM, Guo ML, Jin DZ, Fibuch EE, Choe ES, Wang JQ. (2011) Post-translational 
modification biology of glutamate receptors and drug addiction. Front Neuroanat. 
5:19. 
[58] Marko-Varga G, Berglund M, Malmström J, Lindberg H, Fehniger TE. (2003) Targeting 
hepatocytes from liver tissue by laser capture microdissection and proteomics 
expression profiling. Electrophoresis. 24(21):3800-5. 
[59] McKerrow JH, Bhargava V, Hansell E, Huling S, Kuwahara T, Matley M, Coussens L, 
Warren R. (2000) A functional proteomics screen of proteases in colorectal 
carcinoma. Mol Med. 6(5):450-60. 
[60] Miao J, Chan KW, Chen GG, Chun SY, Xia NS, Chan JY, Panesar NS. (2005) Blocking 
BRE expression in Leydig cells inhibits steroidogenesis by down-regulating 3beta-
hydroxysteroid dehydrogenase. J Endocrinol. 185(3):507-17. 
[61] Miao, J., Panesar, N.S., Chan, K.T., Lai, F.M., Xia, N., Wang, Y., Johnson, P.J. and Chan, 
J.Y. (2001). Differential expression of a stress-modulating gene, BRE, in the adrenal 
gland, in adrenal neoplasia, and in abnormal adrenal tissues. J. Histochem. 
Cytochem. 49, 491-500. 
[62] Mishra S, Ande SR, Nyomba BL. (2010) The role of prohibitin in cell signaling. FEBS J. 
277(19):3937-46.  
[63] Morris, HR, Williams, DH, Ambler RP. (1971) Determination of the Sequences of 
Protein-Derived Peptides and Peptide Mixtures by Mass Spectrometry. Biochem. J. 
125: 189-201. 
[64] Niall HD, Keutmann HT, Copp DH, Potts JT Jr. (1969) Amino acid sequence of salmon 
ultimobranchial calcitonin. Proc Natl Acad Sci U S A. 64(2):771-8. 
[65] Novak A, Amit M, Ziv T, Segev H, Fishman B, Admon A, Itskovitz-Eldor J. (2011). 
Proteomics Profiling of Human Embryonic Stem Cells in the Early Differentiation 
Stage. Stem Cell Rev. 2011 Jul 6.  
[66] O'Farrell PH.(1975) High resolution two-dimensional electrophoresis of proteins. J Biol 
Chem. 250(10):4007-21. 
[67] Ornstein DK, Rayford W, Fusaro VA, Conrads TP, Ross SJ, Hitt BA, Wiggins WW, 
Veenstra TD, Liotta LA, Petricoin EF 3rd. (2004) Serum proteomic profiling can 
discriminate prostate cancer from benign prostates in men with total prostate 
specific antigen levels between 2.5 and 15.0 ng/ml. J Urol. 172(4 Pt 1):1302-5. 
[68] Ornstein DK, Tyson DR. (2006) Proteomics for the identification of new prostate cancer 
biomarkers. Urol Oncol. 24(3):231-6. 
[69] Park YN. (2011) Update on precursor and early lesions of hepatocellular carcinomas. 
Arch Pathol Lab Med. 135(6):704-15. 
[70] Parwaresch R, Rudolph P. (1996) The Cell Cycle – Theory and Application to Cancer. 
Onkologie 19:464-472. 
[71] Perkins DN, Pappin DJ, Creasy DM, Cottrell JS. (1999) Probability-based protein 
identification by searching sequence databases using mass spectrometry data. 
Electrophoresis. 20(18):3551-67. 
[72] Sauter ER, Zhu W, Fan XJ, Wassell RP, Chervoneva I, Du Bois GC. (2002) Proteomic 
analysis of nipple aspirate fluid to detect biologic markers of breast cancer. Br J 
Cancer. 86(9):1440-3. 
 
Proteomics – Human Diseases and Protein Functions 
 
132 
[38] Gu C, Castellino A, Chan JY, Chao MV. (1998) BRE: a modulator of TNF-alpha action. 
FASEB J. 12(12):1101-8. 
[39] Han MJ, Lee JW, Lee SY. (2011) Understanding and engineering of microbial cells based 
on proteomics and its conjunction with other omics studies. Proteomics. 11(4):721-
43.  
[40] Harris JL, Khanna KK. (2011) BRCA1 A‐complex fine tunes repair functions of BRCA1. 
Aging (Albany NY). 3(5):461-3. 
[41] Hillenkamp F, Karas M, Beavis RC, Chait BT. (1991) Matrix-assisted laser 
desorption/ionization mass spectrometry of biopolymers. Anal Chem. 
63(24):1193A-1203A. 
[42] Hu X, Kim JA, Castillo A, Huang M, Liu J, Wang B. (2011) NBA1/MERIT40 and BRE 
interaction is required for the integrity of two distinct deubiquitinating enzyme 
BRCC36-containing complexes. J Biol Chem. 286(13):11734-45.  
[43] Inoue J, Gohda J, Akiyama T, Semba K. (2007) NF-kappaB activation in development 
and progression of cancer. Cancer Sci. 98(3):268-74. 
[44] Joshi B, Rastogi S, Morris M, Carastro LM, DeCook C, Seto E, Chellappan SP. (2007) 
Differential regulation of human YY1 and caspase 7 promoters by prohibitin 
through E2F1 and p53 binding sites. Biochem J. 401(1):155-66. 
[45] Kretz-Remy C, Tanguay RM. (1999) SUMO/sentrin: protein modifiers regulating 
important cellular functions. Biochem Cell Biol. 77(4):299-309. 
[46] Kuwano H, Kato H, Miyazaki T, Fukuchi M, Masuda N, Nakajima M, Fukai Y, Sohda 
M, Kimura H, Faried A. (2005) Genetic alterations in esophageal cancer. Surg 
Today. 35(1):7-18. 
[47] Larbi, NB and Jefferies, C. (2009) 2D-DIGE: Comparative Proteomics of Cellular 
Signalling Pathways. Methods Mol Biol. 517:105-32. 
[48] Lau TY, O'Connor DP, Brennan DJ, Duffy MJ, Pennington SR, Gallagher WM.(2007) 
Breast cancer proteomics: clinical perspectives. Expert Opin Biol Ther. 7(2):209-19.  
[49] Lee KK, Leung AK, Tang MK, Cai DQ, Schneider C, Brancolini C, Chow PH (2001).  
Functions of the growth arrest specific 1 gene in the development of the mouse 
embryo. Dev Biol 234(1):188-203. 
[50] Lengyel P. (1966) Problems in protein biosynthesis. J Gen Physiol. 49(6):305-30. 
[51] Li Q, Ching AK, Chan BC, Chow SK, Lim PL, Ho TC, Ip WK, Wong CK, Lam CW, Lee 
KK, Chan JY, Chui YL. (2004) A death receptor-associated anti-apoptotic protein, 
BRE, inhibits mitochondrial apoptotic pathway. J Biol Chem. 279(50):52106-16.  
[52] Li, L., Yoo, H., Becker, F.F., Ali-Osman, F. and Chan, J.Y. (1995). Identification of a 
brain- and reproductive-organs-specific gene responsive to DNA damage and 
retinoic acid. Biochem. Biophys. Res. Commun. 206, 764-774. 
[53] Lill, J (2003) Proteomic Tools for Quantitation by Mass Spectrometry. Mass Spect Rev. 
22: 182-194. 
[54] Liu C, Pan C, Wang H, Yong L. (2011) Effect of surface-enhanced laser 
desorption/ionization time-of-flight mass spectrometry on identifying biomarkers 
of laryngeal carcinoma. Tumour Biol. 2011 Aug 9.  
[55] Lucas F, Barber M, Wolstenholme WA, Geddes AJ, Graham GN, Morris HR. (1969)  
Mass-spectrometric determination of the amino acid sequences in peptides isolated 
from the protein silk fibroin of Bombyx mori. Biochem J. 114(4):695-702. 
Comparative Proteomics:  
An Approach to Elucidating the Function of a Novel Gene Called BRE 
 
133 
[56] Madhunapantula SV, Robertson GP. (2009) The PTEN-AKT3 signaling cascade as a 
therapeutic target in melanoma. Pigment Cell Melanoma Res. 22(4):400-19.  
[57] Mao LM, Guo ML, Jin DZ, Fibuch EE, Choe ES, Wang JQ. (2011) Post-translational 
modification biology of glutamate receptors and drug addiction. Front Neuroanat. 
5:19. 
[58] Marko-Varga G, Berglund M, Malmström J, Lindberg H, Fehniger TE. (2003) Targeting 
hepatocytes from liver tissue by laser capture microdissection and proteomics 
expression profiling. Electrophoresis. 24(21):3800-5. 
[59] McKerrow JH, Bhargava V, Hansell E, Huling S, Kuwahara T, Matley M, Coussens L, 
Warren R. (2000) A functional proteomics screen of proteases in colorectal 
carcinoma. Mol Med. 6(5):450-60. 
[60] Miao J, Chan KW, Chen GG, Chun SY, Xia NS, Chan JY, Panesar NS. (2005) Blocking 
BRE expression in Leydig cells inhibits steroidogenesis by down-regulating 3beta-
hydroxysteroid dehydrogenase. J Endocrinol. 185(3):507-17. 
[61] Miao, J., Panesar, N.S., Chan, K.T., Lai, F.M., Xia, N., Wang, Y., Johnson, P.J. and Chan, 
J.Y. (2001). Differential expression of a stress-modulating gene, BRE, in the adrenal 
gland, in adrenal neoplasia, and in abnormal adrenal tissues. J. Histochem. 
Cytochem. 49, 491-500. 
[62] Mishra S, Ande SR, Nyomba BL. (2010) The role of prohibitin in cell signaling. FEBS J. 
277(19):3937-46.  
[63] Morris, HR, Williams, DH, Ambler RP. (1971) Determination of the Sequences of 
Protein-Derived Peptides and Peptide Mixtures by Mass Spectrometry. Biochem. J. 
125: 189-201. 
[64] Niall HD, Keutmann HT, Copp DH, Potts JT Jr. (1969) Amino acid sequence of salmon 
ultimobranchial calcitonin. Proc Natl Acad Sci U S A. 64(2):771-8. 
[65] Novak A, Amit M, Ziv T, Segev H, Fishman B, Admon A, Itskovitz-Eldor J. (2011). 
Proteomics Profiling of Human Embryonic Stem Cells in the Early Differentiation 
Stage. Stem Cell Rev. 2011 Jul 6.  
[66] O'Farrell PH.(1975) High resolution two-dimensional electrophoresis of proteins. J Biol 
Chem. 250(10):4007-21. 
[67] Ornstein DK, Rayford W, Fusaro VA, Conrads TP, Ross SJ, Hitt BA, Wiggins WW, 
Veenstra TD, Liotta LA, Petricoin EF 3rd. (2004) Serum proteomic profiling can 
discriminate prostate cancer from benign prostates in men with total prostate 
specific antigen levels between 2.5 and 15.0 ng/ml. J Urol. 172(4 Pt 1):1302-5. 
[68] Ornstein DK, Tyson DR. (2006) Proteomics for the identification of new prostate cancer 
biomarkers. Urol Oncol. 24(3):231-6. 
[69] Park YN. (2011) Update on precursor and early lesions of hepatocellular carcinomas. 
Arch Pathol Lab Med. 135(6):704-15. 
[70] Parwaresch R, Rudolph P. (1996) The Cell Cycle – Theory and Application to Cancer. 
Onkologie 19:464-472. 
[71] Perkins DN, Pappin DJ, Creasy DM, Cottrell JS. (1999) Probability-based protein 
identification by searching sequence databases using mass spectrometry data. 
Electrophoresis. 20(18):3551-67. 
[72] Sauter ER, Zhu W, Fan XJ, Wassell RP, Chervoneva I, Du Bois GC. (2002) Proteomic 
analysis of nipple aspirate fluid to detect biologic markers of breast cancer. Br J 
Cancer. 86(9):1440-3. 
 
Proteomics – Human Diseases and Protein Functions 
 
134 
[73] Schwartz JC, Jardine I. (1996) Quadrupole ion trap mass spectrometry. Methods 
Enzymol. 270:552-86. 
[74] Shen Z, Cen S, Shen J, et al. 2000. Study of immortalization and malignant 
transformation of human embryonic esophageal epithelial cells induced by HPV18 
E6E7. J Cancer Res Clin Oncol, 126(10):589-94. 
[75] Sirot LK, Hardstone MC, Helinski ME, Ribeiro JM, Kimura M, Deewatthanawong P, 
Wolfner MF, Harrington LC. (2011) Towards a semen proteome of the dengue 
vector mosquito: protein identification and potential functions. PLoS Negl Trop 
Dis. 5(3):e989. 
[76] Tang, M.K., Wang, C.M., Shan, S.W., Chui, Y.L., Ching, A.K., Chow, P.H., Grotewold, 
L., Chan, J.Y. and Lee, K.K. (2006). Comparative proteomic analysis reveals a 
function of the novel death receptor-associated protein BRE in the regulation of 
prohibitin and p53 expression and proliferation. Proteomics 6, 2376-2385. 
[77] Tang, MK, Liu, G, Hou, Z., Chui, YL, Chan, JYH, Lee, KKH (2009) Livers 
overexpressing BRE transgene are under heightened state of stress-response, as 
revealed by comparative proteomics. Proteomics Clin. Appl. 3(12):1362-70. 
[78] Tung CS, Wong KK, Mok SC. (2008) Biomarker discovery in ovarian cancer. Womens 
Health (Lond Engl). 4:27-40. 
[79] Vercauteren FG, Arckens L, Quirion R. (2007) Applications and current challenges of 
proteomic approaches, focusing on two-dimensional electrophoresis. Amino Acids. 
33(3):405-14.  
[80] Voss T, Ahorn H, Haberl P, Döhner H, Wilgenbus K. (2001) Correlation of clinical data 
with proteomics profiles in 24 patients with B-cell chronic lymphocytic leukemia. 
Int J Cancer. 91(2):180-6. 
[81] Weiss W, Görg A. (2009)  High-resolution two-dimensional electrophoresis. Methods 
Mol Biol. 564:13-32. 
[82] Wilkins MR, Sanchez JC, Gooley AA, Appel RD, Humphery-Smith I, Hochstrasser DF, 
Williams KL.(1996) Progress with proteome projects: why all proteins expressed by 
a genome should be identified and how to do it. Biotechnol Genet Eng Rev. 13:19-
50. 
[83] Zhang Z, Bast RC Jr, Yu Y, Li J, Sokoll LJ, Rai AJ, Rosenzweig JM, Cameron B, Wang 
YY, Meng XY, Berchuck A, Van Haaften-Day C, Hacker NF, de Bruijn HW, van der 
Zee AG, Jacobs IJ, Fung ET, Chan DW. (2004)  Three biomarkers identified from 
serum proteomic analysis for the detection of early stage ovarian cancer. Cancer 
Res. 64(16):5882-90. 
[84] Zhu, W, Smith, JW and Hung, CM (2010). Mass Spectrometry-Based Label-Free 
Quantitative Proteomics. J. Biomed and Biotech 2010: 840518. 
7 
Proteomic Approaches to Unraveling  
the RB/E2F Regulatory Pathway 
Jone Mitxelena1, Nerea Osinalde2, Jesus M. Arizmendi2,  
Asier Fullaondo1 and Ana M. Zubiaga1 
1Dept. Genetics, Physical Anthropology and Animal Physiology 
University of the Basque Country, UPV/EHU, Bilbao 
2Dept. Biochemistry and Molecular Biology,  
University of the Basque Country, UPV/EHU, Bilbao 
Spain  
1. Introduction 
Correct entry into and progression through the cell cycle require an intact RB/E2F pathway, 
and its deregulation is now considered a general hallmark of cancer (Nevins 2001). Pioneer 
work in the early 90’s showed that E2F activity is controlled through the temporal 
association of E2F factors with Retinoblastoma (RB) tumor suppressor proteins (pRB, p107 
and p130), also called pocket proteins (Bandara & La Thangue 1991; Chellappan et al. 1991). 
The additional finding that RB activity is regulated through phosphorylations by cyclin 
dependent kinases (CDKs) provided the groundwork for the current model of cell cycle 
control (Weinberg 1995). According to this model, non-phosphorylated RB binds to E2F in 
G0/G1, leading to the repression of E2F target genes. Subsequent phosphorylation of RB by 
CDKs in mid-to late G1 disrupts its association with E2F. As a result, free E2F triggers the 
expression of target genes necessary for entry into and progression through the cell cycle 
(Burkhart & Sage 2008). This pathway is thought to be disrupted in most human cancers, 
either by activation of positively acting components such as G1 cyclins and CDKs, or the 
inactivation of negatively acting components such as RB and cyclin kinase inhibitors 
(Nevins 2001). The predicted consequence of deficient RB-mediated regulation is that E2F 
activity is constantly unleashed from the inhibitory effects of RB (DeGregori & Johnson 
2006; Dimova & Dyson 2005; Iaquinta & Lees 2007).  
Mammalian E2F is a family of related factors (E2F1-8), originally discovered for their pivotal 
role in transcriptional regulation of genes associated with DNA replication and G1/S 
progression (Attwooll et al. 2004; Trimarchi & Lees 2002). More recently, microarray 
expression profiling analyses and ChIP-chip analyses (chromatin immunoprecipitation 
coupled to microarray technology) in cells overexpressing individual E2Fs have revealed 
that the transactivation function of these factors exceeds beyond G1/S transition regulation. 
In fact, E2Fs regulate a wide spectrum of genes with diverse biological functions, including 
regulation of apoptosis, autophagy, mitosis, chromosome organization, macromolecule 
metabolism, or differentiation (Ma et al. 2002; Muller et al. 2001; Polager et al. 2008; Ren et 
al. 2002; Weinmann et al. 2002; Young et al. 2003). Thus, the role of E2F transcription factors 
in cellular physiology is probably more complex than it was originally thought to be.  
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Traditionally, the mammalian E2F family has been divided into “activators” (E2F1-3) and 
“repressors” (E2F4-8). However, recent in vivo data have questioned this oversimplified 
classification. Indeed, accumulating evidence suggests that most E2Fs can function both as 
activators as well as repressors, depending on the cellular context (Balciunaite et al. 2005; 
Iglesias et al. 2004; Infante et al. 2008; Lang et al. 2001; Lee et al. 2011; Ma et al. 2002; Morris 
et al. 2000; Muller et al. 2001; Polager et al. 2008; Young et al. 2003). Likewise, both 
oncogenic and tumor suppressor properties have been assigned to these factors (DeGregori 
& Johnson 2006; Johnson & DeGregori 2006). The mechanisms underlying this bimodal 
impact of individual E2Fs, and their implication in human cancer development remain to be 
elucidated. This is a particularly relevant point that needs to be addressed, since strategies 
based on E2F biology are being devised for the development of anticancer therapies (Kaelin, 
Jr. 2003). An additional level of complexity in the understanding of E2F function in vivo 
derives from the considerable functional overlap existing among several E2F members 
(Chen et al. 2009a; DeGregori & Johnson 2006). Nonetheless, the characterization of mouse 
models lacking individual E2Fs has revealed that these factors play unique roles in 
development, tissue homeostasis and tumor formation (Chen et al. 2009a; DeGregori & 
Johnson 2006; Trimarchi & Lees 2002). 
Functional specificity of individual E2F factors is thought to be established through the 
regulation of distinct sets of target genes. In fact, there is growing evidence that this 
specificity is achieved by interaction of E2Fs with other proteins or by post-translational 
modifications (PTMs) on E2Fs or E2F-containing complexes. Much of this evidence has been 
gathered through proteomic approaches such as yeast two-hybrid screening, two-
dimensional electrophoresis (2-DE) followed by mass spectrometry (MS) or shotgun 
proteomics (Figure 1). In this review, the application of proteomics in the study of RB/E2F 
regulatory pathway is summarized. Results derived from these experiments are expanding 
our current understanding of the RB/E2F biology in several important ways. They are 
piecing together the interactions within macromolecular complexes that regulate 
transcription of E2F target genes. Furthermore, they are helping define the mechanisms 
underlying RB/E2F–dependent control of cellular physiology and pathology. 
2. Identification of proteins that interact with E2Fs 
It has long been recognized that E2F activity is regulated through the association of E2F 
factors with specific protein partners. In fact, E2F1, the founder member of the family, was 
first identified as a sequence-specific DNA-binding activity that co-precipitated with RB 
(Chittenden et al. 1991). Recent development of non-hypothesis driven proteomic 
approaches has allowed a more extensive analysis of protein-protein interactions in the E2F 
field. Several methods have been successfully applied in the identification of RB/E2F 
interacting partners, in particular, yeast two-hybrid screenings and affinity purification 
coupled to MS.  
2.1 Genome-wide yeast two-hybrid interaction screening 
The yeast two-hybrid method is one of the most widely used methods for mapping protein-
protein interactions. In this method, the “bait” protein is typically expressed in yeast as a 
chimeric protein fused to the DNA-binding domain of a known transcription factor (usually 
Gal4). All other “target” proteins that the bait protein is going to be screened against are 
expressed within the cell fused to the activation domain of this same transcription factor.  
 




Fig. 1. A schematic diagram showing proteomic approaches to analyzing regulatory 
signaling pathways.  
The interaction between the bait and target proteins brings into close proximity the DNA 
binding and activation domains of the transcription factor, resulting in the activation of a 
reporter gene (Fields & Song 1989). Given that the conditions applied in this methodology 
are not physiological, some of the detected interactions may not represent true interactions. 
Consequently, this experimental system is thought to yield a high false positive rate. 
Consequently, interactions detected by this system need to be further validated in an 
appropriate physiological system. Despite the mentioned drawbacks, it is also true that the 
yeast two-hybrid interaction screening provides a method to scrutinize protein-protein 
interactions within living cells, whereas other approaches measure protein interactions after 
the complexes have been removed from the cellular environment. 
Interaction proteomics has been helpful in exploring the intricate macromolecular 
interactions established by RB and E2F for the regulation of gene expression. Work from 
many laboratories has shown that RB mediates transcriptional repression through the 
recruitment of a large number of co-repressors, resulting in an alteration of chromatin 
conformation that hinders transcription. Most RB/E2F co-repressors, including histone 
deacetylases (HDAC1-3), nucleosome remodeling proteins (BRG1), DNA methyl 
transferases (DNMT1) or RBP1 have been identified through hypothesis-driven classical 
biochemical approaches (Brehm et al. 1998; Luo et al. 1998; Magnaghi-Jaulin et al. 1998). 
Interestingly, HBP1 and CtIP/CtBP co-repressors were discovered by yeast two-hybrid 
screening analyses using the pocket protein p130 as the bait (Meloni et al. 1999a; Tevosian et 
al. 1997). HBP1, a tumor suppressor member of the HMG family of transcription factors, 
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was found to function as a transcriptional repressor of N-MYC in association with RB in 
terminally differentiated muscle cells. This finding implies a role of this complex in the 
initiation and establishment of cell cycle arrest during differentiation (Tevosian et al. 1997). 
However, E2F proteins were not found in this repressor complex. By contrast, the complex 
formed by CtIP/CtBP and p130 also included E2F1, and provided an additional mechanism 
for RB/E2F-mediated repression (Meloni et al. 1999b). In agreement with the original 
findings, it has been recently shown that CtIP/CtBP plays a transcriptional co-repressor role 
in ZBRK1 expression. ZBRK1 is a zinc finger-containing transcriptional repressor that can 
modulate the expression of GADD45A to induce cell cycle arrest in response to DNA 
damage (Liao et al. 2010). It has been proposed that the contribution of RB to DNA damage-
induced growth arrest may depend on the formation of this complex and loss of CtIP/CtBP–
mediated repression could affect the cellular sensitivity to DNA damage. Conversely, 
CtIP/CtBP is able to activate the expression of a subset of E2F-target genes after its release 
from RB-imposed repression, implying that it can also function as an activator in other 
cellular contexts (Liu & Lee 2006). 
Yeast two-hybrid screening has been particularly valuable to delve into the mechanistic 
basis for the functional specificity of E2F factors, particularly the so-called E2F “activators” 
(E2F1-3). This E2F subfamily exhibits a significant degree of functional redundancy among 
its members. However, E2F1 appears to be a stronger inducer of apoptosis than E2F2 and 
E2F3 (DeGregori et al. 1997; Hong et al. 2008; Kowalik et al. 1998; Lazzerini et al. 2005). The 
predominant role of E2F1 over the other E2F members in triggering apoptosis is thought to 
be conferred by unique protein partners that E2F1 associates with. The critical domain to 
specifically induce apoptosis has been shown to lie in the marked box of E2F1 (Hallstrom & 
Nevins 2003). Taking advantage of this knowledge, the E2F1 marked box has been used by 
Hallstrom and Nevins as the bait to screen for protein partners that could mediate E2F1-
dependent apoptosis. JAB1 (c-JUN activating-binding protein) was identified as an E2F1-
specific binding protein that functions synergistically with E2F1 to induce apoptosis 
coincident with an induction of p53 protein accumulation (Hallstrom & Nevins 2006). 
Interestingly, JAB1 association appears to regulate exclusively the apoptotic role of E2F1, as 
cell cycle entry is not affected by this E2F protein partner. In addition to JAB1, several more 
E2F1-interacting proteins were detected in this screen (Table 1), although their functional 
relevance in E2F1 function remains to be determined.  
Remarkably, the E2F marked box has emerged as an important domain for mediating 
protein interactions that could dictate specificity of promoter recognition. For example, E2F2 
and E2F3, but not E2F1 or E2F4, have been shown to interact specifically with RYBP (Ring-1 
and YY1-binding protein) through their marked box. RYBP recruits these E2Fs to target 
promoters containing YY1 binding sites such as the CDC6 promoter. It has been proposed 
that the formation of an E2F2/3-RYBP-YY1 complex would facilitate the timely activation of 
CDC6 (Schlisio et al. 2002). An independent yeast two-hybrid screen with E2F3 as the bait 
discovered TFE3 (an E-box binding factor) as a protein that specifically interacts with E2F3. 
This association, which is dependent on the marked box of E2F3, facilitates transcriptional 
activation of the p68 subunit gene of DNA Polα (Giangrande et al. 2003). Furthermore, this 
screen also yielded several more proteins that bound specifically the marked box of E2F3 
(Table 1). Some of these proteins, such as CBP, RYBP or MGA had previously been shown to 
interact with E2Fs (Morris et al. 2000; Ogawa et al. 2002; Schlisio et al. 2002; Trouche et al. 
1996), providing a strong validation of the screen. By contrast, E2F1, E2F2 and E2F4 are 
unable to bind TFE3 or to activate transcription of p68. Based on the characterization of all  
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E2F member Interacting Protein Function Reference 
E2F1 
JAB1 Promotes apoptosis Hallstron & Nevins 2006 
EAPP 
Activates transcription of TK 
and represses transcription of 
p14ARF. Promotes 
proliferation 
Novy et  al. 2005 
SKIP, CBP, TEF-5, 






n.d. Hallstron & Nevins 2006 
E2F2 
RYBP Activates transcription of CDC6 Schlisio et al. 2002 
B-MYB n.d. Giangrande et al. 2003 
ALIEN n.d. Escher et al. 2007 
EAPP n.d. Novy et  al. 2005 
E2F3 
RYBP Activates transcription of CDC6 Schlisio et al. 2002 
TFE3 Activates the p68 subunit gene of DNA Polα Giangrande et al. 2003 
RXR-BP, WNK1, 
PKI-B, SKIP, RYBP, 
CBP, TEF-5, B-
MYB, MGA, SPIB 




n.d. Hallstron & Nevins 2006 
ALIEN n.d. Escher et al. 2007 
EAPP n.d. Novy et  al. 2005 
E2F4 ALIEN n.d. Escher et al. 2007 MGA n.d. Giangrande et al. 2003 
E2F5 ALIEN n.d. Escher et al. 2007 
E2F6 ALIEN n.d. Escher et al. 2007 
Table 1. E2F-specific binding partners identified through proteomic approaches. n.d.: not 
determined 
these interactions it has been proposed that transcriptional regulation of  specific E2F target 
genes can only be achieved when relevant interacting proteins act jointly forming a functional 
complex on the promoter (Freedman et al. 2009). Therefore, the unique marked box of each 
individual E2F factor appears to play a pivotal role in determining the specificity of 
interaction. 
Other proteins exhibit E2F-binding activity independently of the marked box, allowing the 
mapping of distinct functional domains within the E2Fs. A yeast two-hybrid interaction 
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This association, which is dependent on the marked box of E2F3, facilitates transcriptional 
activation of the p68 subunit gene of DNA Polα (Giangrande et al. 2003). Furthermore, this 
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E2F member Interacting Protein Function Reference 
E2F1 
JAB1 Promotes apoptosis Hallstron & Nevins 2006 
EAPP 
Activates transcription of TK 
and represses transcription of 
p14ARF. Promotes 
proliferation 
Novy et  al. 2005 
SKIP, CBP, TEF-5, 






n.d. Hallstron & Nevins 2006 
E2F2 
RYBP Activates transcription of CDC6 Schlisio et al. 2002 
B-MYB n.d. Giangrande et al. 2003 
ALIEN n.d. Escher et al. 2007 
EAPP n.d. Novy et  al. 2005 
E2F3 
RYBP Activates transcription of CDC6 Schlisio et al. 2002 
TFE3 Activates the p68 subunit gene of DNA Polα Giangrande et al. 2003 
RXR-BP, WNK1, 
PKI-B, SKIP, RYBP, 
CBP, TEF-5, B-
MYB, MGA, SPIB 




n.d. Hallstron & Nevins 2006 
ALIEN n.d. Escher et al. 2007 
EAPP n.d. Novy et  al. 2005 
E2F4 ALIEN n.d. Escher et al. 2007 MGA n.d. Giangrande et al. 2003 
E2F5 ALIEN n.d. Escher et al. 2007 
E2F6 ALIEN n.d. Escher et al. 2007 
Table 1. E2F-specific binding partners identified through proteomic approaches. n.d.: not 
determined 
these interactions it has been proposed that transcriptional regulation of  specific E2F target 
genes can only be achieved when relevant interacting proteins act jointly forming a functional 
complex on the promoter (Freedman et al. 2009). Therefore, the unique marked box of each 
individual E2F factor appears to play a pivotal role in determining the specificity of 
interaction. 
Other proteins exhibit E2F-binding activity independently of the marked box, allowing the 
mapping of distinct functional domains within the E2Fs. A yeast two-hybrid interaction 
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screen with the amino-terminal region of E2F1 comprising the NLS but lacking the marked 
box led to the cloning of EAPP (E2F-associated phosphoprotein) (Novy et al. 2005). EAPP 
appears to potentiate the proliferative functions of E2F1 in several ways. It enhances the 
transcription of growth-correlated E2F-target genes like thymidine kinase whereas it 
represses the expression of the tumor suppressor p14ARF, an E2F1-target gene that can 
mediate E2F-induced apoptosis. Of note, EAPP can also interact with E2F2 and E2F3a 
through their amino-terminal regions (Novy et al. 2005). Consequently, EAPP could mediate 
proliferation related redundant functions of the E2F “activators” through binding to their 
well-conserved N-terminal region.  
E2F6 together with E2F7 and E2F8 have features that set them apart from other members of 
the E2F family. These factors lack RB-binding and transactivation domains, and pocket 
proteins are thought not to complex with E2F6-8 (Cartwright et al. 1998; Gaubatz et al. 1998; 
Trimarchi et al. 1998). Thus, there is a particular interest in identifying the proteins that 
interact with these non-classical E2F members and determining their mechanism for 
transcriptional regulation of target genes. Two independent yeast two-hybrid analyses have 
described distinct interactions between E2F6 and components of the Polycomb Group (PcG), 
known mammalian transcriptional repressors (Bunker & Kingston 1994). In the first study, 
E2F6 was shown to associate with members of the PRC1 complex, including some PcG 
proteins (RING1, MEL-18, MPH1, and BMI1) as well as RYBP (Trimarchi et al. 2001). The 
second screening identified the PcG protein EPC1 as a novel E2F6-binding protein, in 
complex with EZH2 and SIN3B (Attwooll et al. 2005). In both cases, the association of E2F6 
with PcG proteins could account for an RB-independent mechanism for the recruitment of 
repressive complexes to E2F6 target promoters and the consequent transcriptional 
repression (Trimarchi et al. 2001). It should be mentioned that this work did not detect an 
interaction between RYBP and E2F2 or E2F3, as shown by Schlisio and co-workers (Schlisio 
et al. 2002). The basis for this discrepancy is not clear, but could reflect methodological 
differences. However, the common ability of E2F2, E2F3 and E2F6 to interact with RYBP, 
suggests that E2F2 and E2F3 may be able to repress a subset of target genes by RB-
independent mechanisms.  
2.2 Affinity purification coupled to mass spectrometry 
Identification of protein-protein interactions is becoming increasingly easier since the 
extraordinary advances that have taken place in recent years in mass spectrometry (MS). 
Affinity purification coupled to mass spectrometry is currently the preferred method for 
screening protein-protein interactions, owing to the sensitivity, specificity and reliability 
of this approach (Gavin et al. 2002; Ho et al, 2002; Krogan et al. 2006; Sellers et al. 1998). In 
contrast to classical biochemical methods, MS-based proteomics is a discovery or 
explorative non-hypothesis driven science. However, it should be noted that the 
identification of protein complexes remains a significant challenge. This is because many 
interactions are transient and can be easily lost during sample preparation. Additionally, 
many proteins are expressed at low levels, and it remains difficult to purify them. In fact, 
isolating the protein complex is the most critical step in determining the success of a 
proteomic analysis. The most widely used method for protein complex isolation is 
antibody-based immunoprecitation (IP), although MS is also compatible with other 
affinity purification methods used to map protein-protein interactions, such as 
oligoprecipitation and tagged protein precipitation by affinity (“protein pull-
down”)(Gavin et al. 2002; Meng et al. 2006).  
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A wide range of RB/E2F partners have been identified to date by MS. Remarkably, the 
discovered proteins are mainly involved in transcriptional repression, which highlights the 
critical role of the RB/E2F network in the timely suppression of target gene expression. 
Combining immunological methods with an uncommon mass spectrometric technique 
named SELDI (surface-enhanced laser desorption/ionization)(Lehmann et al. 2005), co-
repressor ALIEN was identified in E2F1 containing endogenous protein complexes (Escher 
et al. 2007). Additional co-immunoprecipitation experiments revealed specific interactions of 
ALIEN with E2F2 through E2F6. ALIEN is able to repress E2F1 transcriptional activity when 
tethered to target promoters containing E2F binding sites (Tenbaum et al. 2007). The 
mechanism for this repressive activity remains undetermined. An RB-dependent process 
has been proposed, based on the finding that ALIEN interacts with pRB/p107 and HDAC 
(Escher et al. 2007). However, ALIEN-mediated co-repression is also evident in cells lacking 
functional RB (Tenbaum et al. 2007). 
Affinity purification coupled to MS analysis has been particularly useful in the identification of 
native RB/E2F transcriptional repressor complexes (Table 2). They were firstly characterized 
in Drosophila melanogaster (Korenjak et al. 2004). Subsequently, homologous complexes were 
identified in other animal species, including Caenorhabditis elegans and human (Harrison et al. 
2006; Litovchick et al. 2007), emphasizing the importance of this pathway. Before the 
application of proteomic methods, a wide assortment of chromatin-modifying and binding 
complexes had been implicated in RB-mediated repression (Frolov & Dyson 2004). However, it 
is unclear which of the many reported interactions are biologically meaningful, due to the non-
physiological methods employed for the screening. In an effort to characterize native RB/E2F 
repressor complexes in Drosophila, Brehm´s group took advantage of the relative simplicity of 
the Drosophila dRB/E2F network, consisting of two pocket proteins, RBF1 and RBF2, and two 
E2F proteins, dE2F1 and dE2F2 that heterodimerize with a common partner, dDP. By classical 
chromatography followed by MS analysis of the resulting fractions, they isolated an RBF 
multisubunit complex, termed dREAM (Korenjak et al. 2004), which contains RBF1/2, dE2F2, 
dDP, dMyb and dMyb-interacting proteins (Mip/TWIT, CAF1p55, Mip40 and Mip120). 
Interestingly, an independent analysis of Myb-associated proteins, involving affinity 
chromatography and DALPC mass spectrometry analysis (direct analysis of large protein 
complexes) resulted in the identification of a similar complex in Drosophila that was called 
Myb–MuvB complex (Lewis et al. 2004). 
In agreement with a role in transcriptional repression, the identified complexes localize to 
transcriptionally silent sites on polytene chromosomes and mediate stable repression of a 
specific set of E2F targets that have sex- and differentiation-specific expression patterns. The 
mechanism by which these repressive complexes mediate the silencing of their target genes 
has been controversial, and enzymatic and non-enzymatic modes of repression have been 
suggested (Korenjak et al. 2004; Lewis et al. 2004). The finding that dREAM only binds 
deacetylated histone H4, characteristic of repressed chromatin, suggests that dREAM 
complexes perform their repressive function through binding unmodified nucleosomes and 
therefore protecting them from activating modifications (Korenjak et al. 2004). This 
hypothesis was further supported by the identification of histone deacetylase Rpd3, the 
HDAC1 homolog in Drosophila, associated with the repressor complex (Lewis et al. 2004). 
Strikingly, at least seven, and possibly all dREAM subunits are related to C. elegans synMuv 
class B genes (Fay & Han 2000). These proteins encompass the DRM complex, genetically 
resolved by Harrison and collaborators, which controls vulval differentiation in the worm 
(Harrison et al. 2006). The similarity between the worm DRM and the fly dREAM and Myb– 
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independent mechanisms.  
2.2 Affinity purification coupled to mass spectrometry 
Identification of protein-protein interactions is becoming increasingly easier since the 
extraordinary advances that have taken place in recent years in mass spectrometry (MS). 
Affinity purification coupled to mass spectrometry is currently the preferred method for 
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of this approach (Gavin et al. 2002; Ho et al, 2002; Krogan et al. 2006; Sellers et al. 1998). In 
contrast to classical biochemical methods, MS-based proteomics is a discovery or 
explorative non-hypothesis driven science. However, it should be noted that the 
identification of protein complexes remains a significant challenge. This is because many 
interactions are transient and can be easily lost during sample preparation. Additionally, 
many proteins are expressed at low levels, and it remains difficult to purify them. In fact, 
isolating the protein complex is the most critical step in determining the success of a 
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A wide range of RB/E2F partners have been identified to date by MS. Remarkably, the 
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critical role of the RB/E2F network in the timely suppression of target gene expression. 
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repressor ALIEN was identified in E2F1 containing endogenous protein complexes (Escher 
et al. 2007). Additional co-immunoprecipitation experiments revealed specific interactions of 
ALIEN with E2F2 through E2F6. ALIEN is able to repress E2F1 transcriptional activity when 
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mechanism for this repressive activity remains undetermined. An RB-dependent process 
has been proposed, based on the finding that ALIEN interacts with pRB/p107 and HDAC 
(Escher et al. 2007). However, ALIEN-mediated co-repression is also evident in cells lacking 
functional RB (Tenbaum et al. 2007). 
Affinity purification coupled to MS analysis has been particularly useful in the identification of 
native RB/E2F transcriptional repressor complexes (Table 2). They were firstly characterized 
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identified in other animal species, including Caenorhabditis elegans and human (Harrison et al. 
2006; Litovchick et al. 2007), emphasizing the importance of this pathway. Before the 
application of proteomic methods, a wide assortment of chromatin-modifying and binding 
complexes had been implicated in RB-mediated repression (Frolov & Dyson 2004). However, it 
is unclear which of the many reported interactions are biologically meaningful, due to the non-
physiological methods employed for the screening. In an effort to characterize native RB/E2F 
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the Drosophila dRB/E2F network, consisting of two pocket proteins, RBF1 and RBF2, and two 
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Lewis et al. 2004 
E2F1 
CtIP/CtBP, p130 
Repression of ZBRK1. 
RB-dependent growth 
arrest after DNA 
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expression and cellular 
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Escher et al. 2007 








repression of cell cycle 
genes in G0 




RYBP, RING1, MEL-18, 
MPH1, BMI1 
not determined Trimarchi et al. 2001 
Complex: 
EPC1, EZH2, SIN3B 
Target gene repression 
in proliferating cells Attwoll et al. 2005 
Complex: 
MGA, MAX RING1/2, 
MBLR, h-l(3)MBT-like, 
YAF2, HP1γ 
Target gene repression 
in quiescent cells Ogawa et al. 2002 
Table 2. Multiprotein complexes encompassing E2F factors identified by proteomic 
approaches. 
MuvB complexes indicates that the DRM complex likely acts in transcriptional repression of 
E2F targets, and implies a remarkable conservation in the mechanism of pocket protein 
function across species. 
An integration of proteomic, genomic, and bioinformatic approaches has allowed 
DeCaprio’s group the identification and functional characterization of human DREAM, the 
homolog of the fly dREAM (Litovchick et al. 2007). To determine the composition of this 
complex the authors purified p130-associated proteins and applied a multidimensional 
protein identification method (MudPIT). This method couples biphasic and triphasic 
microcapillary columns to high performance liquid chromatography followed by tandem 
mass spectrometry analysis (Florens & Washburn 2006). The core components of the 
identified complex include p130, E2F4/5, DP1/2 and mammalian orthologs of synMuvB 
proteins LIN9, LIN37, LIN52, LIN54, and LIN53/RBBP4 (also known as LIN complex). 
Interestingly, the human DREAM repressor complex differs from the fly complex in that it 
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lacks MYB. In fact, MYB immunoprecipitates with LIN9, LIN37, and LIN54, but not with 
E2F or p130 in human cells, indicating the existence of two distinct transcriptional 
complexes incorporating either p130 or MYB. Indeed, several reports have demonstrated 
that the complex composition is dynamic and cell cycle phase-dependent. In quiescent cells 
LIN complex proteins associate with p130 and E2F4, and the complex binds to its target 
genes. In late G1/S phase, E2F4 and p130 dissociate and the LIN complex associates with 
MYB (Litovchick et al. 2007; Schmit et al. 2007), forming a new complex that is required for 
activation of G2/M genes. The dynamic interaction of the LIN complex with different 
DNA-binding proteins (E2F4 vs. MYB) supports a model in which DREAM is bound in G0 
to E2F-regulated promoters via E2F4/p130 and in S-phase to G2/M promoters via MYB. 
Another finding that distinguishes the human complex from its fly and worm orthologs is 
that human DREAM does not appear to regulate target genes involved in development 
(Litovchick et al. 2007). 
Mass spectrometry has also been applied to elucidate the mechanism by which E2F6 
regulates transcriptional repression in quiescent cells. E2F6 was shown to interact directly 
with MGA and MAX (Ogawa et al. 2002). These proteins are known to bind as heterodimers 
to E boxes such as the MYC binding elements, and to antagonize MYC function (Hurlin et 
al. 1999). Given that MYC and E2F share common functions such as mitotic responses, cell 
cycle stimulation and induction of apoptosis, it has been proposed that E2F- and MYC-
responsive genes could be co-regulated by E2F6 (Ogawa et al. 2002). In the complex 
containing E2F6-MGA-MAX, several Polycomb group proteins (RING1/2, MBLR, h-
l(3)MBT-like protein, and YAF2) are also present, together with HP1γ, a methyltransferase 
related to gene silencing in euchromatic loci (Horsley et al. 1996). The recruitment of E2F6 to 
its target genes could form a “platform” that is required for nucleating PcG proteins. 
Subsequent recruitment of HP1γ to this platform would propagate chromatin inactivation, 
leading to entire repressed regions (Ogawa et al. 2002). It is remarkable that as many as 
three types of E2F6 repressor complexes containing different PcG proteins have been 
identified by proteomic methods (Table 2). The biological relevance for such diversity has 
not been clarified, although there is evidence that these complexes could be formed at 
different phases throughout the cell cycle. MAX and HP1γ were found associated with E2F 
target promoters in G0, but not following re-entry into the cell cycle, suggesting a role for 
this complex in gene repression in quiescent cells (Ogawa et al. 2002). By contrast, the PcG 
protein EZH2 only forms complexes with E2F6-EPC1 in proliferating cells, suggesting that 
this complex regulates genes required for cell cycle progression (Attwooll et al. 2005). 
Deciphering the protein interactome of upstream components of the RB/E2F pathway has 
also led to the characterization of new functions of the pathway. This is the case of a recently 
work published by Sicinski´s group in which cyclin D1 protein partners were characterized 
by immunoaffinity purification coupled to MS analysis (Jirawatnotai et al. 2011). 
Identification of cyclin D1 interactors revealed a network of DNA repair proteins, including 
RAD51, a key DNA recombinase that drives the homologous recombination process in 
response to DNA damage (Baumann & West 1998). Remarkably, the finding that Cyclin 
D1´s function in DNA repair appears to be independent of its kinase activity could have 
clinical applications. For instance, a large pool of RB-negative cancers, which do not require 
D-cyclins for proliferation, may still be benefited by therapeutic interventions targeting 
cyclin D1 in combination with radiation treatment. This work clearly shows how 
interacting-proteomics can fundamentally change our understanding of signaling networks 
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lacks MYB. In fact, MYB immunoprecipitates with LIN9, LIN37, and LIN54, but not with 
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complexes incorporating either p130 or MYB. Indeed, several reports have demonstrated 
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and how combining multiple approaches is possible to unveil novel therapeutic strategies to 
different disorders such as oncogenic malignancies. 
3. Post-translational modifications on E2F transcription factors 
Post-translational modifications (PTMs) are gene non-template chemical modifications 
occurring at distinct amino acid side chains of proteins. PTMs can change the size, charge-
state, structure or conformation of proteins. As a result, PTMs influence several aspects that 
directly or indirectly affect protein function. Sub-cellular localization (Mueller et al. 2009), 
protein half-life (Min et al. 2010) or binding affinity to other molecules such as nucleic acids, 
lipids or other proteins (Takasaki et al. 1999) are usually conditioned by these modifications. 
Consequently, PTMs play a key role in functional proteomics and are involved in the 
modulation of almost every single cellular process. Not surprisingly, malfunctions on these 
critical cellular processes have usually been related to several diseases (Ko et al. 2010; Song 
et al. 2010). More than 300 types of PTMs have been described to date and the number and 
variety of identified modifications is continuously increasing (Zhao & Jensen 2009). Some 
modifications such as phosphorylation, acetylation, glycosylation and methylation are very 
common and are found in almost every protein while others, for example biotinylation, are 
very rare. Given the high abundance, dynamism and diversity of PTMs, they likely 
constitute one of the most complex regulatory mechanisms in eukaryotic cells. 
The E2F transcription factors are not an exception to such modifications, as they are known 
to be regulated by a variety of PTMs. In the mid 90’s in vitro assays showed that 
ubiquitination occurring at the C-terminal end of E2F1 is determinant in mediating cell 
cycle-dependent degradation of this transcription factor by the ubiquitin/proteasome 
pathway (Hofmann et al. 1996). Additionally, two independent studies concluded that E2F1-
3 but not E2F4-6 can be acetylated by p300/CBP acetyltransferases. Further in vitro 
acetylation assays using deletion mutants of E2F1, restricted the site of acetylation to three 
conserved lysine residues located at the N-terminal region of its DNA binding domain. This 
modification could be reversed by HDAC1, and was found to influence the DNA-binding 
ability of E2F1 and consequently its transcriptional activity (Martinez-Balbas et al. 2000; 
Marzio et al. 2000). More recently, Set9 methyltransferase and LSD1 demethylase have been 
shown to regulate E2F1-mediated p53-independent cell death (Kontaki & Talianidis 2010; 
Xie et al. 2011). Interestingly, a complex cross-talk between different PTMs was found on 
E2F1. Precisely, Set9-catalyzed methylation at Lys185 inhibits acetylation and 
phosphorylation events involved in the stabilization of E2F1, while ubiquitination, known to 
favor protein degradation, is stimulated (Kontaki & Talianidis 2010). Although these diverse 
PTMs have been described to affect the biological functions of E2Fs, phosphorylation has 
been the most studied modification. 
3.1 Biochemical analysis of phosphorylations 
Phosphorylation of proteins is a highly dynamic process involved in the regulation of 
several essential cellular functions such as cell cycle regulation, differentiation and signal 
transduction. Given its biological relevance, the identification and kinetic studies of protein 
phosphorylation have become a major challenge in molecular biology. Pioneer works 
describing phosphorylation events on E2F were mainly based on results obtained from 
electrophoretic mobility shift assays (Peeper et al. 1995) and in vitro kinase assays (Lin et al. 
2001; Vandel & Kouzarides 1999). A major common feature of these studies is that they were 
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hypothesis-driven, that is, the identification of the PTMs was, to an extent, a targeted 
approach. Moreover, each work was focused on individual proteins where a single or a few 
modifications were described at a time. Consequently, the information about PTMs affecting 
the biological function of E2Fs has been considerably limited. Indeed, these classical 
approaches have led to the identification and characterization of merely 7 phosphorylations 
on E2F1 over a period of 10 years, all of which are registered in the Phosphosite database 
(Hornbeck et al. 2004). Phosphorylation of E2F1 at Ser332 and Ser337 disrupts its interaction 
with RB to become transcriptionally active (Fagan et al. 1994). By contrast, phosphorylation 
at Ser375 increases its ability to interact with RB and, consequently, decreases its DNA 
binding capacity (Peeper et al. 1995). Phosphorylation of E2F1 residues Ser403 and Thr433 
by TFIIH kinase in S-phase triggers rapid degradation of the transcription factor (Vandel & 
Kouzarides 1999). Finally, two residues on E2F1, Ser31 and Ser364, can be phosphorylated in 
response to DNA damage by ATM/ATR and Chk1 kinases, respectively. Both 
phosphorylations are involved in E2F1-mediated apoptosis (Lin et al. 2001; Stevens et al. 
2003). Phosphorylation of E2F3a at Ser124 and its role in DNA-damage induced apoptosis 
has also been described by classical biochemical approaches (Martinez et al. 2010).  
3.2 MS-based identification of phosphorylations 
Recent advances in mass spectrometry have largely overcome the disadvantages faced by 
classical biochemical approaches allowing the large-scale identification of phosphorylated 
peptides and the more challenging localization of them within the peptide sequence. In 
order to decipher the biological meaning of site-specific phosphorylation events in the 
regulation of cellular processes, quantitative phosphoproteomics studies have produced a 
considerable body of work during the last 5 years. As a result, thousands of new 
phosphorylations have been identified (Huttlin et al. 2010; Monetti et al. 2011), some of them 
corresponding to E2F family members.  
Due to the low stoichiometry of site-specific phosphorylation, refinement of phosphopeptide 
enrichment methodologies has been crucial for the fruitful characterization of this type of PTM 
by MS. Currently, there are several phosphopeptide enrichment methods available, such as 
strong cation exchange chromatography (SCX) (Beausoleil et al. 2004), hydrophilic interaction 
chromatography (HILIC) (Boersema et al. 2007), immobilized metal affinity chromatography 
(IMAC) (Li & Dass 1999) and titanium dioxide enrichment method (TiO2) (Larsen et al. 2005; 
Pinkse et al. 2004). They all manage to separate phosphorylated peptides from non-
phosphorylated ones taking advantage of the properties that the negative charge of the 
phosphate groups confer to phosphopeptides. Antibody-based enrichment approaches have 
also been demonstrated to be very efficient and useful for phosphoprotein/phosphopeptide 
enrichment (Choudhary et al. 2009). For optimal analysis of the phosphoproteome these 
methods are usually combined in multi-stage enrichment strategies (Thingholm et al. 2008). In 
addition, implementation of quantitation methods has opened new perspectives in studies of 
complex and dynamic biological signaling networks. In the past decade, highly accurate 
techniques based on stable isotope labeling for protein quantitation by MS have been 
developed. Stable isotope labeling of amino acids in cell culture (SILAC) (Ong et al. 2002) and 
iTRAQ (Ross et al. 2004) are currently the most frequently used techniques in quantitative MS-
based phosphoproteomics.  
The first global in vivo SILAC-based quantitative phosphoproteomic study to be reported 
was performed by Mann’s group. It combined SCX and TiO2 enrichment of 
phosphopeptides followed by LC-MS/MS analysis to quantify changes in phosphopeptide 
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levels in response to EGF treatment (Olsen et al. 2006). From the 6,600 phosphosites 
corresponding to 2,244 proteins that were detected in this study, the previously described 
E2F1 phosphoserine-375 (pSer375) (Peeper et al. 1995) was identified. This large-scale 
analysis showed that the phosphorylation state of E2F1 Ser375 is independent of EGF 
treatment, since the amount of phosphopeptide remained constant over time after the 
addition of the stimulus (Olsen et al. 2006). 
Similar studies carried out by Dephoure and colleagues combined SILAC-based 
quantitation with SCX followed by TiO2 and IMAC to assess the quantitative atlas of mitotic 
phosphorylation on HeLa cells. MS analysis of enriched phosphopeptides revealed the 
presence of E2F1 pSer375 in G1 phase cell lysates. In addition, two new phosphorylations 
were identified on E2F2 and a single one on E2F7. E2F2 residues Ser133 and Tyr130 were 
shown to be phosphorylated during the M phase of the cell cycle while E2F7 Ser410 was 
found to be phosphorylated in G1 phase (Dephoure et al. 2008).  
Additional quantitative phosphoproteomic studies have reported the identification of a 
large number of phosphoresidues on various members of the E2F family, some of which had 
not been reported before (Figure 2). To decipher the phosphorylation dynamics occurring 
during early differentiation of human embryonic stem cells, a SILAC-based quantitation 
combined with SCX and TiO2 followed by MS analysis was performed (Van et al. 2009). Of 
the 5,222 identified proteins, 1,399 were phosphorylated in 3,067 residues. Two 
phosphorylated residues, pSer16 and pThr14 precisely, corresponded to E2F4 and were first 
described in this work. Quantitative phosphoproteomic analysis of T cell receptor signaling 
revealed the existence of 2 new phosphorylations on E2F family members. Apart from the 
phosphorylations at Ser375 and Ser332, previously described to affect E2F1 binding affinity 
for RB (Fagan et al., 1994; Peeper et al., 1995), a new phosphorylated serine at position 340 
was detected on E2F1. Moreover, phosphorylation on E2F2 Ser117 was also observed in this 
analysis (Mayya et al. 2009).  
A quantitative phosphoproteomic analysis focused on dissecting the rapamycin-dependent 
activation of oncogenic cascades also identified several new phosphorylation sites on E2Fs 
(Chen et al. 2009b). Differentially SILAC labeled cells were cultured in the presence or 
absence of rapamycin, and stimulated with EGF. Both protein lysates were combined, 
digested and phosphopeptides were subjected to double IMAC purification followed by 
MudPIT LC-MS/MS analysis. Of the 6,175 phosphosites identified in this screening, 3 
corresponded to E2F8. For the first time, E2F8 Ser355, Ser357 and Ser358 were found 
phosphorylated. Quantitative phosphoproteomics was also applied in mouse cells to 
unravel the signaling cascade initiated in response to the oncogenic mutant receptor 
tyrosine kinase FIt3. This kinase has been involved in the development of several 
hematopoietic malignancies (Stirewalt & Radich 2003). A total of 14,700 phosphosites were 
identified, of which 1 corresponded to E2F7 (pTyr416) and 5 to E2F8 (pSer20, pSer71, 
pSer102, pSer358 and pSer429) (Choudhary et al. 2009). The Tyr416 residue of mouse E2F7 is 
not conserved in humans. By contrast, 4 of the 5 novel murine E2F8 phosphosites identified 
in this screening are conserved in humans, suggesting that they may be biologically relevant 
(Choudhary et al. 2009). In fact, pSer71 of E2F8 has recently been detected in the 
phosphoproteome of human embryonic stem cells undergoing differentiation (Rigbolt et al. 
2011). In this report, an additional phosphosite on E2F8, pSer316, was described. Recently, in 
an attempt to elucidate the mechanism that regulates the switch of the MuvB core from B-
MYB to DREAM, phosphorylation of E2F4 at Ser384 was detected. This phosphorylation 
could contribute to entry of cells into quiescence (Litovchick et al. 2007).  
 




Fig. 2. Phosphorylations detected in human E2F family members. In black phosphorylations 
detected by classical biochemical methods; in red, phosphorylations detected by MS; in bold 
red, phosphorylations detected by both methods. S: Serine; T: Threonine; Y: Tyrosine. 
Novel methodological approaches in SILAC-based quantitative phosphoproteomics include 
a double phosphopeptide enrichment using IMAC followed by HILIC. This kind of strategy 
has allowed the identification of pSer7 on E2F8 (Yao et al. 2011). Furthermore, quantitative 
data indicated that protein SUMOylation influences phosphorylation detected at residue 
Ser7, since inhibition of SUMOylation was found to increase the amount of pSer7. This new 
evidence of cross-talk between different PTMs underscores once more the complexity of 
PTMs and the relevance of the combinatorial PTM patterns.  
4. Protein profiling to elucidate E2F function 
A large number of potential E2F targets have been discovered recently through the 
application of high throughput transcriptomic analyses. However, mRNA abundance 
poorly correlates with protein levels. This discrepancy can in part be explained by several 
post-transcriptional mechanisms such as alternative splicing of pre-mRNAs, microRNA 
mediated regulation, or selective degradation and post–translational modifications of 
proteins. Therefore, protein expression analyses should be carried out in addition to mRNA 
expression analyses to achieve a full picture of E2F regulated pathways.  
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Two-dimensional gel electrophoresis (2-DE) combined with protein identification by MS has 
been the most popular method in expression proteomics. In this global protein profiling 
approach, 2-DE is used to separate proteins within a complex mixture based on their pI and 
molecular weight. Subsequent staining and image analysis can detect differences in spot 
intensities, rendering a list of proteins that are differentially expressed between the 
conditions under comparison. The resulting spots are then excised and analyzed by MS 
(Görg et al. 2004). Global protein expression analyses of cells that either overexpress or are 
deficient for individual E2Fs have emerged as a useful methodology to elucidate the 
spectrum of E2F activity. Pützer’s group analyzed protein expression in p53-deficient 
osteosarcoma cells (Saos-2) expressing E2F1 fused to the murine estrogen receptor ligand-
binding domain (ER). This construction permitted conditional activation of E2F1 after 
addition of 4-hydroxytamoxifen (4-OHT) to the cultures (Stanelle et al. 2002). 2-DE analysis 
of E2F1 induced and non-induced Saos-2 cells’ proteome led to the identification of 33 novel 
differentially regulated E2F1 target proteins by MALDI-MS (Li et al. 2006b), 15 upregulated 
and 18 dowregulated. Only eight of these differentially regulated proteins harbor E2F-
consensus sites in their promoter (Rabinovich et al. 2008): SRSF1, TUBB, GDI2, H2B.1, 
TCP1γ, HNRNPA2/B1, HNRNPK and MATR3. Nevertheless, since E2F1 overexpression 
was the only stimulus applied to the culture, most of the identified target genes are 
probably E2F1 targets. Functional analysis of E2F1-regulated target genes suggests that E2F1 
plays predominantly a negative role in Saos-2 cellular proliferation. By altering the balance 
between anti- and pro-apoptotic Bcl-2 family members, E2F1 would render cells susceptible 
to both mitochondrial apoptosis and ER-stress related death signals (Li et al. 2006b). These 
results are consistent with the findings described by several groups, including ours, in 
mouse models lacking E2F1, and favor the hypothesis that E2F1 plays anti-proliferative and 
pro-apoptotic roles in vivo (Field et al. 1996; Garcia et al. 2000; Yamasaki et al. 1996). 
A similar pro-apoptotic role has been attributed to E2F1 in proteomic analyses involving 
p53-wild-type osteosarcoma cells (U2OS) carrying an inducible E2F1 transgene. 2-DE 
followed by MS led to the identification of 76 proteins, 53 overexpressed and 23 suppressed 
after E2F1 induction (Liontos et al. 2009). Many of them appear to be potentially novel E2F1-
regulated targets. As many as 63% and 77% of the overexpressed and suppressed proteins, 
respectively, harbor E2F1 responsive elements in their promoters. The spectrum of 
identified E2F1-regulated proteins included chaperones, metabolic enzymes, proteins 
associated with RNA processing, components of the protein degradation/turnover 
machinery, cytoskeletal and motor/contractile related proteins, regulatory and cell signaling 
molecules, transport carriers and channels, as well as putative oncogenes. A significant 
number of the identified E2F1 downstream targets are part of pro-apoptotic signaling 
cascades regulating ATM and/or p53. In agreement with an oncosuppressor function for 
E2F1 in vivo, the authors reported a positive correlation between E2F1 expression and DNA 
damage response and apoptosis in primary osteosarcoma tumors with wild-type p53. This 
picture is contrary to the general view that the increased levels of E2F activators, such as 
those observed in many cancer types, are mediating uncontrolled proliferation (Chen et al. 
2009a). Whether deregulated expression of E2F proteins promotes or limits cancer 
progression has not been unequivocally established. Other factors, such as RB or p53 status 
may determine the final outcome of E2F-dependent activity in each particular context. 
Protein profiling analyses performed by our group are also helping to unveil the 
physiological role of E2F2. A repressor function for E2F2 is emerging from these studies, in 
agreement with DNA microarray and functional data. When quiescent E2F2-/- and wild-
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type T lymphocyte expression profiles were gathered by 2-DE followed by MS, we 
identified a set of deregulated proteins involved in TCR-mediated signaling, cell survival 
and stress responses (Azkargorta et al. 2006). The aberrant expression of these proteins was 
linked to the hyperproliferative phenotype that characterizes E2F2-deficient cells (Iglesias et 
al. 2004; Infante et al. 2008; Murga et al. 2001; Zhu et al. 2001). Interestingly, comparative 
proteomics has also revealed novel pathways regulated by E2F2. We have recently found 
that mediators of the Aryl-hydrocarbon receptor (AHR) are aberrantly expressed in the 
proteome of proliferating E2F2-/- lymphocytes relative to wild-type counterparts 
(Azkargorta et al. 2010). Consequently, E2F2-/- cells exhibit an increase in their sensitivity to 
dioxin-triggered apoptosis. These results suggest that E2F2 modulates cellular sensitivity to 
xenobiotic signals through the negative regulation of the AHR pathway. 
Remarkably, a comparison of proteome and transcriptome profiling results derived from the 
same cellular systems has shown a clear discrepancy in individual targets regulated by E2Fs 
(Azkargorta et al. 2006; Azkargorta et al. 2010; Infante et al. 2008; Li et al. 2006a; Liontos et 
al. 2009; Muller et al. 2001). These discrepancies may be explained by the different methods 
of assay/sample preparation, different detection sensitivity, alternative splicing, post-
transcriptional regulation, PTMs, selective degradation of proteins, and the time 
discrepancy between mRNA and protein expression. Thus, proteomics and DNA-based 
technologies should be considered as complementary approaches.  
4.1 The RB/E2F pathway in cancer protein profiling 
Transcriptomic analyses have demonstrated a commonly conserved RB/E2F-dependent 
“proliferation signature” in cancer cells, supporting a role for this pathway in regulation of 
cellular proliferation in normal as well as tumor cells (Whitfield et al. 2006). Given the 
prevalence of this signature in cancer, a similar finding would be expected at the protein 
level. However, most 2-DE/MS-based proteomic analyses of tumor cells performed to date 
have not displayed this pathway unequivocally, probably due to the limitations of the 
technology. An important drawback of traditional 2-DE-based proteomic methods is that 
they can only reveal the presence of highly abundant proteins within the cells, whereas 
proteins that function at low levels, such as certain transcription factors and 
checkpoint/regulatory proteins, are not easily identified if no pre-enrichment and/or pre-
fractionation steps are applied (Gygi et al. 2000). In general, the number of proteins 
identified in these experiments is quite low, in the range of 100-300 proteins per experiment. 
This number is several orders of magnitude lower than the thousands of genes that can be 
interrogated by DNA microarray analyses. Consequently, cancer proteome profiles gathered 
to date with this technology should, in general, be considered as preliminary. 
An RB/E2F dependent signature was appreciable in the proteome of cervical cancer cells 
with high-risk HPV infection analyzed by 2-DE and MS. Differentially expressed proteins in 
cervical cancer cells were identified and functionally classified as proteins involved in the 
regulation of the cell cycle, general genomic stability, telomerase activation and cell 
immortalization (Choi et al. 2005). A significant proportion of these genes (30%), particularly 
those present in the nuclear fraction, are well-known E2F transcriptional targets (PCNA, 
CDC25A, MCM3,4,8, CHRAC-1), most of which were upregulated. As exceptions, XRCC2 
involved in DNA repair and CASP-2 involved in apoptosis induction, which were 
downregulated. These results are consistent with a model in which functional inactivation of 
RB by HPV oncoprotein E7 unleashes E2F and triggers aberrant E2F-dependent gene 
expression (McLaughlin-Drubin & Munger 2009). By contrast, a similar type of analysis 
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performed with retinoblastoma tumors, whereby both copies of the RB1 gene are 
inactivated, did not identify any E2F targets among the 27 differentially expressed proteins 
(Mallikarjuna et al. 2010). In this work, more aggressive tumors showed significantly higher 
expression of CRABP2, APOA1, PRDX6 and RCVRA, and lower expression of CRABP1. 
Differentially expressed proteins were shown to be involved in metabolic process, transport 
activity, response to oxidative stress, development, and cell signaling and transduction, 
reflecting the important role of these processes during retinoblastoma progression.  
In general, 2-DE/MS-based proteomic analyses of cancer cells have barely yielded a handful 
of E2F-target genes among the differentially expressed proteins. For example, the 
comprehensive proteome profiles of mouse lung adenocarcinoma cell lines, have revealed 
82 and 40 unique proteins significantly up- or down-regulated respectively in highly 
metastatic cells compared to low metastatic controls (Zhang et al. 2008). Several of the 
proteins are involved in proteasome, cell-cycle and cell-cell communication pathways. 
Among them, several E2F targets have previously been associated with cancer development 
and metastasis: KRT8, the main cytokeratin in lung cancer, MCM7, a highly informative 
biomarker for cervical cancer, or ANX4, overexpressed in pancreatic adenocarcinoma. 
Similarly, a comparative proteome analysis of human lung squamous carcinoma and paired 
normal bronchial epithelial tissues revealed some deregulated E2F target genes in a list of 68 
proteins that were identified by MS (LTBP4, GNB1L, MDM2, IRS1)(Li et al. 2006a).  
As 2-DE/MS methodology is being replaced by more powerful techniques, the number of 
proteins that can be identified in a given proteome is increasing rapidly, allowing for a more 
accurate definition of the pathways involved in cancer. A recent report has described the use 
of 1-D gel electrophoresis followed by tryptic in-gel digestion and chromatography coupled to 
MS. This shotgun proteomic approach revealed changes in the expression levels of 281 
proteins in meningiomas compared to normal human arachnoidal cells (Saydam et al. 2010). 
Interestingly, a highly significant functional network involved in DNA replication, 
recombination and repair, and in cell cycle was exclusively expressed in cancer cells, arguing 
for a prevalent RB/E2F signature in the meningioma proteome. Similar results have been 
gathered recently with high-risk neuroblastoma proteomes analyzed by another type of 
shotgun proteomics approach. Quantitative global protein expression profiling performed 
using isotope-coded affinity tags (ICAT) followed by LC-MS/MS analysis identified a total of 
1,461 proteins that were differentially expressed in neuroblastoma. Again, pathway analysis of 
these proteins showed enrichment in the RB/E2F regulated network (Chen et al. 2010). These 
results underscore the power of shotgun proteomics, and suggest that many novel insights 
regarding RB/E2F function will be unraveled by this approach.  
5. Future perspectives 
Much has been learned on RB/E2F-mediated regulation of gene transcription by proteomic 
approaches to date. The identification of E2F interacting proteins as well as transcriptional 
complexes encompassing RB and E2F has helped elucidating the regulation of this pathway. 
However, the current knowledge is still too limited to fully understand the complex 
RB/E2F-regulated network. Further work involving high throughput proteomic approaches 
should help elucidate the nature of the diverse macromolecular complexes that are thought 
to harbor RB/E2F, and the role of these complexes in different biological settings.  
Development of modified peptide enrichment methods together with recent advances in MS 
has allowed large-scale analyses of PTMs, providing a large pool of new PTM 
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identifications. With regard to E2Fs, MS-based phosphorylation analyses have greatly 
increased the number of phosphorylated residues identified within this transcription factor 
family, and many more will probably be identified in the future. However, they will need to 
be validated and functionally characterized in vivo in order to decipher the influence of each 
individual PTM on E2F activity. As works focused on MS-based identification are gaining 
relevance, other types of PTMs such as acetylations and ubiquitinations, will probably be 
identified on E2Fs in a short period of time. Furthermore, multiple PTMs should be possible 
to analyze in the same system, producing direct data on their crosstalk at the global level in 
regulating E2F function. In addition, implementation of quantitative methods will allow 
studying the dynamics of site-specific PTMs on E2Fs, which was almost unachievable a 
decade ago. Defining their kinetics will be crucial to understand how PTMs influence on 
protein regulation and function. This explosion of information, still very descriptive, opens a 
huge range of possible new studies in the field of RB/E2F network. 
Several differential proteomic analyses have been performed to examine how the 
presence/absence of each individual E2F is reflected in the proteome. The strategy to 
accomplish this objective will surely move from the low scale approach that represents 2-
DE/MS used so far, to gel-free high throughput strategies. This approach has been widely 
adopted in proteomics lately, owing to its superior performance compared to 2-DE 
technology. Advances in sample preparation, including novel fractionation methods, 
together with more powerful mass spectrometers have been proved to qualitatively and 
quantitatively assess changes in large scale protein analyses. Indeed, large-scale protein 
expression analysis of cancer cell proteomes by shotgun proteomics promises to be valuable 
for investigating mechanisms of cancer transformation (Chen & Yates, III 2007). 
Nonetheless, the limitations of global proteomic analyses in identifying and quantifying low 
abundant proteins such as transcription factors will push the emergence of hypothesis-
driven strategies based on targeted proteomic approaches. 
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1. Introduction 
The aim of this review is to provide insight and encouragement into the development of 
new proteomic approaches aimed at analyzing the relationship between structure and 
function of ATP synthase in different organisms and under different metabolic conditions. 
Particular attention will be paid to the preparation of the sample for the mass spectrometry 
(MS) analyses, which is also a critical step and requires a specific competence. 
2. The nano-motor enzyme F0F1ATP synthase 
F0F1ATP synthase is the terminal enzyme of the oxidative phosphorylation pathway (named 
complex V of the OXPHOS system) that is responsible for the majority of ATP synthesis in 
all living cells (Boyer, 1997). It is an exceptionally complicated protein complex, whose 
molecular mass varies from 540 to 585 kDa depending on the source, which is organized 
into a globular catalytic part (F1) and a membranous moiety (F0) linked by central and 
peripheral stalks.  
The enzyme is present in bacterial plasma membranes and chloroplast thylakoids, where it 
contains 8 and 9 subunits, respectively (Borghese et al,. 1998; Richter et al,. 2000), and in 
mitochondria, where it is located in the inner membrane and consists of at least 15 and 17 
different subunits in mammals and yeasts, respectively (Wittig and Schägger, 2008). The F1 
sector always consists of five subunits α3β3γ1δ1ε1 and the α- and β-subunits are arranged 
alternatively, forming a hexagonal cylinder around the coiled-coil structure of the γ subunit. 
The F0 part, which is responsible for ion translocation across the membrane, has instead a 
variable composition. The simplest form is present in bacteria and consists of the subunits 
ac10-14. The c subunits form a ring structure with variable stoichiometry among species 
connected to F1 by the central stalk, constituted by the subunits γ and ε, latter being 
homologous to subunit δ of the mitochondrial enzyme (Vignais and Satre, 1984) and able to 
modulate the catalysis (Suzuki et al,. 2011). The a subunit associates with the c-ring 
peripherally and with the lateral stalk, which is formed by the homo-dimer of subunits b 
and by subunit δ, present in single copy  and located at the top of F1(Walker and Dickson, 
2006)(Fig.1A). 
In mitochondria the additional subunits d, e, f, g, A6L, F6 and OSCP are associated to the 
complex, of which the subunits b, d, F6 and OSCP form the lateral stalk in single copies, 
OSCP homologous to prokaryotic subunit δ (Walker and Dickson, 2006). The so-called  
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The F0 part, which is responsible for ion translocation across the membrane, has instead a 
variable composition. The simplest form is present in bacteria and consists of the subunits 
ac10-14. The c subunits form a ring structure with variable stoichiometry among species 
connected to F1 by the central stalk, constituted by the subunits γ and ε, latter being 
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modulate the catalysis (Suzuki et al,. 2011). The a subunit associates with the c-ring 
peripherally and with the lateral stalk, which is formed by the homo-dimer of subunits b 
and by subunit δ, present in single copy  and located at the top of F1(Walker and Dickson, 
2006)(Fig.1A). 
In mitochondria the additional subunits d, e, f, g, A6L, F6 and OSCP are associated to the 
complex, of which the subunits b, d, F6 and OSCP form the lateral stalk in single copies, 
OSCP homologous to prokaryotic subunit δ (Walker and Dickson, 2006). The so-called  
 




(A) Bacterial (E.coli) enzyme is assembled with a stiochiometry of α (3), β (3), γ, δ, ε, b (2), a, c (10-14). 
The central stalk is composed of γ and ε subunits, the peripheral one is composed of subunits b and δ, 
the proton channel is formed by the subunits ac10-14. 
(B) In the eukaryotic enzyme (Bos taurus) the central stalk is formed by subunits γ, δ and ε, the 
peripheral stalk is composed of subunits OSCP, b, d and F6 and the additional subunits A6L, e, f, g are 
associated to the proton channel ac10.  
Fig. 1. Schematic representation of bacterial and mitochondrial F0F1 ATP synthase. 
minor subunits e, f, g and A6L all span the membrane and, apart for subunit e (Bisetto et al, 
2008), their exact stoichiometries are poorly defined (Fig. 1B). Other subunits are species-
specific, such as subunit i and k in Saccharomyces cerevisiae (Wittig and Schägger, 2008) and 
coupling factor B in Bos taurus (Lee et al,. 2008).  
Besides these subunits, in some mammals such as beef, rat and man two hydrophobic 
proteins namely MLQ/6.8-kDa proteolipid (Chen et al,. 2007; Meyer et al,. 2007), and 
AGP/DAPIT (Ohsakaya et al,. 2011) are associated to the F0 part when phospholipids are 
not extracted. All together, the mitochondrial membrane domain is constituted by 
approximately 30 trans-membrane α-helices (Carroll et al,. 2009). In addition, the 
mitochondrial complex can bind the inhibitor protein IF1, which reversibly binds to F1 with 
a 1:1 stoichiometry and fully inhibits the enzyme activity (Bason et al,. 2011;  Harris and Das, 
1991). In yeast, along with IF1, the enzyme can be regulated by two additional proteins, 
namely Stf1 and Stf2 (stabilizing factor 1 and 2) (Andrianaivomananjaona et al,. 2010). The 
subunit composition of the ATP synthase from prokaryotic and eukaryotic sources along 
with the subunit homology and the corresponding nomenclature is reported in Table 1. The 
molecular masses of the different subunits are reported in Table 2, based on ATP synthase 
from Bos taurus and Bacillus pseudofirmus.  
Despite the differences in the complexity, functionally important subunits are conserved 
and in all sources the enzyme catalyses the synthesis of ATP by using the energy of the 
electrochemical gradient of protons (or less commonly of sodium) generated by the 
respiratory chain. F0F1 is an unusually efficient rotary motor that synthesizes ATP at rates 
exceeding 100 molecules per second (Senior, 2007). Protons traveling down the H+ gradient 
generate the rotation of the F0 c-ring, making the central stalk also rotates, which in turn 
drives ATP synthesis from ADP and Pi by forcing different conformations sequentially on 
each of the catalytic sites in the three F1 subunits β. The enzyme is able to work in the  
 





Stoichiometry Prokaryotes Eukaryotes 
 E.coli S. cerevisiae B. taurus H. sapiens 
F1 
3 α α α α 
3 β β β β 
1 γ γ γ γ 
1 ε δ δ δ 
1 - ε ε ε 
F0 
1 δ 5 OSCP OSCP 
1 a 6 a a 
1 - 8 A6L A6L 
10-14 c 9 c c 
1-2 b 4 b b 
1 - d d d 
1 - h F6 F6 
1 - f f f 
1-2 - e e e 
n.d* - g g g 
Species specific 
subunits 
1  i - - 
n.d* - k - - 
1 - - Coupl. fact.B - 
Inhibitor 
Protein 0-1 - Inh1 IF1 IF1 
Stabilizing 
factor for IF1 
n.d*  Stf1 - - 
n.d* - Stf2 -  
Associated 
proteins 
 - - AGP or DAPIT 
AGP or 
DAPIT 
 - - MLQ or 6.8 PL 
MLQ or 6.8 
PL 
*n.d.- not determined 
Table 1. Subunit composition and nomenclature of the ATP synthases from prokaryotes 
(Escherichia coli) and Eukaryotes (Saccharomyces cerevisiae, Bos taurus and Homo sapiens). 
direction of ATP hydrolysis, sustaining the formation of the proton gradient, when there is 
loss of membrane potential (Fig. 2). 
First direct visualization of ATP-driven rotation of Bacillus F1 immobilized on the glass 
surface via the N-termini of its β-subunits was obtained more than 10 years ago (Noji et al,. 
1997). These experiments showed that a fluorescent actin filament attached on the γ-subunit 
rotates uni-directionally, counterclockwise when viewed from membrane side, upon 
addition of ATP. A further technical sophistication used a sub-millisecond resolution 
camera to detect the rotation of gold beads attached to the γ subunit of the α3β3γ  sub-
complex along with fluorescence changes of an ATP hydrolysable analog. This technique 
allowed to display in real time the binding and release of nucleotides at the three catalytic 
sites simultaneously with the γ rotation (Adachi et al,. 2007). The rotation probe reports a 
pause, which corresponds to the period during which ATP binds to the empty catalytic site,  
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The central stalk is composed of γ and ε subunits, the peripheral one is composed of subunits b and δ, 
the proton channel is formed by the subunits ac10-14. 
(B) In the eukaryotic enzyme (Bos taurus) the central stalk is formed by subunits γ, δ and ε, the 
peripheral stalk is composed of subunits OSCP, b, d and F6 and the additional subunits A6L, e, f, g are 
associated to the proton channel ac10.  
Fig. 1. Schematic representation of bacterial and mitochondrial F0F1 ATP synthase. 
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Stoichiometry Prokaryotes Eukaryotes 
 E.coli S. cerevisiae B. taurus H. sapiens 
F1 
3 α α α α 
3 β β β β 
1 γ γ γ γ 
1 ε δ δ δ 
1 - ε ε ε 
F0 
1 δ 5 OSCP OSCP 
1 a 6 a a 
1 - 8 A6L A6L 
10-14 c 9 c c 
1-2 b 4 b b 
1 - d d d 
1 - h F6 F6 
1 - f f f 
1-2 - e e e 
n.d* - g g g 
Species specific 
subunits 
1  i - - 
n.d* - k - - 
1 - - Coupl. fact.B - 
Inhibitor 
Protein 0-1 - Inh1 IF1 IF1 
Stabilizing 
factor for IF1 
n.d*  Stf1 - - 
n.d* - Stf2 -  
Associated 
proteins 
 - - AGP or DAPIT 
AGP or 
DAPIT 
 - - MLQ or 6.8 PL 
MLQ or 6.8 
PL 
*n.d.- not determined 
Table 1. Subunit composition and nomenclature of the ATP synthases from prokaryotes 
(Escherichia coli) and Eukaryotes (Saccharomyces cerevisiae, Bos taurus and Homo sapiens). 
direction of ATP hydrolysis, sustaining the formation of the proton gradient, when there is 
loss of membrane potential (Fig. 2). 
First direct visualization of ATP-driven rotation of Bacillus F1 immobilized on the glass 
surface via the N-termini of its β-subunits was obtained more than 10 years ago (Noji et al,. 
1997). These experiments showed that a fluorescent actin filament attached on the γ-subunit 
rotates uni-directionally, counterclockwise when viewed from membrane side, upon 
addition of ATP. A further technical sophistication used a sub-millisecond resolution 
camera to detect the rotation of gold beads attached to the γ subunit of the α3β3γ  sub-
complex along with fluorescence changes of an ATP hydrolysable analog. This technique 
allowed to display in real time the binding and release of nucleotides at the three catalytic 
sites simultaneously with the γ rotation (Adachi et al,. 2007). The rotation probe reports a 
pause, which corresponds to the period during which ATP binds to the empty catalytic site,  
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α P19483 55263.39 AAG48361.1 54674.48 
β P00829 51562.97 AAG48363.1 51752.14 
γ P05631 30255.71 AAG48362.1 31835.49 
δ P05630 15064.93 AAG48360.1 20534.63 
ε P05632 5651.67 AAG48364.1 14327.68 
a P00847 24787.91 AAG48358.1 26863.77 
b P13619 24668.72 AAG48359.1 18510.16 
c P32876 14223 AAC08039.1 6956.06 
c P07926 15029 - - 
c Q3ZC75 14693 - - 
d P13620 18561.28 - - 
e Q00361 8189.47 - - 
f Q28851 10165.99 - - 
g Q28852 11286.26 - - 
8 or A6L P03929 7936.56 - - 
F6 P02721 8958.09 - - 
OSCP P13621 20929.75 - - 
Total F0F1 583442a 540290.53b 
*Accession numbers were obtained from UniProt 
+Molecular masses are shown in Dalton 
aAssuming the assigned stoichiometry for Bos taurus including the subunits e1 and g1 (excluding the 
amino-terminal modifications). If proteins MLQ and AGP are considered, the total protein mass 
increases to 596579 Da (Wittig and Schägger, 2008). 
bAccording to the stoichiometry (α3β3γδεab2c13) for Bacillus pseudofirmus  
Table 2. Molecular masses of subunits of Bos taurus and Bacillus pseudofirmus F0F1 ATP 
synthase 
and a 120° step rotation, constituted by two sub-steppings, whose duration is still debated, 
during which ATP hydrolysis and release occur. Single molecule technology studies have 
been applied also to the whole F0F1 complexes from Propionigenium modestum and Escherichia 
coli. Rotation was probed with probes attached to the c-ring in the immobilized F0F1 and, as 
expected, occurred in the opposite direction when c-ring rotation was driven by ATP or by 
proton-flow (Ueno et al,. 2005).  
2.1 ATP synthase biogenesis 
The mitochondrial F0F1 complex is composed of both nuclear and mitochondrial gene 
products. In yeast the three F0 core proteins a (Su6), A6L (Su8) and c (Su9) are encoded by 
mDNA, while in mammals only subunits a and A6L are encoded by mitochondrial genome. 
This arrangement highlights the complexity of enzyme assembly, which requires accessory 
factors, whose definition is still under investigation (Wittig and Schägger, 2008). Altogether 
9 factors have been identified in yeast, but, until now, the role of only five of them has been 
defined. Three factors mediate the F1 formation (Atp11p, Atp12p and possibly Fmc1p) 
(Ackerman, 2002; Lefebvre-Legendre et al,. 2001) and two the F0 assembly (Atp10p and  
 




Fig. 2. Schematic representation of ATP synthesis and hydrolysis by F0F1 ATP synthase (A) 
Proton powered rotation of c ring makes the central stalk turn with it, generating torque and 
conformational changes in the catalytic αβ domain to synthesize ATP from ADP and Pi. (B) 
The hydrolysis of ATP sustains proton flow in opposite direction. 
 
Eukaryotes Factors Mass (Da) Swiss-Prot Accession 
Yeast Fmc1p ≤18364 P40491 
Yeast Atp10p 32093.91 P18496 
Yeast ATP11p ≤36581 P32453 
Yeast ATP12p ≤36554 P22135 
Yeast ATP22p ≤79756 A6ZYV0 
Yeast ATP23p 26890.37 P53722 
Yeast Mdm38p 58610.83 Q08179 
Yeast Aep3p 70310.03 Q12089 
Yeast Oxa 1p 40000.09 P39952 
Human ATPF2 32772 Q8N5M1* 
Human ATPF1 36437 Q5TC12* 
* UNIPROT accession number 
Table 3. Assembly factors of yeast and human F0F1 ATP Synthase. The assembly factors for 
F1 are in blue and F0 are in red (Wittig and Schägger, 2008). 
Atp22p) (Helfenbein et al,. 2003; Rak et al,. 2011). In mammalian cells only two factors are 
known, which are orthologus to yeast F1 assembly factors (Table 3). 
The assembly process is best characterized in yeast, where recent in organello pulse-labeling 
and pulse-chase experiments have enabled to identify three different assembly 
intermediates and to demonstrate that the whole enzyme is formed by two separate 
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pathways that converge to form the ATP synthase from their respective end-products. One 
pathway leads to the formation of F1, which was already known to assemble as an 
independent unit (Tzagoloff, 1969), and of the Su9-ring. These two sub-complexes 
subsequently combine to constitute the F1/Su9-ring end-product. The other pathway leads 
to the formation of the Su6/Su8/stator sub-complex, which, in addition to Su6 and Su8, 
contains the chaperone Atp10p and additional still undefined proteins of the lateral stalk 
(Rak et al., 2011) (Fig. 3).  
Because in yeast the interaction between Su6 and Su8 is kinetically much more rapid, the 
entire process is regulated by the control of the Su6 and Su8 translation by F1 in order to 
obtain a balanced production of the different intermediates (Rak et al., 2011). Conversely, in 
mammals the amount of ATP synthase seems to be controlled by the availability of subunit 
c, as demonstrated in brown fat (Houstek et al,. 1995) and other tissues (Andersson et al,. 
1997).  
Independent of the mechanism, it has been proposed that the ATP synthase assembly may 
recapitulate some of the evolutionary events that gave rise to this enzyme. In fact, there is 
evidence that F1 evolved from an ATP-dependent helicase (Gomis-Rüth et al,. 2001), while 
the Su9 derived from an ion channel (Rak et al., 2011), so that their combination converted a 
passive channel into an active pump.  
 
 
Fig. 3. Assembly of F0F1 ATP synthase in yeast. The scheme shows the two separate 
pathways, leading to two separate end-products, i.e. the F1/Su9-ring and Su6/Su8/stator 
sub-complexes that converge at the end to form the whole F0F1 complex (Rak et al., 2011). 
So far there is little evidence for tissue-specific or developmentally regulated isoforms of 
ATP synthase subunits. In tobacco plants three isoforms of the F1 subunit β have been 
identified, of which only one is exclusively expressed in pollen (Lalanne et al,. 1998). In 
mammals, two tissue-specific isoforms of the F1 γ subunit, heart and liver type, were 
identified in bovine F0F1-ATP synthase (Matsuda et al,. 1993). These two isoforms are 
generated by alternative splicing and their Vmax and Km are identical (Matsuda et al,. 1994). 
In addition, three isoforms (P1, P2, and P3) of the F0 subunit c have been identified (Vives-
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Bauza et al,. 2011). These isoforms differ in their cleavable mitochondrial targeting peptides, 
whereas the mature peptides are identical. Considering that in mammals c genes determine 
the ATP synthase content, the existence of iso-genes would be advantageous for regulation 
of subunit c synthesis, and thus ATP synthase biogenesis, by multiple factors. It appears that 
much remains to be learned about this argument.  
2.2 ATP synthase self-association 
Biochemical evidence and electron microscopy studies recently demonstrated that within 
the inner mitochondrial membrane the enzyme is organized in dimers and oligomers, which 
possibly associate with other inner mitochondrial membrane proteins, e.g. with phosphate 
and adenine nucleotide carriers in the “phosphorylating assemblies”– the so called ATP 
synthasome (Chen et al,. 2004;  Wittig and Schägger, 2008). Elucidation of dimer/oligomers 
structural properties and of their formation process is quite important. In fact, proposed 
roles of the ATP synthase oligomers are higher efficiency and higher stability. In this regard, 
we demonstrated that dimers have a greater specific activity than monomers (Bisetto et al,. 
2007). In accordance, a recent numerical simulation indicated a significant increase in charge 
density in regions of high membrane curvature induced by ATP synthase dimerization, thus 
favoring effective ATP synthesis under proton-limiting conditions (Fig. 4) (Strauss et al,. 
2008). Moreover, these oligomers appear to play a special role for mitochondrial 
morphology, being involved in cristae formation (Couoh-Cardel et al,. 2010;  Paumard et al,. 
2002). 
The structural properties of dimers/oligomers were initially characterized in yeast where 
genetic approaches, cross-linking analyses and electron microscopy images established 
preferential interactions within the inner membrane (Thomas et al,. 2008) mainly through 
the subunits Su6 (Wittig et al,. 2008), Su4 (Spannagel et al,. 1998), e (Everard-Gigot et al,. 
2005) and g (Bustos and Velours, 2005), which are conserved in mammals, and also through 
the F0 subunits h and i in yeast (Fronzes et al,. 2006). High-resolution images showed that 
both in yeast and mammals the dimers display angles between two F1-F1 ranging from 35° 
to 180°. Recent images of yeast dimers at 27 Å resolution showed that the dominant angle is 
42°, suggesting that this is the most stable conformation (Couoh-Cardel et al., 2010).  
We recently demonstrated by a structural proteomic approach that also in mammals the e 
subunit is essential for ATP synthase self-association in dimers and oligomers. Selective 
degradation by in situ limited proteolysis caused an alteration of the oligomeric distribution 
of ATP synthase by eliminating oligomers and reducing dimers in favor of monomers 
(Bisetto et al., 2008).  
A critical aspect of F0F1 dimerization is related to the role of IF1, which is still controversial 
(Wittig and Schägger, 2008). IF1 is well known to bind ATP synthase under energy 
deficiency, i.e. at low pH and membrane potential, when the enzyme hydrolyzes rather than 
synthesizes ATP. Therefore, IF1 is considered responsible for the beneficial down-regulation 
of F0F1 during ischemia in in vitro experimental models, but also in vivo, as demonstrated by 
our group in anaesthetized open-chest goat heart (Di Pancrazio et al,. 2004). Nevertheless, 
because isolated IF1 from bovine heart is present in dimeric form in solution where it has 
been shown to link two F1-subcomplexes (Cabezón et al,. 2003), it seemed conceivable that 
dimeric IF1 might also be able to link two F0F1 complexes in the inner mitochondrial 
membrane. However, in yeast deletion of IF1 and of the associated proteins Stf1 and Stf2 did 
not eliminate dimers and oligomers (Dienhart et al,. 2002), thus excluding an essential role 
of IF1 in ATP synthase self-association. On the other hand, a very recent study revealed that  
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Fig. 4. Model of ATP synthase dimers. Dimers mainly interact through F0 sector and enforce 
a strong local curvature on the inner mitochondrial membrane, where an increased charge 
density favors effective ATP synthesis (Strauss et al., 2008).   
also in yeast oligomers contain considerable amounts of IF1, raising the question of whether 
bound IF1 inhibits the oligomer activity (Couoh-Cardel et al., 2010).  
In bovine heart mitochondria, we demonstrated that physical release of IF1 from the inner 
membrane did not markedly alter the amount of dimers separated by Blue Native 
electrophoresis (Tomasetig et al,. 2002), suggesting that F0F1 dimers could form 
independently from IF1. Nevertheless, in human HeLa cells IF1 overexpression increased 
ATP synthase dimers, as revealed by native electrophoresis, and this was paralleled by a 
higher ATP synthesis efficiency (Campanella et al,. 2009). However, it should be noted that 
in this paper the identification and quantification of ATP synthase dimers, as well as of their 
IF1 content, seems questionable due to the use of  dodecylmaltoside as detergent, which is 
well known to alter the dimer/monomer ratio (Tomasetig et al., 2002). 
2.3 Disorders related to ATP synthase  
In spite of the fact that the assembly process of the mitochondrial ATP synthase is still 
poorly characterized in humans, its defects have been recognized as a cause of  human 
diseases (Houstek et al,. 2006;  Kucharczyk et al,. 2009). Alteration of ATP synthase 
biogenesis leading to mitochondrial ATP synthase deficiency may cause two types of 
defects: qualitative when the enzyme is structurally modified and does not function 
properly, and quantitative when it is present in insufficient amounts. Examples of 
qualitative defects are those caused by missense mutations in the mitochondrially-
encoded subunit a gene. Eight point mutations and a two-nucleotide micro-deletion in the 
ATP6 gene have been identified, of which the most common and best studied is the 
T8993G mutation that leads to replacement of a highly conserved leucine by arginine 
(Kucharczyk et al,. 2009). These mutations prevent ATP synthesis but not ATP hydrolysis 
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because mutated F0 can translocate protons from the cytosol to the mitochondrial matrix, 
thus sustaining membrane potential (Sgarbi et al,. 2006). The impaired ATP synthesis 
mainly affects brain tissue and at high mutation load, up to approximately 95%, the 
heteroplasmic ATP6 gene mutations manifest as neuropathy, ataxia, retinitis pigmentosa 
(NARP) or as fatal encephalopathy known as Leigh syndrome (Houstek et al., 2006). 
Examples of quantitative defects are those in which the cellular content of the enzyme is 
reduced to less than 30%. Apparently, these disorders are caused by different nuclear 
genetic defects that remain to be identified, but most of them display a uniform fatal 
phenotype with onset in newborns characterized by lactic acidosis and hypertrophic 
cardiomyopathy (Houstek et al., 2006). In both types of ATP synthase disorders, 
hyperpolarization due to decreased ATP synthesis promotes ROS production by the 
respiratory chain, an event that can contribute to the clinical phenotypes as suggested by 
the beneficial effect of antioxidants observed in NARP cells (Mattiazzi et al,. 2004). This 
finding is quite important, considering that, in spite of the considerable progress in 
understanding of the molecular mechanisms of ATP synthase disorders, the available 
therapeutic approaches are still extremely limited (Kucharczyk et al., 2009). It has been 
proposed that other secondary effects possibly involved in the pathogenic pathways of 
ATP synthase deficiency could be changes in mitochondrial cristae morphology, which is 
mediated by ATP synthase oligomerization (Couoh-Cardel et al., 2010;  Paumard et al., 
2002), and/or a concomitant impairment of an ectopic function of ATP synthase localized 
on cell surface (see paragraph 4) (Kucharczyk et al., 2009).  
Microarray analyses have been performed in an attempt to gain a more global view of the 
cellular consequences of ATP synthase deficiency. In fibroblast cell lines from 13 genetically 
heterogeneous patients, 1632 human genes involved in mitochondrial biology, cell cycle 
regulation, signal transduction and apoptosis have been analysed. Surprisingly, only minor 
changes in expression of ATP synthase related genes were shown. Moreover, the cellular 
gene expression phenotypes were different depending on the site (mtDNA vs nuclear DNA) 
and the severity (ATP synthase content) of the underlying defect, indicating the need for 
further investigation of these pathways in other ATP synthase disorders (Cížková et al,. 
2008). As far as our knowledge is concerned, the proteomic profiles of ATP synthase-related 
diseases have not yet been reported. 
Other intriguing examples of ATP synthase-related diseases are Batten disease in man or 
ceroid lipofuscinosis in sheep. Both are storage diseases with abnormal accumulation of 
subunit c in lysosomes occurring in the brain and liver, respectively. MS and protein 
sequencing have shown that the stored protein is structurally identical to the normal 
mitochondrial subunit c (Chen et al,. 2004). 
Up- and down-regulation of ATP synthase biogenesis has been observed under different 
pathophysiological conditions (Houstek et al., 2006). We developed polyspecific antibodies 
directed against the whole human mitochondrial subproteome by hyperimmunization of 
rabbits with purified skeletal muscle mitochondria, which allowed detection of up-
regulation of ATP synthase, in muscle biopsies from patients affected by MELAS 
(mitochondrial encephalomyopathy with lactic acidosis and stroke-like episodes) which are 
characterized by a drastic reduction of OXPHOS complex 1 (Loro et al,. 2009). MS 
approaches have also been applied to compare the ATP synthase expression levels in vivo 
and in vitro. Recent examples of ATP synthase down-regulation have been obtained by the 
mitochondrial proteome analyses in heart from type 2 diabetic patients (Heather and Clarke, 
2010) and in pancreatic β-cells exposed to high glucose (Ahmed et al,. 2010).  
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3. Mass spectrometry data of F0F1 ATP synthase 
The whole F0F1 complex, as well as individual subunits or sub-complexes, have been 
purified by classical approaches and their amino acid sequences determined almost entirely 
by direct protein sequence analysis (Walker et al,. 1991). The detailed molecular structures 
of F0F1 from several species have been studied intensively by different groups (Chen et al,. 
2006;  Cingolani and Duncan, 2011; Dautant et al,. 2010), and the importance of these studies 
is highlighted by the award of the Nobel Prize to John Walker in 1997. The structural 
analyses by X-ray diffraction required the identification of the subunit composition by 
measurement of accurate molecular masses by mass spectrometry, allowing the detection of 
posttranslational modifications. The exploration of the exposed regions by limited 
proteolysis had similar analytical requirements.  
Mass spectrometry of F0F1 has been a methodological challenge due to the presence of both 
hydrophilic parts and hydrophobic subunits, which are difficult to detect by standard 
ionization techniques, and the fact that all subunits are bound non-covalently. More than 15 
years ago, reverse phase liquid chromatography methods were applied to purify the 
hydrophilic subunits and also some membrane-bound subunits (b, d, F6, e, f, g and A6L) of 
the bovine heart enzyme, so as to allow their molecular masses to be measured by a mass 
spectrometer with electrospray ionization (Collinson et al,. 1994). Over the years, direct 
identification of all the hydrophilic and most of the hydrophobic subunits of ATP synthase 
from many sources has been obtained by MALDI- and ESI-MS/MS analyses of the tryptic 
peptides of individual bands or spots on native polyacrylamide or SDS gels. However, the 
most hydrophobic membrane proteins, such as subunit c and A6L, could not be detected by 
these approaches (Wittig et al,. 2010). All of the hydrophobic subunits have been identified 
by tandem mass spectrometry after optimization of their purification in organic solvents 
and by fragmenting the intact protein ions by collision induced dissociation (CID) with 
argon (Carroll et al,. 2007). Moreover, a procedure that allows to measure the molecular 
masses of all of the 17 subunits of F0F1 from bovine heart in a single experiment has been 
published, this approach is based on the use of a mobile phase during liquid 
chromatography separation, in which the hydrophilic and hydrophobic components 
remained soluble, linked directly via an electrospray interface to a triple quadrupole mass 
spectrometer operated in positive ion mass spectrometry. The method has been used to 
characterize the ATP synthase subunits from a variety of species and to follow the progress 
of mild trypsinolysis of the enzyme (Carroll et al., 2009). 
3.1 Phosphoproteome of ATP synthase 
The measurement of the mass of a protein allows the presence but not the location of any 
posttranslational modifications (PTMs) to be detected. Phosphorylation of serine, threonine 
and tyrosine residues is one of the most prominent PTMs and a key regulator of nearly all 
biological processes including mitochondrial oxidative phosphorylation (Hüttemann et al,. 
2007). However, phosphorylation is often a sub-stoichiometric process and usually only a low 
percentage of a given protein is present in phosphorylated state at a given time, making its 
observation challenging. In the past, phosphorylation analysis was mostly done by 
radiolabeling with 32/33P (Bendt et al,. 2003;  MacDonald et al,. 2002) combined with amino acid 
analysis. In the last decade, considerable effort has been devoted to improving the analysis of 
phospho-proteome by MS (Eyrich et al,. 2011;  Gerber et al,. 2003). The main criticisms are ion 
suppression of phosphorylated species in a high background of non-phosphorylated ones, 
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specificity lack of the proteolytic cleavage and lability of phosphoester bonds during MS 
analysis. Different enrichment strategies for phosphorylated peptides or proteins, such as 
immunoaffinity chromatography (IMAC) or metal oxide affinity chromatography (MOAC), 
have been established to reduce sample complexity. Concurrently, attention has been paid to 
the LC-MS instrumentation to avoid loss of phosphorylated peptides within the analytical 
system. In addition, specific MS techniques have been developed for the identification and 
relative quantification of phosphorylation sites down to the femtomole range. Nevertheless, 
phospho-proteomics still remains far from being routine.  
Regarding ATP synthase, in a recent phospho-proteomic study an improved protocol called 
BEMAD enabled to identify in a cytosolic lysate from mouse brain Ser76 of the F1 subunit α 
as being phosphorylated (Vosseller et al,. 2005). This method involved differential isotopic 
labeling of O-phosphate-modified serine/ threonine residues through Michael addition with 
normal or deuterated dithiothreitol and enrichment of these peptides by thiol 
chromatography. Specificity of O-phosphate mapping was achieved by blocking of cysteine 
labeling by prior oxidation and by subsequent enzymatic dephosphorylation of O-
phosphate-modified peptides. In a single mass spectrometry analysis along with αSer76 
other 20 phosphorylation sites (5 previously reported) were identified and quantified.  
MS allowed to identify phosphorylated tyrosine and serine residues in the F1 subunits α and 
β from yeast, which was long considered a “zero background” organism for tyrosine 
phosphorylation (Krause-Buchholz et al,. 2006). A novel screening technique was applied in 
combination with Blue Native electrophoresis to separate the ATP synthase complex in 
native state and second dimension SDS-PAGE to resolve its subunit composition (see 
below). LA–ICP–MS (Laser ablation inductively coupled plasma mass spectrometry) was 
used to rapidly screen for the presence of phosphorus in the subunits using sulfur as the 
internal standard element for quantification. The subunits containing phosphorus were then 
identified by MALDI–FTICR–MS (matrix-assisted laser desorption/ionization Fourier 
transform ion cyclotron resonance mass spectrometry) as Tyr434, Ser 413 and Ser426 of the α 
subunit and Tyr7 of the β subunit (Krause-Buchholz et al., 2006).  
At variance from yeast, by combining Blue Native electrophoresis and second/third 
dimension SDS-PAGEs with LC-ESI/MS analysis we found that in bovine heart 
mitochondria only the F1 γ subunit contained one phosphorylated tyrosine (Di Pancrazio et 
al,. 2006). Moreover, the tyrosine residue was phosphorylated only in the monomeric form 
of ATP synthase and was present in low amount (about 6% of the total protein monomer), 
while the ATP synthase dimers were lacking. Interestingly, this finding suggested that the 
oligomerization process might be regulated through cell signaling (Di Pancrazio et al., 2006), 
but the pathway is still to be clarified. To obtain these results a novel procedure was 
developed because, due to the low percentage of the phosphorylated species, standard 
MS/MS analysis failed to detect phosphorylated peptides. The screening of the 
phosphorylated subunits was done by immunoblotting using anti-phosphotyrosine 
antibody after the third SDS-PAGE and after trypsin digestion the phosphorylated fragment 
of γ subunit was identified and quantified by a novel LC-ESI/MS method. This latter was 
based on the use of two different de-clustering potential values that allowed to obtain, with 
a single LC-ESI/MS run, the pattern of the phosphorylated and unphosphorylated species. 
These species were further analyzed by tracing back the origin of the HPO3-deprived forms 
using tandem MS (Alverdi et al,. 2005).  
Several other studies have shown that phoshorylation can occur on different sites of ATP 
synthase in mammals (HÃ¸jlund et al,. 2003;  Ko et al,. 2002), yeast and plants (Struglics et 
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al,. 1998). Nevertheless, a comprehensive mapping is still lacking. The constant 
technological progress might soon enable to generate the quantitative and temporal 
phosphorylation pattern of the enzyme in all organisms and under different 
pathophysiological conditions, thus allowing understanding of the regulation of ATP 
synthase in light of cell signaling. 
3.2 Native mass spectrometry 
ESI-MS and the novel LILBID-MS (laser induced liquid bead ion desorption mass 
spectrometry) are two techniques that can be used under native conditions to determine the 
molecular mass of  non-covalently assembled complexes up to the MDa-range with high 
accuracy. The techniques are complementary, LILBID being more tolerant than nESI to 
addition of detergents, which are necessary to solubilise membrane proteins such as ATP 
synthase. Very recently, LILBID-MS combined with Blue Native electrophoresis was 
successfully applied to compare the subunit composition of the whole F0F1 from Bacillus 
pseudofirmus and from bovine and human heart (Hoffmann et al,. 2010), but also to 
determine the subunit composition of other even larger membrane complexes such as the 
NADH-dehydrogenase (complex I of the OXPHOS system) from Yarrowia lipolytica 
(Sokolova et al,. 2010). LILBID-MS can be applied in several modes, from soft laser 
desorption (yielding the intact macromolecular complexes) to medium to high laser 
intensity (which disassembles the protein complexes partially into sub-complexes and these 
latter into the single subunits). The analysis of the bacterial enzyme revealed at low laser 
intensity the masses of the F1 sub-complex, the F1 sub-complex lacking the δ-subunit and the 
F0 sub-complex, while at high laser energy the signal of the 8 subunits appeared. In the case 
of the mammalian enzymes, the spectra evidenced all of the 15 subunits, of which the 
masses agreed within ± 150 Da with theoretical masses (see Table 2). While functionally 
important subunits are conserved, others, such as the so-called minor F0 subunits, show 
differences in their masses among the species. Determination of their masses from many 
sources might help to clarify their structural and functional roles, which are still only 
partially known, and LILBID-MS certainly offers a novel and rapid way to obtain such 
results using very low material and in detergent solution.  
LILBID-MS has also provided an accurate determination of stoichiometry (cn) of the sub-
complex formed by the c-ring from the thermoalkaliphilic bacterium Bacillus sp. (Meier et al,. 
2007). This result is particularly interesting, considering the difficulty to detect c subunit by 
classical MALDI-MS and LC-MS/MS (Bisetto et al., 2008;  Wittig et al., 2010). Moreover, it 
represents an important MS application in cell bioenergetics, the number of c-subunits being 
in principle equals to the number of H+ transported across the membrane for every 360° 
rotation of the rotor in which three ATP molecules are synthesized in the three β subunits. 
Hence the H+/ATP ratio can be expressed by cn/3.  
At variance from LILBID, nESI is ideal for soluble complexes and we recently applied this 
technique to determine the exact molecular mass of the non-covalent complex formed in 
solution by the ATP synthase inhibitor IF1 and Calmodulin, the archetypal EF-hand calcium 
sensor. Interestingly, nESI established a 1:1 stoichiometry between IF1 and Calmodulin, 
suggesting that binding to Calmodulin promotes the dissociation of the pre-existing dimeric 
form of IF1 (Cabezon et al,. 2001). Furthermore, native mass analysis was paralleled to the 
definition of the IF1-CaM complex topology by combining limited proteolysis and cross-
linking data with MALDI-MS and LC-MS/MS analyses (Pagnozzi et al,. 2010). 
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3.3 AQUA workflow 
Native mass spectrometry is a powerful technique to define the stoichiometry of protein 
complexes, but this can be defined also by quantifying the absolute amounts of the different 
subunits and therefore by calculating their molar ratio. An interesting approach is the 
AQUA workflow, which is a variation of isotope dilution MS techniques used for decades 
for quantification of small molecules and more recently successfully applied in the 
proteomics context to the absolute quantification of proteins and their modification states in 
whole cell lysates (Gerber et al., 2003). This approach is based on the addition of synthetic 
isotopically labeled reference peptides in known amounts to a protein sample in solution 
prior to tryptic digestion and LC-MS analysis. Being gel-free, this approach avoids errors 
due to incomplete peptide extraction from the gel or impaired protein digestion within the 
gel matrix. 
Regarding ATP synthase, we recently applied the AQUA workflow to determine the 
stoichiometry of the F0 subunit e in bovine heart mitochondria (Bisetto et al., 2008). This 
subunit is involved in dimer/oligomer formation both in yeast (Fronzes et al., 2006) and 
mammals (Bisetto et al., 2008), but its stoichiometry was still unknown (Arakaki et al,. 2001;  
Hong and Pedersen, 2003). A critical point of the AQUA approach is the design of the 
heavy-labeled peptides, which must be unique to the proteins of interest and show high 
ionization efficiency (proteotypic peptides). In addition, such peptides should have a good 
fragmentation pattern with reliable matching of b- and γ- ion series, a preferable length 
between 7 and 15 amino acid residues and contain no chemically unstable residues (M,W, C 
or N-terminal Q or N) or unstable peptide bonds (e.g. D-P). Moreover, it is necessary to 
choose reference subunits, whose stoichiometry is already known, to validate the method. 
We have chosen the F0 subunit b and the F1 subunit γ as reference subunits which are 
present in single copies in the whole F0F1 complex, as defined by crystal structures. After 
having chosen among the proteotypic peptides characterized by LC-MS/MS three peptides - 
one from subunits e, b and γ-, the corresponding isotopically labeled analogues were added 
in known amounts to the detergent extracts of bovine heart mitochondria prior to tryptic 
digestion. The absolute quantification of the three subunits was then achieved by 
comparison of the areas under the curve (AUC) of the extracted ion chromatograms of the 
endogenous and labeled peptides in LC-MS mode. Accuracy of the method was 
demonstrated by confirming the 1:1 stoichiometry of subunit γ and b and by the low 
coefficients of variation which were <12% for technical and biological replicates. In the 
samples analyzed, which contained extracts of mitochondria in resting state, subunit e was 
present in 1:1 molar ratio with respect to subunit b or γ, demonstrating that in F0F1 it is 
contained as unique copy.  
4. Native electrophoresis of F0F1 ATP synthase 
Classical 2D IEF-SDS-PAGE do not resolve all the subunits of ATP synthase, because they 
are quite often small, hydrophobic and basic (pI>9). For this reason, in some studies MS 
analysis has been run on peptide mixtures obtained after in-solution trypsinization of 
sample extracts (Bisetto et al., 2008). Alternatively, a powerful approach for efficient 
separation from tissue homogenates, tissue biopsies and cell cultures of the whole complex 
of ATP synthase, as well as of assembly intermediates and supra-molecular structures is the 
native polyacrylamide gel electrophoresis after mild detergent extraction (Wittig et al,. 
2006). Following native PAGE, proteins of interest can be extracted in native state and 
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suggesting that binding to Calmodulin promotes the dissociation of the pre-existing dimeric 
form of IF1 (Cabezon et al,. 2001). Furthermore, native mass analysis was paralleled to the 
definition of the IF1-CaM complex topology by combining limited proteolysis and cross-
linking data with MALDI-MS and LC-MS/MS analyses (Pagnozzi et al,. 2010). 
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3.3 AQUA workflow 
Native mass spectrometry is a powerful technique to define the stoichiometry of protein 
complexes, but this can be defined also by quantifying the absolute amounts of the different 
subunits and therefore by calculating their molar ratio. An interesting approach is the 
AQUA workflow, which is a variation of isotope dilution MS techniques used for decades 
for quantification of small molecules and more recently successfully applied in the 
proteomics context to the absolute quantification of proteins and their modification states in 
whole cell lysates (Gerber et al., 2003). This approach is based on the addition of synthetic 
isotopically labeled reference peptides in known amounts to a protein sample in solution 
prior to tryptic digestion and LC-MS analysis. Being gel-free, this approach avoids errors 
due to incomplete peptide extraction from the gel or impaired protein digestion within the 
gel matrix. 
Regarding ATP synthase, we recently applied the AQUA workflow to determine the 
stoichiometry of the F0 subunit e in bovine heart mitochondria (Bisetto et al., 2008). This 
subunit is involved in dimer/oligomer formation both in yeast (Fronzes et al., 2006) and 
mammals (Bisetto et al., 2008), but its stoichiometry was still unknown (Arakaki et al,. 2001;  
Hong and Pedersen, 2003). A critical point of the AQUA approach is the design of the 
heavy-labeled peptides, which must be unique to the proteins of interest and show high 
ionization efficiency (proteotypic peptides). In addition, such peptides should have a good 
fragmentation pattern with reliable matching of b- and γ- ion series, a preferable length 
between 7 and 15 amino acid residues and contain no chemically unstable residues (M,W, C 
or N-terminal Q or N) or unstable peptide bonds (e.g. D-P). Moreover, it is necessary to 
choose reference subunits, whose stoichiometry is already known, to validate the method. 
We have chosen the F0 subunit b and the F1 subunit γ as reference subunits which are 
present in single copies in the whole F0F1 complex, as defined by crystal structures. After 
having chosen among the proteotypic peptides characterized by LC-MS/MS three peptides - 
one from subunits e, b and γ-, the corresponding isotopically labeled analogues were added 
in known amounts to the detergent extracts of bovine heart mitochondria prior to tryptic 
digestion. The absolute quantification of the three subunits was then achieved by 
comparison of the areas under the curve (AUC) of the extracted ion chromatograms of the 
endogenous and labeled peptides in LC-MS mode. Accuracy of the method was 
demonstrated by confirming the 1:1 stoichiometry of subunit γ and b and by the low 
coefficients of variation which were <12% for technical and biological replicates. In the 
samples analyzed, which contained extracts of mitochondria in resting state, subunit e was 
present in 1:1 molar ratio with respect to subunit b or γ, demonstrating that in F0F1 it is 
contained as unique copy.  
4. Native electrophoresis of F0F1 ATP synthase 
Classical 2D IEF-SDS-PAGE do not resolve all the subunits of ATP synthase, because they 
are quite often small, hydrophobic and basic (pI>9). For this reason, in some studies MS 
analysis has been run on peptide mixtures obtained after in-solution trypsinization of 
sample extracts (Bisetto et al., 2008). Alternatively, a powerful approach for efficient 
separation from tissue homogenates, tissue biopsies and cell cultures of the whole complex 
of ATP synthase, as well as of assembly intermediates and supra-molecular structures is the 
native polyacrylamide gel electrophoresis after mild detergent extraction (Wittig et al,. 
2006). Following native PAGE, proteins of interest can be extracted in native state and 
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analyzed by MS or electroblotted for immunodetection or analyzed by in-gel catalytic 
activity assays. In addition, subunit composition of the complexes can be identified by 
various denaturating techniques: SDS-PAGE, doubled SDS-PAGEs, as we used to detect 
phosphotyrosine in monomer/dimers of ATP synthase (Di Pancrazio et al., 2006) and 
IEF/SDS PAGEs (Wittig et al., 2006), as shown in Fig. 5. These advantages make this 
approach superior for functional proteomic analyses. For this reason, a brief introduction to 
native electrophoresis will be presented. 
 
 
Fig. 5. Applications of native electrophoresis for functional proteomic analyses. 
Blue native electrophoresis, abbreviated as BNE, was developed to isolate native membrane 
proteins and complexes on micro-scale. It separates proteins in the mass range of 10 kDa to 
10 MDa. It is a one step technique to isolate proteins from mitochondria, whole cell lysates 
and tissue homogenates (Wittig et al., 2006). BNE has also been used for the identification of 
protein-protein interactions, as we recently did to define the new interaction between ATP 
synthase and Cyclophilin D in mammalian mitochondria (Giorgio et al,. 2009). Besides BNE 
a similar native electrophoresis method was developed that is called Clear native 
electrophoresis (CNE) with its variant high resolution CNE (hr CNE). Fig. 6 depicts the 
resolution of the five OXPHOS complexes including ATP synthase with its dimeric form 
obtained by BNE and hr CNE. All these methods are quite similar and have been used for 
MS analyses, but differ in few aspects, which are discussed below, with their drawbacks and 
applications. 
From a practical stand point BNE, CNE and hr CNE differ in the composition of cathode 
buffers as well as in the mechanisms by which proteins migrate in the gel. What makes BNE 
different from CNE and hr CNE is the incorporation of Coomassie Brilliant Blue G-250 both 
in the cathode buffer as well as in loading dye. Coomassie is an anionic dye, it binds to the 
proteins and imparts negative charge over their surface. In this way proteins migrate with  
 




Fig. 6. BNE and hr CNE of DDM extracts of bovine heart mitochondria showing OXPHOS 
complexes. 
respect to their native masses independently of their pI. Negative charge also helps in 
preventing protein aggregation as negative charges repel each other and this is the reason 
for its very good resolution. Furthermore, upon binding the previously detergent-
solubilised membrane, proteins lose their hydrophobic character and become water soluble 
hence no further detergent is required in these gels minimising the risk of detergent-
dependent protein denaturation (Wittig et al., 2006). Besides Coomassie, the presence of 
Imidazole in anode and cathode buffer (BNE, CNE, hr CNE) helps in maintaining pH in the 
range 7.0-7.5, and incorporation of high concentration of 6-aminohexanoic acid (a 
zwitterionic substance) improves the solubilisation of membranes (Wittig and Schägger, 
2008). Separation of proteins as blue bands helps in gel excision and recovery of blue stained 
native proteins by electroelution (Wittig et al., 2006) for further MS analysis, as recently 
applied for LILBID MS (Hoffmann et al., 2010). 
A rapid way to identify ATP synthase in BNE is to monitor ATP hydrolysis by in-gel activity 
staining, which was developed in our lab and is based on the formation of a white lead 
phosphate precipitate from phosphate (Pi) released during the reaction (Fig. 7) (Zerbetto et al,. 
1997). The catalytic activity can be obtained by incubating the gels in glycine buffer 
supplemented with Mg-ATP in the presence of 0.2% Pb(NO3)2. The native staining of ATP 
synthase is reproducible and the white bands on gel can be easily quantified by densitometry 
(Bisetto et al., 2007). Moreover, the bands can be excised and easily destained in acetic acid 
solution giving a colourless protein complex ready for MS analysis. This method had been 
successfully applied by our group to analyse skeletal muscle and heart biopsies from patients 
with oxidative phosphorylation enzyme deficiencies (Zerbetto et al., 1997) 
Detection limits of in-gel activity staining are in the microgram range of protein or 
micromolar phosphate and the resulting white bands are challenging for detection and 
documentation of low activity due to interference of Coomassie dye. Different strategies of 
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others (Suhai et al,. 2009; Wittig and Schägger, 2005). Alternatively, CNE can be used that 
was introduced to circumvent this disadvantage of BNE. In fact, it uses the same buffers and 
conditions for electrophoresis but the difference lies on the absence of Coomassie dye both 
in cathode buffer as well as in sample buffer. In this way, much higher activity staining has 
been obtained (Wittig et al,. 2007). However, due to the absence of Coomassie there is no 
negative charge shift and the movement of proteins totally depends on their intrinsic mass 
and pI. Therefore CNE suffers from a poor resolution and is limited to proteins having a 
pI<7 unlike BNE where even proteins having pI>10.5 migrate towards anode (Wittig and 
Schägger, 2008). Anyway, CNE offers advantage over BNE for isolation of supra-molecular 
structures, including ATP synthase dimers and oligomers, being the mildest technique to 
separate mitochondrial membrane proteins. 
 
 
Fig. 7. In-gel ATPase activity staining of the different oligomeric forms of ATP synthase 
extracted by Digitonin (0.5 g/g protein) from mouse heart mitochondria and analyzed by 
BNE. 
To preserve the advantages of both the techniques Wittig et al introduced hr CNE. In this 
technique cathode buffer is supplemented with a combination of colourless anionic and 
neutral detergents such as Triton X-100, Deoxycholate, or Dodecyl-β-D-maltoside (DDM). 
This leads to a charge shift over the surface of the proteins and helps them in migration with 
a resolution comparable with BNE. Also there is no interference in in-gel assays due to 
absence of Coomassie.  
An interesting recent application of hr CNE is related to the molecular characterization of 
assembly intermediates of ATP synthase in mammals. In fact, using particularly mild 
detergent conditions and hr CNE, Wittig et al. were able to separate the assembly 
intermediate in human ρ0 cells, which lack the mitochondrial DNA encoding subunits a and 
A6L (Wittig et al., 2010). By analyzing its subunit composition by ESI-MS/MS after excising 
the native band from 1D hr CN-PAGE or by MALDI-MS (MS/MS) after 2D hr CN-/SDS-
PAGE they established that this intermediate contains all the nuclear-encoded subunits. 
These results allowed to propose that in mammals, differently from yeast (Hoffmann et al., 
2010), the assembly of the whole enzyme is a linear process and the subunits of the lateral 
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stalk combine with the F1 sector and the c-ring independently from the mitochondrial 
encoded subunits a and A6L which bind at the late stage. Conversely it has been proposed 
that in yeast the subunits Su6/Su8, homologous to subunits a and A6L, first combine to the 
subunits of the lateral stalk, forming the sub-complex Su6/Su8/stator, which finally binds 
to the sub-complex F1/c-ring, as already shown in Fig. 3. Moreover, the finding that ρ0 
mitochondria still contain dimers/oligomers of ATP synthase although in lower amounts 
than control mitochondria, supported the idea that subunits a/A6L contribute, together 
with subunits e/g (Bisetto et al., 2008), to stabilize the supra-molecular structures, but they 
are not the most important interface as previously proposed in yeast (Wittig et al., 2008).  
Recently Yan et al., using rat brain mitochondria, demonstrated that a non-gradient highly 
porous BNE of 8% polyacrilamide is an efficient technique to resolve all OXPHOS complex 
along with other mitochondrial proteins, such as DLDH and Hsp60 polymer. Further, the 
gel strips can be even used to perform 2D BN-/SDS PAGE or the bands can be excised for 
MS peptide sequencing (Yan and Forster, 2009). 
4.1 Types of detergents and their use in native electrophoresis  
The choice of detergent for protein extraction is an integral part of a successful native 
electrophoresis. The principal effect of detergents during solubilisation is the breaking of 
lipid-lipid and lipid-protein interactions present on biomembranes. Competing with lipids 
for the occupation of the surface of integral hydrophobic proteins, they form mixed micelles 
containing detergent, lipids and proteins. The solubilisation effect is maximum when the 
detergent is used at a concentration equal or higher to the Critical Micelle Concentration 
(CMC), the concentration at which the detergent molecules form micelles. These are 
detergent self associating structures with hydrophobic ends facing inside and hydrophilic 
groups facing outside the aqueous phase. CMC is a characteristic of each detergent and 
depends on pH, temperature and ionic strength (Reisinger and Eichacker, 2008). 
The anionic SDS is, in principle, not suitable for native electrophoresis as besides 
solubilising membranes, it dissociates and denatures the enzyme complex leading to loss of 
activity. Non-ionic detergents are uncharged and milder and hence can be used in 
membrane solubilisation to isolate mitochondrial complexes with varying degrees of 
association dependent on the kind of detergent used and its concentration. The most 
commonly used non-ionic detergents are Triton X-100, Digitonin and Dodecyl-β-D-
maltoside (DDM) which form micelles at very low concentration, thus avoiding protein 
denaturation (Wittig and Schägger, 2008). Regarding isolation of OXPHOS complexes, these 
non-ionic detergents behave very differently from each other. For example, Digitonin can be 
used in a very broad concentration range (from 0.5 to 8 g/g proteins), as compared to Triton 
and DDM which work in the range of 1-2 g/g proteins (Schägger and Pfeiffer, 2000). Besides 
this, Digitonin is the best candidate for the isolation of supercomplexes due to its milder 
nature (Reisinger and Eichacker, 2008). They can be used to extract OXPHOS complexes 
from bacteria, yeast and mammals, as well as from subcellular fractions or total membranes 
(Wittig et al., 2006). The quantity of detergent required to solubilise membrane proteins vary 
in the different cells/tissues and optimal solubilisation conditions for each membrane and 
each membrane complex should be experimentally investigated.  
Recently, an interesting modification of classical native PAGE has been proposed. 
Klodmann et al. reported the treatment of the samples with low amounts of SDS before 
BNE. This allowed to destabilize the OXPHOS complexes in sub-complexes in a very 
defined and reproducible manner and to study their internal architectures. SDS was added 
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stalk combine with the F1 sector and the c-ring independently from the mitochondrial 
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that in yeast the subunits Su6/Su8, homologous to subunits a and A6L, first combine to the 
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to the mitochondrial Digitonin extracts from Arabidopsis in the range of 0.05-1.0% just before 
BNE loading. By combining with 2D BN-/ SDS or 2D BN/BN PAGE, the authors clearly 
demonstrated the variable effect of SDS on the OXPHOS complexes. As an example, at 0.2% 
SDS concentration, the ATP synthase complex dissociated in to F0 and F1. At 0.3% F0 even 
dissociated in to a sub-complex composed of c-ring (Klodmann et al,. 2011). 
5. Ectopic F0F1ATP synthase of mammalian cells 
The application of proteomic analyses to sub-cellular mammalian fractions other than 
mitochondria revealed the presence of mitochondrial membrane components in unexpected 
cellular locations, such as plasma membranes or nuclei. Some of these studies ascribed it to 
cross-contamination, due to the contiguity of the different membranes within the cell and to  
the high sensitivity of  MS which identifies the proteins up to subfentomolar levels, but  in 
others cases the parallel demonstration of such unusual locations obtained in cells and tissues 
by immunofluorescence and functional studies led the scientists  to consider the proteomics 
results a mainstay to discover new scenarios in the intracellular traffic connections.  
Regarding ATP synthase, many proteomics studies have recently reported that subunits of 
this complex, along with other OXPHOS complexes, are expressed in extra-mitochondrial 
membranes of different mammalian cell types – especially on the cell surface, but also in the 
endoplasmic reticulum and nuclear envelope (Panfoli et al,. 2011). In human apoptotic T-
leukemia cells the presence of eight ATP synthase subunits was revealed in the nucleus 
fraction obtained by differential extraction and stable isotope labeling of cell culture 
followed by LC-MS/MS analysis and it has been ascribed to a dynamic recruitment of 
mitochondria into nuclear invaginations during apoptosis (Hwang et al,. 2006). In mouse 
brain a proteomics analysis of microsomal fraction obtained both by 2D-LC-MS/MS and 
shotgun LC-MS/MS found many subunits of the OXPHOS complexes, including ATP 
synthase, which were proposed to represent mitochondrial proteins with high turnover 
rates in the cell (Stevens Jr et al,. 2008). Conversely, ATP synthase is now considered a true 
resident on the plasma membranes. In fact, the identification by MS of ATP synthase 
subunits in plasma membrane preparations from different sources has been paralleled by 
the demonstration of  the enzyme expression with the F1 sector facing outside (and for this 
reason the enzyme is named ecto-F0F1) obtained by cytometry, confocal microscopy and 
functional studies (Vantourout et al,. 2010). ATP synthase subunits were identified in 
plasma membranes isolated from cell culture, i.e. in hypoxia-adapted tumor cells where 
differential 16O/18O stable isotopic labeling and multidimensional LC-MS/MS revealed an 
increased expression of ATP synthase α subunit with respect to normoxia (Stockwin et al,. 
2006), and in tissues that were characterized by high purity, i.e. obtained by combining 
subcellular fractionation with immunoisolation strategies so that no proteins from 
endoplasmic reticulum and nuclear envelope were detected (Zhang et al,. 2007). In other 
studies, the presence of ATP synthase subunits was found in the detergent-resistant 
fragments of plasma membranes, i.e. in the lipid rafts which are cholesterol and 
sphingolipid-rich microdomains involved in signal trasduction. In particular, in lipid rafts 
isolated from rat liver and subjected to an efficient in solution digestion followed by 
cRPLC/MS/MS four subunits both of F1 and F0 sector were identified (Bae et al,. 2004).  
The major limit of the proteomic studies related to plasma membranes is that in no one the 
complete subunit composition of ecto-F0F1 has been recognized, leaving open the possibility 
of a different assembly of the ectopic enzyme with respect to the mitochondrial ATP 
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synthase. We recently separated by detergent extraction and BNE the whole ecto- F0F1 from 
plasma membranes of rat liver (Giorgio et al,. 2010) and we found that the low, but constant 
amounts of F0F1 complexes display a similar molecular weight to the monomeric form of the 
mitochondrial F0F1 ATP synthase, as evidenced by in-gel ATPase activity staining and 
immunoblotting. This suggests that the plasma membranes of normal liver do contain 
complete, functional F0F1 ATP synthase complexes, which display very similar subunit 
composition and assembly of the mitochondrial enzymes for which MS analysis is in 
progress in our laboratory. 
All together these studies support the view that ATP synthase is mainly located in lipid rafts 
of plasma membranes, is enzymatically active and functions as a cell-surface receptor 
involved in different biological effects depending on the cell types (Fig. 8). In hepatocytes 
ecto-F0F1 functions as high affinity ApoA1 receptor and regulates HDL metabolism, in 
endothelial cells it functions as angiostatin receptor thus mediating angiogenesis, in tumour 
cells it functions as a pH regulator and  participates in  tumor recognition by cytotoxic 
Vγ9/Vδ2 T lymphocytes (Vantourout et al., 2010). Various independent studies have 
reported that ecto-F0F1 can synthesize ATP from ADP and Pi extruding protons from 
cytoplasm in different cell types, such as endothelial cells or hepatocytes. The resulting ATP 
can triggers cation influx into the cells through ATP-gated ion channels (P2X 
purinoreceptors) or can bind to G-protein coupled receptors (P2Y purinoreceptors) 
activating a downstream signaling pathways (Mowery and Pizzo, 2010). However, whether 
or not ecto-F0F1 can synthesize ATP is still debated, as there are several conflicting reports. 
Conversely, it is widely accepted that ecto-F0F1 catalyses the hydrolysis of ATP, potentially 
affecting purinergic signaling (Fig. 8). As an example, in hepatocytes, ADP generated by 
 
 
Fig. 8. The model depicts the orientation of ectopic F0F1 ATP synthase in eukaryotes with the 
F1 sector facing outside. In some cells the ATP synthesized by the enzyme leads to influx of 
cations such as Ca2+ through P2X receptors and in others the ADP generated by ATP 
hydrolysis triggers signaling pathways through activation of G-protein coupled P2Y receptors. 
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5. Ectopic F0F1ATP synthase of mammalian cells 
The application of proteomic analyses to sub-cellular mammalian fractions other than 
mitochondria revealed the presence of mitochondrial membrane components in unexpected 
cellular locations, such as plasma membranes or nuclei. Some of these studies ascribed it to 
cross-contamination, due to the contiguity of the different membranes within the cell and to  
the high sensitivity of  MS which identifies the proteins up to subfentomolar levels, but  in 
others cases the parallel demonstration of such unusual locations obtained in cells and tissues 
by immunofluorescence and functional studies led the scientists  to consider the proteomics 
results a mainstay to discover new scenarios in the intracellular traffic connections.  
Regarding ATP synthase, many proteomics studies have recently reported that subunits of 
this complex, along with other OXPHOS complexes, are expressed in extra-mitochondrial 
membranes of different mammalian cell types – especially on the cell surface, but also in the 
endoplasmic reticulum and nuclear envelope (Panfoli et al,. 2011). In human apoptotic T-
leukemia cells the presence of eight ATP synthase subunits was revealed in the nucleus 
fraction obtained by differential extraction and stable isotope labeling of cell culture 
followed by LC-MS/MS analysis and it has been ascribed to a dynamic recruitment of 
mitochondria into nuclear invaginations during apoptosis (Hwang et al,. 2006). In mouse 
brain a proteomics analysis of microsomal fraction obtained both by 2D-LC-MS/MS and 
shotgun LC-MS/MS found many subunits of the OXPHOS complexes, including ATP 
synthase, which were proposed to represent mitochondrial proteins with high turnover 
rates in the cell (Stevens Jr et al,. 2008). Conversely, ATP synthase is now considered a true 
resident on the plasma membranes. In fact, the identification by MS of ATP synthase 
subunits in plasma membrane preparations from different sources has been paralleled by 
the demonstration of  the enzyme expression with the F1 sector facing outside (and for this 
reason the enzyme is named ecto-F0F1) obtained by cytometry, confocal microscopy and 
functional studies (Vantourout et al,. 2010). ATP synthase subunits were identified in 
plasma membranes isolated from cell culture, i.e. in hypoxia-adapted tumor cells where 
differential 16O/18O stable isotopic labeling and multidimensional LC-MS/MS revealed an 
increased expression of ATP synthase α subunit with respect to normoxia (Stockwin et al,. 
2006), and in tissues that were characterized by high purity, i.e. obtained by combining 
subcellular fractionation with immunoisolation strategies so that no proteins from 
endoplasmic reticulum and nuclear envelope were detected (Zhang et al,. 2007). In other 
studies, the presence of ATP synthase subunits was found in the detergent-resistant 
fragments of plasma membranes, i.e. in the lipid rafts which are cholesterol and 
sphingolipid-rich microdomains involved in signal trasduction. In particular, in lipid rafts 
isolated from rat liver and subjected to an efficient in solution digestion followed by 
cRPLC/MS/MS four subunits both of F1 and F0 sector were identified (Bae et al,. 2004).  
The major limit of the proteomic studies related to plasma membranes is that in no one the 
complete subunit composition of ecto-F0F1 has been recognized, leaving open the possibility 
of a different assembly of the ectopic enzyme with respect to the mitochondrial ATP 
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synthase. We recently separated by detergent extraction and BNE the whole ecto- F0F1 from 
plasma membranes of rat liver (Giorgio et al,. 2010) and we found that the low, but constant 
amounts of F0F1 complexes display a similar molecular weight to the monomeric form of the 
mitochondrial F0F1 ATP synthase, as evidenced by in-gel ATPase activity staining and 
immunoblotting. This suggests that the plasma membranes of normal liver do contain 
complete, functional F0F1 ATP synthase complexes, which display very similar subunit 
composition and assembly of the mitochondrial enzymes for which MS analysis is in 
progress in our laboratory. 
All together these studies support the view that ATP synthase is mainly located in lipid rafts 
of plasma membranes, is enzymatically active and functions as a cell-surface receptor 
involved in different biological effects depending on the cell types (Fig. 8). In hepatocytes 
ecto-F0F1 functions as high affinity ApoA1 receptor and regulates HDL metabolism, in 
endothelial cells it functions as angiostatin receptor thus mediating angiogenesis, in tumour 
cells it functions as a pH regulator and  participates in  tumor recognition by cytotoxic 
Vγ9/Vδ2 T lymphocytes (Vantourout et al., 2010). Various independent studies have 
reported that ecto-F0F1 can synthesize ATP from ADP and Pi extruding protons from 
cytoplasm in different cell types, such as endothelial cells or hepatocytes. The resulting ATP 
can triggers cation influx into the cells through ATP-gated ion channels (P2X 
purinoreceptors) or can bind to G-protein coupled receptors (P2Y purinoreceptors) 
activating a downstream signaling pathways (Mowery and Pizzo, 2010). However, whether 
or not ecto-F0F1 can synthesize ATP is still debated, as there are several conflicting reports. 
Conversely, it is widely accepted that ecto-F0F1 catalyses the hydrolysis of ATP, potentially 
affecting purinergic signaling (Fig. 8). As an example, in hepatocytes, ADP generated by 
 
 
Fig. 8. The model depicts the orientation of ectopic F0F1 ATP synthase in eukaryotes with the 
F1 sector facing outside. In some cells the ATP synthesized by the enzyme leads to influx of 
cations such as Ca2+ through P2X receptors and in others the ADP generated by ATP 
hydrolysis triggers signaling pathways through activation of G-protein coupled P2Y receptors. 
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ecto-F0F1 upon binding of ApoA1 activates the P2Y receptors resulting in HDL endocytosis 
and downstream the small GTPase RhoA and its effector ROCK I (Malaval et al,. 2009).  
The mechanism used by ATP synthase to reach the plasma membrane is still unknown 
(Vantourout et al., 2010). The hypothesis that the single ATP synthase subunits are routed to 
plasma membrane instead of the mitochondria seems unlikely, because different mRNA 
isoforms of ATP synthase subunits have not been found in mammals apart for the bovine 
subunit c (Vives-Bauza et al., 2011). The simpler explanation seems that once assembled into 
mitochondria, the whole complex reaches the cell surface via vescicular transport or fusion 
of mitochondrial membranes with plasma membranes (Vantourout et al., 2010). It is 
tempting to hypothesize that the new technology of imaging MS (MALDI MS 
profiling/imaging), which can acquire individual spectra from the surface of frozen tissue 
sections (Chaurand et al,. 2006), could give important answers regarding the trafficking of 
the enzyme to cell surface.  
6. Conclusions 
F0F1 ATP synthase is an intensely studied enzyme complex, for which single molecule 
studies have allowed to define the fascinating catalysis in great detail. In addition, high-
resolution molecular structures have been obtained mainly by X-ray crystal analyses. In 
spite of this tremendous progress, many aspects of ATP synthase physiology, such as 
biogenesis or super-complex formation, and its role in pathology are still unknown. The 
omni-comprehensive nature of proteomics, unlike the more reductionistic approaches of 
classical biochemistry and genetics, makes it the best candidate for revealing changes in the 
expression level of the whole complex and/or of its single subunits, but also to define the 
quantitative and temporal phosphorylation pattern of the enzyme in all organisms and 
under different physiopathological conditions, thus allowing the understanding of the ATP 
synthase regulation in a better way. In addition, the constant technological progress will 
enable to define the intriguing enzyme intracellular trafficking and its translocation to cell 
surface. In this context, native electrophoresis combined with MS techniques offers a 
powerful top-down approach for functional and structural analyses of such complicated 
enzyme using minimal amount of cell lysates or tissue homogenates and making this 
approach useful also for clinical investigation.  
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1. Introduction 
Wnt signaling is critical and indispensable for numerous cellular pathways including 
embryonic development and adult tissue homeostasis such as determination, proliferation, 
migration and differentiation (Clevers, 2006; Glass and Karsenty, 2006; Nusse, 2005; Wang 
and Wynshaw-Boris, 2004). There are three independent branches of the Wnt signaling 
cascade, Wnt canonical beta-catenin/Lef-Tcf-sensitive transcriptional response, the planar 
cell polarity (PCP) response, and the Wnt5a/Frizzled-2/Ca2+/cGMP response (He et al., 
2004; Katanaev et al., 2005; Liu et al., 2001; Malbon, 2005; Wallingford and Habas, 2005; 
Willert et al., 2003). Dishevelleds (Dvls) are essential components in three major Wnt 
signaling pathways. Dvls function as scaffold protein bridging the receptors and distinct 
downstream signaling components. Through formation of dynamic multiprotein complexes, 
signal is transduced to inside cells.  
In Wnt/beta-catenin signaling pathway, Wnts bind to members of the Frizzled (Fz) family 
of G protein-coupled receptors and to co-receptor low density lipoprotein receptor related 
protein LRP5 and LRP6 (LRP5/6). Binding of Wnt3a to these receptors facilitates a variety of 
intracellular events. Phosphorylation of LRP5/6 triggers the interaction of Fz-LRP5/6 
complex with dynamic multiprotein complexes, including adenomatous polyposis coli (APC), 
Dishevelled (Dsh/Dvl), Axin, glycogen synthase kinase-3β (GSK3β) and casein kinase 
1α (Hart, 1998; Kishida et al., 1998). Scaffold protein Dvl facilitates destruction of 
multiprotein complexes (Hart, 1998 ; Kishida et al., 1998; Malbon, 2005). As a results, 
stabilized β-catenin, translocates to nuclear and enhances Lef/Tcf-sensitive transcription 
(Angers & Moon, 2009; Clevers, 2006; van Amerongen and Nusse, 2009). 
Fly Dsh and three isoforms of mammals Dvls (Dvl1-3) all share several prominent, highly-
conserved domains: a Dsh homology domain called DIX; a conserved sequence element 
with homology to the postsynaptic density protein PSD-95, Discs-large, and ZO-1, termed 
PDZ; and Disheveled, Egl-10, Pleckstrin domain, termed DEP (Wharton, 2003). In addition, 
there are conserved sequence regions harboring basic amino acids residues and a proline-
rich putative Src homology 3 (SH3) binding domain (Penton et al., 2002). Dvl3 knockout 
mouse is lethal, whereas Dvl1 or Dvl2 knockout mouse is viable (Hamblet et al., 2002; 
Etheridge et al., 2008; Lijam et al., 1997). The isoforms of mammals Dvl are not truly 
“redundant” with respect to function (Hamblet et al., 2002; Etheridge et al., 2008; Lee et al., 
2008), although functions of each isoform of Dvls are not fully resolved. Previous studies 
reveal distinct localization of Dvl isoforms in totipotent mouse F9 embryonal 
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1. Introduction 
Wnt signaling is critical and indispensable for numerous cellular pathways including 
embryonic development and adult tissue homeostasis such as determination, proliferation, 
migration and differentiation (Clevers, 2006; Glass and Karsenty, 2006; Nusse, 2005; Wang 
and Wynshaw-Boris, 2004). There are three independent branches of the Wnt signaling 
cascade, Wnt canonical beta-catenin/Lef-Tcf-sensitive transcriptional response, the planar 
cell polarity (PCP) response, and the Wnt5a/Frizzled-2/Ca2+/cGMP response (He et al., 
2004; Katanaev et al., 2005; Liu et al., 2001; Malbon, 2005; Wallingford and Habas, 2005; 
Willert et al., 2003). Dishevelleds (Dvls) are essential components in three major Wnt 
signaling pathways. Dvls function as scaffold protein bridging the receptors and distinct 
downstream signaling components. Through formation of dynamic multiprotein complexes, 
signal is transduced to inside cells.  
In Wnt/beta-catenin signaling pathway, Wnts bind to members of the Frizzled (Fz) family 
of G protein-coupled receptors and to co-receptor low density lipoprotein receptor related 
protein LRP5 and LRP6 (LRP5/6). Binding of Wnt3a to these receptors facilitates a variety of 
intracellular events. Phosphorylation of LRP5/6 triggers the interaction of Fz-LRP5/6 
complex with dynamic multiprotein complexes, including adenomatous polyposis coli (APC), 
Dishevelled (Dsh/Dvl), Axin, glycogen synthase kinase-3β (GSK3β) and casein kinase 
1α (Hart, 1998; Kishida et al., 1998). Scaffold protein Dvl facilitates destruction of 
multiprotein complexes (Hart, 1998 ; Kishida et al., 1998; Malbon, 2005). As a results, 
stabilized β-catenin, translocates to nuclear and enhances Lef/Tcf-sensitive transcription 
(Angers & Moon, 2009; Clevers, 2006; van Amerongen and Nusse, 2009). 
Fly Dsh and three isoforms of mammals Dvls (Dvl1-3) all share several prominent, highly-
conserved domains: a Dsh homology domain called DIX; a conserved sequence element 
with homology to the postsynaptic density protein PSD-95, Discs-large, and ZO-1, termed 
PDZ; and Disheveled, Egl-10, Pleckstrin domain, termed DEP (Wharton, 2003). In addition, 
there are conserved sequence regions harboring basic amino acids residues and a proline-
rich putative Src homology 3 (SH3) binding domain (Penton et al., 2002). Dvl3 knockout 
mouse is lethal, whereas Dvl1 or Dvl2 knockout mouse is viable (Hamblet et al., 2002; 
Etheridge et al., 2008; Lijam et al., 1997). The isoforms of mammals Dvl are not truly 
“redundant” with respect to function (Hamblet et al., 2002; Etheridge et al., 2008; Lee et al., 
2008), although functions of each isoform of Dvls are not fully resolved. Previous studies 
reveal distinct localization of Dvl isoforms in totipotent mouse F9 embryonal 
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teratocarcinoma (F9) cells. Dvl1 and Dvl2 are found in the cytosol-enriched fraction (80 %), 
the least amount of each of these isoforms is observed in the nuclear-enriched fraction (5 %). 
Dvl3 content in the cytosol-enriched fraction is reduced to 60 %, whereas content of Dvl3 in 
the nuclear-enriched fraction is several fold greater than that for either Dvl1 or Dvl2 (20 %). 
Abundance of Dvl3 and Dvl1 following Wnt3a stimulation is increased and Wnt3a 
stimulates dramatic Dvl3 trafficking to the plasma membrane. Thus, Dvl3 has a role in 
Wnt/β-catenin signaling that is distinct from those of the Dvl1 and Dvl2 (Yokoyama et al., 
2007). Dvl3 has unique roles in Wnt/β-catenin signaling pathway (Lee et al., 2008; 
Yokoyama et al., 2007). Dvls are believed to be recruited Fz receptor through their PDZ 
domain. Many Dvls associating proteins also interact with Dvls via their PDZ domain 
(Wong et al., 2003). The DIX domain is critical for the ability of Dvl to recruit Axin and for 
the dynamic self-association of Dvls. Fluorescence microscopy in cells suggests that Dvls 
undergo dynamic oligomerization associated with activation of Wnt/β-catenin signaling by 
Wnt3a (Axelrod et al., 1998; Kishida et al., 1999; Rothbacher et al., 2000). Properties of 
dynamic polymerization correlate with the activation of Wnt/β-catenin signaling (Schwarz-
Romond et al., 2007a; Schwarz-Romond et al., 2007b). Wnt induces LRP6 aggregation and 
phosphorylation in a Dvl-dependent manner. Furthermore, Dvl mutants that lack normal 
oligomerization also influence the formation of LRP6 complexes (Bilic et al., 2007). 
Thus, Dvls scaffold many interacting proteins temporally/spatially to transduce Wnt 
signaling. To define a regulation of Wnt signaling, it is necessary to establish the regulatory 
mechanism of assembly of Dvls-based supermolecular complexes. Tight regulation of Wnt 
signaling by protein-protein interaction involves many post-translational modifications such 
as phosphorylation, ubiquitination, sumoylation and methylation. Phosphorylation is a 
crucial and central mechanism of regulating docking of signal molecules to Dvl scaffold. 
Phosphorylation of protein regulates protein activities, binding affinities, stability and its 
trafficking to distinct cellular compartments (Yokoyama and Malbon, 2007; Yokoyama et al., 
2007; Yokoyama and Malbon, 2009). 
To probing Dvls-based complexes, two different approaches were employed. First, our 
attention is to identify interacting proteins of Dvl2 (most abundant form of Dvl in F9 cells). 
Dvl2 interacting proteins have been established using glutathione-S-transferase (GST) fusion 
protein pull down. Interacting proteins were pulled down and eluted from the beads. Eluted 
proteins were separated by immobilized pH gradient (IPG) strips (pH 3-10, first dimension 
separation) and subjected to second dimensional SDS-gel electrophoresis. Samples were 
analyzed by liquid chromatography electrospray ionization mass spectrometry (LC-ESI-MS-
MS). Novel Dvls interacting proteins were identified. In addition, immobilized Dvl2 
domains pull down is able to find novel roles of Src in Wnt signaling. Identification of 
tyrosine phosphorylation sites on Dvl2 by Src family tyrosine kinases led to discover that 
Src family tyrosine kinases are a positive regulator of Wnt/β-catenin signaling (Yokoyama 
and Malbon, 2009). Second attempt is designed to probe Wnt-dependent assembly of Dvls-
based supermolecular complexes. Dishevelled-based “punctae” had been observed earlier 
by fluorescence microscopy. These “punctae” have been shown to be the assemblies of 
protein and the size and cellular distribution changed in response to Wnt stimulation. The 
physical evidence for the existence for these putative “aggregates” or “punctae” of Dvl3-
based complexes was established using size-exclusion chromatography (SEC) technique, 
affinity pull-downs, proteomics, and fluorescent correlation microscopy (fcs). Dvl3-based 
complexes were interrogated physically in vitro by SEC analysis of cell extracts and in vivo 
by fcs analysis in live cells (Yokoyama et al., 2010). Establishment of physical nature and 
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dynamic character of the Dvls-based complexes is the key to understand Wnt signaling. For 
the first time, the assembly of supermolecular Dvl3-based complexes is shown in response 
to Wnt3a. Peak fractions (Dvl3-based supermolecular complexes) separated by SEC were 
subjected to LC-ESI-MS-MS. To avoid eliminating potential contamination of 
proteins/complexes, analysis was carried out at distinct time points. These approaches 
identified both expected and also novel components. 
2. Proteomic analysis of Dvls-based multiprotein complexes 
Wnt signaling is spatially and temporally transduced through the assembly of dynamic 
multiprotein complexes. Dvls, scaffold proteins, provide dynamic protein platform 
including protein kinases, phosphatases, receptors, adaptor molecules, and other signaling 
molecules. The Wnt home page provides an invaluable frame of Dvls interacting proteins 
(http://www.stanford.edu/~rnusse/wntwindow.html), although real Dvls-based complexes 
seem much more complicated. Recent measurement of the mass of Dvl3-based complexes 
showed that the MW of the complexes is >2 MegaDa by SEC and ~35 MegaDa by fcs  
(Yokoyama et al., 2010). Structure and functional analysis of these Dvls-based 
supermolecular complexes is critical to understanding Wnt signaling. Proteomics provide a 
portal to identify complex partners assembled into signalsomes. In this study, two distinct 
approaches are employed.  
2.1 Analysis of Dvl2 interacting proteins using glutathione-S-transferase (GST) fusion 
protein pull down 
The pull-down technique is an invaluable tool for studying cellular pathways via protein-
protein interactions. GST fusion protein pull down experiments are one approach to identify 
interaction of between probe protein and unknown targets. GST fusion protein pulls down 
offers an important biological assay for direct protein-to-protein interactions. In this study, 
GST fusion proteins of Dvl2 domain are employed to discover novel Dvl2 interacting 
proteins. Identification of novel Dvls interacting proteins facilitates understanding the 
regulatory mechanism of Wnt signaling. 
2.1.1 Glutathione-S-transferase (GST) fusion protein pulls down 
GST fusion proteins of the conserved domains DIX, PDZ, and DEP and the putative SH3 
binding domain of Dvl2 were immobilized on glutathione-derivatized agarose matrix. 
Immobilized GST-PDZ (aa 267-309), GST-DIX (aa 11-93), GST-DEP (aa 433-507), GST-
putative SH3 binding containing region (aa 356-378) and GST itself (as a control) were 
incubated with cell lysates from F9 cells stimulated with or without Wnt 3a. The interacting 
proteins were pulled down and eluted from the beads. Eluted proteins were separated by 
immobilized pH gradient (IPG) strips (pH 3-10, first dimension separation) and subjected to 
second dimensional SDS-gel electrophoresis. Proteins were stained with SYPRO Ruby. Non 
specific proteins were eliminated by comparing gel patterns obtained with GST-Dvl2 
domains with those obtained by GST itself (fig. 1).  
To identify Wnt-dependent interacting proteins, spots according in response to Wnt3a 
stimulation were excised from the gel (fig. 2), digested with trypsin overnight at 37 oC and 
analyzed by liquid chromatography electrospray ionization mass spectrometry (LC-ESI-MS-
MS, Applied Biosystems/MDS SCIEX) using a micro-column reverse phase HPLC 
interfaced to an LTQ ion trap mass spectrometer. Electrospray tandem mass spectrometry  
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teratocarcinoma (F9) cells. Dvl1 and Dvl2 are found in the cytosol-enriched fraction (80 %), 
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dynamic character of the Dvls-based complexes is the key to understand Wnt signaling. For 
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F9 cells were stimulated or unstimulated with Wnt3a for 30 min. Cell lysates were incubated with either 
GST domain beads or GST beads for 15 min. Bound proteins were eluted by SDS-running buffer and 
purified using ready prep 2-D cleanup kit. Samples were applied to pH 3-10 IPG strips, and then 
subjected to second dimensional gel electrophoresis.  
Fig. 1. Second dimensional SDS-gel of GST pulls down. 
 
 
Wnt-dependent spots were selected by comparing gel patterns with or without Wnt stimulation. Spots 
with red numbers were further analyzed. 
Fig. 2. Analysis of Wnt-dependent spots on a second dimensional gel.  
based sequencing was performed. Data were analyzed by the Mascot search engine to 
identify amino acid sequences. LC-ESI-MS-MS analyses were performed at the Stony Brook 
Proteomics Center. 
2.1.2 Identification of Dvl2 interacting proteins 
The identified Dvl2 interacting proteins by GST fusion pull down are summarized in Table 1. 
Dvls are known to oligomerize via their DIX domain. Purified DIX domain polymerizes in 
vitro to form fibris and to puncta in vivo (Schwarz-Romond et al., 2005). DIX domain 
mediates dynamic polymerization platform with a high concentration of binding sites for 
Wnt signaling partners such as Axin and GSK3β. Axin also has a DIX domain at the C-
terminus which mediates self–interaction in a head to tail fashion, similar to Dvls (Schwarz-
Romond et al., 2007b; Schwarz-Romond et al., 2005). Known interacting proteins pulled 
down by the DIX domain-GST included all three Dvl isoforms and Axin2. Presence of PDZ 
and DEP peptides of Dvl2 in GST-DIX pulled down fraction demonstrated that Dvl2 forms 
homo oligomer. Dvl2 also forms complexes with the other two isoforms, Dvl1 and Dvl3;  
 
Proteomic Analysis of Wnt-Dependent Dishevelled-Based Supermolecular Complexes 
 
193 
Domain Protein # of independent 
peptide identified




DIX Dvl2 7 38 8 
Dvl1 6 14 6.9 
RGS18 2 5 6.8 
Dvl3 3 4 3.2 
Rho-associated protein 
kinase 3 3 2.6 
PLK4 2 4 1.45 
Axin 2 2 2 2.42 
PTPRR 1 1 0.8 
PDZ Tropomyosine α 7 9 23.4 
Actin 8 18 21.9 
Cyclin 2 2 5.36 
PKC and casein kinase 
substrate in neuron 
protein 1 
2 2 4.08 
Axin 2 1 1 1.42 
Axin 1 1 1 1.0 
B-Raf 1 1 0.91 
DEP Actin 6 14 18.1 
Adenylate kinase 1 2 2 8.76 
Ubiquitin-conjugating 
enzyme E2M 1 1 4.91 
Cyclin 1 1 3.7 
SH3 
binding 
Tropomyosine α 8 12 22.6 
Actin 12 46 31 
HSP 70K 3 4 5.6 
PARD-3 2 14 1.56 
Desmoplakin-3 3 3 1.0 
Junction plakoglobin 2 2 3.4 
Rho-associated protein 
kinase 2 8 1.0 
Cullin 3 1 1 1.3 
Table 1. Identified Dvl2 interacting proteins. 
demonstrating Dvls assemble Dvls-based complexes and thus provide a Dvls platform. 
Polo-like kinase 4 (PLK4), Regulator of G protein signaling (RGS) 18, Rho-associated protein 
kinase and Receptor-type protein tyrosine phosphatase R (PTPRR) were identified as novel 
DIX domain interacting proteins.  
PDZ domain beads pulled down interacting proteins Axin1 and Axin2. Novel interacting 
proteins were Tropomyosine α, cyclin, PKC and casein kinase substrate in neuron protein 1 
and B-Raf proto-oncogen serine/threonine kinase. Adenylate kinase 1, cyclin and ubiquitin-
conjugating enzyme E2M were identified as novel DEP domain interacting proteins. SH3 
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demonstrating Dvls assemble Dvls-based complexes and thus provide a Dvls platform. 
Polo-like kinase 4 (PLK4), Regulator of G protein signaling (RGS) 18, Rho-associated protein 
kinase and Receptor-type protein tyrosine phosphatase R (PTPRR) were identified as novel 
DIX domain interacting proteins.  
PDZ domain beads pulled down interacting proteins Axin1 and Axin2. Novel interacting 
proteins were Tropomyosine α, cyclin, PKC and casein kinase substrate in neuron protein 1 
and B-Raf proto-oncogen serine/threonine kinase. Adenylate kinase 1, cyclin and ubiquitin-
conjugating enzyme E2M were identified as novel DEP domain interacting proteins. SH3 
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binding domain pulled down Tropomyosine α, HSP 70K, PARD-3, desmoplakin-3, 
plakoglobin, Rho-associated protein kinase, and Cullin 3. Actin, known Dvl interacting 
protein, was pulled down by PDZ, DEP and SH3 binding domains of Dvl2. 
2.1.3 Assay for Lef/Tcf-sensitive transcription 
Lef/Tcf-sensitive transcription is the read out of Wnt/beta-catenin signaling pathway. F9 
cells were grown on 12-well plates and co-transfected with rat Fz1 (Rfz1) and 
Super8xTOPFlash (M50) (Seto and Bellen, 2006). After 1-2 days of transfection, cells were 
treated with Wnt3a (20 ng/ml) for up to 8 hours. Cells were lysed in a reporter gene lysis 
buffer [12.5 mM Tris-H3PO4 pH 7.8, 1 mM trans-1, 2-cyclohexanediaminetetraacetic acid 
(CDTA), 2 mM DTT, 10% glycerol and 1 % Triton X-100] (Promega) and further analyzed. 
Lef/Tcf-sensitive transcription activity was determined using cell lysates according to the 
manufacture’s instructions (Stratagene) and displayed to relative to unstimulated cells (set 
to “1”). 
2.1.4 Evaluation of novel Dvl2 interacting proteins  
Dvl proteins are phosphorylated in response to Wnt and display a shift of electrophoretic 
mobility on SDS-PAGE. Dvl activity itself is reported to be controlled by multiple 
phosphorylation events (McKay et al., 2001; Sun et al., 2001; Willert et al., 1997). Thus, Dvl 
phosphorylation is implicated in the Wnt signaling pathway. Many serine/threonine 
protein kinases and phosphatases are known to interact with Dvls. CK1ε, CK2 and Par1 are 
proposed to phosphorylate Dvls (Cong et al., 2004; Sun et al., 2001; Willert et al., 1997). Not 
only serine/threonine kinases, but also Src family tyrosine kinases phosphorylate Dvl2 
(Yokoyama and Malbon, 2009). Protein phosphatase 2C (PP2C) and protein phosphatase 2A 
(PP2A) dock to Dvls (Strovel et al., 2000; Yokoyama and Malbon, 2007).  
Treatment with okadaic acid (chemical inhibitor of serine/threonine phosphatases, PP1 and 
PP2A) mimics Wnt 3a action, increasing the cellular abundance of Axin and GSK3β and β-
catenin as well as the trafficking of signaling elements in Wnt/β-catenin signaling pathway. 
Although mimicking effects of Wnt3a on the cellular abundance and trafficking of key 
signaling elements in Wnt /β-catenin signaling, suppression of PP2A alone does not 
provoke activation of Lef/Tcf-sensitive transcription, but potentiates its activation by 
Wnt3a. PP2A activity declines dramatically after Wnt stimulation and direct binding of Dvl2 
to PP2A suppresses a phosphatase activity. PP2A dephosphorylates Dvl2 (Yokoyama and 
Malbon, 2007). Thus, phosphorylation-dephosphorylation is a central regulatory mechanism 
of docking proteins–Dvls interaction. 
Consistent with the critical roles of phosphorylation-dephosphorylation in Wnt signaling 
pathway, several kinases and phosphatase were identified as novel Dvl2 interacting 
proteins. One tyrosine phosphatase PTPRR and two serine/threonine kinases, PLK4 and B-
Raf, were further analyzed to confirm their functions in the Wnt/β-catenin signaling 
pathway. 
Receptor-type protein tyrosine phosphatase R (PTPRR), also known as PTP-SL, contains a 
kinase interacting motif (KIM), located just N-terminal of the phosphatase domain, and 
associates with the mitogen-activated protein (MAP) kinase. PTPRR associates with MAPKs 
and inactivates kinases by dephosphorylating tyrosine residue (Hendriks et al., 2009). 
MAPKs promote Wnt/β-catenin signaling pathway via LRP6 phosphorylation suggesting 
convergence between Wnt/β-catenin signaling pathway and the mitogenic pathway 
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(Cervenka et al., 2011). F9 cell extracts from stimulated or unstimulated cells were incubated 
with GST beads or one of the distinct GST-domain beads. PTPRR displayed prominent 
docking to DIX and DEP domains, modestly to the PDZ domain and weakly to the  
putative SH3 binding domain. Wnt stimulation slightly enhanced docking of PTPRR  
to Dvl2 DIX domain (fig. 3A). Association of Dvl2 and PTPRR was confirmed by Dvl2 
immunoprecipitation followed by proved with either anti-Dvl2 antibody or anti-PTPRR 
antibody. Association of Dvl2 and PTPRR was enhanced by Wnt3a in a time-dependent 
manner (fig. 3B). Docking of PTPRR to Dvl2 increased over 1hour post Wnt3a stimulation. 
The functional role of PTPRR in Wnt/β-catenin pathway was investigated by measuring 
Lef/Tcf-sensitive transcriptional activity, a hallmark of activation of the Wnt/β−catenin 
pathway, by knocking down of PTPRR. siRNA mediated knockdown of PTPRR resulted in 
enhancement of Lef/Tcf-sensitive transcription activity, while overexpression of PTPRR 
attenuated Lef/Tcf-sensitive transcription activity (fig. 3C and 3D) confirming that PTPRR is 
a novel Dvl2 interacting protein and functions as a negative regulator of the Wnt/β-catenin 
signaling pathway. Association of tyrosine phosphatase with Dvl2 is a novel finding. 
Polo-like kinase 4 (PLK4) is another novel DIX domain interacting protein which was 
identified in this study. PLK4 is the most structurally divergent Polo family kinase and is 
essential for mouse embryonic development (Swallow et al., 2005). PLK4 is required for the 
reproduction of centrosomes during cell cycle (Habedanck et al., 2005). Interaction of PLK4 
and Dvl2 was confirmed by co-immunoprecipitation with an anti-Dvl2 antibody. Lef/Tcf-
sensitive transcription was enhanced by knockdown of PLK4, while overexpression of PLK4 
attenuated Lef/Tcf-sensitive transcription, suggesting negative roles of PLK4 in Wnt/β-
catenin signaling pathway (fig. 3E, 3F and 3G). Thus PLK4 is evaluated as functional novel 
interacting protein of Dvl2.  
B-Raf proto-oncogen serine/threonine kinase, which transduces signals from Ras to MEK 
and ERK/MAPK, was identified as a novel PDZ interacting protein. These pathways 
regulate many cellular functions, including cell proliferation, differentiation, apoptosis, 
motility and metabolism (Wellbrock et al., 2004); and implicated in many human diseases 
such as cancer. (Rapp et al., 2006). Docking of B-Raf to PDZ domain was regulated by Wnt3a 
(fig. 4A). DIX, DEP and putative SH3 binding domains were also involved in the interaction 
of the two molecules. Docking of B-Raf to Dvl2 was Wnt-dependent and dramatically 
increased 15 min after Wnt3a stimulation. The association persisted for 2hours (fig. 4B). 
Attenuation of Lef/Tcf-sensitive transcription by knocking down of B-Raf demonstrated 
that B-Raf regulates positively Wnt/β-catenin signaling pathway (fig. 4C). Dose-dependent 
enhancement of Lef/Tcf-sensitive transcription is occurred by expression of B-Raf (fig. 4D).  
Thus, the newly identified Dvl2 interacting proteins, PTPRR, PLK4 and B-Raf are indeed 
docked to Dvl2 in a Wnt- and time-dependent manner and, regulate Wnt pathway either 
negatively (PTPRR and PLK4) or positively (B-Raf). 
2.2 Tyrosine phosphorylation of Dvl2 regulates Wnt/β-catenin signaling pathway 
Dvl proteins are highly phosphorylated in response to Wnt stimulation and Wnt-dependent 
phosphorylation sites on Dvls have been poorly analyzed. Dvl phosphorylations regulate 
the Wnt signaling pathway, especially with regard to serine/threonine protein kinases 
(Kishida et al., 2001; Yanagawa et al., 1995). Involvement of tyrosine kinases in Wnt 
signaling pathway has not been established, except tyrosine phosphorylation of β-catenin. 
The phosphorylation sites on Dvls are presumably many and several mechanisms of Dvls  
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binding domain pulled down Tropomyosine α, HSP 70K, PARD-3, desmoplakin-3, 
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(Cervenka et al., 2011). F9 cell extracts from stimulated or unstimulated cells were incubated 
with GST beads or one of the distinct GST-domain beads. PTPRR displayed prominent 
docking to DIX and DEP domains, modestly to the PDZ domain and weakly to the  
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transcription activity. Statistical significance is indicated (*, p< 0.05). 
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(G) Overexpression of PLK4 attenuates Lef/Tcf-sensitive transcription. Cells were co-transfected with 
PLK4, Rfz1 and M50 for one day before Wnt stimulation. Assay for Lef/Tcf-sensitive transcription was 
performed. Statistical significance is indicated (*, p< 0.005). 
Fig. 3. Analysis of novel Dvl2 interacting proteins. 
 




(A) B-Raf docks to Dvl2. Lysates from cells treated or untreated with Wnt3a were incubated with either 
GST itself or one of the immobilized Dvl2 domains. Bound proteins were proved with either anti-B-Raf 
antibody or anti-GST antibody. 
(B) Time course of the association of Dvl2 and B-Raf. Cell lysates were subjected to Dvl2 
immunoprecipitation. Bound proteins were analyzed by SDS-PAGE and immunoblotting with either 
anti-Dvl2 antibody or anti-B-Raf antibody. 
(C) Effect of knockdown of B-Raf on Lef/Tcf-sensitive transcription. F9 cells were transfected with 
siRNA targeting B-Raf one day before co-transfection of the cells with Rfz1 and M50. On the following 
day, the cells were stimulated and Lef/Tcf-sensitive transcription was assayed. Statistical significance is 
indicated (*, p< 0.005). Cell lysates were analyzed by immunoblotting with either anti-B-Raf antibody or 
anti-GAPDH antibody (as a control). 
(D) Overexpression of B-Raf enhances Wnt3a-sensitive Lef/Tcf-sensitive transcription. F9 cells were co-
transfected with Rfz1, M50, and B-Raf expression vector one day before cells were stimulated with or 
without purified Wnt3a for 7 hours. Cell lysates were assayed for Lef/Tcf-sensitive luciferase 
transcription activity. Statistical significance is indicated (*, p< 0.005). 
Fig. 4. Analysis of B-Raf in Wnt/β-catenin signaling pathway. 
phosphorylation may be involved; distributive phosphorylation, sequential priming 
phosphorylation, processive phosphorylation, and combination of distributive 
phosphorylation/sequential priming phosphorylation or processive phosphorylation. 
Similar to LRP5/6, several kinases may phosphorylate same sites on Dvls. Dvl kinases may 
play multiple opposing roles in Wnt signaling pathway like CK1 and GSK3β do. Thus, 
regulations by phosphorylation in Wnt signaling pathway are a complicated process, since 
many important molecules in the pathway are positively or negatively regulated by 
phosphorylation. To avoid such a complexity, in vitro systems are employed, although 
functional and physiological analysis in vivo is required. The amino acid region 370-376 of 
Dvl2 displays a consensus sequence for a class I core SH3 protein-binding motif RTEPVRP 
(Penton et al., 2002). This region is conserved in all three mammalian isoforms of Dvl 
suggesting that tyrosine phosphorylation may be functional in Dvl biology and Wnt 
signaling. In developmentally relevant signaling, Src is reported to elevate the expression 
(Karni et al., 2005) and phosphorylation at Tyr Y654 of β-catenin. The phosphorylation of 
Tyr654 blocked the E-cadherin-β-catenin interaction (Roura et al., 1999). In addition to Src, 
other tyrosine kinases such as Fyn, Fer, transmembrane tyrosine kinase EGFR and c-Met, 
downregulate E-cadherin-mediated adhesion via enhanced tyrosine phosphorylation of β-
catenin (Lilien and Balsamo, 2005; Piedra et al., 2001). In chronic myeloid leukemia cells, 
oncogenic tyrosine kinase Bcr-Abl triggers tyrosine phosphorylation of β-catenin, stabilizes 
β-catenin levels and enhances nuclear signaling activation (Coluccia et al., 2007). A possible 
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signaling. In developmentally relevant signaling, Src is reported to elevate the expression 
(Karni et al., 2005) and phosphorylation at Tyr Y654 of β-catenin. The phosphorylation of 
Tyr654 blocked the E-cadherin-β-catenin interaction (Roura et al., 1999). In addition to Src, 
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involvement of tyrosine kinases, particularly Src family tyrosine kinases, in Wnt/β-catenin 
signaling pathway was investigated. 
2.2.1 Baculovirus expression and purification of Dvl2  
Baculovirus/Sf9 cell system was employed to express Dvl2. Full length Dvl2 was subcloned 
into plasmid pBACgus-9 (N-terminal T7 tag and C-terminal CBD-tag and poly Histidine-
tag, Novagen), and expressed in Sf9 cells using the Bac Vector-3000 DNA transfection kit 
(Novagen). Sf9 cells were grown in Ex-cell-401 medium supplemented with L-glutamine 
and 2.5% fetal bovine serum. Sf9 cells were infected with recombinant Dvl2 baculovirus at a 
MOI (multiplicity of infection) of 5. Cells were harvested after 4 days of infection and lysed 
in a French pressure cell twice in 20 mM Tris-HCl buffer (pH 8.0) containing 1% 
deoxycholate, 2 mM Na3VO4, 20 mM NaF, 5 mM 2-mercaptoethanol, 10 μg/ml leupeptin, 
10μg/ml aprotinin, and 1 mM phenylsulfonyl fluoride (PMSF). After centrifugation, rDvl2 
was purified by Ni2+-affinity chromatography. 
2.2.2 Phosphorylation of Dvl2 by Src family kinase and identification of tyrosine 
phosphorylation sites on Dvl2 
Phosphorylation of rDvl2 was performed in a kinase buffer (10 mM Tris-HCl, pH7.4, 10mM 
MgCl2, 10 mM MnCl2, 1 mM Na3VO4, 50 mM NaF, 0.5 mM ATP) with purified rSrc (from 
Sf9 cell) for 1 hour at 30 oC. Phosphorylated rDvl2 was digested with trypsin and subjected 
to analysis using API QSTAR Pulsar LC/MS/MS (Applied Biosystems/MDS SCIEX) 
equipped with a Protana nanospray source (Protana Engineering A/S) and an UltiMate 
capillary high pressure liquid chromatography (LC Packings) with a PepMap C18 nano-
column (75 μm x 15 cm, LC Packings). Phosphopeptides were detected by a data base search 
using Pro ID software (Applied Biosystems/MDS SCIEX). 
2.2.3 Functional analysis of tyrosine phosphorylation on Dvl2 
The functional relevance of the detected tyrosine phosphorylation sites was assessed 
following site-directed mutagenesis using Qickchange Mutagenesis system (Stratagene). The 
functional ability of the mutational constructs (YF mutants of Dvl2; Y18F, Y27F, Y275F, 
Y295F and Y463F) analyzed by Lef/Tcf-sensitive transcription in Dvl2-deficient cells. F9 cell 
stably expressing Rfz1 and M50 were transfected with siRNA targeting Dvl2 one day before 
transfection of cells with either wild-type or an YF mutant of Dvl2. On the following day, 
cells were stimulated with Wnt3a for 7 hours and Lef/Tcf-sensitive transcription was 
assayed.  
2.2.4 Dvl2 docks to and activates Src in a Wnt-dependent manner 
F9 cell extracts were incubated with immobilized Dvl2 domains (GST-DIX, GST-DEP, GST-
PDZ, GST-putative SH3 binding site, and GST-C-terminus of Dvl2). Src family kinases (Src 
and Hck) displayed prominent docking on the putative SH3 binding region (aa 356-378) and 
the proline-rich region of the C-terminus of Dvl2 (aa 511-736) (fig. 5A). The ability of the 
SH3 domains of Src family tyrosine kinases, but not Nck SH3 domain to enable docking to 
Dvl2 reflects the specificity of the scaffold-kinase interaction (Yokoyama and Malbon, 2009). 
Positive roles of Src family tyrosine kinases in the Wnt/β-catenin signaling pathway were 
confirmed by either treatment with an inhibitor of the Src family tyrosine kinases (PP2) or 
with a siRNA-induced knockdown of Src. Treatment with PP2 or siRNA targeting Src 
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attenuated the formation of primitive endoderm (another readout of Wnt signaling 
pathway) as well as Lef/Tcf-sensitive transcription (Yokoyama and Malbon, 2009). Analysis 
of phosphorylation sites on Dvl2 by Src was performed in vitro. Purified rDvl2 from Sf9 cell 
was phosphorylated by a Src family kinase. The five tyrosine residues (Y18, Y27, Y275, Y295 
and Y463) were identified by mass spectrometry. One example was shown in fig. 5B. Src 
family tyrosine kinases can phosphorylate in vitro two tyrosine residues (Y18 and Y27) of the 
DIX domain, two residues (Y275 and Y295) of the PDZ domain, and a single residue (Y463) 
in the DEP domain. Dvl2 levels were knocked-down by siRNA targeting Dvl2; the ability of 
YF mutants (Dvl2 Y18F, Y27F, Y275F, Y295F and Y463F) versus wild-type Dvl2 to rescue 
Wnt3a-stimulated Lef/Tcf-sensitive transcription was probed. Expression of the wild-type 
Dvl2 in Dvl2 knockdown cells restored the Wnt3a-stimulated Lef/Tcf-sensitive 
transcription, whereas the Y18F Dvl2 mutant in particular attenuated the response by more 





(A) Dvl2 docks to Src and Hck tyrosine kinases. Cell lysates were incubated with one of the 
immobilized Dvl2 domain, DIX, DEP, PDZ, putative SH3 binding region (SH3B), C-terminus (aa 511-
736) and GST itself. Proteins docking to the Dvl2 domains were resolved by SDS-PAGE and analyzed 
by immunoblotting, staining with: anti-Src, anti-Hck, and anti-GST antibodies (loading control).  
(B) Mass spectrum of the Y27 phosphopeptide. Phosphorylated Dvl2 was digested with trypsin and 
analyzed by LC/MS/MS. Tyrosine 27 was identified as phosphorylation site.  
(C) Tyrosine-to-phenylalanine substitution mutants of Dvl2 attenuate Lef/Tcf-sensitive transcription. F9 
cells stably expressing Rfz1 and M50 were transfected with siRNA targeting Dvl2 one day before 
transfection of the cells with either wild-type or one of the YF-mutants of Dvl2 (Y18F, Y27F, Y275F, 
Y295F and Y463F). On the following day, cells were stimulated with Wnt3a. Assay for Lef/Tcf-sensitive 
transcription was performed. Data are adapted with permission from the publication (Yokoyama, N. & 
Malbon, C. C. (2009). J Cell Sci 122, 4439-4451). 
Fig. 5. Src family tyrosine kinases are involved in Wnt/β-catenin signaling. 
At least two prominent components of the multiprotein complexes, Dvl2 and β-catenin, 
were phosphorylated on tyrosine residues in response to Wnt stimulation. Tyrosine 
phosphorylation of Y18, Y27 and Y275 of Dvl2 appears to contribute, in some complex 
manner, to the ability of Src to enhance Wnt3a/β-catenin signaling. Wnt stimulated Src 
docking to Dvl2 through the SH3-binding domain and the C-terminus proline-rich domain. 
Src activity is regulated by intramolecular interactions, an interaction between the SH2 
domain and the C-terminal tail as well as an interaction between the SH3 domain and a 
polyproline-type helix in the SH2-kinase linker region (Sicheri et al., 1997; Williams et al., 
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involvement of tyrosine kinases, particularly Src family tyrosine kinases, in Wnt/β-catenin 
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1997; Xu et al., 1997). Docking of Src to Dvl2 SH3 binding domain and C-terminus proline--rich 
domain disrupts Src autoinhibition, therefore enabling phosphorylation of Src substrates 
(Brown and Cooper, 1996; Miller, 2003). Activated Src enhances Wnt activation of the 
canonical pathway via phosphorylation of Dvl2 and β-catenin (Yokoyama and Malbon, 2009). 
Many Src family kinase substrates themselves possess SH2 and/or SH3 ligands, which couple 
enzyme activation to substrate phosphorylation (Brown and Cooper, 1996; Miller, 2003; Porter 
et al., 2000). In deed, total Src activity was increased after Wnt stimulation. Dvl2 bound form of 
Src showed higher activity than that of free form of Src. Furthermore, knockdown of Dvl2 
blocked Wnt3a-induced activation of Src. Previously Y27D mutant of Dvl2 was shown as a 
polymerization defective mutant (Schwarz-Romond et al., 2007a). Roles of tyrosine residues 
Y18 and Y27 are the keenest interest. The tyrosine residue in the DIX domain plays an 
important role in polymerization of Dvl (i.e., form  punctae). Application of GST pulled down 
and proteomics led to discover novel positive roles of Src family tyrosine kinase in Wnt/β-
catenin signaling (Yokoyama and Malbon, 2009).  
2.3 Assembly of Dvls-based supermolecular complexes in response to Wnt 
stimulation 
Establishment of the physical nature and dynamic character of the Dvls-based complexes is 
a key to understanding Wnt signaling. The second approach is designed to probe Wnt-
dependent assembly of Dvls-based supermolecular complexes. Dishevelled-based 
“punctae” have been observed earlier by fluorescence microscopy. Wnt treatment resulted 
in change of size of the “punctae” as well as their cellular localization. The physical evidence 
for the existence of these putative “aggregates” or “punctae” of Dvl3-based complexes was 
established using size-exclusion chromatography (SEC), affinity pull-downs, proteomics, 
and fluorescent correlation microscopy (fcs). Dvl3-based complexes were interrogated 
physically in vitro by SEC analysis of cell extracts and in vivo by fcs analysis in live cells 
(Yokoyama et al., 2010). Fcs enabled to analyze single molecules in live cells and is exploited 
for the study of the signalsomes mass and dynamic mobility. For the first time, assembly of 
supermolecular Dvl3-based complexes was shown in response to Wnt3a. Proteomics 
dissected the compositions of Dvls-based supermolecular complexes in response to Wnt 
stimulation.  
2.3.1 Preparation of Dvl3-based supermolecular complexes and quantification of 
proteins 
F9 cells co-expressing rat fz1(Rfz1) were suspended in ice-cold buffer (20 mM Tris-HCl pH 
8.0, 0.2 M NaCl, 1 % NP-40, 1 mM PMSF, 10 µg/ml leupeptin, and 10 µg/ml aprotinin) and 
disrupted by repeated passage through a 23-gauge needle, and then centrifuged to remove 
unbroken cells, nucleus and mitochondria. Supernatants were filtered (0.45 μm) and diluted 
with buffer without detergent. 20 mg proteins were applied to a Superdex 200 gel filtration 
column (HiLoad Superdex TM 200 prep grade 26/60, fast-performance liquid 
chromatography system AKTA, GE Healthcare) which was preequilibrated with 20 mM 
Tris-HCl (pH 8.0), 0.2 M NaCl, and 10 % glycerol. Each fraction was analyzed by SDS-PAGE 
and Western immunoblotting. Protein concentration was determined by use of the Bradford 
assay. The immunoreactive bands were scanned by calibrated Umax 1000 scanner equipped 
with SilverFast software (LaserSoft Imaging Inc.). The bands were quantified by using Aida 
software (Raytest, Germany).  
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2.3.2 High–performance size-exclusion analysis of Dvls-based supermolecular 
complexes 
Size-exclusion chromatography (SEC) is one of the approaches for separating protein 
mixtures into numerous clusters of reduced complexity. Separation of Dvl3-based 
signalsomes was established by SEC for the first time. Cell lysates prepared from cells 
stimulated with or without Wnt3a were subjected to size-exclusion column 
chromatography. This high-pressure column (very long and well packed, HiLoad Superdex 
TM 200 prep grade 26/60) permitted high resolution over a Mr range of 43 kDa to ~2.0 
MegaDa (i.e., 2,000,000 daltons). The operation was carried out with AKTA system (GE 
Healthcare). Molecular weight standards showed excellent and reproducible peak 
separation. The identified peaks are, discrete and highly reproducible Mr (fig. 6A). Thus 
size-exclusion column chromatography allows separation of Dvls-based supermolecular 
complexes for a reproducibly and accurate. Individual fractions were subjected to SDS-
PAGE and analyzed by immunoblotting with isoform-specific antibodies. Dvl2, the major 
isoform of Dvls in F9 cell (>95%), displayed two major peaks (one with a peak Mr of ~1.6 
MegaDa, and other centered around 0.5 MegaDa-Mr), and a minor peak (~80 kDa of Mr), 
likely a monomeric Dvl2. Dvl1 revealed the two similar high-Mr supermolecular forms of 1.6 
and 0.5 MegaDa-Mr. In contrast, Dvl3 supermolecular complexes appeared a broad peak 
and the Mr of the resolved complexes spanning from the homodimeric Dvl3 (150-210 kDa) to 
the well-defined peaks with Mr from 0.8 to 2.0 MegaDa (fig. 6B). All three Dvls isoforms 
migrated to ~ 2 MegaDa regions without Wnt stimulation. GSK3β and Axin, components of 
the Dvls-based supermolecular complexes, also migrated to similar positions (Yokoyama et 
al., 2010). 
2.3.3 Wnt stimulation provokes assembly of dynamic Dvl3-based supermolecular 
complexes 
To address the functional significance of Dvls-based supermolecular complexes, we 
investigated whether their formation was regulated by Wnt3a stimulation. As seen in fig. 7A 
and 7B, Wnt3a provoked a dramatic shift in the apparent Mr of the Dvl3-based complexes to 
populations with sharply larger masses (>2.0 MegaDa-Mr). The abundance of Dvl3 based 
complexes (>2.0 MegaDa-Mr) was increased in a time-dependent manner (30min-60min 
after Wnt 3a stimulation) (fig. 7A and 7B). The upfield shift of Dvl3-based supermolecular 
complexes, derived at the expense of lower–Mr peaks, was detected as early as 5 min post-
Wnt3a stimulation (unpublished data). In contrast, the shifts of other two isoforms, Dvl1 
and Dvl2, to > 2.0 MegaDa-Mr were relatively small in response to Wnt. Dvl1/2-based 
complexes did not approach the limit size of those formed by Dvl3-based complexes. GSK3β 
and Axin also migrated with supermolecular complexes of increasing apparent mass (>2 
MegaDa-Mr) in response to Wnt3a stimulation for 30 min (Yokoyama et al., 2010).  
To ascertain whether mimicking Wnt3a action could result in the assembly of Dvl3-based 
supermolecular complexes, several distinct approaches were employed. The first approach 
is overexpression of Dvls. Assembly of Dvl3-based supermolecular complexes varied with 
the isoform of Dvls. It is known that overexpression of Dvl1 and Dvl3 in mouse F9 cells 
stimulated Lef/Tcf-sensitive transcription (Lee et al., 2008). Overexpression of Dvls 
provoked the formation of very large, Dvl3-based supermolecular complexes (fig. 7C), even 
larger than those observed in response to Wnt3a (fig. 7B). Overexpression of Dvl1 
stimulated both activation of the canonical Lef/Tcf-sensitive transcription and an increase in 
the formation of the very large (>2.0 MegaDa-Mr) Dvl3-based supermolecular complexes  
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1997; Xu et al., 1997). Docking of Src to Dvl2 SH3 binding domain and C-terminus proline--rich 
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2.3.2 High–performance size-exclusion analysis of Dvls-based supermolecular 
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(A) Resolution of Superdex 200 column. Mixtures of molecular weight markers (Blue Dextran 2000, 
thyroglobulin, ferritin, aldolase, conalbumin and ovaalbumin) were applied to Superdex 200 column. 
The elution profile was monitored by absorbance at 280 nm. 
(B) F9 cells expressing Rfz1 were disrupted and cell lysates were applied to the Superdex 200 column. 
Proteins were analyzed by SDS-PAGE and immunoblotted with Dvl isoform-specific antibodies. Blots 
were quantified by the calibrated scanner. The calculated, relative molecular weight (Mr) positions from 
the calibration curve are labeled at the top, fraction numbers on the bottom. Arrows indicate the precise 
position at which calibration proteins elute from the Superdex 200 column. Data are adapted with 
permission from the publication (Yokoyama, N., Golebiewska, U., Wang, H. Y. & Malbon, C. C. (2010) J 
Cell Sci 123, 3693-3702). 
Fig. 6. Separation of Dvls-based supermolecular complexes using size-exclusion column 
chromatography. 
(fig. 7C and Table 2). Overexpression of Dvl3 provoked a prominent activation of Lef/Tcf-
sensitive transcription and a sharp increase in the formation of very large (>2.0 MegaDa-Mr) 
Dvl3-based complexes (fig. 7C and Table 2). In contrast, overexpression of the most 
abundant Dvl isoform (i.e., Dvl2 which constitutes >95% of Dvls in F9 cell) provoked only a 
modest Lef/Tcf-sensitive transcriptional response and little formation of the very large, 
(>2.0 MegaDa-Mr) Dvl3-based complexes (fig. 7C and Table 2). Thus, the formation of the 
very large Dvl3-based supermolecular complexes can be specifically mimicked by the 
overexpression of either Dvl1 or Dvl3, which can uniquely activate the Lef/Tcf-sensitive 
pathway in the absence of Wnt3a. Lef/Tcf-sensitive transcriptional activation (the hallmark 
of activation of Wnt/beta-catenin pathway) and the assembly of Dvl3-based supermolecular 
complexes were followed and summarized in Table 2. The second approach to mimicking 
Wnt stimulation is the expression of constitutively active mutant (CA-delta-N) LRP6. 
Expression of the constitutively active mutant of LRP6 (CA-delta-N-LRP6) resulted in Wnt 
stimulation (Tamai et al., 2004). Mimicking Wnt3a action (in the absence of Wnt3a) by CA-
delta-N-LRP6 was performed. Overexpression of CA-delta-N-LRP6 likewise provoked 
formation of the very large, supermolecular Dvl3-based complexes, just like Wnt3a itself 
(Table 2). Conversely, expression of the dominant-interfering delta-C-LRP6 blocked the 
canonical pathway and also abolished the formation of Dvl3-based supermolecular 
complexes. Inhibition of GSK3β activity is a third approach. The chemical inhibition of  
 




(A, B) Dvl3 assembles supermolecular multi-protein complexes in response to Wnt3a, in a time-dependent 
manner. F9 cells were stimulated with Wnt3a for the indicated times. Cells were lysed and subject to steric-
exclusion chromatography on Superdex 200. Fractions were analyzed by SDS-PAGE and resolved proteins 
immunoblotted with isoform-specific Dvl antibodies. Dvl3 blot (A) and quantitative analysis of Dvl3 (B) in 
the region above 750 kDa-Mr. 
(C) Overexpression of Dvls provoked formation of supermolecular Dvl3-based complexes without Wnt3a 
stimulation. F9 cells were co-transfected with Rfz1 and either GFP- and HA-tagged mouse Dvl1, or Dvl2 or 
Dvl3. F9 cells were either unstimulated or stimulated with Wnt3a for 30 minutes. Cells lysates were 
applied to Superdex 200 gel filtration column. Fractions were analyzed by SDS-PAGE. Resolved proteins 
were immunoblotted with anti-Dvl3 antibody and quantified. Data are adapted with permission from the 
publication (Yokoyama, N., Golebiewska, U., Wang, H. Y. & Malbon, C. C. (2010) J Cell Sci 123, 3693-3702). 
Fig. 7. Assembly of Dvl3-based supermolecular complexes by Wnt stimulation and 
overexpression of Dvls.  
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(fig. 7C and Table 2). Overexpression of Dvl3 provoked a prominent activation of Lef/Tcf-
sensitive transcription and a sharp increase in the formation of very large (>2.0 MegaDa-Mr) 
Dvl3-based complexes (fig. 7C and Table 2). In contrast, overexpression of the most 
abundant Dvl isoform (i.e., Dvl2 which constitutes >95% of Dvls in F9 cell) provoked only a 
modest Lef/Tcf-sensitive transcriptional response and little formation of the very large, 
(>2.0 MegaDa-Mr) Dvl3-based complexes (fig. 7C and Table 2). Thus, the formation of the 
very large Dvl3-based supermolecular complexes can be specifically mimicked by the 
overexpression of either Dvl1 or Dvl3, which can uniquely activate the Lef/Tcf-sensitive 
pathway in the absence of Wnt3a. Lef/Tcf-sensitive transcriptional activation (the hallmark 
of activation of Wnt/beta-catenin pathway) and the assembly of Dvl3-based supermolecular 
complexes were followed and summarized in Table 2. The second approach to mimicking 
Wnt stimulation is the expression of constitutively active mutant (CA-delta-N) LRP6. 
Expression of the constitutively active mutant of LRP6 (CA-delta-N-LRP6) resulted in Wnt 
stimulation (Tamai et al., 2004). Mimicking Wnt3a action (in the absence of Wnt3a) by CA-
delta-N-LRP6 was performed. Overexpression of CA-delta-N-LRP6 likewise provoked 
formation of the very large, supermolecular Dvl3-based complexes, just like Wnt3a itself 
(Table 2). Conversely, expression of the dominant-interfering delta-C-LRP6 blocked the 
canonical pathway and also abolished the formation of Dvl3-based supermolecular 
complexes. Inhibition of GSK3β activity is a third approach. The chemical inhibition of  
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GSK3β by LiCl stimulates Lef/Tcf-sensitive transcription (Stambolic et al., 1996). Inhibition 
of GSK3β provoked increased formation of the very large (>2.0 MegaDa-Mr) Dvl3-based 
supermolecular complexes (Table 2). 
To define precisely roles of Dvl isoforms on the assembly of Dvl3-based supermolecular 
complexes, the effect of knockdown of each Dvl isoform was investigated (Table 2). 
Knockdown of each Dvl isoform resulted in attenuation of the assembly of Dvl3-based 
supermolecular complexes as well as Lef/Tcf-sensitive transcription. Knockdown of Dvl1 
and Dvl3, lower abundance of Dvls in F9 cells, was more effective on both parameters. 
Knockdown of Dvl3 essentially precluded formation of the supermolecular complex in the 
absence or presence of Wnt3a. Knockdown of Dvl1 had little effect on the abundance of the 
basal Dvl3-based complex (i.e., without Wnt3a stimulation), but attenuated Wnt3a provoked 
formation of Dvl3-based supermolecular complexes (>2.0 MegaDa-Mr). Knockdown of the 
most abundant isoform Dvl2 severely reduced the abundance of the Dvl3-based complexes 
in the absence of Wnt3a. Wnt3a failed to stimulate the formation of supermolecular Dvl3-
based complexes as well as activation of the canonical pathway. Thus, clearly Dvl1 and Dvl2 
cooperate in catalyzing the formation of supermolecular, Dvl3-based complexes in either the 
absence or presence of Wnt3a. Finally, Dickkopf homologue 1 (DKK1), a well known Wnt 
antagonist (Nusse, 2001), blocked both activation of the Wnt canonical pathway and 
formation of very large, Dvl3-based supermolecular complexes (Table 2).  
 
 (-) Wnt3a 
 
    Oligomerization              Lef/Tcf 
                                 transcription 
(+) Wnt3a 
 
   Oligomerization             Lef/Tcf 
                              transcription 
Control - - + + 
DKK1 - - - - 
delta-N-
LRP6 
+ + + + 
delta-C-
LRP6 
- - - - 
LiCl ++ ++ ++ ++ 
Dvl1 OE ++ ++ ++ ++ 
Dvl2 OE + + + + 
Dvl3 OE +++ +++ +++ +++ 
Dvl1KD + - + - 
Dvl2 KD + - + - 
Dvl3 KD - - - - 
OE: overexpression; KD: knockdown; Data are adapted with permission from the publication 
(Yokoyama, N., Golebiewska, U., Wang, H. Y. & Malbon, C. C. (2010) J Cell Sci 123, 3693-3702). 
Table 2. Summary of Wnt activation and formation of Dvl3-based supermolecular 
complexes. 
Thus, through targeted activation and disruption of Wnt3a signaling, a linkage between the 
ability to form very large (>2.0 MegaDa-Mr) Dvl3-based supermolecular complexes and the 
level of activation of Lef/Tcf-sensitive transcription (functional downstream signaling) was 
established. Unique rolls of Dvl3 in Wnt/β-catenin signaling demonstrate Dvl isoforms are 
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not redundant with respect to function. Several key Dvl-interacting proteins (e.g., Dvl1, 
Dvl2, Dvl3, GSK3β and Axin) were present in these very large, Dvl3-based supermolecular 
complexes. Manipulations that provoked the formation of these Dvl3-based complexes also 
provoked activation of the Wnt/beta-catenin canonical pathway. Mutations of Dvl2 that 
block punctae formation inhibit the canonical Wnt signaling (Schwarz-Romond et al., 
2007a). Dvl2/3 mutants, that do not form punctae, failed to assemble Dvl3-based 
supermolecular complexes (unpublished data). Phosphorylation-defective mutant of Dvl3 
abolished assembly of Dvl3-based supermolecular complexes as well as activation of 
Wnt/beta-catenin signaling. On the other hand, Phosphorylation-mimetic mutant provoked 
both assembly of Dvl3-based supermolecular complexes and Lef/Tcf-sensitive transcription 
(unpublished data). The phosphorylation site was identified by CK1δ in vitro followed by 
proteomics. Data established that phosphorylation of Dvls is a crucial regulatory mechanism 
for the spatial/temporal assembly of dynamic supermolecular complexes to transduce Wnt 
signaling. Recent report provided compelling evidence that phosphorylation by CK1δ/ε 
sequentially regulates activation and de-activation of Dvls. Phosphorylated Dvls stimulate 
the oligomerization of Dvls, whereas the hyper-phosphorylated Dvls have less ability to 
oligomerize also form punctae (Bernatik et al., 2011).  
2.3.4 Analysis of Dvl3-based supermolecular complexes by fluorescence correlation 
spectroscopy (fcs) 
Fluorescence correlation spectroscopy (fcs) is used to probe the apparent size of the Dvl3- 
and Dvl2-based complexes in F9 cell. Fcs measurements were performed on a Zeiss LSM 510 
Meta/Confocor 2 apparatus (Jena, Germany) fitted with a 40 × NA 1.2 C-Apochromat water 
immersion objective. Fcs of eGFP-tagged Dvl3 or Dvl2 in F9 cells was performed. In live cells 
the MW of Dvl3- and Dvl2-based supermolecular complexes was calculated. eGFP-tagged 
Dvl3 was tracked and the molecular weight calculated from the diffusion coefficients (Hess 
et al., 2002; Lakowicz, 2006; Schwille et al., 1999, Yokoyama et al., 2010). Two populations of 
eGFP-Dvl3 in unstimulated cells were obtained (Dvl3 dimers, i.e. ~132 kDa, and very large 
oligomers of ~35 MegaDa). Wnt stimulation slowed down the diffusion of the large 
complexes and increased the molecular mass of Dvl3-based complexes to ~40 MegaDa. The 
diffusion of the smaller complexes did not change in response to Wnt treatment. By sharp 
contrast, Dvl2-based complexes did not change molecular mass before and after stimulation 
with Wnt3a. This phenomenon is coinciding with those obtained by SEC. Wnt treatment 
resulted in increase of the mass of Dvl3-based supermolecular complexes, similar to those 
by SEC. The MW determined by fcs is much larger than that reported on the bases of SEC 
analysis with a Sephacryl S-400 column (HiPrep Sephacryl S400 high-resolution column 16/ 
60, fast-performance AKTA liquid chromatography) (3-7 MegaDa-Mr). The size of Dvl3-
based supermolecular complexes by SEC is reassessed and amended to 35 MegaDa, similar 
to those identified by fcs (Patel & Winzor., 2010).  
2.3.5 Proteomic analysis of Dvl3-based supermolecular complexes in response to 
Wnt3a 
Thus the assembly of Dvl3-based supermolecular complexes in response to Wnt stimulation 
is established. Next important questions are “What are the compositions in Dvl3-based 
supermolecular complexes?” and “How is assembly/disassembly of Dvl3-based complexes 
regulated?” Proteomic analysis was employed to dissect the compositions of supermolecular 
 
Proteomics – Human Diseases and Protein Functions 
 
204 
GSK3β by LiCl stimulates Lef/Tcf-sensitive transcription (Stambolic et al., 1996). Inhibition 
of GSK3β provoked increased formation of the very large (>2.0 MegaDa-Mr) Dvl3-based 
supermolecular complexes (Table 2). 
To define precisely roles of Dvl isoforms on the assembly of Dvl3-based supermolecular 
complexes, the effect of knockdown of each Dvl isoform was investigated (Table 2). 
Knockdown of each Dvl isoform resulted in attenuation of the assembly of Dvl3-based 
supermolecular complexes as well as Lef/Tcf-sensitive transcription. Knockdown of Dvl1 
and Dvl3, lower abundance of Dvls in F9 cells, was more effective on both parameters. 
Knockdown of Dvl3 essentially precluded formation of the supermolecular complex in the 
absence or presence of Wnt3a. Knockdown of Dvl1 had little effect on the abundance of the 
basal Dvl3-based complex (i.e., without Wnt3a stimulation), but attenuated Wnt3a provoked 
formation of Dvl3-based supermolecular complexes (>2.0 MegaDa-Mr). Knockdown of the 
most abundant isoform Dvl2 severely reduced the abundance of the Dvl3-based complexes 
in the absence of Wnt3a. Wnt3a failed to stimulate the formation of supermolecular Dvl3-
based complexes as well as activation of the canonical pathway. Thus, clearly Dvl1 and Dvl2 
cooperate in catalyzing the formation of supermolecular, Dvl3-based complexes in either the 
absence or presence of Wnt3a. Finally, Dickkopf homologue 1 (DKK1), a well known Wnt 
antagonist (Nusse, 2001), blocked both activation of the Wnt canonical pathway and 
formation of very large, Dvl3-based supermolecular complexes (Table 2).  
 
 (-) Wnt3a 
 
    Oligomerization              Lef/Tcf 
                                 transcription 
(+) Wnt3a 
 
   Oligomerization             Lef/Tcf 
                              transcription 
Control - - + + 
DKK1 - - - - 
delta-N-
LRP6 
+ + + + 
delta-C-
LRP6 
- - - - 
LiCl ++ ++ ++ ++ 
Dvl1 OE ++ ++ ++ ++ 
Dvl2 OE + + + + 
Dvl3 OE +++ +++ +++ +++ 
Dvl1KD + - + - 
Dvl2 KD + - + - 
Dvl3 KD - - - - 
OE: overexpression; KD: knockdown; Data are adapted with permission from the publication 
(Yokoyama, N., Golebiewska, U., Wang, H. Y. & Malbon, C. C. (2010) J Cell Sci 123, 3693-3702). 
Table 2. Summary of Wnt activation and formation of Dvl3-based supermolecular 
complexes. 
Thus, through targeted activation and disruption of Wnt3a signaling, a linkage between the 
ability to form very large (>2.0 MegaDa-Mr) Dvl3-based supermolecular complexes and the 
level of activation of Lef/Tcf-sensitive transcription (functional downstream signaling) was 
established. Unique rolls of Dvl3 in Wnt/β-catenin signaling demonstrate Dvl isoforms are 
 
Proteomic Analysis of Wnt-Dependent Dishevelled-Based Supermolecular Complexes 
 
205 
not redundant with respect to function. Several key Dvl-interacting proteins (e.g., Dvl1, 
Dvl2, Dvl3, GSK3β and Axin) were present in these very large, Dvl3-based supermolecular 
complexes. Manipulations that provoked the formation of these Dvl3-based complexes also 
provoked activation of the Wnt/beta-catenin canonical pathway. Mutations of Dvl2 that 
block punctae formation inhibit the canonical Wnt signaling (Schwarz-Romond et al., 
2007a). Dvl2/3 mutants, that do not form punctae, failed to assemble Dvl3-based 
supermolecular complexes (unpublished data). Phosphorylation-defective mutant of Dvl3 
abolished assembly of Dvl3-based supermolecular complexes as well as activation of 
Wnt/beta-catenin signaling. On the other hand, Phosphorylation-mimetic mutant provoked 
both assembly of Dvl3-based supermolecular complexes and Lef/Tcf-sensitive transcription 
(unpublished data). The phosphorylation site was identified by CK1δ in vitro followed by 
proteomics. Data established that phosphorylation of Dvls is a crucial regulatory mechanism 
for the spatial/temporal assembly of dynamic supermolecular complexes to transduce Wnt 
signaling. Recent report provided compelling evidence that phosphorylation by CK1δ/ε 
sequentially regulates activation and de-activation of Dvls. Phosphorylated Dvls stimulate 
the oligomerization of Dvls, whereas the hyper-phosphorylated Dvls have less ability to 
oligomerize also form punctae (Bernatik et al., 2011).  
2.3.4 Analysis of Dvl3-based supermolecular complexes by fluorescence correlation 
spectroscopy (fcs) 
Fluorescence correlation spectroscopy (fcs) is used to probe the apparent size of the Dvl3- 
and Dvl2-based complexes in F9 cell. Fcs measurements were performed on a Zeiss LSM 510 
Meta/Confocor 2 apparatus (Jena, Germany) fitted with a 40 × NA 1.2 C-Apochromat water 
immersion objective. Fcs of eGFP-tagged Dvl3 or Dvl2 in F9 cells was performed. In live cells 
the MW of Dvl3- and Dvl2-based supermolecular complexes was calculated. eGFP-tagged 
Dvl3 was tracked and the molecular weight calculated from the diffusion coefficients (Hess 
et al., 2002; Lakowicz, 2006; Schwille et al., 1999, Yokoyama et al., 2010). Two populations of 
eGFP-Dvl3 in unstimulated cells were obtained (Dvl3 dimers, i.e. ~132 kDa, and very large 
oligomers of ~35 MegaDa). Wnt stimulation slowed down the diffusion of the large 
complexes and increased the molecular mass of Dvl3-based complexes to ~40 MegaDa. The 
diffusion of the smaller complexes did not change in response to Wnt treatment. By sharp 
contrast, Dvl2-based complexes did not change molecular mass before and after stimulation 
with Wnt3a. This phenomenon is coinciding with those obtained by SEC. Wnt treatment 
resulted in increase of the mass of Dvl3-based supermolecular complexes, similar to those 
by SEC. The MW determined by fcs is much larger than that reported on the bases of SEC 
analysis with a Sephacryl S-400 column (HiPrep Sephacryl S400 high-resolution column 16/ 
60, fast-performance AKTA liquid chromatography) (3-7 MegaDa-Mr). The size of Dvl3-
based supermolecular complexes by SEC is reassessed and amended to 35 MegaDa, similar 
to those identified by fcs (Patel & Winzor., 2010).  
2.3.5 Proteomic analysis of Dvl3-based supermolecular complexes in response to 
Wnt3a 
Thus the assembly of Dvl3-based supermolecular complexes in response to Wnt stimulation 
is established. Next important questions are “What are the compositions in Dvl3-based 
supermolecular complexes?” and “How is assembly/disassembly of Dvl3-based complexes 
regulated?” Proteomic analysis was employed to dissect the compositions of supermolecular 
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Dvl3-based complexes. Over 3 MegaDa-Mr peak fractions of Dvl3-based supermolecular 
complexes separated by SEC from Wnt3a treated or untreated cells were subjected to LC-
ESI-MS-MS. Dvl3-based supermolecular complexes (>3 MegaDa-Mr) isolated by SEC are 
distributed in a less populated region of the chromatogram (i.e., near void volume). Limited 
amount of proteins (~1% of total proteins) migrate to >3 MegaDa-Mr peak without Wnt 
stimulation. Wnt stimulation enhanced the abundance of these proteins 2-4 times  in > 3 
MegaDa-Mr region. The low amount of proteins in > 3 MegaDa-Mr region allowed executing 
proteomic analysis, although a main concerning of this application is potential 
contamination of proteins/complexes of Mr similar to that of the Dvl3-based supermolecular 
complexes. However, unrelated proteins/complexes (contamination) would not co-migrate 
with the Dvl3-based supermolecular complexes and also would not response to Wnt 
stimulation.  
To minimize potential contamination, the analysis was carried out at distinct time points (0, 
5, 10 and 30 min). By comparing the proteomic profiles from >3 MegaDa-Mr complexes with 
Wnt stimulation versus without Wnt stimulation, it will be possible to define the relative 
abundance of partners in >3 MegaDa-Mr peak in a Wnt- and time-dependent manner.  
2.3.6 Proteomics of Dvl3-based supermolecular complexes 
Pooled peaks (over 3 MegaDa-Mr) were subjected to TCA precipitation. Protein TCA pellets 
were resuspended in 10 μl of 8M urea, and diluted to 2M urea with 0.1M ammonium 
bicarbonate. The proteins were reduced with 5mM DTT and alkylated with 10mM 
iodoacetamide. 2 μg of trypsin was added to the proteins and incubated overnight at 37 oC. 
The digestion reaction was stopped with formic acid (5% final concentration). 
Multidimensional chromatography was applied. Peptide mixtures were pressure-loaded 
onto a 250 µm inner diameter (i.d.) fused-silica capillary packed first with 3 cm of 5 μm 
strong cation exchange material (Partisphere SCX, Whatman), followed by 3 cm of 10 μm 
C18 reverse phase (RP) particles (Magic, Michrom). Loaded and washed microcapillaries 
were connected to a 100 µm i.d. column, which had been pulled to a 5 μm i.d. tip using a 
P-2000 CO2 laser puller (Sutter Instruments), then packed with 13 cm of 3 μm C18 reverse 
phase (RP) particles (Magic, Michrom) and equilibrated in 2% acetonitrile, 0.1 % formic 
acid (Buffer A). This split-column was then installed in-line with Thermo Surveyor MS 
HPLC pump. The flow rate was ~500 nl/min. Fully automated 12-step chromatography 
runs were carried out. Three different elution buffers were used: 2% acetonitrile, 0.1 % 
formic acid (Buffer A); 98% acetonitrile, 0.1% formic acid (Buffer B); and 0.5 M ammonium 
acetate, 2% acetonitrile, 0.1% formic acid (Buffer C). In such sequences of 
chromatographic events, peptides were sequentially eluted from the SCX resin to the RP 
resin by increasing salt steps (increase in Buffer C concentration), followed by organic 
gradients (increase in Buffer B concentration). The last chromatography step consisted in a 
high salt wash with 100% Buffer C followed by acetonitrile gradient. The application of a 
1.8 kV distal voltage electrosprayed the eluting peptides directly into a LTQ mass 
spectrometer equipped with a nano-LC electrospray ionization source. Full MS spectra 
were recorded on the peptides over a 400 to 2000 m/z range, followed by five tandem 
mass (MS/MS) events sequentially generated in a data-dependent manner on the first, 
second, third, fourth, fifth most intense ions selected from the full MS spectrum (at 35% 
collision energy). Mass spectrometer scan functions and HPLC solvent gradients were 
controlled by the Xcalibur data system (ThermoFinnigan).  
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Tandem mass spectra were extracted by RawXtract version 1.9.7. All MS/MS samples were 
analyzed using Sequest (Thermo Fisher Scientific). Sequest was set up to search a mouse IPI 
database (ver. 3.75), including reversed sequences (in total 113990 entries) assuming no 
specific protease. Sequest was searched with a parent ion tolerance of 1.5Da. Iodoacetamide 
derivative of cysteine was specified in Sequest as a fixed modification. 
Scaffold (version Scaffold_3_00_08, Proteome Software Inc.) was used to validate MS/MS 
based peptide and protein identifications. Peptide identifications were accepted if they 
could be established at greater than 95.0% probability as specified by the Peptide Prophet 
algorithm (Keller et al., 2002). Protein identifications were accepted if they could be 
established at greater than 99.0% probability and contained at least 2 identified peptides. 
Protein probabilities were assigned by the Protein Prophet algorithm (Nesvizhskii et al., 
2003). Proteins that contained similar peptides and could not be differentiated based on 
MS/MS analysis alone were grouped to satisfy the principles of parsimony. 
2.3.7 Evaluation of compositions of Dvl3-based supermolecular complexes in 
response to Wnt3a 
Data were normalized between distinct time points and positive identification was ascribed 
to a protein which had at least 30 unique fragments. Proteins, which abundance was 
changed during Wnt stimulation, were further analyzed. This strategy may identify other 
supermolecular complexes occurred in advance of Wnt signaling as well. Analysis of 
proteomics identified both expected and also novel components. Identified compositions of 
Dvl3-based complexes included protein kinases and phosphatases (serine/threonine and 
tyrosine), guanine nucleotide binding proteins, inositol phosphate related proteins, Wnt 
signaling related proteins and other signaling molecules. 
Detected known Dvls interacting proteins are listed in Table 3. Presence of Dvls interacting 
proteins (17 distinct proteins) in the above ~ 3 MegaDa-Mr region strongly indicated these 
proteins may assemble with Dvl3-based supermolecular complexes. 
 
Identified known Dvls interacting proteins 









Table 3. Identified known Dvls interaction proteins. 
Identified key molecules involving in Wnt signaling pathway include Rho, Gα family, Gβ1 
and mTOR, and abundance of these proteins was changed after Wnt stimulation (Table 4).  
Data represent the diversities and complexities of Wnt signaling pathways which Dvls are 
involved in. Proteomic analysis identified proteins related in the Wnt/β-catenin signaling 
pathway, but also proteins involved in the planar cell polarity (PCP) pathway, Wnt/Ca2+ 
pathway and other signaling pathway.  
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onto a 250 µm inner diameter (i.d.) fused-silica capillary packed first with 3 cm of 5 μm 
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chromatographic events, peptides were sequentially eluted from the SCX resin to the RP 
resin by increasing salt steps (increase in Buffer C concentration), followed by organic 
gradients (increase in Buffer B concentration). The last chromatography step consisted in a 
high salt wash with 100% Buffer C followed by acetonitrile gradient. The application of a 
1.8 kV distal voltage electrosprayed the eluting peptides directly into a LTQ mass 
spectrometer equipped with a nano-LC electrospray ionization source. Full MS spectra 
were recorded on the peptides over a 400 to 2000 m/z range, followed by five tandem 
mass (MS/MS) events sequentially generated in a data-dependent manner on the first, 
second, third, fourth, fifth most intense ions selected from the full MS spectrum (at 35% 
collision energy). Mass spectrometer scan functions and HPLC solvent gradients were 
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Tandem mass spectra were extracted by RawXtract version 1.9.7. All MS/MS samples were 
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Protein probabilities were assigned by the Protein Prophet algorithm (Nesvizhskii et al., 
2003). Proteins that contained similar peptides and could not be differentiated based on 
MS/MS analysis alone were grouped to satisfy the principles of parsimony. 
2.3.7 Evaluation of compositions of Dvl3-based supermolecular complexes in 
response to Wnt3a 
Data were normalized between distinct time points and positive identification was ascribed 
to a protein which had at least 30 unique fragments. Proteins, which abundance was 
changed during Wnt stimulation, were further analyzed. This strategy may identify other 
supermolecular complexes occurred in advance of Wnt signaling as well. Analysis of 
proteomics identified both expected and also novel components. Identified compositions of 
Dvl3-based complexes included protein kinases and phosphatases (serine/threonine and 
tyrosine), guanine nucleotide binding proteins, inositol phosphate related proteins, Wnt 
signaling related proteins and other signaling molecules. 
Detected known Dvls interacting proteins are listed in Table 3. Presence of Dvls interacting 
proteins (17 distinct proteins) in the above ~ 3 MegaDa-Mr region strongly indicated these 
proteins may assemble with Dvl3-based supermolecular complexes. 
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Table 3. Identified known Dvls interaction proteins. 
Identified key molecules involving in Wnt signaling pathway include Rho, Gα family, Gβ1 
and mTOR, and abundance of these proteins was changed after Wnt stimulation (Table 4).  
Data represent the diversities and complexities of Wnt signaling pathways which Dvls are 
involved in. Proteomic analysis identified proteins related in the Wnt/β-catenin signaling 
pathway, but also proteins involved in the planar cell polarity (PCP) pathway, Wnt/Ca2+ 
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Table 4. Identified Wnt signaling related proteins. 
Many proteins such as PI4 kinase, CK1γ, Src, LRP6, PP2A, Par1, CK1α, CK2α and CK2β are 
important key molecules in Wnt/β-catenin signaling pathway and are already known Dvl 
interacting proteins. Wnt treatment quickly produces plasma-membrane-associated LRP6 
aggregates (Bilic et al., 2007). CK1γ phosphorylates LRP5/6 in response to Wnt3a (Davidson 
et al., 2005). Phosphorylation of LRP5/6 promotes Axin recruitment (Davidson et al., 2005; 
Tolwinski et al., 2003; Zeng et al., 2005). PI4 kinase together with PI5K kinase enhances PIP2 
production and stimulates clustering of Dvls and LRP5/6 receptor (Pan et al., 2008). To see 
whether key parameters in the Dvl3-based supermolecular complexes will change in 
response to Wnt stimulation, tentative analysis of these parameters was carried out, 
although these data are not precisely quantitative (fig. 8A and 8B). First key step after Wnt 
stimulation is the phosphorylation of LRP6 by CK1γ. The abundance of LRP in the Dvl3-
based supermolecular complexes was increased two times 5 min post stimulation by Wnt3a 
and sustained over 30 min. The abundance of CK1γ in the Dvl3-based supermolecular 
complexes was increased 5 min post Wnt stimulation and peaked at 10min thereafter 
decreased (fig. 8A). Thus, similar migration of two components was obtained in response to 
Wnt3a. These time courses fit quite well to a previous report, which demonstrated that LRP6 
starts coalescing into punctate structures at or below the plasma membrane within 15min 
Wnt stimulation. PI4 kinase, which is involved in the production of PtdIns (4, 5)P2, 
dramatically increased 10 min post Wnt stimulation (fig. 8A). Data fits well with a previous 
report that significant PtdIns (4,5)P2 formation was detected 15-30 min after Wnt3a 
stimulation (Pan et al., 2008). In contrast, proteins like actin did not change significantly 
upon Wnt stimulation. Many Dvls interacting proteins, which are involved in the Wnt/β-
catenin signaling, CK1α, CK2α, CK1γ, PI4kinaae and Src migrated at >3 MegaDa-Mr region 
after 5-10min Wnt stimulation (fig. 8B). Previous data showed that Src docking to Dvl2 is 
increased after 5-10min Wnt stimulation and sustained for 45min (Yokoyama and Malbon, 
2007). Changing of Src abundance in the Dvl3-based supermolecular complexes was 
matched to the previous finding. Furthermore, not all proteins found in >3 MegaDa-Mr 
region were increased during Wnt stimulation. Migration of Par1 was decreased upon Wnt 
stimulation (fig. 8B). Also proteins such as tubulin, HSP60 and 40S ribosomal protein in >3 
MegaDa-Mr region were decreased upon Wnt stimulation. Together, migrations of proteins 
found in the Dvl3-based supermolecular complexes were responsive to Wnt stimulation 
temporally and some of them were correlated well, suggesting that results obtained by 
proteomic analysis represent proper variations of compositions. 
Interesting observations are several proteins involved in the PCP pathway, Daam 1, PTK7, AP-
2, Par1, Ephrin B1 and Rho GTPase, were also found in >3 MegaDa-Mr peak. Therefore, 
whether or not activation of PCP pathway would provoke assembly of Dvl3-based 
supermolecular complexes was investigated. Wnt5a has been classified as a non-canonical Wnt 
family member. Rat Fz2 (Rfz2) expressing F9 cells were stimulated with Wnt5a for 30 min and 
cell lysates were separated by SEC and further analyzed by immunoblotting with anti-Dvl3  
 








(A) Time courses of LRP, CK1γ and PI4K in >3 MegaDa-Mr peak. Changes of LRP, CK1γ, PI4K and actin 
in response to Wnt3a stimulation are displayed. 
(B) Wnt3a responsive Dvls interacting proteins in >3 MegaDa-Mr peak are displayed.  
Fig. 8. Time courses of key components presented in >3 MegaDa-Mr.. 
antibody. Indeed, assembly of Dvl3-based supermolecular complexes was detected in Rfz2 
expressing F9 cell in response to Wnt5a, demonstrating Wnt5a-dependent assembly of the 
large complexes is provoked in the PCP pathway as well (fig. 9). PCP signaling is pivotal for 
establishing cell polarity and activation of PCP pathway leads to the activation of Rho-
family GTPase and JNK through Dvls and Dishevelled-associated activator of 
morphogenesis 1 (Daam1) (Wallingford and Habas, 2005). Daam 1 bound to both Rho 
GTPase and Dvl, mediates Wnt-induced Dvl/Rho complex formation, which in turn 
activates Rho-associated protein kinase (ROCK) and remodels cytoskeleton (Habas et al., 
2001). Daam1 is imprecated in cancer through its regulation of endocytosis of Ephrin B1 
(Kida et al., 2007). Furthermore, proteomics also identified Ror2, which is involved in 
Wnt/Ca2+ pathway. Ror2 is a receptor tyrosine kinase. Wnt interaction with Fz and co-
receptor Kyn or Ror2 provokes increase of intracellular Ca2+ level and subsequently activates 
calcium/calmodulin-dependent protein kinase II (CaMKII), protein kinase C (PKC) and 
nuclear factor of activated T cells (NFAT). Ca2+ is a central regulator of many cell functions 
and its downstream targets are numerous. Ror2  also shown as a receptor for Wnt5a, 
stimulating the non-canonical pathway (Oishi et al., 2003). In addition, Ror2 has a opposing 
role in the canonical signaling pathway and is able to inhibit Wnt/β-catenin signaling 
(Mikels and Nusse, 2006). Tyrosine kinase activity of Ror2 is indispensable for Wnt5a-
induced inhibition of Wnt/β-catenin signaling (Mikels et al., 2009). Direct interaction of 
Ror2 with phosphorylated Dvl is required for the inhibition of Wnt/β-catenin signaling 
(Witte et al., 2010). Thus, Ror2 plays diverse roles in the discrete Wnt signaling pathways.  
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antibody. Indeed, assembly of Dvl3-based supermolecular complexes was detected in Rfz2 
expressing F9 cell in response to Wnt5a, demonstrating Wnt5a-dependent assembly of the 
large complexes is provoked in the PCP pathway as well (fig. 9). PCP signaling is pivotal for 
establishing cell polarity and activation of PCP pathway leads to the activation of Rho-
family GTPase and JNK through Dvls and Dishevelled-associated activator of 
morphogenesis 1 (Daam1) (Wallingford and Habas, 2005). Daam 1 bound to both Rho 
GTPase and Dvl, mediates Wnt-induced Dvl/Rho complex formation, which in turn 
activates Rho-associated protein kinase (ROCK) and remodels cytoskeleton (Habas et al., 
2001). Daam1 is imprecated in cancer through its regulation of endocytosis of Ephrin B1 
(Kida et al., 2007). Furthermore, proteomics also identified Ror2, which is involved in 
Wnt/Ca2+ pathway. Ror2 is a receptor tyrosine kinase. Wnt interaction with Fz and co-
receptor Kyn or Ror2 provokes increase of intracellular Ca2+ level and subsequently activates 
calcium/calmodulin-dependent protein kinase II (CaMKII), protein kinase C (PKC) and 
nuclear factor of activated T cells (NFAT). Ca2+ is a central regulator of many cell functions 
and its downstream targets are numerous. Ror2  also shown as a receptor for Wnt5a, 
stimulating the non-canonical pathway (Oishi et al., 2003). In addition, Ror2 has a opposing 
role in the canonical signaling pathway and is able to inhibit Wnt/β-catenin signaling 
(Mikels and Nusse, 2006). Tyrosine kinase activity of Ror2 is indispensable for Wnt5a-
induced inhibition of Wnt/β-catenin signaling (Mikels et al., 2009). Direct interaction of 
Ror2 with phosphorylated Dvl is required for the inhibition of Wnt/β-catenin signaling 
(Witte et al., 2010). Thus, Ror2 plays diverse roles in the discrete Wnt signaling pathways.  
 






F9 cells expressing either Rfz1 or Rfz2 were stimulated with Wnt3a or Wnt5a for 30min, respectively. 
Cell lysates were subjected to the gel filtration chromatography and then fractions were analyzed by 
SDS-PAGE and blotted with anti-Dvl3 antibody. The regions above 750 kDa-Mr were shown. 
Fig. 9. Dvl3-based supermolecular complexes are assembled in the PCP pathway. 
Similarly, Par1 is discovered as a Dsh-associated kinase in Drosophila (Sun et al., 2001) and 
an essential for canonical signaling pathway, but also functions in non-canonical pathway 
(Wharton, 2003). Thus, certain molecules are involved in several distinct pathways. Presence 
of mammalian target of rapamycin (mTOR) in the >3 MegaDa-Mr region also demonstrates 
diversity of Wnt signaling pathways (Table 4), and  supporting a previous finding that Wnt-
mediated signaling activates mTOR mediated translational regulation in tumorigenesis 
(Inoki et al., 2006). Wnt activates mTOR via inhibiting GSK3 (Inoki et al., 2006) and the 
phosphorylation of tuberous sclerosis complex 2 (TSC2), a tumor-suppressor which 
negatively regulates mTOR, is suppressed (Mak et al., 2005). These data suggesting that Wnt 
signaling pathway is integrated to control mTOR activity (Choo et al., 2006).  
G proteins found in the Dvl3-based supermolecular complexes are reasonable and expected 
one. Requirement of Gαo and Gαq in Wnt/β-catenin signaling was established earlier in F9 
cell (Liu et al., 1999). Gα13, essential for the formation of the primitive endoderm, induces 
the activation of Rho protein, mitogen-activated protein kinase kinase (MEKK) and Jun-N-
terminal kinase-1 (JNK1) in P19 embryonal carcinoma cells (Jho and Malbon, 1997; Lee et al., 
2004). Gα13and Gαi family functions in development and deficiency of these G proteins 
causes embryonic lethality (Offermanns et al., 1997; Wettschureck et al., 2004). Novel classes 
of signaling proteins found in this large Mr peak included cAMP-dependent protein kinase, 
cell division protein kinase, Yes, Fyn, serine/threonine and tyrosine protein phosphatases, 
inositol 1, 4, 5-triphosphate receptor, phosphoinositide 3-kinase, phosphatidylinositol-4-
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phosphate 3-kinase, AKAP 1 and 14-3-3. Many proteolytic targeting proteins including E3 
ubiquitin-protein ligase NEDD4, Cullin 4B etc. were also found in >3 MegaDa-Mr peak, 
suggesting an important implication for Wnt-initiated tumorigenesis. Functional analysis 
demonstrated that Dvls stability is regulated by Cullin 3 ubiquitin ligase complex containing 
KLH12 (Angers et al., 2006). Some of them were identified by two distinct approaches (GST 
fusion pulls down and application of proteomics to Dvl3-based supermolecular complexes). 
Overall, the combined approaches of SEC and proteomics are successful to dissect Dvl3-
based supermolecular complexes. Key Dvls interacting proteins, known functions in 
Wnt/beta-catenin signaling, present in >3 MegaDa-Mr peak, suggesting a compelling 
evidence that these proteins form complexes with Dvl3. Dvl3-based supermolecular 
complexes assemble at early stage and their compositions are dynamically changed 
during Wnt stimulation. Data agrees well with the fact that the size and localization of 
Dishevelled-based “punctae” have been changed upon Wnt stimulation observed earlier 
by fluorescence microscopy. Further segregation of unrelated proteins from the enriched 
Dvl3-based complexes, if possible, will be a benefit to analyze dynamic assembly of 
molecules central to the function of the Wnt/beta-catenin canonical signaling.  
There are at least three major Wnt signaling branches, Wnt/β-catenin (canonical) 
pathway, PCP pathway (non-canonical) and Wnt/Ca2+ pathway. Proteomics in the >3 
MegaDa-Mr region have identified proteins, which are involved in Wnt/β-catenin 
signaling pathway as well as the PCP and Wnt/Ca2+ pathways, suggest that these 
pathways may share a large signaling network. Wnt signaling pathways may not tightly 
isolate or share intracellular components between pathways. In this way, Wnt signaling 
pathways can cross talk with each other or other signaling pathways. Accumulated 
evidences show the cross talk between distinct Wnt pathways as well as other signaling 
pathways. Diversities of Wnt ligands and its receptors contribute to the complexities of 
Wnt signaling pathways. Distinct Wnt ligands can initiate discrete signaling pathways 
through its distinct receptors; however, signaling by different Wnt family members is not 
only intrinsically regulated by the Wnt proteins themselves, but also by receptor 
availability (cellular context of the receptor). Some Wnt ligand can bind to non-Frizzled 
receptor like Ror2 or RYK (an atypical Tyrosine kinase receptor) etc. RYK lacks a 
functional tyrosine kinase domain, but contains a module homologous to the Wnt-binding 
domain (Lu et al., 2004). Moreover, same Wnt ligand stimulates or inhibits distinct Wnt 
signaling pathways through its distinct receptors. Certain Wnt ligand activates the PCP 
and Wnt/Ca2+ pathways. Our SEC data demonstrate that Dvl3-based supermolecular 
complexes (~2 MegaDa-Mr) are assembling at the basal level (i.e., without Wnt 
stimulation) and Wnt stimulation provokes the upshift of molecular mass of Dvl3-based 
mutiprotein complexes. Data may suggest that without Wnt stimulation, Wnt signaling 
pathways may share fundamental platform of Dvls-based complexes, because Dvls are 
essential scaffold components in all three branches and transduce signals to distinct 
downstream pathways. In one way, we could say that distinct Wnt ligands provoke 
assembly of distinct multiprotein complexes. However, more detailed knowledge of the 
specificity of Wnt ligand and receptor, the receptor availability and protein components 
mediating signals to downstream are required to answer “How Dvls transduce signals to 
distinct Wnt signaling pathways?” and “How Wnt signaling integrates with other 
signaling pathways to form signaling network?” Dvls are a major player  in Wnt signaling 
pathways and scaffold multiproteins to form the platform. Therefore, more precise 
analysis of protein compositions in the supermolecular complexes, not only Wnt/β-
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phosphate 3-kinase, AKAP 1 and 14-3-3. Many proteolytic targeting proteins including E3 
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catenin signaling pathway as well as PCP pathway and Wnt/Ca2+ pathway, is required. 
Our data demonstrate that the assembly of Dvl3-based supermolecular complexes is 
provoked in the PCP pathway. Similar to the Wnt/β-catenin signaling, the molecular 
mass of Dvl3-based supermolecular complexes is upshifted in the response to Wnt5a. 
There is no information whether Dvls-based supermolecular complexes form in Wnt/Ca2+ 
signaling pathway. Comparison of proteomic profiles of Dvl3-based supermolecular 
complexes in the Wnt/β-catenin signaling versus the PCP pathway may provide a clearer 
image of signaling specific compositions of the supermolecular complexes. Precise 
regulations of Wnt signaling pathway by the Dvls-based supermolecular complexes are 
needed to analyze more widely in all branches. Advanced proteomic analysis of the Dvls-
based supermolecular complexes with high-throughput screening offers an ideal strategy 
to interrogate the composition of Dvl3-based supermolecular complexes in the Wnt/β-
catenin signaling pathway as well as in the non-canonical signaling pathway. 
3. Conclusion 
Dvls are scaffold proteins and Wnt signaling is transduced through the dynamic 
assembly/disassembly of protein complexes with Dvls called “signalsomes”. Dvls-based 
supermolecular complexes provide a platform for recruiting many docking proteins and 
organizing dynamic assembly of proteins. Dvls-based punctae have been visualized by 
fluorescence microscopy and displayed dynamic protein assemblies. Proteomics of 
immobilized GST-domain pull down identified several novel and functional Dvl2 
interacting proteins. Novel positive roles for Src family tyrosine kinases in Wnt/β-catenin 
signaling also have been established by GST-domain pull down and proteomics. 
Identification of tyrosine phosphorylation sites on Dvl2 leads to the discovery of the positive 
role of Src family kinases in Wnt/β-catenin signaling. Wnt stimulates Src docking to Dvl2 
and activates Src tyrosine kinase. Activated Src enhances Wnt activation of the canonical 
pathway via phosphorylation of Dvl2 and β-catenin. 
The physical nature and the dynamic character of the Dvl3-based supermolecular complexes 
have been established first time. The formation of these very large, supermolecular Dvl3-
based complexes in response to Wnt3a is found to be a time-dependent manner and 
dynamic in character. The assembly of Dvl3-based supermolecular complexes (>3 MegaDa-
Mr) occurred at very early stage (detected as early as 5 min post-Wnt3a stimulation) and 
maximized 30-60 min post-Wnt stimulation, in advances of the Lef/Tcf sensitive-
transcription. Formation of very large Dvl3-based supermolecular complexes is essential in 
Wnt canonical signaling. Data demonstrate “punctae”, Lef/Tcf-sensitive transcription 
(hallmark of activation of Wnt/beta catenin pathway) and dynamically assembled Dvl3-
based supermolecular complexes are functionally obligate to Wnt signaling. The mass of 
very huge Dvl3-based supermolecular complexes reveals MW ranging from 25-35 MegaDa 
by fcs. Reassessed size of Dvl3-based supermolecular complexes is 35 MegaDa by SEC, 
similar to those obtained by fcs. This study demonstrates successful probing of signalsomes 
by SEC, fcs, affinity pull down and advanced proteomics. 
Application of the proteomics in Dvl3-based supermolecular complexes provides physical 
properties of the assemblies. This approach is still experimental and challenging efforts, 
because cardinal concern is that Dvl3-based supermolecular complexes separated by SEC 
may contain unrelated proteins. Unsuccessful further separation of pure Dvl3-based 
supermolecular complexes is the barrier of this approach, because the size of the very huge 
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Dvl3-based complexes interfered with further purification. Immunoprecipitation might be a 
useful approach, although there are difficulties to precipitate very large complexes, because 
epitope sites in the supermolecular complexes are not fully exposed. Under these 
circumstances, employed proteomics in the Dvl3-based supermolecular complexes provide 
invaluable information to address “What are the compositions of Dvl3-based 
supermolecular complexes?” and “How is the assembly/disassembly of Dvl3-based 
complexes temporally and spatially regulated?” More detailed analysis of the Dvls-based 
supermolecular complexes in all three Wnt signaling pathways is necessary. Thus, 
compelling, albeit indirect, studies established the natures of Dvl3-based supermolecular 
complexes by advanced proteomics. Novel proteins found in Dvl3-based supermolecular 
complexes need to be validated with functional analysis in vivo and in vitro.  
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Plasminogen Receptor, Plg-RKT 
Lindsey A. Miles1, Nicholas M. Andronicos2, Emily I. Chen3,  
Nagyung Baik1, Hongdong Bai4, Caitlin M. Parmer5,  
Shahrzad Lighvani1, Samir Nangia4,6, William B. Kiosses1,  
Mark P. Kamps6, John R. Yates III1 and Robert J. Parmer4,6 
1. Introduction 
1.1 The plasminogen activation system 
Initiation of the plasminogen activation system results in generation of the broad spectrum 
serine protease, plasmin, from the circulating zymogen, plasminogen. Plasminogen is 
activated to plasmin by plasminogen activators (PA’s), either urokinase type-plasminogen 
activator (u-PA) or tissue-type plasminogen activator (t-PA), via specific proteolytic 
cleavage (Castellino & Ploplis, 2005). Plasmin is the major enzyme responsible for 
degradation of fibrin clots (fibrinolysis) to maintain normal blood homeostasis (Bugge et al., 
1995; Ploplis et al., 1995). Dysregulation of the plasminogen activation system can result in 
hemorrhage (excess fibrinolysis) or thrombosis (insufficient fibrinolysis). The plasminogen 
activation system is regulated by direct inhibition of plasmin (by the circulating serpin, α2-
antiplasmin) and by synthesis and secretion of plasminogen activators and the serpin, 
plasminogen activator inhibitor 1 (PAI-1)] (Collen, 1999). In a key regulatory step, 
plasminogen activation is promoted when plasminogen and its activator, t-PA, bind 
concomitantly to lysine residues on the surface of fibrin clots, resulting in a marked 
reduction in the Km for activation of plasminogen compared with the reaction in solution 
(Hoylaerts et al., 1982). 
1.2 Functions of plasminogen receptors 
In the past 25 years an additional mechanism for positive regulation of plasminogen 
activation has been recognized: co-localization of plasminogen and PA’s on cell surfaces 
markedly decreases the Km for plasminogen activation in a mechanism analogous to 
assembly of components of the plasminogen activation system on fibrin (Miles et al., 2005). 
The plasmin produced is retained on the cell surface where it is protected from its inhibitor, 
α2-antiplasmin (Figure 1) (Hall et al., 1991; Plow et al., 1986). Thus, the cell surface becomes 
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armed with the broad spectrum proteolytic activity of plasmin. Cell surface plasmin plays a 
key role in processes in which cells must degrade an extracellular matrix in order to migrate, 
including inflammation (Busuttil et al., 2004; Ploplis et al., 1998; Plow et al., 1999), wound 
healing (Creemers et al., 2000; Romer et al., 1996), metastasis (Palumbo et al., 2003; Ranson et 
al., 1998) and neurite outgrowth (Gutierrez-Fernandez et al., 2009; Jacovina et al., 2001). Cell 
surface plasmin also plays a key role in myogenesis (Lopez-Alemany et al., 2003) and 




Activation of cell-associated plasminogen (Plg) to plasmin (Pm) by cell-associated plasminogen 
activators (PA) is markedly enhanced compared to the reaction in solution. The Pm formed remains on 
the cell surface where it is relatively protected from its inhibitor, α2-antiplasmin (α2-AP). 
Fig. 1. Enhancement of plasminogen activation on the cell surface. 
1.3 Characteristics of plasminogen receptors 
Cellular plasminogen binding sites are very broadly distributed on both prokaryotic and 
eukaryotic cells. Of the many cell types examined to date, only red cells do not exhibit 
detectable plasminogen binding ability (Miles et al., 2005). The interactions of plasminogen 
with cells are of very high capacity, reaching 3 X 107 molecules/cell on lung fibrolasts (Plow 
et al., 1986), for example. Thus, the plasminogen binding capacity of a cell is made up of 
contributions from a set of distinct cell surface proteins. 
An important aspect of the mechanism of promotion of plasminogen activation on cell 
surfaces is that a subset of carboxypeptidase-B-sensitive plasminogen binding proteins is 
responsible for enhancement of plasminogen activation on eukaryotic cells. When cells are 
treated with carboxypeptidase B, the ability to stimulate plasminogen activation is lost 
(Félez et al., 1996). Since carboxypeptidase B removes C-terminal basic residues, these 
results imply that proteins exposing C-terminal basic residues on cell surfaces are 
responsible for stimulation of plasminogen activation (Figure 2,A). Known 
carboxypeptidase-B-sensitive cell surface plasminogen receptors could previously be 
divided into two classes: 1) proteins synthesized with C-terminal lysines and having 
 
Identification of the Novel Plasminogen Receptor, Plg-RKT 
 
221 
additional known intracellular functions, including α-enolase (Miles et al., 1991; Redlitz et 
al., 1995), cytokeratin 8 (Hembrough et al., 1995, 1996), S100A10 (Choi et al., 2003; Kassam 
et al., 1998), TIP49a (Hawley et al., 2001) and histone H2B (Herren et al., 2006) and; 2) 
proteins requiring proteolytic processing in order to reveal a C-terminal basic residue 
(lysine), including actin (Dudani & Ganz, 1996; Miles et al., 2006) and annexin 2 (Hajjar et 
al., 1994). However, until recently, no integral membrane plasminogen binding proteins 
synthesized with a C-terminal basic residue had been identified. The existence of a 
plasminogen receptor with the latter characteristics would reveal a novel mechanism for 
stimulation of plasminogen activation because release and rebinding of intracellular 
proteins or proteolytic cleavage of membrane proteins to expose C-terminal basic residues 
would not be required. 
 
 
Plasminogen binding to carboxyl terminal lysines on the cell surface. Panel A) The binding of 
plasminogen to cell surface proteins occurs via receptors exposing carboxyl terminal lysines to the 
extracellular environment. Cell surface proteins with carboxyl terminal lysines that are masked or in 
other inaccessible orientations on the cell surface, or membrane-associated proteins with carboxyl 
terminal lysines that are located on the inner face of the membrane, cannot serve as plasminogen 
receptors. Panel B) CpB treatment of intact cells removes carboxyl terminal lysines from plasminogen 
receptors, and plasminogen binding to the cell surface is reduced. Reprinted with permission from 
(Hawley, Green, and Miles 2000, 84:882-890). 
Fig. 2. Plasminogen binding to carboxyl terminal lysines on the cell surface. 
1.4 Need for a proteomics approach to identify integral membrane plasminogen 
receptor(s) with C-terminal basic residues 
Previous methodologies and characteristics of plasminogen binding proteins may have 
precluded identification of an integral membrane plasminogen binding protein with a C-
terminal basic residue. The identification of plasminogen receptors has relied previously on 
cell surface labeling followed by affinity chromatography on plasminogen-Sepharose 
columns and N-terminal sequencing of fractions eluted from SDS gels. Thus, many 
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intracellular proteins that are also present on the cell surface were readily identified because 
protein fractions that bound to plasminogen-Sepharose included the labeled, surface-
associated protein, as well as nonlabeled intracellular protein. Using these methods, a lower 
abundance integral membrane plasminogen binding protein might not have been 
detectable.  
Previously, we used a proteomics approach to examine monocytoid cell membranes for the 
presence of proteins exposing carboxyl terminal lysines on the extracellular face of the cell 
membrane (Hawley et al., 2000). We compared plasminogen ligand blots of 2-D gels of 
membrane fractions of intact cells treated with carboxypeptidase B with untreated 
membranes (e.g. Figure 2,B). We eluted a prominent carboxypeptidase B-sensitive protein 
from the 2-D gels and obtained two peptide sequences using tandem mass spectrometry. 
These peptide sequences corresponded to TATA-binding protein-interacting protein 
(TIP49a) (Hawley et al., 2001). However, TIP49a is a member of the class of cell surface 
plasminogen receptors synthesized with a C-terminal lysine and also having intracellular 
functions and is not an integral membrane protein.  
The methodology used to identify TIP49a and other plasminogen receptors has required 
elution of candidate proteins from 2-D SDS polyacrylamide gels. However, many membrane 
proteins are not well resolved on SDS polyacrylamide gels. Therefore, we used an isolation 
method that used column chromatography instead of SDS polyacrylamide gel analysis:  We 
took advantage of the exquisite sensitivity of multidimensional protein identification 
technology (MudPIT) to search for integral membrane plasminogen receptor(s) exposing a 
C-terminal basic residue on the cell surface and present on viable cells.  
2. Methods 
2.1 Plasminogen receptor isolation 
Plasminogen receptor isolation was performed as described (Andronicos et al., 2010). 
Briefly, progenitor and M-CSF-differentiated Hoxa9-ER4 cells were separately biotinylated, 
using EZ-Link Amine-PEO3-Biotin. The cells were then subjected to dead cell removal on 
annexin V-coated magnetic microspheres that resulted in a 99% enrichment of viable cells. 
Membrane fractions were prepared from the viable cells by dounce homogenization in the 
presence of Complete Protease Inhibitor Cocktail in Invitrosol, followed by centrifugation 
steps as used in our laboratory (Hawley et al., 2000, 2001) and were applied to a 
plasminogen-Sepharose affinity column as described (Miles et al., 1991). The column was 
washed in phosphate buffered saline containing 1 X Invitrosol until no protein was detected 
at 280 nm followed by elution with the washing buffer containing 0.2 M ε-aminocaproic acid 
(EACA). The eluant from the plasminogen-Sepharose column was incubated with 50μl of 
immobilized avidin for 30 minutes at 4°C. The proteins bound to the immobilized avidin 
were resuspended in Invitrosol and heated at 60°C. Then, 80% acetonitrile was added and 
the samples were digested with trypsin. After 24 h, the solvent was evaporated in a 
speedvac, and peptides were dissolved in buffer A (95% H2O, 5% acetonitrile, and 0.1% 
formic acid).  
2.2 Multidimensional chromatography and tandem mass spectrometry 
Multidimensional chromatography and tandem mass spectrometry were performed as 
described (Andronicos et al., 2010). Briefly, the protein digest was subjected to MudPIT 
[reviewed in (Eng et al., 1994)]. Peptide mixtures were resolved by strong cation exchange 
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liquid chromatography upstream of reversed phase liquid chromatography (Larmann, Jr. et 
al., 1993; Link et al., 1999; Opiteck & Jorgenson, 1997; Wolters et al., 2001). Eluting peptides 
were electrosprayed onto an LTQ ion trap mass spectrometer equipped with a nano-LC 
electrospray ionization source. Full MS spectra were recorded over a 400–1600 m/z range, 
followed by three tandem mass (MS/MS) events sequentially generated in a data-dependent 
manner on the first, second, and third most intense ions selected from the full MS spectrum 
(at 35% collision energy). Mass spectrometer scan functions and HPLC solvent gradients 
were controlled by the Xcalibur data system. 
2.3 Database search and interpretation of MS/MS datasets 
Database searching and interpretation of MS/MS Datasets were performed as described 
(Andronicos et al., 2010). Briefly, tandem mass spectra were extracted from raw files, and a 
binary classifier (Bern et al., 2004), previously trained on a manually validated data set, was 
used to remove low quality MS/MS spectra. Remaining spectra were searched against a 
mouse protein database containing 50,370 protein sequences downloaded as FASTA-
formatted sequences from EBI-IPI and 124 common contaminant proteins, for a total of 
66,743 target database sequences (Peng et al., 2003). To calculate confidence levels and false 
positive rates, a decoy database containing the reverse sequences of the 66,743 proteins 
appended to the target database and the SEQUEST algorithm (Yates, III, 1998) were used to 
find the best matching sequences from the combined database.  
SEQUEST searches were done on an Intel Xeon 80-processor cluster running under the 
Linux operating system. The peptide mass search tolerance was set to 3 Da. No differential 
modifications were considered. No enzymatic cleavage conditions were imposed on the 
database search, so the search space included all candidate peptides whose theoretical mass 
fell within the 3 Da mass tolerance window, despite their tryptic status. 
The validity of peptide/spectrum matches was assessed in DTASelect2 (Tabb et al., 2002) 
using SEQUEST-defined parameters, the cross-correlation score (XCorr) and normalized 
difference in cross-correlation scores (DeltaCN). The search results were grouped by charge 
state (+1, +2, and +3) and tryptic status (fully tryptic, half-tryptic, and non-tryptic), resulting 
in 9 distinct sub-groups. In each one of the sub-groups, the distribution of XCorr and 
DeltaCN values for direct and decoy database hits was obtained, and the two subsets were 
separated by quadratic discriminant analysis. Outlier points in the two distributions (for 
example, matches with very low Xcorr but very high DeltaCN) were discarded. Full 
separation of the direct and decoy subsets is not generally possible; therefore, the 
discriminant score was set such that a false positive rate of 5% was determined based on the 
number of accepted decoy database peptides. This procedure was independently performed 
on each data subset, resulting in a false positive rate independent of tryptic status or charge 
state.  
3. Results 
3.1 Isolation of an integral membrane plasminogen receptor exposing a C-terminal 
lysine on the cell surface 
We used specific proteolysis followed by MudPIT to probe the membrane proteome of 
differentiated mouse monocyte progenitor cells (Hoxa9-ER4) for the presence of integral 
membrane plasminogen receptor(s) exposing a C-terminal basic residue on the cell surface, 
as outlined in Figure 3. [The Hoxa9-ER4 cell line was derived from primary murine bone 
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marrow myeloid precursors immortalized with an estrogen regulated conditional 
oncoprotein, HoxA9-ER4 (Wang et al., 2006). The Hoxa9-ER4 line is factor-dependent and 
differentiates to monocytes when estrogen is removed from the medium, thereby 
inactivating the Hoxa9-ER protein. The mature monocytes respond to M-CSF (Odegaard et 
al., 2007)]. First, the  Hoxa9-ER4 monocyte progenitor cells were differentiated with 
macrophage colony stimulating factor (M-CSF), which induces plasminogen receptors on 
these cells (Andronicos et al., 2010). Then intact cells were biotinylated. Because early 
apoptotic and non-viable/necrotic cells exhibit markedly enhanced plasminogen binding 
ability (Mitchell et al., 2006; O'Mullane & Baker, 1998, 1999) we passed the biotinylated cells 
over a dead cell removal column to enrich for live cells. Cells were then lysed and 
membrane fractions prepared and passed over a plasminogen-Sepharose affinity column 
and specifically eluted with ε-aminocaproic acid (EACA), a lysine analog that blocks the 
binding of plasminogen to cells (Miles & Plow, 1985). Biotinylated proteins bound to the 
avidin column and were digested with trypsin while still on the column. The peptide digest 
was then subjected to MudPIT. 
 
 
Monocyte (Hoxa9-ER4) progenitor cells were differentiated with macrophage colony stimulating factor 
(M-CSF), which induces plasminogen receptors (▲) on these cells. Then intact cells were biotinylated 
(●) and passed over a dead cell removal column. Live cells were then lysed and membrane fractions 
prepared and passed over a plasminogen-Sepharose affinity column and specifically eluted. 
Biotinylated plasminogen receptors (▲●) were then bound to an avidin column and digested with 
trypsin. 
Fig. 3. Isolation of plasminogen receptors. 
 
Identification of the Novel Plasminogen Receptor, Plg-RKT 
 
225 
In MudPIT, the peptide mixtures were first resolved by strong cation exchange liquid 
chromatography followed by reversed phase liquid chromatography. Eluting peptides were 
electrosprayed onto an LTQ ion trap mass spectrometer and full MS spectra were recorded 
over a 400-1600 m/z range, followed by three tandem mass events. The spectra obtained 
were searched against a mouse protein database. Using this method, only one protein with a 
predicted transmembrane sequence and a C-terminal basic residue was identified: the 
hypothetical protein, C9orf46 homolog (IPI00136293), homologous to the protein predicted 
to be encoded by human chromosome 9, open reading frame 46. The peptides 
corresponding to C9orf46 homolog that were obtained in the MudPIT analysis are shown in 
Table 1. We have designated the protein, Plg-RKT, to indicate a plasminogen receptor with a 
C-terminal lysine and having a transmembrane domain (see below). [A limitation of 
shotgun proteomics, such as MudPIT, is that they typically under sample a proteome 
because they use data dependent data acquisition (a computer-driven data acquisition 
approach). This can lead to variations in the proteins identified, particularly amongst the 
lower abundant proteins. Thus, we cannot exclude the possibility that other membrane 
proteins exposing C-terminal lysines were present in the membrane proteome.] 
 
Xcorr DeltCN Conf% ObsM+H+ CalcM+H+ Peptide Sequences 
3.8378 0.2884 99.8% 2195.8743 2196.4788 K.SMNENMKNQQEFMVTHAR.L (3+) 
2.6749 0.1167 95.2% 1359.5521 1361.5181 K.NQQEFMVTHAR.L (2+) 
2.6771 0.2534 99.8% 1160.4321 1160.3514 R.HLTMQNEMR.E (2+) 
4.7468 0.3052 100% 1523.5322 1523.6954 R.MKSEAEDILETEK.T (2+) 
5.1774 0.3788 100% 2335.5544 2333.6997 R.MKSEAEDILETEKTKLELPK.G (3+) 
3.775 0.3164 100% 1264.0922 1264.3287 K.SEAEDILETEK.T (2+) 
2.995 0.0655 96.8% 1137.2722 1137.3184 K.GLITFESLEK.A (2+) 
2.893 0.2591 99.7% 1364.4922 1364.5848 K.GLITFESLEKAR.R (2+) 
SEQUEST-defined parameters (Xcorr, DeltCN, and Conf%) are shown for each peptide. (core: cross-
correlation score; DeltCN: normalized difference in cross-correlation scores; Conf%: confidence level of 
the peptide; ObsM+H+: observed peptide mass; CalcM+H+: theoretical peptide mass). Observed 
peptide mass, theoretical peptide mass, and charges of the peptide identified (3+ or 2+) are also shown 
to demonstrate accurate peptide identification. This research was originally published in Blood, 
Andronicos, N.M., Chen, E.I., Baik, N., Bai, H., Parmer, C.M., Kiosses, W.B., Kamps, M.P., Yates, J.R., III, 
Parmer, R.J., Miles, L.A., Proteomics-based discovery of a novel, structurally unique, and 
developmentally regulated plasminogen receptor, Plg-RKT, a major regulator of cell surface 
plasminogen activation, Blood. 2010, 115: 1319-30. 
Table 1. Peptides obtained corresponding to C9orf46 homolog  
A key advantage of MudPIT is that proteins in a given proteome can be identified 
simultaneously. As proof of principle of our isolation method, peptides corresponding to 
other proteins previously identified as plasminogen binding proteins on monocytes were 
also detected in the membrane preparations: α-enolase, gamma actin, S100A10, histone H2B, 
annexin 2, and β2 integrin. 
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avidin column and were digested with trypsin while still on the column. The peptide digest 
was then subjected to MudPIT. 
 
 
Monocyte (Hoxa9-ER4) progenitor cells were differentiated with macrophage colony stimulating factor 
(M-CSF), which induces plasminogen receptors (▲) on these cells. Then intact cells were biotinylated 
(●) and passed over a dead cell removal column. Live cells were then lysed and membrane fractions 
prepared and passed over a plasminogen-Sepharose affinity column and specifically eluted. 
Biotinylated plasminogen receptors (▲●) were then bound to an avidin column and digested with 
trypsin. 
Fig. 3. Isolation of plasminogen receptors. 
 
Identification of the Novel Plasminogen Receptor, Plg-RKT 
 
225 
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Xcorr DeltCN Conf% ObsM+H+ CalcM+H+ Peptide Sequences 
3.8378 0.2884 99.8% 2195.8743 2196.4788 K.SMNENMKNQQEFMVTHAR.L (3+) 
2.6749 0.1167 95.2% 1359.5521 1361.5181 K.NQQEFMVTHAR.L (2+) 
2.6771 0.2534 99.8% 1160.4321 1160.3514 R.HLTMQNEMR.E (2+) 
4.7468 0.3052 100% 1523.5322 1523.6954 R.MKSEAEDILETEK.T (2+) 
5.1774 0.3788 100% 2335.5544 2333.6997 R.MKSEAEDILETEKTKLELPK.G (3+) 
3.775 0.3164 100% 1264.0922 1264.3287 K.SEAEDILETEK.T (2+) 
2.995 0.0655 96.8% 1137.2722 1137.3184 K.GLITFESLEK.A (2+) 
2.893 0.2591 99.7% 1364.4922 1364.5848 K.GLITFESLEKAR.R (2+) 
SEQUEST-defined parameters (Xcorr, DeltCN, and Conf%) are shown for each peptide. (core: cross-
correlation score; DeltCN: normalized difference in cross-correlation scores; Conf%: confidence level of 
the peptide; ObsM+H+: observed peptide mass; CalcM+H+: theoretical peptide mass). Observed 
peptide mass, theoretical peptide mass, and charges of the peptide identified (3+ or 2+) are also shown 
to demonstrate accurate peptide identification. This research was originally published in Blood, 
Andronicos, N.M., Chen, E.I., Baik, N., Bai, H., Parmer, C.M., Kiosses, W.B., Kamps, M.P., Yates, J.R., III, 
Parmer, R.J., Miles, L.A., Proteomics-based discovery of a novel, structurally unique, and 
developmentally regulated plasminogen receptor, Plg-RKT, a major regulator of cell surface 
plasminogen activation, Blood. 2010, 115: 1319-30. 
Table 1. Peptides obtained corresponding to C9orf46 homolog  
A key advantage of MudPIT is that proteins in a given proteome can be identified 
simultaneously. As proof of principle of our isolation method, peptides corresponding to 
other proteins previously identified as plasminogen binding proteins on monocytes were 
also detected in the membrane preparations: α-enolase, gamma actin, S100A10, histone H2B, 
annexin 2, and β2 integrin. 
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3.2 Conservation of Plg-RKT across species 
The C9orf46 homolog/Plg-RKT murine DNA sequence encodes a protein of 147 amino acids 
with a molecular mass of 17,261 Da and a C-terminal lysine (Table 2, first line). We blasted 
the C9orf46 homolog/Plg-RKT sequence against all species using NCBI Blast and obtained 
unique human, rat, dog, cow, dog, giant panda, gibbon, horse, pig, rabbit, and rhesus 
monkey predicted orthologs, with high identity and homology (e.g. human versus rhesus 
monkey = 99% similarity), high identity (e.g. human vs rhesus monkey = 98% identity) and 
no gaps in the sequence (Table 2). Of key importance, a C-terminal lysine was predicted for 
all of the mammalian orthologs obtained in the blast search. In a query of the Ensembl Gene 
Report, DNA sequences of all 10 other sequenced mammalian orthologs encoded C-terminal 
lysines (Table 2).  
In addition, the DNA sequences of xenopus and the green lizard also encoded C-terminal 
lysines (Table 2). Furthermore, Plg-RKT orthologs with 149 amino acids with a C-terminal 
lysine were encoded in bony fish (salmon and zebrafish) and the high similarity with a 
mammalian ortholog is illustrated in the alignment of the mouse and zebrafish proteins in 
Table 3.  
The Plg-RKT sequence also encodes a putative conserved DUF2368 domain (encompassing 
amino acids 1-135), an uncharacterized protein with unknown function conserved from 
nematodes to humans. Notably, Plg-RKT orthologs of lower organisms were of different 
predicted lengths and did not consistently predict C-terminal lysines. It is interesting to note 
that the evolutionary origin of plasminogen is currently believed to originate with 
protochordates (Liu & Zhang, 2009), so that lower organisms without plasminogen would 
not utilize the C-terminal lysine of Plg-RKT to bind plasminogen. 
 
 
Table 3. Alignment of Mouse and Zebrafish Plg-RKT Sequences 
It is also noteworthy that the primary sequence of C9orf46 homolog/Plg-RKT is apparently 
tightly conserved in humans, with no validated polymorphisms (cSNPs) within the 6 exons 
encoded by the gene (on chromosome 9p24.1) in the NCBI human genome sequence 
variation database (dbSNP, http://www.ncbi.nlm.nih.gov/SNP). 
3.3 Topology of Plg-RKT 
The C9orf46 homolog/Plg-RKT sequence was analyzed in the TMpred site 
(www.ch.embnet.org/cgi-bin/TMPRED). The model predicted two transmembrane helices 
extending from F53-L73 (secondary helix, oriented from outside the cell to inside the cell) and 
P78-Y99 (primary helix, oriented from inside the cell to outside the cell) (Figure 4). Hence a 52 
amino acid N-terminal region and a 48 amino acid C-terminal tail with a C-terminal lysine 
were predicted to be exposed on the cell surface. 
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Green indicates amino acids within the predicted primary transmembrane helix. Orange indicates 
amino acids within the predicted secondary transmembrane helix. Red indicates basic amino acids. This 
research was originally published in Blood, Andronicos, N.M., Chen, E.I., Baik, N., Bai, H., Parmer, C.M., 
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Fig. 4. Structural model of Plg-RKT. 
We experimentally tested predictions of the model. First, we raised a monoclonal antibody 
against the synthetic peptide, CEQSKLFSDK (corresponding to the nine C-terminal amino 
acids of murine Plg-RKT with an amino terminal cysteine added for coupling). To examine 
subcellular localization, membrane and cytoplasmic fractions from progenitor and 
differentiated Hoxa9-ER4 monocyte progenitor cells were electrophoresed and western 
blotted with anti-Plg-RKT mAb or isotype control mAb. A specific immunoreactive band 
migrating with an Mrapp of ~17,000, was detected in membrane fractions of differentiated 
monocyte progenitor cells, clearly demonstrating the existence of this new protein (Figure 
5,A). The protein was not detected in undifferentiated cells or in the cytoplasmic fraction of 
the differentiated cells. 
To test the prediction that Plg-RKT is an integral membrane protein, membranes from 
differentiated monocyte progenitor cells were subjected to phase separation in Triton X-114 
as described (Bordier, 1981; Estreicher et al., 1989). In this method, integral membrane 
proteins form mixed micelles with the nonionic detergent and are recovered in the Triton X-
114 detergent phase, whereas hydrophilic proteins remain in the aqueous phase. An 
immunoreactive band migrating with an Mrapp of ~17,000 was detected in the detergent 
phase in western blotting with anti-Plg-RKT mAb, but was not detected in the aqueous phase 
(Figure. 5,B). These data support the prediction that Plg-RKT is an integral membrane 
protein. 
To experimentally test whether the C-terminal lysine of Plg-RKT was exposed on the cell 
surface, we treated intact biotinylated cells with carboxypeptidase B prior to performing our 
isolation procedure. Under this condition, C-terminal lysines exposed on the cell surface are  
 




A. Membrane fractions or cytoplasmic fractions from either undifferentiated or M-CSF-treated Hoxa9-
ER4 cells were electrophoresed on 12% sodium dodecyl sulfate polyacrylamide gels under reducing 
conditions and western blotted with either anti-Plg-RKT mAb, anti-α-enolase mAb as a loading control, 
or isotype control mAb. B. M-CSF-treated Hoxa9-ER4 cell membranes were solubilized in 3% Triton X-
114. After heating at 37ºC and separation of the phases by centrifugation, an aliquot of both phases was 
electrophoresed and western blotted with anti-Plg-RKT mAb. This research was originally published in 
Blood, Andronicos, N.M., Chen, E.I., Baik, N., Bai, H., Parmer, C.M., Kiosses, W.B., Kamps, M.P., Yates, 
J.R., III, Parmer, R.J., Miles, L.A., Proteomics-based discovery of a novel, structurally unique, and 
developmentally regulated plasminogen receptor, Plg-RKT, a major regulator of cell surface 
plasminogen activation, Blood. 2010, 115: 1319-30. 
Fig. 5. Plg-RKT behaves as a regulated integral membrane protein. 
removed but intracellular C-terminal lysines are protected (see Figure 2,B). Under this 
condition, no peptides corresponding to Plg-RKT were obtained in the MudPIT analysis, 
consistent with cell surface exposure of the C-terminal lysine of Plg-RKT.  
In order to experimentally evaluate whether the N-terminus of Plg-RKT was exposed on the 
cell surface, PC12 (rat pheochromocytoma) cells were stably transfected with V5-pCIneo-
Plg-RKT that expressed a V5 tag at the N-terminus of Plg-RKT. (The V5 sequence was added 
in front of the mammalian expression vector, pCIneo using PCR and then the full-length 443 
bp Plg-RKT cDNA was subcloned into the V5-pCIneo vector using the Xho1 and Sma1 
cloning sites. Constructs were transfected into cells using Lipofectamine 2000 and  stable 
transfectants were selected with G418.) 
A specific band migrating with a Mrapp of 17,000 was detected in cell membranes of the 
stably transfected cells with both anti-V5 mAb and anti-Plg-RKT mAb (Figure 6, lane 1). The 
band was not detected by either mAb after trypsin digestion of the isolated membrane 
fraction (lane 2). When intact cells were incubated with trypsin and the trypsin neutralized  
with SBTI prior to preparation of the membrane fraction, the majority of the band detectable 
with either anti-V5 or anti-Plg-RKT was lost (lane 4). In controls, treatment with soybean 
trypsin inhibitor (SBTI) fully neutralized the ability of trypsin to degrade the V5-tagged Plg-
RKT in purified membrane fractions (lane 3), demonstrating that the trypsin had been 
neutralized prior to membrane fractionation of the treated cells. These results suggest that 
the N- terminus of Plg-RKT is accessible to trypsin proteolysis of intact cells and is, therefore,  
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Membrane fractions of PC12 cells stably transfected with V5-pCIneo-Plg-RKT were incubated with either 
buffer (lane 1), trypsin (1mg/ml ) (lane 2) or trypsin 1 mg/ml  + soybean trypsin inhibitor (SBTI) (2 
mg/ml) (lane 3) for 30 minutes at 37ºC or intact PC12 cells were incubated with 1 mg/ml trypsin for 2 
hr at 37ºC, followed by 2 mg/ml SBTI for 15 min . Following neutralization of trypsin with SBTI, the 
membrane fraction was prepared from the treated, intact cells (lane 4). 30 µg/lane of membrane 
fractions were electrophoresed on 18% SDS PAGE under reducing conditions and western blotted with 
either anti-V5, anti-Plg-RKT mAb  or isotype control. 
Fig. 6. The N-termini and C-termini of Plg-RKT are exposed on the cell surface. 
exposed on the extracellular face. Furthermore, because the anti-Plg-RKT mAb reacts with 
the C-terminus of Plg-RKT, these data also confirm the exposure of the C-terminus on the 
extracellular face of the cell membrane. 
3.4 Role of the C-terminal lysine of Plg-RKT in plasminogen binding 
We further addressed the exposure of the C-terminus of Plg-RKT on the cell surface using 
confocal microscopy with a mAb raised against the Plg-RKT C-terminal peptide. (The mAb 
reacted with the C-terminal peptide of murine Plg-RKT and blocked plasminogen binding to 
CEQSKLFSDK). When cells were incubated with  anti-Plg-RKT mAb and a polyclonal anti-
plasminogen antibody, Plg-RKT and plasminogen were both immunodetected in small 
aggregates dispersed over the cell surface (Figure 7,A), in a similar distribution to that 
published for confocal analyses of monocyte-associated plasminogen (Das et al., 2007). Most 
importantly, after preincubation of monocytes with plasminogen, immunodetection of Plg-
RKT was reduced by half (Figure 7,A,B). These results demonstrate that the C-terminus of 
Plg-RKT is exposed on the cell surface. Furthermore, these results show that plasminogen 
binds to the C-terminal domain of Plg-RKT on the cell surface. 
 




A. M-CSF-differentiated (Hoxa9-ER4) cells were grown on coverslips  and preincubated with either 
phosphate buffered saline (- plasminogen) or 2 μM plasminogen (+ plasminogen), then fixed in 1% 
formaldehyde, washed and stained with polyclonal anti-plasminogen IgG or anti-Plg-RKT mAb and 
stained with a combination of Alexa 488- F(ab’)2  of goat anti-rabbit IgG and Alexa 568- F(ab’)2 fragment 
of goat anti-mouse IgG. 
B. The number and size of each labeled aggregate was determined. The results reflect counts from over 
40 cells in 2 independent experiments. Data represent mean ± SEM. *p < 0.001. This research was 
originally published in Blood, Andronicos, N.M., Chen, E.I., Baik, N., Bai, H., Parmer, C.M., Kiosses, 
W.B., Kamps, M.P., Yates, J.R., III, Parmer, R.J., Miles, L.A., Proteomics-based discovery of a novel, 
structurally unique, and developmentally regulated plasminogen receptor, Plg-RKT, a major regulator of 
cell surface plasminogen activation, Blood. 2010, 115: 1319-30. 
Fig. 7. Plg-RKT binds plasminogen on the cell surface. 
To further address the plasminogen binding function of the C-terminus of Plg-RKT , we 
tested whether the synthetic peptide, corresponding to the C-terminus of Plg-RKT could bind 
plasminogen. The peptide, CEQSKLFSDK, was coupled to BSA and then coated onto wells 
of microtiter plates. Biotinylated Glu-plasminogen was incubated with the wells and specific 
binding was detected with HRP-streptavidin (Figure 8). We tested the ability of the soluble 
C-terminal peptide to inhibit Glu-plasminogen binding under solution phase equilibrium 
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To further address the plasminogen binding function of the C-terminus of Plg-RKT , we 
tested whether the synthetic peptide, corresponding to the C-terminus of Plg-RKT could bind 
plasminogen. The peptide, CEQSKLFSDK, was coupled to BSA and then coated onto wells 
of microtiter plates. Biotinylated Glu-plasminogen was incubated with the wells and specific 
binding was detected with HRP-streptavidin (Figure 8). We tested the ability of the soluble 
C-terminal peptide to inhibit Glu-plasminogen binding under solution phase equilibrium 
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conditions. The soluble peptide competed for Glu-plasminogen binding in a dose-
dependent manner with an IC50 of 2 μM (Figure 8), similar to the Kd values we have 
previously determined for Glu-plasminogen binding to cells (Miles et al., 2005). In addition, 
a mutated peptide with the C-terminal lysine substituted with alanine did not compete for 
plasminogen binding at concentrations up to 1 mM (Figure 8), further supporting the role of 
the C-terminal lysine in the interaction of Plg-RKT with plasminogen.  
 
 
The peptide, CEQSKLFSDK, was coupled to BSA and immobilized on microtiter wells. Biotinylated-Glu-
plasminogen (25 nM) was incubated with immobilized CEQSKLFSDK in the  presence of increasing 
concentrations of CEQSKLFSDK (●) or a K147A mutant peptide, CEQSKLFSDA (○). Biotinylated Glu-
plasminogen binding was detected with HRP-streptavidin. Data are as mean ± SEM, n=3, for each 
determination. This research was originally published in Blood, Andronicos, N.M., Chen, E.I., Baik, N., Bai, 
H., Parmer, C.M., Kiosses, W.B., Kamps, M.P., Yates, J.R., III, Parmer, R.J., Miles, L.A., Proteomics-based 
discovery of a novel, structurally unique, and developmentally regulated plasminogen receptor, Plg-RKT, a 
major regulator of cell surface plasminogen activation, Blood. 2010, 115: 1319-30. 
Fig. 8. Plasminogen binds to the C-terminal peptide of Plg-RKT. 
3.5 Plg-RKT regulates cell surface plasminogen activation 
We verified that plasminogen activation was promoted in the presence of differentiated 
Hoxa9-ER4 cells. Plasminogen activation was stimulated 12.7-fold in the presence of 
differentiated monocyte progenitor cells, compared to the reaction in the absence of cells 
(Figure 9). In order to test the role of Plg-RKT in plasminogen activation, we tested the effect 
of anti-Plg-RKT mAb raised against the synthetic peptide, CEQSKLFSDK . Anti-Plg-RKT mAb 
substantially suppressed cell-dependent plasminogen activation (Figure 9). In controls, 
plasminogen activation in the absence of cells was not affected by anti-Plg-RKT mAb. 
3.6 Tissue and cellular distribution and regulation of the Plg-RKT transcript 
We searched results of gene expression array analyses for expression of the C9orf46 
homolog/Plg-RKT transcript. The transcript is broadly expressed in normal human and 
mouse tissues [as determined in high-throughput gene expression profiling in which RNA 
samples from human and murine tissues were hybridized to high-density gene expression 
arrays (Su et al., 2002; Su et al., 2004)]. The C9orf46 homolog/Plg-RKT transcript has been  
 




Plasminogen activation was determined in either the presence or absence of differentiated Hoxa9-ER4 
cells and in the presence of either anti-Plg-RKT mAb (filled bars) or isotype control rat IgG2a (open bars). 
***p < 0.001, compared to the corresponding isotype control. This research was originally published in 
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conditions. The soluble peptide competed for Glu-plasminogen binding in a dose-
dependent manner with an IC50 of 2 μM (Figure 8), similar to the Kd values we have 
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the C-terminal lysine in the interaction of Plg-RKT with plasminogen.  
 
 
The peptide, CEQSKLFSDK, was coupled to BSA and immobilized on microtiter wells. Biotinylated-Glu-
plasminogen (25 nM) was incubated with immobilized CEQSKLFSDK in the  presence of increasing 
concentrations of CEQSKLFSDK (●) or a K147A mutant peptide, CEQSKLFSDA (○). Biotinylated Glu-
plasminogen binding was detected with HRP-streptavidin. Data are as mean ± SEM, n=3, for each 
determination. This research was originally published in Blood, Andronicos, N.M., Chen, E.I., Baik, N., Bai, 
H., Parmer, C.M., Kiosses, W.B., Kamps, M.P., Yates, J.R., III, Parmer, R.J., Miles, L.A., Proteomics-based 
discovery of a novel, structurally unique, and developmentally regulated plasminogen receptor, Plg-RKT, a 
major regulator of cell surface plasminogen activation, Blood. 2010, 115: 1319-30. 
Fig. 8. Plasminogen binds to the C-terminal peptide of Plg-RKT. 
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• Monocytes • B-cell precursor cells 
• NK cells • Acute lymphoblastic leukemia cells 
• T cells • Molt-4 acute lymphoblastic leukemia cells 
• Myeloid cells • Breast cancer cells, SKBR3, MDA468, BT474, T47D 
• Dendritic cells  
• Plasmacytoid cells  
www.ebi.ae.uk/microarray-as/aew/ 
Table 5. Microarray Expression Data for Plg-RKT mRNA 
These data are consistent with previous reports documenting expression of plasminogen 
binding sites on peripheral blood leukocytes (Miles & Plow, 1987), breast cancer cells 
(Correc et al., 1990; Ranson et al., 1998) and other tissues [reviewed in (Miles et al.,  
2005)]. In addition, results obtained by searching the ArrayExpress Warehouse 
(http://www.ebi.ac.uk/microarray) indicated that the C9orf46 homolog gene is also 
regulated in other tissues by lipopolysaccharide, aldosterone, canrenoate, H2O2, and 
dexamethasone (Table 6). 
In a previously published genome-scale quantitative image analysis, overexpression of a 
cDNA that we now recognize to be the Plg-RKT cDNA, resulted in dramatic increases in cell 
proliferation whereas knockdown of the corresponding mRNA resulted in apoptosis 
(Harada et al., 2005). Consistent with an anti-apoptotic role of Plg-RKT, we have shown that 
cell-bound plasminogen inhibits TNFα-induced apoptosis (Mitchell et al., 2006). In 
microarray studies, C9orf46 homolog mRNA expression has a high power to predict cervical 
lymph node metastasis in oral squamous cell carcinoma (Nguyen et al., 2007).  
 
Experiment Tissue Agonist Effect* 
E-MEXP-420 Hippocampal microglial cells lipopolysaccharide ↓ 
E-TABM-229 Kidney aldosterone ↓ 
E-TABM-229 Kidney canrenoate ↓ 
E-MEXP-710 Cholinergic cells H2O2 ↓ 
E-MEXP-774 Preadipocytes Dexamethasone ↓ 
Data were obtained from ArrayExpress Warehouse (http://www.ebi.ac.uk/microarray). 
* ↓ = downregulation. This research was originally published in Blood, Andronicos, N.M., Chen, E.I., 
Baik, N., Bai, H., Parmer, C.M., Kiosses, W.B., Kamps, M.P., Yates, J.R., III, Parmer, R.J., Miles, L.A., 
Proteomics-based discovery of a novel, structurally unique, and developmentally regulated 
plasminogen receptor, Plg-RKT, a major regulator of cell surface plasminogen activation, Blood. 2010, 
115: 1319-30. 
Table 6. Regulation of C9orf46 homolog/Plg-RKT mRNA in Tissues 
4. Conclusions 
In conclusion, MudPIT has allowed us to identify a new protein, Plg-RKT, a novel 
plasminogen receptor with unique characteristics: integral to the cell membrane and 
exposing a C-terminal lysine on the cell surface in an orientation to bind plasminogen and 
promote plasminogen activation. Thus, Plg-RKT is likely to play a key role in plasminogen-
dependent functions of cells including inflammation, wound healing, development, 
metastasis, neurite outgrowth, fibrinolysis, myogenesis and prohormone processing. The 
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broad distribution of the Plg-RKT transcript and its regulation in tissues that have been 
demonstrated to express plasminogen binding sites, suggest that Plg-RKT provides 
plasminogen receptor function that may serve to modulate plasmin proteolytic functions 
(both physiologic and pathologic) specific to a large number of tissues. Furthermore, the 
potential function of Plg-RKT in the regulation of apoptosis and proliferation may play a key 
role in cancer and metastasis. Future studies with knockout mice should build on our initial 
results using MudPIT to elucidate the role of Plg-RKT. 
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1. Introduction 
The advances in proteomics over the last decade have made it possible for a more detailed 
study of protein posttranslational modifications. Posttranslational modification of proteins 
is an important signaling mechanism regulating vital pathways ranging from transcription 
to translation, in metabolism, cell survival, and cell death. Posttranslational modification of 
proteins has commonly been associated with the loss/gain of function and signal 
transduction with the concept of phosphorylation being the hallmark. However, many other 
posttranslational modifications of proteins have been detected and their implication to 
overall cellular homeostasis remains to be elucidated. 
The cardiovascular system, in particular the heart due to its high metabolic rates, sensitivity 
to oxidative stress and necessity to adapt quickly to new environments, is an ideal candidate 
to the study of posttranslational modifications in physiology and pathology. Cardiac 
contractile function relies significantly on the integrity of its contractile apparatus, with the 
myosin light chains being important contractile elements. We have recently described the 
role of nitration and nitrosylation of ventricular myosin light chains (MLCs) on its 
degradation by the proteolytic enzyme matrix metalloproteinase-2 (MMP-2) (Doroszko et al. 
2010; Doroszko et al. 2009; Polewicz et al. 2010). Using distinct experimental models of 
oxidative stress, such as hypoxia-reoxygenation or ischemia/reperfusion, we have detected 
pathological nitration and nitrosylation of MLC induced by oxidative stress. According to 
our findings, nitration and nitrosylation of MLCs is associated with an increased affinity for 
MMP-2 and a consequent increase in degradation of these proteins that is associated with a 
worsening in cardiac contractile function during either reoxygenation or reperfusion. 
Since contractile dysfunction is a predictor of patient outcome (Antman et al. 2004), it is 
crucial to understand the mechanisms behind the development of contractile dysfunction. 
Moreover, the identification of mechanisms that lead to contractile dysfunction can help and 
result in the development of new therapeutic approaches aiming at preventing and/or 
treating contractile dysfunction following oxidative stress. 
This review will focus on the current knowledge of posttranslational modification of myosin 
light chain, a cardiac contractile protein, and how these modifications contribute to 
protection or pathogenesis in the setting of cardiac injury and contractile dysfunction 
triggered by oxidative stress. Moreover, this review will deal with the importance of 
posttranslational modifications of proteins and its determination of protein fate. 
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crucial to understand the mechanisms behind the development of contractile dysfunction. 
Moreover, the identification of mechanisms that lead to contractile dysfunction can help and 
result in the development of new therapeutic approaches aiming at preventing and/or 
treating contractile dysfunction following oxidative stress. 
This review will focus on the current knowledge of posttranslational modification of myosin 
light chain, a cardiac contractile protein, and how these modifications contribute to 
protection or pathogenesis in the setting of cardiac injury and contractile dysfunction 
triggered by oxidative stress. Moreover, this review will deal with the importance of 
posttranslational modifications of proteins and its determination of protein fate. 
 




The term “PROTEOME” (PROTEin complement to the genOME), introduced in 1994, has 
attracted great attention, as approximately 30,000 human genes correspond to several 
million different gene products (proteins, peptides). The genome is intrinsically static and 
basically the same in every cell type, while the proteome is highly dynamic, differs between 
cell types, and does all the work. Proteins are the most common diagnostic and therapeutic 
targets in medicine, and the search for the proteome may lead to the discovery of new 
diagnostic and therapeutic targets. Classical proteomics, or what is now referred as 
“expression profiling”, is a process in which total cellular or tissue proteins are separated on 
2D gels and the visible protein spots are identified by peptide mass fingerprinting (Dunn 
2000; Pandey and Mann 2000). This approach has been used to generate extensive 
proteomics online databases containing protein data obtained from the hearts of animals 
with cardiovascular disease states (Arrell et al. 2001a; Arrell et al. 2001b; Evans et al. 1997; 
Scheler et al. 1999). 
The field of proteomics has its roots in the marriage between 2D electrophoresis and mass 
spectrometry. In most cases, 2-dimensional electrophoresis is used to separate individual 
proteins and their modified forms, which are then identified and further 
characterized/analyzed by mass spectrometry. To date, proteomics has identified changes 
in more than 40 proteins in heart diseases such as dilated cardiomyopathy, varying degrees 
of I/R injury, and heart failure (Arrell et al. 2001a; Corbett et al. 1998; Foster and Van Eyk 
1999; Jager et al. 2002; Jiang et al. 2001; Schwertz et al. 2002). 
Proteomics is an ideal approach to elucidate PTMs associated with kinase activity. Positive 
and negative modulation of heart contractility by short-term phosphorylation reactions at 
multiple sites in MLC2, TnI, TnT, α-tropomyosin, and myosin binding protein-C, have been 
known for almost a decade (Schaub et al. 1998). An example of this modification is the 
discovery of novel phosphorylation of MLC1 in preconditioned cardiomyocytes (Arrell et al. 
2001a). However, the role of this PTM is not known. Phosphorylation of MLC1 was also 
detected in congestive heart failure (CHF) and this was associated with a decreased 
sensitivity to 8-Br-cGMP-mediated smooth muscle relaxation (Karim et al. 2004). Similarly, 
three different PTMs were found in functionally important N-terminal sites of MLC2, two 
occurred in normal hearts (phosphorylation and deamidation) and one (n-terminal 
truncation) was associated with I/R injury (White et al. 2003). We have found the same 
PTMs in MLC1 in our model IR with the exception that phosphorylation and deamidation 
were associated with truncated forms of MLC1. Thus, the use of the proteomics approach to 
investigate mechanisms underlying heart disease should result in the generation of new 
therapeutic strategies and the establishment of precise and sensitive diagnostic markers. A 
schematic representation of a proteomic workflow is given in figure 1. 
2.1 Methodology used in the study of myosin light chains posttranslational 
modifications 
Although new advances have been made recently in the development of new technology for 
protein separation, the proteomic method relies significantly on 2-dimensional 
electrophoresis (2-DE) for protein separation for further analysis by mass spectrometry. One 
of the early limitations of the use of 2-DE for sample generation for mass spectrometry 
analysis was reproducibility. The problem was generated by the fact that gradient gels are 
difficult to cast consistently and only 2 gels could be run simultaneously. Recent  
 




Fig. 1. Schematic representation of a proteomic method workflow. Samples are loaded and 
separated using 2-dimensional eletrophoresis (2-DE). Following 2-DE, protein spots of 
interest are identified and subjected to in-gel tryptic digestion followed by a mass 
spectrometry protocol (typically LC/MS/MS or MALDI TOF-TOF). Data generated from 
mass spectrometry can be used to identify the protein using the Mascot search database or, 
after protein identification, for detection of posttranslational modifications (PTMs) using the 
ExPASy-FindMod tool (http://web.expasy.org/findmod/findmod_masses.html). 
technological advances gave rise to commercially available pre-cast gels (Criterion pre-cast 
gels, BioRad, Hercules, CA, USA) and the development of dodeca electrophoresis systems 
allowing for the simultaneous run of up to 12 gels (Criterion Dodeca Cell, BioRad, Hercules, 
CA, USA). These advances were very important in the achievement of reproducibility of 
sample generation by 2-DE. 
The majority of the results here described in terms of the study of posttranslational 
modifications of myosin light chain 1 and 2 were obtained using the following methodology 
as described by: 
Protein samples for 2-DE were prepared by mixing frozen (-80°C), powdered heart tissue 
(40 to 60mg wet weight) with 200 µL rehydration buffer (8 mol/L urea, 4% CHAPS, 10 
mmol/L DTT, 0.2% Bio-Lytes 3/10 [BioRad, Hercules, CA, USA]) at room temperature. 
Samples were sonicated for 2X5 seconds and centrifuged (10 minutes at 10,000g) to remove 
insoluble particles. Protein content of the heart extract in rehydration buffer was measured 
with the BioRad Bradford protein assay. 
Protein samples (400 g) were applied to each of 11 cm immobilized linear pH gradient (5-8) 
strips (IPG, BioRad, Hercules, CA, USA), with rehydration for 16–18 h at 20ºC. 
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Fig. 1. Schematic representation of a proteomic method workflow. Samples are loaded and 
separated using 2-dimensional eletrophoresis (2-DE). Following 2-DE, protein spots of 
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after protein identification, for detection of posttranslational modifications (PTMs) using the 
ExPASy-FindMod tool (http://web.expasy.org/findmod/findmod_masses.html). 
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Isoelectrofocusing was performed using the BioRad Protean IEF cell with the following 
conditions at 20ºC with fast voltage ramping: step 1: 15 min with end voltage at 250 V; step 
2: 150 min with end voltage at 8000 V; step 3: 35 000 V-hours (approximately 260 min). 
Following isoelectrofocusing the strips were equilibrated according to the manufacturer’s 
instructions. The second dimension of 2-DE was performed with Criterion pre-cast gels (8 – 
16%) (BioRad). After separation, proteins were detected with Coomassie Briliant Blue R250 
(BioRad). To minimize variations in resolving proteins during the 2-DE run, 12 gels were 
run simultaneously using a Criterion Dodeca Cell (BioRad, Hercules, CA, USA). Because of 
this limitation for 2-DE analysis we used 4 hearts from each group. All the gels were stained 
in the same bath and next scanned with a calibrated densitometer GS-800 (BioRad, Hercules, 
CA, USA). Quantitative analysis of MLC1 and MLC2 spot intensities from 2-DE were 
measured with PDQuest 7.1 measurement software (BioRad, Hercules, CA, USA). 
MLC1 and MLC2 protein spots were manually excised from the 2-DE gel. These spots were 
then processed using a MassPrep Station (Waters, Milford, MA, USA) using the methods 
supplied by the manufacturer. The excised gel fragment containing the protein spot was 
first destained in 200 µl of 50% acetonitrile with 50 mM ammonium bicarbonate at 37°C for 
30 minutes. Next, the gel was washed twice with water. The protein extraction was 
performed overnight at room temperature with 50 µL of a mixture of formic acid, water, and 
isopropanol (1:3:2, vol:vol). The resulting solution was then analyzed by mass spectrometry 
(MS). For electrospray, quadruple time-of-flight (Q-TOF) analysis, 1 µl of the solution was 
used. Liquid chromatography/mass spectrometry (LC/MS) was performed on a CapLC 
high-performance liquid chromatography unit (Waters, Milford, MA, USA) coupled with Q-
TOF-2 mass spectrometer (Waters, Milford, MA, USA). A mass deviation of 0.2 was 
tolerated and one missed cleavage site was allowed. Resulting values from mass 
spectrometry (MS/MS) analysis were used to search against the NCBInr and SwissProt 
databases with Mammalia specified. We used the Mascot (www.matrixscience.com) search 
engine to search the protein database. Posttranslational modifications were determined 
using the ExPASy-FindMod tool (http://web.expasy.org/findmod/findmod_masses.html). 
3. Cardiac contractile proteins 
The heart is the central organ for the circulatory system and is responsible for providing an 
efficient flow of blood to the whole body in order to meet the metabolic demands of the 
organism by delivering oxygen and nutrients and, at the same time, removing metabolic 
waste. Often seen as a pump, the heart relies on the integrity of its contractile machinery in 
order to efficiently perform its function. The basic unit of contraction is the sarcomere. The 
sarcomere is constituted of thick and thin filaments that, during contraction, slide over each 
other leading to the shortening of the sarcomere and contraction. The thick filament is 
mainly constituted of myosin while the thin filament is mainly constituted of actin, 
tropomyosin, and troponins (Figure 2). The interaction between thin and thick filaments, the 
crucial component for the generation of a contractile force, occurs between actin and the 
myosin head. 
3.1 Myosins 
Myosin is a large complex molecule. It consists of two heavy chains, an �-helical tail, and 
four myosin light chains (Craig and Woodhead 2006; Dominguez et al. 1998; Rayment et al. 
1993b). The heavy chains (myosin heavy chain, MHC) have the ATPase activity necessary to 
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trigger sliding between filaments and the consequent contraction. The two light chains 
(myosin light chain 1 and 2, MLC1 and MLC2) confer stability to the myosin head and also 
have actin binding motifs. MLC1 is also referred to as the essential light chain (ELC) and is 
present in the hinge of the myosin head for stability purposes. MLC2 is also referred as 
regulatory light chain (RLC) and together with MLC1 forms the hinge region between the 
globular head and the α-helical tail of myosin.  
The essential light chains (ELC) are expressed by three different genes (MYL1, 3 and 4) 
which give rise to four isoforms of ELC/MLC (Hernandez et al. 2007). The nomenclature 
adopted depends on the tissue expressed (ELCa and ELCv for atrium and ventricular 
ELC/MLC, respectively) or whether it is full or short MLC (MLC1 and MLC3 for long and 
short MLCs, respectively) (Hernandez et al. 2007). The nomenclature for myosin light chains 
is not always obvious and for this manuscript we will refer to MLC1 as the full length 
myosin light chain present in the sarcomeres of the ventricle.  
It has been described that the amino terminus of MLC1 interacts with the carboxy terminus 
of actin during contraction (Andreev and Borejdo 1999; Efimova et al. 1998; Henry et al. 
1985; Milligan et al. 1990; Miyanishi et al. 2002; Morano et al. 1995; Nieznanska et al. 1998; 
Nieznanska et al. 2002; Nieznanski et al. 2003; Timson et al. 1999; Trayer et al. 1987; 
VanBuren et al. 1994). This interaction of MLC1 with actin suggests an important role of 
MLC1 in the regulation of contraction. Indeed, selective removal of MLC1 from the myosin 
molecule resulted in a reduction of ~50% of the force generated (VanBuren et al. 1994).  
The regulatory light chain (RLC), referred as MLC2 in this review, is involved, as the name 
suggests, in the regulation of contraction. In the heart, two isoforms are found: a ventricular 
specific (MLC2v) and an atrium specific (MLC2a) isoform (Collins 2006). MLC2, together 
with MLC1, contributes to the mechanical stability of the hinge of the head region of the 
myosin molecule. MLC2 has been better studied and characterized due to the fact that it can 
be phosphorylated. MLC2 phosphorylation under basal conditions has been demonstrated 
to regulate Ca2+-dependent contraction (High and Stull 1980; Mizuno et al. 2008; Stull et al. 
1980; Sweeney and Stull 1986). 
In order for proper sarcomeric contraction, the myosin structure has to be stable and fine 
tuned. It is the role of the light chains, present in the hinge of the head region, to assure 
stability of the head region and fine tune contraction by regulating the interaction between 
MHC and actin. 
4. Posttranslational modifications 
Virtually all proteins are subjected to posttranslational modifications. In this text, 
posttranslational modification will refer to the addition of a chemical group to amino acid 
residue which has a biological functional. Mass spectrometry can be used to determine 
peptide masses belonging to the native protein. According to the mass of each peptide  
one can infer about the presence or absence of a posttranslational modification that  
has a unique mass signature. A useful tool in determining posttranslational  
modifications by using peptide masses is ExPASy-FindMod tool (available at 
http://web.expasy.org/findmod/findmod_masses.html). Up to date the available 
information from ExPASy-FindMod tool, shows seventy one groups of posttranslational 
modifications that can be detected from analysis of peptide mass fingerprints. Of these, 
phosphorylation is by far the most studied and well know, mainly due to the identification 
of enzymes mediating phosphorylation of protein residues: protein kinases. 
 
Proteomics – Human Diseases and Protein Functions 
 
242 
Isoelectrofocusing was performed using the BioRad Protean IEF cell with the following 
conditions at 20ºC with fast voltage ramping: step 1: 15 min with end voltage at 250 V; step 
2: 150 min with end voltage at 8000 V; step 3: 35 000 V-hours (approximately 260 min). 
Following isoelectrofocusing the strips were equilibrated according to the manufacturer’s 
instructions. The second dimension of 2-DE was performed with Criterion pre-cast gels (8 – 
16%) (BioRad). After separation, proteins were detected with Coomassie Briliant Blue R250 
(BioRad). To minimize variations in resolving proteins during the 2-DE run, 12 gels were 
run simultaneously using a Criterion Dodeca Cell (BioRad, Hercules, CA, USA). Because of 
this limitation for 2-DE analysis we used 4 hearts from each group. All the gels were stained 
in the same bath and next scanned with a calibrated densitometer GS-800 (BioRad, Hercules, 
CA, USA). Quantitative analysis of MLC1 and MLC2 spot intensities from 2-DE were 
measured with PDQuest 7.1 measurement software (BioRad, Hercules, CA, USA). 
MLC1 and MLC2 protein spots were manually excised from the 2-DE gel. These spots were 
then processed using a MassPrep Station (Waters, Milford, MA, USA) using the methods 
supplied by the manufacturer. The excised gel fragment containing the protein spot was 
first destained in 200 µl of 50% acetonitrile with 50 mM ammonium bicarbonate at 37°C for 
30 minutes. Next, the gel was washed twice with water. The protein extraction was 
performed overnight at room temperature with 50 µL of a mixture of formic acid, water, and 
isopropanol (1:3:2, vol:vol). The resulting solution was then analyzed by mass spectrometry 
(MS). For electrospray, quadruple time-of-flight (Q-TOF) analysis, 1 µl of the solution was 
used. Liquid chromatography/mass spectrometry (LC/MS) was performed on a CapLC 
high-performance liquid chromatography unit (Waters, Milford, MA, USA) coupled with Q-
TOF-2 mass spectrometer (Waters, Milford, MA, USA). A mass deviation of 0.2 was 
tolerated and one missed cleavage site was allowed. Resulting values from mass 
spectrometry (MS/MS) analysis were used to search against the NCBInr and SwissProt 
databases with Mammalia specified. We used the Mascot (www.matrixscience.com) search 
engine to search the protein database. Posttranslational modifications were determined 
using the ExPASy-FindMod tool (http://web.expasy.org/findmod/findmod_masses.html). 
3. Cardiac contractile proteins 
The heart is the central organ for the circulatory system and is responsible for providing an 
efficient flow of blood to the whole body in order to meet the metabolic demands of the 
organism by delivering oxygen and nutrients and, at the same time, removing metabolic 
waste. Often seen as a pump, the heart relies on the integrity of its contractile machinery in 
order to efficiently perform its function. The basic unit of contraction is the sarcomere. The 
sarcomere is constituted of thick and thin filaments that, during contraction, slide over each 
other leading to the shortening of the sarcomere and contraction. The thick filament is 
mainly constituted of myosin while the thin filament is mainly constituted of actin, 
tropomyosin, and troponins (Figure 2). The interaction between thin and thick filaments, the 
crucial component for the generation of a contractile force, occurs between actin and the 
myosin head. 
3.1 Myosins 
Myosin is a large complex molecule. It consists of two heavy chains, an �-helical tail, and 
four myosin light chains (Craig and Woodhead 2006; Dominguez et al. 1998; Rayment et al. 
1993b). The heavy chains (myosin heavy chain, MHC) have the ATPase activity necessary to 
 
Posttranslational Modifications of Myosin Light Chains Determine the Protein Fate 
 
243 
trigger sliding between filaments and the consequent contraction. The two light chains 
(myosin light chain 1 and 2, MLC1 and MLC2) confer stability to the myosin head and also 
have actin binding motifs. MLC1 is also referred to as the essential light chain (ELC) and is 
present in the hinge of the myosin head for stability purposes. MLC2 is also referred as 
regulatory light chain (RLC) and together with MLC1 forms the hinge region between the 
globular head and the α-helical tail of myosin.  
The essential light chains (ELC) are expressed by three different genes (MYL1, 3 and 4) 
which give rise to four isoforms of ELC/MLC (Hernandez et al. 2007). The nomenclature 
adopted depends on the tissue expressed (ELCa and ELCv for atrium and ventricular 
ELC/MLC, respectively) or whether it is full or short MLC (MLC1 and MLC3 for long and 
short MLCs, respectively) (Hernandez et al. 2007). The nomenclature for myosin light chains 
is not always obvious and for this manuscript we will refer to MLC1 as the full length 
myosin light chain present in the sarcomeres of the ventricle.  
It has been described that the amino terminus of MLC1 interacts with the carboxy terminus 
of actin during contraction (Andreev and Borejdo 1999; Efimova et al. 1998; Henry et al. 
1985; Milligan et al. 1990; Miyanishi et al. 2002; Morano et al. 1995; Nieznanska et al. 1998; 
Nieznanska et al. 2002; Nieznanski et al. 2003; Timson et al. 1999; Trayer et al. 1987; 
VanBuren et al. 1994). This interaction of MLC1 with actin suggests an important role of 
MLC1 in the regulation of contraction. Indeed, selective removal of MLC1 from the myosin 
molecule resulted in a reduction of ~50% of the force generated (VanBuren et al. 1994).  
The regulatory light chain (RLC), referred as MLC2 in this review, is involved, as the name 
suggests, in the regulation of contraction. In the heart, two isoforms are found: a ventricular 
specific (MLC2v) and an atrium specific (MLC2a) isoform (Collins 2006). MLC2, together 
with MLC1, contributes to the mechanical stability of the hinge of the head region of the 
myosin molecule. MLC2 has been better studied and characterized due to the fact that it can 
be phosphorylated. MLC2 phosphorylation under basal conditions has been demonstrated 
to regulate Ca2+-dependent contraction (High and Stull 1980; Mizuno et al. 2008; Stull et al. 
1980; Sweeney and Stull 1986). 
In order for proper sarcomeric contraction, the myosin structure has to be stable and fine 
tuned. It is the role of the light chains, present in the hinge of the head region, to assure 
stability of the head region and fine tune contraction by regulating the interaction between 
MHC and actin. 
4. Posttranslational modifications 
Virtually all proteins are subjected to posttranslational modifications. In this text, 
posttranslational modification will refer to the addition of a chemical group to amino acid 
residue which has a biological functional. Mass spectrometry can be used to determine 
peptide masses belonging to the native protein. According to the mass of each peptide  
one can infer about the presence or absence of a posttranslational modification that  
has a unique mass signature. A useful tool in determining posttranslational  
modifications by using peptide masses is ExPASy-FindMod tool (available at 
http://web.expasy.org/findmod/findmod_masses.html). Up to date the available 
information from ExPASy-FindMod tool, shows seventy one groups of posttranslational 
modifications that can be detected from analysis of peptide mass fingerprints. Of these, 
phosphorylation is by far the most studied and well know, mainly due to the identification 
of enzymes mediating phosphorylation of protein residues: protein kinases. 
 
Proteomics – Human Diseases and Protein Functions 
 
244 
Phosphorylation is commonly associated with signal transduction, the hallmark of signaling 
cascades mediated by kinases. Other posttranslational modifications have recently gained 
more attention, mainly due to the fact that they are associated with oxidative stress. Protein 
nitration and nitrosylation are common events occurring in cells subjected to oxidative 
stress. Contrary to phosphorylation, no enzyme has been described to mediate nitration and 
nitrosylation and these modifications are often seen as a non-enzymatic posttranslational 
modification dependent on the presence, identity and concentration of reactive nitrogen 
species. The role of protein nitration on cellular signal transduction pathways has been 
reviewed by Yakovlev and Mikkelsen (Yakovlev and Mikkelsen 2010). The authors conclude 
that the gathered evidence supports the notion of protein nitration being a specific reaction. 
Though not entirely clear, it appears that nitration of protein residues by reactive nitrogen 
species is dependent on the tertiary structure of the protein and in particular the chemical 
environment of the tyrosin residues. 
Due to the number of possible posttranslational modifications currently identified and the 
fact that the same posttranslational modification can occur in different amino acids, it is 
clear that the study of posttranslational modifications of protein under physiological and 
pathological conditions is a difficult task. Moreover, posttranslational modifications are not 
isolated reactions. A protein molecule present in physiological or pathological conditions 
may have more than one posttranslational modification. Also, the same protein can exhibit 
different types of posttranslational modifications at one time. Hence, the study of 
posttranslational modifications of proteins is difficult but also of high importance due to the 
nature of physiological and pathological consequences these modifications often cause. Also 
of importance is the fact that the study of posttranslational modification of cardiac 
contractile proteins can result in the identification of disease-specific markers of heart injury, 
hence contributing to the development of more sensitive and specific biomarkers of heart 
injury. 
4.1 Biomarkers of heart injury 
A biomarker is defined as a reproducibly detectable molecular feature, usually present in an 
accessible bodily fluid or tissue, that is correlated with a disease state. Cardiac enzymes 
have long been used as front-line diagnostic tools in the detection of myocardial injury 
caused by myocardial ischemia. However, the most commonly used enzymes (such as 
creatine kinase (CK) and its myocardial fraction CK myocardial band (MB), aspartic 
aminotransferase, and lactate dehydrogenase) are limited in their ability to detect 
myocardial injury by short diagnosis windows, have limited sensitivities, and lack 
specificity because of their presence in skeletal muscle. Similarly, myoglobin also lacks 
specificity because its release from skeletal muscle cannot be distinguished from its release 
from the heart muscle (Christenson and Azzazy 1998). Thus, there is a need to develop 
novel biomarkers in order to more effectively treat and diagnose myocardial infarction (MI). 
Using the proteomics approach a time-dependent increase of TnI in the serum from patients 
with MI was reported (Labugger et al. 2000). This new finding led to the suggestion that 
MLC1, as a contractile protein, could be considered as a new protein biomarker in I/R 
injury of the heart (Lee and Vasan 2005; Sato et al. 2004). The list of biomarkers in 
cardiovascular diseases will grow, particularly when the proteomics approach is used. This 
method has already identified 177 different proteins (including their different molecular 
forms) with the potential to be good candidates as biomarkers (Anderson 2005) in 
cardiovascular disease such as stroke. 
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4.2 MLCs in heart injury 
Muscles contract when filaments containing a molecular motor, myosin, pull against 
another set of filaments containing mainly actin. The source of energy for this directional 
movement is provided by the hydrolysis of ATP, which is catalyzed by myosin. Muscle 
myosin is a hexamer consisting of two heavy chains (MHC), two regulatory (or 
phoshorylatable) light chains (known as MLC2 or RLC) and two essential chains (known as 
MLC1, and alkali or ELC). The myosin heavy chain is an elongated molecule where more 
then 90% of the protein is a coiled coil tail formed by the two heavy chains. However, the N-
terminus of MHC is globular and contains ATPase activity, the actin binding site, and MLC1 
and MLC2 binding sites (Rayment et al. 1993a; Rayment et al. 1993b). The light chains from 
cardiac and skeletal muscles are not directly involved in the regulation of contraction. 
However, both MLC1 and MLC2 can exert a subtle modulatory effect. 
The precise molecular basis for myocardial stunning remains unknown, but protein damage 
within the myofilament is a likely mechanism. It is almost certain that stunning is a 
multifactoral process. One potential target is ventricular MLC2, which via changes in its 
phosphorylation status, modulates contractile force generation arising from actin-myosin 
MHC interaction (the structure, function and malfunction of MLC2 have been reviewed by 
Szczesna, (Szczesna 2003)). Three years ago an Australian group, using an experimental 
protocol similar to ours, found changes in phosphorylation of MLC2 and showed how these 
changes are correlated with the function of stunned myocardium (White et al. 2003). In 
another model, involving pharmacologically preconditioned isolated cardiomyocytes, 
altered phosphorylation of MLC1 was also found, but the role of this modification is not yet 
known (Arrell et al. 2001a). 
Not only does heart injury induce chemical modification of MLCs, but during acute 
congestive heart failure entire MLC molecules, or their degradation products, are released 
into the circulation (Goto et al. 2003; Hansen et al. 2002). Van Eyk and colleagues have 
shown that the release of degradation products of MLC1 to coronary effluent is positively 
correlated with the duration of ischemia (Van Eyk et al. 1998). And White and co-workers 
found that both to MLC1 and MLC2 are released into the effluent of ischemic hearts (White 
et al. 2003). There was no evidence as to what proteolytic enzyme could be responsible for 
MLC degradation or what molecular mechanism could account for the release of their 
products into the circulation. Our work on the degradation of MLC1 in I/R heart shows that 
MMP-2 is responsible (at least in part) for the degradation of this protein (Doroszko et al. 
2009; Polewicz et al. 2010; Sawicki et al. 2005). Although, the mechanism of release is still 
unknown, it could result from a loss of cell membrane integrity. Despite the many 
unanswered questions about the molecular basis of I/R injury in the heart, cardiac MLC1 is 
becoming a very important candidate as a biomarker of heart injury. 
4.3 Phosphorylation 
Phosphorylation is a posttranslational modification that consists of the addition of a 
phosphate group to serine (Ser), threonine (Thr) or tyrosine (Tyr). The addition of the 
phosphate group to these amino acids is catalyzed by kinases. The currently described 
mechanism of phosphorylation is that it essentially works as a switch, turning the function 
the phosphorylated protein on or off. Other consequences of protein phosphorylation may 
involve subcellular localization of proteins, protein-protein interaction, and proteolytic 
degradation. In fact, our ongoing studies on role of posttranslational modifications in the 
development of cardiac contractile dysfunction implies that the phosphorylation of MLC1 
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phosphate group to these amino acids is catalyzed by kinases. The currently described 
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during ischemia/reperfusion results in its increase degradation, possibly by MMP-2, 
contributing to ischemia/reperfusion injury. 
Phosphorylation of MLC1 has been demonstrated previously (Arrell et al. 2001a) but it has 
been associated with stability of the myosin head. The authors reported phosphorylation of 
rat/human Thr 69/64 and Ser 200/194 or 195. Our unpublished data demonstrates that 
phosphorylation of MLC1 has direct implications in its degradation by MMP-2. We 
observed in vitro phosphorylation (by myosin light chain kinase) of human recombinant 
MLC1 at Thr127, Thr129 or Tyr 130, as well as Ser179 and Tyr186. In MLC1 from isolated rat 
hearts subjected to ischemia/reperfusion we observed six phosphorylated residues: Thr69, 
Thr77 or Tyr78, Thr132, Thr134 or Tyr135, Thr164, Ser184 and Tyr190. Our data suggests a 
physiological role for MLC1 phosphorylation of Thr69 and Thr132, Thr134 or Tyr135, since 
these phosphorylations are present in aerobic control hearts, with the remaining four 
phosphorylations being induced by ischemia/reperfusion (Table 1). The observed 
phosphorylations of MLC1 induced by ischemia/reperfusion resulted in an increased 
degradation of MLC1. In an unpublished in vitro study we observed that when MLC1 was 
phosphorylated by the myosin light chain kinase (MLCK), the affinity of MMP-2 for MLC1 
was increased and this increase in affinity resulted in an increase in the degradation of 
MLC1. Taken together, these observations suggest a role for protein phosphorylation in the 
induction of proteolytic degradation, namely by MMP-2. 
 
 Identified posttranslational modified residues 
Posttranslational 
Modification MLC1 MLC2 
Phosphorylation 
in vitro (human recombinant) 
Thr127/Thr129/Tyr130, Ser179, 
Tyr186  






in vitro (human recombinant) 
Tyr73, Tyr130, Tyr185 Tyr152 
in vivo (piglet heart) 
Tyr141 Tyr118, Tyr152 
ex vivo (rat heart) 
Tyr78, Tyr190  
Cys S-nitrosylation 
in vitro ( human recombinant) 
Cys67, Cys76  
in vivo (piglet heart) 
Cys138  
ex vivo (rat heart) 
Cys81  
Table 1. Identification of MLC1 and MLC2 protein residues subjected to posttranslational 
modification leading to protein degradation. 
 
Posttranslational Modifications of Myosin Light Chains Determine the Protein Fate 
 
247 
To our knowledge these are the first observations concerning phosphorylation of a target 
protein contributing to the direct proteolytic degradation of that protein. Since it is well 
known that during several distinct disease processes the activation of phosphorylation 
cascades occur we speculate that besides up- and down-regulation of protein activity, 
phosphorylation is responsible for signaling protein degradation contributing directly to the 
progression of the disease process. 
4.4 Nitration and S-nitrosylation 
Protein tyrosine nitration has been implicated in many pathological conditions and diseases 
such as inflammation, chronic hypoxia, myocardial infarction and diabetes among others 
(Blantz and Munger 2002; Brindicci et al. 2010; Donnini et al. 2008; Giasson et al. 2000; Jones et 
al. 2009; Kang et al. 2010; Koeck et al. 2009; MacMillan-Crow et al. 1996; Naito et al. 2008; 
Pacher et al. 2007; Pavlides et al. 2010; Pieper et al. 2009; Reyes et al. 2008; Reynolds et al. 2005; 
2007; Smith 2009; Upmacis 2008; Zhang et al. 2010). However, a physiological role for protein 
tyrosine nitration should not be excluded. Not all the tyrosine residues in a protein are targets 
for nitration either in vitro or in vivo. Moreover, the observed nitrations of tyrosine very seldom 
coincide between in vitro and in vivo studies. Of importance is the fact that nitration of tyrosine 
residues is a selective process that appears to be under tight control, even though the exact 
mechanisms for the regulation of tyrosine nitration remain unknown.  
Nitration of protein tyrosine residues (formation of nitrotyrosine) has been suggested to 
facilitate proteolysis of the nitrated protein (Yakovlev and Mikkelsen 2010). We have 
recently shown that the contractile proteins MLC1 and MLC2 (part of the thick filament of 
the sarcomere) are subjected to tyrosine nitration and cysteine s-nitrosylation in cardiac 
models of oxidative stress (Doroszko et al. 2010; Doroszko et al. 2009; Polewicz et al. 2010). 
Using an in vivo model of neonatal asphyxia in piglets we have shown that both MLC1 and 
MLC2 are significantly decreased following hypoxia-reoxygenation (Doroszko et al. 2010; 
Doroszko et al. 2009). Mass spectrometry analysis for nitration and nitrosylation revealed 
that MLC1 is S-notrosylated at Cys 138 and nitrated at Tyr 141. Interestingly, these residues 
are located at the positions P3 and P1’ of the cleavage site for MMP-2 and hypoxia-
reoxygenation was associated with an increase in MMP-2 activity. Also, MLC2 from hearts 
subjected to hypoxia-reoxygenation was nitrated at Tyr 118 and Tyr 152, while no nitration 
was observed for the control group (Table 1). These data suggest a pathological role for 
MLC2 tyrosine nitration associated with hypoxia-reoxygenation. Using human recombinant 
mutant MLC2, in which the tyrosine residue is replaced with phenylalanine, (Y152F) the in 
vitro incubation with peroxynitrite as a nitrating agent resulted in the prevention of MLC2 
degradation by MMP-2, with no nitration observed at position 152. These observations 
indicate that although MLC2 has two nitration sites, it is Tyr 152 that mediates the signaling 
of degradation by MMP-2. MLC1 was also studied in a model of isolated adult rat 
cardiomyocytes subjected to simulated ischemia. Mass spectrometry analysis revealed 
nitration of Tyr 190, consistent with what was observed in piglet hearts. However, the Cys 
in the P3 position of the MMP-2 cleavage site was not S-nitrosylated as observed in MLC1 
from piglet hearts. Moreover, MLC1 from rat cardiomyocytes was also nitrated at Tyr 78 
and S-nitrosylated at Cys 81. In vitro human recombinant MLC1 was nitrated by 
peroxynitrite (used as a nitrating agent) at Tyr 73 (corresponding to rat MLC1 Tyr 78) Tyr 
185 (corresponding to rat MLC1 Tyr 190), Tyr 140 and S-nytrosilated at Cys 76 
(corresponding to rat Cys 81) and Cys 67. In vitro nitrated and S-nitrosylated MLC1 was 
more susceptible to degradation by MMP-2. 
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These data support the concept of highly regulated nitration and S-nitrosylation of proteins 
previously suggested, even though the exact mechanism remains unknown. Moreover, not 
only these processes are highly specific, they are also tightly associated with 
pathophysiological consequences. In this case, nitration and S-nitrosylation of protein 
residues is associated with an increase in its degradation by the proteolytic enzyme MMP-2 
both in vitro and in vivo. 
 
 
Fig. 2. Cartoon representation of our proposed model for regulation of contractile protein 
fate by posttranslational modifications. Reactive oxygen species (ROS) generated during 
ischemia/reperfusion or hypoxya-reoxygenation can lead to the direct nitration/S-
nitrosylation of tyrosine and cysteine residues of MLC1 and MLC2. Also, ROS can lead to 
the phosphorylation of MLC1 and MLC2. 
 




With the development of proteomics technology over the last two decades, more and more 
information about protein posttranslational modifications has been gathered. The difficulty 
of studying posttranslational modification of proteins and their physiological and 
pathological consequences lies on the fact that often (if not always) a protein will exhibit 
more than one type of posttranslational modification at any given time or more than one 
posttranslational modification of the same type.  
Classically, enzymatic production of a certain product, from a given substrate, was limited 
by the enzyme activity. Also, posttranslational modification of the enzyme, such as 
phosphorylation, is a valid process to increase enzyme activity. We propose a new 
paradigm in the regulation of enzymatic activity by modification of proteins previously 
resistant to degradation. Here we have described the role of nitrosylation, nitration and 
phosphorylation of cardiac contractile proteins, as substrates for enzymatic reaction, in 
models of oxidative stress which result in their increased degradation by a proteolytic 
enzyme (MMP-2) both in vitro and in vivo (Figure 2). 
It has been described that posttranslational modification of MMP-2 triggered by oxidative 
stress can activate the enzyme (Viappiani et al. 2009). Although this may be the case in the in 
vivo and ex vivo models, the same observations were made in in vitro experiments in which 
MMP-2 is not posttranslational modified. This new paradigm, that posttranslational 
modification determine fate of proteins, is an important advance in the understanding of the 
molecular mechanisms by which oxidative stress can trigger cardiac contractile dysfunction 
in pathological processes such as ischemia/reperfusion and hypoxia-reoxygenation. 
activation of MLCK and phosphorylation of MLC1. These posttranslational modifications 
increase the affinity of MMP-2 for MLC1 and MLC2. MMP-2 degrades MLC1 and MLC2 
leading to cardiac contractile dysfunction. 
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1. Introduction 
Comprehensive profiling of genome and transcriptome has identified myriads of 
alternations at the level of gene and gene expression, which drive malignant development 
and progression in context of oncology. As a result, qualitative or quantitative changes of 
protein expression pattern will inevitably ensue during multi-stage of carcinogenesis. In this 
sense, the proteome is a functional translation of the genome and is the actual manipulator 
of cellular behavior. Therefore, proteomic profiling of cellular protein constituents should 
generate the most relevant marker of the functional state of a cell. On the other hand, lack of 
correlation between mRNA and protein expression have been documented for a variety of 
genes. Unlike the genome which is static in certain sense, the proteome of a cell is dynamic 
and changes over time in terms of protein pattern, protein interactions and modifications 
triggered by external or internal signals[Kolch et al., 2004; Kolch et al., 2005]. Only dynamic 
information flow through protein circuitry reflects the course of a disease and allows us to 
track the pathogenetic mechanisms as well as treatment response[Kolch et al., 2005]. 
Furthermore, examining DNA sequences and measuring mRNA expression do not specify 
splicing, post-translational modifications, cleavages, protein subcellular localization and 
complex formations[Banks et al., 2000; Chambers et al., 2000]. There exists a huge 
information gulf between RNA transcription and protein expression. Proteome represents a 
much richer source for the functional description of diseases and the biomarker discovery 
implicated in cancer. Moreover, most of diagnostic assays currently applied in clinical 
practice are protein-based immunological methods, which are well adapted to 
standardization and clinical implementation. Proteomic profiling during disease formation 
and evolution not only provides an integrated understanding of pathogenesis in context of 
genome and proteome but also holds greater promise to identify the biomarkers of 
diagnosis and therapeutic targets for diseases such as cancer.  
1.1 Epidemiology and etiology of ESCC 
Accounting for more than 400,000 deaths per year, esophageal cancer (EC) ranks as the sixth 
most common cause of cancer-related mortality worldwide[Parkin et al., 2005]. Moreover, 
about half of world’s EC cases newly diagnosed each year occurred in China[Holmes & 
Vaughan, 2007]. Histologically, esophageal squamous cell carcinoma (ESCC) and esophageal  
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adenocarcinoma (EAC) contribute to more than 90% of EC[Daly et al., 2000]. In China, ESCC is 
the predominant histological subtype and account for nearly 90% of all EC[Li et al., 2011]. In 
developed countries, in contrast, EAC has been increasingly more frequent over the past two 
decades and has now surpassed the previously more predominant ESCC[Brown et al., 2008; 
Trivers et al., 2008]. The incidence of ESCC is characterized by its striking geographical 
distribution across the world. In the extremely high incidence areas, e.g. northern China, the 
incidence of EC exceeds 100/100 000/year, while the incidence is less than 5/100 000/year in 
Europe and the USA[Cheng & Day, 1996]. Heavy smoking and alcohol consumption are 
associated with increased risk of ESCC in developed countries[Brown et al., 2008; Messmann, 
2001; Morita et al., 2010], but not major contributing factors in the pathogenesis of ESCC in 
China, where major risk factors include nutritional deficiency, consumption of pickled 
vegetables, dietary contamination with nitrosamine or mycotoxin, and low socioeconomic 
status[Kamangar et al., 2009; Yang et al., 1984]. In light of the poor nutrition status in Linxian, 
one of the highest incidence areas for ESCC in the world, two large nutrition intervention 
studies implemented in the late 1980s reported that the combination of selenium/vitamin E/β-
carotene significantly reduced total mortality, total cancer mortality and stomach cancer 
incidence[Blot et al., 1993; Li et al., 1993]. High baseline serum selenium concentrations 
showed strong protective effects on ESCC and stomach cancer in prospective studies[Mark et 
al., 2000]. Recently, opposing trends in incidence of EAC and ESCC, i.e. decrease of ESCC 
incidence and reciprocal increase of EAC incidence has been observed not only worldwide but 
also in high risk areas in China, pointing to the roles of economic level and lifestyle factors in 
EC pattern change[Devesa et al., 1998; Fan et al., 2008; Hongo et al., 2009]. In addition, familial 
aggregation of ESCC has been reported in high-risk areas for ESCC[Chang-Claude et al., 1997]. 
Taken together, these facts indicate that both genetic susceptibility and environmental risk 
factors contribute to the etiology of ESCC.  
1.2 Current situation of clinical management of ESCC 
Early detection of ESCC is formidable and the majority of ESCC patients have advanced 
metastatic disease at initial diagnosis. Therefore, 40-60% ESCC patients are inappropriate for 
curative resection, which remains the primary treatment of ESCC as it provides sustained 
palliation of dysphagia and the best chance of cure[Hagymasi & Tulassay, 2007; Triboulet et 
al., 2001]. Nonetheless, more than 50% ESCC develop recurrence within 2-3 years after 
surgery[Dresner & Griffin, 2000; Hulscher et al., 2000; Nakagawa et al., 2004]. Moreover, the 
overall 5-year survival rate is < 10% despite significant improvements in surgical techniques 
and adjuvant chemoradiation[Lightdale, 1999]. In contrast, the 5-year survival rate for EC 
patients at early stages could be as high as 90%[Hu et al., 2001]. Long-term survival 
correlates with stages of EC, as evidenced by 40-62% of 5-year survival rate for stage I and 
IIA contrasting with 18-25% for stage IIB and III of EC[Iizuka et al., 1989]. This suggests that 
the reasons for this disappointingly low survival rate include ineffective screening tools for 
high-risk population, cancer detection at an advanced stage, high-risk for recurrence, lack of 
targets for treatment, unreliable noninvasive tools to monitor complete response to 
chemoradiotherapy and so on. Clearly, identification of effective biomarkers for early 
detection, monitoring tumor progression and potential therapeutic targets offer the best 
chances to lower the morbidity and mortality of ESCC.  
1.3 Molecular biology studies of ESCC and its contribution to clinical management 
Extensive molecular biology studies of ESCC have identified a wealth of dysregulated 
molecular events involved in esophageal carcinogenesis, which cover a broad range of genes 
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with diverse functions, such as vulnerable genes to chemicals, tumor-related genes, tumor 
suppressor genes, metastasis genes, apoptosis gene, proliferation genes, etc[Enzinger & 
Mayer, 2003; Greenawalt et al., 2007; Kwong, 2005; Lin et al., 2009]. Moreover, epigenetic 
alterations, chromosomal changes and transcriptional changes have also been found to play 
crucial roles in the pathogenesis of ESCC[Abnet et al., 2010; Greenawalt et al., 2007; Wang et 
al., 2010]. Although these findings improve our general understanding about the molecular 
biology of ESCC, the appropriate biomarkers for high-risk population screening, for clinical 
diagnosis and prognosis, for evaluation of treatment efficiency have not been identified yet. 
Therefore, it is imperative to search more effective biomarkers for such purposes. 
2. ESCC analysis by proteomics 
2.1 Advantages of proteomics compared with genomics 
The completion of human genome sequence did not ensure panacea solutions to all 
problems related to biological deregulation. In fact, human proteome is far more complex 
and dynamic than genome sequence. It is estimated that the human genome contains about 
32 000 protein coding genes, which code for 100 000 to 10 million proteins due to alternative 
RNA splicing, overlapping of transcription units, post-translational processing and 
modifications[Lander et al., 2001; Venter et al., 2001]. Thus, a big disparity between genome 
and proteome exists, which indicates that the combinatorial diversification of regulatory 
networks lead to functional evolution of proteins. Through detecting the functioning units, 
proteomic studies generate a protein fingerprint, which reflects both the intrinsic genetic 
programme of the cell and the impact of its immediate environment.  Therefore, proteomics 
is valuable for biomarker discovery since its application provides higher opportunity to 
identify genuine determinants or causal factors involved in biological functions or the 
pathogenesis of disease.  
2.2 Two-dimensional electrophoresis-based proteomic findings of ESCC 
Two-dimensional electrophoresis (2DE) has been used for over 30 years now due to its high 
resolution for the separation of complex protein mixtures. In combination with mass 
spectrometry, 2DE has been so far the most commonly used method for analyzing protein 
expression and identity. Our laboratory used 2DE to profile the proteome from ESCC 
tumors and matched adjacent non-cancer mucosa, and proteome from immortalized 
esophageal cell line and cancer cell lines. Comparative analysis and MS for protein 
identification showed that the over-expressions of four proteins were common in ESCC 
tissues and cancer cell lines, which include tropomyosin isoform 4 (TPM4), prohibitin, 
peroxiredoxin (PRX1) and manganese superoxide dismutase (MnSOD); the expressions of 
another three proteins, i.e. stratifin, prohibitin, squamous cell carcinoma antigen 1 (SCCA1), 
were correlated inversely with dedifferentiation of ESCC[Qi et al., 2005; Qi et al., 2008]. 
Immunohistochemistry (IHC) analysis showed that loss of expressions of annexin A2 and 
stratifin were 45% and 64% in ESCC, respectively[Qi et al., 2007a; Qi et al., 2007b; Ren et al., 
2010]. Differential expressions of ten proteins including TPM1, SCCA1, stratifin, 
peroxiredoxin 2 isoform a, alpha B-crystalline, annexin A2, heterogeneous nuclear 
ribonucleoprotein L (hnRNP L), triosephosphate isomerase1 (TPI), laminA/C, and 
cyclophilin A (CypA) can be observed as well. Our findings may suggest that these 
differential proteins contribute to the multistage process of carcinogenesis, tumor 
progression, and invasiveness of ESCC. Published in the same issue, Zhou et al found 28 
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stratifin were 45% and 64% in ESCC, respectively[Qi et al., 2007a; Qi et al., 2007b; Ren et al., 
2010]. Differential expressions of ten proteins including TPM1, SCCA1, stratifin, 
peroxiredoxin 2 isoform a, alpha B-crystalline, annexin A2, heterogeneous nuclear 
ribonucleoprotein L (hnRNP L), triosephosphate isomerase1 (TPI), laminA/C, and 
cyclophilin A (CypA) can be observed as well. Our findings may suggest that these 
differential proteins contribute to the multistage process of carcinogenesis, tumor 
progression, and invasiveness of ESCC. Published in the same issue, Zhou et al found 28 
 
Proteomics – Human Diseases and Protein Functions 
 
260 
proteins aberrantly expressed in ESCC cancer cells with at least three-fold difference 
between ESCC and normal epithelial cells[Zhou et al., 2005]. The overlap between these two 
studies was quite small. Only expression of SCCA1 was commonly down-expressed in 
ESCC, but transgelin showed increased expression in tumor in our study and decreased 
expression in Zhou’s study. The disparity of proteins identified between these two studies 
may be due to different sample source, different methods used by these two groups, such as 
laser capture microdissection vs. bulk tissues, 2D-DIGE vs. silver staining. Later, five groups 
reported proteomic signatures associated with ESCC using ESCC samples collected from 
different regions of China, including high risk areas for ESCC such as Linzhou, Xinjiang and 
low risk areas like Beijing and Guangdong, but only four reports displayed details of 
identified proteins. Interestingly, more overlap of the identified proteins came from Fu’s 
study and ours, both of which used ESCC samples from Linzhou, one of the highest areas 
for ESCC adjacent to Taihang Mountain[Fu et al., 2007]. The commonly identified proteins 
with the same change direction included alpha enolase, TPM, tubulin, prohibitin and PRX2. 
Although the prevalence of ESCC in Xinjiang is comparable to Linzhou, the protein 
signatures were unique to sample origin, indicative of more important roles of 
environmental, ethnic or hereditary factors in the carcinogenesis of ESCC[Liu et al., 2011]. It 
seems that hsp27 was a general molecular events involved in ESCC since four out of five 
studies observed down-expression in ESCC except ours. Only one among seven studies 
performed survival assay after identifying the candidate proteins by ESCC proteomic 
profiling. Du et al. reported that over-expression of calreticulin and GRP78 could predicate 
poor prognosis of ESCC[Du et al., 2007]. Although 2DE is indeed a very useful method for 
biomarker discovery, more examinations of the biological functions and the clinical 
relevance of biomarker candidates involved in ESCC are necessary to verify its clinical 
value.  
Two reports described the proteomic signatures of ESCC with samples from Japan. 
Nishimori et al. used the agarose IEF gel in the first dimension, which not only allows for 
large-scale quantitative comparisons of protein expression but also is able to resolve high 
molecular mass proteins larger than 150 kDa[Nishimori et al., 2006]. As a result, a different 
protein pattern was revealed, including a few protein candidates with MW > 70 kDa. 
Western blot and IHC verified the different expression of a 195 kDa protein, periplakin, 
between cancer and adjacent non-cancer tissues. Not only was the expression of periplakin 
significantly down-regulated in ESCC but also translocation of periplakin was observed, 
which localized at cell-cell boundaries in normal epithelium and dysplastic precursor 
lesions, and disappeared from cell boundaries and shifted to cell cytoplasm in early cancers. 
The other research group from Japan used unsupervised classification to analyze the 2D-
DIGE protein spots and procured the protein signatures most relevant to clinical parameters 
with progression of ESCC[Hatakeyama et al., 2006]. The authors developed the largest 
protein database relevant to ESCC, which identified 240 proteins with expression level 
associated with carcinogenesis, histological differentiation and the number of lymph node 
metastases. A significant overlapping was observed between the proteins identified in ESCC 
with other different types of tumor. In addition, Jazii et al did proteomic profiling using 
ESCC samples from Iran, another high incidence area for ESCC like northern China, and 
identified six over-expressed proteins and six under-expressed proteins associated with 
ESCC[Jazii et al., 2006]. However, the authors only used RT-PCR to verify the loss of β-
tropomyosin in ESCC. The functions of identified proteins associated with the development 
and progression of ESCC include cytoskeletal/structural organization, transport, chaperon, 
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oxioreduction, proliferation, glycolysis, cell motility, transcription, signal transduction, 
suggesting multiple dysregulated pathways involved in ESCC. For better understanding the 
pathogenesis of ESCC and development of biomarkers, integrated and comprehensive 
studies on these protein candidates are needed.  
An alternative approach to identify novel tumor biomarkers is the assessment of immune 
response elicited by tumor antigen since the humoral immune response to cancer in humans 
has been evidenced by the identification of autoantibodies to a variety of intracellular and 
surface antigens in cancer patients with different types of tumors[Chen et al., 2007; Disis et 
al., 1997; Hong et al., 2004; Soussi, 2000]. In ESCC, a number of reports have documented the 
presence of autoantibodies in serum against various proteins, including p53, cytokeratins, 
myomegalin, TRIM21, peroxiredoxin VI proteins, Hsp70, and CDC25B[Bergqvist et al., 2001; 
Fujita et al., 2006; Fujita et al., 2008; Liu et al., 2008; Shimada et al., 2007; Shimada et al., 2005; 
Veale et al., 1988]. The proteomic-based approach to identify panels of tumor antigens and 
related autoantibodies was introduced by Brichory et al. in 2001, which identified anti-
annexin I and II antibodies in sera from patients with lung cancer[Brichory et al., 2001]. 
There have been four articles published by two research groups, which reported the 
existence of autoantibodies in sera of ESCC patients. The first report was published by Fujita 
et al from Japan, who used 2DE to resolve protein extracts from ESCC cell line TE-2 as 
tumor antigens and then probed the blot with sera of ESCC patients, healthy controls and 
patients with other cancers[Fujita et al., 2006]. One positive spot was identified as PRX VI by 
MALDI TOF/TOF MS. The frequency of autoantibody against PRX VI was 50% (15/30) in 
ESCC, only 6.6% (2/30) in health controls and 3.3% (1/30) in colon cancer. Two years later, 
the same research group discovered augmented concentration of Hsp70 autoantibody in the 
serum of ESCC patients, which was significantly higher in ESCC patients than gastric and 
colon cancer, healthy controls[Fujita et al., 2008]. On the other hand, Liu et al. used ESCC 
tissue protein extracts and autologous sera to search for autoantibodies in ESCC patients 
and identified autoantibody CDC25B[Liu et al., 2008]. Furthermore, CDC25B expression was 
significantly higher in ESCC tissues with positive autoantibody CDC25B and significantly 
correlated with tumor stage. The sensitivity and specificity of autoantibody CDC25B for 
ESCC detection was 56.7% and 91%, respectively[Dong et al., 2010]. The autoantibody-
driven research is indeed a promising approach for the identification of novel serum 
biomarkers present in ESCC and for the tumor antigen itself, which may aid the diagnosis of 
ESCC and development of more effective immunotherapies.   
Similar to other cancers, development of multiple drug resistance in ESCC is one of major 
causes of failure to chemotherapy treatment. Furthermore, recent studies have shown that 
there exists intrinsic sensitivity and resistance to chemotherapy and/or radiotherapy in 
malignant cells of ESCC, which may predict clinical outcome of ESCC patients receiving 
neoadjuvant chemotherapy. Prior stratification of ESCC patients according to reliable 
biomarkers could not only save patients unnecessary adverse effects of chemotherapeutic 
agents but also render patients more chance to access to alternative curative treatment 
options. Therefore, it is imperative to define new diagnostic indicators that can reliably 
predict response to chemotherapy and radiotherapy in advance. A recent study compared 
the 2DE gels of parental esophageal cancer cell line EC109 and its resistant sub-cell line 
EC109/CDDP to determine the different proteins spots and identified 44 proteins with 
potential contribution to chemotherapy resistance[Wen et al., 2010]. In another study, 
radioactive 2DE proteomic comparative analysis was performed using protein extracts of 
biopsies from 34 patients with locally advanced EAC receiving neoadjuvant chemotherapy. 
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oxioreduction, proliferation, glycolysis, cell motility, transcription, signal transduction, 
suggesting multiple dysregulated pathways involved in ESCC. For better understanding the 
pathogenesis of ESCC and development of biomarkers, integrated and comprehensive 
studies on these protein candidates are needed.  
An alternative approach to identify novel tumor biomarkers is the assessment of immune 
response elicited by tumor antigen since the humoral immune response to cancer in humans 
has been evidenced by the identification of autoantibodies to a variety of intracellular and 
surface antigens in cancer patients with different types of tumors[Chen et al., 2007; Disis et 
al., 1997; Hong et al., 2004; Soussi, 2000]. In ESCC, a number of reports have documented the 
presence of autoantibodies in serum against various proteins, including p53, cytokeratins, 
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Veale et al., 1988]. The proteomic-based approach to identify panels of tumor antigens and 
related autoantibodies was introduced by Brichory et al. in 2001, which identified anti-
annexin I and II antibodies in sera from patients with lung cancer[Brichory et al., 2001]. 
There have been four articles published by two research groups, which reported the 
existence of autoantibodies in sera of ESCC patients. The first report was published by Fujita 
et al from Japan, who used 2DE to resolve protein extracts from ESCC cell line TE-2 as 
tumor antigens and then probed the blot with sera of ESCC patients, healthy controls and 
patients with other cancers[Fujita et al., 2006]. One positive spot was identified as PRX VI by 
MALDI TOF/TOF MS. The frequency of autoantibody against PRX VI was 50% (15/30) in 
ESCC, only 6.6% (2/30) in health controls and 3.3% (1/30) in colon cancer. Two years later, 
the same research group discovered augmented concentration of Hsp70 autoantibody in the 
serum of ESCC patients, which was significantly higher in ESCC patients than gastric and 
colon cancer, healthy controls[Fujita et al., 2008]. On the other hand, Liu et al. used ESCC 
tissue protein extracts and autologous sera to search for autoantibodies in ESCC patients 
and identified autoantibody CDC25B[Liu et al., 2008]. Furthermore, CDC25B expression was 
significantly higher in ESCC tissues with positive autoantibody CDC25B and significantly 
correlated with tumor stage. The sensitivity and specificity of autoantibody CDC25B for 
ESCC detection was 56.7% and 91%, respectively[Dong et al., 2010]. The autoantibody-
driven research is indeed a promising approach for the identification of novel serum 
biomarkers present in ESCC and for the tumor antigen itself, which may aid the diagnosis of 
ESCC and development of more effective immunotherapies.   
Similar to other cancers, development of multiple drug resistance in ESCC is one of major 
causes of failure to chemotherapy treatment. Furthermore, recent studies have shown that 
there exists intrinsic sensitivity and resistance to chemotherapy and/or radiotherapy in 
malignant cells of ESCC, which may predict clinical outcome of ESCC patients receiving 
neoadjuvant chemotherapy. Prior stratification of ESCC patients according to reliable 
biomarkers could not only save patients unnecessary adverse effects of chemotherapeutic 
agents but also render patients more chance to access to alternative curative treatment 
options. Therefore, it is imperative to define new diagnostic indicators that can reliably 
predict response to chemotherapy and radiotherapy in advance. A recent study compared 
the 2DE gels of parental esophageal cancer cell line EC109 and its resistant sub-cell line 
EC109/CDDP to determine the different proteins spots and identified 44 proteins with 
potential contribution to chemotherapy resistance[Wen et al., 2010]. In another study, 
radioactive 2DE proteomic comparative analysis was performed using protein extracts of 
biopsies from 34 patients with locally advanced EAC receiving neoadjuvant chemotherapy. 
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The identified proteins with different expression between responders and non-responders 
were classified into two major families, cytoskeleton proteins and molecular chaperon 
proteins. Further validation by IHC and RT-PCR showed that weak expression of HSP27 at 
protein level and mRNA level were associated with non-response to platin-based 
chemotherapy[Langer et al., 2008]. As serum represents a rich source for biomarker 
discovery, proteomic spectra were examined using 27 and 12 serum samples of responders 
and non-responders, respectively, to preoperative chemoradiotherapy in a training set by 
surface-enhanced laser desorption and ionization coupled with mass spectrometry analysis. 
A proteomic classifier comprising four mass peaks, at 7 420, 9 112, 17 123 and 12 867 m/z 
was identified with 93.3% predicative accuracy in the validation set[Hayashida et al., 2005]. 
Since chemotherapy resistance is a complex and multi-factorial event, proteomic-based 
studies enable comprehensive characterization of resistance phenotype of malignant 
cancers, which may lead to identification of potential distinguishing biomarkers between 
responders and non-responders and lay foundation for further molecular mechanism 
studies.  
In addition of 2DE gel for proteomic studies, surface enhanced laser desorption/ionization 
time-of-flight mass spectrometry (SELDI-TOF-MS) is an alternative proteomic tool to profile 
the serum or other body fluids and define potential protein pattern with diagnostic 
potential. By profiling of the serum proteome with SELDI-TOF-MS combined with 
bioinformatics tools, a number of highly sensitive and specific potential diagnosis markers 
have been revealed in various types of cancers. Wang et al. used weak cation exchange 
(WCX2) protein chips and SELDI-TOF-MS to profile 130 symptom-free serum samples 
collected from high-incidence area of ESCC in northern China, Linzhou, which included 63 
subjects with normal esophageal mucosa, 40 subjects with basal cell hyperplasia, 27 subjects 
with dysplasia and 30 ESCC patients. Biomarker pattern’s software identified four protein 
features at m/z of 9 306.61, 13 765.9, 2 942.15 and 15 953.4, which could distinguish normal 
esophageal epithelium, basal cell hyperplasia, dysplasia and ESCC with satisfactory 
diagnostic accuracy[Wang et al., 2006]. Xinjiang is one of the high-incidence areas for ESCC 
and comprise different ethnic peoples including Han decent. Using CM10 protein chips to 
capture targets from serum, SELDI-TOF-MS and bioinformatics analysis resulted in 
identification of six protein peaks (m/z 5667, 5790, 5876, 5979, 6043 and 6102) with 
diagnostic power with sensitivity and specificity of 91.43% and 88.89%, respectively[Xu et 
al., 2009]. In the case of ESCC profiled by SELDI-TOF-MS, further purification and 
identification of discriminatory peaks is necessary for development of simple methods for 
wider clinical application, and to enhance our understanding of the molecular mechanisms 
of esophageal carcinogenesis as well.  
2.3 SILAC-based proteomic findings of ESCC 
Quantitative proteomics is one of the hot research fields in post-genomic era, which has 
been used extensively in oncology to identify biomarkers with diagnostic and therapeutic 
potential, thereby avoiding proteins without biological importance. In traditional 2DE, 
quantitative information of protein spots on 2DE gels is represented by staining intensity. 
Although 2DE is a versatile tool for visualization of thousands of proteins, detection of post-
translational modified isoforms and targeting of protein expression alternations, it has 
inherent limitations, such as limited resolution of membrane or extreme pI proteins, low 
sensitivity and throughput, poor reproducibility, etc., which result in only part of proteome 
uncovered[Ong & Mann, 2005]. In this context, two classes of MS-based quantitative  
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Protein name T/N ratio Functions References 
Annexin A2 ↑or ↓ 
Calcium-dependent 
phospholipid binding 
calcium ion binding 
[Du et al., 2007; Liu et al., 2011] 
Annexin A8 ↓ [Nishimori et al., 2006] 
Annexin I ↓or↑ 
[Du et al., 2007; Jazii et al., 2006; Liu 
et al., 2011; Nishimori et al., 2006; 
Zhou et al., 2005; Zhu et al., 2010] 
Annexin V ↑ [Du et al., 2007] 
Annexin VI ↓ [Nishimori et al., 2006] 
Reticulocalbin ↑ [Zhou et al., 2005] 
S100 A9 ↓ 
calcium ion binding 
[Zhou et al., 2005] 
Syntaxin binding protein ↑ [Liu et al., 2011] 
Translationally controlled tumor 
protein ↑ [Zhu et al., 2010] 
Zinc finger protein 410 ↑ Zink/DNA binding [Du et al., 2007] 
Mutuant hemoglobin beta chain ↓ Heme binding [Du et al., 2007] Myoglobin ↓ [Zhu et al., 2010] 
TPM-4-ALK fusion oncoprotein type 2 ↑ NA [Du et al., 2007; Jazii et al., 2006] 
TPM ↓ 
Cytoskeleton constituent  
[Fu et al., 2007; Liu et al., 2011; 
Nishimori et al., 2006; Zhou et al., 
2005] 
TPM2 ↓ [Jazii et al., 2006; Nishimori et al., 2006; Zhu et al., 2010] 
TPM1 ↓ [Qi et al., 2005] 
TPM3 ↑or ↓ [Fu et al., 2007; Zhu et al., 2010] 
TPM4 ↑ [Qi et al., 2005] 
TPM isoform  ↑ [Fu et al., 2007; Qi et al., 2005] 
Vinculin ↓ [Nishimori et al., 2006] 
Capping protein, gelsolin-like ↓ [Fu et al., 2007] 
Smooth muscle myosin heavy chain 11 
isoform SM1 ↓ [Nishimori et al., 2006] 
Smooth muscle protein ↓ [Liu et al., 2011] 
Apha-actinin 4 ↑ [Fu et al., 2007] 
Tubulin alpha-6, ubiquitous ↑ [Fu et al., 2007] 
Tubulin beta-5 chain ↑ [Fu et al., 2007; Qi et al., 2005] 
Gamma-actin ↑ [Qi et al., 2005] 
Beta-actin ↑ [Fu et al., 2007] 
ACTB protein ↑ [Liu et al., 2011] 
Profilin-1 ↑ [Zhu et al., 2010] 
Periplakin ↓ [Nishimori et al., 2006] 
Calreticulin ↑ Stress response and 
immunity 
[Du et al., 2007; Jazii et al., 2006] 
Calreticulin precursor ↑ [Nishimori et al., 2006] 
Keratin 6A ↑ Intermediate filament [Du et al., 2007] 
Keratin 1 ↑ 
Intermediate filament 
[Jazii et al., 2006; Zhou et al., 2005] 
Keratin 6 ↑ [Nishimori et al., 2006] 
Keratin 8 ↓ [Zhou et al., 2005] 
Keratin 13 ↓ [Nishimori et al., 2006; Zhou et al., 2005] 
Desmin ↓ [Nishimori et al., 2006; Zhou et al., 2005] 
Vimentin ↑ [Nishimori et al., 2006] 
MnSOD ↑ Superoxide dismutase activity [Du et al., 2007; Qi et al., 2005] 
Proliferation cell nuclear antigen 
(PCNA) ↑ DNA polymerase activity [Du et al., 2007; Zhou et al., 2005] 
PRO1708 ↑ 
Stress response and 
chaperone binding 
[Du et al., 2007] 
Dank-type molecular chaperone 
HSPAIL ↑ or ↓ [Du et al., 2007; Nishimori et al., 2006] 
DnaJ(Hsp40) homolog ↑ [Nishimori et al., 2006] 
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al., 2009]. In the case of ESCC profiled by SELDI-TOF-MS, further purification and 
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Protein name T/N ratio Functions References 
Heat shock protein 27 kDa ↓ or ↑ [Du et al., 2007; Fu et al., 2007; Liu et al., 2011; Zhou et al., 2005] 
Similar to heat shock congnate 71-kDa 
protein ↑ [Du et al., 2007] 
Heat shock 70kDa protein 8 ↓ [Nishimori et al., 2006] 
Heat shock protein 70 kDa ↑ [Jazii et al., 2006] 
gp96 ↑ [Zhou et al., 2005] 
GRP78 ↑ [Du et al., 2007] 
Alpha-B-Crystalline ↓ [Qi et al., 2005; Zhu et al., 2010] 
Fibrin beta ↓ [Liu et al., 2011] 
Crystal structure of huma recombinant 
procathepsin B ↑ NA [Du et al., 2007] 
M2-type pyruvate kinase ↑or ↑ 
Energy metabolism 
[Du et al., 2007; Fu et al., 2007; Liu et 
al., 2011] 
Mutant beta-actin(Q6F5I1) ↑ [Du et al., 2007] 
Phosphoglycerate kinase 1 ↑ [Du et al., 2007; Nishimori et al., 2006] 
Alpha enolase ↑ [Du et al., 2007; Fu et al., 2007; Nishimori et al., 2006; Qi et al., 2005] 
Beat-enolase ↑ [Fu et al., 2007] 
Triosephosphate isomerase ↑ [Zhu et al., 2010] 
GAPDH ↑ [Qi et al., 2005] 
Aldolase A ↓ [Nishimori et al., 2006] 
Fructose-bisphosphate aldolase A ↓ [Zhu et al., 2010] 
RNA binding motif protein 8A ↑ mRNA/nucleotide/protein binding [Zhou et al., 2005] 
Translation initiation factor Eif-1A ↑ Translation [Zhou et al., 2005] 
Transmembrane protein 4 ↑ 
Protein binding 
[Zhou et al., 2005] 
Transgelin ↓or ↑ [Liu et al., 2011; Qi et al., 2005; Zhou et al., 2005; Zhu et al., 2010] 
COMT protein ↑ [Liu et al., 2011] 
Early endosome antigen 1 ↓ 
Protein binding 
[Liu et al., 2011] 
Crystal structure of recombinant human 
fibrinogen fragment ↑ [Nishimori et al., 2006] 
Similar to ubiquitin -conjugating 
enzyme E2 variant 1 isoform ↓ 
Protein degradation 
[Du et al., 2007] 
Ubiquitin C-terminal esterase ↑ [Zhou et al., 2005] 
Ubiquinol-cytochrome C reductase 
complex core protein2 ↑ [Nishimori et al., 2006] 
Proteosome ↑ [Liu et al., 2011] 
Galectin-7 ↓ Interactionof cells and cell-matrix  [Zhou et al., 2005; Zhu et al., 2010] 
Fatty acid-binding protein ↓ Lipid metabolism [Zhou et al., 2005] 
TGase  ↓ Protein modification [Zhou et al., 2005] 
Fascin  ↑ actin cross-lining [Zhou et al., 2005] 
SCCA1 ↓ Cysteine proteinase inhibitor [Qi et al., 2005; Zhou et al., 2005] 
Proteinase inhibitor, Clade B ↓ Neutrophil elastase inhibitor [Zhou et al., 2005] 
Thioredoxin perosidase ↑ 
Redox homeostasis 
[Zhou et al., 2005; Zhu et al., 2010] 
Peroxiredoxin 1 ↑or ↓ [Fu et al., 2007; Qi et al., 2005] 
Peroxiredoxin 2 ↓ [Jazii et al., 2006; Qi et al., 2005] 
ARK family 1 ↑ Carcinogen metabolism [Zhou et al., 2005] 
GST M2 ↑ 
glutathione transferase 
activity [Zhou et al., 2005] 
Proteasome subunit βtype 4 ↑ 
Protein degradation 
[Zhou et al., 2005] 
Proteasome subunit βtype 9 ↓ [Zhou et al., 2005] 
Prosomal protein p30-33k ↑ [Zhou et al., 2005] 
Elongation factor Tu ↑ Translation [Qi et al., 2005] 
(NADP) cytoplasmic  ↑ NAD binding [Qi et al., 2005] 
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Protein name T/N ratio Functions References 
Prohibitin ↑or ↓ Transcription regulation [Fu et al., 2007; Qi et al., 2005] 
Neuronal protein ↑ Neuronal growth [Qi et al., 2005] 
Nuclear autoantigenic sperm protein 
isoform 1 ↑ Hsp90 protein binding [Nishimori et al., 2006] 
Myosin heavy chain nonmuscle form A ↓ Actin binding or 
calmodulin binding 
[Nishimori et al., 2006] 
Caldesmon 1 isoform 1 ↓ [Nishimori et al., 2006] 
Myosin regulatory light chain 2 ↓ Ventricular/cardiac muscle isoform [Jazii et al., 2006; Zhu et al., 2010] 
Myosin light chain 2 ↓ Regulatory light chain of 
myosin 
[Jazii et al., 2006] 
Myosin light chain 1 ↓ [Zhu et al., 2010] 
Heterogeneous nuclear 
ribonucleoprotein A2/B1:B1 ↑ RNA binding and 
processing 
[Nishimori et al., 2006] 
Heterogeneous nuclear 
ribonucleoprotein A2/B1:A2 ↑ [Nishimori et al., 2006] 
Myosin light chain 3 ↓ Regulatory light chain [Zhu et al., 2010] Myosin light polypeptide 6 ↑ [Jazii et al., 2006] 
Myosin light chain 6B ↓ Regulatory light chain [Zhu et al., 2010] 
Similar to alpha-fetoprotein ↓ NA [Nishimori et al., 2006] 
Trnasferrin ↓ ferric iron binding [Nishimori et al., 2006] 
Alpha-1-antitrypsin precursor ↓ Proteinase inhibitor [Nishimori et al., 2006] Alpha-1-antitrypsin ↑ [Fu et al., 2007] 
Procollagen-proline ↓ Oxidoreductase activity [Nishimori et al., 2006] 
Calponin 1, basic ↓ actin binding ; calmodulin binding [Nishimori et al., 2006] 
DNA directed RNA polymerase B 
(ropB) ↑ Transcription [Jazii et al., 2006] 
GH16431P ↑ NA [Jazii et al., 2006] 
OPTN protein ↓ Protein C-terminus binding [Fu et al., 2007] 
67 kDa laminin receptor ↑ 
Signal transduction 
[Fu et al., 2007] 
TNF receptor associated factor 7 ↑ [Liu et al., 2011] 
Stratifin ↓ [Du et al., 2007; Qi et al., 2005] 
Cathepsin D ↑ Aspartyl proteinase activity [Liu et al., 2011] 
Chromosome1 open reading frame 8 ↑ NA [Liu et al., 2011] 
Cdc42 ↑ GTPase activator activity [Liu et al., 2011] 
LLDBP ↑ NA [Liu et al., 2011] 
Adenylate kinase 1 ↓ Adenylate kinase activity [Liu et al., 2011] 
General transcription factor IIH ↓ Transcription [Liu et al., 2011] 
Serpin B5 precursor ↑ serine proteinase inhibitor [Zhu et al., 2010] Serpin B3 ↑ [Zhu et al., 2010] 
Transthyretin [Precursor] ↑ Thyroid hormone-binding protein [Zhu et al., 2010] 
Apolipoprotein A-I [Precursor] ↑ lipid metabolism [Zhu et al., 2010] 





[Zhu et al., 2010] 
Serum amyloid P-component 




endopeptidase inhibitor [Zhu et al., 2010] 
Carbonic anhydrase 1 ↓ Carbonate dehydratase 
activity 
[Zhu et al., 2010] 
Carbonic anhydrase 3 ↓ [Zhu et al., 2010] 
Creatine kinase M-type ↓ Creatine kinase activity [Zhu et al., 2010] 
Table 1. Reported differential proteins in esophageal cancer tissues 
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proteomics methods have been developed, which include extracted ion current (XIC)-based 
label-free quantification and stable isotope labeling quantification. Stable isotope labeling by 
amino acids in cell culture (SILAC) is an in vivo metabolic labeling method in which stable 
isotope-labeled amino acids (Heavy vs. Light amino acids) replace the natural amino acids 
of preexisting proteome[Ong & Mann, 2006]. We used SILAC medium to label immortalized 
cells (NE3 and NE6) with heavy stable isotope [U-13C6]-H-Lysine and [U-13C6]-H-Arginine 
and cancer cells (EC1, EC109, EC9706) with light stable isotope [12C6]-L-Lysine and [12C6]-L-
Arginine, respectively. After complete labeling of the cellular proteome, equal quantity of 
proteins from immortalized cells and cancer cells were mixed and then subjected to SDS-
PAGE separation, in-gel trypsin digestion and high performance liquid chromatography on-
line with electrospray ionization-MS/MS analysis (HPLC-ESI-MS/MS). Forty-seven 
candidate proteins with differential expression were identified with our arbitrary criteria, 
which contains ratio change > 1.5 folds, ≥ 2 peptides for quantification and coefficient of 
variation < 50%. Then, we characterized the cellular protein expression pattern and 
secretome derived from cisplatin-resistant sub-cell line EC9706 and its parental sensitive cell 
line EC9706. By SILAC labeling and MS-based quantification, we successfully identified 74 
proteins of cellular origin and 57 proteins of secretome with altered expression levels. 
Similar to our approach, Kashyap et al. used a SILAC-based quantitative proteomic 
approach to compare the secretome of ESCC cells with that of non-neoplastic esophageal 
squamous epithelial cells and identified 120 up-regulated proteins with >2-fold difference in 
the ESCC secretome[Kashyap et al., 2010]. In addition of previously known increased ESCC 
biomarkers, i.e. matrix metalloproteinase 1, transferrin receptor, and transforming growth 
factor beta-induced 68 kDa, a number of novel proteins showed distinct expression pattern, 
among which protein disulfide isomerase family a member 3 (PDIA3), GDP dissociation 
inhibitor 2 (GDI2), and lectin galactoside binding soluble 3 binding protein (LGALS3BP) 
were further validated by immunoblot analysis and immunohistochemical labeling using 
tissue microarrays. These identified proteins participate in multiple biological functions, 
including molecular chaperones, cytoskeletal proteins, and members of protein inhibitors 
family, reducing protein, etc., suggesting multiple dysregulated pathways involving in 
ESCC.  
2.4 Clinical relevance of potential protein biomarkers in ESCC 
To answer clinical questions, the protein biomarkers identified by proteomic techniques 
with potential diagnosis and therapeutic targets for ESCC need to be translated into clinical 
scenario, which is realized by using clinical samples, such as biopsy samples, resected tissue 
samples, plasma or serum samples, urine samples, saliva samples, etc. The methods used for 
validation generally comprise Western blot, IHC and ELISA at protein level, and RT-PCR at 
transcription level. Using 2DE- and SILAC-based quantitative proteomic approaches, we 
have identified a total of 78 non-redundant proteins with aberrant expression associated 
with ESCC, suggesting that these proteins may play functional roles in carcinogenesis of 
ESCC and may have clinical values. Afterwards, Western blot analysis verified the 
decreased expressions of three proteins, i.e. SCCA1, TPM1 and αB-Cryst in cancer, in 
accordance with 2DE quantitative results. At transcription level, SCCA1 mRNA was down-
regulated in tumor as well. More importantly, the expression of SCCA1 decreased step by 
step as a function of precancer lesions progression, which suggests that SCCA1 may take 
part in the multi-stage transformation of ESCC, even in the earliest stages[Qi et al., 2005]. In 
the 2DE-based comparative proteomic study using immortalized and cancer cell model, we  
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Accession no. Protein name MW/PI Scores Ratio(T/N)
Matched 
peptides Functions 
TPM3 HUMAN Tropomyosin alpha-3 chain 32.80/4.53 330.06 0.47 2 Actin binding TPM4 HUMAN Tropomyosin alpha-4 chain 28.50/4.52 199.64 0.37 2 
K2C8  HUMAN Keratin, type II cytoskeletal 8 53.67/5.38 907.48 0.51 4  FSCN1  HUMAN Fascin 54.50/7.02 296.56 0.45 2 
LEG1  HUMAN Galectin-1 14.71/5.18 424.98 0.49 3 Signal 
transduction CLIC1  HUMAN Chloride channel ABP 26.91/4.94 447.94 0.63 4 1433E  HUMAN 14-3-3 protein epsilon 29.16/4.48 400.71 0.66 3 
PRDX1  HUMAN Peroxiredoxin-1 22.10/9.22 689.77 0.55 7 
Redox 
homeostasis 
PRDX2  HUMAN Peroxiredoxin-2 21.88/5.59 238.11 0.65 5 
PRDX4  HUMAN Peroxiredoxin-4 30.52/5.85 367.60 0.34 2 
PRDX5  HUMAN Peroxiredoxin-5 22.01/9.93 522.84 0.60 2 
CBR1  HUMAN Carbonyl reductase [NADPH]1 30.36/9.53 467.30 0.59 2 
KCRB  HUMAN Creatine kinase B-type 42.62/5.25 711.33 1.67 4 
Metabolic 
process 
GSTP1  HUMAN Glutathione S-transferase P 23.34/5.32 1140.8 0.45 6 
GDIB  HUMAN Rab GDI beat 50.63/6.08 614.67 0.47 2 
DHSA  HUMAN Favoprotein subunit complex II 72.65/7.31 207.55 0.5 2 
ACBP  HUMAN Acyl-CoA-binding protein 10.04/6.16 135.03 0.64 2 
PHS  HUMAN PHS 2 11.99/6.33 170.64 0.43 3 
RL27A  HUMAN 60S ribosomal protein L27a 16.55/11.78 233.25 0.59 2 Translation RSSA  HUMAN 40S ribosomal protein SA 32.83/4.64 298.67 0.58 2 
IF4G1_HUMAN eIF-4-gamma 1 175.4/5.1 650.5 2.15 14 
NPM  HUMAN Nucleophosmin 32.55/4.49 444.46 0.52 2 DNA binding 
GRP78  HUMAN GRP78 72.29/4.92 1869.09 0.50 14 Chaperone binding CH10  HUMAN Hsp 10 10.92/9.44 219.29 0.40 3 
G6PI  HUMAN Glucose-6-phosphate isomerase 63.11/9.10 510.30 0.48 5 
Energy 
metabolism 
UGDH  HUMAN UDP-glucose 6-dehydrogenase 54.99/6.89 604.20 0.53 2 
PPIA  HUMAN Peptidyl-prolyl isomerase A 18.00/9.05 770.25 0.59 9 
ALDOA HUMAN Fructose-bisphosphate aldolase A 39.40/9.18 386.91 0.59 2 
PGK1  HUMAN Phosphoglycerate kinase 1 44.59/9.22 1020.8 0.50 6 
G3P  HUMAN GAPDH 36.03/9.26 1127.9 0.52 8 
IPYR  HUMAN Inorganic pyrophosphatase 32.64/5.47 485.51 0.45 3 
ENOA  HUMAN Alpha-enolase 47.14/7.71 1998.1 0.55 15 
CYTB  HUMAN Cystatin-B 11.13/7.85 144.98 0.43 2 
CPSM  HUMAN Carbamoyl-phosphate synthase 1 
164.83/6.3
0 3115.1 0.24 6 
PHB2  HUMAN Prohibitin-2 33.28/10.21 546.79 0.47 2 Transcription 
regulation CAND1_HUMAN TBP-interacting protein 120A 136.3/5.4 617.2 1.8 15 
PSME2 HUMAN Proteasome activator complex subunit2 27.34/5.33 367.19 0.48 2 Cell cycle 
MCM7_HUMAN DNA replication licensing factor MCM7 81.3/6.1 510.8 1.97 13 
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PSME2 HUMAN Proteasome activator complex subunit2 27.34/5.33 367.19 0.48 2 Cell cycle 
MCM7_HUMAN DNA replication licensing factor MCM7 81.3/6.1 510.8 1.97 13 
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Accession no. Protein name MW/PI Scores Ratio(T/N)
Matched 
peptides Functions 
ACADV HUMAN VLCAD 70.35/9.63 841.39 0.35 2 Lipid 
metabolism ATPA  HUMAN ATP5A1 59.71/9.61 963.07 0.47 5 THIL  HUMAN Acetoacetyl-CoA thiolase 45.17/9.63 330.39 0.45 2 
MIF  HUMAN Macrophage migration inhibitory factor 12.47/9.12 267.01 0.61 3 
Cytokine 
activity 
ATPB  HUMAN ATPB-3 56.52/5.14 1704.2 0.40 5 Ion transport 
VDAC1 HUMAN VDAC-1 30.75/9.22 548.36 2.32 2 Anion transport 
VPS35_HUMAN hVPS35 91.6/5.2 602.6 1.67 12 Protein transport 
HYOU1 HUMAN Hypoxia up-regulated protein 1 
111.27/5.0
2 1206.8 0.56 2 ATP binding 
SMD3  HUMAN Small nuclear ribonucleoprotein 3 
13.91/11.0
7 330.93 0.49 2 
mRNA 
processing 
Table 2. Differential proteins between immortalized and cancer cell lines derived from ESCC 
identified by SILAC-based proteomics 
selected Annexin A2 for validation by Western blot and IHC. Stepwise decrease in annexin 
A2 protein expression was observed when epithelial cell was transformed malignantly. In 
poorly-differentiated squamous carcinoma, 46% (5/11) of cancer tissue sample lost annexin 
A2 protein and 36% (4/11) expressed at weak intensity[Qi et al., 2007b]. In a separate study, 
IHC was used to determine 14-3-3σ in 60 cases of ESCC, nearby matched normal esophageal 
epithelium and a variety of ESCC precursor lesions. High level of 14-3-3σ expression was 
found ubiquitously in normal esophageal epithelium with an immuonstaining score of 8.22 
in expression. Protein 14-3-3σ was down-regulated stepwise during the multi-stage 
development of ESCC. Sixty-four percent of poorly-differentiated squamous cancer lost 14-
3-3σ expression with a score of 0.45[Qi et al., 2007a]. In agreement with our results, Ren et al. 
documented that the level of 14-3-3σ in terms of mRNA and protein was markedly down-
regulated in ESCC compared with nearby matched non-cancer tissues. Furthermore, 
decrease of 14-3-3σ expression was correlated with tumor infiltration depth, lymph node 
metastasis, distant metastasis and lymphovascular invasion and shorter 5-year survival 
rate[Ren et al., 2010]. Among the different proteins identified by SILAC-based quantitative 
analysis using immortal cell and cancer cell model, the clinical values of MIF in 
tumorigenesis of ESCC was determined as well. Not only the increased expression of MIF 
was detected in cellular protein but also in the conditioned medium of esophageal cancer 
cell lines EC1, EC109 and EC9706 compared with immortal cell lines NE3 and NE6. Low 
frequency and very weak expression of MIF was detected predominantly in basal cells in 
normal esophageal epithelium, with an immunostaining score of 1.13. Pronouncedly up-
regulated expression of MIF occurred in severe dysplasia compared with weak 
immunostaining in mild and moderate dysplasia. In ESCC, high frequency of intense 
expression of MIF was observed with a score of 5.46. Furthermore, high expression of MIF 
was significantly correlated with advanced clinical stages. ELISA tests revealed that there 
was an increase trend in serum level of MIF in clinically advanced stage IV compared to 
stage I-III. Functional studies on MIF indicated that MIF knockdown resulted in decrease in 
proliferation, clonogenicity, non-adherent growth and invasive potential. Our findings 
indicate that MIF may play crucial roles in malignant transformation of pathogenesis of EC 
and MIF could become a potential biomarker for high-risk population screening, assessment 
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of therapeutic efficiency, prognostic evaluation, and molecular targets of developing novel 
therapeutic regimen as well. In addition of our proteomic results in ESCC, several other 
reports have looked at the clinical value of potential biomarkers, including cytokeratin 14, 
Annexin I, SCCA1/2, calgulanulin B and HSP 60, alpha-actinin 4 and 67 kDa laminin 
receptor, cathepsin D and PKM2, periplakin, calreticulin and GRP78, galectin-7, anti-CD25B 
antibody[Dong et al., 2010; Du et al., 2007; Fu et al., 2007; Hatakeyama et al., 2006; Liu et al., 
2011; Nishimori et al., 2006; Zhu et al., 2010]. Nevertheless, further extensive studies are still 
necessary to determine the clinical utility of the identified proteins in tumorigenesis and 
progression of ESCC. 
3. Conclusions 
Nowadays, the dilemma for cancer control and management is not due to lack of efficient 
treatment options but diagnosis at late stages. In the case of ESCC in China, five-year 
survival rate for early stage tumor reaches around 90%[Hu et al., 2001]. Obviously, to detect 
tumor as early as possible is the key for reducing the mortality and morbidity of ESCC. It is 
believed that development of ESCC from normal esophageal epithelium takes at least about 
10 years, during which diseased epithelium manifests as basal cell hyperproliferation, 
dysplasia, carcinoma in situ in terms of morphology and finally evolves to malignant 
neoplasms. As such, carcinogenesis of ESCC is a multi-stage and dynamic process which 
accumulates ongoing changes at the level of both gene and protein expression.  
Proteomic studies from various research groups worldwide have identified distinct 
dysregulated protein expression pattern associated with ESCC. The discrepancy might 
reflect the different etiology, different stages of disease and diverse pathways involved, 
which makes identification of biomarkers for ESCC difficult. In light of a wealth of potential 
biomarkers associated with ESCC identified so far in the exploratory phase, future large-
scale validation studies involving symptom-free patients with precursor lesions in high-
incidence area and ESCC patients compared with controls are essential toward clinical 
application. Therefore, ultimate translation from laboratory into bedside for ESCC 
biomarkers will require close collaboration and cooperation between researchers and 
clinicians to look into the clinical utility in diagnosis at early stage, prognosis and 
monitoring treatment efficiency for ESCC. 
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1. Introduction 
1.1 Endothelial apoptosis and vascular remodeling 
Atherosclerotic diseases (AD) and immune-mediated vasculopathy of the transplanted 
organ (referred to as transplant vasculopathy (TV)) are both characterized by vessel wall 
thickening and fibrotic changes that lead to progressive vascular obliteration (Al-Lamki et 
al., 2008; Cailhier et al., 2006; Cornell et al., 2008; Mitchell, 2009; Rahmani et al., 2006; 
Valantine, 2003). The endothelium, positioned at the interface of blood flow and the vessel 
wall, serves as a physiological barrier and sensor of environmental stress. The “response to 
injury hypothesis“ proposed by Russell Ross in the 70’s suggested that endothelial injury 
prompts vascular smooth muscle cell (VSMC) migration and proliferation, therefore 
initiating neointima formation (Ross et al., 1977; Ross and Glomset, 1976). Initially, vascular 
remodeling is beneficial but repeated cycles of injury, proliferation and repair lead to 
maladaptive remodeling and lumen narrowing. To date, in vitro and in vivo studies in 
animals and humans confirmed that endothelial apoptosis is a key determinant in the 
development of AD and TV (Rossig et al., 2001). Various immune and non-immune factors, 
such as cytotoxic T-cells, donor-specific antibodies, high cholesterol and hyperglycemia 
account for increased endothelial apoptosis (Cailhier et al., 2006). In turn, migration and 
accumulation of VSMC, surviving and accumulating within a hostile environment through 
acquisition of an anti-apoptotic phenotype, form the initial neointima. Histological and 
biochemical features characterizing AD and TV include 1) extracellular matrix (ECM) 
degradation that likely facilitate VSMC migration; 2) acquisition of a synthetic and anti-
apoptotic phenotype by neointimal cells (VSMC), mesenchymal stem cells (MSC) and 
fibroblasts associated with Bcl-xl overexpression (Gennaro et al., 2004; Hirata et al., 2000; 
Pollman et al., 1998) and 3) differentiation of fibroblasts into myofibroblasts of importance in 
fibrogenic vascular changes (Tomasek et al., 2002) (Figure 1). The molecular interplay 
regulating intercellular communication between apoptotic endothelial cells (EC) and 
neointimal cells are only beginning to be unraveled. 
1.2 Proteomics for studying Post Mortem Signals (PMS) exported by apoptotic EC 
Apoptotic programmed cell death is classically considered a silent process. The first clues 
suggesting that apoptotic endothelial cells may not "go quietly" stems from pharmacological  
 
Proteomics – Human Diseases and Protein Functions 
 
274 
Trivers, K. F., Sabatino, S. A. & Stewart, S. L. (2008). Trends in esophageal cancer incidence 
by histology, United States, 1998-2003. Int J Cancer, Vol.123, No.6, (Sep 15), pp: 
1422-1428, ISSN 1097-0215 
Veale, R. B., Thornley, A. L., Scott, E., et al. (1988). Quantitation of autoantibodies to 
cytokeratins in sera from patients with squamous cell carcinoma of the oesophagus. 
Br J Cancer, Vol.58, No.6, (Dec), pp: 767-772, ISSN 0007-0920 
Venter, J. C., Adams, M. D., Myers, E. W., et al. (2001). The sequence of the human genome. 
Science, Vol.291, No.5507, (Feb 16), pp: 1304-1351, ISSN 0036-8075 
Wang, L. D., Wang, D. C., Zheng, S., et al. (2006). [Serum proteomic profiles of the subjects 
with esophageal precancerous and cancerous lesions from Linzhou, an area with 
high incidence of esophageal cancer in Henan Province, Northern China]. Ai Zheng, 
Vol.25, No.5, (May), pp: 549-554, ISSN 1000-467X 
Wang, L. D., Zhou, F. Y., Li, X. M., et al. (2010). Genome-wide association study of 
esophageal squamous cell carcinoma in Chinese subjects identifies susceptibility 
loci at PLCE1 and C20orf54. Nat Genet, Vol.42, No.9, (Sep), pp: 759-763, ISSN1546-
1718 
Wen, J., Zheng, B., Hu, Y., et al. (2010). Comparative proteomic analysis of the esophageal 
squamous carcinoma cell line EC109 and its multi-drug resistant subline 
EC109/CDDP. Int J Oncol, Vol.36, No.1, (Jan), pp: 265-274, ISSN 1791-2423 
Xu, S. Y., Liu, Z., Ma, W. J., et al. (2009). New potential biomarkers in the diagnosis of 
esophageal squamous cell carcinoma. Biomarkers, Vol.14, No.5, (Aug), pp: 340-346, 
ISSN 1366-5804 
Yang, C. S., Sun, Y., Yang, Q. U., et al. (1984). Vitamin A and other deficiencies in Linxian, a 
high esophageal cancer incidence area in northern China. J Natl Cancer Inst, Vol.73, 
No.6, (Dec), pp: 1449-1453, ISSN 0027-8874 
Zhou, G., Li, H., Gong, Y., et al. (2005). Proteomic analysis of global alteration of protein 
expression in squamous cell carcinoma of the esophagus. Proteomics, Vol.5, No.14, 
(Sep), pp: 3814-3821, ISSN 1615-9853 
Zhu, X., Ding, M., Yu, M. L., et al. (2010). Identification of galectin-7 as a potential biomarker 
for esophageal squamous cell carcinoma by proteomic analysis. BMC Cancer, 
Vol.10, (Jun 15), pp: 290, ISSN 1471-2407 
13 
Multidimensional Proteomics for the 
Identification of Endothelial Post Mortem 
Signals of Importance in Vascular Remodeling 
Isabelle Sirois, Alexey V. Pshezhetsky and Marie-Josée Hébert 
Université de Montréal 
Canada 
1. Introduction 
1.1 Endothelial apoptosis and vascular remodeling 
Atherosclerotic diseases (AD) and immune-mediated vasculopathy of the transplanted 
organ (referred to as transplant vasculopathy (TV)) are both characterized by vessel wall 
thickening and fibrotic changes that lead to progressive vascular obliteration (Al-Lamki et 
al., 2008; Cailhier et al., 2006; Cornell et al., 2008; Mitchell, 2009; Rahmani et al., 2006; 
Valantine, 2003). The endothelium, positioned at the interface of blood flow and the vessel 
wall, serves as a physiological barrier and sensor of environmental stress. The “response to 
injury hypothesis“ proposed by Russell Ross in the 70’s suggested that endothelial injury 
prompts vascular smooth muscle cell (VSMC) migration and proliferation, therefore 
initiating neointima formation (Ross et al., 1977; Ross and Glomset, 1976). Initially, vascular 
remodeling is beneficial but repeated cycles of injury, proliferation and repair lead to 
maladaptive remodeling and lumen narrowing. To date, in vitro and in vivo studies in 
animals and humans confirmed that endothelial apoptosis is a key determinant in the 
development of AD and TV (Rossig et al., 2001). Various immune and non-immune factors, 
such as cytotoxic T-cells, donor-specific antibodies, high cholesterol and hyperglycemia 
account for increased endothelial apoptosis (Cailhier et al., 2006). In turn, migration and 
accumulation of VSMC, surviving and accumulating within a hostile environment through 
acquisition of an anti-apoptotic phenotype, form the initial neointima. Histological and 
biochemical features characterizing AD and TV include 1) extracellular matrix (ECM) 
degradation that likely facilitate VSMC migration; 2) acquisition of a synthetic and anti-
apoptotic phenotype by neointimal cells (VSMC), mesenchymal stem cells (MSC) and 
fibroblasts associated with Bcl-xl overexpression (Gennaro et al., 2004; Hirata et al., 2000; 
Pollman et al., 1998) and 3) differentiation of fibroblasts into myofibroblasts of importance in 
fibrogenic vascular changes (Tomasek et al., 2002) (Figure 1). The molecular interplay 
regulating intercellular communication between apoptotic endothelial cells (EC) and 
neointimal cells are only beginning to be unraveled. 
1.2 Proteomics for studying Post Mortem Signals (PMS) exported by apoptotic EC 
Apoptotic programmed cell death is classically considered a silent process. The first clues 
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remodeling, suggesting a paracrine role for the apoptotic endothelium in triggering 
pathways of importance in neointima formation (Cailhier et al., 2006; Choy et al., 2004a; 
Choy et al., 2004b; Shimizu et al., 2000a; Shimizu et al., 2000b, 2002a, b). Cell biology 
approaches supported this contention and showed that medium conditioned by apoptotic 
EC regulates the survival and differentiation of major cellular constituents of the vessel wall 
(Cailhier et al., 2006; Laplante et al., 2005; Raymond et al., 2004; Soulez et al., 2010). 
Execution of the apoptotic program relies mainly on post-translational modifications, such 
as protein-protein interactions, protein translocation and proteolysis that will set in motion 
the molecular pathways regulating the various phases of apoptosis (Thiede and Rudel, 
2004;Wang and Chen, 2011; Mahrus et al., 2008). The caspase family of cysteine proteases is 
central to the regulation of the various phases of apoptosis. Their activation in association 
with mitochondrial destabilization or extracellular death receptor activation leads to 
modifications in the architecture of intracellular organelles and fragmentation of the 
cytoskeleton, the ER and the nucleus (Taylor et al., 2008). Apoptosis triggers changes in the 
cell membrane including blebbing and extracellular exposure of PS of importance as a 
phagocyte recognition signal (Leroyer et al., 2008; Martinez et al., 2005; Pober and Sessa, 
2007; Verhoven et al., 1995). In addition, mounting evidence suggests that the apoptotic 
program also regulates the extracellular export of a finely regulated set of signals of 
importance in leukocyte trafficking, phagocytosis and coagulation (Bournazou et al., 2009; 
Lauber et al., 2003; Truman et al., 2008).  
The complete set of mediators released by a cell at a given time, defined as a secretome, 
can be decrypted through high-throughput methods based on mass-spectrometry. Use of 
technology focusing on post-transcriptional events bears special importance in dying cells 
where the various levels of molecular regulation depend on protein degradation, 
translocation and specific protein-protein interactions rather than gene transcription. 
Proteomics was instrumental in characterizing the complex mixture of several secretomes 
composed of both soluble and vesicular mediators including microparticles and exosomes 
(Mathivanan and Simpson, 2009). As illustrated by the following reports, large-scale 
mass-spectrometry also eased the identification of paracrine signals (lipids, proteins and 
microparticles) specifically enriched within the secretome of apoptotic cells. For example, 
apoptotic Burkitt lymphoma cells release lysophosphatidylcholine (LPC) through 
activated caspase-3 dependent mechanisms, which in turn favors recruitment of 
macrophages and clearance of apoptotic bodies (Lauber et al., 2003). Apoptotic MCF7 
epithelial cells secrete lactoferrin as a means of promoting migration of mononuclear 
leukocytes while inhibiting migration of polymorphonuclear leukocytes (Bournazou et al., 
2009). Apoptotic EC shed microparticles with potent immunogenic and pro-coagulant 
abilities (Smalley and Ley, 2008; Smalley et al., 2007). In sum, these proteomic-based 
reports suggested that a paracrine response embedded within the apoptotic program and 
herein referred to as post mortem signals (PMS), controls a finely orchestrated network of 
intercellular communication.  
In the following sections, we will highlight the advantage of different proteomic strategies 
for characterization of PMS released by apoptotic cells. The systematic analysis of the 
secretome of apoptotic EC is central to gain insights into novel mechanisms of intercellular 
communication of importance in TV and AD. Also, the characterization of endothelial 
apoptotic secretome represents a unique opportunity to identify biomarkers of the initial 
stage of vascular remodeling. 
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2. Studying the secretome of apoptotic EC: Methodological aspects 
2.1 In vitro experimental systems aimed at studying endothelial apoptosis 
Two major pathways, the intrinsic and extrinsic pathways, regulate the initiation of 
apoptosis. The intrinsic pathway is activated by metabolic disturbances, such as nutrient 
deprivation and oxidative stress, leading to mitochondrial permeabilization, release of 
cytochrome C and activation of caspase-9. The extrinsic pathway is activated by death 
receptors that, upon ligand-mediated activation, recruit an initiator caspase (ex. caspase-
8). The effector phase of apoptosis responsible for cleavage of key substrates that bring 
about the morphological changes of apoptosis is controlled by a common phase regulated 
by effector caspases (-3, -6, -7) (Taylor et al., 2008). Serum starvation (SS) is a classical 
inducer of the intrinsic apoptotic pathway in EC and offers several advantages for the 
characterization of an apoptotic secretome. First, four hours of SS in cultured EC induces 
sequentially mitochondrial permeabilization, activation of caspases -9 and -3, PARP 
cleavage and chromatin condensation characteristic of apoptotic cell death. The functional 
importance of caspase activation in SS-induced apoptosis was validated with caspase 
inhibitors (the pan-caspase inhibitor (ZVAD-FMK) and caspase-3 inhibitor (DEVD-FMK)) 
as well as small interfering RNA (siRNA) targeting caspase-3 (Sirois et al., 2011). Second, 
apoptosis induced by brief SS does not induce necrotic features and cell membrane 
permeabilization, as assessed by fluorescence microscopy with propidium iodide and 
evaluation of lactacte dehydrogenase (LDH) activity in medium conditioned by serum-
starved EC (Laplante et al., 2010; Sirois et al., 2011). The absence of necrosis in this system 
is an asset for studying secretory events in absence of uncontrolled leakage secondary to 
cell membrane damage. Finally, SS circumvents contamination of the secretome by 
residual components of culture medium (such as albumin) that could interfere with the 
identification of less abundant proteins specifically released by apoptotic EC downstream 
of caspase activation.  
2.2 Identification of endothelial PMS by multidimensional proteomics 
A comparative and multidimensional proteomic analysis was undertaken to characterize the 
secretome of apoptotic EC (Sirois et al., 2011) (Figure 2). Proteins specifically released by 
apoptotic EC were identified through comparison of the secretomes generated by equal 
numbers of serum-starved apoptotic EC (SSC-apo) and serum-starved EC in which 
apoptosis was blocked by the irreversible pan-caspase inhibitor ZVAD-fmk (SSC-no-apo). 
Cell media were cleared of cell debris and apoptotic blebs prior to proteomic analysis 
(Cailhier et al., 2008; Laplante et al., 2010; Sirois et al., 2011; Soulez et al., 2010). An 
equivalent amount of proteins were fractionated either by SDS-PAGE or by HPLC anion 
exchange chromatography followed by protein identification by MS/MS (Pshezhetsky et al., 
2007). The two comparative strategies were complemented by a functional approach aimed 
at identifying proteins with an anti-apoptotic activity on VSMC, therefore recapitulating 
induction of the neointimal anti-apoptotic phenotype (Raymond et al., 2004). Proteins 
present in SSC-apo were fractionated by ultrafiltration followed by ion-exchange FPLC. 
Eluted fractions were individually tested in vitro for their ability to inhibit apoptosis of 
VSMC and the fraction displaying a significant anti-apoptotic activity was further 
fractionated by SDS-PAGE followed by protein identification by LC-MS/MS. 
Computational analysis of the peptides identified by mass-spectrometry generated three 
lists built by the functional and the two semi-quantitative comparative approaches.  
Multidimensional Proteomics for the Identification of  




Fig. 2. Schematic representation of the experimental strategy for generating serum-free 
media (conditioned by equal EC numbers in equal volumes of serum-free media for 4 hours) 
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and depleted of cell debris and apoptotic blebs prior to fractionation. Multidimensional 
proteomics of the secretomes was performed using one functional and two comparative 
approaches. SSC-apo was fractionated by FPLC and each eluted fraction was tested for its 
anti-apoptotic activity in serum-starved VSMC. The fraction with the most significant 
activity was further separated by SDS-PAGE followed by silver staining and in-gel trypsin 
digestion. SSC-apo and SSC-no-apo proteins were also compared and fractionated by HPLC 
or SDS-PAGE prior to protein identification by mass-spectrometry analysis. Identification of 
specific components of the SSC-apo was achieved using stringent selection criteria. To be 
considered a specific component of the apoptotic secretome, the protein had to meet the 
following criteria: protein present in SSC-apo only; protein identified by 2 out of the 3 
proteomic approaches; protein of human origin. 27 proteins were identified and classified 
according to their mode of secretion and the presence of signal peptide, generating novel 
hypotheses that were further validated by cell biology methods. 
3. The caspase-specific endothelial secretome 
A targeted screening strategy was developed to focus on the proteins with the highest 
likelihood of representing caspase-specific secretome components of importance in vascular 
remodeling. 1300 proteins were identified by LC- MS/MS analysis, 2385 were detected by 
SDS-PAGE-MS/MS and 28 proteins were identified by the functional approach. To be 
considered a specific component of the secretome of apoptotic EC, identified proteins had to 
meet concomitantly the following criteria: 1) they had to be identified by at least 2 out of the 
3 different MS/MS approaches, 2) they had to be found exclusively in SSC-Apo, and 3) they 
had to be of human origin. According to these criteria, 27 proteins were classified as specific 
components of endothelial apoptotic secretome  (Table 1) (Sirois et al., 2011). In the 
following section we will describe some of the observed changes and discuss the potential 
function of this apoptotic secretome. 
3.1 Enrichment of proteins associated with non-classical modes of secretion 
Most proteins that are directed to the cell surface or the extracellular space through a 
conventional secretory pathway contain a signal peptide (Nickel and Rabouille, 2009). 
Recent evidence suggests alternative modes of secretion for leaderless proteins, i.e. proteins 
without a signal peptide (Schotman et al., 2008) (Nickel and Rabouille, 2009). To define the 
contribution of classical and non-classical secretory pathways during apoptotic cell death, 
the 27 specific constituents of the endothelial apoptotic secretome were classified according 
to the presence of a signal peptide in their primary amino acid sequence, their mode of 
secretion, and their intracellular distribution (Table 1). This analysis showed that 25 out of 
the 27 proteins appeared to be associated with non-classical modes of secretion, based on 
recent literature and/or the absence of a secretion signal. 13 out of the 27 proteins were 
previously identified as a component of exosomal nanovesicles. Reevaluation of the 
comparative and functional proteomic results identified ten additional exosomal proteins in 
SSC-apo only, whereas only two exosomal proteins were identified in SSC-no-apo (Sirois et 
al., 2011). Finally, 4 proteins (Table 1 group 2) were annotated as potential components of 
exosome-like nanovesicles in other cell types. In total, 31 proteins associated with exosome-
like nanovesicles were considered to be specific components of the secretome of apoptotic 
EC. 
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Abbreviations: Mem: Membranne; V.E.: endocytic pathway including endosomes, MVB and lysosomes; 
C: cytoplasmic; N: nuclear, Ext.:  Identified in the extracellular milieu; N.D.: information non available; 
Mito: mitochondria; WPBs: Weibel Palade Bodies;  **: shedding; Sec. Gran. : Secretory granules 
Table 1. Specific components of the apoptotic secretome (SSC-apo) regrouping 27 mediators 
selected according to stringent criteria (see Figure 2 and the text). Proteins were listed 
according to their mode of secretion, the presence of a signal peptide and their intracellular 
localization. Classical type of secretion was defined as a protein containing a signal peptide 
with secretion mechanism described in the literature. Non-classical type of secretion was 
defined by the absence of a signal peptide or by reports describing their non-classical secretion.  
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Initially characterized by Rose Johnstone in the 80’s, exosomes are now recognized as 
important intercellular carrier devices detected in most biological liquids including plasma 
and urine as well as in the media of cultured mammalian cells (Mathivanan et al., 2010; Pan 
and Johnstone, 1983; Pan et al., 1985). These nanovesicles with a diameter ranging for 50-100 
nm are generated from inward budding of multivesicular bodies (MVB). Exosomes contain 
proteins of the MVB machinery including TSG101 and Alix, both considered classical exosome 
markers (Keller et al., 2006; Thery et al., 2002). Exosomes express MHC class I and II associated 
proteins and play important role in the innate immune system and in antigen presentation 
(Thery et al., 2009). They also contain different cargos including proteins, lipids, microRNAs 
and mRNA (Valadi et al., 2007). Their extracellular release stems from the fusion of MVB with 
the cell membrane but the molecular regulation of MVB exocytosis remains ill defined. A wide 
diversity of cell types have been shown to secrete exosomes but their protein composition 
appears to be cell specific and/or dependent on the metabolic state of the cell.  
Guided by the proteomic results, we hypothesized that apoptotic cells release nanovesicle-
associated mediators and that this process was triggered by caspase activation. This 
hypothesis was further validated by several biochemical techniques, cell biology approaches 
and electron microscopy (Sirois et al., 2011). Apoptotic nanovesicles were shown to express 
classical constituents of exosomes. Electron microscopy with morphometry analysis 
demonstrated that secreted nanovesicles are structurally and functionally distinct from 
apoptotic bodies and represent a novel entity of potential significance in vascular remodeling.  
3.1.1 Nanovesicular PMS as novel anti-apoptotic factors exported by apoptotic EC 
Translationally Controlled Tumour Protein (TCTP) was identified by both functional and 
comparative proteomics in SSC-apo (Table 1, group 1). TCTP is an evolutionarily conserved 
protein of crucial importance during development (Chen et al., 2007) and for intracellular 
inhibition of apoptosis (Telerman and Amson, 2009). TCTP does not contain a secretion 
peptide signal and its extracellular export depends on the exosomal pathway (Amzallag et 
al., 2004; Lespagnol et al., 2008). Using electron microscopy in association with immunogold 
labeling we showed that TCTP was present on the outer surface of endothelial apoptotic 
nanovesicles (Sirois et al., 2011). Caspase-activated apoptotic VSMC and fibroblasts also 
released TCTP-positive nanovesicles in association with apoptosis, suggesting that this 
pathway is active in various cellular components of the vessel wall. TCTP was found to play 
a central role in the activation of an anti-apoptotic phenotype in neointimal cells. VSMC 
exposed to TCTP(+) apoptotic nanovesicles mounted a robust anti-apoptotic response 
whereas VSMC exposed to nanovesicles generated by TCTP-silenced EC failed to develop 
an anti-apoptotic phenotype. Collectively these results suggest that TCTP released by 
apoptotic nanovesicles is a novel and central inducer of resistance to apoptosis in VSMC and 
a biomarker of apoptotic endothelial nanovesicles. 
3.2 PMS characterized as biological mediators of vascular remodeling 
We further addressed the relevance of the secretome released by apoptotic EC in vascular 
remodeling. Since development of AD and TV depends initially on ECM degradation and 
phenotypical changes within neointimal cells (i.e. anti-apoptotic and fibrogenic), the list of 
proteins generated by the multidimensional proteomic strategy was screened for the 
presence of mediators sharing these biological functions. Functional studies on EC, VSMC, 
MSC and fibroblasts highlighted a multifunctional and biochemically complex paracrine 
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activity of the endothelial apoptotic secretome (Cailhier et al., 2008; Laplante et al., 2006; 
Raymond et al., 2004; Raymond et al., 2002; Sirois et al., 2011; Soulez et al., 2010).  
3.2.1 Anti-apoptotic PMS 
The importance of ECM proteolysis in association with endothelial apoptosis was 
highlighted by the identification of the C-terminal perlecan fragment referred to as LG3 by 
MS/MS and validated by western blot analysis (Raymond et al., 2004). This fragment 
induces a significant anti-apoptotic activity on MSC through alpha-integrin-dependent 
activation of the ERK1-2 pathway leading to Bcl-xl overexpression (Soulez et al., 2010). LG3 
also interacts with beta-integrins on fibroblasts to induce an anti-apoptotic response but the 
intermediate signaling component differs (Laplante et al., 2006). LG3–integrin interactions in 
fibroblasts leads to sequential activation of Src family kinases with downstream 
phosphatidylinositol 3-kinase (PI3K)-dependent induction of Bcl-xl (Laplante et al., 2006). In 
support of a functionally important role for LG3 in TV, increased LG3 urinary levels were 
reported in renal allograft recipients with chronic rejection (Goligorsky et al., 2007).  
Comparative and functional proteomics of media conditioned by apoptotic and non-apoptotic 
EC also revealed the presence of proteases, including ADAM17, ADMTS4, SPUVE, tPA and 
cathepsin L of potential importance in ECM proteolysis (Cailhier et al., 2008). The extracellular 
export of cathepsin L, which was validated by WB analysis and functional studies, was found 
to occur through caspase-3 dependent pathways and to play a central role in cleavage of 
perlecan and generation of the bioactive LG3 anti-apoptotic fragment (Cailhier et al., 2008). 
Apoptotic EC export a complex array of soluble and vesicular transport-assisted mediators 
sharing a common anti-apoptotic activity. Interestingly, these mediators target differentially 
the cellular components of the vascular wall through non-redundant signaling mechanisms, 
adding specificity to the secreted signals.  
3.2.2 Fibrogenic PMS 
Vascular remodeling is associated with fibrogenic changes characterized by the accumulation 
of myofibroblasts within the vessel wall. Myofibroblasts represent a differentiated and 
activated subset of fibroblasts characterized by de novo expression of contractile stress fibers 
and alpha-smooth-muscle actin (α-SMA) and enhanced production of collagen I and II. The 
accumulation of myofibroblasts plays an important role in myointimal thickening and 
vascular stiffness characteristic of AD and TV. The fibrogenic mediator Connective Tissue 
Growth Factor (CTGF) was identified with an abundance ratio of 2.5 in medium conditioned 
by apoptotic EC as compared with medium conditioned by non-apoptotic EC (Laplante et al., 
2010). Western blotting confirmed that caspase activation significantly increased the release of 
CTGF by EC during apoptosis. The central importance of CTGF in the fibrogenic response 
triggered by the endothelial secretome was highlighted by injecting mice sub-cutaneously with 
medium conditioned by apoptotic or non-apoptotic EC. A significant fibrogenic response with 
increased skin thickness and enhanced production of collagen I developed in mice injected 
with medium conditioned by apoptotic EC. Also, CTGF immunodepletion abrogated the 
fibrogenic activity of medium conditioned by apoptotic EC.  
3.2.3 PMS with potential biological activity on vascular repair 
Besides PMS characterized and described above, other components of the secretome 
released by apoptotic EC are potential regulators of vascular remodeling. PLA2G2D was 
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3.2 PMS characterized as biological mediators of vascular remodeling 
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presence of mediators sharing these biological functions. Functional studies on EC, VSMC, 
MSC and fibroblasts highlighted a multifunctional and biochemically complex paracrine 
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activity of the endothelial apoptotic secretome (Cailhier et al., 2008; Laplante et al., 2006; 
Raymond et al., 2004; Raymond et al., 2002; Sirois et al., 2011; Soulez et al., 2010).  
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export of cathepsin L, which was validated by WB analysis and functional studies, was found 
to occur through caspase-3 dependent pathways and to play a central role in cleavage of 
perlecan and generation of the bioactive LG3 anti-apoptotic fragment (Cailhier et al., 2008). 
Apoptotic EC export a complex array of soluble and vesicular transport-assisted mediators 
sharing a common anti-apoptotic activity. Interestingly, these mediators target differentially 
the cellular components of the vascular wall through non-redundant signaling mechanisms, 
adding specificity to the secreted signals.  
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and alpha-smooth-muscle actin (α-SMA) and enhanced production of collagen I and II. The 
accumulation of myofibroblasts plays an important role in myointimal thickening and 
vascular stiffness characteristic of AD and TV. The fibrogenic mediator Connective Tissue 
Growth Factor (CTGF) was identified with an abundance ratio of 2.5 in medium conditioned 
by apoptotic EC as compared with medium conditioned by non-apoptotic EC (Laplante et al., 
2010). Western blotting confirmed that caspase activation significantly increased the release of 
CTGF by EC during apoptosis. The central importance of CTGF in the fibrogenic response 
triggered by the endothelial secretome was highlighted by injecting mice sub-cutaneously with 
medium conditioned by apoptotic or non-apoptotic EC. A significant fibrogenic response with 
increased skin thickness and enhanced production of collagen I developed in mice injected 
with medium conditioned by apoptotic EC. Also, CTGF immunodepletion abrogated the 
fibrogenic activity of medium conditioned by apoptotic EC.  
3.2.3 PMS with potential biological activity on vascular repair 
Besides PMS characterized and described above, other components of the secretome 
released by apoptotic EC are potential regulators of vascular remodeling. PLA2G2D was 
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enriched in the secretome of apoptotic EC (Table 1, Group 1) and recent evidence suggests 
that it could participate in vascular remodeling. PLA2G2D belongs to a family of secreted 
phospholipases (sPLA2), which catalyze hydrolysis of membrane glycerophospholipids to 
release fatty acids and lysophospholipids (Murakami et al., 2010). PLA2G2D secreted 
through the exosomal pathway favors intercellular transfer of inflammatory molecules, 
including prostaglandins (Subra et al., 2010). Tissue plasminogen activator (tPA) was also 
identified in the secretome of apoptotic EC (Table 1, Group 4) (Cailhier et al., 2008). Recent 
studies suggest that extracellular release of tPA fosters the development of fibrogenic 
changes (Edgtton et al., 2004; Hu et al., 2008b; Zhang et al., 2007). Convincing evidence also 
suggests a predominant role for tPA in atherosclerotic diseases (Gramling and Church, 
2010). In fibroblasts and myofibroblasts, tPA favors myofibroblast differentiation and 
induces anti-apoptotic phenotypes through phosphorylation of Bad and the inhibition of the 
intrinsic apoptotic pathway (Hu et al., 2008a). 
4. Conclusion 
Characterizing secretomes released by apoptotic cells implies inherent experimental 
challenges. Cell death is regulated by post-transcriptional events based on protein 
translocation and cleavage. Failure to take into consideration the importance of proteolysis, 
protein translocation and activation of non-classical secretion pathways during apoptosis 
will undermine the experimental strategy. The type of initiating apoptotic signal and the 
phase of apoptosis to be studied should also guide the design of the proteomic strategy. 
Creative data mining based on a combination of technical and functional criteria is 
necessary to gain novel insights into the modes of intercellular communication associated 
with cell death. The use of a multidimensional proteomics was instrumental in 
characterizing the importance of caspase activation as a novel regulator of non-classical 
modes of secretion. It allowed us to demonstrate that apoptotic cells release apoptotic 
nanovesicles, a novel type of membrane vesicle distinct from apoptotic bodies and 
reminiscent of exosomes. Mediators of importance in vascular remodeling and of potential 
use as biomarkers of endothelial injury, such as TCTP, LG3, CTGF, cathepsin L, EGF, 
PLA2GD2 and tPA were also identified. Further analysis of the complex secretome of 
apoptotic cells, including biochemical and functional characterization of apoptotic blebs and 
nanovesicles, should provide further insights into the mechanisms of intercellular 
communication between dying cells and the local microenvironment.  
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1. Introduction 
Around 24 million of people worldwide have some kind of dementia, and most of them are 
diagnosed to suffer from Alzheimer's disease (AD). In fact, every seven second a new case of 
dementia is identified, arriving to the rate of 4,6 new million cases per year. It is expected 
that by 2040 over 80 million of people will be affected. Neurological diseases are therefore a 
major public health problem due to the rise in the aging population, only in Europe these 
disorders cover approximately 35% of the burden of all diseases. In economical terms, brain 
diseases in Europe cost a total of 386 billion of euros per year, with an average of 829€ per 
inhabitant. AD and other dementias represent the second-leading cause of brain disorders 
after affective ones and equal with addiction diseases (Wittchen and Jacobi, 2005). 
Altogether dementias, and in particular AD represent a huge socio-economical impact, not 
only regarding the cost from the pharmacological point of view but also familiar cares 
which increase in an alarming rate in the last stages of the disease. Worthy to mention is the 
role of the family during the progression of this kind of diseases, relatives have to watch the 
patient every moment above all during the first lapses of memory and some of them need 
psychological help to assume the situation and the change in their lifestyle. 
The incidence and prevalence of this group of diseases explain the need to understand 
mechanisms underlying dementia to uncover early and discriminative diagnostic markers 
as well as new therapeutic targets in order to improve the quality of life of these patients 
and the efficacy of the treatements. For these reasons research in AD is currently considered 
as a priority. At this time, the pharmacological treatments available aim to enhance the 
cognitive impairments once the disease is diagnosed, only cholinesterase inhibitors and one 
NMDA receptor antagonist are commercialized. Despite these products can alleviate the 
symptomatology, they are far away to constitute an effective remedy to cure or prevent the 
deleterious effect of the disease. In line of these observations, methods for improving 
diagnosis are needed, the search of biomarkers and neuroimaging techniques might help to 
support clinical diagnosis and detect the disease in the earliest stages. The identification of 
potential genetic and environmental risk factors as well as protective ones may provide a 
new window of action even if interventions at this level are more complex and controversial 
(Ballard C et al., 2011). 
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Despite AD covers between 60 to 80% of the causes of dementia, there are many other 
causes: vascular dementia, mixed dementia, dementia with Lewy bodies, Parkinson's 
disease, frontotemporal dementia, Creutzfeldt-Jakob disease, Huntington's disease and 
Wernicke-Korsakoff syndrome are some of them (http://www.alz.org). Current available 
diagnosis of AD is based mainly on the severity of cognitive impairments. However, even 
with the help of several neuroimaging techniques it is not simple to discriminate among AD 
and other age-related cognitive impairments. Unfortunately only an accurate diagnosis of 
AD can be reached after autopsy examination. Nonetheless, it is necessary and desirable to 
incorporate new biomarkers that are more sentitive, specific and may facilitate the diagnosis 
not only among the different disorders but also to discern the clinical progression (Seshadri 
S et al., 2011). 
As it is described along this chapter the field of proteomics provides a powerful tool, which 
might enable to identify new proteins for early diagnostic and potentially therapeutic 
targets in AD. It is also remarkable the mandatory use of animal models in order to 
elucidate new pathways involved in the pathogenesis. Transgenic mouse models provide 
biochemical modulable approches where in a dependent or independent way several 
parameters can be studied (Sowell RA et al., 2009). 
2. Historical input of proteomics to Alzheimer´s disease and other 
neurological disorders 
AD is a progressive neurodegenerative disorder that leads to dementia. This pathology is 
characterized by two histopathological features: senile plaques and neurofibrillary 
degeneration (NFD) (Alzheimer A et al., 1907). Senile plaques are an extracellular 
accumulation of amyloid deposits formed by Aβ peptide. Aβ is a small 39 to 43 amino acid 
peptide produced by the complex catabolism of a type I transmembrane glycoprotein 
precursor named amyloid precursor protein (APP). Despite in AD only 1% of the cases have 
a familial history or inherited, most of the mutations described are related to APP, presenilin 
1 (PSEN1), PSEN2 and SORL1 genes. Indeed the amyloid hypothesis of AD is considered 
almost like a dogma regarding the number of therapeutical research focused on this event 
(Hardy J and Selkoe DJ 2002). NFD has been consistently found in many neurodegenerative 
diseases among which the most prevalent is AD. Others include corticobasal degeneration 
(CBD), dementia pugilistica, fronto-temporal dementia with parkinsonism linked to 
chromosome 17 (FTDP-17), head trauma, Down syndrome, postencephalic parkinsonism, 
progressive supranuclear palsy (PSP), myotonic dystrophy (DM) and in Pick´s disease (Buee 
L et al, 2000). Nonetheless, the vast majority of studies have been performed in AD. 
At the molecular level NFD corresponds to the aggregation of hyper- and abnormally 
phophorylated Tau proteins into filaments referred to paired helical filaments (PHFs) (Brion 
JP et al., 1985; Ihara Y et al., 1986). The spatiotemporal distribution of NFD in the diseased 
human nervous system is well correlated with the clinical expression of cognitive deficits 
(Delacourte A et al., 1999). However, there is a long and clinically silent period during 
which the lesions slowly developed and progress in several brain areas and are yet clinically 
silent. Neuropathological studies show that NFD is already detected in locus coeruleus of 
some people under 30. Moreover, the entorhinal cortex of non-demented individuals aged 
over 50 years, and the hippocampus are also often affected. During the earliest stages of AD 
with cognitive functions impairment, NFD is quite specific, spreading from the 
hippocampal formation to the anterior, inferior, and mid temporal cortex. NFD follows a 
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stereotyped, sequential and hierarchical pathway. The progression is categorized into ten 
stages according to the brain regions affected: transentorhinal cortex (S1), entorhinal (S2), 
hippocampus (S3), anterior temporal cortex (S4), inferior temporal cortex (S5), medium 
temporal cortex (S6), polymodal-association areas (prefrontal, parietal inferior and temporal 
superior) (S7), unimodal areas (S8), primary motor (S9a) or sensory (S9b, S9c) areas and all 
neocortical areas (S10). Up to stage 6, the disease can be asymptomatic (Figure 1).  
 
 
Fig. 1. NFD evolution in AD and cognitive decline. Watches represent the perception of the 
objects depending on the stage of the disease. 
Despite tau proteins are heat stable, acid stable and very soluble in its native unfolded form 
(Cleveland DW et al., 1997), numerous methods have been used in order to dissect tau 
aggregates. First, PHFs in AD were initially observed by electron microscopy in 1963 (Kidd 
M. 1963). Then, in chronological order, Selkoe and collaborators described in 1982 a partial 
purification of PHFs from human brain tissue. PHFs showed a small solubility in urea, 
guanidine and detergents as sodium dodecyl sulphate (SDS), representing an example in 
neurons of a rigid intracellular polymer maybe as a consequence of covalent bonds that 
avoid a molecular separation by gel electrophoresis (Selkoe DJ et al., 1982). The first 
commonly used PHF preparation is that described by Nukina N and Ihara Y in 1985 and 
consists to have PHF in Sarkosyl insoluble fractions. Further purification of Sarkosyl pellets 
was described by Hasegawa and collaborators in 1992. Pellets were suspended in a small 
volume of 50 mM Tris-HCI (pH 7.6), and dissolved with 6 M guanidine HCI for further 
purification. The guanidine HCI suspension was centrifuged at 500,000 X g for 30 min on a 
TL100.3 microcentrifuge (Heckman). The supernatants were treated with iodoacetate after 
 
Proteomics – Human Diseases and Protein Functions 292 
Despite AD covers between 60 to 80% of the causes of dementia, there are many other 
causes: vascular dementia, mixed dementia, dementia with Lewy bodies, Parkinson's 
disease, frontotemporal dementia, Creutzfeldt-Jakob disease, Huntington's disease and 
Wernicke-Korsakoff syndrome are some of them (http://www.alz.org). Current available 
diagnosis of AD is based mainly on the severity of cognitive impairments. However, even 
with the help of several neuroimaging techniques it is not simple to discriminate among AD 
and other age-related cognitive impairments. Unfortunately only an accurate diagnosis of 
AD can be reached after autopsy examination. Nonetheless, it is necessary and desirable to 
incorporate new biomarkers that are more sentitive, specific and may facilitate the diagnosis 
not only among the different disorders but also to discern the clinical progression (Seshadri 
S et al., 2011). 
As it is described along this chapter the field of proteomics provides a powerful tool, which 
might enable to identify new proteins for early diagnostic and potentially therapeutic 
targets in AD. It is also remarkable the mandatory use of animal models in order to 
elucidate new pathways involved in the pathogenesis. Transgenic mouse models provide 
biochemical modulable approches where in a dependent or independent way several 
parameters can be studied (Sowell RA et al., 2009). 
2. Historical input of proteomics to Alzheimer´s disease and other 
neurological disorders 
AD is a progressive neurodegenerative disorder that leads to dementia. This pathology is 
characterized by two histopathological features: senile plaques and neurofibrillary 
degeneration (NFD) (Alzheimer A et al., 1907). Senile plaques are an extracellular 
accumulation of amyloid deposits formed by Aβ peptide. Aβ is a small 39 to 43 amino acid 
peptide produced by the complex catabolism of a type I transmembrane glycoprotein 
precursor named amyloid precursor protein (APP). Despite in AD only 1% of the cases have 
a familial history or inherited, most of the mutations described are related to APP, presenilin 
1 (PSEN1), PSEN2 and SORL1 genes. Indeed the amyloid hypothesis of AD is considered 
almost like a dogma regarding the number of therapeutical research focused on this event 
(Hardy J and Selkoe DJ 2002). NFD has been consistently found in many neurodegenerative 
diseases among which the most prevalent is AD. Others include corticobasal degeneration 
(CBD), dementia pugilistica, fronto-temporal dementia with parkinsonism linked to 
chromosome 17 (FTDP-17), head trauma, Down syndrome, postencephalic parkinsonism, 
progressive supranuclear palsy (PSP), myotonic dystrophy (DM) and in Pick´s disease (Buee 
L et al, 2000). Nonetheless, the vast majority of studies have been performed in AD. 
At the molecular level NFD corresponds to the aggregation of hyper- and abnormally 
phophorylated Tau proteins into filaments referred to paired helical filaments (PHFs) (Brion 
JP et al., 1985; Ihara Y et al., 1986). The spatiotemporal distribution of NFD in the diseased 
human nervous system is well correlated with the clinical expression of cognitive deficits 
(Delacourte A et al., 1999). However, there is a long and clinically silent period during 
which the lesions slowly developed and progress in several brain areas and are yet clinically 
silent. Neuropathological studies show that NFD is already detected in locus coeruleus of 
some people under 30. Moreover, the entorhinal cortex of non-demented individuals aged 
over 50 years, and the hippocampus are also often affected. During the earliest stages of AD 
with cognitive functions impairment, NFD is quite specific, spreading from the 
hippocampal formation to the anterior, inferior, and mid temporal cortex. NFD follows a 
 
The Microtubule-Dissociating Tau in Neurological Disorders 293 
stereotyped, sequential and hierarchical pathway. The progression is categorized into ten 
stages according to the brain regions affected: transentorhinal cortex (S1), entorhinal (S2), 
hippocampus (S3), anterior temporal cortex (S4), inferior temporal cortex (S5), medium 
temporal cortex (S6), polymodal-association areas (prefrontal, parietal inferior and temporal 
superior) (S7), unimodal areas (S8), primary motor (S9a) or sensory (S9b, S9c) areas and all 
neocortical areas (S10). Up to stage 6, the disease can be asymptomatic (Figure 1).  
 
 
Fig. 1. NFD evolution in AD and cognitive decline. Watches represent the perception of the 
objects depending on the stage of the disease. 
Despite tau proteins are heat stable, acid stable and very soluble in its native unfolded form 
(Cleveland DW et al., 1997), numerous methods have been used in order to dissect tau 
aggregates. First, PHFs in AD were initially observed by electron microscopy in 1963 (Kidd 
M. 1963). Then, in chronological order, Selkoe and collaborators described in 1982 a partial 
purification of PHFs from human brain tissue. PHFs showed a small solubility in urea, 
guanidine and detergents as sodium dodecyl sulphate (SDS), representing an example in 
neurons of a rigid intracellular polymer maybe as a consequence of covalent bonds that 
avoid a molecular separation by gel electrophoresis (Selkoe DJ et al., 1982). The first 
commonly used PHF preparation is that described by Nukina N and Ihara Y in 1985 and 
consists to have PHF in Sarkosyl insoluble fractions. Further purification of Sarkosyl pellets 
was described by Hasegawa and collaborators in 1992. Pellets were suspended in a small 
volume of 50 mM Tris-HCI (pH 7.6), and dissolved with 6 M guanidine HCI for further 
purification. The guanidine HCI suspension was centrifuged at 500,000 X g for 30 min on a 
TL100.3 microcentrifuge (Heckman). The supernatants were treated with iodoacetate after 
 
Proteomics – Human Diseases and Protein Functions 294 
reduction and fractionated on a TSK gel G-3000 SW column (7.8 X 600 mm, Tosoh) 
equilibrated with 6 M guanidine HCI in 10 mM phosphate buffer (pH 6.0), at a flow rate of 
1.0 ml/min. The TSK fractions contain full-length tau with unusually slow mobilities in 
SDS-PAGE. The second commonly used preparation is that of Greenberg and Davies: about 
50% of PHF immunoreactivity can be obtained in 27,200 x g supernatants following 
homogenization in buffers containing 0.8 M NaCl. Further enrichment was made by taking 
advantage of PHF insolubility in the presence of zwitterionic detergents and 2-
mercaptoethanol, then removal of aggregates by filtration through 0.45-microns filters, and 
sucrose density centrifugation. PHF-enriched fractions contained proteins of 57-68 kDa that 
displayed the same antigenic properties as PHFs. The next stept was to develop an amino 
acid sequencing technique for PHFs combining a purification and solubilization procedure. 
After electrophoresis the insoluble fraction presented identical amino acid composition 
despite successive electrophoresis. Electron microscopy confirmed no changes in PHFs 
structures for the insoluble fraction even after electrophoresis. Moreover, this insoluble 
fraction displayed immunoreactivity against purified PHFs antibodies. Almost totally 
solubilization for the insoluble part was achieved by increasing the time of electrophoresis 
till almost 35 h showing one predominant band at 66 kDa and three additional bands 
between 50 and 70 kDa (Vogelsang GD et al., 1990).  
Further studies based on the soluble and insoluble fractions after sucrose density gradient 
showed tau amino-terminal epitopes were more abundant in the soluble part and almost 
nonexistent in the insoluble one, in the other way around carboxy-terminal epitopes were 
observed in both fractions. These last observations pointed out the proteolytic degradation 
involved tau amino-terminal region and not in the carboxy-terminal part in the formation of 
PHFs in NFD (Ksiezak-Reding H et al., 1994). 
Apart from characterization of PHFs from the solubility point of view, the development of 
additional approaches as electronic microscopy has definitely contributed to elucidate their 
ultrastructure. For instance, scanning transmission electron microscopy (STEM) provides 
accurate measurements of samples purified from human tissue and allows quantitave 
comparison between aggregated and dispersed population (Ksiezak-Reding H et al., 2005). 
Information regarding the filamentous conformation contributes to uncover the 
phosphorylation role in their formation. PHFs display ultrastructural different 
characteristics in AD and other neurological disorders. One possible classification is 
according to the straight or twisted filaments, based on the width of them along the length. 
Particularly twisted filaments are more abundant in AD and straight ones in PSP and both 
can be easily differentiated in CBD.  
Along this section it has been described the main attempts to solubilize PHFs in order to 
clarify their composition, structure and their role in the aetiology in neurodegenerative 
disorders, mainly focused on AD. It can be considered that these were the first proteomics 
contribution to uncover the NFD progress involved in the cognitive impairments and loss of 
memory. In the next section we will discuss about the more modern and current proteomics 
methods and their application in the field of neurodegeneration. 
3. Proteomic methods 
Proteomics is the study of proteome, which are the whole set of proteins expressed by a genome 
of a cell, tissue or organism. So the analysis of a proteome is any study directed to level 
expression, degradation or post-translational modifications of proteins. Proteomics methods 
enable the identification and composition of these proteins from diverse biological samples.  
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Proteomics field may be divided into two main areas: protein profiling and functional 
proteomics. Profiling proteomics provides all the proteins of a sample, level of expression 
and global profile. At a functional level proteomics afford a lot of new and challenge 
pathways that may be related to disease aetiology and development of the symptoms. 
Identification of theses pathways and protein changes in expression or post-translational 
modifications might lead to a novel window of therapeutical targets. A better knowledge of 
the evolution in these proteins during the pathological process may also increase the 
accuracy for an early clinical diagnosis. In that sense, the most challenging discovery would 
be to find characteristic biomarkers of each disease and their modifications concerning the 
worsening of the symptoms during the progress of the illness. The study of the human brain 
proteome is one of the most challenging aspects in science during the last decades. Brain 
functions and their involvement in process like memory, behavior, and emotions in 
physiological as well as in pathological orchestration remain far from understood. 
Independently where samples come from tissue, cells or body fluids as cerebrospinal fluid 
(CSF), the extraction of proteins is the caput anguli in all experiments. It is mandatory to 
establish the brain area, neuronal population or affected region, which is object of study. 
Moreover, thanks to the enormous protocols available for protein isolation, it is possible to 
achieve material enough from subcellular regions such as mitochondria or lipid rafts. 
Nowadays it is very useful and worldwide use the microdissection that enables to select a 
homogenous tissue or neuronal population, using a laser-dissecting microscope. 
Noteworthy that proteome analysis is not always reliable, not only because of changes in the 
expression profile as a consequence of genomic modifications, but also due to variability in 
extraction protocols and the quality of the sample after autopsy. 
Proteomics analyses include two key steps, on one hand the separation and isolation of the 
protein to study and on the other hand the identification of proteins by mass spectrometry. 
In addition to separation and identification methods, there are also many well characterized 
technology to quantify protein as 2D differential gel electrophoresis (2D-DIGE), iTRAQ-
Isobaric Tags for Relative and Absolute Quantification or SILAC-Stable Isotope Labeling by 
Amino Acids. Proteomics and bioinformatic developing technologies run in pararell since it 
is not possible to achieve hight standards in protein quantification and reliable identification 
if softwares do not allow discriminating among the possible variants and erasing the 
background that all the experimental conditions generate. Filters and integrators constitutes 
a general paradigm for signal detection in biology (Ideker T et al., 2011). In any case the 
researcher owns the most powerful weapon that is the capacity to assume the feasibility of a 
biological data, it means how the system is constructed and the functions carried out. 
Software enables to have update database easily accessible on internet including genome, 
transcriptome, metabolome, interactome and of course proteome (Brewis IA and Brennan P, 
2010). There are several databases available for the research community dedicated to the 
analysis of protein sequences and structures, some of them are NCBI Peptidome, Expert 
Protein Analysis System (ExPASy), PeptideAtlas, the PRoteomics IDEntifications database 
(PRIDE) and Global Proteome Machine Database (GPMDB) (Vizcaíno JA et al., 2010). 
3.1 Identification methods 
Mass spectrometry (MS) is one of the most widespread developed analytical technique in 
biological sciences. Analysis of the amino acid sequence, tridimensional structure and 
characterization of post-translational modifications has allowed elucidating protein 
functions. Despite it is not the aim of this chapter it is useful to say that MS is also used in 
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DNA studies (Murray KK, 1996). MS is nowadays used in a large number of fields including 
from biochemistry to genome studies (Pandey A and Mann M, 2000). In combination with 
separation techniques, MS due to its sensitivity and speed may have an important role in 
identifying and monitoring biomarkers in physiological fluids as well as in drug discovery. 
This approach enables to identify therapeutic targets present at low concentrations in 
complex biological samples. 
From the theorical point of view MS is not a measure of the mass, indeed it is a mass-to-
charge (m/z) ratio of gas-phase ion. The values should be represented in terms of Daltons 
(Da) per unit of charge and the unit in the International System are Kilograms per Columb. 
In spite of the information obtained with this analysis is directly associated with the 
molecular weight and amount of protein, the results offered the possibility to acquire 
additional information as structural disposition (Zellner M et al., 2009). 
MS are composed by three different parts: an ionization source, a mass analyser and a 
detector. The development of this technique is strengthly linked to the introduction of new 
and more sensitive components in these equipments.  
Ionization source 
Ionization can be defined as any process by which electrically neutral compounds are 
converted into ions (electrically charged atoms or molecules). Samples must be ionised and 
transferred to the gas phase, as a consequence of this step sample is destroyed. Classically 
ionization takes places in two separate steps, one in which the sample is volatilized and 
another one where it is ionized. The improvement in ionization methods permits to ionise 
large, non-volatile and thermally labile biomolecules and convert them into a gas phase 
without dissociation (Chait BT and Kent SB, 1992). The importance of these improvements 
was awarded in 2002 by the Nobel Prize in Chemistry "for the development of methods for 
identification and structure analyses of biological macromolecules" with one half jointly to 
John B. Fenn and Koichi Tanaka "for their development of soft desorption ionisation 
methods for mass spectrometric analyses of biological macromolecules" and the other half to 
Kurt Wüthrich "for his development of nuclear magnetic resonance spectroscopy for 
determining the three-dimensional structure of biological macromolecules in solution". 
Electrospray ionization (ESI) and matrix-assisted laser desorption/ionization (MALDI) are 
the most worldwide ionization sources used nowadays. 
In ESI the ion transfer from the solution to the gas phase ocurrs at atmospheric pressure 
(Zellner M et al., 2009). It is a process by which an aerosol is generated between two 
electrodes through a capillary held at a high potential (classically 3–4 kV), ions are separated 
of the solvent and get into the mass analyser. This method does not present a limit of size of 
the molecule to ionize and it can be easily coupled to MS and liquid separation techniques. 
Another variation of ESI is nanospray that owns a higher ionisation efficacy and it is less 
sensible to salt contamination. ESI might be the technique of choice for the design and 
development of quenchers against α,β-unsaturated aldehydes that are strongly associated 
with the oxidative stress (Beretta G et al., 2008), it has been used for instance to identify a 
human T-cell activation RhoGTPase-activating protein in a high frequency electromagnetic 
field irradiation model to induce AD features (Chang IF and Hsiao HY, 2005), to identify 
phosphorylation sites on tau (Reynolds CH et al., 2008) and analysis of phospholipids in 
CSF of AD patients (Kosicek M et al., 2010). 
MALDI is maybe the most common ionization source used at the present time in proteomics 
era. Above all because it can be easily coupled to time-of-flight (TOF) mass analysers. 
 
The Microtubule-Dissociating Tau in Neurological Disorders 297 
MALDI was introduced by Hillenkamp and Karas and currently is like ESI a suitable 
technique to the study of complex biological samples (Hillenkamp F and Karas M, 1990). 
MALDI produces mostly singly charged ions by a pulsed-laser irradiation. Moreover, 
MALDI owns a really high sensibility with almost no sample wasting and no desalting 
process is necessary since it works at physiological concentration of salts. In addition, 
MALDI requires relatively cheap equipment and quite easy to handle. MALDI TOF mass 
spectrometry is the technique of choice for protein identification separated by two-
dimensional gel electrophoresis. MALDI TOF is widely used in the study of AD in different 
cellular compartment as synaptosomes proteins (Yang H et al., 2011), Aβ isoforms and their 
effect on tau phosphorylation in transgenic mouse model overexpressing Aβ1-40 and Aβ1-
42 (Mustafiz T et al., 2011), evalutation of a vaccine specifically targeting the pathological 
amino-truncated species of Aβ42 that induces the production of specific antibodies against 
pathological Aβ products (Sergeant N et al., 2003), the possible role of heavy metal as copper 
(II) in the formation of PHFs (Zhou LX et al., 2007), identification of lipids containing in the 
PHFs from human brain as phosphatidylcholine, cholesterol, galactocerebrosides and 
sphingomyelin (Gellermann GP, et al 2006), identification of post-translational changes of 
proteins involved in AD as JNK-interacting protein 1 that is hyperphosphorylated following 
activation of stress-activated and MAP kinases (D'Ambrosio C et al., 2006), enrichment of 
more truncated glycans in PHFs (Sato Y et al., 2001) and decrease in the expression of M2 
acetylcholine receptor (Zuchner T et al., 2005) are some examples. 
Mass analyser 
Once ions have been originated they are transported to the mass analyser region and 
separated according to their m/z. The election of one o the type of analyser will depend on 
their resolution, when more resolutive high capacity to defferentiate two close signals. Mass 
analysers available in the market are electric- and magnetic-field, depending on the way to 
separate the ions. The choise among them will depend on the application needed and the 
budget since each analyzer type has its strengths and weaknesses. Mass analysers systems 
are Quadrupoles, Sectors, Fourier transform cyclotrons and TOF. Quadrupole analysers are 
normally coupled to ESI ion sources and TOF analysers are often used with MALDI ion 
sources. Anyway, hybrid systems are also employed as ESI–TOF and MALDI–QTOF. 
TOF spectrometer separates ions based on their velocity with a theorical mass gap 
unlimitated. TOF consists basically of a flight tube in high vacuum where ions are 
accelerated with equal energies and fly along the tube with different velocities. The flight 
time is related to the m/z values of the ions. The combination of high m/z range and 
compatibility with pulsed-ionization methods has made TOF the most commonly used 
analyser for MALDI experiments. 
In Peptide Mass Fingerprinting approach gel-separated proteins are digested in the gel with 
a site-specific proteinase as trypsin (Hellman U et al., 1995). Then MS measurement of the 
cleavaged proteins is performed generally by MALDI TOF equipment. Finally Fingerprint 
peptides are compared to databases in which protein sequences have been already digested 
with the same proteinase. This is the method of choise for highthroughput identification of 
numerous samples. Moreover, robotic systems launched onto the market make possible the 
automation from detection spot in the gel till MS identification (Henzel WJ et al., 1993). 
Tandem Mass Spectrometry (MS/MS) is another identification method predominantly 
suitable for analysing complex samples and a routine method used in research. This 
technique permits the identification of unkown proteins by sequencing their peptides. 
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DNA studies (Murray KK, 1996). MS is nowadays used in a large number of fields including 
from biochemistry to genome studies (Pandey A and Mann M, 2000). In combination with 
separation techniques, MS due to its sensitivity and speed may have an important role in 
identifying and monitoring biomarkers in physiological fluids as well as in drug discovery. 
This approach enables to identify therapeutic targets present at low concentrations in 
complex biological samples. 
From the theorical point of view MS is not a measure of the mass, indeed it is a mass-to-
charge (m/z) ratio of gas-phase ion. The values should be represented in terms of Daltons 
(Da) per unit of charge and the unit in the International System are Kilograms per Columb. 
In spite of the information obtained with this analysis is directly associated with the 
molecular weight and amount of protein, the results offered the possibility to acquire 
additional information as structural disposition (Zellner M et al., 2009). 
MS are composed by three different parts: an ionization source, a mass analyser and a 
detector. The development of this technique is strengthly linked to the introduction of new 
and more sensitive components in these equipments.  
Ionization source 
Ionization can be defined as any process by which electrically neutral compounds are 
converted into ions (electrically charged atoms or molecules). Samples must be ionised and 
transferred to the gas phase, as a consequence of this step sample is destroyed. Classically 
ionization takes places in two separate steps, one in which the sample is volatilized and 
another one where it is ionized. The improvement in ionization methods permits to ionise 
large, non-volatile and thermally labile biomolecules and convert them into a gas phase 
without dissociation (Chait BT and Kent SB, 1992). The importance of these improvements 
was awarded in 2002 by the Nobel Prize in Chemistry "for the development of methods for 
identification and structure analyses of biological macromolecules" with one half jointly to 
John B. Fenn and Koichi Tanaka "for their development of soft desorption ionisation 
methods for mass spectrometric analyses of biological macromolecules" and the other half to 
Kurt Wüthrich "for his development of nuclear magnetic resonance spectroscopy for 
determining the three-dimensional structure of biological macromolecules in solution". 
Electrospray ionization (ESI) and matrix-assisted laser desorption/ionization (MALDI) are 
the most worldwide ionization sources used nowadays. 
In ESI the ion transfer from the solution to the gas phase ocurrs at atmospheric pressure 
(Zellner M et al., 2009). It is a process by which an aerosol is generated between two 
electrodes through a capillary held at a high potential (classically 3–4 kV), ions are separated 
of the solvent and get into the mass analyser. This method does not present a limit of size of 
the molecule to ionize and it can be easily coupled to MS and liquid separation techniques. 
Another variation of ESI is nanospray that owns a higher ionisation efficacy and it is less 
sensible to salt contamination. ESI might be the technique of choice for the design and 
development of quenchers against α,β-unsaturated aldehydes that are strongly associated 
with the oxidative stress (Beretta G et al., 2008), it has been used for instance to identify a 
human T-cell activation RhoGTPase-activating protein in a high frequency electromagnetic 
field irradiation model to induce AD features (Chang IF and Hsiao HY, 2005), to identify 
phosphorylation sites on tau (Reynolds CH et al., 2008) and analysis of phospholipids in 
CSF of AD patients (Kosicek M et al., 2010). 
MALDI is maybe the most common ionization source used at the present time in proteomics 
era. Above all because it can be easily coupled to time-of-flight (TOF) mass analysers. 
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MALDI was introduced by Hillenkamp and Karas and currently is like ESI a suitable 
technique to the study of complex biological samples (Hillenkamp F and Karas M, 1990). 
MALDI produces mostly singly charged ions by a pulsed-laser irradiation. Moreover, 
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amino-truncated species of Aβ42 that induces the production of specific antibodies against 
pathological Aβ products (Sergeant N et al., 2003), the possible role of heavy metal as copper 
(II) in the formation of PHFs (Zhou LX et al., 2007), identification of lipids containing in the 
PHFs from human brain as phosphatidylcholine, cholesterol, galactocerebrosides and 
sphingomyelin (Gellermann GP, et al 2006), identification of post-translational changes of 
proteins involved in AD as JNK-interacting protein 1 that is hyperphosphorylated following 
activation of stress-activated and MAP kinases (D'Ambrosio C et al., 2006), enrichment of 
more truncated glycans in PHFs (Sato Y et al., 2001) and decrease in the expression of M2 
acetylcholine receptor (Zuchner T et al., 2005) are some examples. 
Mass analyser 
Once ions have been originated they are transported to the mass analyser region and 
separated according to their m/z. The election of one o the type of analyser will depend on 
their resolution, when more resolutive high capacity to defferentiate two close signals. Mass 
analysers available in the market are electric- and magnetic-field, depending on the way to 
separate the ions. The choise among them will depend on the application needed and the 
budget since each analyzer type has its strengths and weaknesses. Mass analysers systems 
are Quadrupoles, Sectors, Fourier transform cyclotrons and TOF. Quadrupole analysers are 
normally coupled to ESI ion sources and TOF analysers are often used with MALDI ion 
sources. Anyway, hybrid systems are also employed as ESI–TOF and MALDI–QTOF. 
TOF spectrometer separates ions based on their velocity with a theorical mass gap 
unlimitated. TOF consists basically of a flight tube in high vacuum where ions are 
accelerated with equal energies and fly along the tube with different velocities. The flight 
time is related to the m/z values of the ions. The combination of high m/z range and 
compatibility with pulsed-ionization methods has made TOF the most commonly used 
analyser for MALDI experiments. 
In Peptide Mass Fingerprinting approach gel-separated proteins are digested in the gel with 
a site-specific proteinase as trypsin (Hellman U et al., 1995). Then MS measurement of the 
cleavaged proteins is performed generally by MALDI TOF equipment. Finally Fingerprint 
peptides are compared to databases in which protein sequences have been already digested 
with the same proteinase. This is the method of choise for highthroughput identification of 
numerous samples. Moreover, robotic systems launched onto the market make possible the 
automation from detection spot in the gel till MS identification (Henzel WJ et al., 1993). 
Tandem Mass Spectrometry (MS/MS) is another identification method predominantly 
suitable for analysing complex samples and a routine method used in research. This 
technique permits the identification of unkown proteins by sequencing their peptides. 
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MS/MS involved two steps of MS. In the first analyser ions with a desired m/z are 
separated (product ions) from the rest of the ions coming from the ionization source, and in 
the second type of analyser the mass spectrum is measured. Furthermore, MS/MS 
experiments improve the ratio signal/noise facilitating the resolution. 
The product ions can be used to find out the primary structure of the peptide but nowadays 
most efforts are directed towards identification of post-translational modifications. In the 
case of tau protein is particulary special, since phosphorylation provides an additional 
negative charge to the sample. This fact complicates the analysis by MS because of detection 
of phosphopeptides is highly dependant on the equipment used as well as the software 
applied to analyze the spectra. Moreover, the existence of several adjacent serine or 
threonine residues allows MS/MS not to attribute the exact position of a phophate group as 
a result of the fragmentation of the peptide data.  
The team of Hasegawa performed the earliest application for identification of Tau into PHFs. 
They used different fractions: purified PHF-tau, AD-soluble tau, or normal tau treated or not 
with alkaline phosphatase. The digests were applied to a Superspher Select B column (2.1 X 
125 mm, Merck) and eluted with a linear gradient of 4-48% acetonitrile in 0.1% trifluoroacetic 
acid in 20 min at a flow rate of 0.2 ml/min. Amino Acid Sequence and Mass Spectrometric 
Analyses of the API Peptides-Fractionated peptides were sequenced on an Applied 
Biosystems 477A Protein Sequencer equipped with an on-line 120A PTH Analyzer or on an 
Applied Biosystems 473A Protein Sequencer. Mass spectral analysis was performed on a PE-
SCIEX API 111 Hiomolecular Mass Analyzer (triple-stage quadrupole mass spectrometer) 
equipped with a standard atmospheric pressure ion source. Detailed comparison of peptide 
maps of PHF-tau and normal tau before and after dephosphorylation pointed to three 
anomalously eluted peaks which contained abnormally phosphorylated peptides, residues 
191-225,226-240,260-267, and 386-438, according to the numbering of the longest tau isoform. 
Protein sequence and mass spectrometric analyses localized Thr-231 and ser-235 as the 
abnormal phosphorylation sites and further indicated that each tau 1 site (residues 191-225) 
and the most carboxyl-terminal portion of the protein (residues 386-438) carries more than two 
abnormal phosphates. Ser-262 was also phosphorylated in a fraction of PHF-tau. Modifications 
other than phosphorylation, removal of the initiator methionine, and Nu-acetylation at the 
amino terminus and deamidation at 2 asparaginyl residues were found in PHF-tau, but these 
modifications were also present in normal tau (Hasegawa et al., 1992). 
NMR spectroscopy is an alternative to MS and it has been used to uncover physiological 
and pathological roles of tau protein. However, this is challenging since tau protein has 441 
amino acids and an unfavorable amino acid composition. Quantification of phosphorylated 
tau samples is complex and studies are being performed in vitro using recombinant kisases 
(Landrieu I et al., 2010). 
3.2 Separation methods 
Analysis of a sample is always a challenge, it depends on the origin and of the aim of the 
experiment. Separation of the components of a sample offers the possiblility to establish a 
pre-selection and to perform a study concerning parameters as molecular weight (MW) and 
isoelectric point (pI). The separation methods available today have the enormous advantage 
that they can be coupled to other quantification techniques, including in this way not only 
the identification of the protein of interest, but also it relative amount compared to the 
control conditions. During this section we will converse abouth two separation approaches 
such as bidimensional electrophoresis and liquid chromatography. 
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3.2.1 Two-dimensional gel electrophoresis in AD brain 
Two-dimensional gel electrophoresis (2D) is one of the most often-used separation methods 
in proteomics since first description by O´Farrell PH in 1975. This approach combines two 
electrophoretic methods: in the first dimension proteins are separated on an immobilized 
pH gradient strip with isoelectric focusing and migrate to the point on the strip at which 
their net charge is zero or pI, and in the second dimension or SDS-PAGE, proteins are 
separated according to their MW and thus isolating isoforms and isovariants of a certain 
protein.  
This approache provides two kinds of information depending on the aim of the study. On one 
hand it can offer the global proteome profile with a high resolution containing nearly one 
thousand protein spots. However, the main limitation of the 2D is that several replicates of the 
same gel should be performed in order to reach statistically differences. The lack of a loading 
control makes complicated to rule out between differences in protein expression and loading 
variability among gels (Molloy MP et al., 2003). In addition, absence of an internal control for 
loading makes this approche very hand variable. On the other hand, this method is quite 
indicated if qualitative analysis is pointed out, ie if post-translational modifications are 
searched, the performance of a 2D western blot for two different conditions may supply 
changes in pI and /or MW. More specifically in the case of the tau protein, this method might 
give interesting data about the acidification or alkalinization as a consequence of 
phosphorylation process, which is the most common post-translational modification. For 
instance in figure 2 is shown 2D western blots for human total tau and phospho dependent 
AD2 antibodies in AD brain sample. Remarkably in the acidic part of the membrane it can be 
observed the characteristic triplet of phosphorylated tau (2A) in AD (60,64,69 kDa), while in 
the basic region all the tau isovariants dephosphorylated with postmorten delay are revealed 
(2B). Interestingly, in a recent study of our group it has been shown that the use of 2D may 
provide evidence that tau mutations dysregulate tau phosphorylation status. This event could 
be one of the first steps in the NFD cascade (Bretteville A et al., 2009). 
 
 
Fig. 2. 2D profiles of phospho-tau (A) and total tau (B) antibodies. Number 1 represents the 
hyperphosphorylated isovariants of tau while number 2 shows the low phosphorylated 
ones. Number 3 displays the native form of tau (Fernandez-Gomez FJ et al., personal 
unpublished data). 
3.2.2 Quantitative proteomics by Two-Dimensional Differential Gel Electrophoresis 
(2D-DIGE) 
2D-DIGE method is based on the same principle as “classical” 2D. The main differences rely 
on the fact that proteins are labeled with fluorescent dyes and all the samples are separated at 
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MS/MS involved two steps of MS. In the first analyser ions with a desired m/z are 
separated (product ions) from the rest of the ions coming from the ionization source, and in 
the second type of analyser the mass spectrum is measured. Furthermore, MS/MS 
experiments improve the ratio signal/noise facilitating the resolution. 
The product ions can be used to find out the primary structure of the peptide but nowadays 
most efforts are directed towards identification of post-translational modifications. In the 
case of tau protein is particulary special, since phosphorylation provides an additional 
negative charge to the sample. This fact complicates the analysis by MS because of detection 
of phosphopeptides is highly dependant on the equipment used as well as the software 
applied to analyze the spectra. Moreover, the existence of several adjacent serine or 
threonine residues allows MS/MS not to attribute the exact position of a phophate group as 
a result of the fragmentation of the peptide data.  
The team of Hasegawa performed the earliest application for identification of Tau into PHFs. 
They used different fractions: purified PHF-tau, AD-soluble tau, or normal tau treated or not 
with alkaline phosphatase. The digests were applied to a Superspher Select B column (2.1 X 
125 mm, Merck) and eluted with a linear gradient of 4-48% acetonitrile in 0.1% trifluoroacetic 
acid in 20 min at a flow rate of 0.2 ml/min. Amino Acid Sequence and Mass Spectrometric 
Analyses of the API Peptides-Fractionated peptides were sequenced on an Applied 
Biosystems 477A Protein Sequencer equipped with an on-line 120A PTH Analyzer or on an 
Applied Biosystems 473A Protein Sequencer. Mass spectral analysis was performed on a PE-
SCIEX API 111 Hiomolecular Mass Analyzer (triple-stage quadrupole mass spectrometer) 
equipped with a standard atmospheric pressure ion source. Detailed comparison of peptide 
maps of PHF-tau and normal tau before and after dephosphorylation pointed to three 
anomalously eluted peaks which contained abnormally phosphorylated peptides, residues 
191-225,226-240,260-267, and 386-438, according to the numbering of the longest tau isoform. 
Protein sequence and mass spectrometric analyses localized Thr-231 and ser-235 as the 
abnormal phosphorylation sites and further indicated that each tau 1 site (residues 191-225) 
and the most carboxyl-terminal portion of the protein (residues 386-438) carries more than two 
abnormal phosphates. Ser-262 was also phosphorylated in a fraction of PHF-tau. Modifications 
other than phosphorylation, removal of the initiator methionine, and Nu-acetylation at the 
amino terminus and deamidation at 2 asparaginyl residues were found in PHF-tau, but these 
modifications were also present in normal tau (Hasegawa et al., 1992). 
NMR spectroscopy is an alternative to MS and it has been used to uncover physiological 
and pathological roles of tau protein. However, this is challenging since tau protein has 441 
amino acids and an unfavorable amino acid composition. Quantification of phosphorylated 
tau samples is complex and studies are being performed in vitro using recombinant kisases 
(Landrieu I et al., 2010). 
3.2 Separation methods 
Analysis of a sample is always a challenge, it depends on the origin and of the aim of the 
experiment. Separation of the components of a sample offers the possiblility to establish a 
pre-selection and to perform a study concerning parameters as molecular weight (MW) and 
isoelectric point (pI). The separation methods available today have the enormous advantage 
that they can be coupled to other quantification techniques, including in this way not only 
the identification of the protein of interest, but also it relative amount compared to the 
control conditions. During this section we will converse abouth two separation approaches 
such as bidimensional electrophoresis and liquid chromatography. 
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3.2.1 Two-dimensional gel electrophoresis in AD brain 
Two-dimensional gel electrophoresis (2D) is one of the most often-used separation methods 
in proteomics since first description by O´Farrell PH in 1975. This approach combines two 
electrophoretic methods: in the first dimension proteins are separated on an immobilized 
pH gradient strip with isoelectric focusing and migrate to the point on the strip at which 
their net charge is zero or pI, and in the second dimension or SDS-PAGE, proteins are 
separated according to their MW and thus isolating isoforms and isovariants of a certain 
protein.  
This approache provides two kinds of information depending on the aim of the study. On one 
hand it can offer the global proteome profile with a high resolution containing nearly one 
thousand protein spots. However, the main limitation of the 2D is that several replicates of the 
same gel should be performed in order to reach statistically differences. The lack of a loading 
control makes complicated to rule out between differences in protein expression and loading 
variability among gels (Molloy MP et al., 2003). In addition, absence of an internal control for 
loading makes this approche very hand variable. On the other hand, this method is quite 
indicated if qualitative analysis is pointed out, ie if post-translational modifications are 
searched, the performance of a 2D western blot for two different conditions may supply 
changes in pI and /or MW. More specifically in the case of the tau protein, this method might 
give interesting data about the acidification or alkalinization as a consequence of 
phosphorylation process, which is the most common post-translational modification. For 
instance in figure 2 is shown 2D western blots for human total tau and phospho dependent 
AD2 antibodies in AD brain sample. Remarkably in the acidic part of the membrane it can be 
observed the characteristic triplet of phosphorylated tau (2A) in AD (60,64,69 kDa), while in 
the basic region all the tau isovariants dephosphorylated with postmorten delay are revealed 
(2B). Interestingly, in a recent study of our group it has been shown that the use of 2D may 
provide evidence that tau mutations dysregulate tau phosphorylation status. This event could 
be one of the first steps in the NFD cascade (Bretteville A et al., 2009). 
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3.2.2 Quantitative proteomics by Two-Dimensional Differential Gel Electrophoresis 
(2D-DIGE) 
2D-DIGE method is based on the same principle as “classical” 2D. The main differences rely 
on the fact that proteins are labeled with fluorescent dyes and all the samples are separated at 
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the same time in the same gel reducing spot pattern variability and the number of gels in an 
experiment. The reduction in number of gels during the manipulation increases the cost 
effectiveness and accurate spot matching. 2D-DIGE presents also the advantage that it is a 
quantitative approche since each protein spot has its own internal standard (IS), which ensure 
that the differences found are real and not due to a gel-to gel variation. Moreover, 2D-DIGE is 
a very sensitive technique with a detection threshold of around 1 femtomole of protein (Gong 
L et al., 2004). In the minimal labeling proteins are stained by cyanines, these dyes has a N-
hydroxysuccinimidyl ester reactive group which forms a covalent bond with the epsilon 
amino group of the lysine in proteins via an amide connection. The single positive charge of 
the cyanine replaces the single positive charge of the lysine and the pI of the protein is not 
altered. This labeling reaction is minimal since only affects between 1-3% of the lysine 
residues. Using different cyanines dyes as Cy2, Cy3 and Cy5 covalently coupled to one protein 
sample each, then they can be mixed and loaded in the same gel (Viswanathan S et al., 2006) as 
it is shown in figure 3. A pool of all the samples is labeled with Cy2 and in this way the 
loading variability among gel is reduced to about 7% (Tannu NS et al., 2006). Differences will 
be observed after measurement of the intensity of the fluorescence for each cyanine. The 2D 
analysis software using the IS achieves a fast detection of less than 10% of differences between 
samples with more than 95% of statistical confidence (Gharbi S et al., 2002). 
 
 
Fig. 3. Cy2, Cy3 and Cy5 merged (A) Cy2 labels IS (B) Cy3 pool of control (C) and Cy5 pool 
of AD samples (D). The software overlaps Cy2, Cy3 and Cy5 in order to establish the 
statistical differences among the replicates of the gels for each spot (Fernandez-Gomez FJ et 
al., personal unpublished data). 
Despite the fact that it is far less used, there is in the market another 2D-DIGE method called 
saturation labeling where only two cyanines are used. Cy3 is the pool of samples and it 
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constitute the IS and Cy5 is the sample object of study. In this technique saturation dyes 
have a maleimide reactive group, which is designed to form a covalent bond with the thiol 
group of cysteine residues on proteins via a thioether linkage, and a high dye-to-protein 
labeling ratio is required. This type of labeling approach tries to label all available cysteines 
on every protein. This method has the main inconvenient that only one sample can be 
loaded in a gel apart from the IS and not two sample like in the minimal labelling. The big 
adventage is that cyanines offer great sensitivity with detection over 5 orders of magnitude 
(Shaw J et al., 2003). 
The main limitation inherent to 2D method is that the gap of separation is among pH 3-10. 
As a consequence of this, poor solubilisation of highly acidic and basic proteins is reached. 
Proteins strongly attached to the biological membranes and samples with high 
concentration of salt own difficulty to be separated by isoelectric focusing, for this reason it 
is strong recommended to perform a purification step previous to the first dimension. 
2D-DIGE application accomplishes one of the new perpectives in the medical research. This 
approach is been widely used for many studys in neurodegenerative disorders including 
AD. 2D-DIGE has been utilized in the search for biomarkers in CSF in amyotrophic lateral 
sclerosis (Brettschneider J et al., 2008), in Creutzfeldt-Jakob disease (Brechlin P et al., 2008) in 
AD patients (Maarouf CL et al., 2009), in frontal cortex brain samples of AD (Müller T et al., 
2008) and in animal models. 
3.2.3 Quantitative proteomics by Liquid Chromatography linked to Mass Spectrometry 
(LC-MS) 
Liquid chromatography (LC) consist in separating proteins eluted from a LC column after 
the peptides are enzimatically digested, then they can be measured by MS. LC separation 
takes place when the sample components interact to a different extent with a mobile or 
stationary phase and elute at different times from this system. Normally several 
chromatographic systems are used in order to achieve a high resolution separation since 
only one system may not separate the complex mixture of peptides successfully. Then 
eluted fractions are undertaken to MS. The biggest adventage of LC coupled with MS is that 
this system presents a high-speed identification of the sample in an automatically way 
avoiding interindividual variability (Zellner et al., 2009). LC-MS is not a quantitative 
method per se, the peptide products coming from the proteolytic cleavage may alter the 
intensity of the signal in MS analysis due to their physicochemical characteristics. In order to 
discard this problem the use of stable isotopes has had a wide acceptance in the science 
community to achive accurancy in the quantification. The approach is based on the idea that 
a stable isotope-labeled peptide is chemically identical to its native counterpart and behaves 
identically during fractionation, digestion, chromatographic and MS analysis, but is 
distinguishable in a MS due to the mass diference. The ratio of signal intensities for the 
labeled and unlabeled peptide pairs provides an accurate measure of relative abundance of 
peptides from different samples. Stable isotopic tags can be introduced onto selective sites 
on peptides via metabolically, chemically, enzymatically, or provided by adding synthetic 
peptide standards to the sample. Strategies for isotope-based quantitative proteomics can be 
divided into two groups, depending on whether the isotopic tag is incorporated in vitro 
during sample preparation (iTRAQ, ICAT) or in vivo (SILAC) (Colucci-D´Amato et al., 2011). 
Isotope Coded Affinity Tagging (ICAT) reagents consist of an affinity biotin tag for selective 
purification, a linker that incorporates stable isotopes and an iodoacetamide group that 
specifically reacts with free thiol of cysteines. Proteins from two different samples are 
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the same time in the same gel reducing spot pattern variability and the number of gels in an 
experiment. The reduction in number of gels during the manipulation increases the cost 
effectiveness and accurate spot matching. 2D-DIGE presents also the advantage that it is a 
quantitative approche since each protein spot has its own internal standard (IS), which ensure 
that the differences found are real and not due to a gel-to gel variation. Moreover, 2D-DIGE is 
a very sensitive technique with a detection threshold of around 1 femtomole of protein (Gong 
L et al., 2004). In the minimal labeling proteins are stained by cyanines, these dyes has a N-
hydroxysuccinimidyl ester reactive group which forms a covalent bond with the epsilon 
amino group of the lysine in proteins via an amide connection. The single positive charge of 
the cyanine replaces the single positive charge of the lysine and the pI of the protein is not 
altered. This labeling reaction is minimal since only affects between 1-3% of the lysine 
residues. Using different cyanines dyes as Cy2, Cy3 and Cy5 covalently coupled to one protein 
sample each, then they can be mixed and loaded in the same gel (Viswanathan S et al., 2006) as 
it is shown in figure 3. A pool of all the samples is labeled with Cy2 and in this way the 
loading variability among gel is reduced to about 7% (Tannu NS et al., 2006). Differences will 
be observed after measurement of the intensity of the fluorescence for each cyanine. The 2D 
analysis software using the IS achieves a fast detection of less than 10% of differences between 
samples with more than 95% of statistical confidence (Gharbi S et al., 2002). 
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al., personal unpublished data). 
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constitute the IS and Cy5 is the sample object of study. In this technique saturation dyes 
have a maleimide reactive group, which is designed to form a covalent bond with the thiol 
group of cysteine residues on proteins via a thioether linkage, and a high dye-to-protein 
labeling ratio is required. This type of labeling approach tries to label all available cysteines 
on every protein. This method has the main inconvenient that only one sample can be 
loaded in a gel apart from the IS and not two sample like in the minimal labelling. The big 
adventage is that cyanines offer great sensitivity with detection over 5 orders of magnitude 
(Shaw J et al., 2003). 
The main limitation inherent to 2D method is that the gap of separation is among pH 3-10. 
As a consequence of this, poor solubilisation of highly acidic and basic proteins is reached. 
Proteins strongly attached to the biological membranes and samples with high 
concentration of salt own difficulty to be separated by isoelectric focusing, for this reason it 
is strong recommended to perform a purification step previous to the first dimension. 
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(LC-MS) 
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only one system may not separate the complex mixture of peptides successfully. Then 
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community to achive accurancy in the quantification. The approach is based on the idea that 
a stable isotope-labeled peptide is chemically identical to its native counterpart and behaves 
identically during fractionation, digestion, chromatographic and MS analysis, but is 
distinguishable in a MS due to the mass diference. The ratio of signal intensities for the 
labeled and unlabeled peptide pairs provides an accurate measure of relative abundance of 
peptides from different samples. Stable isotopic tags can be introduced onto selective sites 
on peptides via metabolically, chemically, enzymatically, or provided by adding synthetic 
peptide standards to the sample. Strategies for isotope-based quantitative proteomics can be 
divided into two groups, depending on whether the isotopic tag is incorporated in vitro 
during sample preparation (iTRAQ, ICAT) or in vivo (SILAC) (Colucci-D´Amato et al., 2011). 
Isotope Coded Affinity Tagging (ICAT) reagents consist of an affinity biotin tag for selective 
purification, a linker that incorporates stable isotopes and an iodoacetamide group that 
specifically reacts with free thiol of cysteines. Proteins from two different samples are 
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labeled with either light or heavy ICAT reagents obtaining a distinctive mass (eight or nine 
Da). To minimise the error, the labeled mixture of protein samples are combined, digested 
with protease to peptides and fractionated by multidimensional chromatography and 
analysed by LC-MS. The ratios of signal intensities of differentially mass-tagged peptide 
pairs are quantified to determine the relative levels of proteins in the two samples. An 
interesting application of this technique is for the redox proteomic since ICAT labels 
cysteine residues (Sethuraman M et al., 2004). However, this method is not suitable for 
quantifying proteins that do not contain enough residues of cysteine and it presents the 
limitation that only two samples can be done at once (Shiio Y and Aebersold R, R 2006). For 
this reason this approach is limited for studying of post-translational modifications and 
splice isoforms. 
Another amino group-based isotope labeling approach is isobaric tagging for relative and 
absolute protein quantification (iTRAQ). Unlike ICAT this method allows identification and 
quantification as well as comparison of up to eight conditions at the same time. This strategy 
has been developed in order to overcome the limitations of the previous one, so this method 
targets the peptide N-terminus of the residues (Ross PL et al., 2004). The iTRAQ reagent 
consists of a reporter group that is a tag with a specific mass in each individual reagent and 
a balance group to ensure that the reporter and balanced groups remain invariant without 
changing the mass. After collision-induced dissociation reporter ions spectra is correlating 
with the protein-sequence database and relative quantification of proteins with high 
accuracy is reached (Gevaert K et al., 2008). 
Stable Isotope Labeling by Amino Acids (SILAC) is a metabolic stable isotope labeling 
during cell growth and division in bacteria and afterwards was adapted to amino acids in 
cell cultures (Ong SE et al., 2002). SILAC is a simple procedure in which natural variants of 
essential amino acids are replaced by deuterated, carbon-13 or more currently by nitrogen-
15. Using nitrogen-15 the number of incorporate labels is defined and not dependent of the 
number of carbons that constitute the peptide sequence, this facilitates the analysis of the 
results. The advantage of this method relies on it accurate quantification since stable 
isotopes are incorporated very early in the sample. The main inconvenient of this technique 
is that isotopes can only be incorporated during protein synthesis. This is a huge limitation 
for the study of CSF and human brain tissue taking into account that neurons are post-
mitotic cells (Bantscheff M et al., 2007). Despite this handicap SILAC is a powerful tool to 
study cellular pathways as polyubiquitin involment in the aetiology of AD (Dammer EB et 
al., 2011), neuroinflamation (McGeer EG and McGeer PL, 2010), reactive microglia (Klegeris 
A et al., 2008), neurotrophin signaling (Zhang G et al., 2011), oxidative stress (Akude E et al., 
2011), TDP-43 proteinopathy in frontotemporal lobar degeneration and amyotrophic lateral 
sclerosis (Seyfried NT et al., 2010) mitochondrial alterations in dopaminergic cells (Jin J et 
al., 2007) and modulation of ion channels by phosphorylation (Park KS et al., 2006). 
Other methods for protein quantification are multiple reaction monitoring (MRM) that has 
been successfully used for low abundant proteins in plasma (Anderson L and Hunter CL, 
2006) and phosphopeptides quantification (Lange V et al., 2008). The absolute quantification 
of proteins (AQUA) technology uses a known quantity of heavy isotope labeled peptides as 
IS added as soon as possible in the analytical process (Kettenbach AN et al., 2011). 
3.2.4 Surface-enhanced laser desorption/ionization mass spectrometry 
Surface-enhanced laser desorption/ionization mass spectrometry (SELDI) method combines 
retention chromatography with MS detection, and it can be used in biological samples such 
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as cancer cells, CSF and tissue lysates. A few microliters of a sample of interest are deposited 
on the chromatographic surface. The protein chip arrays are incubated and then washed 
with a suitable buffer. SELDI protein chip surfaces are uniquely designed to retain proteins 
from complex mixtures according to their specific properties using chromatographic-based 
selectivity. The proteins of interest are captured on the chromatographic surface by 
adsorption, partition, electrostatic interaction or affinity chromatography depending on 
their properties, and analyzed by MS. SELDI is frequently coupled to MALDI-TOF and 
possess the significative advantage that minimal amount of sample is consuming and 
consequently not destroyed. 
The main application of this technique is in the search of biomarker in cancer as well as in 
neurodegenerative disorders. In the field of AD, SELDI has been used to find significantly 
higher levels of amyloid-beta peptides monomer and dimer in the blood of AD subjects 
compare to controls (Villemagne VL et al., 2010) and in CSF the enrichment in Aβ10-40 
paralleled by depletion of the fragment Aβ1-42 seems to be a common event in familial AD 
(Ghidoni R et al., 2009). 
4. Contribution of proteomics to Tauopathies classification 
Classification and characterization of neurodegenerative disorders have been one of the 
biggest achievements in proteomic field. Proteomics enable to separate, identify and study 
protein-protein interactions within the different pathologies. Nowadays the term 
tauopathies includes more than twenty well-characterized diseases. The high resolution 
separations of tau proteins in electrophoretic profiles as well as the immunoreactivity with a 
wide range of antibodies provide substantial information to discriminate among the 
different diseases. Major post-translational modification in tau proteins is phophorylation. 
For this reason vast of studies are focused on the role of this modification in the structure, 
function, pI and signalling pathways of tau proteins during the progression of the diseases. 
4.1 Tau proteins 
Tau (tubulin associated unit) is the major component of PHFs. Weingarten MD et al. described 
this protein for the first time in 1975 as an essential factor for the organization, stabilization, 
and dynamics of microtubules (Weingarten MD et al., 1975). Tau is essentially a neuronal 
phosphoprotein located within the axonal compartment (Butler M and Shelanski ML, 1986). 
Tau is prone to modulate the axonal transport and neuronal plasticity (Sergeant N et al., 2005). 
Recently, it has been established that tau regulates the motility of dynein and kinesin motors 
proteins by an isoform-dependent mechanism. Indeed, the shortest tau isoform lacking exon 2, 
3 and 10 impedes the motility of both kinesin and dynein whereas the longest tau isoforms 
with all exons less affects motor protein motility (Dixit R et al., 2008). Therefore, a modified 
pattern of tau isoform expression/ratio, due to tau aggregation for instance, may profoundly 
affect the axonal transport and could possibly lead to neurodegeneration (Crosby AH, 2003). 
Besides its known role as a microtubule-stabilizer and organizer, tau may exert several other 
functions as signalling pathway in neurons (Ittner LM et al., 2010 and Leugers CJ, 2010) and 
DNA protection under stress stimuli (Sultan A et al., 2011). 
A unique human tau (MAPT) gene is located on chromosome 17 at the band position 17q21. 
The restriction analysis and sequencing of the gene shows that it contains two CpG islands, 
one associated with the promoter region and the other with the exon 9 (Andriadis A et al., 
1992). The human tau primary transcript contains 16 exons and in the adult human brain, 
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has been developed in order to overcome the limitations of the previous one, so this method 
targets the peptide N-terminus of the residues (Ross PL et al., 2004). The iTRAQ reagent 
consists of a reporter group that is a tag with a specific mass in each individual reagent and 
a balance group to ensure that the reporter and balanced groups remain invariant without 
changing the mass. After collision-induced dissociation reporter ions spectra is correlating 
with the protein-sequence database and relative quantification of proteins with high 
accuracy is reached (Gevaert K et al., 2008). 
Stable Isotope Labeling by Amino Acids (SILAC) is a metabolic stable isotope labeling 
during cell growth and division in bacteria and afterwards was adapted to amino acids in 
cell cultures (Ong SE et al., 2002). SILAC is a simple procedure in which natural variants of 
essential amino acids are replaced by deuterated, carbon-13 or more currently by nitrogen-
15. Using nitrogen-15 the number of incorporate labels is defined and not dependent of the 
number of carbons that constitute the peptide sequence, this facilitates the analysis of the 
results. The advantage of this method relies on it accurate quantification since stable 
isotopes are incorporated very early in the sample. The main inconvenient of this technique 
is that isotopes can only be incorporated during protein synthesis. This is a huge limitation 
for the study of CSF and human brain tissue taking into account that neurons are post-
mitotic cells (Bantscheff M et al., 2007). Despite this handicap SILAC is a powerful tool to 
study cellular pathways as polyubiquitin involment in the aetiology of AD (Dammer EB et 
al., 2011), neuroinflamation (McGeer EG and McGeer PL, 2010), reactive microglia (Klegeris 
A et al., 2008), neurotrophin signaling (Zhang G et al., 2011), oxidative stress (Akude E et al., 
2011), TDP-43 proteinopathy in frontotemporal lobar degeneration and amyotrophic lateral 
sclerosis (Seyfried NT et al., 2010) mitochondrial alterations in dopaminergic cells (Jin J et 
al., 2007) and modulation of ion channels by phosphorylation (Park KS et al., 2006). 
Other methods for protein quantification are multiple reaction monitoring (MRM) that has 
been successfully used for low abundant proteins in plasma (Anderson L and Hunter CL, 
2006) and phosphopeptides quantification (Lange V et al., 2008). The absolute quantification 
of proteins (AQUA) technology uses a known quantity of heavy isotope labeled peptides as 
IS added as soon as possible in the analytical process (Kettenbach AN et al., 2011). 
3.2.4 Surface-enhanced laser desorption/ionization mass spectrometry 
Surface-enhanced laser desorption/ionization mass spectrometry (SELDI) method combines 
retention chromatography with MS detection, and it can be used in biological samples such 
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as cancer cells, CSF and tissue lysates. A few microliters of a sample of interest are deposited 
on the chromatographic surface. The protein chip arrays are incubated and then washed 
with a suitable buffer. SELDI protein chip surfaces are uniquely designed to retain proteins 
from complex mixtures according to their specific properties using chromatographic-based 
selectivity. The proteins of interest are captured on the chromatographic surface by 
adsorption, partition, electrostatic interaction or affinity chromatography depending on 
their properties, and analyzed by MS. SELDI is frequently coupled to MALDI-TOF and 
possess the significative advantage that minimal amount of sample is consuming and 
consequently not destroyed. 
The main application of this technique is in the search of biomarker in cancer as well as in 
neurodegenerative disorders. In the field of AD, SELDI has been used to find significantly 
higher levels of amyloid-beta peptides monomer and dimer in the blood of AD subjects 
compare to controls (Villemagne VL et al., 2010) and in CSF the enrichment in Aβ10-40 
paralleled by depletion of the fragment Aβ1-42 seems to be a common event in familial AD 
(Ghidoni R et al., 2009). 
4. Contribution of proteomics to Tauopathies classification 
Classification and characterization of neurodegenerative disorders have been one of the 
biggest achievements in proteomic field. Proteomics enable to separate, identify and study 
protein-protein interactions within the different pathologies. Nowadays the term 
tauopathies includes more than twenty well-characterized diseases. The high resolution 
separations of tau proteins in electrophoretic profiles as well as the immunoreactivity with a 
wide range of antibodies provide substantial information to discriminate among the 
different diseases. Major post-translational modification in tau proteins is phophorylation. 
For this reason vast of studies are focused on the role of this modification in the structure, 
function, pI and signalling pathways of tau proteins during the progression of the diseases. 
4.1 Tau proteins 
Tau (tubulin associated unit) is the major component of PHFs. Weingarten MD et al. described 
this protein for the first time in 1975 as an essential factor for the organization, stabilization, 
and dynamics of microtubules (Weingarten MD et al., 1975). Tau is essentially a neuronal 
phosphoprotein located within the axonal compartment (Butler M and Shelanski ML, 1986). 
Tau is prone to modulate the axonal transport and neuronal plasticity (Sergeant N et al., 2005). 
Recently, it has been established that tau regulates the motility of dynein and kinesin motors 
proteins by an isoform-dependent mechanism. Indeed, the shortest tau isoform lacking exon 2, 
3 and 10 impedes the motility of both kinesin and dynein whereas the longest tau isoforms 
with all exons less affects motor protein motility (Dixit R et al., 2008). Therefore, a modified 
pattern of tau isoform expression/ratio, due to tau aggregation for instance, may profoundly 
affect the axonal transport and could possibly lead to neurodegeneration (Crosby AH, 2003). 
Besides its known role as a microtubule-stabilizer and organizer, tau may exert several other 
functions as signalling pathway in neurons (Ittner LM et al., 2010 and Leugers CJ, 2010) and 
DNA protection under stress stimuli (Sultan A et al., 2011). 
A unique human tau (MAPT) gene is located on chromosome 17 at the band position 17q21. 
The restriction analysis and sequencing of the gene shows that it contains two CpG islands, 
one associated with the promoter region and the other with the exon 9 (Andriadis A et al., 
1992). The human tau primary transcript contains 16 exons and in the adult human brain, 
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alternative splicing of exons 2, 3 and 10 gives rise to six tau isoforms where exon 3 never 
appears independently of exon 2. Alternative splicing is regulated during development and 
differentially between tissues. A single isoform lacking the 3 alternative exons 2, 3 and 10 is 
expressed in the foetal brain. Exon 10 encodes an additional microtubule-binding motif 
numbered R1 to R4. Half of tau proteins contain three microtubule-binding motifs and the 
other halves have four microtubule-binding motifs (figure 4A). Constitutive exons are 1, 4, 5, 
7, 9, 11, 12 and 13 and the start codon is located in exon 1. There are two alternate stop 
codons located either following exon 13 or inside exon 14 (Andreadis A, 2005 and Sergeant 
N et al., 2008). Human brain tau isoforms have a range from 352 to 441 amino acids and a 
molecular weigth between 45 to 65 kDa in polyacrylamide gel electrophoresis (figure 4B). 
Primary sequence analysis of tau protein shows that it can be subdivided in four structural 
regions. The amino-terminal region is acidic and variable, depending on the presence or 
absence of exons 2/3 and a proline-rich domain follows it. The latter is followed by 3 or 4 
imperfect repeat motifs (R1 to R4; see figure 4A) - depending on the presence or absence of 
exon 10 - and corresponding to the microtubule-binding domain of tau. Finally, a short 
carboxy-terminal region is found and it is the basic region of the protein (figure 4C). 
 
 
Fig. 4. Six tau isoforms are presented in human brain. These isoforms differ by the absence 
or presence of one or two 29 amino acids inserts encoded by exon 2 (green box) and 3 (violet 
box) in the amino-terminal part. Exon 3 is always incorporated with exon 2. R2 corresponds 
to the presence of exon 10 (orange box) that encodes an additional microtubule-binding 
motif numbered R1 to R4 in the carboxy-terminal part and they are represented as black 
boxes. (A). Molecular weight in mono-dimensional electrophoresis for the six isoforms of 
tau (B) and tau protein regions corresponding to the full-length isoform (C).  
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The amino-terminal region together with the proline-rich domain is referred to as the 
“projection domain”. This unstructured and negatively charged region detaches from the 
surface microtubules (Hirokawa N et al., 1988) and can interact with the plasma membrane 
or cytoskeletal proteins (Brandt R et al., 1995). Tau may therefore contribute to spacing in 
between microtubule lattice and to the parallel ordered organization of microtubules in 
axons (Chen J et al., 1992). Amino-terminal region of tau also interacts with a growing panel 
of polypeptides including motor proteins such as kinesin-1 (Utton MA et al., 2005) and 
dynactin/dynein complex (Magnani E et al., 2007). All interacting polypeptides constitute 
the interactome of tau and indicate the functions in which tau may be implicated. The 
application of 2D gel electrophoresis method has been used to study tau (Janke C et al., 
1996). The six main isoforms of tau are separated as several isovariants with isoelectric 
points comprised between 9.5 and 6.5 due to the alternative splicing and to post-
translational modifications. The amino-terminal region has a pI of 3.8, proline domain has a 
pI of 11.4 and carboxy-terminal has a pI of 10.8. Regarding to the primary structure, the 
polypeptide sequences encoded by exons 2/3 add to tau acidity, whereas exon 10 encodes a 
positively charged sequence that adds to the basic character of tau. Thus tau is rather a 
dipole with two domains with opposite charge modulated either by post-translational 
modifications or tau proteolysis (Wischik CM et al., 1988). 
Tau stabilizes oligomers of tubulins, it is partially folded while interacting with 
microtubules and it was shown to link laterally protofilaments made of tubulin (Santarella 
RA et al., 2004). NMR investigations showed that residues between Val226 to Glu372 are 
binding to microtubule surface involving the all four repeat binding motifs showing that 
amino- and carboxy-terminal domains do not participate in the binding properties of tau 
to microtubules (Sillen A et al., 2007). Tau mutations like in FTDP may impair the binding 
of tau to microtubules (Delobel P et al., 2002). Regarding the physic-chemical properties of 
tau protein it has been addressed that tau protein owns pro-aggregative motifs called 
PHF6 and PHF6* in its carboxi-terminal region at the level of R2 and R3. The amino acids 
sequence of these motifs (306)VQIVYK(311) and (275)VQIINK(280) are prone to promote 
aggregation by the formation of beta-structure (von Bergen M et al., 2001). This 
aggregation and accumulation of misfolded proteins might have a common cause and 
pathological pathway in several neurodegenerative disorders resulting in neuronal loss 
(Tyedmers J et al., 2010). Several studies have revealed that truncated tau drive NFD in 
vivo (Zilka N et al., 2006) and caspase activation lead to tangles formation (de Calignon et 
al., 2010). 
4.2 Post-translational changes of Tau proteins 
Phosphorylation of tau is instrumental to NFD and it is the main post-translational 
modification in tau isovariants as it was shown by 2D immunoblots (Butler M and Shelanski 
ML, 1986). These data shed light to the impact of tau protein for tau biology. There are 85 
potential phosphorylation sites on the longest brain tau isoform. Phosphorylation sites were 
identified with proteomic approaches as MS, NMR, phospho-peptide mapping and the use 
of site-specific phosphorylation dependent tau antibodies (Hanger et al., 2007). Among them 
around 71 correspond to putative phosphorylation sites in physiological and pathological 
conditions. It is worthy to remark that most of the phosphorylation sites surround the 
microtubule-binding domains in the proline-rich region and carboxi-terminal region of tau. 
Phosphorylation regulates several functions of tau such as its binding to microtubules, the 
axonal transport of tau as well as its interactions with amino-terminal partners’ particularly 
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RA et al., 2004). NMR investigations showed that residues between Val226 to Glu372 are 
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amino- and carboxy-terminal domains do not participate in the binding properties of tau 
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aggregation and accumulation of misfolded proteins might have a common cause and 
pathological pathway in several neurodegenerative disorders resulting in neuronal loss 
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vivo (Zilka N et al., 2006) and caspase activation lead to tangles formation (de Calignon et 
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4.2 Post-translational changes of Tau proteins 
Phosphorylation of tau is instrumental to NFD and it is the main post-translational 
modification in tau isovariants as it was shown by 2D immunoblots (Butler M and Shelanski 
ML, 1986). These data shed light to the impact of tau protein for tau biology. There are 85 
potential phosphorylation sites on the longest brain tau isoform. Phosphorylation sites were 
identified with proteomic approaches as MS, NMR, phospho-peptide mapping and the use 
of site-specific phosphorylation dependent tau antibodies (Hanger et al., 2007). Among them 
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SH3-containing proteins (Rosenberg KJ et al., 2008). For instance, tau transport along the 
axon is negatively regulated by its phosphorylation by GSK3β leading to a reduced binding 
to kinesin-1 (Cuchillo-Ibanez I et al., 2008). By phosphorylating amino-terminal serines 212 
and 217, GSK3β also reduces the binding of SH3-containing proteins, such as Fyn, PLC-γ1, 
p85α (Reynolds CH et al., 2008). Once tau proteins are phosphorylated they cannot 
polymerize tubulin into microtubules and do not stabilize the latter.  
Tau phosphorylation is mainly regulated through kinases and phosphatases, but other 
enzymes are also involved, such as Pin1 isomerase (Buee L et al., 2000). A total of more than 
20 protein kinases can phosphorylate tau proteins (Sergeant N et al., 2008). This includes 
four groups of protein kinases. (a) Proline-directed protein kinases (PDPKs), which 
phosphorylate tau on serines or threonines that are followed by a proline residue. This 
group includes CDK1 and 5 (Hamdane M et al., 2003), MAPK and several SAPKs (Ferrer I et 
al., 2005). (b) The non-PDPK group includes tau-tubulin kinases 1 and 2, casein kinases 1 
and 2, DYRK1A (dual-specificity tyrosine-phosphorylated and –regulated kinase 1A), 
phosphorylase kinase, Rho kinase, PKA, PKB/Akt, PKC and PKN (Sergeant N 2005). (c) The 
third group includes protein kinases that phosphorylate tau on serine or threonine residues 
followed or not by a proline. GSK (glycogen synthase kinase) 3α and GSK3β and AGC 
kinases (such as MSK1 (mitogen- and stressactivated protein kinase) belong to this group 
and have recognition motifs SXXXS or SXXXD/E and RXRXXS/T respectively (Buée L et al., 
2010). (d) The fourth group corresponds to tyrosine protein kinases such as Src kinases, c-
Abl and c-Met (http://cnr.iop.kcl.ac.uk/hangerlab/tautable). The principal role of tau 
phosphorylation is related to microtubule binding. However, phosphorylation or 
dephosphorylation of tau may also contribute to the cell localization of tau. For instance, 
phosphorylation of tau by GSK3β regulates its axonal transport by reducing its interaction 
with kinesin. In sharp contrast, dephosphorylated tau is located to the cell nucleus and is 
suggested to contribute to nucleolar organization and/or contribute to chromosome 
stability. Mutations in TAU gene lead to a change in the affinity of kinases that 
phosphorylate tau near the site of the mutation. Some mutations like R406W may reduce the 
phosphorylation of tau at Ser404, which is necessary for GSK3-β to phosphorylate tau at 
Ser396 afterwards (Tatebayashi Y et al., 2006). However, this priming putative 
phosphorylation site is not a prerequisite for JNK3 to phosphorylate tau at Ser396. These 
data provide evidence that tau mutations may potentially modify the global phophorylation 
state of tau. 
Abnormal phospho sites on PHF-tau were identified on constitutive exons, such as Ser212–
214 together and Ser422. These three new sites were identified on the alternative sequence 
encoded by exon 2. As tau isoforms expression may be different in subneuronal 
populations, these phospho epitopes would be of interest in identifying such subneuronal 
populations or the laminar distribution of NDF in AD (Delacourte A et al., 1996). 
In normal brains the phospho-epitopes are rapidly dephosphorylate during postmorten 
delay, this effect may be due to the drop in ATP and inactivation of phophatases. However, 
in AD brains this dephosphorylatyon does not occur. Some of the hypotheses are that 
aggregation of tau proteins into filaments render them inaccessible to phosphatases, 
phosphatases are not activated any more or their activity is suddenly decreased. 
Other post-translational modification of tau proteins is O-glycosylation. O-glycosylation 
results from the attachment of a sugar on the hydroxyl radical of serine or threonine residue 
in the vicinity of the proline-rich domain. Glycosylation decreases tau phosphorylation by 
CDK5, PKA and and GSKβ, probably due to a competition between phosphorylation and 
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glycosylation for the same sites. In fact, tau proteins from AD brains present abnormally 
glycosylation in comparison with controls. Using a recombinant O-GlcNAc modified tau, 
MS has mapped O-GlcNAc on tau at Thr-123, Ser-400 sites and a third one on either Ser-409, 
Ser-412, or Ser-413 (Yuzwa SA et al., 2011). The identification of these sites may provide 
evidence to elucidate the role of glycosylation in tau function. 
The microtubule-associated protein tau is known to be post-translationally modified also by 
acetylayion. Recent studies reported that tau is acetylated and this acetylation avoids its 
degradation. Tau acetylation impares tau-microtubules interactions and facilitates tau 
aggregation. In fact, specific antibodies for acetylated tau showed an increase in acetylation in 
several Braak stages with the involment of histone acetyltransferase p300 and the deacetylase 
SIRT1 (Min SW et al., 2010). MS provides specific lysines within the microtubule-binding 
domain including lysine 280 (K280) that are main sites of tau acetylation. One model shows 
that K280 is exclusively acetylated in pathological conditions (Cohen TJ et al., 2011). 
4.3 Tau as a bar code for neurodegenerative diseases 
The most obvious pathological event in tauopathies is the presence of aggregates of tau 
isoforms into intraneuronal filamentous inclusions. The evolution in the proteomics era 
allows to establish different physiological and pathological electrophoretical patterns to 
distinguish among the diversity of tauopathies. Comparative biochemistry of tau aggregates 
differs in both isoform phosphorylation and content, which enables a molecular 
classification of tauopathies. In postmorten brain tissue tau proteins are resolved as six 
bands (figure 4B) whereas more acidic hyperphosphorylated isoforms present four bands 
between 60 and 74 kDa depending on the disorder (figure 5). The classification presented 
here is composed by five classes of tauopathies, depending on the type of tau aggregates 
that constitute the bar code for neurodegenerative diseases (Sergeant et al., 2005).  
Class 0: frontal lobe degeneration non-Alzheimer non-Pick 
Frontal lobe degeneration is the second more common presinile disorder that leads to 
dementia after AD. This class is genetically linked to mutations in the progranulin gene 
(Baker M et al., 2006 and Cruts M et al., 2006). Frontal lobe degeneration presents no specific 
neuropathological hallmarks, no tau aggregation and a loss of expression in tau proteins. 
The transactive response (TAR)-DNA-binding protein with a molecular weight of 43 kDa 
(TDP-43), encoded by the TARDBP gene, has been recently identified as a major 
pathological protein of frontotemporal lobar degeneration with ubiquitin-positive and tau-
negative inclusions. It is the most common underlying pathology in frontotemporal 
dementias with and without motor neuron disease. In fact TDP-43 pathology is identified 
till the 50% of AD cases and it is the main component in the amyotrophic lateral sclerosis 
(Wilson AC et al., 2011). This pathology from the clinical point of view is quite similar to 
Pick´s disease. It is characterized by a frontal distribution of morphologic changes involves 
neuronal cell loss, spongliosis and gliosis mainly in the superficial cortical layers of the 
frontal and temporal cortex (Delacourte A et al., 1977). 
Class I: all brain Tau isoforms are aggregated 
Class I is characterized by a pathological tau quartet at 60, 64 and 69 kDa, and a minor 
pathological tau at 72/74 kDa (figure 5). This pathological tau quartet corresponds to the 
aggregation of the six tau isoforms (Sergeant N et al., 1997b and Goedert M et al., 1992). The 
pathological tau 60 is composed of the shortest tau isoform (2–3-10-). The pathological tau 64 
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SH3-containing proteins (Rosenberg KJ et al., 2008). For instance, tau transport along the 
axon is negatively regulated by its phosphorylation by GSK3β leading to a reduced binding 
to kinesin-1 (Cuchillo-Ibanez I et al., 2008). By phosphorylating amino-terminal serines 212 
and 217, GSK3β also reduces the binding of SH3-containing proteins, such as Fyn, PLC-γ1, 
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suggested to contribute to nucleolar organization and/or contribute to chromosome 
stability. Mutations in TAU gene lead to a change in the affinity of kinases that 
phosphorylate tau near the site of the mutation. Some mutations like R406W may reduce the 
phosphorylation of tau at Ser404, which is necessary for GSK3-β to phosphorylate tau at 
Ser396 afterwards (Tatebayashi Y et al., 2006). However, this priming putative 
phosphorylation site is not a prerequisite for JNK3 to phosphorylate tau at Ser396. These 
data provide evidence that tau mutations may potentially modify the global phophorylation 
state of tau. 
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214 together and Ser422. These three new sites were identified on the alternative sequence 
encoded by exon 2. As tau isoforms expression may be different in subneuronal 
populations, these phospho epitopes would be of interest in identifying such subneuronal 
populations or the laminar distribution of NDF in AD (Delacourte A et al., 1996). 
In normal brains the phospho-epitopes are rapidly dephosphorylate during postmorten 
delay, this effect may be due to the drop in ATP and inactivation of phophatases. However, 
in AD brains this dephosphorylatyon does not occur. Some of the hypotheses are that 
aggregation of tau proteins into filaments render them inaccessible to phosphatases, 
phosphatases are not activated any more or their activity is suddenly decreased. 
Other post-translational modification of tau proteins is O-glycosylation. O-glycosylation 
results from the attachment of a sugar on the hydroxyl radical of serine or threonine residue 
in the vicinity of the proline-rich domain. Glycosylation decreases tau phosphorylation by 
CDK5, PKA and and GSKβ, probably due to a competition between phosphorylation and 
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glycosylation for the same sites. In fact, tau proteins from AD brains present abnormally 
glycosylation in comparison with controls. Using a recombinant O-GlcNAc modified tau, 
MS has mapped O-GlcNAc on tau at Thr-123, Ser-400 sites and a third one on either Ser-409, 
Ser-412, or Ser-413 (Yuzwa SA et al., 2011). The identification of these sites may provide 
evidence to elucidate the role of glycosylation in tau function. 
The microtubule-associated protein tau is known to be post-translationally modified also by 
acetylayion. Recent studies reported that tau is acetylated and this acetylation avoids its 
degradation. Tau acetylation impares tau-microtubules interactions and facilitates tau 
aggregation. In fact, specific antibodies for acetylated tau showed an increase in acetylation in 
several Braak stages with the involment of histone acetyltransferase p300 and the deacetylase 
SIRT1 (Min SW et al., 2010). MS provides specific lysines within the microtubule-binding 
domain including lysine 280 (K280) that are main sites of tau acetylation. One model shows 
that K280 is exclusively acetylated in pathological conditions (Cohen TJ et al., 2011). 
4.3 Tau as a bar code for neurodegenerative diseases 
The most obvious pathological event in tauopathies is the presence of aggregates of tau 
isoforms into intraneuronal filamentous inclusions. The evolution in the proteomics era 
allows to establish different physiological and pathological electrophoretical patterns to 
distinguish among the diversity of tauopathies. Comparative biochemistry of tau aggregates 
differs in both isoform phosphorylation and content, which enables a molecular 
classification of tauopathies. In postmorten brain tissue tau proteins are resolved as six 
bands (figure 4B) whereas more acidic hyperphosphorylated isoforms present four bands 
between 60 and 74 kDa depending on the disorder (figure 5). The classification presented 
here is composed by five classes of tauopathies, depending on the type of tau aggregates 
that constitute the bar code for neurodegenerative diseases (Sergeant et al., 2005).  
Class 0: frontal lobe degeneration non-Alzheimer non-Pick 
Frontal lobe degeneration is the second more common presinile disorder that leads to 
dementia after AD. This class is genetically linked to mutations in the progranulin gene 
(Baker M et al., 2006 and Cruts M et al., 2006). Frontal lobe degeneration presents no specific 
neuropathological hallmarks, no tau aggregation and a loss of expression in tau proteins. 
The transactive response (TAR)-DNA-binding protein with a molecular weight of 43 kDa 
(TDP-43), encoded by the TARDBP gene, has been recently identified as a major 
pathological protein of frontotemporal lobar degeneration with ubiquitin-positive and tau-
negative inclusions. It is the most common underlying pathology in frontotemporal 
dementias with and without motor neuron disease. In fact TDP-43 pathology is identified 
till the 50% of AD cases and it is the main component in the amyotrophic lateral sclerosis 
(Wilson AC et al., 2011). This pathology from the clinical point of view is quite similar to 
Pick´s disease. It is characterized by a frontal distribution of morphologic changes involves 
neuronal cell loss, spongliosis and gliosis mainly in the superficial cortical layers of the 
frontal and temporal cortex (Delacourte A et al., 1977). 
Class I: all brain Tau isoforms are aggregated 
Class I is characterized by a pathological tau quartet at 60, 64 and 69 kDa, and a minor 
pathological tau at 72/74 kDa (figure 5). This pathological tau quartet corresponds to the 
aggregation of the six tau isoforms (Sergeant N et al., 1997b and Goedert M et al., 1992). The 
pathological tau 60 is composed of the shortest tau isoform (2–3-10-). The pathological tau 64 
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and 69 are each composed of two tau isoforms: tau isoforms with either the exon 2 or exon 
10 alone compose the pathological tau 64, while the pathological tau 69 is made of tau 
isoforms with either exon 2 + 10 or 2 + 3. The longest tau isoform containing exons 2, 3 and 
10 (2 + 3 + 10) constitutes the 72/74-kDa pathological component, as determined by 2D gel 
electrophoresis coupled to western blotting using exon-specific tau antibodies (Sergeant N 
et al., 1997a). This typical tau profile was first characterized in AD, but now includes nine 
additional neurological disorders AD as cerebral aging (over 75 years), ALS/parkinsonism–
dementia complex of Guam, Parkinson with dementia of Guadeloupe, Niemann–Pick 
disease type C, Postencephalitic parkinsonism, Familial British dementia, Dementia 
pugilisticia, Down’s syndrome and FTDP-17. Using histochemistry, aggregates of this class 
can be observed with AD2 and antibodies against exon 2 and exon 10 (Buee L et al., 2000 
and Sergeant N et al., 2008). 
 
 
Fig. 5. Bar Code for neurodegenerative diseases. Schematic representation of the 
modifications leading to tau proteins aggregation in Tauopathies. Native tau proteins are 
detected as a triplet of bands ranging between 60 and 74 kDa by numerous 
phosphorylation-dependent antibodies. Tau proteins are shown by western blotting as three 
major bands between 60 and 69 kDa, and a minor band at 74 kDa. AD pattern is also found 
in Down’s syndrome, post-encephalitic parkinsonism, ALS/parkinsonism–dementia 
complex of Guam among others (class I). The doublet tau 64, 69 represent the aggregation of 
hyperphosphorylated tau isoforms with exon 10 (orange box) typical for CBP and CBD 
(class II), the exclusion of exon 10 (only black boxes) in hyperphosphorylated tau 
aggregation lead to tau 60, 64 doublet characteristic for Pick’s disease (class III). The 
aggregation of Tau isoforms lacking exons 2 (green box) and 3 (violet box) is found in 
myotonic dystrophy (class IV). 
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Class II: Tau isoforms containing the exon 10 encoding sequence aggregate 
Aggregation of tau proteins with four microtubule-binding domains is the characteristic of 
class II (figure 5). This pathological tau profile is observed in CBD, argyrophilic grain 
dementia, PSP and FTDP-17 due to tau gene mutations (Sergeant N et al., 1999 and Tolnay 
M et al., 2002). PSP, CBD and argyrophilic grain dementia are rare atypical parkinsonism 
disorders. 
Class III: Tau isoforms lacking the exon 10 encoding sequence aggregate 
This class of tauopathies includes Pick’s disease and autosomal dominant inherited FDTP-17 
(figure 5). Pick’s disease is a rare form of neurodegenerative disorder characterized by a 
progressive dementing process. Early in the clinical course, patients show signs of frontal 
disinhibition. Neuropathologically, Pick’s disease is characterized by the presence of typical 
spheroid inclusions in the soma of neurons called Pick bodies. Pick bodies are labeled by tau 
antibodies, with a higher density in neurons of the dentate gyrus of the hippocampal 
formation than in the temporal and frontal cortices. The pathological tau profile of Pick’s 
disease contrasts with that of class II tauopathies, with the pathological tau isoforms 
consisting essentially of the 3R tau isoforms.  
Immunohistologic staining of these aggregates is positive for AD2 and exon 2 antibodies but 
negative for exon 10 antibodies. In addition, aggregated tau proteins in Pick’s disease are 
not detected by the monoclonal antibody 12E8 raised against the phosphorylated residue 
Ser262/Ser356, whereas this phosphorylation site is detected in other neurodegenerative 
disorders. The lack of phosphorylation at Ser262 and Ser356 sites is likely to be related to 
either a kinase is not active in neurons that degenerate in Pick’s disease or those neurons do 
not constitutively express these kinases within degenerating neurons (Mailliot C et al., 1998). 
Class IV: Tau isoform lacking exon 2, 3 and 10 principally aggregate 
This group is represented by a single neurological disorder: myotonic dystrophy (DM) of 
types I and II (figure 5). DM is the commonest form of adult-onset muscular dystrophy. 
Genetically it is an inherited autosomal dominant disorder caused by a single gene mutation 
consisting of expansion of a CTG trinucleotide motif in the 3V untranslated of the myotonic 
dystrophy protein kinase gene (DMPK), located on chromosome 19q. It is a multisystemic 
disease affecting many systems as the central nervous system (cognitive and 
neuropsychiatric impairments), the heart, the genital tract, the eyes, the ears, gastrointestinal 
tract, endocrine system, thus leading to a wide and variable complex panel of symptoms 
(Meola G, 2000). Cognitive impairments, as memory, visuo-spatial recall and verbal scale, 
cortical atrophy essentially of the frontal and the temporal lobe and white matter lesions are 
often described in both DM1 and DM2 (Sansone V et al., 2007). 
Neuropathological lesions, as neurofibrillary tangles (NFTs), have been observed in adult 
DM1 individuals aged over 50 years. The pathological tau profile of DM1 is characterized by 
a strong pathological tau band at 60 kDa and, to a lesser extent, a pathological tau 
component at 64 and 69 kDa. This typical pathological tau profile is reflected by a reduced 
number of tau isoforms expressed in the brain of individuals with DM1, both at the protein 
and mRNA levels (Sergeant N et al., 2001). In addition, tau protein expression is also 
demonstrated to be altered in transgenic mice with human DM1 locus (Gomes-Pereira M et 
al., 2007). Using specific immunological probes against exon 2 and exon 3 corresponding 
amino acid sequences, the neurofibrillary lesions were shown to be devoid of tau isoforms 
with amino-terminal inserts (Maurage CA et al., 2005). An altered splicing of tau 
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and 69 are each composed of two tau isoforms: tau isoforms with either the exon 2 or exon 
10 alone compose the pathological tau 64, while the pathological tau 69 is made of tau 
isoforms with either exon 2 + 10 or 2 + 3. The longest tau isoform containing exons 2, 3 and 
10 (2 + 3 + 10) constitutes the 72/74-kDa pathological component, as determined by 2D gel 
electrophoresis coupled to western blotting using exon-specific tau antibodies (Sergeant N 
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additional neurological disorders AD as cerebral aging (over 75 years), ALS/parkinsonism–
dementia complex of Guam, Parkinson with dementia of Guadeloupe, Niemann–Pick 
disease type C, Postencephalitic parkinsonism, Familial British dementia, Dementia 
pugilisticia, Down’s syndrome and FTDP-17. Using histochemistry, aggregates of this class 
can be observed with AD2 and antibodies against exon 2 and exon 10 (Buee L et al., 2000 
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Class II: Tau isoforms containing the exon 10 encoding sequence aggregate 
Aggregation of tau proteins with four microtubule-binding domains is the characteristic of 
class II (figure 5). This pathological tau profile is observed in CBD, argyrophilic grain 
dementia, PSP and FTDP-17 due to tau gene mutations (Sergeant N et al., 1999 and Tolnay 
M et al., 2002). PSP, CBD and argyrophilic grain dementia are rare atypical parkinsonism 
disorders. 
Class III: Tau isoforms lacking the exon 10 encoding sequence aggregate 
This class of tauopathies includes Pick’s disease and autosomal dominant inherited FDTP-17 
(figure 5). Pick’s disease is a rare form of neurodegenerative disorder characterized by a 
progressive dementing process. Early in the clinical course, patients show signs of frontal 
disinhibition. Neuropathologically, Pick’s disease is characterized by the presence of typical 
spheroid inclusions in the soma of neurons called Pick bodies. Pick bodies are labeled by tau 
antibodies, with a higher density in neurons of the dentate gyrus of the hippocampal 
formation than in the temporal and frontal cortices. The pathological tau profile of Pick’s 
disease contrasts with that of class II tauopathies, with the pathological tau isoforms 
consisting essentially of the 3R tau isoforms.  
Immunohistologic staining of these aggregates is positive for AD2 and exon 2 antibodies but 
negative for exon 10 antibodies. In addition, aggregated tau proteins in Pick’s disease are 
not detected by the monoclonal antibody 12E8 raised against the phosphorylated residue 
Ser262/Ser356, whereas this phosphorylation site is detected in other neurodegenerative 
disorders. The lack of phosphorylation at Ser262 and Ser356 sites is likely to be related to 
either a kinase is not active in neurons that degenerate in Pick’s disease or those neurons do 
not constitutively express these kinases within degenerating neurons (Mailliot C et al., 1998). 
Class IV: Tau isoform lacking exon 2, 3 and 10 principally aggregate 
This group is represented by a single neurological disorder: myotonic dystrophy (DM) of 
types I and II (figure 5). DM is the commonest form of adult-onset muscular dystrophy. 
Genetically it is an inherited autosomal dominant disorder caused by a single gene mutation 
consisting of expansion of a CTG trinucleotide motif in the 3V untranslated of the myotonic 
dystrophy protein kinase gene (DMPK), located on chromosome 19q. It is a multisystemic 
disease affecting many systems as the central nervous system (cognitive and 
neuropsychiatric impairments), the heart, the genital tract, the eyes, the ears, gastrointestinal 
tract, endocrine system, thus leading to a wide and variable complex panel of symptoms 
(Meola G, 2000). Cognitive impairments, as memory, visuo-spatial recall and verbal scale, 
cortical atrophy essentially of the frontal and the temporal lobe and white matter lesions are 
often described in both DM1 and DM2 (Sansone V et al., 2007). 
Neuropathological lesions, as neurofibrillary tangles (NFTs), have been observed in adult 
DM1 individuals aged over 50 years. The pathological tau profile of DM1 is characterized by 
a strong pathological tau band at 60 kDa and, to a lesser extent, a pathological tau 
component at 64 and 69 kDa. This typical pathological tau profile is reflected by a reduced 
number of tau isoforms expressed in the brain of individuals with DM1, both at the protein 
and mRNA levels (Sergeant N et al., 2001). In addition, tau protein expression is also 
demonstrated to be altered in transgenic mice with human DM1 locus (Gomes-Pereira M et 
al., 2007). Using specific immunological probes against exon 2 and exon 3 corresponding 
amino acid sequences, the neurofibrillary lesions were shown to be devoid of tau isoforms 
with amino-terminal inserts (Maurage CA et al., 2005). An altered splicing of tau 
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characterized by a reduced expression of tau isoforms containing the amino-terminal inserts 
characterizes both DM1 and DM2. Overall, it demonstrates that the central nervous system 
is affected and that DMs are real tauopathies (Dhaenens CM et al., 2011). The direct 
relationship between the altered splicing of tau and NFD in DM remains to be established. 
Indeed, such an altered splicing of tau is commonly observed in FTDP- 17 and considered as 
reminiscent to NFD and tauopathies. 
5. Use of proteomics to investigate the mechanisms leading to Tauopathies 
Induction of tau fibrillization in cells remain unsatisfactory, this is a limiting factor since 
NFD cannot be totally reproduced in vitro (Sibille N et al., 2006). The development of in vivo 
models has provided an important tool to precise sequence of molecular events leading to 
tau aggregation. The use of proteomics in these transgenic animals has permitted to go 
further in the uncovering of the cellular and molecular pathways involved in NFD 
spreading within the brain and its relationship with the clinical expression of neurological 
disorders. In this section we will focus on the overexpresion either several isoforms of tau 
protein or mutated forms in animal models. 
5.1 Tau models 
Several animal models have been created to recapitulate the two main hallmarks of AD, 
refearing as amyloid plaques and PHFs. Despite the numerous models existing to mimic the 
features of this disease, none of them cover all the neuropathological, biochemical and 
behaviour alterations so far. There are models focus on overexpression of APP and/or 
presenilin containing one or more mutations linked to familial AD but they do not present 
NFD. Inspite tau mutations have not been described in AD patients, mutations in tau result 
in NFTs in an inherited form of FTDP and this dysfunction can lead to neurodegeneration 
and dementia. Taking into account that AD is a complex disorder and the perfect model 
does not exist, the large number of tau transgenic models with their strengths and 
weaknesses may allow for both understanding tau pathology and developing innovative 
therapeutic strategies. Nowadays there are several transgenic models which own 
combination of mutant APP, presenilin and tau (Chin J 2011). However, this triple model 
presents the “limitation” that tau pathology cannot be studied independently of the amyloid 
effects (Sergeant N and Buée L 2011). 
5.1.1 Caenorhabditis elegans 
The nematode Caenorhabditis elegans is widely being used to study neurodegenerative 
disorders despite the evolutionary difference. C. elegans has a short lifespan and it is easy to 
manipulate genetically. Modelling tauopathies is achieved through pan-neuronal 
overexpression either wild-type or mutated tau leading to a progressive uncoordinated 
locomotion which is directly correlated with the nervous system alterations in worms. This 
model is very useful to identify new genetic targets (Wolozin B et al., 2011). Recent data 
point out that tau pathology may lead to specific interference with intracellular mechanisms 
of axonal outgrowth and pathfinding (Brandt R et al., 2009). 
5.1.2 Drosophila melanogaster 
Another model used is the fruitfly Drosophila melanogaster. Regarding tauopathies, many 
groups developed fruitfly models by overexpressing wild-type and mutant forms of human 
 
The Microtubule-Dissociating Tau in Neurological Disorders 311 
tau. Transgenic fruitflies showed key features of tauopathies as tissue- and temporal-specific 
effects as adult onset, progressive neurodegeneration, early death, enhanced toxicity of 
mutant tau, accumulation of abnormal tau and relative anatomic selectivity coupled with 
differential effects of distinct tau isoforms (Papanikolopoulou K and Skoulakis EM, 2011). 
5.1.3 Zebrafish 
The novel use of the vertebrate zebrafish as a model system for AD research offers a 
powerful platform for genetic and chemical screens as well as developmental studies 
(Tomasiewicz HG et al., 2002). The transgenic expression of the human tau mutation P301L 
in zebrafish neurons by Gal4/UAS–based vector system recapitulates most pathological 
features of tauopathies as abnormally phosphorylated reactivity with the epitopes AT180, 
AT270, 12E8, PHF1, 422, and AT8 in spinal cord neurons, aggregation and behavioral 
impairments (Paquet D et al., 2010). Application of inhibitors of human GSK3β reduced tau 
phosphorylation showing that zebrafish kinases are sufficiently conserved with respect to 
their human orthologues. Current evidence point out that zebrafish tau models recapitulate 
pathological and biochemical events that occur in tauopathies and therefore may be useful 
tools for further studies in the aetiology of dementia (Bai Q and Burton EA, 2011). 
5.1.4 Tau knock out mice and transgenic mice with wild-type human Tau 
Tau mouse models where tau expression is suppressed by MAPT deletion or invalidation 
present no major changes and animals are physiologically normal (Harada A et al., 1994). It 
seems other microtubule-associated proteins such as MAP1A probably compensate tau 
deficiency. Among the mice models available with wild-type human tau it is remarkable to 
note that overexpression of 3R tau isoforms lead to an accumulation of 
hyperphosphorylated tau proteins in spinal cord neurons and axonal degeneration as well 
as a reduction in axonal transport (Brion JP et al., 1999). Similar data were observed in 
transgenic mice expressing the longest human brain tau isoform under the control of the 
human Thy-1 promoter. Hyperphosphorylated human tau protein was present in nerve cell 
bodies, axons and dendrites (Gotz J et al., 1995). Furthermore, recent studies in transgenic 
mouse models that express the entire human MAPT gene in the presence and absence of the 
mouse Mapt gene show differences between mouse and human tau in the regulation of exon 
10 inclusion during development and in the young adult. In addition, it was observed 
species-specific variations in the expression of 3R- and 4R-tau within the frontal cortex and 
hippocampus during the development as well as in cell distribution of the isoforms 
(McMillan P et al., 2008). 
5.1.5 Transgenic mice with mutated human Tau 
Mutated tau transgenes have been used under various promoters (2’,3’-cyclic nucleotide 3’-
phosphodiesterase, CaMKII, PDGF, Prion, or Thy1.2) with or without inducible systems. 
The most common phenotype of transgene tau animal is the motor alterations. Tau 
transgenic mice rTg4510 present P301L mutation in an inductible way and develop NFTs, 
neuronal loss and behavioural impairments (Santacruz K et al., 2005). Nonetheless the 
suppression of the expression of this mutated tau revers behavioural impairements despite 
the NFTs formation keeps on, indeed it seems soluble tau rather than NFTs may be 
deleterious. These observations are in agreement with a recent report in which brain extract 
injection from mutant P301S tau expressing mice into brain of transgenic wild-type tau-
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characterized by a reduced expression of tau isoforms containing the amino-terminal inserts 
characterizes both DM1 and DM2. Overall, it demonstrates that the central nervous system 
is affected and that DMs are real tauopathies (Dhaenens CM et al., 2011). The direct 
relationship between the altered splicing of tau and NFD in DM remains to be established. 
Indeed, such an altered splicing of tau is commonly observed in FTDP- 17 and considered as 
reminiscent to NFD and tauopathies. 
5. Use of proteomics to investigate the mechanisms leading to Tauopathies 
Induction of tau fibrillization in cells remain unsatisfactory, this is a limiting factor since 
NFD cannot be totally reproduced in vitro (Sibille N et al., 2006). The development of in vivo 
models has provided an important tool to precise sequence of molecular events leading to 
tau aggregation. The use of proteomics in these transgenic animals has permitted to go 
further in the uncovering of the cellular and molecular pathways involved in NFD 
spreading within the brain and its relationship with the clinical expression of neurological 
disorders. In this section we will focus on the overexpresion either several isoforms of tau 
protein or mutated forms in animal models. 
5.1 Tau models 
Several animal models have been created to recapitulate the two main hallmarks of AD, 
refearing as amyloid plaques and PHFs. Despite the numerous models existing to mimic the 
features of this disease, none of them cover all the neuropathological, biochemical and 
behaviour alterations so far. There are models focus on overexpression of APP and/or 
presenilin containing one or more mutations linked to familial AD but they do not present 
NFD. Inspite tau mutations have not been described in AD patients, mutations in tau result 
in NFTs in an inherited form of FTDP and this dysfunction can lead to neurodegeneration 
and dementia. Taking into account that AD is a complex disorder and the perfect model 
does not exist, the large number of tau transgenic models with their strengths and 
weaknesses may allow for both understanding tau pathology and developing innovative 
therapeutic strategies. Nowadays there are several transgenic models which own 
combination of mutant APP, presenilin and tau (Chin J 2011). However, this triple model 
presents the “limitation” that tau pathology cannot be studied independently of the amyloid 
effects (Sergeant N and Buée L 2011). 
5.1.1 Caenorhabditis elegans 
The nematode Caenorhabditis elegans is widely being used to study neurodegenerative 
disorders despite the evolutionary difference. C. elegans has a short lifespan and it is easy to 
manipulate genetically. Modelling tauopathies is achieved through pan-neuronal 
overexpression either wild-type or mutated tau leading to a progressive uncoordinated 
locomotion which is directly correlated with the nervous system alterations in worms. This 
model is very useful to identify new genetic targets (Wolozin B et al., 2011). Recent data 
point out that tau pathology may lead to specific interference with intracellular mechanisms 
of axonal outgrowth and pathfinding (Brandt R et al., 2009). 
5.1.2 Drosophila melanogaster 
Another model used is the fruitfly Drosophila melanogaster. Regarding tauopathies, many 
groups developed fruitfly models by overexpressing wild-type and mutant forms of human 
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tau. Transgenic fruitflies showed key features of tauopathies as tissue- and temporal-specific 
effects as adult onset, progressive neurodegeneration, early death, enhanced toxicity of 
mutant tau, accumulation of abnormal tau and relative anatomic selectivity coupled with 
differential effects of distinct tau isoforms (Papanikolopoulou K and Skoulakis EM, 2011). 
5.1.3 Zebrafish 
The novel use of the vertebrate zebrafish as a model system for AD research offers a 
powerful platform for genetic and chemical screens as well as developmental studies 
(Tomasiewicz HG et al., 2002). The transgenic expression of the human tau mutation P301L 
in zebrafish neurons by Gal4/UAS–based vector system recapitulates most pathological 
features of tauopathies as abnormally phosphorylated reactivity with the epitopes AT180, 
AT270, 12E8, PHF1, 422, and AT8 in spinal cord neurons, aggregation and behavioral 
impairments (Paquet D et al., 2010). Application of inhibitors of human GSK3β reduced tau 
phosphorylation showing that zebrafish kinases are sufficiently conserved with respect to 
their human orthologues. Current evidence point out that zebrafish tau models recapitulate 
pathological and biochemical events that occur in tauopathies and therefore may be useful 
tools for further studies in the aetiology of dementia (Bai Q and Burton EA, 2011). 
5.1.4 Tau knock out mice and transgenic mice with wild-type human Tau 
Tau mouse models where tau expression is suppressed by MAPT deletion or invalidation 
present no major changes and animals are physiologically normal (Harada A et al., 1994). It 
seems other microtubule-associated proteins such as MAP1A probably compensate tau 
deficiency. Among the mice models available with wild-type human tau it is remarkable to 
note that overexpression of 3R tau isoforms lead to an accumulation of 
hyperphosphorylated tau proteins in spinal cord neurons and axonal degeneration as well 
as a reduction in axonal transport (Brion JP et al., 1999). Similar data were observed in 
transgenic mice expressing the longest human brain tau isoform under the control of the 
human Thy-1 promoter. Hyperphosphorylated human tau protein was present in nerve cell 
bodies, axons and dendrites (Gotz J et al., 1995). Furthermore, recent studies in transgenic 
mouse models that express the entire human MAPT gene in the presence and absence of the 
mouse Mapt gene show differences between mouse and human tau in the regulation of exon 
10 inclusion during development and in the young adult. In addition, it was observed 
species-specific variations in the expression of 3R- and 4R-tau within the frontal cortex and 
hippocampus during the development as well as in cell distribution of the isoforms 
(McMillan P et al., 2008). 
5.1.5 Transgenic mice with mutated human Tau 
Mutated tau transgenes have been used under various promoters (2’,3’-cyclic nucleotide 3’-
phosphodiesterase, CaMKII, PDGF, Prion, or Thy1.2) with or without inducible systems. 
The most common phenotype of transgene tau animal is the motor alterations. Tau 
transgenic mice rTg4510 present P301L mutation in an inductible way and develop NFTs, 
neuronal loss and behavioural impairments (Santacruz K et al., 2005). Nonetheless the 
suppression of the expression of this mutated tau revers behavioural impairements despite 
the NFTs formation keeps on, indeed it seems soluble tau rather than NFTs may be 
deleterious. These observations are in agreement with a recent report in which brain extract 
injection from mutant P301S tau expressing mice into brain of transgenic wild-type tau-
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expressing animals induces assembly of wild-type human tau into filaments and spreading 
of pathology from the site of injection to neighbouring brain regions (Clavaguera et al., 
2009). 
Another transgenic mice model is TauRD/ΔK280 that expresses only the 4R tau domains 
and carry the ΔK280 mutation with a deletion of the amino- and carboxy terminal regions of 
tau protein. This mutation leads to tau aggregation followed by astrogliosis and neuronal 
loss. When the transgene is switched off the aggregation of the exogenous tau disappears 
within around one month and a haf and only aggregated murine tau proteins remain acting 
as a nucleation factor for tau aggregation (Mocanu MM et al., 2008). Other study suggest a 
“prion –like” propagation since aggregation continues even if the original tau species have 
disappeared (Sydow A and Mandelkov EM, 2010). 
The K3 transgenic mouse strain expresses human tau carrying the K369I mutation under the 
Thy1 promoter (Ittner LM et al., 2008). This tau mutation was found in a family of patients 
presenting with Pick’s disease without parkinsonism and amyotrophy (Neumann M et al., 
2001). The transgenic mice present early-onset memory impairment and amyotrophy in the 
absence of overt neurodegeneration. Tau transgene is mainly expressed in the substantia 
nigra and such expression leads to an early-onset parkinsonism phenotype. Interestingly, 
motor performance of young, but not old K3 mice improves upon L-dopa treatment. 
Amyotrophy is probable to be related to tau expression in the sciatic nerve in the same way 
as in Tg30tau model where pathogenic mutations (P301S and G272V) are expressed in the 
forebrain and the spinal cord showing progressive motor impairment with neurogenic 
muscle atrophy besides the hippocampal atrophy (Leroy K et al., 2007). Moreover, 
transgenic mouse model overexpressing human 1N4R double-mutant tau (P301S and 
G272V) and invalidated endogenous TAU gene show an accelerated human mutant tau 
aggregation (Ando K et al., 2011) suggesting that murine tau proteins may act as inhibitors 
of tau aggregation. 
Thy-Tau22 mouse transgenic line exhibits progressive neuron-specific AD-like tau 
pathology devoid of any motor deficits (Schindowski K et al., 2006). In addition to 
neurofibrillary tangle-like inclusions and mild astrogliosis, this model shows hyper- and 
abnormally phosphorylated tau on several Alzheimer’s disease-relevant tau epitopes that 
accumulates within the somato-dendritic area in the hippocampus (Schindowski K et al., 
2008). A progressive development of NFTs is observed in the hippocampus and amygdala, 
which parallels behavioural impairments as well as electrophysiological alterations (Van der 
Jeugd et al., 2011). These latter changes are observed despite any striking loss of 
neuronal/synaptic markers until 12 months of age in the hippocampus. Interestingly, at that 
time point, THY-Tau22 mice exhibit septo-hippocampal tau pathology accompanied by 
altered retrograde transport from hippocampus to medial septum (Belarbi K et al., 2009) 
with an accumulation of the nerve growth factor (NGF) levels in the hippocampus 
consistent with a decrease of its uptake or retrograde transport by cholinergic terminals 
(Belarbi K et al., in press). Recent data indicate that voluntary exercise prevented memory 
alterations in these transgenic mice and increased mRNA levels of genes involved in 
cholesterol trafficking such as NPC1 and NPC2 (Belarbi K et al., 2011). 
6. Tau proteins as biomarkers of Tauopathies 
Searching for biomarkers is one of the most challenges in current medicine. Biomarkers 
must be not only specific for a single pathology but also indicative of its progression 
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(Mayeux R et al., 2011). This is extremely complex in diseases concerning elderly since many 
symptoms are common and indistinguishable among them as the dementia sign. It is 
compulsory to find proteins and their post-translational modifications that may provide 
accuracy on the early diagnosis of the disease and eventually could serve as a therapeutic 
target. Successfully the development in neuroimaging techniques enables to facilitate and 
establish a preliminary diagnosis of different neurodegenerative disorders. 
Focusing on tauopathies, the presence of tau in CSF was first described in 1993. In AD, tau 
inclusions in the brain associated with neuronal damages lead to the leakage of abnormal 
forms of tau in the CSF resulting in quantitative and qualitative changes in CSF-tau 
composition. Numerous studies demonstrated increased CSF total tau and phosphorylated 
tau levels in AD, with mean levels 2-3 times higher compared to healthy controls. Tau is 
now a validated biomarker for AD, it improves the clinical diagnostic accuracy and its 
assessment for AD diagnosis is now proposed (Dubois B et al., 2010). As the brain lesions 
develop very early during the disease course even before the first clinical symptoms appear, 
CSF tau is not only a useful diagnostic marker in the advanced stages of the disease but also 
a usefull predictive marker in the earliest stages when clinical expression is weak (Hertze J 
et al., 2010). However, for differential diagnosis of dementia, the actually available tests 
measuring tau and phosphorylated tau levels in CSF are not sufficient and the identification 
of more specific postranslational modifications of tau in AD by proteomic approaches is 
needed. In the future, for the use of tau as biomarker in large clinical trials or in clinical 
practice, one important goal will be to develop sensitive methods to detect the very low 
concentration of tau in the blood (<1 pMol). Therefore, sample pre-treatment and handling 
will be crucial in developing a reliable tau assay in blood/plasma. 
7. Conclusion 
Tau is a neuronal protein that promotes neuronal survival, it is essentially located within the 
axonal and indispensable for the organization, stabilization, and dynamics of microtubules. 
The interaction between tau and microtubules is regulated by phosphorylation. It is widely 
reported that abnormally and hyperphosphorylated tau proteins lead to insoluble 
aggregates. The presence of these aggregates is clinically correlated with cognitive decline in 
a process called NFD; this event common to more than twenty diseases is referred as 
tauopathies. 
The development of the proteomics era has achieved to go further in the characterization of 
tauopathies and shed light to the mechanism involved in their aetiology. Proteomics 
approaches as chromatography, mono- and bi-dimensional gel electrophoresis have reached 
to separate proteins with a quite high resolution after fractioning precedures, selecting a 
concrete population of cells or organelle isolation. The use of additional reagents to the 
extraction buffer such as detergents and the evolution of concomitant technologies as 
microscopy have provided a broad spectrum to characterize the structure and size of a large 
number of biological complex samples. The combination of protein separation methods with 
fluorescence dyes and radioactive isotopes (ICAT, iTRAQ, SILAC) makes possible not only 
more sensitive and reproducible results but also provides a quantitative analysis among 
samples (2D-DIGE, LC-MS, SELDI). 
The previous hallmark is extremely linked to the identification of the separated or isolated 
proteins. MS has provided the composition of the molecules and also their post-translational 
modifications since changes in amino acid residues may be identified and characterized by 
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muscle atrophy besides the hippocampal atrophy (Leroy K et al., 2007). Moreover, 
transgenic mouse model overexpressing human 1N4R double-mutant tau (P301S and 
G272V) and invalidated endogenous TAU gene show an accelerated human mutant tau 
aggregation (Ando K et al., 2011) suggesting that murine tau proteins may act as inhibitors 
of tau aggregation. 
Thy-Tau22 mouse transgenic line exhibits progressive neuron-specific AD-like tau 
pathology devoid of any motor deficits (Schindowski K et al., 2006). In addition to 
neurofibrillary tangle-like inclusions and mild astrogliosis, this model shows hyper- and 
abnormally phosphorylated tau on several Alzheimer’s disease-relevant tau epitopes that 
accumulates within the somato-dendritic area in the hippocampus (Schindowski K et al., 
2008). A progressive development of NFTs is observed in the hippocampus and amygdala, 
which parallels behavioural impairments as well as electrophysiological alterations (Van der 
Jeugd et al., 2011). These latter changes are observed despite any striking loss of 
neuronal/synaptic markers until 12 months of age in the hippocampus. Interestingly, at that 
time point, THY-Tau22 mice exhibit septo-hippocampal tau pathology accompanied by 
altered retrograde transport from hippocampus to medial septum (Belarbi K et al., 2009) 
with an accumulation of the nerve growth factor (NGF) levels in the hippocampus 
consistent with a decrease of its uptake or retrograde transport by cholinergic terminals 
(Belarbi K et al., in press). Recent data indicate that voluntary exercise prevented memory 
alterations in these transgenic mice and increased mRNA levels of genes involved in 
cholesterol trafficking such as NPC1 and NPC2 (Belarbi K et al., 2011). 
6. Tau proteins as biomarkers of Tauopathies 
Searching for biomarkers is one of the most challenges in current medicine. Biomarkers 
must be not only specific for a single pathology but also indicative of its progression 
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(Mayeux R et al., 2011). This is extremely complex in diseases concerning elderly since many 
symptoms are common and indistinguishable among them as the dementia sign. It is 
compulsory to find proteins and their post-translational modifications that may provide 
accuracy on the early diagnosis of the disease and eventually could serve as a therapeutic 
target. Successfully the development in neuroimaging techniques enables to facilitate and 
establish a preliminary diagnosis of different neurodegenerative disorders. 
Focusing on tauopathies, the presence of tau in CSF was first described in 1993. In AD, tau 
inclusions in the brain associated with neuronal damages lead to the leakage of abnormal 
forms of tau in the CSF resulting in quantitative and qualitative changes in CSF-tau 
composition. Numerous studies demonstrated increased CSF total tau and phosphorylated 
tau levels in AD, with mean levels 2-3 times higher compared to healthy controls. Tau is 
now a validated biomarker for AD, it improves the clinical diagnostic accuracy and its 
assessment for AD diagnosis is now proposed (Dubois B et al., 2010). As the brain lesions 
develop very early during the disease course even before the first clinical symptoms appear, 
CSF tau is not only a useful diagnostic marker in the advanced stages of the disease but also 
a usefull predictive marker in the earliest stages when clinical expression is weak (Hertze J 
et al., 2010). However, for differential diagnosis of dementia, the actually available tests 
measuring tau and phosphorylated tau levels in CSF are not sufficient and the identification 
of more specific postranslational modifications of tau in AD by proteomic approaches is 
needed. In the future, for the use of tau as biomarker in large clinical trials or in clinical 
practice, one important goal will be to develop sensitive methods to detect the very low 
concentration of tau in the blood (<1 pMol). Therefore, sample pre-treatment and handling 
will be crucial in developing a reliable tau assay in blood/plasma. 
7. Conclusion 
Tau is a neuronal protein that promotes neuronal survival, it is essentially located within the 
axonal and indispensable for the organization, stabilization, and dynamics of microtubules. 
The interaction between tau and microtubules is regulated by phosphorylation. It is widely 
reported that abnormally and hyperphosphorylated tau proteins lead to insoluble 
aggregates. The presence of these aggregates is clinically correlated with cognitive decline in 
a process called NFD; this event common to more than twenty diseases is referred as 
tauopathies. 
The development of the proteomics era has achieved to go further in the characterization of 
tauopathies and shed light to the mechanism involved in their aetiology. Proteomics 
approaches as chromatography, mono- and bi-dimensional gel electrophoresis have reached 
to separate proteins with a quite high resolution after fractioning precedures, selecting a 
concrete population of cells or organelle isolation. The use of additional reagents to the 
extraction buffer such as detergents and the evolution of concomitant technologies as 
microscopy have provided a broad spectrum to characterize the structure and size of a large 
number of biological complex samples. The combination of protein separation methods with 
fluorescence dyes and radioactive isotopes (ICAT, iTRAQ, SILAC) makes possible not only 
more sensitive and reproducible results but also provides a quantitative analysis among 
samples (2D-DIGE, LC-MS, SELDI). 
The previous hallmark is extremely linked to the identification of the separated or isolated 
proteins. MS has provided the composition of the molecules and also their post-translational 
modifications since changes in amino acid residues may be identified and characterized by 
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MS/MS, Peptide Mass Fingerprinting and NMR. The utilization of the current available 
ionization sources as ESI and MALDI coupled to mass analysers mainly TOF allows almost 
any compound to be analysed by MS at low levels in complex mixtures. Furthermore, there 
are a large number of software tools dedicated to facilitate raw data processing, database-
dependent search, statistical evaluation of the search result, quantitative algorithms and 
statistical analysis of quantitative data. 
The generation of animal models helps to elucidate the genetic and proteomics aspects 
involved during the origin and development of tauopathies. Only by the knowledge of the 
different components of the disease and their contribution, it will be possible to proceed in 
the right way. 
In summary, numerous proteomics approaches are available in order to accomplish new 
perspectives in the neurodegenerative disorders field. At the moment there are many 
studies focused on finding out the functions of tau protein thoughtout proteomics 
approaches. Proteomics methods allow to uncover the different signaling pathways 
involved in tau biology, proteomics data are intimately related to the protein state: post-
translational modifications, cleavage, conformation, synthesis, degradation and activity (if it 
is known). The selection of the different techniques depends on the aim of the research: 
protein identification, de novo peptide sequencing, and identification of post-translational 
modifications or determination of protein-protein interactions. Understanding the human 
proteome and its variations in physiological and pathological conditions will be intimately 
related to uncover cellular and molecular pathways involved in the aetiology and 
progression of the tauopathies as well as to identify potential targets for drug design. 
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Neurogenesis insures the production of functional neurons throughout life and occurs in 
two narrow regions of the adult mammalian brain, the subventricular zone (SVZ) lining the 
lateral ventricles and the subgranular zone in the hippocampus (Alvarez-Buylla&Lim,2004). 
The adult SVZ, which is separated from the lateral ventricle by a layer of epithelial cells 
known as ependymal cell, contains three main populations of neural progenitors: neural 
stem cells (NSCs), transit-amplifying cells (TAPs) and neuroblasts. NSCs are 
undifferentiated cells generally characterized by their functional capacities to both self-
renew and to generate a large number of differentiated progeny cells (Song, et al.,2011). 
Adult NSCs have an astrocyte-like phenotype (type B cells) and represent only 0.2-0.4 % of 
the SVZ cells, they are relatively quiescent and divide very slowly in vivo with a cell cycle 
length of 14 days (Morshead, et al.,1994). These cells are the precursors of rapidly dividing 
TAPs, or type C cells, which have the capacity to differentiate into neuroblasts (type A). 
Neuroblasts are organized as migratory chains along the rostral migratory stream (RMS) 
and integrate the Olfactory bulb (OB) to become interneurons (Fig. 1). 
The highly organised cytoarchitecture of the SVZ constitutes a niche for NSCs 
(Ihrie&Alvarez-Buylla, 2011). Cells localized in this specific microenvironment secrete a 
variety of factors involved in NSC proliferation, migration and/or differentiation  
                                                 
* Contributed equally to this work 
 
Proteomics – Human Diseases and Protein Functions 326 
Zilka, N.; Filipcik, P.; Koson, P.; Fialova, L.; Skrabana, R.; Zilkova, M.; Rolkova, G.; 
Kontsekova, E. & Novak, M. (2006). Truncated tau from sporadic Alzheimer's 
disease suffices to drive neurofibrillary degeneration in vivo. FEBS Lett, Vol. 
580(15), pp. 3582-3588. 
Zuchner, T.; Schliebs, R. & Perez-Polo, JR. (2005). Down-regulation of muscarinic 
acetylcholine receptor M2 adversely affects the expression of Alzheimer's disease-
relevant genes and proteins. J Neurochem, Vol. 95(1), pp. 20-32. 
Alzheimer’s Association. Copyright © 2011 Alzheimer's Association®. All rights reserved. 
http://www.alz.org 
Diane Hanger, MRC Centre for Neurodegeneration Research, King's College London, UK 
http://cnr.iop.kcl.ac.uk/hangerlab/tautable 
15 
Identification of Factors  
Involved in Neurogenesis Recovery  
After Irradiation of the Adult Mouse  
Subventricular Zone: A Preliminary Study 
François Chevalier1*, Alexandra Chicheportiche2,3,4,5*,  
Mathieu Daynac2,3,4,5, Jordane Depagne1, Pascale Bertrand1,  
François D. Boussin2,3,4,5 and Marc-André Mouthon2,3,4,5 
1CEA DSV iRCM, Plateforme de Protéomique, F-92265 Fontenay-aux-Roses 
2CEA DSV iRCM SCSR, Laboratoire de Radiopathologie, F-92265 Fontenay-aux-Roses 
3INSERM, U967, F-92265 Fontenay-aux-Roses 
4Université Paris Diderot, Sorbonne Paris Cité, UMR 967, F-92265 Fontenay-aux-Roses 
5Université Paris Sud, UMR 967, F-92265 Fontenay-aux-Roses,  




Neurogenesis insures the production of functional neurons throughout life and occurs in 
two narrow regions of the adult mammalian brain, the subventricular zone (SVZ) lining the 
lateral ventricles and the subgranular zone in the hippocampus (Alvarez-Buylla&Lim,2004). 
The adult SVZ, which is separated from the lateral ventricle by a layer of epithelial cells 
known as ependymal cell, contains three main populations of neural progenitors: neural 
stem cells (NSCs), transit-amplifying cells (TAPs) and neuroblasts. NSCs are 
undifferentiated cells generally characterized by their functional capacities to both self-
renew and to generate a large number of differentiated progeny cells (Song, et al.,2011). 
Adult NSCs have an astrocyte-like phenotype (type B cells) and represent only 0.2-0.4 % of 
the SVZ cells, they are relatively quiescent and divide very slowly in vivo with a cell cycle 
length of 14 days (Morshead, et al.,1994). These cells are the precursors of rapidly dividing 
TAPs, or type C cells, which have the capacity to differentiate into neuroblasts (type A). 
Neuroblasts are organized as migratory chains along the rostral migratory stream (RMS) 
and integrate the Olfactory bulb (OB) to become interneurons (Fig. 1). 
The highly organised cytoarchitecture of the SVZ constitutes a niche for NSCs 
(Ihrie&Alvarez-Buylla, 2011). Cells localized in this specific microenvironment secrete a 
variety of factors involved in NSC proliferation, migration and/or differentiation  
                                                 
* Contributed equally to this work 
 





(A) In adult mouse brain, neurons are continuously produced in two restricted regions: the subgranular 
zone (SGZ) of the dentate gyrus in the hippocampus and the subventricular zone (SVZ) lining the 
lateral ventricles (LV). The former produces neurons that functionally integrate into the granular cell 
layer of the hippocampus, whereas the SVZ produces neuroblasts, which migrate along the rostral 
migratory stream (RMS) to integrate the olfactory bulbs (OB) and differentiate into interneurons. 
(B) The SVZ is an highly organized neurogenic area which contains three cell types of neural cells: 
neural stem cells (NSCs), transit-amplifying progenitors (TAPs) and neuroblasts. Ependymal cells that 
contact the NSCs are organized as a single layer of epithelial cells separating the SVZ from the 
ventricles. 
(C) NSCs are defined as slow dividing cells having capacities to self-renew and to generate multiple cell 
types (neurons, astrocytes and oligodendrocytes). NSCs give rise to highly proliferating TAPs, which 
differentiate mostly in neuroblasts. NSCs are also able to produce oligodendrocytes and astrocytes 
according to development stages, in response to brain injury or in vitro conditions. The length of the cell 
cycle for NSCs and TAPs lasts 22 days and 12 h, respectively (Doetsch, et al.,1999, Morshead, et 
al.,1994). BV (blood vessel). 
Fig. 1. Neurogenesis in the adult mouse brain 
(Doetsch,2003). For example, GABA released from neuroblasts provides a feedback 
mechanism to control proliferation of NSCs in the SVZ (Liu, et al.,2005). Bone 
morphogenetic proteins signalling can direct neural progenitors to glial fate in the adult 
brain (Lim, et al.,2000), whereas the secretion by ependymal cells of Noggin, a polypeptide 
Identification of Factors Involved in Neurogenesis Recovery  
After Irradiation of the Adult Mouse Subventricular Zone: A Preliminary Study 
 
329 
antagonist of bone morphogenetic proteins, antagonizes Bone morphogenetic protein 
signalling and stimulates neurogenesis (Lim, et al.,2000). Brain endothelial cells are thought 
to be crucial for the NSC niche because they lie in close proximity to NSCs (Tavazoie, et 
al.,2008), where they probably regulate self-renewal of NSCs and their differentiation into 
neurons (Ramirez-Castillejo, et al.,2006). Brain endothelial cells may also balance 
proliferation/quiescence of NSCs by secreting Bone morphogenetic proteins (Mathieu, et 
al.,2008).  
A number of studies indicate that brain injury can induced SVZ cells to migrate towards 
non-OB areas especially towards lesions and participate in neuronal and glial repair 
(Alonso,1999, Cayre, et al.,2006, Goings, et al.,2004, Jankovski, et al.,1998, Macas, et al.,2006, 
Picard-Riera, et al.,2002, Yamashita, et al.,2006). Adult NSCs may therefore promise hopes in 
the repair of damaged central nervous system (Dubois-Dalcq,2005).  
Adult NSCs survive anti-mitotic cytosine arabinoside treatment in vivo unlike actively 
dividing TAPs and neuroblasts, which rapidly disappear. This assay has been used by 
Doetsch et al. to demonstrate that quiescent NSCs are able regenerate to the neurogenic SVZ 
niches (Doetsch, et al.,1999). Exposition of the brain to ionizing radiation induces apoptosis 
of proliferating cells in the SVZ (Shinohara, et al.,1997). For high doses of irradiation an 
incomplete repopulation of the SVZ occurred and neurogenesis is collapsed for long term 
(Tada, et al., 1999).  
However, exposition to low doses allows SVZ to be replenished. A recovery of proliferating 
cells is observed starting 3 days after radiation and peaking at day 7 (Hopewell and 
Cavanagh 1972; Tada, et al.,1999).  
In light of the recovery capacity of SVZ, we developed a model of low dose irradiation (2 
Gy) of adult mouse brain, which provokes a transient collapse of neurogenesis followed by 
a rapid recovery of the SVZ. The repopulation of the SVZ was most probably due to the 
stimulation of relatively quiescent NSCs and their proliferation (Morshead, et al.,1994, 
Pastrana, et al.,2009). 
Seek for factors involved in the stimulation of neurogenesis and production of new neurons 
remains a challenging task. We assume that our in vivo irradiation model will be helpful to 
identify proteins coinciding with SVZ reconstitution, i.e. those involved in NSC 
proliferation.  
Only few global proteomic analyses on rodent brains have been reported, attempting to 
identify proteins that are involved in brain injury such as middle cerebral artery occlusion 
ischemia (Sung, et al. 2010), or to gain further insight into the molecular mechanisms of 
neurodegenerative diseases (Broadwater, et al., Castegna, et al.,2002). Others proteomic 
studies aimed to identify crucial proteins by comparison between different brain 
developmental stages and during brain aging (Shoemaker, et al. 2010, Yang, et al.,2008). 
Therefore, we performed a global proteomic analysis based on 2 dimensional-gels and 
identification by mass spectroscopy in our SVZ reconstitution model. We decided to work 
with proteins extracted from SVZ, instead of cells isolated using a specific marker. Indeed, 
with all SVZ extract, including NSC, progenitor cells and the SVZ extracellular matrix, it 
was possible to search for protein and secreted factors potentially involved in NSC 
proliferation, migration and/or differentiation. 
In this preliminary study, an accurate analysis of 2D-gel revealed that several proteins from 
SVZ appeared as modulated following brain radiation. Important issues of this study are the 
identification of candidates possibly involved in the stimulation of quiescent NSCs.  
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2. Material and methods 
2.1 Mouse irradiation 
We used eight-week old male C57BL/6J mice (Janvier, Le Genest-Saint-Isle, France). All 
experimental procedures complied with the European Communities Council Directive of 24 
November 1986 (86/609/EEC) and European Union guidelines. 
Mice were irradiated with a medical Alcyon irradiator (γ-rays 60Co) (Fig. 2). Prior to 
radiation, mice were anesthetized with ketamine (75 mg/kg, Merial, Lyon, France) and 
medetomidine (1 mg/kg, Pfizer, Paris, France) by intraperitoneal (i.p.) route. Immobilized 
mice were placed under a lead shield in order to expose the head and to protect the rest of 
the body. A total dose of 2 Gy was delivered with a dose rate of 1 Gy/mn. After exposure, 
mice were woken up by i.p. injection of antipamezole (1 mg/kg, Pfizer, Paris, France).  
 
 
Irradiation was performed with a medical irradiator (Alcyon, 60Co source). Irradiation window was 
focused at the level of the head of the anesthetized mouse. The rest of the body was protected by a lead 
shield. 
Fig. 2. Schematic representation of brain irradiation  
2.2 Micro-dissection of the brain 
At different time points after radiation, mice were euthanatized and SVZ and striatum (STR) 
were micro-dissected (Fig. 3). The micro-dissection method used to isolate SVZ is very tricky 
since SVZ is a very tiny part of brain tissue. Briefly, skull was cut with scissors at the 
midline and carefully removed with forceps. The brain was transferred into a Petri dish 
containing phosphate buffered saline and 6g/L of glucose. OBs were removed and a coronal 
cut was made at the optical chiasma. Then, under a stereomicroscope, septum was removed 
from the fore part of the brain with small forceps. Lateral walls of ventricle, containing the 
SVZ, were microdissected using small forceps and cleared out of contaminating corpus 
callosum and STR. A piece of STR adjacent to SVZ was taken. Tissue pieces were 
immediately frozen in liquid nitrogen. 
2.3 Protein extraction 
Proteins were extracted from SVZ and STR of control (Ctr) and irradiated mice. Tissues 
were homogenized in buffer containing 9M urea, 4% CHAPS, 0.05% Triton X100, 65 mM 
DTT and a protease inhibitor cocktail (Roche) with a small Teflon pestle and cell debris were 
removed by ultra-centrifugation at 100 000g for 1 hour (TL100, Beckman). The protein  
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(A) A schematic representation of ventral face of the brain with the two cuts: one at the front just behind 
the OB and one at the level of optic chiasma. (B) Representative photographs of dorsal face and (C, D) 
ventral face of the mouse brain. (E, F) Coronal views of brain slices after cuts. (E) Lateral ventricles are 
visible from each part the septum. The ventricular walls to be dissected out containing the SVZ are 
indicated by arrow and light blue lines.  
Cx: cortex; cc: corpus callosum; St: striatum; Sp: septum. 
Fig. 3. Process for micro-dissection of the SVZ 
content was estimated in the supernatant using the Bradford assay. To limit variability, 
tissue pieces from mice with the same treatment were mixed together in proteomic sample 
buffer.  
2.4 Two-dimensional electrophoresis 
Two-dimensional electrophoresis was performed with at least 5 technical replicates. Briefly, 
precast 18 cm strips, pH range 3-10 NL (GE), were rehydrated in the presence of 100 µg of 
protein extract. Isoelectric focusing was carried out using a Protean IEF Cell (Bio-Rad, 
Hercules, CA, USA) isoelectric focusing system until 80 KV h-1. The strips were then 
incubated in the first equilibration solution (50 mM Tris–HCl pH 8.8, 6 M urea, 30% (v/v) 
glycerol, 2% (w/v) SDS) with 130 mM DTT and then in the second equilibration solution (50 
mM Tris–HCl pH 8.8, 6 M urea, 30% (v/v) glycerol, 2% (w/v) SDS) with 130 mM 
iodoacetamide. Strips were then embedded using 1% (w/v) low-melting agarose on the top 
of the acrylamide gel. SDS-PAGE was carried out on a 12% acrylamide SDS-polyacrylamide 
gel, using the Dodeca Cell electrophoresis unit (Bio-Rad).  
Gels were stained with Sypro-Ruby and scanned to images, which were digitized with a 
Typhoon 9400 fluorescent scanner (Typhoon 9400 GE) using the 532 nm excitation laser and 
the 610BP emission filter. Image were acquired at a 100 µm resolution with a 550 voltage 
applied to the photomultiplier tube. 
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the 610BP emission filter. Image were acquired at a 100 µm resolution with a 550 voltage 
applied to the photomultiplier tube. 
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2.5 Image analysis 
Images from stained gels were analyzed using the Samespots software v4.1 (Non-linear 
Dynamics, UK). All pictures were first aligned and gel replicates were then grouped to create a 
global analysis with all conditions. Spots of each sample were compared between control and 
irradiated conditions. A multivariate statistic analysis was performed using the statistic mode 
of the Samespots software v4.1 (Non-linear Dynamics, UK). Spots with significant differences 
between control and irradiated cells (Anova t-test p<0.05) were first extracted. Then, only spots 
with a P value < 0.05 and a power > 0.8 were finally selected. Spots of interest were selected for 
subsequent protein identification by mass spectrometry analysis. 
2.6 Two-D gel reproductibility 
Using gel-based proteomics analysis, it is important to estimate the contribution of 
biological and technical variations. We assessed the degree of biological variation inherent 
to the 2-DE process. SVZ were extracted separately from 9 mice. For each mouse, about 150 
µg proteins were extracted in buffer containing 9M urea, 4% CHAPS, 0.05% Triton X100, 65 
mM DTT and a protease inhibitor cocktail (Roche) then were used to produce a 
corresponding 2D-gel. Protein spot volume was determined for all spots matched in an 
experimental set using the Samespots software packages with default settings, as used for 
all the study. Coefficients of variation (CV) were calculated for each protein sample, or as a 
function of spot intensity. CV was calculated as a percentage of standard variation as related 
to mean: (SD/mean) x100 (Anderson, et al., 1985). 
The SVZ of each animal were used to perform a single 2-D gel. All spots of the 
corresponding 9 gels were compared as biological replicates (Fig. 4 A).  
 
 
(A) coefficient of variation of SVZ Ctr samples between 9 biological replicates, as a function of spot 
intensity (HAS: high abundant spots; MHAS: medium high abundant spots; MLAS: medium low 
abundant spots; LAS: low abundant spots). 
(B) coefficient of variation of all technical replicates, as a function of spot intensity. 
(C) comparison between coefficients of variation of biological replicates (BR) and technical replicates 
(TR) of SVZ and STR samples.  
Fig. 4. Biological and technical variability of proteomes as measured by 2-D gel 
electrophoresis.  
Coefficient of variation grew up from 20% for high abundant spots to about 40% for low 
abundant spots. As a comparison, the degree of technical variation inherent to the 2-DE 
process was estimated for each SVZ and STR samples. Biological samples corresponding to 
the same treatment were mixed and the resulting protein samples were used to perform 
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technical 2-D gel replicates (Fig. 4 B). In this case, a constant coefficient of variation was 
observed (about 20%) whatever spot abundance (Fig. 4 B) and sample treatment (Fig. 4 C). 
This analysis of 2-D gel reproducibility clearly showed the advantage to perform technical 
replicates with mixed biological samples. 
2.7 MALDI-TOF MS analysis 
Spots were excised from preparative two-dimensional electrophoresis gels by hand, and 
processed using a Packard Multiprobe II liquid-handling robot (Perkin Elmer, Courtaboeuf, 
France). After washing successively with water, 25 mM ammonium bicarbonate, acetonitrile 
/ 25 mM ammonium bicarbonate (1:1, v/v) and acetonitrile, gel fragments were dried at 
37°C. Protein digestion was carried out at 37°C for 5 hours following addition of 0.125 μg 
trypsin (sequencing grade, modified, Promega, Charbonières, France), and resulting 
fragments were extracted twice with 50 μL acetonitrile / water (1:1, v/v) containing 0.1 % 
trifluoroacetic acid for 15 min. Pooled supernatants were concentrated with a speedvac to a 
final volume of 20 μL. Peptides were simultaneously desalted and concentrated with C18 
Zip-Tip micro-columns to a final volume of 3 μL, an aliquot of each sample was mixed (1/1) 
with the alpha-cyano-4- hydroxycinnamic acid matrix at half saturation in 
acetonitrile/water (1:1, v/v) and the mixture was immediately spotted on the MALDI target 
by the Multiprobe II robot. Mass spectra were recorded in the reflector mode on a UltraFlex 
II MALDI-TOF/TOF mass spectrometer (Bruker Daltonics, Bremen, Germany). Automatic 
annotation of monoisotopic masses was performed using Bruker’s SNAPTM procedure. The 
MASCOT search engine software (Matrix Science, London, UK) was used to search the 
NCBInr database.  
The following parameters were used: mass tolerance of 30 to 100 ppm, a minimum of five 
peptides matching to the protein, carbamidomethylation of cysteine as fixed modification, 
oxidation of methionine as variable modification, and one missed cleavage allowed. 
2.8 Nano LC MS analysis 
When low abundant spots could not be identified by PMF, LC-MS/MS analysis was 
conducted. Stained protein spots were excised manually, washed, digested with trypsin and 
extracted using formic acid. Protein digests were analysed using an ion trap mass 
spectrometer (Esquire HCT plus; Bruker, Billerica, MA, USA) coupled to a nano-
chromatography system (HPLC 1200, Agilent, Santa Clara, CA, USA) interfaced with an 
HPLC-Chip system (Chip Cube, Agilent). MS/MS data were searched against NCBI 
(National center for Biotechnology information) and MSDB databases using Mascot 
software. 
3. Results and discussion 
3.1 Regeneration of the SVZ after radiation 
We have developed a model of SVZ reconstitution after low dose irradiation (2 Gy) of adult 
mouse brain. Radiation exposure provoked a transient collapse of neurogenesis followed by 
a rapid recovery of the SVZ (Fig. 5).  
Cell proliferation was assessed in the SVZ by injection with the thymidine analog 5-bromo-
2’-deoxyuridine (BrdU). We observed a sharp decrease in BrdU incorporation 72h after 
radiation, however, BrdU labelling subsequently recovered within 7 days after exposure 
(Fig. 6A). BrdU positive cells were scarce 72h after irradiation but most of them expressed  
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Radiation exposure of mice at 2Gy provoked a transient disappearance of progenitors of the 
subventricular zone (SVZ) such as transit-amplifying cells (Type C cell) and neuroblasts (Type A cell) at 
72 hours. Four days later, those cells had almost completely replenished the SVZ. 
Fig. 5. Schematic representation of SVZ reconstitution model after adult mouse brain 
irradiation. 
Glial Fibrillary acidic protein (GFAP), a marker for NSCs, suggesting that quiescent NSCs 
are activated to re-enter cell cycle. Seven days after radiation, more numerous BrdU positive 
cells were observed and expressed the neuroblast marker PSA-NCAM arguing that 
neurogenesis recovered (Fig. 6B).  
On the basis of these data and with the aim of finding proteins, such as growth factors 
secreted in the microenvironment involved in regeneration of the cells of the SVZ after 
radiation, we extracted proteins of non-irradiated SVZ and 2 Gy-irradiated SVZ at 3 and 7 
days after exposure. 
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Mice were injected with BrdU 3 hours before sacrifice to label proliferating cells in control mice and 
after 2Gy-irradiation. Brain slices were counterstained with 4',6-diamidino-2-phenylindole (DAPI). (A) 
BrdU positive cells almost completely disappeared 72h post irradiation then they subsequently 
recovered in the SVZ niches.(B) 72 hours post-irradiation, some GFAP positive cells (pink), 
corresponding to candidate NSCs, have incorporated BrdU positive (green). At that time after 
irradiation, essentially NSCs proliferated in the SVZ niche. This result might underlie an activation of 
relatively quiescent NSCs 72h after irradiation. (C) 7 days after irradiation, the SVZ regeneration is 
evidenced by numerous neuroblasts PSA-NCAM postivie (green) and BrdU positive (red) in the SVZ. 
Fig. 6. Regeneration of the SVZ after irradiation  
 
















Radiation exposure of mice at 2Gy provoked a transient disappearance of progenitors of the 
subventricular zone (SVZ) such as transit-amplifying cells (Type C cell) and neuroblasts (Type A cell) at 
72 hours. Four days later, those cells had almost completely replenished the SVZ. 
Fig. 5. Schematic representation of SVZ reconstitution model after adult mouse brain 
irradiation. 
Glial Fibrillary acidic protein (GFAP), a marker for NSCs, suggesting that quiescent NSCs 
are activated to re-enter cell cycle. Seven days after radiation, more numerous BrdU positive 
cells were observed and expressed the neuroblast marker PSA-NCAM arguing that 
neurogenesis recovered (Fig. 6B).  
On the basis of these data and with the aim of finding proteins, such as growth factors 
secreted in the microenvironment involved in regeneration of the cells of the SVZ after 
radiation, we extracted proteins of non-irradiated SVZ and 2 Gy-irradiated SVZ at 3 and 7 
days after exposure. 
Identification of Factors Involved in Neurogenesis Recovery  





Mice were injected with BrdU 3 hours before sacrifice to label proliferating cells in control mice and 
after 2Gy-irradiation. Brain slices were counterstained with 4',6-diamidino-2-phenylindole (DAPI). (A) 
BrdU positive cells almost completely disappeared 72h post irradiation then they subsequently 
recovered in the SVZ niches.(B) 72 hours post-irradiation, some GFAP positive cells (pink), 
corresponding to candidate NSCs, have incorporated BrdU positive (green). At that time after 
irradiation, essentially NSCs proliferated in the SVZ niche. This result might underlie an activation of 
relatively quiescent NSCs 72h after irradiation. (C) 7 days after irradiation, the SVZ regeneration is 
evidenced by numerous neuroblasts PSA-NCAM postivie (green) and BrdU positive (red) in the SVZ. 
Fig. 6. Regeneration of the SVZ after irradiation  
 
Proteomics – Human Diseases and Protein Functions 
 
336 
3.2 Proteomic strategy 
We combined 2D-gel electrophoresis and MS analyses of SVZ samples to determine proteins 
that are altered following radiation in adult neurogenic niches in comparison to a non-
neurogenic brain region, i.e. STR. Protein samples were separated using two-dimensional 
electrophoresis in 3-10 non-linear pH gradient strips and 12% acrylamide gels.  
SVZ samples obtained from irradiated mice at 3 and 7 days after radiation were compared 
with SVZ samples from non-irradiated control mice (Fig. 7). Along with micro-dissection 
procedures, SVZ can be contaminated with STR. For that reason and because the striatum is 







Fig. 7. Proteomic strategy of SVZ and STR samples comparison with no radiation (Ctr) and 3 
days (IR 3) or 7 days (IR 7) after radiation. 
3.3 Proteomic map analysis 
As it can be observed in Fig. 7, pictures corresponding to the different samples analysed 
were very close and only minor differences can be observed, using a dedicated image 
analysis software. 
From the 871 spots observed, a total of 36 spots were significantly modified for all the 
comparisons (Fig. 8). Thirty-two spots were modulated after irradiation and 4 spots were 
different between SVZ and STR. From these last spots, only one spot was more abundant in 
the SVZ than in STR suggesting a protein specifically expressed in the SVZ.  
Using non-irradiated SVZ as control, 5 spots were modulated 3 days after radiation, 16 spots 
were modulated at 7 days (Table 1). Sixteen spots were altered at day 7 after radiation when 
compared with day 3. In addition, SVZ samples were also compared with STR and 4 spots 
appeared as modulated 7 days following radiation. The variation in spot intensity was 
ranged between 1.2 and 1.9 that was in agreement with previously published data using 
similar 2D-gel approach (Broadwater, et al. 2011, Gasperini, et al. 2011). 
These spots, according to their localisation on the 2D reference map (Fig. 8), displayed an 
heterogeneous repartition on the gel, with a large range of iso-electric points (from 4 to 8) 
and of molecular weights (from 13 to 46 kDa).  
Different profiles were established according to spot modifications, as illustrated in the Fig. 9.  
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Fig. 8. Two-dimensional electrophoresis of SVZ proteins, separated under reducing 
conditions using 18-cm pH 3-10 strips for the first dimension, and a 12% acrylamide gel for 
the second dimension. 
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In comparison to non-irradiated SVZ: (A,A’) early modified from 3 days after radiation, (B) downregulated 
by irradiation from 3 days to 7days or (C,C’) late response to radiation at 7 days. In comparison to STR (D): 
no response to radiation. Numbers of spots corresponded to those listed in Fig. 3 and Table 1. Results are 
representative of volume intensity of the spot ± standard deviation from 5 technical replicates. 
Fig. 9. Intensity profiles of spots specifically modified in the SVZ 
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Interestingly, 79% of the spot variations were obtained from comparison between non-
irradiated SVZ and irradiated SVZ and appeared to be specific of the SVZ. Forty three 
percent of these spots were found modified between 3 and 7 days post-irradiation that 
might underlie functions of these proteins during the intense proliferation phase. Thirteen 
percent of them were modified 3 days after radiation as compared with control SVZ 
suggesting a role for the proteins in the activation of quiescent NSCs. 
The rest of them (21%) corresponded to spots altered in both regions after radiation in 
comparison to respective region controls, suggesting a role of these proteins in the response 
to radiation. 
Among the 32 spots identified with a significant response to radiation, we eliminated 9 
abundant spots (more than 0.1% of the total volume of spots) because they might not 
correspond to proteins involved in proliferation processes but rather have a cytoarchitecture 
function in the tissue. In a first round of analysis, among the 21 remaining spots, only 15 
were abundant enough and well separated in the gel to be excised allowing identification by 
MS (Table 1).  
3.4 Biological functions of the proteins 
We verified the expression of the genes corresponding to the identified proteins (Table1) 
using the Allen Brain Atlas database (Fig. 10). This database contained a thorough list of 
genes expression in the mouse brain by RNA hybridization (http://mouse.brain-map.org) 
(Lein, et al.,2007). We found that indeed 47% of our identified proteins have its gene 
expressed in the SVZ; the others being at least expressed in the adjacent regions, i.e. striatum 
or in the corpus callosum (Fig. 10). 
Identified proteins were classified according to their known biological activity (Fig. 11). 
Surprisingly, we did not identify proteins matching with growth factors or cell cycle 
regulation, as they may be present in too small quantity to be identified. Otherwise, we 
cannot exclude that gel resolution might not be optimized for the identification of this type 
of proteins.  
Myelin basic protein (MBP) that wraps axons has been identified in two adjacent spots (41, 
42) that varied according to Pi but not in their MW indicating posttranslational 
modifications. Strikingly, the amount of these spots decreased after radiation, which 
suggested a degradation of myelin sheets by radiation. This is of importance because MBP 
modifications have never been reported with such a low radiation dose (Tian, et al.,2008).  
Otherwise, this current proteomic analysis of SVZ demonstrates that a 2 Gy-radiation 
exposure affected major cellular functions such as proteasome, energy production, vesicle 
trafficking and cytoskeletal maintenance.  
Thirteen percent of the spots belong to the proteasome system known to be involved in the 
degradation of unneeded or damaged proteins by proteolysis (Mcbride, et al.,2003). The 
intensity of these spots were decreased between 3 and 7 days (spot) 34 or only 7 days post 
irradiation (spot 3) that might underscore a decrease of proteasome activity that has already 
been reported after irradiation in a variety of cell types (Mcbride, et al.,2002, 
Pajonk&Mcbride,2001). This reduction of proteasome activity has been proposed to be 
related, at least in part, to an increased expression of proteasome inhibitors 
(Conconi&Friguet, 1997, Zaiss, et al., 2002). 
Twenty percent of the spots corresponded to proteins having functions in metabolism 
pathways. Two of them (5, 44) were modified within 3 days after radiation. Another was 
increased 7 days after radiation and the identified protein have been implicated in  
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Spot Observed pI MW Abundance Variations reference sample ANOVA (p)
1 5.28 16 0.03899 -1.9 in SVZ IR 7 SVZ CT 0.008 
  -1.8 in SVZ IR 7 SVZ IR 3 0.013 
2 6.53 49 0.09853 -1.3 in SVZ IR 7 SVZ IR 3 0.022 
3 5.95 25 0.05079 +1.3 in SVZ IR 7 SVZ CT 0.033 
4 6.4 62 0.06269 +1.3 in SVZ IR 7 SVZ IR 3 0.004 
5 6.41 36 0.04725 -1.3 in SVZ IR 3 SVZ CT 0.012 
7 6.68 60 0.27306 +1.3 in SVZ IR 7 SVZ IR 3 0.043 
8 4.3 68 0.19432 +1.4 in STR CT SVZ CT 0.05 
9 6.44 68 0.01876 +1.3 in SVZ IR 7 SVZ IR 3 0.019 
11 6.12 57 0.04227 -1.3 in STR IR 7 STR CT 0.031 
12 6.61 49 0.10724 +1.2 in SVZ IR 7 SVZ CT 0.05 
    +1.2 in SVZ IR 7 SVZ IR 3 0.010 
13 6.43 49 0.06881 +1.2 in SVZ IR 7 SVZ IR 3 0.028 
    +1.3 in STR CT SVZ CT 0.007 
14 5.74 48 0.08356 +1.2 in SVZ IR 7 SVZ IR 3 0.004 
15 5.82 46 0.08980 +1.3 in SVZ IR 7 SVZ CT 0.02 
16 5.98 44 0.06190 +1.4 in SVZ IR 7 SVZ CT 0.021 
17 6.53 43 0.10764 +1.3 in SVZ IR 7 SVZ IR 3 0.003 
18 7.18 41 0.25750 +1.2 in STR CT SVZ CT 0.018 
19 5.58 40 0.07969 -1.2 in SVZ IR 3 SVZ CT 0.012 
20 5.72 37 0.09955 -1.2 in STR CT SVZ CT 0.012 
21 7.28 36 0.03971 -1.4 in SVZ IR 7 SVZ CT 0.038 
22 7.29 34 0.12789 +1.2 in SVZ IR 3 SVZ CT 0.021 
    +1.4 in STR IR 7 STR CT 0.001 
23 6.47 33 0.38047 +1.2 in STR CT SVZ CT 0.011 
25 6.47 30 0.03257 -1.7 in SVZ IR 7 SVZ CT 0.027 
  -1.6 in SVZ IR 7 SVZ IR 3 0.047 
26 7.04 30 0.05344 -1.5 in SVZ IR 7 SVZ CT 0.04 
27 6.35 30 0.02708 -1.6 in SVZ IR 7 SVZ CT 0.01 
    -1.6 in SVZ IR 7 SVZ IR 3 0.015 
29 7.33 27 0.10550 -1.3 in SVZ IR 7 SVZ IR 3 0.041 
    +1.4 in STR IR 7 STR CT 0.004 
30 6.88 27 0.05109 -1.3 in SVZ IR 7 SVZ CT 0.038 
31 6.37 27 0.04457 -1.4 in SVZ IR 7 SVZ CT 0.01 
34 6.24 24 0.05691 -1.3 in SVZ IR 7 SVZ CT 0.017 
  -1.3 in SVZ IR 7 SVZ IR 3 0.036 
35 6.45 22 0.03776 -1.4 in SVZ IR 7 SVZ CT 0.016 
36 7.49 20 0.06499 -1.6 in SVZ IR 7 SVZ IR 3 0.046 
39 5.92 17 0.02929 -1.4 in SVZ IR 7 SVZ CT 0.015 
    -1.4 in SVZ IR 7 SVZ IR 3 0.018 
41 5.74 16 0.07440 -1.9 in SVZ IR 7 SVZ CT 0.001 
  -1.9 in SVZ IR 7 SVZ IR 3 0.001 
42 5.5 16 0.04760 -1.6 in SVZ IR 7 SVZ CT 0.002 
    -1.5 in STR IR 7 STR CT 0.013 
44 7.09 13 0.02003 +1.5 in SVZ IR 3 SVZ CT 0.018 
45 4.63 13 0.06425 -1.4 in SVZ IR 3 SVZ CT 0.028 
46 8.48 12 0.94660 +1.4 in STR IR 7 STR CT 0.002 
Table 1. List of spots significantly modified in: control SVZ; 3 days following radiation SVZ, 
7 days following radiation SVZ, control STR; 7 days following radiation STR. Spot number; 
experimental protein molecular weight and pI; variation level, under-expressed (-) or over-
expressed (+) in the corresponding sample, vs reference sample; and ANOVA, (significant 
when p<0.05). Spots indicated in bold were excised from the gels and analysed by MS to 
allow the identification the proteins. The abundance corresponds to the ratio (%) of the 
volume one spot on the total volume of spots. 
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Fig. 10. An example of the expression of one gene corresponding to an identified protein 
using the Allen Brain Atlas database. This gene is expressed along the SVZ, a part of the 
RMS and also in the cortex (cx) but not in the corpus callosum (cc). 
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Spot Observed pI MW Abundance Variations reference sample ANOVA (p)
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7 6.68 60 0.27306 +1.3 in SVZ IR 7 SVZ IR 3 0.043 
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phospholipid biosynthesis that might correspond to proteins involved in the organisation of 
membrane structure during cell proliferation. In our context, these identified proteins might 
interfere with the proliferation wave during SVZ regeneration.  
Thirteen percent of the modulated proteins (spots 34, 30, 20) are central effectors in 
intracellular signal transduction pathways like GTPases mediating the formation of 
vesicles in neural cells, a fundamental process of neurotransmitter release (De Camilli, et 
al.,1995). 
Thirteen percent of the spots referred to cytoskeleton proteins (spots 1, 19) showing 
alteration from day 3 to 7. Thus, this proteomic analysis revealed that radiation exposure 
influence the expression of proteins involved the reorganisation of actin cytoskeleton 
probably associated with proliferation and/or migration.  
It appeared that 20% of the modulated proteins were known for being implicated in 
oxidative metabolism. One of them (spot 45) decreased early after radiation that might 
reflect a radio-induced defect of mitochondrial metabolism. The two other spots (3, 15) were  
 
 
From 871 spots, 32 spots showed variations of intensity after irradiation. Among the last spots, we 
analysed and identified 17 spots. Twenty-six percents of the identified proteins matched with proteins 
already described in oxidative metabolism. The next step of this work will consist firstly, in confirming 
these variations of intensity by other technical approaches such as western blot and 
immunohistochemistry and secondly, in demonstrating their involvement in the neurogenesis 
stimulation after SVZ irradiation. 
Fig. 12. Schematic representation of the current comparative proteomic analysis from control 
SVZ and 2Gy-irradiated SVZ at 3 and 7 days after exposure.  
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increased 7 days after radiation probably as a consequence of an increased metabolic activity 
of proliferating SVZ cells.  
The approach of the current proteomic analysis and the main results are represented in the 
Fig. 12. The next step of this work will be the validation of the variation of identified 
proteins and a deep analysis to demonstrate their involvement in neurogenesis stimulation 
following SVZ radiation and their potential use to stimulate neurogenesis in aged brains 
and/or neurodegenerative diseases.  
4. Conclusion 
This preliminary study demonstrates that 2D-gel electrophoresis is an accurate global 
proteomic analysis to analyse modifications in very small brain regions. In our model of 
neurogenic niche regeneration after 2Gy irradiation, which is associated with stem cell 
proliferation, we have identified proteins, which have major cellular functions such as energy 
production, cytoskeletal maintenance and vesicle trafficking. Interestingly, identified proteins 
have functions known to be involved in pathways previously reported to be altered by 
radiation which underscores the reliability of our proteomic approach. Especially, proteins 
involved in mitochondrial respiratory chain have been identified in our study; they produce 
energy and generate reactive oxygen species. Acharya et al. have shown that human NSCs 
significantly increased their oxidative and nitrosative stresses after radiation (Acharya, et al. 
2010). The importance of endogenous oxygen reactive species to control NSC proliferation has 
been reported as well (Le Belle, et al. 2010). Moreover, oxidative stress is implicated in the 
progression of aging and neurodegenerative disorders (Berlett&Stadtman, 1997, Butterfield, et 
al.,1997, Lauderback, et al.,2002, Richardson, 2009). In light of theses studies, our data 
concerning mitochondrial respiratory chain are very promising. This chapter describes the first 
part of our project, including a validation of the technical strategy, with examples of protein 
functions, associated with SVZ regeneration following 2Gy irradiation. The characterization of 
identified proteins is still under investigation, and needs further biological validations. 
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1. Introduction 
A major goal of cell biology is to understand the dynamic interplay between different 
reactions in the cell. In eukaryotes, compartmentalization of the cytoplasm into organelles 
facilitates the coordinated execution of many cellular functions. To understand how this is 
achieved, it is important to know the protein composition of the different organelles, and to 
determine how it may change over time. In addition, the activity of many proteins is 
regulated by often reversible and dynamic post-translational modifications (PTMs). In 
recent years, proteomics has matured into a staple technique for cell biology. Modern 
approaches of proteomics rely on mass-spectrometry. Here, we build on several reviews 
(Aebersold and Mann, 2003; Choudhary and Mann, 2010; Walther and Mann, 2010) to 
summarize and highlight contemporary applications of MS-based proteomics to the analysis 
of organelle dynamics.  
2. MS-based quantitative proteomics approaches for proteins and their post-
translational modifications 
Most proteomics studies aim to not just identify proteins but to quantitate their abundance 
in different samples. In the past few years, several quantitative proteomics approaches have 
been developed to accomplish this task. 
2.1 MS-based quantitative proteomics approaches 
2.1.1 Stable isotope labeling by amino acids in cell culture (SILAC) 
The most commonly used method to quantitate proteins is stable isotope labeling by amino 
acids in cell culture (SILAC; (Ong et al., 2002)) in combination with liquid chromatography 
(LC) and tandem high resolution mass spectrometry (LC-MS/MS). Cells are labeled with 
non-radioactive heavy labeled amino acids, typically arginine and /or lysine. After cell lysis, 
extracts from differently labeled and differently treated cells are mixed and digested with a 
protease that cuts after the labeled amino acids, such as trypsin for the case of 
arginine/lysine. The resulting peptide mixture is fractionated by LC on a C18 column and 
analyzed in a high resolution mass spectrometer. The mass shift between labeled and 
unlabeled peptides allows the quantification of intensities of peptides, and based on that of 
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proteins, derived from cells differentially labeled and subjected to different conditions. Since 
chemically identical peptides are quantitated in the same spectrum, the accuracy of this 
methodology is very high. In addition, mixing samples directly after lysis limits the chance 
for experimental errors. However, in its simplest rendition, SILAC-based proteomics is 
limited to samples that can be metabolic labeled, including cells and model organisms 
(ranging from yeast to mice) (de Godoy et al., 2008; Kruger et al., 2008). Recently developed 
“spike-in” approaches that use isotope labeled cell extracts as standards for analysis of 
samples of interests from sources that cannot be labeled, such as patient samples, are 
compared. In case a single cell extract does not adequately represent a particular tissue or 
sample, several extracts can be mixed to obtain a “super-SILAC” standard (Geiger et al., 
2010). This approach of SILAC reference standards is not limited to quantitation of protein 
abundance but can also be applied to quantify changes in PTMs, such as phosphorylation. In 
an example of such an analysis, a phosphopeptide standard combining untreated or insulin 
treated mouse liver cell lines were spiked into samples derived from the liver of insulin 
treated or untreated mice. This method led to the identification of over 15,000 and 
quantitation of 10,000 phosphosites (Monetti et al., 2011). 
2.1.2 Isobaric tags for relative and absolute quantification (iTRAQ) 
Chemically labeling of proteins in different samples can also be used for their quantitation. 
One such technique uses isobaric tags for relative and absolute quantification (iTRAQ). In 
iTRAQ experiments, different chemical groups modify the primary amino group of either 
the N-terminus or lysine side chains of peptides in different samples (Ross et al., 2004). 
These differentially labeled peptides are pooled and analyzed by LC-MS/MS setup. Each of 
the labels has the same mass and therefore each peptide is visible in a single peak in the MS 
spectrum. However, fragmentation of that peak leads to formation of a low molecular mass 
reporter ion characteristic for each tag in the MS/MS spectrum that is used to quantify the 
relative amounts of the corresponding peptides and proteins. It is very important for this 
technique to distinguish peptides which have a similar mass and elute at the same time 
because this would lead to false ratios as both peptides contribute to the abundance of the 
same reporter ions (Ow et al., 2009; Zhang et al., 2010). In addition, it is crucial to ensure 
complete labeling of the sample. Moreover, side reactions of chemical labeling may be 
unavoidable, but can lead to false positive identifications of PTMs. For example, alkylation 
of a peptide mixture with iodoacetamide can produce a 2-acetamidoacetamide covalent 
adduct to lysine. This has the same atomic composition as a diglycine adduct of a 
ubiquitinated peptide after tryptic digest (Nielsen et al., 2008).   
2.1.3 Label free approaches 
In addition to the described labeling methods, so called “label-free” approaches that directly 
compare the abundance of peptides and proteins between samples are very attractive to 
analyze complex protein mixtures. Such approaches enable the analysis of samples which 
cannot be easily labeled. One type of label free quantitation approaches uses alignments of 
separate LC-MS/MS runs to compare peptide intensities between different samples. Recent 
advances in computational proteomics enable quantification of peptides from less complex 
samples by this approach (Mueller et al., 2008; Wong and Cagney, 2010). However, the 
accuracy of this approach is still somewhat lower compared to measurements from 
metabolic labeled samples. The analysis is particularly challenging for PTMs. Post 
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translational modified peptides are generally of low abundance and even small changes can 
have important effects on the cell. 
Sometimes only a few modified peptides are of interest for the question under 
consideration. In these cases, proteomics can be targeted to sequencing to a subset of 
previously identified peptides (Schmidt et al., 2009). One method to achieve this, called 
multiple reaction monitoring (MRM), is performed on so called triple quadrupole mass 
analyzers. In the first quadrupole, peptides of interest are isolated by their mass. The second 
quadrupole is a collision cell where the peptides are fragmented. The last quadrupole is set 
to some specific fragments that are characteristic for the peptide. The advantage of MRMs 
over unbiased approaches is the high sensitivity and speed (Kitteringham et al., 2009; 
Malmstrom et al., 2009; Wolf-Yadlin et al., 2007). However, false positive rates in these 
experiments can be high due to limited resolution of the quadrupole instruments compared 
to orbitraps. In alternative approaches using high resolution orbitrap instruments, the 
specific m/z of peptides of interest are written in an “inclusion list” (Jaffe et al., 2008). 
Whenever a peptide of this m/z is found in the MS spectrum it is selected for fragmentation 
and MS/MS analysis. If higher sensitivity of the instrument is required, selected ion 
monitoring (SIM) scans can be used to survey one or several pre-defined ranges of the m/z 
spectrum rather than a full spectrum during the chromatography run (Michalski et al., 
2011). 
2.2 Posttranslational modifications 
Quantitative proteomics can detect changes of the abundance of proteins in a whole 
proteome from cells in different conditions. In addition biological activity of proteins 
varies and is often regulated by PTMs. Therefore, it is important to measure changes of 
PTMs spatially and temporarily. MS is ideal to study PTMs because it can detect specific 
mass shifts due to the modification and assign its exact position in the amino acid 
sequence. 
2.2.1 Phosphorylation 
The most studied PTM is phosphorylation of the amino acids serine, threonine or 
tyrosine. Phosphorylation is important for many cellular processes. Protein 
phosphorylation conventionally is analyzed by 32P labeling, band shifts on SDS-PAGE 
gels or the detection of phosphorylated residues by site-specific antibodies. While these 
techniques yielded great insights, they focus usually on just one or a few proteins at a 
time. To study the complexity of signaling networks, systematic methods to study 
phosphorylation of many proteins at the same time are required. MS-based methods 
analyzing phosphorylation of proteins by detecting the phosphorylated peptides resulting 
from their digestion require enrichment of phosphorylated peptides to overcome their 
low abundance in cells. Several different methods have been established to enrich 
phosphorylated peptides. Antibodies specific for a specific phosphorylated amino acid, 
e.g., phospho-tyrosine, are used. These enrichment methods are very useful to study a 
specific phosphorylation species. A different enrichment method is immobilized metal 
(e.g., Fe3+) affinity chromatography (IMAC) (Corthals et al., 2005; Muszynska et al., 1992). 
With IMAC, all phosphopeptides are enriched due to the interaction between negatively 
charged phosphate groups and the immobilized positive metal ions. A similar technique 
uses TiO2 to complex phosphorylated peptides on a resin by their charge (Pinkse et al., 
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proteins, derived from cells differentially labeled and subjected to different conditions. Since 
chemically identical peptides are quantitated in the same spectrum, the accuracy of this 
methodology is very high. In addition, mixing samples directly after lysis limits the chance 
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translational modified peptides are generally of low abundance and even small changes can 
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techniques yielded great insights, they focus usually on just one or a few proteins at a 
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(e.g., Fe3+) affinity chromatography (IMAC) (Corthals et al., 2005; Muszynska et al., 1992). 
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2004). In contrast to IMAC, phosphopeptide enrichment by TiO2 requires a competitor for 
the binding sites, such as dihydrobenzoic acid (DHB) or lactic acid, to exclude 
unphosphorylated negatively charged peptides (Larsen et al., 2005). A drawback of these 
competitors is possible contamination of the MS instruments by the competitor. In 
organisms of relatively low proteome complexity, such as Saccharomyces cerevisiae, this 
setup was sufficient to identify 5534 phosphosites (Soufi et al., 2009). However, due to the 
much higher complexity of the mammalian phosphoproteome, some studies use a pre-
fractionation step of peptides before phosphopeptides enrichment, e.g., by strong cation 
exchange chromatography (SCX) (Villen and Gygi, 2008). 
After enrichment of phosphorylated peptides, samples are analyzed by LC-MS/MS. To 
identify phosphorylated peptides and assign the localization of the phosphorylation site 
with high confidence, distinct fragmentation methods have been used. Collision induced 
dissociation (CID) fragmentation often results in a neutral loss because the phosphoester 
bond is relatively fragile. The resulting lost ions of 98 or 80 Da were used to scan specifically 
for phosphorylated peptides. However, this phenomenon often dominates the MS/MS 
scans (Tholey et al., 1999) and leads to reduced backbone fragmentation. For efficient 
identification of phosphorylated peptides in ion traps, the neutral loss signal can be isolated 
after MS/MS and subjected to additional CID to yield a MS3 spectrum (Jin et al., 2004). 
Multistage activation virtually combines MS2 and MS3 by parallel excitation and 
fragmentation (Schroeder et al., 2004). Even with multistage activation, fragmentation of 
phosphopeptides can be insufficient to identify the peptide sequence or to assign the 
phosphorylation site correctly with high confidence. Recent technical developments allow 
for different fragmentation techniques. Electron capture dissociation (ECD) or electron 
transfer dissociation (ETD) lead to sole backbone fragmentation between N and C bonds 
thereby generating c and z ions (Syka et al., 2004; Zubarev et al., 2000). PTMs unstable 
during CID fragmentation therefore stay intact with ETD fragmentation and make site 
specific assignment easier. Higher collision energy dissociation (HCD) uses the same 
principle of CID but higher collision energies, thus efficiently fragmenting the peptide 
backbone even in the presence of a low energy bond to a PTM. A recent study used a LTQ 
OrbitrapVelos to analyze both the precursor ion and its peptide fragments after HCD with 
high resolution in an orbitrap. This so called “high-high” technique yielded up to 16,000 
identified phosphorylation sites with high confident assignments (Nagaraj et al., 2010).  
Data quality is a particularly important issue for large scale PTM studies. For example, it is 
possible to identify a phosphorylated peptide with high confidence (>99%), but it is 
sometimes impossible to assign its site with high confidence between two adjacent serines. 
Therefore large scale datasets should always contain a peptide identification score and a 
PTM localization score (Beausoleil et al., 2006; Gnad et al., 2011; Olsen et al., 2006).  
2.2.2 Glycosylation 
Although phosphorylation is by far the most studied PTM, MS can also be used to study 
other PTMs. Another example for a prominent PTM is N-glycosylation of asparagine 
residues occurring in the endoplasmic reticulum. N-glycosylation plays an important role in 
the assembly of complex organelles and is involved in many cellular processes, such as 
apoptosis and the immune response (Varki, 2009). Due to the complexity of sugar moieties it 
is very challenging to analyze N-glycosylated proteins or peptides by MS approaches. 
Additionally the abundance of N-glycosylated proteins is usually very low in comparison to 
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their unmodified counterparts. Thus, N-glycosylated proteins are enriched for analysis by 
affinity purification using lectins (Bunkenborg et al., 2004) or by chemical linkage of the 
sugar moiety to a solid phase (Zhang et al., 2003).  
After enrichment, samples are treated with a global deglycosylating enzyme leading to the 
deamidation of the asparagine residue to aspartic acid. The resulting mass increase of 0.9848 
Da can be detected in the precursor scan as well as in the peptide fragments (Kuster and 
Mann, 1999). Previously, N-glycosylated peptides were identified with low resolution of the 
peptide precursor mass. A recent study, using high resolution MS instead, mapped roughly 
6,400 N-glycosylation sites in different murine cell lines quantitatively (Zielinska et al., 
2010). 
2.2.3 Acetylation and methylation 
Other common PTMs are acetylation or methylation of lysines and arginines. These are 
reversible PTMs that change the charge of the amino acid thereby possibly regulating 
protein function. The most prominent example is histone acetylation or methylation, which 
regulates transcription. Acetylated or methylated peptides are relatively low abundant and 
specific enrichment is required, similar as in the case of phosphorylation analysis. 
Enrichment with antibodies which recognize the modified amino acid is generally 
performed prior to analysis by MS. A recent study identified an unexpected large number of 
acetylation sites. By using high resolution MS in combination with SILAC, 3600 acetylation 
sites were identified on 1750 proteins. Due to the low abundance of acetylated peptides, 
Choudhary et al used isoelectric focusing after enrichment of acetylated peptides to further 
reduce sample complexity (Choudhary et al., 2009). A previous study revealed an 
unexpected role of acetylation in mitochondrial function (Kim et al., 2006). A method to 
measure methylation quantitatively is heavy methyl- SILAC. In this approach, heavy 
methionine serves as the sole donor for the methyl group. The mass shift of the peptide 
containing the heavy versus light methyl groups is detected by high resolution mass 
spectrometry (Ong et al., 2004). 
2.2.4 Ubiquitination 
Ubiquitination of proteins is another PTM amenable to MS based proteomics. The protein 
ubiquitin is crosslinked to lysine residues on target proteins. Ubiquitination plays an 
important role in proteasomal degradation and endocytosis of plasma membrane proteins. 
Since ubiquitin is a protein, it can be tagged for subsequent affinity enrichment. HIS tagged 
versions of ubiquitin can be used to isolate ubiquitinated proteins by affinity purification, 
leading in one example to the identification of 110 ubiquitination sites on 72 proteins in 
Saccharomyces cerevisiae (Peng et al., 2003). Instead of isolating ubiquitinated proteins, a site 
specific antibody that detects the diGly motif of ubiquitinated peptides, yielded 374 
diglycine modified lysines on 236 ubiquitinated proteins from HEK293 cells (Xu et al., 2010). 
One problem analyzing ubiquitinated proteins are their very complex fragmentation 
spectra. In addition it is difficult to distinguish by MS analysis modification by ubiquitin or 
by other ubiquitin-like molecules, such as interferon-induced 17kDA protein (ISG15) that 
leave the same diGly tag after digestion. Furthermore, it is not possible to distinguish if a 
protein is mono- or polyubiquitinated by LC MS/MS since digestion of the proteins with a 
protease is necessary and cleaves polyubiquitin chains. For a representative analysis of post 
translational modified proteins see Figure 1. 
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possible to identify a phosphorylated peptide with high confidence (>99%), but it is 
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Although phosphorylation is by far the most studied PTM, MS can also be used to study 
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containing the heavy versus light methyl groups is detected by high resolution mass 
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Ubiquitination of proteins is another PTM amenable to MS based proteomics. The protein 
ubiquitin is crosslinked to lysine residues on target proteins. Ubiquitination plays an 
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Since ubiquitin is a protein, it can be tagged for subsequent affinity enrichment. HIS tagged 
versions of ubiquitin can be used to isolate ubiquitinated proteins by affinity purification, 
leading in one example to the identification of 110 ubiquitination sites on 72 proteins in 
Saccharomyces cerevisiae (Peng et al., 2003). Instead of isolating ubiquitinated proteins, a site 
specific antibody that detects the diGly motif of ubiquitinated peptides, yielded 374 
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Cells are grown (label free or SILAC) and lysed for protein extraction. Extracted proteins are digested 
with an endoproteinase (Trypsin; LysC) and resulting peptides are fractionated (strong cation 
exachange (SCX) or strong anion exchange (SAX) chromatography). Peptides are enriched by their 
PTMs (specific antibodies, IMAC, TiO2, lectin affinity). Enriched peptides are fractionated by nano-flow 
LC and directly injected by electrospray ionization into the MS. Relative abundances of peptides are 
quantified by the first, full-scan MS event (MS). Peptide identification and determination of the PTM is 
achieved by fragmentation (CID, HCD, ETD, ECD) in the second stage of MS (MS/MS). 
Fig. 1. Workflow for quantitative proteomics of post translational modified proteins.  
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3. Spatial analysis of the cellular proteome 
3.1 MS-based proteomics approaches to map protein composition of organelles 
Each organelle is composed of a specific set of proteins that contribute to its function and 
that allow for communication with the rest of the cell. The content of organelles is highly 
dynamic and includes resident as well as transient proteins coming from and going to other 
compartments in the cell. Traditionally, to identify protein localization, cell biologists 
employ protein tagging by fluorescent labels or subcellular fractionation of cells in 
combination with detection of proteins by immunolabeling. These techniques have been 
successfully applied over many years and were adapted to high throughput studies, for 
example to tag nearly the complete proteome of budding (Huh et al., 2003) or of fission 
yeast (Matsuyama et al., 2006). However, technical limitations (e.g., absence of homologous 
recombination in many systems) and the enormous effort required for these approaches 
impede its application to more complex systems, such as mammalian cells. Therefore, 
organelle proteomics based on LS-MS was developed into a complementary approach that 
has made valuable contributions to the elucidation of organelles’ inventory in many 
systems. In this approach, organelles or parts thereof, including protein complexes, are 
purified biochemically and analyzed by MS-based techniques. 
3.1.1 MS based proteomics of purified organelle 
For few compartments, such as nucleus or mitochondrion, that are rather easy to isolate 
with high purity, MS-based proteomics has yielded protein inventories (Andersen et al., 
2002; Taylor et al., 2003). These and all other organellar proteomics experiments usually start 
with cell disruption under mild conditions designed to maintain organelle integrity. 
Organelles are then purified from crude cell extracts by differential centrifugations and are 
then processed for MS analysis. In this scheme, separation of organelles depends on their 
sedimentation velocity, a function of their size and density. Generally purification is 
improved by combining velocity sedimentation centrifugation with density gradient 
centrifugation (Michelsen and von Hagen, 2009; Wiederhold et al., 2010). Alternatively, 
higher purity is obtained by affinity purification using e.g., an antibody directed against a 
surface protein of the organelle, free flow electrophoresis (Islinger et al., 2010) or by 
modification of organelles density. An example for the latter is the report of phagosomes or 
endosomes inventories isolated after flotation gradient. In these cases, latex beads of 
different diameters can be internalized either by phagocytosis (Duclos and Desjardins, 2011; 
Jutras et al., 2008) or endocytosis (Duclos et al., 2011) and the resulting organelles are 
purified by a single step flotation gradient centrifugation before analysis by MS.  
For some organelles, no efficient purification schemes exist based solemnly on differences of 
density or sedimentation. Therefore, in some instances, chemical modification is used to 
facilitate the purification. For example, cell surface modification by cell impermeable 
chemicals is commonly used to modify plasma membrane proteins from the extracellular 
environment. In such strategy, plasma membrane proteins are covalently linked to biotin, 
which in turn is used as an affinity tag for subsequent purification on a column carrying 
streptavidin. Cell surface modification relying on different chemical properties of proteins 
such as the reactivity of primary amines (N-termini of proteins and side chains of lysines, 
(Elia, 2008; Scheurer et al., 2005), thiols (Laragione et al., 2003) or of carbohydrates 
(Teckchandani et al., 2009) have been developed to analyze the proteome of plasma 
membranes in normal (Zhao et al., 2004) and in pathological conditions (Hubbard et al., 
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systems. In this approach, organelles or parts thereof, including protein complexes, are 
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For few compartments, such as nucleus or mitochondrion, that are rather easy to isolate 
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2002; Taylor et al., 2003). These and all other organellar proteomics experiments usually start 
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different diameters can be internalized either by phagocytosis (Duclos and Desjardins, 2011; 
Jutras et al., 2008) or endocytosis (Duclos et al., 2011) and the resulting organelles are 
purified by a single step flotation gradient centrifugation before analysis by MS.  
For some organelles, no efficient purification schemes exist based solemnly on differences of 
density or sedimentation. Therefore, in some instances, chemical modification is used to 
facilitate the purification. For example, cell surface modification by cell impermeable 
chemicals is commonly used to modify plasma membrane proteins from the extracellular 
environment. In such strategy, plasma membrane proteins are covalently linked to biotin, 
which in turn is used as an affinity tag for subsequent purification on a column carrying 
streptavidin. Cell surface modification relying on different chemical properties of proteins 
such as the reactivity of primary amines (N-termini of proteins and side chains of lysines, 
(Elia, 2008; Scheurer et al., 2005), thiols (Laragione et al., 2003) or of carbohydrates 
(Teckchandani et al., 2009) have been developed to analyze the proteome of plasma 
membranes in normal (Zhao et al., 2004) and in pathological conditions (Hubbard et al., 
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2011; Yang et al., 2011) or to identify the dynamic proteome of the plasma membrane 
(Christiano et al., 2010).  
3.1.2 Differential proteomics 
Despite the remarkable success of these simple organelle proteomics approaches in some 
cases, formidable technical challenges to obtain pure organelles remain. Particularly in 
combination with highly sensitive mass spectrometers, simple purification schemes often 
result in the identification of large numbers of proteins. It is difficult to determine which 
ones among them are bona fide constituents of the target organelle and which ones are 
contaminants. One solution to overcome this limitation is the application of differential 
proteomics to subtract the proteins in the fraction in which the target organelle is found 
from a closely resembling fraction containing the most prominent contaminants. For this 
approach to work, the target organelle of interest should be enriched to the highest possible 
degree in one fraction, but be absent completely from the control fraction. This control 
sample could be as simple as a crude cell extract devoid of the target organelle, or better, 
reflect a similar purification in the absence of the organelle. After analysis of both samples, 
proteins that have been exclusively identified in the fraction enriched in the target organelle 
are considered as genuine proteins. In this approach, the accuracy of the obtained results 
strongly depends on the quality of two different MS analyses, as missing a protein in the 
control will lead its assignment to the target organelle. This point is critical considering the 
variability of analysis inherent to many MS approaches. For example, identification of a 
particular protein depends on different properties of the protein (such as abundance in the 
sample, ability of its peptide to be ionized in the mass spectrometer), as well as the MS 
methodology used. Failure to detect a protein does not necessarily mean it is absent from 
the sample. In differential proteomics approaches, this may lead to false negative or positive 
results, if a protein is randomly not detected in either the organelle enriched or the control 
fraction, respectively. Moreover, as sensitivity of MS analysis is improved and hence the 
number of identified proteins in each sample increases, the lists derived from each of the 
two fractions will more and more overlap, since proteins are likely to differ only in 
abundance and not strictly be absent from one sample. Thus, a large set of false negative 
proteins of the target organelle may be subtracted due to their identification in both 
samples.  
3.1.3 Quantitative organellar MS-based proteomics 
Quantitative proteomics is particularly useful in cases where sufficient enrichment for a 
specific organelle cannot be achieved. For example, organelles of the secretory pathway are 
similar to each other in their physical properties, with their content dynamically exchanging 
between them. Methods that only catalogue proteins in a sample cannot provide 
information on the dynamic behavior of proteins and are prone to detect contamination 
from co-purifying organelles. Intensive efforts have focused on sample preparation prior to 
MS. Successful strategies combine gradient profiling and quantitative MS-based proteomics.  
Such strategies rely on partial separation and distribution of subcellular compartments 
along density gradients. In protein correlation profiling (PCP) protein abundance profiles 
along the gradient are obtained by MS analysis and matched to profiles of known organelle 
markers. In this strategy, the accuracy of the quantification is a critical parameter to obtain 
reliable mapping of the organelle constituents. To date MS-based quantitative PCP analyses 
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have been performed using label free (Andersen et al., 2003) and SILAC quantitation 
(Dengjel et al., 2010). SILAC-PCP allows determination of accurate profiles. In that case, two 
independent gradients are obtained from two differently labeled cells. A fraction enriched 
for the organelle of interest is isolated from a gradient and spiked into each fraction of the 
other gradient (with a ratio 1 to 1). Profiles based on SILAC ratios can be extracted from 
each fraction of the gradient. Genuine proteins from the organelle of interest will show the 
highest ratio (close to one) in the organelle fraction, but have lower fractions elsewhere in 
the profile. In contrast, contaminants have higher ratios in other fractions that represent the 
organelles that they mostly purify with (Figure 2). Such approaches rely on the 
reproducibility of the gradient separation. An alternate gradient-based approach, 
localization of proteins by isotope tagging (LOPIT) has been successfully applied to plant  
 
 
PCP-SILAC: A light labeled (L) fraction enriched in a target organelle by gradient centrifugation is 
spiked into each fraction of a gradient of heavy (H) labeled cells Then, each combined fraction is 
analyzed independently. H/L ratios are extracted for proteins in all fractions and then abundance 
profiles are estimated. LOPIT: Specific organelle enriched fractions from a gradient are separated and 
labeled separately with different iTRAQ reagents. Fractions are pooled and processed into peptides. 
Then, the fraction is analyzed in a single MS run. Ratios from pair wise analyses are extracted and 
submitted to multivariate data analyses to identify genuine proteins. 
Fig. 2. Gradient Profiling based organelle proteomics.  
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organelles (Dunkley et al., 2004; Lilley and Dunkley, 2008). In that case, several organelle-
enriched fractions from one gradient are separately labeled with different iTRAQ reagents 
and pooled. Ratios derived from pair-wise comparisons are analyzed by multivariate data 
analyses to assign organelle localization to the proteins identified. (Figure 2) 
3.2 Protein complexes 
Proteins interact with each other to form complexes that contribute to cellular functions. 
Therefore, identifying protein interactions is of critical importance to unravel mechanisms 
underlying cellular functions. To identify complexes, affinity purification-based MS (AP-
MS) is the method of choice: Prior to MS analysis, protein complexes are purified with 
affinity matrices that bind to one subunit of the complex. The confident identification of true 
binders to the bait protein relies on the comparison with a good control fraction of the 
affinity purification. The emergence of affinity tags and robust antibodies greatly 
contributed to the success of AP-MS. 
The use of affinity tags is particularly attractive because it allows standardizing procedures 
that can be applicable to any system or protein. To date, a wide variety of tags has been used 
in AP-MS ranging from small peptides to proteins of several kDa. Fluorescent tags, such as 
green fluorescent protein (GFP), are common because they can also be used for live cell 
imaging. Furthermore, GFP purification allows recovery of most of the GFP-fused protein 
from a complex mixture in a single step. In this approach, proteins co-purifying with the 
bait are compared to a control condition where only the GFP protein is expressed (Figure 3 
B). Nevertheless, tag insertion might affect protein functions or prevent/trigger interactions 
with other proteins. Moreover, expression levels of fusion protein can be significantly 
different compared to their native counterparts and can affect binding capacities. Therefore, 
when efficient and specific antibodies are available, it is preferable to rely on purification of 
the native protein subunits to purify complexes. In that case, the control fraction can be 
obtained by incubating lysates with the beads alone (Trinkle-Mulcahy et al., 2008) or by 
depleting the protein of interest by RNA interference (quantitative immunoprecipitation 
combined with knockdown, QUICK) (Selbach and Mann, 2006) (Figure 3 A). Recently, 
Hubner et al. (Hubner et al., 2010) described quantitative bacterial artificial chromosome 
interactomics (QUBIC), using tagged proteins expressed under endogenous control in 
mammalian cells. Identification of interacting partners is achieved by robust and efficient 
affinity purification based on the GFP tag (Hubner and Mann, 2011; Vermeulen et al., 2010). 
However, most protein-protein interactions are dynamic and are hardly assessed by single 
AP-MS experiments. Depending on internal or external cues protein binding specificities 
can be modulated, e.g., by post-translational modification. This can result in their release 
from or recruitment to specific protein complexes thus potentially affecting their function(s) 
or their localization.  
At steady state, different forms of a protein are present in the cell which can hinder the 
discrimination among its interactors. A solution to this problem can be to use exogenous 
baits corresponding to a specific state of the protein of interest or of a peptide to identify 
interactions specific to a particular state. Different strategies have been developed for the 
identification of genuine interactors with high confidence. Generally, single step 
purifications are associated with a large number of contaminants. Lower background signal 
is achieved using more stringent purification, for instance by sequential purification using 
two affinity tags (tandem affinity purification; TAP). In TAP, two tags separated by a  
 






A) Immunoprecipitation of endogenous proteins. Complexes from heavy (red) and light (green, control) 
labeled cells are purified using antibody-conjugated beads that target a specific subunit. Then the 
fractions are pooled before sample preparation and subsequent MS analysis. Control fraction can be 
obtained by using a cell lysate devoid of the target subunit by siRNA (QUICK) or by incubating a total 
lysate with the beads alone. B) One step purification of tagged proteins. A tagged subunit is expressed 
in heavy labeled cells (red). Using affinity columns, protein complexes are affinity purified using the tag 
and then eluted before being pooled with the control light fraction (green). After sample preparation the 
combined fraction is analyzed by MS. The control light fraction is obtained by expressing the tag alone 
in the cells. 
Fig. 3. Affinity purification based MS (AP-MS).  
cleavage site are fused to the protein of interest. In a first step the  complex is purified with 
the fusion protein using the first tag, then the protein of interest (along with its interactors) 
is released from the affinity matrix by specific cleavage of the tag before performing a 
second round of purification with the remainder of the tag. Different combinations of tags 
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have been combined and TAP strategies have been extensively used for AP-MS purification 
in many model systems (Gavin et al., 2006; Krogan et al., 2006). However, one drawback is 
the loss of weak interactors during stringent purification. A compromise is achieved by 
inserting a cleavage site between a tag and the protein of interest thus reducing the 
number of treatments and decreasing significantly the number of non-specific binders 
(Aguilar et al., 2010). In case of weak interactions, complexes can be fixed by treating with 
cross-linking chemicals either in live cells (Stingl et al., 2008; Yong et al., 2010) or cell 
lysates (Sinz, 2010). 
In general, quantitation greatly helps to discriminate false positive from true interactors. 
SILAC quantitation is more accurate and has advantages for protein complexes that are 
difficult to purify and where enrichment over background is smaller. As in all SILAC 
experiments, two differently labeled samples, here a control and a sample enriched in the 
target complex, are mixed and relative abundances of protein ratios are extracted from the 
MS spectra. In case of AP-MS, background proteins have a ratio of one as they bind as 
efficiently in both conditions. In contrast, true interactors have a high ratio as they are 
preferable purified from the labeled sample enriched in the complex of interest. Samples can 
be mixed either before (purification after mixing, PAM, (Wang and Huang, 2008)) or after 
purification (mixed after purification, MAP). The main drawback of PAM strategies is that 
dynamic interactions result in equilibrium between the light and heavy form during the 
purification, thus decreasing the observed ratio even for true interactors. 
4. Temporal analysis of proteomes 
4.1 Quantification of protein turnover by pulsed SILAC 
Protein turnover and protein degradation are critical for numerous biological processes, 
including the cell cycle, signal transduction and apoptosis. Organelle proteomes change 
over time and can be quickly adapted to respond to changing conditions. Therefore, 
unraveling mechanisms that determine protein abundances is important for understanding 
organelle dynamics and regulation.  
In general, quantitative approaches described before can be employed to gather snapshots of 
protein repertoires over time or in different conditions. However, such approaches quantify 
abundance changes of a given protein but fail to address what are the mechanisms 
underlying protein dynamics (decrease/increase turnover). Pulse-chase isotope tracer-based 
methods have been the method of choice to study protein degradation for decades. In such 
approaches, cells or animals are first metabolically pulse-labeled with radioisotope tracers 
(most commonly 3H, 15N, 35S are used). After a chase period concomitant with the beginning 
of the experiment, loss of the radiolabel from the protein of interest is followed by 
scintillation or autoradiography as a readout of protein degradation. Such classical pulse 
chase experiments have been successfully translated to protein turnover analyses by MS. In 
MS-based turnover analyses, cells are only pulsed. For cells in culture, the most common 
approach is a modification of SILAC. Instead of combining two differently labeled cell 
populations, cells are pulsed with stable isotope containing amino acids (pSILAC). The 
replacement of amino-acids in proteins is followed by MS analysis over time to extract 
turnover rates. Similarly to results from a standard SILAC experiment, pSILAC yields two 
forms of the same peptide. At the time point corresponding to the half-life (t1/2) of a specific 
protein, the intensities of the light and heavy peaks for a peptide pair derived from this 
protein are equal (Figure 4). 
 




Light labeled cells (green) are pulsed with heavy amino acid containing medium (red). Cells are harvested 
at different time points, lysed, processed into peptides and analyzed independently. Ratios H/L are 
derived from intensities of heavy (H, red) and light (L, green) peptide peaks in the MS spectra. Note, at 
protein half life (T1/2) intensity of light and heavy peptides are equal in the mass spectra. Then loss of light 
label can be calculated over time and turnover rates are extracted from non-linear curve fitting. 
Fig. 4. pSILAC to analyze protein turnover.  
To date, pSILAC has been mostly applied to cells in culture: Saccharomyces cerevisiae (Pratt et 
al., 2002), Streptomyces coelicolor (Jayapal et al., 2010) and human cells (Doherty et al., 2009; 
Schwanhäusser et al., 2011; Zee et al., 2010). Schwanhäusser et al. measured protein 
abundances and turnover of more than 5,000 proteins in HeLa cells. Combination of pSILAC 
with metabolic pulse labeling of mRNA in the same cells enabled comparison of proteins 
and mRNAs turnover at an unprecedented depth.  
At steady state, protein levels are constant. Therefore synthesis and degradation rates are 
equal. This feature is critical when comparing proteome turnover, but this assumption may 
not always be fulfilled when comparing different conditions. An alternative approach 
overcoming this limitation is to follow synthesis and degradation independently from each 
other. To follow regulation of protein synthesis during changes of cellular iron, 
Schwannäusser et al. combined control (non-treated) and iron-treated HeLa cells that have 
been differently SILAC pulsed (Schwanhäusser et al., 2009). At the beginning of the 
experiment, cells in both conditions were identically light labeled (L). Concomitantly with iron 
treatment, cells were differently pulsed with medium (M) or heavy (H) amino-acids. Then cell 
lysates were combined and analyzed by MS. The relative abundance of newly synthesized 
proteins in both conditions was then extracted from intensities of the M and H peaks in the MS 
spectrum. As expected, most of the 1311 proteins identified in this study do not present 
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specific synthesis regulation upon iron treatment (ratio M/H of 1). However proteins such as 
ferritins show up to 13 fold synthesis upregulation compared to normal conditions.  
4.2 Analysis of cell signaling as an example of dynamic PTM analysis 
Unbiased, quantitative proteomics enables studying signaling networks in a time resolved 
manner. Protein abundance is often the output of complete signaling cascades. MS can 
detect PTM changes as an early response to system perturbations, as well as the changed 
protein abundance as the output of a signaling cascade.  
Combination of phosphoproteomics with quantitative approaches such as SILAC enables 
the temporal analysis of signaling networks. In these experiments, cells are labeled in 
different SILAC states and stimulated for different periods of time. Applying this 
methodology, Olsen et al. quantified 6,600 phosphorylation sites in HeLa cells at 5 different 
time points after stimulation with epidermal growth factor (EGF) (Olsen et al., 2006). These 
experiments revealed insights into the early response of cells to EGF stimulation. 
Interestingly, this study showed that different phosphorylation sites on the same protein can 
react with completely different timing to a stimulus. Such results are easiest obtained by MS 
because it allows for detection of phosphorylation changes at particular amino acids of the 
protein sequence. Effects at different sites can otherwise easily be missed with classical 
methods that detect total phosphorylation of a protein. Other studies used a combination of 
SILAC labeling and different drug treatments to analyze the proteome and 
phosphoproteome of HeLa cells over the complete cell cycle (Olsen et al., 2010). A similar 
study in Saccharomyces cerevisiae used a mutant of the cell cycle kinase Cdk1 that allows 
inhibition of the kinase with an ATP analogue (Holt et al., 2009). Another recent 
phosphoproteome revealed great insights into the early differentiation of embryonic stem 
cells after stimulation with a diacylglycerol analogue. This study yielded roughly 20,000 
phosphosites with almost 50% of them responding to the stimulus (Rigbolt et al., 2011). 
These experiments help to dissect complex signaling networks since proteins are clustered 
into certain groups according to their response. In addition, the high resolution datasets 
serve as a great resource for the scientific community and provide data for further analyses 
to generate models for signaling networks.  
5. Conclusion 
Quantitative mass spectrometry based proteomics emerged over the last few years as a 
crucial technique for cell biology and biochemistry research. The exciting developments in 
this field discussed in this chapter have provided unexpected aspects of organelle dynamics, 
protein turnover and PTMs. Future developments in methodology, computation and 
technical developments will make these technologies accessible for a larger group of 
scientists. This should help to generate more high quality datasets which will serve as a 
reference for the larger scientific community. In addition, integration of proteomics data 
with data from other system-wide approaches, such as genetic screens or transcriptome 
analysis, will help to understand complex biological processes.  
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scientists. This should help to generate more high quality datasets which will serve as a 
reference for the larger scientific community. In addition, integration of proteomics data 
with data from other system-wide approaches, such as genetic screens or transcriptome 
analysis, will help to understand complex biological processes.  
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1. Introduction 
Mitochondria may be considered an evolutionary product originating from the 
endosymbiotic process of an aerobic bacterium with a protoeukaryotic cell, which started 
about 2 billion years ago. This hypothesis was based on the similarities in DNA and protein 
synthesis machinery between prokaryotic and eukaryotic cells (Margulis, 1970). In 1890, 
Altmann, who termed this organelle the “bioblast”, concluded that these were elementary 
organisms for performing vital functions (Ernster & Schatz, 1981). Furthermore, in 1898 
Benda introduced the name “mitochondrion” from the Greek (Mitos: thread and Chondrion: 
granule). Other authors showed the appearance of these structures during spermatogenesis 
(Ernster & Schatz, 1981) and defined them as subcellular organelles commonly found in the 
cytoplasm, with essential functions of aerobic metabolism for eukaryotic cells. These 
organelles have a wide plasticity and mobility, allowing some modifications in shape. 
Mitochondrial movement into the cytosol has been associated with microtubules, which 
may determine organelle organization in different cell types (Yaffe, 1999). Mitochondria can 
form long filaments of mobile chains, as observed in cardiac muscle cells, or be fixed into a 
single position as studied in sperm flagella (Yaffe, 1999). The number of mitochondria per 
cell may also vary according to cell type, usually located in high ATP utilization regions 
such as cardiac muscle and liver (Frederick & Shaw, 2007; Scheffler, 2008). This organelle 
also occupies a considerable portion of the cytoplasmic volume, being essential for the 
evolution of a number of organisms. 
Mitochondria are also involved in several central metabolic pathways that are important for 
cell function, modulation of cytosolic Ca+2 signaling, determination of cell death (apoptosis) 
(Camara et al., 2011), aging and associated diseases (Kowald & Kirkwood, 2011), 
autophagous embryonic development (Ong & Hausenloy, 2010), as well as being a 
continuous source of superoxide and  reactive oxygen species (Stowe & Camara, 2009; 
Koopman et al., 2010). Nevertheless, the main function of mitochondria is to generate 
chemical energy sources (ATP) through oxidative phosphorylation (Saraste, 1999), acting as 
the organism’s “powerhouse”. Without the presence of this particular organelle, animal cells 
would depend on anaerobic glycolysis for their energy production, which would be 
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chemical energy sources (ATP) through oxidative phosphorylation (Saraste, 1999), acting as 
the organism’s “powerhouse”. Without the presence of this particular organelle, animal cells 
would depend on anaerobic glycolysis for their energy production, which would be 
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completely insufficient to meet demand. Mitochondrial metabolism of sugars is considered 
highly efficient, producing more energy than the glycolysis pathway. 
Each mitochondrion has its own DNA and RNA with a complete system of transcription 
and translation, which synthesizes only a few proteins (Yoon et al., 2010). The 
mitochondrial genome of different tissues  differs in size and gene content (Gray et al., 
1999). In mammals, the mitochondrial genome is composed of a circular DNA molecule 
that has been reduced to approximately 16.5kb in size, encoding genes for only 13 
proteins, all of them indispensable for electron transport chain functioning. The human 
mitochondrial genome is composed of a single double-stranded DNA molecule that 
curiously does not have an intron, but contains 37 genes essential to the mitochondrial 
respiratory function (Wallace, 1999). Moreover, two ribosomal RNAs and 22 transfer 
RNAs are absolutely crucial for the mitochondria translation system (Yoon et al., 2010). 
All other genes responsible for normal mitochondrial operations are encoded in the cell 
nucleus (Wallace, 1999). 
Mitochondria have a double membrane system and are structurally divided into four 
compartments: inner membrane, outer membrane, matrix and intermembrane space (Chan, 
2006), as represented in Figure 1. Several porin molecules are present in the outer 
mitochondrial membrane. Porins are transporter proteins, which form aqueous channels 
through the lipid bilayer (Schirmer, 1998). Thus, the outer membrane functions as a filter, 
being impermeable to molecules above 5,000 kDa (Weissig et al., 2004). However, larger 
proteins can enter the mitochondrion through an N-terminus signal sequence connecting it 
to a specific protein (outer membrane translocase), located in the outer mitochondrial 
membrane (Herrmann & Neupert, 2000). An outer membrane disruption can lead to a  
 
 
Fig. 1. Scheme of the structure and function of mitochondria by a diagrammatic 
representation of the Krebs cycle, electron transport chain and ATP synthesis. 
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diffusion of proteins into the cytosol, inducing possible cell death (Chipuk et al., 2006). The 
intermembrane determines the space between the outer and inner membrane. Some proteins 
enter the intermembrane space, but they do not show the ability to penetrate the inner 
membrane due to enhanced hydrophobicity (Yoon et al., 2010). 
The inner membrane is characterized by a major phospholipid structure termed cardiolipin. 
This structure consists of four fatty acids, allowing the membrane potentially to become 
impervious to almost all molecules (McMillin & Dowhan, 2002). The membrane is 
convoluted in form, due to the presence of numerous cristae, which tend to be projected into 
the matrix, considerably increasing the inner membrane area. Interestingly, mitochondria 
from heart muscle cells have three times more cristae than those from liver cells (Alberts et 
al., 2002). Possibly this difference occurs due to ATP demand for different cell types. Inside 
the inner membrane there is a widely varying number of transporter proteins, which 
provide limited permeability and assist the entry and exit of ions and molecules that are 
required or metabolized by enzymes located in the mitochondrial matrix (Herrmann & 
Neupert, 2000). In summary, the inner membrane proteins have basically three categories 
and corresponding functions: ATP synthase which produces ATP in the matrix, carrier 
proteins to regulate the passage of metabolites from within the matrix to outside it, and 
proteins involved in oxidation reactions in the respiratory chain. 
The matrix is considered the highly functional zone inside mitochondria, due to its 
responsibility for ATP production (Krebs, 1940). It also contains mitochondrial DNA, 
RNA and ribosome special carriers. The matrix contains a vast amount of the enzyme 
responsible for the tricarboxylic acid cycle (TAC), also known as the Krebs cycle. This 
produces NADH + H+ and FADH2, essential for ATP synthesis by electrons donated to 
the electron transport chain (Krebs, 1940). These electron pairs are transferred to an O2 
molecule to form H2O molecules. In this way, protons are loaded from the intermembrane 
space to the mitochondrial matrix by ATP synthase enzyme, yielding ATP for each proton 
loaded (Ernster & Schatz, 1981). 
2. Classic and novel techniques applied to the mitochondrial proteome 
Progress in mitochondrial research has been made with a range of molecular research 
tools that have been used to identify and compare several compounds. Proteins are one of 
the major molecules of interest within mitochondria, because their disturbance is directly 
responsible for several biologic modulations. Proteomics is the study of all proteins at a 
single given moment; it involves tools to identify and elicit the entire protein composition 
of a single tissue, cell or organelle (Wilkins et al., 1996). Proteomic tools have developed 
steadily, and each has been used in its time in mitochondrial proteome research, starting 
with the classic combination of IEF (isoelectric focusing) and SDS-PAGE (sodium dodecyl 
sulfate polyacrylamide gel electrophoresis) known as 2-DE (two-dimensional 
electrophoresis). Next came the DIGE (Differential Gel Electrophoresis) fluorescent 
method, and now tools include several gel-free (MudPIT) and novel peptide labeling 
techniques, in addition to complementary functional analysis methods (e.g. Blue Native 
and Native DIGE). 
The analysis of cell compartments and specific organelles has become more common among 
proteomics researchers, now that subcellular research has provided in-depth knowledge of 
specific cellular signaling and other related functions (Scheffler, 2008). Up to now, 
mitochondria have been one of the main organelles to be investigated with a wide range of 
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research tools (Lopez & Melov, 2002), which have generated valuable molecular data 
(Scheffler, 2008). The main interest driving mitochondrial research stems from the wide 
spectrum of important molecular signaling that this organelle performs within the cell and 
also the entire organism, including its crucial role in energy production (Ernster & Schatz, 
1981), calcium homeostasis (Deluca et al., 1962), programmed cell apoptosis (Liu et al., 1996) 
and several pathologies (Chan, 2006; Pagliarini et al., 2008). Furthermore, mitochondrial 
dysfunction may play a crucial role in neurological (e.g. Alzheimer’s, Parkinson’s) (Lovell et 
al., 2005; Jones, 2010), cardiovascular (e.g. Ischemia, heart failure) and muscular diseases 
(Kim et al., 2006; Finsterer & Stollberger, 2010), as well as in the development of cancer 
(Kamp et al., 2011) and aging processes (Dencher et al., 2007; O'Connell & Ohlendieck, 
2009).  
It is also known that the mitochondrion network within a multicellular organism may be 
coordinated by a proteome reservoir of thousands of polypeptides (~1500), which can be up 
or down-regulated and have not been fully covered until now (Meisinger et al., 2008). 
Therefore the cataloging of the entire organelle proteome is of inestimable value to 
biomedical research, and further understanding of molecular mitochondrial modulation of 
positive stimulus or pathological insults shows enormous pharmacological potential 
(Fearnley et al., 2007; Wang et al., 2009). By different proteomic methods, much progress has 
been made in this direction in order to  target and catalogue mitochondrial  proteins from 
different organisms, such as humans (Rabilloud et al., 1998; Lefort et al., 2009), rodents 
(Zhang et al., 2008; Doran et al., 2009), fungi (Grinyer et al., 2004) and plants (Taylor et al., 
2011). 
In addition to simple proteome cataloging, several studies have been carried out to compare 
mitochondrial proteomes from different tissues (Forner et al., 2006; Fang & Lee, 2009; Forner 
et al., 2009), as well as from organ structures (e.g. heart atria, ventricle) (Forner et al., 2009) 
and  mitochondrial  subpopulations (e.g. intermyofibrillar and subsarcolemmal) (Kavazis et 
al., 2009; Ferreira et al., 2010; Ferreira et al., 2010), with the aim of characterizing specific 
molecular profiles and functions. Using these tissues, specific proteome characterization 
during various biologic stimuli and disturbances, such as aging (Dencher et al., 2007; 
O'Connell & Ohlendieck, 2009), exercise (Kavazis et al., 2009; Egan et al., 2011) and oxidative 
stress (2008; Lee et al., 2008; Zhang et al., 2008) have also been investigated to attempt to 
answer the numerous questions concerning the disturbance and adaptation of 
mitochondrial homeostasis. 
Concerning the delicate process of organelle isolation and some proteomic analysis 
limitations, much has been achieved in surveying the mitochondrial proteome, as 
reviewed elsewhere (Mathy & Sluse, 2008). Classic protein detection methods, such as 2-
DE, have been improved. Moreover, other proteomical techniques have reached higher 
levels of accuracy; data collection has improved with sample labeling and gel-free 
analysis, such as shotgun proteomics performed by multidimensional chromatography 
(2D-LC-MS) directly coupled with high throughput mass spectrometry (Aebersold & 
Mann, 2003; Tao et al., 2009). By means of these classic and up-to-date techniques, 
mitochondrial proteins have also been confirmed by the functional proteomic approach 
using native electrophoresis (e.g. Blue Native PAGE and Native DIGE) to investigate 
protein-protein interactions and membrane protein complexes (Brookes et al., 2002), 
increasing insights into molecular expression and signaling within inner and outer 
mitochondrial compartments. 
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2.1 Proteomic gel-based techniques in mitochondrial research 
The bulk of mitochondria proteome research has been performed using 2-DE associated 
with MS (mass spectrometry) identification. By combining IEF and protein separation by 
molecular mass (SDS-PAGE), after the staining process 2-DE gels may reveal up to 3000 
protein spots (Lopez & Melov, 2002). The capacity to simultaneously resolve thousands of 
proteins and by this technique compare different proteomes is possibly the main strength of 
this technique, which has undergone constant improvement since its invention in the 
middle of the 70´s (Klose, 1975; O'Farrell, 1975). To overcome its various limitations, such as 
sample complexity, poor protein solubilizing (e.g. membrane proteins) and low resolution 
(e.g. hydrophobic and extreme acid or basic proteins) observed in 2-DE analyses, several 
upgrades have been developed, from sample preparation (e.g. protein extraction and 
solubilizing process) to gel conduction. Given the precision needed in mitochondrial 
proteomic analysis, these limitations represent a considerable barrier. Marty and Sluse 
(2008) reported that mitochondrial proteins appear mostly within the pH range of 3 to 11, 
and within the 15 to 100 kDa molecular mass range. Furthermore, several proteins from the 
electron transporter chain, which represent about 40% of inner membrane proteins 
(Schwerzmann et al., 1986), have high hydrophobic properties, a property that clearly makes 
IEF processes more difficult (Santoni et al., 2000). An incomplete proteome map may reflect 
a series of misconducted analyses and slightly erroneous insights, leading overall to a very 
poor understanding of mitochondrial processes.  
Moving on from the classic gel-based technique, the limitations positively promoted a series 
of upgrades in proteomic methods, leading mitochondriomics research to provide more 
accurate, qualitative, quantitative and functional proteome data. Development of several 
fluorescent staining methods and protein labeling prior to 2-DE separation as performed by 
the Difference Gel Electrophoresis method, known as DIGE (Unlu et al., 1997), responded to 
specific concerns about the qualitative and quantitative limitations of protein spot detection. 
The DIGE method is based on the incorporation of different fluorescent cyanide dyes 
(Cydye3, Cydye5 and Cydye7 by GE Healthcare) into lysine residue present in the protein 
samples (Byrne et al., 2009). Once each sample is labeled with a distinct fluorescent dye, 
which includes an internal standard (a mixture of all labeled samples), samples are resolved 
together by the same 2-DE experiment. As the gel is scanned, fluorescent excitation from 
each distinct dye is captured and overlapped for spot expression comparison between the 
other dyes and the standard signal, enabling the results to overcome possible intra-gel 
variability errors (Lilley & Friedman, 2004). In comparison to classic 2-DE, the DIGE 
technique has been successfully used by various research groups to shed some light on the 
mitochondrial proteome in a wide variety of organisms and physiological modulations 
(Jacoby et al., 2010; Egan et al., 2011; Glancy & Balaban, 2011). Because it overcomes the 
problem of data reproducibility, DIGE is the ultimate gel-based method and strongly 
recommended when protein quantification and comparison is desirable, as has been well 
reviewed (Mathy & Sluse, 2008). 
Most of the gel-based methods (2-DE and DIGE) started with treatments using strong 
solubilizing detergents (e.g. SDS, CHAPS, Sulfobetaines, Triton-X) and chaotropic agents 
(e.g Urea, Thiourea) as reviewed by Petriz et al., (2011). The use of such agents leads to a real 
limitation on gel-based analysis caused by denaturing processes, which prevent any 
functional and protein-cross-talk analysis. However, major protein complexes present in 
abundance in the mitochondrial membrane may be analyzed from a functional perspective, 
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as proposed by differential analyses, such as Blue-Native Electrophoresis (BN-PAGE) 
developed by Schagger and Von Jagow (1991). The main idea of BN-PAGE in mitochondrial 
research is first to separate membrane and other functional protein complexes by preserving 
enzyme activity using a non-denaturing gel. These entire complexes are then separated 
within a denaturating SDS-PAGE gel in order to divide protein complexes subunits by their 
molecular weight (Schagger & von Jagow, 1991). Brookes et al. (2002) have shown the great 
potential that this technique has demonstrated in functional proteomics for mitochondrial 
molecular signaling, protein-to-protein interaction and post-translational modifications, 
especially in respiratory chain proteins from the mitochondrial membrane. A variation of 2D 
BN-PAGE is the Native DIGE (Difference Gel Electrophoresis) technique (Dani & Dencher, 
2008), which couples the fluorescent dyes labeling technique to the previously described 
BN-PAGE (Dani & Dencher, 2008). DIGE analyses use fluorescent labeling and internal 
standards to enhance the accuracy of analyses. Thus, non-denaturing techniques have been 
well used (van den Ecker et al., 2010; Phillips et al., 2011), demonstrating that these 
techniques may contribute extensively to greater knowledge on the part that molecular 
signaling plays in mitochondrial functionality.  
2.2 Gel-free and proteomic straightforward methods 
Up-to-date gel-free proteomic techniques, such as LC/LC-MSMS (Reinders & Sickmann, 
2007; Lefort et al., 2009) have complemented gel-based experiments, leading 
mitochondrial molecular investigation to higher levels of data production and accuracy. It 
is well known that protein quantitation and low abundant protein detection have been 
among the major limitations on proteomic research. Fortunately, a series of gel-free 
methods have empowered this research by overcoming some of the main in-gel 
limitations and functioning as complementary tools for proteomic data mining. Gel-free 
methods are based on the separation of complex protein samples by liquid 
chromatography (e.g. reversed-phase, strong cationic exchange) followed by direct mass 
spectrometry analysis. When performed by more than one LC column  this entire process 
characterizes 2D-LC analysis, known as multidimensional protein identification 
technology (MudPIT) (Link et al., 1999). MudPIT has been recognized as a high 
throughput method with enhanced ability to identify thousands of proteins within a 
single experiment (Motoyama & Yates, 2008). To enhance multidimensional 
chromatography for MS analysis, a series of chemical molecular labeling methods were 
developed to facilitate proteomic mining and especially quantitative proteome 
comparisons. Basically, different proteome samples are mixed with isobaric or stable 
isotope chemical tags, digested with proteolytic enzymes such as trypsin and then loaded 
together into MudPIT, enabling quantitative comparisons (Aebersold & Mann, 2003). 
ICAT (Isotope-Coded Affinity Tags), SILAC (Stable Isotope Labeling with Amino acids in 
Cell culture) and iTRAQ (Isobaric Tags for Relative and Absolute Quantitation) are the main 
quantitative-labeling methods for gel-free methodology, permitting comparisons between 
different samples (2 to ~4) within the same experiment, as well as increasing the amount of 
quantitative proteome data that can be gathered by making the final process of peptide MS 
identification easier (Lovell et al., 2005; Jin et al., 2007; Meany et al., 2007). Each of these 
labeling techniques has its own peculiarity; for instance, the SILAC method is based on the 
incorporation of “light” or “heavy” isotope agents (2H, 13C, 15N) within distinct cell cultures, 
which will further synthetize labeled proteins for proteomic comparisons. SILAC was first 
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described by Ong et al., (2002) to quantify protein expression differences from mammalian 
cells through a differentiation process. This method is also known as metabolic stable-
isotope labeling and has been used to investigate thousands of mitochondrial proteins 
identified by a variety of studies in pathology, such as Parkinson’s treatment (Jin et al., 
2007), human cytomegalovirus infection (Zhang et al., 2011) and diabetic sensory 
neuropathy etiology (Akude et al., 2011).  
Another well-established labeling method, ICAT, was first described by Gygi et al., (1999) to 
quantify proteome modulation of yeast metabolic function under glucose-repressed 
stimulus. The ICAT technique labels cysteine (Cys) side chains with “light” or “heavy” 
isotope tags, permitting intensity pair comparison from peptide ions from distinctly labeled 
protein samples. This labeling technique has also been well implemented in mitochondrial 
analysis (Jiang et al., 2005; Lovell et al., 2005), but ICAT fails to identify non-cysteine-
containing proteins, which is its major technical limitation.  
A vital property of gel-free methods (2D-MSMS) is the generation of a great number of MS 
spectra, which may be further quantified by several peptide tagging methods (e.g. ICAT, 
SILAC, iTRAQ). Nevertheless, the identification and analysis of proteins from marked 
peptide spectra is usually time-consuming. Overcoming this limitation, the ultimate labeling 
method is iTRAQ, which has made the entire process less laborious. Another major 
improvement brought by this method is the ability to analyze up to four different protein 
samples in the same experiment, leading to a single MS spectrum peak (Ross et al., 2004). By 
labeling the peptides’ N-termini iTRAQ is a successful tool in mitochondrial proteome 
development, principally within quantitation research design (Jullig et al., 2007; Kavazis et 
al., 2009; Glancy & Balaban, 2011). Gel-based and gel-free methods for mitochondrial 
analysis are schematically represented in Figure 2. Undoubtedly, mitochondrial proteomic 
research still leaves several gaps. It is clear that the classic proteomic approach alone will not 
be enough to fill these gaps. The two strategies together are likely to be the most complete 
and secure path to successful mitochondrial proteome research. 
3. Proteomic tools applied to understanding mitochondria: The effects of 
drugs 
The mitochondrion plays a key role in normal and healthy cells. However, under 
abnormal conditions this organelle can also be involved in cell dysfunction and death. 
Mitochondrial dysfunction may be implicated in a large number of diseases, such as 
cancer, neurodegenerative diseases (such as Alzheimer's), diabetes, ischemia-reperfusion 
injury and aging (Wallace, 1999). The identification of mitochondrial proteins may 
therefore be a beneficial tool in drug development and also to diagnose targets for such 
diseases. The treatment of these illnesses involves the drug-mitochondrial interaction that 
acts in the three main mitochondrial functions: energy production, reactive oxygen 
species fabrication, and cell death control via both apoptotic and necrotic pathways 
(Green & Reed 1998; Kristal & Brown 1999). These organelles have a superoxide radical 
anion source, which arises from oxidative phosphorylation and can produce reactive 
oxygen species and also their precursors. Although protective mechanisms are known to 
regulate these molecular species, reversible and irreversible oxidative damage to proteins, 
nucleic acids and lipids may occur. Under elevated oxidative stress conditions, such as 
cell aging or disease, these oxidative lesions can be accumulated and have drastic 
consequences for cellular function, leading ultimately to senescence, environmental  
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Fig. 2. Proteomic tools for mitochondrial analysis. Schematic workflow of the gel-based (red) 
and gel-free (green) proteomic tools used to compose the mitochondrial proteome after 
extraction process (blue).  
modification, for example in the S-nitrosylation process or the oxidation of cysteine to 
sulfenic acid, and also to cell death (Gibson, 2004).  
In this context, mitochondria are a pharmacological target for drugs that modulate oxidative 
stress (Murphy & Smith, 2000). There are various compounds that can target oxidative stress 
in mitochondria. Coenzyme Q and vitamin E are natural compounds that are both used as 
dietary supplements. MitoQ and MitoVitE are based on triphenylphosphorium 
modifications of coenzyme Q and vitamin E, respectively. They are more potent than their 
natural sources and have been suggested for treating Friedreich’s ataxia, since they prevent 
cell death (Jauslin et al., 2003). Another pharmacological example is flupirtine, a nonopioid 
analgesic drug with mitochondrial antioxidant activity, which acts as a free radical 
scavenger (Schluter et al., 2000). Flupirtine has been shown to inhibit ischemic injury 
(Osborne et al., 1996) and apoptosis, and may be protective against Alzheimer’s and prion 
disease (Perovic et al., 1998). 
In spite of the role of mitochondria in different diseases and their potential target for some 
disease treatments, there is little information about the proteome associated with drug-
mitochondrial interaction and target biomarker drugs for treatment design. Based on 
proteome analysis, with 2D-gel analysis followed by MALDI TOF MS or ESI MS/MS for 
protein identification, Arrell et al., (2006) analyzed  pharmacologically mimicked ischemic 
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preconditioning. This pathology is characterized by resistance to ischemia reperfusion 
injury in response to previous short ischemic episodes. In this study, the authors mimicked 
preconditioning, treating isolated rabbit ventricular myocytes with adenosine or diazoxide. 
They observed a distinctive pattern of affected proteins consistent with specific perturbation 
of mitochondrial metabolism through changes to a selected number of mitochondrial 
protein complexes, with specificity and complexity of the drug response. Compared to the 
vehicle-treated controls, expression of 28 significantly altered proteins was observed and 19 
of them were identified. The majority of these proteins are involved in mitochondrial 
energetics, including subunits of enzymes from the tricarboxylic acid cycle and oxidative 
phosphorylation complexes. Among these changed proteins, the -subunit of ATP synthase 
was adenosine-phosphorylated after 60 min of treatment. These results prove that adenosine 
and diazoxide treatment acts in different cell parts, especially in the mitochondria (Arrell et 
al., 2006). 
Regarding the anti-inflammatory agents that target mitochondria, the proteome-related 
literature has reported some data about simvastatin. Simvastatin is a 3-hydroxy-3-
methylglutaryl coenzyme A reductase inhibitor that provides neuroprotection, acting 
against cell loss resulting from strokes (Law et al., 2003), Alzheimer’s disease (Vega et al., 
2003), Parkinson’s disease (Rajanikant et al., 2007) and traumatic brain injury (Lu et al., 
2004), all of which are pathologies that target mitochondria. In the same line, Pienaar et al., 
(2009) compared rat mitochondrial proteins pre-treated with simvastatin for 14 days, 
followed or not by a unihemispheric injection of a mitochondrial complex S inhibitor. The 
authors identified 24 different mitochondrial proteins by mass spectroscopy, which 
represented many facets of mitochondrial integrity, with most of them forming part of the 
electron transport chain machinery (Pienaar et al., 2009). These results demonstrated that the 
simvastatin-mitochondrial interaction may contribute to beneficial effects, especially when 
associated with statin use.  
Research with cancer has shown that cancer cells are adapted to fast growth and 
proliferation in acid pH conditions and low oxygen tension (Griffiths, 2001). Cancer cells 
have a mitochondrial defect in oxidative phosphorylation, and this can be reversible. 
Therefore, mitochondrial-drug interaction in cancer pathology should divert energy 
production from the anaerobic path to oxidative phosphorylation. The effect is to decrease 
nuclear ATP, leading to a consequent reduction in cell proliferation, so that the tumor cells 
begin cellular differentiation and subsequently undergo cell death and apoptosis (Harris et 
al., 2000).  
Neoplastic drugs that target different mitochondrial proteins are already on the market for 
the treatment of various types of cancer. One of these, doxorubicin, also known by the 
trademark name Adriamycn, is an anthracycline antibiotic and extremely effective 
antineoplastic agent used in a wide variety of solid cancers and hematological malignancies 
since the early 1960’s (Di Marco et al., 1969). Hammer et al., (2010) analyzed proteomically 
the doxorubicin-induced changes in a hepatocellular carcinoma cell model, using 2D DIGE, 
liquid chromatography coupled with electrospray ionization and a hybrid quadrupole 
linear ion-trap and Fourier-transform ion-cyclotron-resonance mass spectrometry (LC-ESI-
LTQ-FTICR-MS) and nano-LC coupled offline to MALDI-TOF/TOF-MS (LC-offline-
MALDI-TOF-TOF-MS.) These methods identified 155 different proteins that could be 
assigned to a wide variety of biological processes, compared to non-treated control cells. 
Functional analysis revealed major influences of doxorubicin on proteins involved in 
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protein synthesis, DNA damage control, electron transport/mitochondrial function and 
tumor growth.  
Further, as regards mitochondrial proteins, the authors above observed that doxorubicin 
increases the Bax level (apoptosis regulator), which is involved in cytochrome C release 
from mitochondria and in turn caspase activation and decreased expression of Bcl-2. 
Oxidative stress induction was also shown by the enhanced levels of ferredoxin reductase 
and transferring receptor protein 1 and decreased levels of ERO1-like protein-. Proteins 
involved in -oxidation, such as acyl-CoA dehydrogenase, acetyl-CoA carboxylase 1 and 
hydroxymethylglutaryl-CoA synthase, were also increased in the doxorubicin-treated 
group. These results demonstrated that application of doxorubicin led to up-regulation of 
proteins involved in adaptation to oxidative stress and maintenance of cell integrity 
(Hammer et al., 2010).  
Doxorubicin is widely used in drug combination strategies for non-Hodgkin lymphoma 
therapy (Multani et al., 2001). Jiang, Sun et al., (2009) used 2D-DIGE in combination with 
ESI-MS/MS to analyze changes in mitochondrial protein expression in controlling Raji 
(lymphoblast-like cells) and doxorubicin-treated Raji cells. Defects in the mitochondrial 
antioxidant defense system, DNA repair, and oxidative phosphorylation may be the main 
mechanisms involved in the effect of doxorubicin on the mitochondria of Raji cells. 
Imperfections in the mitochondrial antioxidant defense system have dual effects on the 
anticancer mechanism and cardiac toxicity. The authors also found numerous proteins 
associated with significant chemo-resistance to doxorubicin, including heat shock protein 
(HSP) 70, prohibitin and ATP-binding cassette B6 transporter isoform. The reported results 
identified several biomarkers with the potential to enable prediction of anticancer therapy 
response (Jiang et al., 2009). 
Another example of a highly potent chemotherapeutic drug that interacts with mitochondria 
is cisplatin, commonly used for a variety of human malignancies, such as testicular, 
prostate, ovarian, cervical, lung, and colon cancers (Wang & Lippard, 2005). Cisplatin 
cytotoxicity is primarily mediated by its ability to cause DNA damage and apoptotic cell 
death (Siddik, 2003). Zhang et al., (2009) demonstrated, by different experimental methods, 
together with proteome analysis, that the induction of phospholipase A2-activating protein 
(PLAA) promoted cisplatin-associated apoptosis in cervical carcinoma HeLa cells by four 
pathways: activation of phospholipase A2 and accumulation of arachidonic acid, which 
causes mitochondrial damage; down-regulation of clusterin, a cytoprotective protein which 
promotes chemoresistance; upregulation of IL-32, which causes apoptosis in HeLa cells; and 
activation of JNK/c-jun signaling, which is an established inducer of Fas ligand expression 
and apoptosis mediated receptor (Zhang et al., 2009). 
Analgesics also interact with mitochondria. The literature has reported the widely used 
analgesic acetaminophen and its mitochondrial interaction, including the fact that 
acetaminophen overdose may cause severe centrilobular hepatic necrosis in experimental 
animal models and humans (Davidson & Eastham, 1966). Ruepp et al., (2002) explored 
acetaminophen overdose effects in mitochondria from animal model liver by genomic and 
proteomic tools. Proteomics showed that protein changes in mitochondria were present at 
15 min post injection, thus preceding most of the gene regulations. The decrease in ATP 
synthase subunits and -oxidation pathway proteins indicated a loss of energy production. 
Since mitochondrial morphology was also affected very early at top dose, they concluded 
that acetaminophen overdose was a direct action of its known reactive metabolite N-acetyl-
p-benzoquinone imine, rather than a consequence of gene regulation (Ruepp et al., 2002).  
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Antipsychotic drugs are another kind of medication that target mitochondria. Psychotic 
brains present anomalies in their mitochondria, including mitochondrial dysfunction or 
abnormal cerebral energy metabolism, which may play an important role in the 
pathophysiology of schizophrenia. Together with this, mitochondrial energy metabolism 
might be disturbed by the antipsychotic drugs used (Modica-Napolitano et al., 2003). 
Various antipsychotic drugs have been available for treatment: chlorpromazine (CPZ), 
was in the first generation and presents serious side-effects (Freedman, 2003); clozapine 
(CLZ), the first atypical antipsychotic drug to present more antipsychotic effects without 
the adverse mobility effects of the first-generation drugs (Freedman, 2003); and quetiapine 
(QTP), an atypical antipsychotic drug that usually acts on both dopamine receptors and 
serotonin receptors (Martorell et al., 2006). Comparative proteomics of all mitochondrial 
proteins from the cerebral cortex and hippocampus of a rat model (Sprague-Dawley rats) 
in response to CPZ, CLZ and QTP antipsychotic medication demonstrated 14 
differentially expressed different proteins. Six of them belong to the respiratory electron 
transport chain of oxidative phosphorylation, showing significant changes in protein 
quantity including NADH dehydrogenase 1  subcomplex 10, NADH dehydrogenase 
flavoprotein 2, NADH dehydrogenase Fe-S protein 3, F1-ATPase beta subunit, ATPase, H+ 
transporting, lysosomal, beta 56/58 kDa, isoform 2 and ATPase, H+ transporting, V1 
subunit A, isoform 1; demonstrating antipsychotic drug-mitochondrial interaction (Ji et 
al., 2009). 
Dietary supplements can also act on the mitochondrial proteome. Epidemiological studies 
suggested that the consumption of soy-containing foods has the ability to prevent or to slow 
down the development of cardiovascular syndromes (Zhang. X, 2003). A systematic review 
suggested that a diet supplemented with soy protein isolate containing isoflavones reduces 
low-density lipoprotein (LDL) and cholesterol (critical risk factor in the development of 
cardiovascular disease), but no effects on triglycerides or high-density lipoprotein 
cholesterol contents were observed (Cassidy & Hooper, 2006). Proteome analysis revealed 
that the LDL-induced alterations of numerous proteins were reversed by the soy extracts 
and also by the combination of genistein/daidzein soy isoflavones. However, both 
treatments regulated only three proteins functionally linked to mitochondrial dysfunction 
and were also connected to reducing the generation of oxidized-LDL-mediated 
mitochondrial reactive oxygen species, which could induce damages.  
Several reports demonstrate the role of specific foods in mitochondrial function (Fuchs. D et 
al., 2007). A nutrient-sensing target of the rapamycin pathway appears to have a conserved 
role in regulating life span. It has been demonstrated that the reduced nutrient-sensing 
target of rapamycin signaling extends yeast’s chronological life-span by increasing 
mitochondrial oxygen consumption, in part by up-regulating mtDNA-encoded oxidative 
phosphorylation subunit translation (Bonawitz et al., 2007). These data demonstrate that 
mitochondrial dysfunction could also be related to aging. Besides, it has been demonstrated 
by 2D DIGE and MALDI MS/MS that the nutrient-sensing target of rapamycin signaling 
has a global role in regulating mitochondrial proteome dynamics and function (Pan & 
Shadel, 2009). 
Another proteomic field that improved the understanding of drug-mitochondria 
interaction is in the elucidation of drug targets and the discovery of mechanisms of 
resistance to different pathogens. Plasmodium falciparum is responsible for approximately 
247 million cases of malaria and one million deaths each year (WHO, 2011). The drug 
doxycycline is currently one of the recommended chemoprophylactic regimens for 
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Another proteomic field that improved the understanding of drug-mitochondria 
interaction is in the elucidation of drug targets and the discovery of mechanisms of 
resistance to different pathogens. Plasmodium falciparum is responsible for approximately 
247 million cases of malaria and one million deaths each year (WHO, 2011). The drug 
doxycycline is currently one of the recommended chemoprophylactic regimens for 
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travellers visiting malaria-endemic areas in southeast Asia, Africa and South America 
(Gras et al., 1993). The emergence of P. falciparum resistance to most anti-malarial 
compounds has highlighted the urgency to develop novel drugs and to clarify the 
mechanisms of anti-malarial medications currently used. In this study, the authors 
analyzed protein expression changes by 2D-DIGE and iTRAQ methods in the schizont 
stage of the malarial parasite, following doxycycline treatment. Although some of these 
proteins have already been described as being deregulated by other drug treatments 
(Lasonder et al., 2008), numerous modifications in protein levels seem to be specific to 
doxycycline treatment, suggesting that apicoplasts and mitochondria are the main targets 
of doxycycline (Briolant et al., 2010).  
Despite the progress made in these combined efforts, human mitochondrial databases have 
not yet been fully exploited to identify or target new candidates for drug development. In 
addition, the proteome of different pathologies and also the interaction between drug-
pathology proteins related to pharmacological action and side effects should be further 
studied. On the other hand, proteomic tools can help to understand this important protein 
relation better, with a view to designing mitochondrial biomarkers that may be useful in 
drug screening, clinical diagnosis, treatment follow-up and in discovering mechanisms of 
drug resistance (Figure 3). 
 
 
Fig. 3. Summary of main pathologies and drugs related to mitochondria, together with the 
main proteomic tools described in the studies above, as well as the proposed targets of this 
triple association. 
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4. Mitochondrial proteomics applied to exercise research 
As reviewed by Lopez and Melov (2002), several studies have shown the characterization 
of complex mixtures of mitochondria proteins expressed in diseased and healthy samples, 
leading to a further understanding of their functions in metabolic or physiological 
processes. This approach has reinforced protein research, leading to important progress in 
the study of mitochondrial functions and cognate molecular signaling. It is well known 
that exercise leads to biological adaptations that are highly specific and directly 
dependent on duration, frequency, intensity and stimulus nature, leading this process to 
require intensified oxygen demand (Hawley et al., 2011). As is recognized, one of the most 
important contributions of mitochondria is ATP synthesis, through oxidative 
phosphorylation (OXPHOS). Therefore, it seems obvious that a large range of decisive 
phenotype modulations associated with exercise occur within mitochondria. Despite the 
great importance of the mitochondrial proteome in several physiologic adaptations, there 
are few data and many questions remaining vis-à-vis molecular signaling, interaction and 
activity following exercise stimulus.  
In this perspective, Bo, Zhang and Ji (2010) indicated that exercise not only raises 
mitochondrial OXPHOS, but also exerts profound influences on mitochondrial morphology 
and biogenesis, being one of the most important influences on the fusion-fission process, 
whose action is responsible for continuous  mitochondrial morphology remodeling. The 
mitochondrion has been seen as a dynamic networking organelle in which fusion and 
fission are intrinsic coupled processes. This process supports deletions of animals’ damaged 
mitochondria according to organelle size (Kowald & Kirkwood, 2011). The complete process 
of mitochondrial fusion-fission has not been thoroughly elucidated, however, because there 
are many proteins involved in execution or modulation that remain to be described. 
Nevertheless, the mitochondrial dynamic appears to be specifically regulated depending on 
cell type or by the given function of certain tissues (Liesa et al., 2009). Mitochondrial fusion 
is a mechanical two-step process, where the outer and inner mitochondrial membranes are 
fused. This process depends on membrane potential and also the presence of GTP 
molecules, and is coordinated by optic atrophy gene 1 (OPA1)  and mitofusins (Mfns), 
which promote the fusion of the lipid membrane (Liesa et al., 2009; Zorzano, 2009; Otera & 
Mihara, 2011). These proteins carry out various activities in promoting fusion and 
modulating the mitochondrial membrane (Zorzano, 2009). Moreover, according to the same 
author, fission is coordinated by dynamin-related protein 1 (Drp1) and Fission 1 homologue 
protein (Fis1) that completes these events. 
Mitochondrial dynamics plays an important role in organelle functionality, contributing 
to an efficient bioenergy supply. The interruption of such processes leads to loss of 
mitochondrial activity and further diminished OXPHOS, suggesting its essentiality for 
mitochondrial function (Misko et al., 2010; Kowald & Kirkwood, 2011) and its 
contribution to the development of some neurodegenerative diseases (Westermann, 2010). 
Dynamic modifications in mitochondrial fusion-fission proteins during a session of 
extended exercise with incremental duration leads to a decrease in mitofusin Mfn1/2 
expression and also an increase in Fis1 expression (Bo et al., 2010). According to the same 
authors, these alterations are related to exercise intensity, suggesting that fission may play 
a compensatory role for OXPHOS injury through improving glucoses and pyruvate 
uptake. This fact could maintain energy supply and prevent lactate accumulation, 
delaying the fatigue process associated with the enhancement of H+ concentration. So it is 
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possible that in severe exercise mitochondrial fission may be a powerful indicator of 
muscle damage (Bo et al., 2010).  
The role of exercise in cardiac health promotion has been well described in literature 
(Ascensao et al., 2007). This cardioprotective phenotype, normally associated with 
endurance exercise, seems to be related to increased myocardial antioxidant capacity 
(Kavazis et al., 2009). Oxidative stress resulting from exercise seems to be part of 
physiological adaptation. Severe exercise intensities activate a cascade of intracellular 
sources for reactive oxygen species (ROS) and it is clear that muscle adaptation depends on 
this process. However, it is important to observe that excessive ROS production can 
negatively influence exercise performance and can also lead to long-term health 
consequences (Bailey et al., 2004; Sahlin et al., 2010; Sun et al., 2010). The mechanism of 
increased ROS production during exercise is not totally clear, but experimental evidence 
suggests that mitochondria are the main source of ROS production during exercise (Di Meo 
& Venditti, 2001; Fernstrom et al., 2007). ROS levels are also described as depending on 
oxygen concentrations, and an additional electron accepted during energy production is 
used to create superoxide, a more reactive form of oxygen, which can be converted to 
hydrogen peroxide (H2O2) (Sarsour et al., 2009). Animal cells have additional antioxidant 
enzymes (e.g. catalase, glutathione peroxidase), and the newly identified family of 
peroxidases (e.g. PRDX) to neutralize H2O2 (Chang et al., 2004). Peroxidases are a family 
with at least six isoforms in mammalian cells. One of these is the mitochondrion-specific 
isoform, PRDXIII, which acts in defense against oxidative stress caused by H2O2 produced 
during the mitochondrial respiratory chain process (Kavazis et al., 2009). By using the 
iTRAQ technique, Kavazis et al., (2009) demonstrated a left ventricular remodeling after 
endurance exercise training in preconditioned animals. This study has shown the up-
regulation of PRDXIII in subsarcolemmal mitochondrial subfraction, demonstrating a 
possible role of PRDXIII in heart remodeling. Exercise has also been demonstrated to reduce 
oxidative stress and dysfunction of mitochondria after myocardial infarction. 
ATP production is well described as declining with age (Drew & Leeuwenburgh, 2003; 
Drew et al., 2003; Short, 2005) leading to metabolic impairment, so endurance exercise seems 
to be an important agent in improving and preserving mitochondrial function. Using mass 
spectrometry methods and the iTRAQ approach, Lanza et al., (2008) demonstrated that 
tricarboxylic cycle enzymes and electron transport protein expression were down-regulated 
in older sedentary people when compared to younger subjects. On the other hand, 
endurance-trained elderly men exhibited an up-regulation of those proteins, suggesting that 
the expression level of key mitochondrial proteins may be a primary determinant for ageing. 
Thus, diminished oxidative capacity and regular endurance exercise appear to be beneficial 
in improving ATP synthesis, partially reversing some metabolic impairment caused by 
aging. Recently, Egan et al., (2011) used the 2-D DIGE technique to demonstrate that 
adaptation of skeletal muscle to endurance exercise occurs within only 7 days of training 
with an increase in ATP generation.  
Exercise is therefore recognized as an important agent in improving health, and it is also an 
auxiliary in numerous medical treatments and therapy. These findings about exercise have 
led to a better perception of the plasticity of skeletal muscle, mainly by the modulation of 
the mitochondrial proteome, contributing to understand muscle sensitivity to exercise 
stimulus. All of these results obviously indicate that phenotype changes associated with 
exercise are linked directly to mitochondrial proteome modulation. This fact makes 
mitochondrial research a promising field in sports and medical science. 
 




In summary, data reported here clearly show the enormous importance of mitochondria in 
multiple processes such as drug metabolism and exercise. These processes could be better 
understood by the use of genomic and proteomic techniques, which are constantly 
improving. In this view, the use of such technologies could bring real benefits in 
physiological understanding and in the improvement of biotechnological research related to 
drug design and activity. 
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1. Introduction 
Although several cell types have important regulatory roles in the induction and 
maintenance of a properly functioning blood-brain barrier (BBB) [Abbott et al., 2006; 
Armulik et al., 2010], it is clear that brain capillary endothelial cells (BCECs) constitute the 
barrier per se in histological terms. In the central nervous system’s blood vessels, BCECs are 
closely interconnected by tight junctions and form a continuous, circular tube lining the 
basal membrane in which pericytes are embedded. The basal membrane surface is itself 
covered by a continuous sleeve of astrocyte endfeet (Fig. 1). The BBB is one of the most 













Fig. 1. Brain capillary endothelial cells constitute the core of the BBB. The endothelial cells 
are surrounded by a tubular sheath of astrocyte end-feet. Pericytes are embedded in the 
basal lamina (between the endothelium and the astrocyte end-feet). Reprinted from [Pottiez 
et al., 2009a], with permission from Elsevier). 
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1. Introduction 
Although several cell types have important regulatory roles in the induction and 
maintenance of a properly functioning blood-brain barrier (BBB) [Abbott et al., 2006; 
Armulik et al., 2010], it is clear that brain capillary endothelial cells (BCECs) constitute the 
barrier per se in histological terms. In the central nervous system’s blood vessels, BCECs are 
closely interconnected by tight junctions and form a continuous, circular tube lining the 
basal membrane in which pericytes are embedded. The basal membrane surface is itself 
covered by a continuous sleeve of astrocyte endfeet (Fig. 1). The BBB is one of the most 













Fig. 1. Brain capillary endothelial cells constitute the core of the BBB. The endothelial cells 
are surrounded by a tubular sheath of astrocyte end-feet. Pericytes are embedded in the 
basal lamina (between the endothelium and the astrocyte end-feet). Reprinted from [Pottiez 
et al., 2009a], with permission from Elsevier). 
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The BBB is a dynamic, regulatory interface that controls the molecular and cellular 
exchanges between the bloodstream and the brain compartment [Abbott et al., 2010]. The 
BCECs’ barrier function depends on the acquisition and maintenance of characteristic 
features (referred to as the “BBB phenotype”), such as the absence of endothelial fenestrae, 
decrease in the number of endocytosis vesicles, the reinforcement of tight junctions and 
changes in the expression pattern of certain proteins. Overall, these physiological 
characteristics condition cell polarisation and permeation, transendothelial electrical 
resistance and a number of metabolic, receptor-based and transport functions. The latter 
mainly rely on the properties of the BCECs’ plasma membrane (PM). Relevant information 
regarding the lipid composition of the whole cell and of the apical and basolateral PMs has 
been reported [Tewes & Galla, 2001]. The latter authors demonstrated that each PM shows a 
unique lipid composition; the apical PM is enriched in phosphatidylcholine, whereas the 
basolateral PM is enriched in sphingomyelin and glucosylceramide. It has also been 
observed that co-culture with glioma C6 cells is able to induce a more in vivo-like fatty acid 
pattern in BCEC-based BBB models, although the intensity of these changes did not reach in 
vivo levels [Kramer et al., 2002]. Given the vital physiological functions performed by 
membrane lipids this aspect merits further investigation. In contrast, the PM’s protein 
moieties have been extensively studied. The protein composition of the PM is determined by 
the balance between membrane protein sorting, internalization and recycling. Briefly, 
biosynthesized PM proteins are translocated from the endoplasmic reticulum to the Golgi 
apparatus, where they undergo posttranslational modifications. Proteins are then sorted to 
the apical or basal membrane of polarized cells. Some PM proteins are subsequently 
internalised and sequestrated in lysosomes and then degraded or recycled to the cell 
surface; endocytic adaptor proteins may have a pivotal role in this process [Howes et al., 
2010; Kelly & Owen, 2011; O'Bryan, 2010; Reider & Wendland, 2011]. Plasma membrane 
proteins are involved in many BBB functions, including (i) cell-extracellular matrix 
interactions, (ii) the cell-cell junctions (especially tight junctions) that impede paracellular 
transport and polarise the cells, (iii) the molecular transport systems that regulate the 
exchange of nutrients and enable the passage of signalling molecules across the BBB and (iv) 
cell signalling via the expression of PM receptors [Leth-Larsen et al., 2010]. 
1.1 Plasma membrane proteins 
Integral PM proteins are polypeptides whose particular physicochemical properties enable 
insertion into the lipid bilayer and interaction with both the extracellular environment 
and/or the intracellular compartment. In all transmembrane polypeptides examined to date, 
the membrane-spanning domains are -helices or multiple -strands. Most integral proteins 
span the entire phospholipid bilayer with one or more membrane domains. The domains 
may have as few as four amino acid residues or as many as several hundred. The integral 
insertion of proteins into the PM means that the side chains of buried amino acids have Van 
der Waals interactions with the fatty acyl chains and shield the peptide bond’s polar 
carbonyl and imino groups. Indeed, integral proteins containing membrane-spanning α-
helical domains are composed mainly of uncharged hydrophobic amino acids. These 
properties probably make spanning regions more resistant to proteolysis by the trypsin 
enzyme used in most proteomics protocols. However, hydrophobic helices are often flanked 
by positively charged amino acids (i.e. lysine and arginine) thought to stabilize the helix by 
neutralizing the helix’s dipole moment and interacting with negatively charged 
phospholipid head groups. The second class of transmembrane proteins displays a radically 
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different structure in which several β strands form a barrel-shaped structure with a central 
pore. These strands contain predominantly polar amino acids and no long hydrophobic 
segments. Nevertheless, the outward-facing side groups on each of the β-strands are 
hydrophobic and interact with the membrane lipids’ fatty acyl groups, whereas the side 
chains facing the inside are mainly hydrophilic [Lodish et al., 2000]. Interestingly, several 
posttranslational modifications that do not occur in the cytosol (such as disulphide bond 
formation and glycosylation) enhance the stability of PM or secreted proteins prior to their 
exposure to the extracellular milieu. Overall, these particularities can dramatically decrease 
the PM proteins’ sensitivity to trypsin digestion. Newly synthesized proteins can also be 
targeted to the PM via the covalent attachment of a lipid anchor. Indeed, some proteins bind 
to the PM’s cytosolic surface via a covalently attached fatty acid (e.g. palmitate or myristate) 
or isoprene group (e.g. a farnesyl or geranyl group, whereas proteins from the PM’s outer 
leaflet are tethered some distance out from the surface by a glycosylphosphatidylinositol 
(GPI) anchor [Paulick & Bertozzi, 2008]. 
1.2 Proteomics of the plasma membrane 
Traditionally, mass spectrometry (MS)-based identification methods, chromatography and 
common cell biology techniques can be combined to form powerful tools for the proteomic 
mapping of PM proteins. Although major technical progress in MS continues to be made 
[Savas et al., 2011], the extraction, purification, separation and analysis of PM proteins 
remains problematic due to the latter’s low abundance, poor solubility in aqueous solution 
and micro-heterogeneity [Santoni et al., 2000]. It is now clear that the development of 
complementary approaches is a prerequisite for the comprehensive analysis of PM proteins, 
including protein isolation and enrichment strategies that best preserve certain functional 
states and minimize the loss of transient and/or peripherally associated non-
transmembrane proteins [Helbig et al., 2010], (Fig. 2). Polarized cells are present in many 
different organs and so their PMs have heterogeneous morphological and functional 
domains. Conventionally, PM proteomics can be performed with either cells cultured in 
suspension or adherent cells. Fig. 2 illustrates the importance of choosing the right method 
for the isolation of PMs and membrane sub- and microdomains and summarizes the 
different methods used in PM proteome analysis. The analysis can be divided into three 
experimental steps, all of which are challenging: (i) PM protein enrichment, (ii) separation 
and quantification and (iii) identification [Sprenger & Jensen, 2010]. 
1.3 Plasma membrane protein enrichment 
Plasma membrane protein enrichment can be achieved either directly by extraction of 
membrane proteins or indirectly by pre-purification of the PM itself (or part of the PM) prior 
to proteome analysis. In view of the PM proteins’ physicochemical properties, it is tempting 
to use of amphoteric agents (such as detergents) for enrichment. However, aqueous phase 
proteins will also be more soluble and may not necessarily be separated from the PM 
proteins. In contrast, the enrichment of membrane proteins based on two-phase partitioning 
(i.e. an aqueous phase and an organic phase) has been widely used and has proved its utility. 
The PM proteins can then be separated from aqueous proteins, due to the difference in 
hydrophobicity. Another way of directly studying the PM protein content involves its 
evaluation through its peptide fingerprinting. To this end, cell surface proteins undergo a 
“proteolytic shaving” procedure. The resulting peptides are purified, separated and then 
identified by liquid chromatography – tandem MS (LC-MS/MS). Although the proteolytic  
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Fig. 2. A schematic drawing of complementary strategies for the comprehensive proteomic 
analysis of PM proteins. Approaches which best preserve certain functional states and 
minimize the loss of transient and/or peripherally associated non-transmembrane proteins 
are preferable [Helbig et al., 2010]. 
shaving offers many advantages in theory (because surface-exposed peptides are more water-
soluble than their intrabilayer counterparts), the main drawback of this approach relates to its 
tendency to trigger cell lysis and thus the significant contamination of surface-exposed 
membrane peptides with cytosol-derived peptides. The glycosylation of PM proteins also 
prevents proteases from accessing the polypeptide moiety [Cordwell & Thingholm, 2010]. 
In view of the PM’s lipid composition, membrane pre-purification and separation from 
soluble proteins is conventionally performed by zone centrifugation with a density gradient. 
Most of the PM-associated (peripheral) proteins are recovered with the integral PM protein 
fraction - which can constitute a drawback or an advantage. To overcome this problem, 
additional high-salt, high-pH washing steps can be used to form easily separable membrane 
sheets that lack peripheral proteins. Furthermore, plasma, mitochondrial and endoplasmic 
reticulum membranes all have similar densities and so membrane fractions prepared by 
ultracentrifugation often contain a mixture of the three [Chen et al., 2006]. 
In fact, the most frequently used methods for the enrichment of PMs are those based on 
affinity chromatography, cationic colloidal silica particles, cell biotinylation or a tissue-specific 
polyclonal antiserum [Agarwal & Shusta, 2009; Shusta et al., 2002]. The cell surface membrane 
proteins may be covalently labelled (e.g. in biotinylation) or not (e.g. with cationic silica and 
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antibodies). The label serves as an anchor for silica bead- or magnetic bead-based separation. 
Loosely PM-associated proteins can always be removed by high-salt/high-pH washing [Josic 
& Clifton, 2007]. Similarly, the generally glycosylated PM proteins can be affinity-purified with 
lectin-based chromatography media [Cordwell & Thingholm, 2010]. 
At a higher organizational level, the topological mapping of plasma protein complexes 
requires the use of chemical or photo- crosslinking prior to unavoidable cell lysis, to keep 
them in a close-to-native state. Crosslinkers are often homo- or hetero-bifunctional agents 
absorbed on the cell surface [Back et al., 2003]; after chemical or photonic triggering, 
polymerization leads to the formation of a network that entraps PM proteins [Cordwell & 
Thingholm, 2010]. The proteomic needs in this field are increasing. A recent review 
described a new strategy and recent progress in the field of chemical cross-linking coupled 
to MS [Tang & Bruce, 2010]. 
Last but not least, membrane enrichment can be achieved by purifying microdomain 
components (e.g. caveolae, rafts and tetraspannin domains) enriched in the cholesterol and 
sphingolipids that give these cell surface structures their concave shape. This method 
exploits the poor solubility of membrane microstructure lipids vis-à-vis certain detergents 
[Zheng & Foster, 2009] (hence the term “detergent-resistant membranes”). Indeed, 
cholesterol- and sphingolipid-enriched membranes are insoluble in cold, non-ionic 
detergents (Triton X-family, NP-40, Tween, etc.) and their low buoyancy makes them 
amenable to purification by density gradient centrifugation. However, the main drawback 
of this method relates to the detergents’ ability to break up protein-protein interactions. It is 
important to note that membrane surface labelling and affinity purification can also be used 
to isolate this particular protein population. 
1.4 The state of the art in BBB PM proteomics 
Proteomics studies of the PM in human umbilical vein endothelial cells (HUVECs) [Karsan 
et al., 2005; Sprenger et al., 2004] and aortic endothelial cells [Dauly et al., 2006] have been 
initiated in the last decade. However, the phenotypic characteristics of these types of 
endothelial cell (EC) differ from those of BCECs. Hence, the use of non-brain ECs in in vitro 
BBB models is subject to debate [Cecchelli et al., 2007; Prieto et al., 2004]. 
To date, the very few studies to have focused on BBB EC proteomics can be divided into two 
distinct categories. The first category is outside the scope of the present review but is 
mentioned here for the sake of completeness. It concerns mid- to high-throughput 
proteomics initiated with in vivo or in vitro cells and that seek to answer a well-defined 
question (e.g. to identify the broadest possible protein expression profile in the brain 
microvascular endothelium [Haseloff et al., 2003; Lu Q. et al., 2008; Pottiez et al., 2010]; 
investigate cerebral ischemia [Haqqani et al., 2007; Haqqani et al., 2005; Haseloff et al., 2006] 
or evaluate a differential solubility approach for the characterization of EC proteins [Lu L. et 
al., 2007; Murugesan et al., 2011; Pottiez et al., 2009b]. Nevertheless, some PM proteins have 
been identified in the course of these high-throughput studies. The second category of truly 
BBB-focused PM proteomic studies arose in 2008 with the work by Terasaki et al.. These 
researchers used the elegant principle of isotopic dilution (see [Brun et al., 2009] for a 
review) to achieve the absolute quantification of 34 proteins known to be of significant 
interest. This list of membrane transporter and receptor proteins has recently been expanded 
to 114, following a human brain microvessel study [Uchida et al., 2011]. In addition to 
studies focusing on known BBB PM proteins, an indirect method based on a multiplex 
expression cloning strategy after fluorescence activated cell sorting with a tissue-specific 
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polyclonal antiserum has been developed [Agarwal & Shusta, 2009; Shusta et al., 2002]. The 
latter researchers identified a total of 30 BBB membrane proteins at the transcript level. Even 
though the expression of the corresponding gene products remains to be confirmed, these 
results constitute a considerable advance. Given that most PM proteins are glycosylated, the 
leverage of this post-translational modification for addressing PM proteins is tempting. 
However, large-scale glycoproteomics studies have only recently been reported. Indeed, a 
methodology based on hydrazine capture of membrane and secreted glycoproteins 
[Haqqani et al., 2011] revealed an enrichment in glycoprotein content (over 90%) and led to 
the identification of 23 new glycoproteins (i.e. not referenced as such in the Uniprot 
database). The full study results will doubtless be published soon. 
1.5 Cell surface biotinylation 
Chemical labelling of cell surface proteins is a novel methodology for the isolation of new 
target proteins. One of the major advantages of this approach is that the labelling reagent’s 
chemical properties can be chosen to suit the biological structures that are being targeted. 
Cell surface biotinylation is a selective technology for the capture of PM proteins. This 
technology comprises several steps: (i) the selective labelling of proteins with a biotinylating 
reagent, (ii) the capture of biotinylated proteins with avidin-coated magnetic beads, resins 
etc. and (iii) elution and digestion (or,  for increased specificity, digestion and elution) of the 
biotinylated proteins [Scheurer et al., 2005]. 
Using our in vitro BBB co-culture model [Dehouck et al., 1990], we have initiated a differential 
PM proteome approach that selects, separates and identifies BCEC cell surface proteins that 
are expressed differently in bovine BCECs with limited BBB functions versus those with re-
induced BBB functions. This method is based on biotinylation of bovine BCECs’ cell surface 
proteins with the reagent sulfosuccinimidyl-2-[biotinamido]ethyl-1,3-dithiopropionate (sulfo-
NHS-SS-biotin), in which biotin is coupled to a reactive ester group. The NHS group 
undergoes a nucleophilic substitution reaction with the primary amines of protein amino acids 
(mainly lysine residues, depending on the local pH). Due to the low dissociation constant for 
biotin and streptavidin, the use of a cleavable spacer arm containing a disulphide bond 
facilitates the release of biotinylated proteins after capture on immobilized streptavidin [Elia, 
2008]. Moreover, the sulfo-NHS-ester derivatives of biotin are preferable for use in PM 
labelling because they are more soluble in water than NHS-esters alone. This enables reactions 
to be performed in the absence of polar aprotic solvents and membrane permeabilizing 
reagents like dimethylsulfoxyde and dimethylformamide. Furthermore, the sulfo-NHS-esters 
are membrane-impermeable reagents, which reduces interference from cytosolic components 
[Daniels & Amara, 1998; Elia, 2008]. After biotinylation and hypotonic cell lysis, biotin-labelled 
proteins can be captured on streptavidin-coated magnetic beads and on-bead digested by 
trypsin. The eluted peptides are separated with nano-liquid chromatography (nano-LC) 
coupled to a MALDI-TOF/TOF mass spectrometer. Proteins are then identified on the basis of 
the MS-fragmented peptide spectra via a protein-database search with Mascot software 
(Matrix Science Ltd, London, UK). 
2. Materials and methods 
2.1 Cell culture  
Bovine BCECs were isolated and characterized as described previously [Meresse et al., 
1989]. Petri dishes (diameter: 100 mm) were coated with an in-house preparation  of rat tail 
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collagen (2 mg/mL) in ten-fold concentrated Dulbecco’s Modified Eagle’s Medium (DMEM) 
from GIBCO (Invitrogen Corporation, Carlsbad, CA, USA) and 0.4 M NaOH. The BCECs (4 
x 105 cells/mL) were seeded and cultured in DMEM supplemented with 10% (v/v) heat-
inactivated foetal calf serum, 10% (v/v) heat-inactivated horse serum (Hyclone 
Laboratories, Logan, UT, USA), 2 mM glutamine, 50 mg/mL gentamicin (Biochrome Ltd, 
Cambridge, UK) and 1 ng/mL basic fibroblast growth factor (GIBCO). The culture medium 
was refreshed every 2 days until confluence (after around 6 days, typically). Co-cultures 
were set in Transwellcell culture inserts (diameter: 100 mm; pore size: 0.4 mm; Corning 
Inc., New York, NY, USA) coated on the upper side with rat tail collagen. Endothelial cells 
were then seeded onto the inserts and transferred to a 100 mm Petri dish containing glial 
cells prepared according to Booher and Sensenbrenner [Booher & Sensenbrenner, 1972]. 
After 12 days of co-culture (in the same medium as mentioned above), the re-induction of 
BBB properties in the BCECs was checked by measuring the paracellular permeability 
coefficient of Lucifer Yellow carbohydrazide (PeLY) and by immunostaining the main tight 
junction proteins (occludin and claudin-5) and the associated intracellular scaffolding 
protein zona occludens 1 (ZO-1). Endothelial cell biotinylation and harvesting were 
performed after 12 days of co-culture. 
2.2 Cell surface biotinylation and cell harvesting 
Bovine BCEC biotinylation was performed by slightly modifying the previously reported 
method [Zhao et al., 2004]. Endothelial cells were washed three times with prewarmed 
(37°C) calcium- and magnesium-free PBS (CMF-PBS, pH 7.4) and gently shaken for 15 min 
at 37°C in CMF-PBS supplemented with 3 mg EZ-link sulfo-NHS-SS-biotin (Thermo 
Scientific, Cergy Pontoise, France) per Petri dish. The labelling reaction was quenched by 
adding 1 mL of 40 mM glycine in CMF-PBS, pH 8.0. Excess quenching buffer was removed 
by washing the cells twice in CMF-PBS. 
The cells were harvested by adding collagenase type XI (Clostridium histolyticum, Sigma, 
Lyon, France) as described previously [Pottiez et al., 2009b]. Briefly, bovine BCECs were 
incubated for 15 min with 1.5 mL of a 0.1% w/v collagenase solution. The cell suspension 
was harvested, washed three times in PBS and pelleted at 500 x g for 5 min at 4°C. The cell 
pellets were stored at -80°C until protein extraction. 
2.3 Preparation of biotinylated cell surface proteins 
Bovine BCEC pellets were lysed with 800 µL of ice-cold hypotonic buffer [10 Mm HEPES, 
pH 7.5, 1.5 mM MgCl2, 10 mM KCl, protease inhibitor cocktail) [Zhao et al., 2004] and 
incubated on ice for 30 min. The cells were lysed by dounce homogenization (50 passes) and 
then sonicated two times (30 W, 20 s). Unbroken cells and nuclei were pelleted from the cell 
homogenate by centrifugation at 1,000 x g for 10 min at 4 °C. Aliquots of supernatants and 
entire pellets were stored at -20°C prior to dot blot biotinylation control. 
The KCl concentration in the supernatants was adjusted to 150 mM. An aliquot (300 µL) of 
streptavidin magnetic beads (10 mg beads/mL, prewashed four times with hypotonic 
buffer) was added to supernatants. The supernatant/bead suspensions were rotated at room 
temperature (RT) for 90 min and then pelleted using a magnetic plate. To obtain the 
biotinylated protein fraction, the resulting preparations were washed three times with 500 
µL of ice-cold 1 M KCl for 15 min, three times again with 500 µL of ice-cold 0.1 M Na2CO3, 
pH 11.5 and lastly once with ice-cold hypotonic buffer for 10 min. The trypsin digestion was 
performed directly on the beads. 
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2.4 On-bead proteolysis and isolation of tryptic peptides 
The on-bead proteolysis of biotinylated protein fractions was carried out overnight at 
37°C in 400 µL of a proteolysis buffer containing 40 mM NH4CO3 (pH 8.0), 0.5 mM CaCl2 
and 12.5 ng/µL trypsin (Promega, Charbonnières-les-Bains, France). The enzyme reaction 
was stopped by heat denaturation at 100°C for 5 min. The magnetic beads were pelleted 
using a magnetic plate and the tryptic digest peptides were transferred into a clean 
microtube. 
The peptides attached to the streptavidin-coupled beads were eluted from beads by means 
of a reduction reaction for 15 min at 60°C with 100 µL of 40 mM NH4CO3 (pH 8.0) 
containing 200 mM dithiothreitol (to disrupt the disulphide bond in the sulfo-NHS-SS-
biotin). The eluate was pooled and tryptic peptides were concentrated under vacuum and 
immediately resolubilized in 30 µL of 0.1% TFA/10% acetonitrile/water prior to nano-LC 
separation. 
2.5 Nano-LC-MALDI-TOF-MS/MS experiments 
Separations were performed on an U3000 nano-LC system (Dionex-LC-Packings, 
Sunnyvale, CA, USA). After a pre-concentration step (C18 cartridge, 300 μm, 1 mm), the 
peptide samples were separated on a Pepmap C18 column (75 μm, 15 cm) using an 
acetonitrile gradient from 5% to 15% over 10 min, from 15% to 65% over 38 min and from 
65% to 100% over 15 min and, lastly, 15 min in 100% acetonitrile. The flow was set to 300 
nl/min and 115 fractions were automatically collected (one per 30 s) on an AnchorChip™ 
MALDI target using a Proteineer™ fraction collector (Bruker Daltonics, Bremen, Germany). 
Next, 2 μl of MALDI matrix (0.3 mg/ml -cyano-4-hydroxycinnamic acid in 
acetone:ethanol:0.1% TFA-acidified water, 3:6:1 v/v/v) were added during the collection 
process. The MS and MS/MS measurements were performed off-line using an Ultraflex™ 
II TOF/TOF mass spectrometer (Bruker Daltonics) in automatic mode (using FlexControl™ 
2.4 software), reflectron mode (for MALDI-TOF PMF) or LIFT mode (for MALDI-TOF/TOF 
peptide fragmentation fingerprint (PFF)). External calibration over the 1000-3500 mass 
range was performed with the [M+H]+ mono-isotopic ions of bradykinins 1-7, angiotensin 
I, angiotensin II, substance P, bombesin and adrenocorticotropic hormone (clips 1-17 and 
clips 18-39) from a peptide calibration standard kit (Bruker Daltonics). Briefly, a 25 kV 
accelerating voltage, a 26.3 kV reflector voltage and a 160 ns pulsed ion extraction were 
used to obtain the MS spectrum. Each spectrum was produced by accumulating data from 
500 laser shots. Peptide fragmentation was driven by Warp-LC software 1.0 (Bruker 
Daltonics) with the following parameters: signal-to-noise ratio > 15, more than 3 MS/MS 
by fraction if the MS signal was available, 0.15 Da of MS tolerance for peak merge and the 
elimination of peaks which appears in more than 35% of fractions. Precursor ions were 
accelerated to 8 kV and selected in a timed ion gate. Metastable ions generated by laser-
induced decomposition were further accelerated by 19 kV in the LIFT cell and their masses 
were measured in reflectron mode. Peak lists were generated from MS and MS/MS spectra 
using Flexanalysis™ 2.4 software (Bruker Daltonics). Database searches with Mascot 2.2 
(Matrix Science Ltd) using combined PMF and PFF datasets were performed in the UniProt 
56.0 and 56.6 databases via ProteinScape 1.3 (Bruker Daltonics). A mass tolerance of 75 
ppm and 1 missing cleavage site were allowed for PMF, with an MS/MS tolerance of 0.5 
Da and 1 missing cleavage site allowed for MS/MS searching. The relevance of protein 
identities was judged according to the probability-based Mowse score [Perkins et al., 1999], 
calculated with p < 0.05. 
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2.6 Bioinformatics resources and sorting protein lists 
Two FASTA sequence protein datasets were extracted from UniProt using the sequence 
retrieval system at the European Bioinformatics Institute [Zdobnov et al., 2002]. The first 
FASTA sequence dataset corresponds to the list (with 18,187 entries) of all mammalian 
proteins having at least one transmembrane domain (the SRS-coding criteria are as follows: 
[uniprot-Taxonomy:mammalia*] & [uniprot-FtKey:transmem*]). The second FASTA 
sequence dataset corresponds to the list (424,819 entries) of all mammalian proteins lacking 
transmembrane domains (the SRS-coding criteria are as follows: [uniprot-
Taxonomy:mammalia*] ! [uniprot-FtKey:transmem*]). The FASTA sequence datasets were 
subjected to in silico trypsin proteolysis using Proteogest [Cagney et al., 2003] and the 
following command line: >perl proteogest.pl –i filename –c trypsin –d –a –g1. 
The protein lists were compared using nwCompare software [Pont & Fournie, 2010] and 
classified according to the Protein Analysis Through Evolutionary Relationships 
(PANTHER) system [Mi et al., 2007; Thomas et al., 2003] (www.pantherdb.org). PANTHER 
is a resource in which genes have been functionally classified by expert biologists on the 
basis of published scientific experimental evidence and evolutionary relationships. Proteins 
are classified into families and subfamilies of shared function, which are then categorized by 
molecular function and biological process ontology terms. 
2.7 Fluorescence microscopy 
For fluorescence microscopy observations, the BCECs were biotinylated according to the 
above-described method, except that a non-cleavable biotinylation reagent (sulfosuccinimidyl-
6-[biotinamido]-6-hexanamido hexanoate; EZ-link sulfo-NHS-LC-biotin (Thermo Scientific, 
Cergy Pontoise, France)) was used. Filters with BCECs were fixed for 10 min in 2% w/v 
paraformaldehyde at RT and washed in PBS. Biotinylated proteins were revealed by 
incubation with a Streptavidin-Cy3 conjugate (1:50 v/v) for 30 min. After washing with PBS, 
cells were incubated for 2 min with the nuclear stain Hoechst 33258 (1 μg/mL) and the filter 
sections were mounted in Mowiol (Merck, France). Fluorescence was visualized with a Leica 
DMR fluorescence microscope (Leica Microsystems, Wetzlar, Germany). 
2.8 Dot blots for estimating the biotinylation efficiency 
Briefly, 15 µg of proteins from pellets and supernatants were dot-blotted on a nitrocellulose 
membrane. The membrane was incubated in blocking buffer [5% bovine serum albumin 
(BSA) in 20 mM Tris-HCl, 150 mM NaCl; pH 7.5, and 0.05% Tween-20 (TBS-T)] for one hour 
at RT and then immersed for 30 min at RT in a solution of alkaline phosphatase-conjugated 
avidin (1:1000 v/v in BSA/TBS-T). After three 15-min washes with TBS-T and one 10-
minute wash with TBS (20 mM Tris-HCl, 150 mM NaCl; pH 7.5), the membrane was 
incubated with 5-bromo-4-chloro-3-indoyl phosphate p-toluidine salt/p-nitro blue 
tetrazolium chloride substrate solution. The reaction was stopped by rinsing with deionised 
water during gentle shaking. The membrane image was acquired at 300 dpi with a Umax 
Scanner (Amersham Biosciences, Orsay, France) and stored in a Tagged Image File format. 
3. Results and discussion 
3.1 Confirmation of BBB-like properties 
Once primary capillary ECs are isolated in vitro, they rapidly lose some of their BBB 
functions. The cells' barrier properties were restored by a 12-day co-culture in which bovine 
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BCECs were seeded on the upper side of a filter placed in a Petri box and glial cells were 
seeded on the underside (see the Materials and Methods for details). Re-induction of BBB 
properties was confirmed by the fact that PeLY for bovine BCECs with re-induced BBB 
functions (0.6 x10-3 cm/min) was just over half that for cells with limited BBB functions (1.0 
x10-3 cm/min). Immunostaining also confirmed the presence and localization of the main 
tight junction proteins occludin and claudin-5 and the associated protein ZO-1, as described 
elsewhere by our group [Gosselet et al., 2009; Pottiez et al., 2009b]. 
3.2 Assessment of the susceptibility of BCEC membrane proteins to trypsin cleavage  
Prior to MS identification, membrane proteins are usually cleaved by proteolytic enzymes. 
Whatever the protein studied, trypsin is often considered as the enzyme of choice for 
proteomics, because it (i) has a specific cleavage site (on the C-terminal side of Arg- Xaa and 
Lys-Xaa, except when Xaa is a Pro), (ii) generates peptides of the right length for MS (in 
terms of sensitivity and accuracy) because the relatively high abundance of Arg and Lys 
(around 6%, compared with 10% for Leu, the most life abundant amino acid) and (iii) yields 
peptides with positive trapped charges. Due to the hydrophobic nature of PM proteins, 
several improvements of trypsin-based digestion methods have been especially developed 
to improve trypsin accessibility to proteins of interest. Most use buffers containing organic 
solvents (methanol, acetone, acetonitrile, etc.) or detergents (SDS, CYMAL-5, n-
octylglucoside, etc.) ([Lu X. & Zhu, 2005]; see [Josic & Clifton, 2007] for a review). 
Other enzymes can also be used in this essential step in proteomics [Wu et al., 2003]. Other 
methods involve enzyme-free, hydrolytic cleavage using various combinations of acidic 
conditions, cyanogen bromide and microwave irradiation [Josic & Clifton, 2007; Zhong et 
al., 2005]. These enzyme-free methods cleave either specifically at methionine (with an 
average abundance of around 2.5%) or non-specifically at any peptide bond [Zhong et al., 
2005]. Clearly, it is important to choose the right cleavage method when seeking to reduce 
bias and erroneous conclusions in the proteomic identification of membrane proteins. 
The susceptibility of mammalian PM proteins to trypsin cleavage was assessed in silico. The 
two Uniprot FASTA sequence datasets (corresponding to all known mammalian 
transmembrane proteins and non-transmembrane proteins, respectively) were analysed 
with Proteogest software. This Perl-written software performs the in silico trypsin digestion 
of all listed proteins and lists the generated peptides according to length or isotopic mass. 
Expression of the results as histograms (Fig. 3) shows that the overall distribution of tryptic 
peptides (in terms of length or isotopic mass) is essentially the same for both datasets and 
suggests that the susceptibility of mammalian transmembrane proteins does not differ from 
that of non-transmembrane proteins. 
As expected, the length-based distribution of peptides matches the isotopic mass 
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Fig. 3. Histograms of peptide counts according to the number of amino acid residues (AA) 
or the isotopic mass after in silico trypsin digestion with Proteogest [Cagney et al., 2003] of 
FASTA sequence datasets for (A) all mammalian proteins displaying at least one 
transmembrane domain (18,187 entries) and (B) all mammalian proteins lacking 
transmembrane domains (424,819 entries). The command line was >perl proteogest.pl –i 
filename –c trypsin –d –a –g1. The histograms show that the overall distribution of tryptic 
peptides (in terms of length or isotopic mass) is essentially the same in the two datasets and 
suggest that the trypsin susceptibility of mammalian transmembrane proteins does not 
significantly differ from that of non-transmembrane proteins. 
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did not differ significantly from one condition to another (Fig. 4) and the signal was 
principally located at the cell boundaries (red colour). Likewise, the EC permeabilities 
(deduced from the PeLY values) evolved similarly in treated and untreated cells.. Taken as a 
whole, these findings demonstrated that biotinylation did not affect the integrity of the BBB 




Fig. 4. Fluorescence microscopy of a bovine BCEC monolayer with limited BBB functions 
(“Lim. BBB”, panel A) or re-induced BBB functions (Re-ind. BBB, panel B). The monolayers 
were biotinylated with a non-cleavable reagent (EZ-link sulfo-NHS-LC-biotin). Biotinylated 
proteins were revealed by incubation with a Streptavidin-Cy3 conjugate (in red), whereas 
nuclei were stained with Hoechst 33258 (in blue). 
3.4 Nano-LC-MALDI-TOF-MS/MS maps 
After in vitro biotinylation, adherent bovine BCECs with limited or re-induced BBB 
functions were detached from the extracellular matrix by collagenase treatment, in order to 
avoid proteolytic damage to the PM proteins. The collected cells were lysed in ice-cold 
hypotonic buffer and pelleted at 1,000 x g for 10 min at 4 °C. Biotinylated proteins in the 
supernatant were trapped using streptavidin-coupled magnetic beads. Elution of non-
bound proteins was monitored with dot blots. Biotinylated proteins immobilised on the 
streptavidin-coated magnetic beads were then on-bead digested with trypsin. The resulting 
peptides were collected, released by reduction and concentrated prior to nano-LC-MALDI-
TOF/TOF mass spectrometry analysis. 
Typical chromatograms for each of the two conditions are shown in Fig. 5. As with two-
dimensional gel electrophoresis, these peptide maps provide an overall, graphic 
representation of a sample’s peptide diversity and abundance. The fact that the 
chromatograms for limited or re-induced BBB sample differ significantly underlines the 
quality of the sample preparation. Indeed, chromatograms that are too similar and/or too 
dense reflect inefficient labelling and purification, leading to the identification of a large set 
of cytosolic proteins. 
3.5 Protein identification 
Proteins were identified according to published guidelines [Wilkins et al., 2006] on the basis 
of PFF data. Briefly, the MS/MS data of all fragmented peptides were processed with the 
Mascot search algorithm, which compares the experimental MS/MS data to the theoretical  
 






Fig. 5. Nano-LC-MALDI-TOF/TOF mass spectrometry analysis. The figure shows typical 
chromatograms of tryptic digests of in vitro biotinylated bovine BCECs monolayers with 
limited BBB functions (panel A) and re-induced BBB functions (panel B). The Y axis 
corresponds to the chromatographic retention time (expressed as a spectrum number, Spect. 
#), whereas the X axis displays the mass/charge (m/z) ratio of the detected peptide ions. 
Each peptide is characterized by its retention time (Spect. #) and molecular mass (more 
exactly, its isotopic distribution). Peptide abundance is grey-scale coded; the darker the 
signal, the more abundant the peptide. 
data from the in silico digestion of all database-referenced proteins (or subsets of the latter). 
The concordance between experimental and theoretical data is then expressed as a Mascot 
score (-10 x log10 (p), where p is the likelihood (with 95% confidence) than the match is not 
due to chance). In other words, if the Mascot score for a given peptide is above the predefine 
threshold, the matching is not probably due to chance (and vice versa). Ultimately, the 
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An illustration of the rigorousness of protein identification is shown in Fig. 6 for the 
sodium/potassium-transporting ATPase subunit alpha-1 precursor (AT1A1_BOVIN), a 
protein with 10 transmembrane domains. This catalytic subunit is located at the PM and 
enables creation of the electrochemical gradient required for the active transport of various 
nutrients. The mature form of bovine AT1A1 is composed of 1016 amino acids and has an 
average molecular weight of around 112 kDa. The individual identification scores of the three 
peptides belonging to this protein are presented in the summary box in Fig. 6. All the scores 
are over the chance-related threshold, demonstrating that the identification is relevant. Hence, 
the cumulative Mascot score of 168.6 for AT1A1 denotes unambiguous identification. 
The location of the matching peptides (in bold red type) within the protein amino acid 
sequence shows that they are clustered in the large cytosolic region (described as “potential” 
in Uniprot database (aa #337 to #770)) of the Na+/K+-transporting ATPase subunit. 
Accordingly, no transmembrane domain-containing peptides served as the basis for protein 
identification, suggesting that the hydrophilic (i.e. cytoplasmic) regions of a given, non-
denatured protein are more accessible to trypsin than their hydrophobic counterparts. 
Lastly, a typical MS/MS spectrum is shown in Fig. 6. The precursor ions displaying an m/z 
ratio of 2834.3838 atomic mass units are in-source fragmented and all the generated 
daughter ions had an m/z ratio below that of the parent ions. The mass differences between 
daughter ions allow deducing the amino acid sequence. 
A typical nano-LC MS/MS analysis reported 761 fragmented peptides from samples of 
BCECs with limited BBB functions, whereas 957 fragmented peptides were reported for 
samples of BCECs with re-induced BBB functions. The efficient MS fragmentation led to the 
identification of 145 and 124 proteins in BCEC samples with limited and re-induced BBB 
functions, respectively. Sixty-three proteins were common to both conditions (Figure 7A). 
Following duplicate experiments on fraction-specific proteins, only 51 and 32 proteins were 
identified twice in BCECs with limited BBB functions and re-induced BBB functions, 
respectively. In all, this approach identified 211 distinct genes, of which 58 are referenced in 
Uniprot as coding for membrane-related proteins. Five of the 63 common proteins were PM 
or membrane-associated proteins, whereas 2 and 3 membrane-related proteins were 
identified in fraction-specific protein sets from BCECs with limited and re-induced BBB 
functions, respectively. Of the 15 membrane-related proteins (Figure 7B), 5 had more than 
one transmembrane domain (range: 2 to 17), 4 had a single transmembrane domain and 6 
were lipid-anchored. Hence, the majority of membrane-related proteins were anchored to 
the membrane by a single domain or a lipid moiety. 
3.6 Sorting protein lists 
After conversion of identified proteins into their corresponding gene names via web-
available bioinformatics resources, protein lists were sorted with PANTHER. The cellular 
locations of identified proteins (Fig. 8) were similar in the two kinds of BCEC. The protein 
sorting results showed that about two thirds of the identified proteins came from the 
cytoplasm or the PM, whereas a quarter were related to the endoplasmic reticulum, the 
mitochondrion, the nucleus and secreted proteins. Very few of the identified proteins 
belonged to the cell junction, endosome or Golgi apparatus. This ranking shows that very 
few proteins belonging to cytoplasm or secreted proteins (or proteins added to the cell 
culture medium) were recovered, despite their cellular abundance. Our findings 
demonstrate the efficiency of the enrichment approach used in the present study, even 
though only about 30 proteins came from the BCEC PM. 
 





m/z meas.  m/z [ppm] Score Range Sequence
2834.3838 -0.17 76.9 525-549
1236.6960 -8.00 34.7 646-656





Sodium/potassium-transporting ATPase subunit alpha-1 precursor (EC 3.6.3.9)
Score: 168
pI: 5. 36
5.4 No. of unique Peptides: 3
MW [kDa]: 112
Sequence Coverage [%]:
Matched peptides shown in Bold Red
 
451 ESALLKCIEV CCGSVKEMRE RYTKIVEIPF NSTNKYQLSI HKNANAGEPR 
501 HLLVMKGAPE RILDRCSSIL IHGKEQPLDE ELKDAFQNAY LELGGLGERV 
551 LGFCHLLLPD EQFPEGFQFD TDDVNFPVDN LCFVGLISMI DPPRAAVPDA 
601 VGKCRSAGIK VIMVTGDHPI TAKAIAKGVG IISEGNETVE DIAARLNIPV 
651 SQVNPRDARA CVVHGSDLKD MTPEQLDDIL KYHTEIVFAR TSPQQKLIIV 
701 EGCQRQGAIV AVTGDGVNDS PALKKADIGV AMGIAGSDVS KQAADMILLD 
751 DNFASIVTGV EEGRLIFDNL KKSIAYTLTS NIPEITPFLI FIIANIPLPL 





Fig. 6. Identification of AT1A1_BOVIN (sodium/potassium-transporting ATPase subunit 
alpha-1 precursor). The summary report describes some of the structural characteristics of 
the three matching peptides. The high Mascot scores correspond to an unambiguous 
identification. The sequences of the matching peptides are highlighted in bold red type 
within the AT1A1 amino acid sequence. For the sake of clarity, the amino acid sequence 
displayed here is truncated (ranging from amino acids #451 to #850). Lastly, the MS/MS 
spectrum of ionized peptides of 2834.3838 atomic mass units illustrates the amino acid 
sequence deduction. 
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Fig. 7. Overall distribution of proteins identified using this approach. Panel A: A Venn 
diagram of proteins identified in BCECs with limited BBB functions and re-induced BBB 
functions, respectively, showing the distribution of proteins identified in both conditions 
and in only one condition. Panel B: The distribution of membrane-related proteins according 




































































Lim. BBB Re-ind. BBB
 
Fig. 8. Cellular location-based sorting of identified proteins. The white histogram shows the 
sorting results for proteins in samples of BCECs with limited BBB functions (Lim. BBB) and 
the grey histogram depicts the result for BCECs with re-induced BBB (Re-ind. BBB) 
functions. Clearly, the grey and white histograms are very similar. More than 50% of the 
identified proteins were related to the cytoplasm and membrane. The remaining proteins 
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The sorting of protein lists by molecular function is presented in Fig. 9. Proteins identified 
from the bovine BCECs with limited (Fig. 9A) or re-induced (Fig. 9B) BBB functions could be 
divided into 8 and 9 activity classes, respectively, of which 7 were common (binding, 
catalytic activity, enzyme regulation activity, ion channel activity, receptor activity, 
transporter activity and structural molecule activity). Briefly, there were twice as many 
proteins with catalytic or receptor activity for BCECs with re-induced BBB functions than for 
BCECs with limited BBB functions. In contrast, the proteins involved in binding, enzyme 
regulation activity and structural molecule activity were less represented (at least two fold) 
in BCECs with re-induced BBB functions. Interestingly, proteins displaying transcription 
regulation activity were only identified in BCECs with limited BBB functions; whereas lists 
from BCECs with re-induced BBB functions also included proteins with motor activity and 
antioxidant activity. 
As expected for our experimental model, 59% of the 211 identified proteins were identified 
as bovine proteins. Indeed, certain proteins not yet reported in bovine samples were 
identified on the basis of inter-species sequence homologies. Given their location, this subset 
of proteins complements the results of our previous work, in which we used a large-scale 
electrophoresis- and chromatography-based approach to identify more than 430 cytoplasmic 
proteins [Pottiez et al., 2010]. Proteins found in both BCECs with limited and re-induced 
BBB functions will not be discussed further here.  
 
 
Fig. 9. Distribution of the proteins specifically identified in each condition according to their 
molecular function. The lists were generated under the PANTHER classification system. 
Proteins only identified in samples of BCECs with limited BBB function were distributed 
across 8 categories (Panel A), whereas those only identified in samples from BCECs with re-
induced BBB functions were distributed over 9 categories (panel B).  
The literature-based sorting of proteins identified in one condition only generated a lot of 
valuable information. A selected subset of these proteins is presented in Table 1. All of the 
listed proteins are found in the inner mitochondria membrane, the endoplasmic reticulum, 
the Golgi membrane and the vesicle membrane as well as the PM; this shows that the 
biotinylation reaction takes also place inside the cell, despite the experimental precautions 
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identified as such in BCECs (notably integrin alpha-D, nitric oxide synthase 3, dysferlin, 
myoferlin, transmembrane 9 superfamily member 4) and confirmed the presence of 
previously reported PM proteins (notably ATP-binding cassette sub-family C member 8, 
platelet endothelial cell adhesion molecule and Na+/K+ ATPase) [Uchida et al., 2011]. 
Although moesin is not a PM protein, it appears to be associated with the PM in BCECs with 
re-induced BBB functions (as previously reported [Pottiez et al., 2009b]).  
In vivo BCECs displaying a BBB phenotype display specific endocytic trafficking that 
regulates (at least in part) the molecular exchanges between the blood and the brain 
[Abbott et al., 2010]. Interestingly, our samples from BCECs with re-induced BBB 
functions contained several proteins involved in cellular endocytosis, endocytic recycling, 
membrane trafficking and receptor internalization, such as EH domain-containing protein 
2, myoferlin, dysferlin and certain cellular partners. Ferlin proteins are calcium-sensing 
proteins involved in vesicle trafficking and PM repair [Glover & Brown, 2007] and 
regulate the fusion of lipid vesicles at the PM. Myoferlin is reportedly strongly expressed 
in ECs and vascular tissues and was identified in a proteomics study of caveolae/lipid 
raft microdomains [Bernatchez et al., 2007]. Repression of myoferlin expression reduces 
not only lipid vesicle fusion in ECs but also protein expression levels of the vascular 
endothelial growth factor receptor-2 (VEGFR-2). In contrast to dysferlin, myoferlin 
regulates the membrane stability and function of VEGFR-2, [Sharma et al., 2010]. 
Dysferlin has been reported as a new marker for leaky brain blood vessels [Hochmeister 
et al., 2006]. 
Furthermore, in vitro myoferlin gene silencing not only decreases both clathrin- and 
caveolin-/raft-dependent endocytosis [Bernatchez et al., 2009] but also attenuates the 
expression of the angiogenic second tyrosine kinase receptor (Tie-2) [Yu et al., 2011]. In 
general, myoferlin appears to be critical for endocytosis events in ECs and could be a 
potential candidate for drug-mediated enhancement of transcytosis pathway and/or 
angiogenic targets. Accordingly, it has been shown that caveolin’s main effect is to retain 
dysferlin at the cell surface [Hernandez-Deviez et al., 2008]; this inhibits the endocytosis of 
dysferlin through clathrin-independent pathway and therefore reinforces its PM-resealing 
activity. Recently, Doherty et al. have described a third interaction partner, EH domain-
containing protein 2 (EHD2) [Doherty et al., 2008]. Although its role was demonstrated in 
myoblasts, EHD2 is an endocytic recycling protein that interacts with myoferlin to regulate 
lipid vesicle fusion. EHD2 binds to lipid membranes and deforms them into tubules. The 
protein regulates trafficking from the PM by controlling Rac1 activity [Benjamin et al., 2011] 
and is important for internalization of the glucose-transporter 4 (GLUT-4) [Park et al., 2004] 
Lastly, EHD2 is required for the translocation of a newly identified ferlin-like protein 
(Fer1L5) to the PM [Posey et al., 2011]. 
4. Conclusions 
The aim of our study was to determine the distribution and the nature of PM proteins in 
BCECs displaying the BBB phenotype. Based in our BBB in vitro model, we developed a 
strategy for labelling these proteins (with biotin), isolating them (with streptavidin affinity 
chromatography) and identify them (with nano-LC MS/MS). The most frequently used 
methods for the enrichment of PMs are based on affinity chromatography, cationic colloidal 
silica particles, cell biotinylation or a tissue-specific polyclonal antiserum. We decided to use 
a biotinylation approach because it avoids many of the drawbacks of the other methods. For 
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not only lipid vesicle fusion in ECs but also protein expression levels of the vascular 
endothelial growth factor receptor-2 (VEGFR-2). In contrast to dysferlin, myoferlin 
regulates the membrane stability and function of VEGFR-2, [Sharma et al., 2010]. 
Dysferlin has been reported as a new marker for leaky brain blood vessels [Hochmeister 
et al., 2006]. 
Furthermore, in vitro myoferlin gene silencing not only decreases both clathrin- and 
caveolin-/raft-dependent endocytosis [Bernatchez et al., 2009] but also attenuates the 
expression of the angiogenic second tyrosine kinase receptor (Tie-2) [Yu et al., 2011]. In 
general, myoferlin appears to be critical for endocytosis events in ECs and could be a 
potential candidate for drug-mediated enhancement of transcytosis pathway and/or 
angiogenic targets. Accordingly, it has been shown that caveolin’s main effect is to retain 
dysferlin at the cell surface [Hernandez-Deviez et al., 2008]; this inhibits the endocytosis of 
dysferlin through clathrin-independent pathway and therefore reinforces its PM-resealing 
activity. Recently, Doherty et al. have described a third interaction partner, EH domain-
containing protein 2 (EHD2) [Doherty et al., 2008]. Although its role was demonstrated in 
myoblasts, EHD2 is an endocytic recycling protein that interacts with myoferlin to regulate 
lipid vesicle fusion. EHD2 binds to lipid membranes and deforms them into tubules. The 
protein regulates trafficking from the PM by controlling Rac1 activity [Benjamin et al., 2011] 
and is important for internalization of the glucose-transporter 4 (GLUT-4) [Park et al., 2004] 
Lastly, EHD2 is required for the translocation of a newly identified ferlin-like protein 
(Fer1L5) to the PM [Posey et al., 2011]. 
4. Conclusions 
The aim of our study was to determine the distribution and the nature of PM proteins in 
BCECs displaying the BBB phenotype. Based in our BBB in vitro model, we developed a 
strategy for labelling these proteins (with biotin), isolating them (with streptavidin affinity 
chromatography) and identify them (with nano-LC MS/MS). The most frequently used 
methods for the enrichment of PMs are based on affinity chromatography, cationic colloidal 
silica particles, cell biotinylation or a tissue-specific polyclonal antiserum. We decided to use 
a biotinylation approach because it avoids many of the drawbacks of the other methods. For 
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example, proteolytic shaving offers many advantages in theory (since surface-exposed 
peptides are more water-soluble than their intrabilayer counterparts) but is handicapped by 
its tendency to trigger cell lysis and thus significantly contaminate surface-exposed 
membrane peptides with cytosol-derived peptides. 
By using the biotinylation approach, we showed that very few cytoplasmic proteins, 
secreted proteins or proteins added to the cell culture medium were recovered - despite 
their relatively high cellular abundance. We reported on the novel identification of 
transmembrane and membrane-associated proteins in bovine BCECs displaying the BBB 
phenotype. Our findings demonstrated the efficiency of the enrichment approach used, even 
though only about 30 proteins came from the BCEC PM. The proteins are variously involved 
in cellular endocytosis, membrane trafficking and receptor internalization and may thus 
have significant roles in BBB function. The fact that transmembrane and membrane-
associated proteins accounted for less than half the identified proteins shows how difficult it 
still is to isolate, solubilise and digest hydrophobic proteins of low cellular abundance. Our 
results suggest that the specific properties of PM proteins must be taken into account when 
seeking to improve biotinylation, purification and identification methods. Moreover, the 
glycocalyx can also impede biotinylation [Ueno, 2009]. The biotinylation targeting could 
probably be improved by the use of new biotin derivatives that are less likely to cross the 
PM. 
Furthermore, the present study reports the identification of several proteins involved in 
cellular endocytosis, membrane trafficking and receptor internalization (such as EHD2 
and myoferlin), together with their cellular partners. These proteins and the pathways of 
which they are a part may become new targets for increasing drug transport across the 
BBB. 
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1. Introduction 
The response of cells to even slight changes in the cellular microenvironment determines the 
reaction of the whole organism and its ability to adapt to macroenvironmental alterations. 
Generally, it is well recognized that the communication between cells, tissues, and organs is 
critical for the maintenance of the entire body homeostasis. The different cell types that 
build the various organs and tissues have an enormous potential to produce proteins that 
once secreted in the extracellular space exert their action in an auto-, para- and/or endocrine 
manner. It is estimated that out of the total 20.500 protein-coding genes in human, 
approximately 10% encode secreted proteins (Clamp et al., 2007; Skalnikova et al., 2011). The 
separate and combinatorial action of these ~2200 secreted proteins can influence the biology 
not only at adjacent sites but also have a clear effect on the whole organism (Lin et al., 2008). 
The secreted factors, which can range from large proteins to short peptides, are divided into 
different groups or classes according to their structural properties and function. The 
prototypical secreted proteins are represented by the group of proteins found in the blood 
stream and other body fluids, the components of the extracellular matrix (ECM) and 
enzymes released in the intestine and stomach. An intriguing group of secreted factors 
comprise cell surface receptor ligands, such as hormones, growth factors, and cytokines. 
These proteins can exert their actions either on a limited number of responsive tissues or can 
act on virtually all cell types dependent on the expression of their specific receptors. It is 
essential to decipher in depth the signaling events that are triggered by the various 
hormones and growth factors to understand the general mechanisms of the biological 
processes that occur in a strictly controlled fashion in both space and time. The processes 
that secreted factors influence and directly regulate range from cellular differentiation, 
growth and survival to apoptosis, autophagy, and ageing. In addition, a growth factor can 
often exert a divergent and even opposite effect depending on the cell type and cellular 
state. Taken in consideration the role of secreted factors in directing biological processes, 
malfunction of the signaling cascades orchestrated by secreted factors can have severe 
consequences and lead to development of a series of complicated diseases and disorders 
(Flier, 2001; Pedersen, 2009; Walsh, 2009). Therefore, a comprehensive characterization of 
secreted molecules by different cellular subtypes, tissues, and organs can contribute to the 
elucidation of the physiological state of a given organism and to the determination of the 
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1. Introduction 
The response of cells to even slight changes in the cellular microenvironment determines the 
reaction of the whole organism and its ability to adapt to macroenvironmental alterations. 
Generally, it is well recognized that the communication between cells, tissues, and organs is 
critical for the maintenance of the entire body homeostasis. The different cell types that 
build the various organs and tissues have an enormous potential to produce proteins that 
once secreted in the extracellular space exert their action in an auto-, para- and/or endocrine 
manner. It is estimated that out of the total 20.500 protein-coding genes in human, 
approximately 10% encode secreted proteins (Clamp et al., 2007; Skalnikova et al., 2011). The 
separate and combinatorial action of these ~2200 secreted proteins can influence the biology 
not only at adjacent sites but also have a clear effect on the whole organism (Lin et al., 2008). 
The secreted factors, which can range from large proteins to short peptides, are divided into 
different groups or classes according to their structural properties and function. The 
prototypical secreted proteins are represented by the group of proteins found in the blood 
stream and other body fluids, the components of the extracellular matrix (ECM) and 
enzymes released in the intestine and stomach. An intriguing group of secreted factors 
comprise cell surface receptor ligands, such as hormones, growth factors, and cytokines. 
These proteins can exert their actions either on a limited number of responsive tissues or can 
act on virtually all cell types dependent on the expression of their specific receptors. It is 
essential to decipher in depth the signaling events that are triggered by the various 
hormones and growth factors to understand the general mechanisms of the biological 
processes that occur in a strictly controlled fashion in both space and time. The processes 
that secreted factors influence and directly regulate range from cellular differentiation, 
growth and survival to apoptosis, autophagy, and ageing. In addition, a growth factor can 
often exert a divergent and even opposite effect depending on the cell type and cellular 
state. Taken in consideration the role of secreted factors in directing biological processes, 
malfunction of the signaling cascades orchestrated by secreted factors can have severe 
consequences and lead to development of a series of complicated diseases and disorders 
(Flier, 2001; Pedersen, 2009; Walsh, 2009). Therefore, a comprehensive characterization of 
secreted molecules by different cellular subtypes, tissues, and organs can contribute to the 
elucidation of the physiological state of a given organism and to the determination of the 
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malfunction in diseased stages. Analyzing on a large scale and in an unbiased manner the 
secretome of any given cell type or tissue, which comprise a unique combination of growth 
factors, hormones, cytokines, inhibitory factors, and components of the extracellular 
environment, has become a whole distinct research field. Although still challenging, this 
endeavor may ultimately prove beneficial for improving human health as it can accelerate 
the bridging of basic research and applied medicine. 
2. Proteomics 
Proteomics has many sides and it is often difficult to combine the different aspects that can 
define or characterize this broad topic. The term proteomics was introduced in 1995, 
describing the entire set of proteins expressed by a given cell, tissue, or organism (Wasinger 
et al., 1995). At present, proteomics is defined as large scale studies of the proteomes that 
encompass protein expression, folding, and localization. It also includes functional analyses 
of large complexes within a cell, tissue, or organism as well as comparison of different 
proteomes. Some of the different aspects of proteomics include analysis of body fluids, 
defining proteomes of pathogens, investigation of tissue proteomes, characterization of 
signaling pathways and the effects of inhibitors and drugs. The term systems biology was 
also introduced to describe the incorporation of genomics, metabolomics, and proteomics 
data for creation of dynamic networks of interacting molecules at a system level. Typically, 
such studies involve following the changes in protein profiles in response to changes in the 
environment and determination of combined action of diverse signaling networks that lead 
to a differential outcome for the living organism. Obtaining and combining information for 
such networks is of particular importance when investigating the role of secreted factors in 
the regulation of major signaling events in any given cell or tissue. Functional quantitative 
mass spectrometry-based proteomics (QMSP) is a powerful approach for creation of maps 
that describe the differential expression and dynamic changes of secretomes. Correlation  of  
these  results  with  clinics  can  help resolve  some  of  the  still  missing  links  in  the 
development of different syndromes. In this review chapter, we focus on the latest advances 
in QMSP for the investigation of secreted factors and we discuss some of the issues and 
challenges that remain to be unveiled. 
2.1 Quantitative mass spectrometry-based proteomics 
The fast development of QMSP techniques added yet another dimension to the proteomic 
research, namely the ability to follow differences and changes of the proteomes in space and 
time (Aebersold and Mann, 2003; Cox and Mann, 2007; Dengjel et al., 2009). QMSP permits 
observation and investigation of a combination of events and interplay of pathways 
involving hundreds of molecules that lead to a defined outcome for the cell. It facilitates 
determination of even slight changes in protein expression or post-translational 
modifications as a result of a drug treatment, changes in the cellular environment or 
alterations in the total body homeostasis. Up to date, QMSP is the only available approach 
that can, with high confidence and in a high throughput manner, generate and combine data 
for the spatial and temporal order of events that take place in a cell directly at protein level 
in order to decipher dynamic complex processes (Dengjel et al., 2009; Rigbolt and Blagoev, 
2010; Walther and Mann, 2010). There are two main QMSP strategies for relative 
quantitation based either on the use of stable isotopes or the label-free approach for 
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quantitation of changes in protein abundance (Ong and Mann, 2005; Schulze and Usadel, 
2010; Walther and Mann, 2010). 
2.1.1 Quantitation without stable isotopes 
Quantitation without stable isotopes generally encompasses a gel electrophoresis approach 
or a chromatography-based approach. In the gel-based approach one-dimensional or two-
dimensional gel electrophoresis is used as a mean of resolving the proteins from complex 
mixtures. This is followed by visualization of the protein bands or spots using different 
types of stains or fluorescent dyes. Typically, the protein samples originating from different 
cellular stages are separated on a gel and then the bands or spots that show distinct changes 
are excised, digested with proteases and identified by mass spectrometry. A major 
disadvantage of two dimensional gel electrophoresis is the relatively low dynamic range 
and inefficient access into the gel of high or very low molecular weight proteins. This results 
in the identification of mainly high abundant molecules, such as cytoskeletal proteins and 
highly expressed metabolic enzymes (Gygi et al., 2000). Reducing the complexity of the 
sample can at least partially overcome such limitation. The introduction of the difference in 
gel electrophoresis (DIGE) approach, which allows proteins from two different samples to 
be separated on the same gel, led to improved quantitatively accuracy of this gel-based 
approach (Unlu et al., 1997).  
The chromatography approach can be divided into two groups, namely peptide-based 
methods and protein-based methods. The peptide-based strategy relies on comparing the 
signal intensity of a peptide originating from one sample to the signal intensity of the same 
peptide originating from a different sample. The extracted ion chromatogram (XIC) for 
every peptide can be derived from the liquid chromatography profile of the two individual 
samples during the analysis by the mass spectrometer and the samples can thereby be 
compared quantitatively. Furthermore, a method called protein correlation profiling was 
established, where the total ion chromatograms of different samples are aligned and 
quantitative comparison of samples is then based on both retention time and accurate mass 
of the peptides. The relative protein quantitation is based on the fact that the peak areas 
obtained from liquid chromatography mass spectrometry correlate to the relative 
concentration of the protein in the sample (Andersen et al., 2003; Ong and Mann, 2005). It 
has been used to obtain semi quantitative data in complex mixtures such as human sera 
(Chelius and Bondarenko, 2002). A disadvantage is that it is only partially quantitative and 
requires highly reliable and reproducible analysis of the samples.  
Another label-free mass spectrometry-based approach used to retrieve quantitative 
measurements is based on spectral count. The “spectral counting” method uses the numbers 
of peptide identification spectra obtained for each protein as representation of the protein 
abundance in a mixture (Liu et al., 2004). One disadvantage of the spectral count method is 
that it is biased toward high abundant proteins since they can mask or suppress the low-
abundance ones in the sample, which is a key issue when analyzing e. g. plasma samples. 
The two label-free methods for quantitation, using either peptide ion intensities or spectral 
counts, are becoming increasingly popular, since they are simpler than the isotope-based 
strategy, despite being less accurate. In addition, both methods require very good 
reproducibility between the different liquid chromatography tandem mass spectrometry 
(LC-MS/MS) runs, high accuracy measurements and higher number of replica analyses. In 
general, the label-free approaches are widely applicable but the methods using stable 
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malfunction in diseased stages. Analyzing on a large scale and in an unbiased manner the 
secretome of any given cell type or tissue, which comprise a unique combination of growth 
factors, hormones, cytokines, inhibitory factors, and components of the extracellular 
environment, has become a whole distinct research field. Although still challenging, this 
endeavor may ultimately prove beneficial for improving human health as it can accelerate 
the bridging of basic research and applied medicine. 
2. Proteomics 
Proteomics has many sides and it is often difficult to combine the different aspects that can 
define or characterize this broad topic. The term proteomics was introduced in 1995, 
describing the entire set of proteins expressed by a given cell, tissue, or organism (Wasinger 
et al., 1995). At present, proteomics is defined as large scale studies of the proteomes that 
encompass protein expression, folding, and localization. It also includes functional analyses 
of large complexes within a cell, tissue, or organism as well as comparison of different 
proteomes. Some of the different aspects of proteomics include analysis of body fluids, 
defining proteomes of pathogens, investigation of tissue proteomes, characterization of 
signaling pathways and the effects of inhibitors and drugs. The term systems biology was 
also introduced to describe the incorporation of genomics, metabolomics, and proteomics 
data for creation of dynamic networks of interacting molecules at a system level. Typically, 
such studies involve following the changes in protein profiles in response to changes in the 
environment and determination of combined action of diverse signaling networks that lead 
to a differential outcome for the living organism. Obtaining and combining information for 
such networks is of particular importance when investigating the role of secreted factors in 
the regulation of major signaling events in any given cell or tissue. Functional quantitative 
mass spectrometry-based proteomics (QMSP) is a powerful approach for creation of maps 
that describe the differential expression and dynamic changes of secretomes. Correlation  of  
these  results  with  clinics  can  help resolve  some  of  the  still  missing  links  in  the 
development of different syndromes. In this review chapter, we focus on the latest advances 
in QMSP for the investigation of secreted factors and we discuss some of the issues and 
challenges that remain to be unveiled. 
2.1 Quantitative mass spectrometry-based proteomics 
The fast development of QMSP techniques added yet another dimension to the proteomic 
research, namely the ability to follow differences and changes of the proteomes in space and 
time (Aebersold and Mann, 2003; Cox and Mann, 2007; Dengjel et al., 2009). QMSP permits 
observation and investigation of a combination of events and interplay of pathways 
involving hundreds of molecules that lead to a defined outcome for the cell. It facilitates 
determination of even slight changes in protein expression or post-translational 
modifications as a result of a drug treatment, changes in the cellular environment or 
alterations in the total body homeostasis. Up to date, QMSP is the only available approach 
that can, with high confidence and in a high throughput manner, generate and combine data 
for the spatial and temporal order of events that take place in a cell directly at protein level 
in order to decipher dynamic complex processes (Dengjel et al., 2009; Rigbolt and Blagoev, 
2010; Walther and Mann, 2010). There are two main QMSP strategies for relative 
quantitation based either on the use of stable isotopes or the label-free approach for 
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quantitation of changes in protein abundance (Ong and Mann, 2005; Schulze and Usadel, 
2010; Walther and Mann, 2010). 
2.1.1 Quantitation without stable isotopes 
Quantitation without stable isotopes generally encompasses a gel electrophoresis approach 
or a chromatography-based approach. In the gel-based approach one-dimensional or two-
dimensional gel electrophoresis is used as a mean of resolving the proteins from complex 
mixtures. This is followed by visualization of the protein bands or spots using different 
types of stains or fluorescent dyes. Typically, the protein samples originating from different 
cellular stages are separated on a gel and then the bands or spots that show distinct changes 
are excised, digested with proteases and identified by mass spectrometry. A major 
disadvantage of two dimensional gel electrophoresis is the relatively low dynamic range 
and inefficient access into the gel of high or very low molecular weight proteins. This results 
in the identification of mainly high abundant molecules, such as cytoskeletal proteins and 
highly expressed metabolic enzymes (Gygi et al., 2000). Reducing the complexity of the 
sample can at least partially overcome such limitation. The introduction of the difference in 
gel electrophoresis (DIGE) approach, which allows proteins from two different samples to 
be separated on the same gel, led to improved quantitatively accuracy of this gel-based 
approach (Unlu et al., 1997).  
The chromatography approach can be divided into two groups, namely peptide-based 
methods and protein-based methods. The peptide-based strategy relies on comparing the 
signal intensity of a peptide originating from one sample to the signal intensity of the same 
peptide originating from a different sample. The extracted ion chromatogram (XIC) for 
every peptide can be derived from the liquid chromatography profile of the two individual 
samples during the analysis by the mass spectrometer and the samples can thereby be 
compared quantitatively. Furthermore, a method called protein correlation profiling was 
established, where the total ion chromatograms of different samples are aligned and 
quantitative comparison of samples is then based on both retention time and accurate mass 
of the peptides. The relative protein quantitation is based on the fact that the peak areas 
obtained from liquid chromatography mass spectrometry correlate to the relative 
concentration of the protein in the sample (Andersen et al., 2003; Ong and Mann, 2005). It 
has been used to obtain semi quantitative data in complex mixtures such as human sera 
(Chelius and Bondarenko, 2002). A disadvantage is that it is only partially quantitative and 
requires highly reliable and reproducible analysis of the samples.  
Another label-free mass spectrometry-based approach used to retrieve quantitative 
measurements is based on spectral count. The “spectral counting” method uses the numbers 
of peptide identification spectra obtained for each protein as representation of the protein 
abundance in a mixture (Liu et al., 2004). One disadvantage of the spectral count method is 
that it is biased toward high abundant proteins since they can mask or suppress the low-
abundance ones in the sample, which is a key issue when analyzing e. g. plasma samples. 
The two label-free methods for quantitation, using either peptide ion intensities or spectral 
counts, are becoming increasingly popular, since they are simpler than the isotope-based 
strategy, despite being less accurate. In addition, both methods require very good 
reproducibility between the different liquid chromatography tandem mass spectrometry 
(LC-MS/MS) runs, high accuracy measurements and higher number of replica analyses. In 
general, the label-free approaches are widely applicable but the methods using stable 
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isotope labels result in better accuracy of quantitation (Lundgren et al., 2010; Schulze and 
Usadel, 2010). 
2.1.2 Quantitation using stable isotopes 
The quantitative mass spectrometry-based methods utilizing stable isotopes can be achieved 
either by in vivo metabolic labeling or in vitro biochemical methods. The principle of the two 
labeling strategies is the generation of peptides labeled with stable isotopes that differ in mass 
from the unlabeled peptides making it possible to distinguish them within the same spectrum. 
2.1.2.1 Chemical labeling strategies 
The prototype of the chemical modification-based methodology for quantitation of protein 
is the isotope coded affinity tag (ICAT) that binds to cysteine residues  (Gygi et al., 1999). It 
employs usage of two isotopically labeled tags - one light and one heavy, which contains 
eight deuterium atoms, to distinctly label the peptides originating from two separate 
samples. The peptides originating from one sample can thereby be distinguished from the 
second sample, since the heavier tag will result in a mass shift readily observable in the 
mass spectrum. One of the advantages of ICAT is the presence of a biotin group in the light 
and heavy tags allowing selective enrichment of the labeled peptides using avidin affinity 
chromatography, thus reducing greatly the complexity of the mixture.  
ICAT has been applied to a variety of cell culture and tissue samples and has been 
demonstrated as a reliable and relatively easy applicable method for performing QMSP 
analysis. Among other applications, ICAT has been used to investigate differential 
expression profiles of microsomal proteins from naive and in vitro- differentiated human 
myeloid leukemia cells, secreted proteins during osteoclast differentiation, the dynamic 
changes of transcription factors during erythroid differentiation as well as comparison of 
livers of mice treated with different peroxisome proliferator-activated receptor agonists 
(Brand et al., 2004; Han et al., 2001; Kubota et al., 2003; Tian et al., 2004). Disadvantages of 
the ICAT strategy are that it targets only the cysteine containing peptides and the retention 
times of the light and heavy form during chromatographic separation are altered due to the 
presence of the deuterium atoms. To overcome some of those problems, a cleavable 12C- 
and 13C-based reagent (cICAT) has been developed, which has an improved peptide co-
elution profile during the liquid chromatography separation and increased recovery after 
enrichment of the labeled peptides (Yi et al., 2005).  
Several other chemical labeling strategies have been developed over the recent years. 
Probably the most popular of those being the isobaric tags for relative and absolute 
quantitation (iTRAQ) where the isobaric chemical groups are attached to the primary amine 
groups of the peptides. With iTRAQ, up to eight different conditions can be compared 
simultaneously since eight distinct isobaric tags for labeling are currently available. The 
quantitation is based on the intensities of the isotopically distinct fragments derived from 
the corresponding isobaric tags obtained in the peptide fragmentation spectrum. This is the 
main advantage of the method but it can also be a disadvantage since often a single 
fragment spectrum per peptide is available, thereby compromising the accuracy of 
quantitation (Ross et al., 2004).  
2.1.2.2 Metabolic labeling 
The metabolic labeling strategies rely on the incorporation of a stable isotope in proteins, 
while they are being de novo synthesized in the cell. In contrast to the standard radioactivity-
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based assays, the stable isotope is fully incorporated thereby encoding the whole proteome. 
There are two means of introducing the stable isotope using either media containing 15N 
labeled ammonium sulfate or media with the addition of a stable isotope labeled amino 
acid. The 15N labeling strategy has been used for quantitative analysis of protein 
phosphorylation in bacteria and a mouse melanoma cell line (Conrads et al., 2001; Oda et al., 
1999). Additionally, entire organisms have been metabolically labeled using the 15N 
strategy, including bacteria (E. coli and Deinococcus), C. elegans, D. melanogaster, and rat 
(Conrads et al., 2001; Krijgsveld et al., 2003; Wu et al., 2004). 
Stable Isotope Labeling by Amino Acids in Cell Culture (SILAC) is an accurate and 
resourceful quantitative proteomics platform, that in combination with high speed and 
accuracy mass spectrometry allows detailed characterization of complex biological systems 
(Ong et al., 2002; Ong et al., 2003). It involves usage of heavy non-  radioactive stable 
isotope-labeled amino acids, which are incorporated directly into the newly synthesized 
proteins of the cell. After SILAC labeling, the entire proteome of a given cell population 
becomes encoded either with a light or heavier version of the same amino acid, thereby 
enabling direct comparison and quantitation using mass spectrometry. With SILAC, the 
“light” and “heavy” samples can be mixed in equal ratios at the initial stages of the 
workflow, which can include subsequent protein purification, interaction assay or other 
manipulation of the mixed sample. Combining samples prior to any further sample 
preparation represents a tremendous advantage, since it results in reduced quantitation 
errors introduced by differences in individual sample handling. Major strength of the SILAC 
method is the ability to discriminate true interaction partners from background, when 
investigating functional protein-protein interactions (Blagoev et al., 2003; Dengjel et al., 
2010). Therefore, it facilitates investigation of cellular signaling cascades and creation of 
reliable protein interaction networks, which represents one of the biggest challenges in the 
field of system biology (Blagoev et al., 2004; Dengjel et al., 2009; Kratchmarova et al., 2005; 
Olsen et al., 2006; Osinalde et al., 2011). In addition, SILAC is invaluable for the 
investigation of secreted factors since it allows the distinction of specific proteins released by 
the cells to the extracellular environment from contaminating proteins like keratins and 
serum derived factors that originate from cell culture media supplements (Henningsen et 
al., 2010). One potential disadvantage with the SILAC protocol arises from cultures of 
primary cells, which usually require specific growth media with a defined formulation. 
Furthermore, such cells have limited division capacity in culture, whereas at least 5 
population doublings are required for complete SILAC encoding of the entire proteome. 
Nevertheless, SILAC-based analyses have been successfully extended to include 
microorganisms, entire mice, and quantitation of proteins in tumor biopsies (Geiger et al., 
2010; Kruger et al., 2008; Soufi et al., 2010). It was also utilized for the quantitative analyses 
of proteins released by omental adipose tissue explants (Alvarez-Llamas et al., 2007). 
3. Application of QMSP for investigation of secreted proteins 
Analysis of secreted proteins using QMSP allows in depth characterization of different 
cellular systems that secrete auto-, para-, and endocrine factors, which can influence the 
entire body homeostasis. Investigation of cellular models such as adult and embryonic stem 
cells, cells originating from a diseased state, immortalized cells representing various models 
for functional abnormalities, extends the knowledge of how changes in secretomes 
contribute to various types of human disorders. It also enables determination and discovery 
 
Proteomics – Human Diseases and Protein Functions 420 
isotope labels result in better accuracy of quantitation (Lundgren et al., 2010; Schulze and 
Usadel, 2010). 
2.1.2 Quantitation using stable isotopes 
The quantitative mass spectrometry-based methods utilizing stable isotopes can be achieved 
either by in vivo metabolic labeling or in vitro biochemical methods. The principle of the two 
labeling strategies is the generation of peptides labeled with stable isotopes that differ in mass 
from the unlabeled peptides making it possible to distinguish them within the same spectrum. 
2.1.2.1 Chemical labeling strategies 
The prototype of the chemical modification-based methodology for quantitation of protein 
is the isotope coded affinity tag (ICAT) that binds to cysteine residues  (Gygi et al., 1999). It 
employs usage of two isotopically labeled tags - one light and one heavy, which contains 
eight deuterium atoms, to distinctly label the peptides originating from two separate 
samples. The peptides originating from one sample can thereby be distinguished from the 
second sample, since the heavier tag will result in a mass shift readily observable in the 
mass spectrum. One of the advantages of ICAT is the presence of a biotin group in the light 
and heavy tags allowing selective enrichment of the labeled peptides using avidin affinity 
chromatography, thus reducing greatly the complexity of the mixture.  
ICAT has been applied to a variety of cell culture and tissue samples and has been 
demonstrated as a reliable and relatively easy applicable method for performing QMSP 
analysis. Among other applications, ICAT has been used to investigate differential 
expression profiles of microsomal proteins from naive and in vitro- differentiated human 
myeloid leukemia cells, secreted proteins during osteoclast differentiation, the dynamic 
changes of transcription factors during erythroid differentiation as well as comparison of 
livers of mice treated with different peroxisome proliferator-activated receptor agonists 
(Brand et al., 2004; Han et al., 2001; Kubota et al., 2003; Tian et al., 2004). Disadvantages of 
the ICAT strategy are that it targets only the cysteine containing peptides and the retention 
times of the light and heavy form during chromatographic separation are altered due to the 
presence of the deuterium atoms. To overcome some of those problems, a cleavable 12C- 
and 13C-based reagent (cICAT) has been developed, which has an improved peptide co-
elution profile during the liquid chromatography separation and increased recovery after 
enrichment of the labeled peptides (Yi et al., 2005).  
Several other chemical labeling strategies have been developed over the recent years. 
Probably the most popular of those being the isobaric tags for relative and absolute 
quantitation (iTRAQ) where the isobaric chemical groups are attached to the primary amine 
groups of the peptides. With iTRAQ, up to eight different conditions can be compared 
simultaneously since eight distinct isobaric tags for labeling are currently available. The 
quantitation is based on the intensities of the isotopically distinct fragments derived from 
the corresponding isobaric tags obtained in the peptide fragmentation spectrum. This is the 
main advantage of the method but it can also be a disadvantage since often a single 
fragment spectrum per peptide is available, thereby compromising the accuracy of 
quantitation (Ross et al., 2004).  
2.1.2.2 Metabolic labeling 
The metabolic labeling strategies rely on the incorporation of a stable isotope in proteins, 
while they are being de novo synthesized in the cell. In contrast to the standard radioactivity-
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based assays, the stable isotope is fully incorporated thereby encoding the whole proteome. 
There are two means of introducing the stable isotope using either media containing 15N 
labeled ammonium sulfate or media with the addition of a stable isotope labeled amino 
acid. The 15N labeling strategy has been used for quantitative analysis of protein 
phosphorylation in bacteria and a mouse melanoma cell line (Conrads et al., 2001; Oda et al., 
1999). Additionally, entire organisms have been metabolically labeled using the 15N 
strategy, including bacteria (E. coli and Deinococcus), C. elegans, D. melanogaster, and rat 
(Conrads et al., 2001; Krijgsveld et al., 2003; Wu et al., 2004). 
Stable Isotope Labeling by Amino Acids in Cell Culture (SILAC) is an accurate and 
resourceful quantitative proteomics platform, that in combination with high speed and 
accuracy mass spectrometry allows detailed characterization of complex biological systems 
(Ong et al., 2002; Ong et al., 2003). It involves usage of heavy non-  radioactive stable 
isotope-labeled amino acids, which are incorporated directly into the newly synthesized 
proteins of the cell. After SILAC labeling, the entire proteome of a given cell population 
becomes encoded either with a light or heavier version of the same amino acid, thereby 
enabling direct comparison and quantitation using mass spectrometry. With SILAC, the 
“light” and “heavy” samples can be mixed in equal ratios at the initial stages of the 
workflow, which can include subsequent protein purification, interaction assay or other 
manipulation of the mixed sample. Combining samples prior to any further sample 
preparation represents a tremendous advantage, since it results in reduced quantitation 
errors introduced by differences in individual sample handling. Major strength of the SILAC 
method is the ability to discriminate true interaction partners from background, when 
investigating functional protein-protein interactions (Blagoev et al., 2003; Dengjel et al., 
2010). Therefore, it facilitates investigation of cellular signaling cascades and creation of 
reliable protein interaction networks, which represents one of the biggest challenges in the 
field of system biology (Blagoev et al., 2004; Dengjel et al., 2009; Kratchmarova et al., 2005; 
Olsen et al., 2006; Osinalde et al., 2011). In addition, SILAC is invaluable for the 
investigation of secreted factors since it allows the distinction of specific proteins released by 
the cells to the extracellular environment from contaminating proteins like keratins and 
serum derived factors that originate from cell culture media supplements (Henningsen et 
al., 2010). One potential disadvantage with the SILAC protocol arises from cultures of 
primary cells, which usually require specific growth media with a defined formulation. 
Furthermore, such cells have limited division capacity in culture, whereas at least 5 
population doublings are required for complete SILAC encoding of the entire proteome. 
Nevertheless, SILAC-based analyses have been successfully extended to include 
microorganisms, entire mice, and quantitation of proteins in tumor biopsies (Geiger et al., 
2010; Kruger et al., 2008; Soufi et al., 2010). It was also utilized for the quantitative analyses 
of proteins released by omental adipose tissue explants (Alvarez-Llamas et al., 2007). 
3. Application of QMSP for investigation of secreted proteins 
Analysis of secreted proteins using QMSP allows in depth characterization of different 
cellular systems that secrete auto-, para-, and endocrine factors, which can influence the 
entire body homeostasis. Investigation of cellular models such as adult and embryonic stem 
cells, cells originating from a diseased state, immortalized cells representing various models 
for functional abnormalities, extends the knowledge of how changes in secretomes 
contribute to various types of human disorders. It also enables determination and discovery 
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of new roads of tissue cross talk and interaction. QMSP has been applied to study 
secretomes of a variety of cell types and tissues including adipose cells and tissues, mouse 
embryonic fibroblasts, astrocytes, mesenchymal stem cells, neuronal progenitor cells, 
kidney, and endothelial cells (Skalnikova et al., 2011). Although, there have been several 
proteomics reports describing the secretory function of cells from mesenchymal origin, the 
role of the muscle secretome has remained elusive. A limited number of studies so far have 
employed mass spectrometry to elucidate the secretory function of the skeletal muscle. In a 
study presented by Chan and coworkers condition media (CM) was collected from 
differentiated C2C12 myotubes at day 5 of differentiation and analyzed by 1D-gel 
electrophoresis combined with matrix-assisted laser desorption/ ionization tandem mass 
spectrometry (MALDI-MS/MS) (Chan et al., 2007). This work led to the identification of 80 
proteins released from skeletal muscle of which 27 were classified as secreted proteins based 
on literature searches. In another study isolated primary human skeletal muscle cells were 
SILAC-labeled (13C6-Lys) to make a quantitative evaluation of muscle secreted proteins 
between extreme obese and lean women (Hittel et al., 2009). Assessment of the identified 
proteins based on published literature and the Swiss-Prot database revealed 28 secreted 
proteins from 42 identified skeletal muscle proteins. Interestingly, the secretion of 
myostatin, a negative regulator of skeletal muscle growth and development but also 
implicated in metabolic homeostasis, was found to be markedly upregulated in extreme 
obesity cases. Subsequently, Yoon and colleagues presented a study investigating the effects 
of insulin on the secretory profile of differentiated myotubes (Yoon et al., 2009). The authors 
combined off-line reverse-phased HPLC fractionation with LC-MS/MS and identified 153 
secreted proteins from rat L6 myotubes. Based on spectral count quantitation, 33 of these 
proteins were classified as differentially regulated in response to insulin. The list of secreted 
proteins was extracted from a total list of 254 identified proteins using three different 
prediction tools, Gene Ontology, SignalP, and SecretomeP. In two more recent studies, a 
total of 108 secreted proteins by skeletal muscle cells were identified (Chan et al., 2011; 
Norheim et al., 2011).  
We have developed a general quantitative proteomics approach for investigation of secreted 
factors released by skeletal muscle cells during the course of muscle differentiation. The 
method utilizes a combination of SILAC labeling and advanced mass spectrometry (Fig. 1) 
(Henningsen et al., 2010).  
Triple encoding SILAC, (Blagoev et al., 2004) was applied to investigate protein secretion at 
three different time points during the course of C2C12 differentiation. Initial evaluation of 
the differentiation protocol with SILAC-labeled cells demonstrated the formation of a high 
number of multinucleated myotubes and increased expression of different muscle-specific 
proteins. The use of three different versions of each labeled amino acid enabled the 
comparison of the secretome at three different time points (day 0, day 2, and day 5) during 
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and lysine, since trypsin, which cleaves solely C-terminal to arginine and lysine, was used 
for in-gel digestion (Olsen et al., 2004). This “double-triple” labeling with isotopic forms of 
both arginine and lysine ensures that every tryptic peptide, except the C-terminal peptides 
of the proteins, contains at least one labeled residue and can therefore be used for 
quantitation (Blagoev and Mann, 2006). This increases the probability of positive protein 
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quantitation. Commercially available dFBS is dialyzed utilizing 10 kDa molecular weight 
cut off (MWCO) filters to remove any amino acids. Unfortunately, this also leads to the 
reduction of low-molecular weight proteins (<10 kDa) including certain growth factors, 
hormones, and cytokines, that may be needed for the growth and maintenance of certain 
cells. Therefore, dFBS is not compatible with all cell types and slower growth rate is 
observed in some cases. Ultimately, dialysis with MWCO 1,000 Da could be sufficient to 
remove amino acids, but it is more costly. 
The myoblasts were cultured in SILAC media for at least 5 passages to ensure complete 
incorporation of labeled amino acids into the proteome. Before the collection of 
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medium to minimize the presence of sera proteins, that would interfere with the 
subsequent mass spectrometry (MS)-analysis. CM was collected from myoblasts on day 0 
and during conversion of myoblasts into myotubes at day 2 and day 5, followed by 
filtration using 0.2 μm filters to remove any floating cells or cell debris, thereby reducing 
the risk of contaminating samples with intracellular proteins. The CM, collected from the 
three time points of differentiation was combined in a 1:1:1 ratio according to measured 
protein concentration. Subsequently, the pool of CM was concentrated by ultrafiltration 
using Vivaspin columns, MWCO 3,000 Da to ensure that proteins were retained in the 
concentrate. To reduce sample complexity, thereby effectively increasing the dynamic 
range of the MS-analysis, concentrated muscle-derived proteins were separated by size 
using 1D- gel electrophoresis. The excised gel bands were subjected to in-gel digestion 
and analyzed via LC-MS/MS using an linear ion trap (LTQ)-Orbitrap mass spectrometer 
followed by processing of the obtained data with the MaxQuant software (Box 2) (Cox 
and Mann, 2008; Cox et al., 2009). The described strategy resulted in the identification of 
635 putatively secreted proteins by skeletal myoblasts based on the GO term 
“extracellular” and signal peptide prediction inbuilt in the MaxQuant and ProteinCenter. 
The commercially available database, ProteinCenter, (www. Proxeon.com) utilizes 
annotation from all major protein sequence databases including Swiss-Prot, NCBI, and 
Ensembl. It allows analysis of large scale proteomic studies to isolate putatively secreted 
factors from the total list of identified proteins. The obtained identification list of IPI 
numbers is filtered and extracted according to the category “extracellular” within GO 
term cellular component. Then, the remaining proteins are filtered using a signal peptide 
predictor incorporated into the ProteinCenter platform, the PrediSi algorithm. Using the 
SILAC strategy, 624 secreted proteins were quantitatively evaluated during the course of 
skeletal muscle differentiation. Proteins already known to be secreted by skeletal muscle 
were identified, in addition to many novel proteins not previously shown to be secreted 
by skeletal myoblasts. Characterization of identified secreted proteins according to GO-
annotations demonstrated proteins involved in many different cellular processes 
including proliferation, differentiation, ECM reorganization, metabolic processes, and 
angiogenesis. According to the statistical analyses provided by MaxQuant, 188 secreted 
proteins were found to be dynamically regulated during skeletal myogenesis suggesting 
their regulatory involvement in skeletal muscle development, which could occur both in 
autocrine and paracrine manner. In a follow up study, focused on comprehensive 
characterization of the low abundant low molecular weight fraction of proteins secreted 
by muscle cells, application of triple encoding SILAC resulted in the generation of 
quantitative profiles of 59 growth factors and cytokines, including nine classical 
chemokines (Henningsen et al., 2011). 
The depicted triple encoding SILAC strategy led to the characterization of the muscle 
secretome and creation of dynamic secretion profiles during the process of muscle 
differentiation. Among the identified secreted factors, we have found components of the 
extracellular matrix, such as collagen, fibronectin and SPARC (secreted protein acidic and 
rich in cysteine), growth factors, including members of the transforming growth factor 
and insulin-like growth factor families, members of the serpin and matrix 
metalloproteases classes, chemokines, and modulators. In addition, proteins such as 
angiopoietin-1, VEGF (Vascular endothelial growth factor), PDGF (Platelet-derived 
growth factor), and FGF21 (Fibroblast growth factor 21) were identified and quantitated. 
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Combining these results indicate that muscle is a prominent secretory organ participating 
actively in the general regulation of body homeostasis. The muscle specific secreted 
factors exert their effects in local and/or systemic manner. In Henningsen et. al., 2010 we 
have identified and characterized the semaphorins as a new family of muscle secreted 
proteins. Semaphorins constitute a large family of secreted, GPI-anchored, and 
transmembrane proteins defined by a conserved semaphorin (sema) domain in their 
amino terminus (Gherardi et al., 2004; Neufeld and Kessler, 2008; Roth et al., 2009; Serini 
et al., 2009; Suzuki et al., 2008; Zhou et al., 2008). Initially, semaphorins were described as 
important regulators of axon guidance during neuronal development. However, an 
increasing number of studies have recognized the semaphorins as pleiotropic signaling 
molecules influencing a wide array of biological processes, such as angiogenesis, immune 
responses, and organ morphogenesis. In addition, semaphorins have also been linked to 
various pathologies including cancer and different diseases of the nervous system 
(Neufeld and Kessler, 2008; Roth et al., 2009). Currently, the mammalian semaphorin gene 
family consists of 20 members and although expression of individual semaphorins has 
been best described in the nervous system, semaphorins appear to be expressed by most if 
not all  tissues (Yazdani and Terman, 2006). We have identified several members of the 
semaphorin family belonging to different subfamilies to be secreted from skeletal 
myoblasts including the soluble Sema3A, Sema3B, Sema3D, Sema3E, the transmembrane 
Sema4B, Sema4C, and Sema6A, and finally the GPI-linked Sema7A. Examination of the 
dynamic secretion profiles of the identified semaphorins demonstrated differential 
secretion of Sema3A, Sema3D, Sema3E, Sema6A, and Sema7A during the course of C2C12 
myoblast differentiation. Interestingly, secretion of Sema3A, Sema3E, Sema3D, and 
Sema6A was markedly enhanced at the early stage of the differentiation, indicating that 
they may serve a role during the initial phase of the conversion process. In contrast, a 
gradually increased secretion of Sema7A was observed during differentiation, suggesting 
that Sema7A plays a role both during early and terminal differentiation. Identification of 
both the transmembrane and GPI-anchor semaphorins in the media would suggest that 
they are released from the plasma membrane in a soluble form either by proteolytic 
shedding, in the case of Sema4 and Sema6, or proteolytic cleavage catalyzed by a 
phospholipase, in the case of Sema7A. Earlier studies have shown that the enzymatic 
activity of metalloproteases can generate and modulate the activity of a soluble form of 
Sema4D (Basile et al., 2007; Elhabazi et al., 2001). Indeed, we did observe an increased 
secretion of various proteases including MMP-2. Western blot analysis of sema6A in 
conditioned media collected from C2C12 myoblasts during differentiation supported the 
idea of Sema6A shedding, as the secreted protein migrated at an apparent molecular 
weight corresponding to the size of the extracellular domain (approx. 71 kDa) and not to 
the size of the full-length Sema6A (approx. 113 kDa). Different members of the 
semaphorin family have been shown to orchestrate the development of different organs 
including bone, lung, kidney, and the cardiovascular system (Roth et al., 2009; 
Tamagnone and Giordano, 2006). The number of studies investigating the function of 
semaphorins in skeletal muscle development and regeneration are more limited. So far, 
studies have demonstrated an enhanced expression of Sema4C but no alterations of 
Sema4B expression during C2C12 myogenesis were detected (Ko et al., 2005; Wu et al., 
2007). In addition, enhanced expression of Sema4C was also observed in vivo in injury-
induced skeletal muscle regeneration. Targeted knockdown of Sema4C expression by 
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chemokines (Henningsen et al., 2011). 
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siRNA caused inhibition of C2C12 myotube formation, demonstrating that semaphorins 
could exert an active autocrine/paracrine function in myogenesis. Interestingly, animal 
models have suggested that semaphorins could be important paracrine factors regulating 
neurogenesis during skeletal muscle growth, development, and regeneration. A delayed 
transient increase of Sema3A expression was observed in response to muscle-induced 
injury (Tatsumi et al., 2009). In addition, a similar delay of Sema3A expression and 
secretion was seen in isolated skeletal muscle cells in response to HGF, which is an 
essential factor in muscle growth and regeneration. In our study, we have identified both 
Sema3A and Sema4C to be released by C2C12 myoblasts during differentiation.  
We have analyzed the mRNA and  protein expression of selected regulated members of the 
semaphorin family (Sema3A, Sema3E, Sema6A, and Sema7A) to investigate if their dynamic 
secretion pattern was regulated by post-transcriptional and post-translational mechanisms. 
Only minor changes were observed in the mRNA expression of Sema3A, Sema3E, Sema6A, 
and Sema7A. The mRNA expression of Sema3A and Sema7A remained constant during 
differentiation, whereas there was a slight decrease and increase in the level of Sema3E and 
Sema6A, respectively. We found that the high levels of secreted Sema3A and Sema3E at 
early stage of myotube formation did not reflect the intracellular protein levels of these 
semaphorins. Expression of Sema3A protein remained constant, whereas a slight decrease 
was observed of Sema3E protein expression in accordance with the corresponding RNA 
profile of Sema3A and Sema3E. Moreover, although the intracellular level of Sema7A 
protein was increased at day 5 of differentiation, it did not correlate with the gradually 
enhanced level of secreted protein. These finding shows that the level of secreted 
semaphorin proteins can be regulated both by post-transcriptional and post-translational 
mechanisms. This is in agreement with previous findings in which imperfect correlation 
between RNA and protein expression was observed (Bonaldi et al., 2008; de Godoy et al., 
2008; Kratchmarova et al., 2002). It also emphasizes the necessity to quantitatively 
investigate protein abundance to understand the functional role exhibited by individual 
genes and their corresponding proteins. These results clearly illustrate, that when studying 
the complex nature of the secreted factors it is important to observe both the intracellular 
level of proteins and their secretion profiles since they might differ due to post-translational 
modification or modulation of their release via the secretory pathway, turnover rate, and/or 
processing. 
4. Pitfalls of the studies on secreted proteins 
One of the major challenges in secretome studies is the identification and classification of 
secreted proteins from the total number of identified proteins from the proteomics 
experiment. Secreted proteins are released in the extracellular space via two routes: the 
classical and non-classical secretory pathways (Box 1). 
4.1 Secretory pathway, classical 
Majority of eukaryotic proteins are secreted by the classical endoplasmic reticulum (ER)-
Golgi secretory pathway consisting of a number of distinct membrane-bound compartments 
interconnected by vesicular traffic (Baines and Zhang, 2007; De Matteis and Luini; Nickel 
and Rabouille, 2009; Nickel and Wieland, 1998; Park and Loh, 2008; Pelham, 1996; Strating 
and Martens, 2009). Many basic cellular functions take place in the ER including folding of 
newly synthesized transmembrane and secretory proteins, lipid synthesis, and the storage  
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Box 1. Classification of secretory pathways 
of high concentrations of calcium ions (Marie et al., 2008; Mayor and Riezman, 2004; Sallese 
et al., 2009; Strating and Martens, 2009). In addition, post-translational modifications of 
soluble and membrane proteins occur in the ER lumen including oxidation of proline, N-
linked glycosylation, proteolytic processing, formation of disulfide bonds, oligomerization, 
and attachment of a GPI-anchor. Whereas the main functions of the Golgi apparatus include 
carbohydrate synthesis, O-linked glycosylation, processing, post-translational modification, 
and sorting both proteins and lipids (De Matteis and Luini, 2008; Marie et al., 2008; Marsh 
and Howell, 2002). Regardless of their subsequent fate, most proteins containing a N-
terminal or internal signal sequence peptide can be targeted to the ER membrane. These 
include transmembrane proteins destined to reside in the ER, plasma membrane or other 
organellar membranes as well as soluble proteins destined to the lumen of an organelle or 
for secretion. With the exception of mitochondria, nuclei, and peroxisomes, all other 
organelles receive their proteins via the ER. Signal peptides show extreme variations in their 
length and amino acid composition, but do contain three distinct domains: a positively 
charged N-terminal region, a hydrophobic core region, typically consisting of at least 6 
hydrophobic residues, and C-terminal region of polar uncharged residues (Hiller et al., 
2004). Soluble proteins are transported from the Golgi to the cell exterior via the constitutive 
secretory pathway transporting proteins directly to the cell surface or the regulated 
secretory pathway in which soluble proteins and other substances are initially stored in 
secretory vesicles, which release proteins to the extracellular space upon extracellular 
signals (Brunner et al., 2009; De Matteis and Luini, 2008; Strating and Martens, 2009). The 
latter pathway only exists in specialized secretory cells including pancreatic β-cell releasing 
insulin from secretory vesicles, nerve cells, and endocrine cells. The secretory vesicles of the 
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secretory vesicles, which release proteins to the extracellular space upon extracellular 
signals (Brunner et al., 2009; De Matteis and Luini, 2008; Strating and Martens, 2009). The 
latter pathway only exists in specialized secretory cells including pancreatic β-cell releasing 
insulin from secretory vesicles, nerve cells, and endocrine cells. The secretory vesicles of the 
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constitutive or regulated pathways fuse with the plasma membrane and release their 
contents by exocytosis. 
4.2 Secretory pathway, non-classical 
Although most identified extracellular proteins are secreted through the classical secretory 
pathway, emerging evidence has shown that several soluble proteins are released to the cell 
exterior via non-classical mechanisms (Nickel and Rabouille, 2009; Nickel and Seedorf, 2008; 
Prudovsky et al., 2008). For example FGF2 and IL-1β, well known extracellular proteins but 
lacking a signal peptide, are being secreted by non-classical routes either directly across the 
membrane or via vesicle intermediates. More specifically, studies investigating IL-1β 
secretion have demonstrated three alternative routes of extracellular translocation involving 
activation of caspase 1 and proteolytic processing of IL-1β. IL-1β can be released through (i) 
microvesicle shedding from the cell surface, (ii) translocation to secretory lysosomes, which 
upon fusion with the PM releases IL-1β to the cell exterior, and (iii) the caspase 1-Il-1β 
complex can be captured by endosomal vesicles creating multivesicular bodies that release 
internal vesicles as exosomes. At present, more than 20 proteins, belonging to different 
functional groups, have been described to be released to the cell exterior by non-classical 
pathways, including proteins that mainly function in the extracellular space as well as 
proteins that serve a role both intracellular and extracellular (Nickel and Seedorf, 2008; 
Prudovsky et al., 2008). Some of these proteins are constitutively secreted, whereas others 
are first released upon specific stimulation. Future studies are warranted to understand the 
biological function and regulation of the many different secretory pathways as well as the 
number and function of proteins devoid of a signal peptide but released to the extracellular 
space. Secretion of proteins by alternative pathways, which require interaction with other 
proteins and/or proteolytic activation, could impose additional levels of regulation to 
protein secretion (Nickel and Rabouille, 2009; Prudovsky et al., 2008). In addition, 
alternative secretion of signal peptide containing proteins that bypass the Golgi apparatus, 
could cause alterations in the structures of post-transcriptional modifications, such as 
glycosylation, or prevent proper proteolytic processing. This could be a way to modulate the 
biological activity of secreted proteins under certain physiological conditions. 
In addition to the two general pathways of secretion, proteins are also being released to the 
cell exterior due to apoptosis or cell leakage, thereby contaminating the pool of true secreted 
proteins. In this regard, the increased performance of MS-instrumentation not only improves 
the dynamic range for the identification of secreted proteins but also increases the number of 
identified proteins originating from the intracellular space. One example was presented in 
the study by Henningsen et al., 2011 focusing on the low molecular weight proteins. The 
quantitative mass spectrometry analysis resulted in the identification of more than 2000 
proteins however, less than 25% of these proteins were predicted to be secreted according to 
conventional database analyses based on the GO term extracellular and signal peptide 
prediction. Among the predicted secreted proteins, there were also tubulins, a number of 
ribosomal proteins, and membrane proteins that are not encountered as being truly secreted. 
Nevertheless, some of the cytoskeletal and ribosomal proteins have been demonstrated to be 
part of the exosomes and as such are being released in the extracellular environment. Major 
part of the exosomes consists of tubulins and Tsg101, which is a well-known exosome 
marker, was also identified as a secreted protein (Henningsen et al., 2011; Thery et al., 2002). 
Different tools are being used to classify the extracellular compartment in various secretome 
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studies, most commonly being assessment based on literature searches, GO-annotations 
and/or algorithms predicting secretion by classical (SignalP) or non-classical (SecretomeP) 
mechanisms (Box 2). Extraction of secreted proteins based on previous reported studies is 
extremely time-consuming considering the large number of identified proteins by today’s 
advanced MS. In addition, this will only result in the identification of proteins already shown 
by experimental data to be secreted. Isolation of secreted proteins from a large list of 
identified proteins can be done combining GO classification as extracellular and/or 
prediction of a signal peptide. However, all these tools do come with certain restrictions that 
could lead to either false positive or false negative identifications of secretion status. The 
presence of a signal peptide is not restricted to extracellular proteins. Proteins destined for 
other intracellular compartments, such as the ER or Golgi, also contains a signal peptide. In 
addition, GO terms are assigned according to different parameters, including computational 
analyses of sequences in addition to experimental data. Again, predictions based on sequence 
information could result in false positive identification of secreted proteins as well. Prediction 
tools always have their own limitations and therefore bona fide secreted proteins could also 
be lost by these tools. Most affected in this regard are the proteins released from cells by non-
conventional mechanisms whose number is still low but steadily increasing (Nickel and 
Rabouille, 2009; Prudovsky et al., 2008).  
 
Open source software and databases 
 
MaxQuant (http://maxquant.org): Advanced software program used as a tool for both 
protein identification and quantitation (Cox and Mann, 2008; Cox et al., 2009). 
 
SignalP (http://www.cbs.dtu.dk/services/SignalP): Predicting the presence of a signal 
peptide, suggesting proteins could be secreted through the classical pathway (Bendtsen et 
al., 2004b; Emanuelsson et al., 2007). 
 
SecretomeP (http://www.cbs.dtu.dk/services/SecretomeP): Prediction of proteins to be 
secreted by non-classical mechanisms (Bendtsen et al., 2004a).  
 
QuickGO provided by the Gene Ontology Annotation (GOA) group 
(http://www.ebi.ac.uk/GOA): Bioinformatics resource integrating various databases to 
assign subcellular localization and functional annotation according to GO terms (Barrell 
et al., 2009; Binns et al., 2009). 
 
GProX (http://gprox.sourceforge.net): Bioinformatics platform, which support the 
analysis and visualization of large-scale proteomics data (Rigbolt et al., 2011). 
 
Commercially available database 
 
ProteinCenter (http://www.proxeon.com): Software tool combining several data bases to 
analyze the biological context of complex proteomics experiments. 
 
Box 2. Software and databases commonly used in quantitative mass spectrometry-based 
proteomics research of secreted proteins 
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The high number of identified proteins in the QMSP experiments, which are not classified 
as secreted could be present in the extracellular space (conditioned medium) due to cell 
leakage or release of intracellular proteins from necrotic or apoptotic cells. The apoptotic 
process is a normal process that all cells grown in culture undergo at a given time point. 
However, the number of dead cells is limited since the protocol for collection of media is 
optimized such as to reduce the number of dying cells. In addition, the collected CM is 
typically filtrated using a 0.2 μm filter to ensure removal of any dead cells and thereby to 
reduce contamination from intracellular proteins. The presence of intracellular proteins 
might be explained by other structures present in the extracellular space such as exosomes 
and their cargo. Another point is that prediction of a signal peptide by itself does not 
exclude the possibility that these proteins are in fact located in other intracellular 
compartments of the cells, such as the ER and Golgi. On the other hand, an increasing 
number of proteins are being recognized as extracellular despite lacking a signal peptide 
and thought to be released through non-classical pathways (Nickel and Rabouille, 2009; 
Prudovsky et al., 2008). In the literature, more than 20 proteins devoid of any signal 
peptide have been shown to reside in the extracellular space and being released by non-
conventional mechanisms. SecretomeP (Box 2) has been designed to predict non-classical 
secreted proteins (Bendtsen et al., 2004a). For that purpose 13 known human non-classical 
secreted proteins were analyzed, but no specific sequence motif was identified to 
characterize non-classical secretion. Instead, the non-classical software for prediction was 
developed using the multiple sequence features of the 13 non-classical secreted proteins 
combined with sequence information obtained from more than 3,000 classical secreted 
proteins. Due to the limited number of identified non-classical proteins, the value of this 
prediction approach is difficult to assess. Submitting either the murine or human 
sequence of galectin-1 to SecretomeP resulted in probability score of < 0.5, thereby 
exemplifying a false negative identification. Galectin-1 is a well-known extracellular 
protein lacking a signal peptide but released by non-conventional ways (Hughes, 1999; 
Sango et al., 2004). On the other hand HMGB1, also not containing a signal peptide and 
mainly known for its role as a chromatin modifying protein, is also serving an 
extracellular function suggesting that proteins with typically intracellular functions could 
also be released to the cell exterior (Bonaldi et al., 2003 2002; Gardella et al., 2002). Future 
studies will help to elucidate how many proteins deficient in a signal peptide are being 
released to the extracellular space. Classifying proteins as extracellular based on GO 
annotation can also lead to false negative or false positive classifications. GO annotation 
are based both on experimental data but also on computational analysis of sequence 
information. With the increasing number of biomarker directed studies analyzing 
biofluids by mass spectrometry, the number of classified secreted proteins is steadily 
increasing. The increased number of identified secreted proteins could be due to 
improvements of mass spectrometry technology, which increased the overall sensitivity of 
protein identification, but could also be artifacts derived from dead cells floating around 
in the circulation.  
In summary, combination of different tools and manually curated data might be beneficial 
when validating the large lists obtained from QMSP experiments focusing on secreted 
factors. Nevertheless, release of cellular components can occur via microvesicles and/or 
exosomes adding to the complexity of secretome studies, thus some of the factors commonly 
counted as contaminants might be truly secreted ones. 
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4.3 Serum contaminants 
Mammalian cell culture models are broadly used in proteomics experiments and often 
contamination with bovine serum proteins, originating from the serum supplement used for 
the culturing of cells, is observed in the results from the mass spectrometric analyses. 
Naturally, when studying the proteins released by specific types of cells, one of the biggest 
challenges remains the presence of serum proteins that could interfere with the 
identification of proteins secreted by the cells. Presence of serum proteins in the sample can 
disrupt the concentration of the CM as well as interfere with the MS analysis, masking the 
presence of other proteins. It has been estimated that a 10% FBS serum complement, which 
is commonly added to the culture media, adds 5-6 mg/ml protein to the media and even 
extensive washing of the cells might not be sufficient to remove the bovine proteins to levels 
below the detection limit of the mass spectrometer (Bunkenborg et al., 2010). The sera-
derived proteins could be falsely identified as proteins being secreted by the cells due to 
sequence homology between species. One suggested solution to exclude bovine 
contaminants was based on expanding the database to include both the human and the 
bovine proteome. Another alternative is to extend the database to include known bovine 
contaminants as a common contaminant list, which is already incorporated in the data 
analysis by programs such as MaxQuant (Bunkenborg et al., 2010; Henningsen et al., 2011; 
Henningsen et al., 2010). In this way, it is possible to exclude the proteins recognized as 
contaminants from the initial list of identifications and thereby to minimize the number of 
identifications originating from sera proteins. Nevertheless, the SILAC strategy is so far the 
best known applicable method to investigate secreted factors by a given type of cells since 
the metabolic labeling makes it possible to distinguish cell-derived secreted proteins, as 
these are SILAC labeled, from residual sera proteins. Only proteins that are synthesized in 
the cells in the presence of the heavy SILAC amino acid will be labeled, thereby these are 
easily distinguished from sera contaminants, which remain unlabeled. In addition, the 
accuracy of protein quantitation could also be compromised by the presence of sera proteins 
in the samples. It is therefore advisable to perform a replica experiment with reverse SILAC 
labeling strategy (Schulze and Mann, 2004), which is an easy solution to overcome this 
possible drawback as well as to ensure high quality quantitation of bona fide secreted 
proteins. 
4.4 Post-translational modifications of secreted proteins 
Glycosylation of secreted proteins is one of the most abundant post-translational 
modifications (PTM), which affects the proteins folding, stability, and activity. The 
oligosaccharides are linked to the proteins via asparagine (N-linked) or serine/threonine (O-
linked) residues. Enrichment of secreted proteins through their glycan structures is an 
alternative experimental strategy for the identification of secreted proteins. Various types of 
enrichment methods have been utilized to capture glycosylated proteins, one of the 
common approaches being lectin affinity chromatography. In an elegant study by Zielinska 
et al., the combinatorial use of optimized lectin-based enrichment step, subcellular 
fractionation, deglycosylation assays, SILAC labeling, advanced mass spectrometry 
followed by integrative bioinformatic analyses  resulted in the identification of 6367 N-
glycosylation sites on 2352 proteins in four mouse tissues and blood plasma. N-
glycosylation was found to occur exclusively on secreted proteins, on the extracellular face 
of membrane proteins, and on the lumenal side of ER, Golgi apparatus, and lysosomes 
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(Zielinska et al., 2010). In a complementary study using formalin-fixed paraffin-embedded 
tissue samples, 1500 N-glycosylation sites were found underlying the increased sensitivity 
and accuracy of the mass spectrometry-based proteomics for identification of post-
translationally modified proteins, even in fixed samples. The comparison of fresh tissue 
using SILAC-labeled mouse (Kruger et al., 2008) with the paraffin embedded tissue showed 
no significant qualitative or quantitative differences between these samples, either at protein 
or peptide level, thereby permitting the use of this methodology in clinical studies 
(Ostasiewicz et al., 2010).  
Hydroxyproline is another type of PTM that is identified predominantly on components of 
the extracellular matrix and especially on different types of collagens. We have recently 
reported the identification of 299 unique high-confidence hydroxyproline sites from 48 
distinct secreted proteins in muscle cells, representing the largest data set so far on this 
proline modification. 231 of the modified prolines were located on various collagen types 
with a large variation of the number of modified sites per individual protein. The number 
ranged from 1 site on collagen alpha-3 type VI to more than 70 on collagen alpha-1 type I, 
highlighting the importance of the proline modification in maintaining the structure of the 
collagens. Motif sequence analysis revealed the canonical motif previously reported for 
collagen proteins as well as a novel hydroxyproline motif. Modified peptides containing 
hydroxyproline sites extend over more than 40 proteins including fatty acid binding protein 
(FABP), several components of the ECM such as SPARC, fibronectin, Lama2, perlecan, and 
different inhibitors of proteolytic enzymes such as serine protease inhibitors (serpinf1 and 
serphinh1) and the metalloproteinase inhibitor 2 (Timp2). These results indicate that 
hydroxyproline could serve as an important secondary modification to confer protein 
stability and interaction with other secreted proteins. 
5. Conclusion 
The rapid development of MS-instrumentation combined with the advances of quantitative 
proteomics strategies, such as SILAC, has had a tremendous impact in the analysis of 
complex biological systems. QMSP is increasingly becoming an essential approach, 
especially for the characterization of entire secretomes and generation of dynamic 
quantitative profiles of secreted factors during the course of cellular differentiation or in 
response to drugs, inhibitors, and modulators. Although there have been a marked 
improvement of the proteomics strategies to characterize secretomes, many challenges still 
remain: minimizing the suppressive effect of growth supplements present in the sample 
during MS analyses, identification of whole tissue secretomes, collection of samples under 
specific conditions to avoid induction of cell death, identification of low abundant low 
molecular weight proteins. However, the most critical point presented by secretome studies 
today is to isolate the bona fide secreted proteins and to validate the obtained results. 
Integrative approaches that combine highly advanced proteomics methodology followed by 
biological functional analyses can lead to the creation of secretome maps that underline 
tissue crosstalk and communication. 
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(Zielinska et al., 2010). In a complementary study using formalin-fixed paraffin-embedded 
tissue samples, 1500 N-glycosylation sites were found underlying the increased sensitivity 
and accuracy of the mass spectrometry-based proteomics for identification of post-
translationally modified proteins, even in fixed samples. The comparison of fresh tissue 
using SILAC-labeled mouse (Kruger et al., 2008) with the paraffin embedded tissue showed 
no significant qualitative or quantitative differences between these samples, either at protein 
or peptide level, thereby permitting the use of this methodology in clinical studies 
(Ostasiewicz et al., 2010).  
Hydroxyproline is another type of PTM that is identified predominantly on components of 
the extracellular matrix and especially on different types of collagens. We have recently 
reported the identification of 299 unique high-confidence hydroxyproline sites from 48 
distinct secreted proteins in muscle cells, representing the largest data set so far on this 
proline modification. 231 of the modified prolines were located on various collagen types 
with a large variation of the number of modified sites per individual protein. The number 
ranged from 1 site on collagen alpha-3 type VI to more than 70 on collagen alpha-1 type I, 
highlighting the importance of the proline modification in maintaining the structure of the 
collagens. Motif sequence analysis revealed the canonical motif previously reported for 
collagen proteins as well as a novel hydroxyproline motif. Modified peptides containing 
hydroxyproline sites extend over more than 40 proteins including fatty acid binding protein 
(FABP), several components of the ECM such as SPARC, fibronectin, Lama2, perlecan, and 
different inhibitors of proteolytic enzymes such as serine protease inhibitors (serpinf1 and 
serphinh1) and the metalloproteinase inhibitor 2 (Timp2). These results indicate that 
hydroxyproline could serve as an important secondary modification to confer protein 
stability and interaction with other secreted proteins. 
5. Conclusion 
The rapid development of MS-instrumentation combined with the advances of quantitative 
proteomics strategies, such as SILAC, has had a tremendous impact in the analysis of 
complex biological systems. QMSP is increasingly becoming an essential approach, 
especially for the characterization of entire secretomes and generation of dynamic 
quantitative profiles of secreted factors during the course of cellular differentiation or in 
response to drugs, inhibitors, and modulators. Although there have been a marked 
improvement of the proteomics strategies to characterize secretomes, many challenges still 
remain: minimizing the suppressive effect of growth supplements present in the sample 
during MS analyses, identification of whole tissue secretomes, collection of samples under 
specific conditions to avoid induction of cell death, identification of low abundant low 
molecular weight proteins. However, the most critical point presented by secretome studies 
today is to isolate the bona fide secreted proteins and to validate the obtained results. 
Integrative approaches that combine highly advanced proteomics methodology followed by 
biological functional analyses can lead to the creation of secretome maps that underline 
tissue crosstalk and communication. 
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